Focal	O
dermal	O
hypoplasia	O
resulting	O
from	O
a	O
new	O
nonsense	O
mutation	O
,	O
p.E300X	B-ProteinMutation
,	O
in	O
the	O
PORCN	O
gene	O
.	O

BACKGROUND	O
:	O
Focal	O
dermal	O
hypoplasia	O
(FDH)	O
(	O
OMIM	O
305600	O
)	O
is	O
an	O
X-linked	O
dominant	O
disorder	O
of	O
ecto-mesodermal	O
development	O
.	O

Also	O
known	O
as	O
Goltz	O
syndrome	O
,	O
FDH	O
presents	O
with	O
characteristic	O
linear	O
streaks	O
of	O
hypoplastic	O
dermis	O
and	O
variable	O
abnormalities	O
of	O
bone	O
,	O
nails	O
,	O
hair	O
,	O
limbs	O
,	O
teeth	O
and	O
eyes	O
.	O

The	O
molecular	O
basis	O
of	O
FDH	O
involves	O
mutations	O
in	O
the	O
PORCN	O
gene	O
,	O
which	O
encodes	O
an	O
enzyme	O
that	O
allows	O
membrane	O
targeting	O
and	O
secretion	O
of	O
several	O
Wnt	O
proteins	O
critical	O
for	O
normal	O
tissue	O
development	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
molecular	O
basis	O
of	O
FDH	O
in	O
a	O
2-year-old	O
Thai	O
girl	O
who	O
presented	O
at	O
birth	O
with	O
depressed	O
,	O
pale	O
linear	O
scars	O
on	O
the	O
trunk	O
and	O
limbs	O
,	O
sparse	O
brittle	O
hair	O
,	O
syndactyly	O
of	O
the	O
right	O
middle	O
and	O
ring	O
fingers	O
,	O
dental	O
caries	O
and	O
radiological	O
features	O
of	O
osteopathia	O
striata	O
.	O

METHODS	O
:	O
Sequencing	O
of	O
genomic	O
DNA	O
from	O
the	O
affected	O
individual	O
and	O
both	O
parents	O
to	O
search	O
for	O
pathogenic	O
mutations	O
in	O
PORCN	O
gene	O
.	O

RESULTS	O
:	O
DNA	O
sequencing	O
disclosed	O
a	O
heterozygous	O
G>T	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
c.898	I-DNAMutation
within	O
exon	O
10	O
(NM_203475.1)	O
,	O
converting	O
a	O
glutamic	O
acid	O
residue	O
(GAA)	O
to	O
a	O
premature	O
termination	O
codon	O
(TAA)	O
.	O

This	O
mutation	O
,	O
designated	O
p.E300X	B-ProteinMutation
,	O
was	O
not	O
detected	O
in	O
DNA	O
from	O
either	O
parent	O
or	O
in	O
100	O
control	O
chromosomes	O
.	O

CONCLUSION	O
:	O
Identification	O
of	O
this	O
new	O
de	O
novo	O
nonsense	O
mutation	O
confirms	O
the	O
diagnosis	O
of	O
FDH	O
in	O
this	O
child	O
and	O
highlights	O
the	O
clinical	O
importance	O
of	O
PORCN	O
and	O
Wnt	O
signalling	O
pathways	O
in	O
embryogenesis	O
.	O

A	O
novel	O
DFNA5	O
mutation	O
,	O
IVS8+4	B-DNAMutation
A>G	I-DNAMutation
,	O
in	O
the	O
splice	O
donor	O
site	O
of	O
intron	O
8	O
causes	O
late-onset	O
non-syndromic	O
hearing	O
loss	O
in	O
a	O
Chinese	O
family	O
.	O

We	O
report	O
here	O
the	O
clinical	O
,	O
genetic	O
,	O
and	O
molecular	O
characteristics	O
of	O
a	O
large	O
Chinese	O
family	O
exhibiting	O
non-syndromic	O
,	O
late-onset	O
autosomal	O
dominant	O
sensorineural	O
hearing	O
loss	O
.	O

Clinical	O
evaluation	O
revealed	O
variable	O
phenotypes	O
of	O
hearing	O
loss	O
in	O
terms	O
of	O
severity	O
and	O
age-at-onset	O
of	O
disease	O
in	O
these	O
subjects	O
.	O

Genome-wide	O
linkage	O
analysis	O
mapped	O
the	O
disease	O
gene	O
to	O
the	O
DFNA5	O
locus	O
with	O
a	O
maximum	O
two-point	O
log	O
odds	O
score	O
of	O
5.39	O
at	O
[theta]	O
=	O
0	O
for	O
marker	O
D7S2457	O
.	O

DNA	O
sequencing	O
of	O
DFNA5	O
revealed	O
a	O
novel	O
heterozygous	O
IVS8+4	B-DNAMutation
A>G	I-DNAMutation
substitution	O
in	O
the	O
splice	O
donor	O
site	O
of	O
intron	O
8	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(RT-PCR)	O
showed	O
skipping	O
of	O
exon	O
8	O
in	O
the	O
mutant	O
transcript	O
.	O

This	O
mutation	O
faithfully	O
cosegregated	O
with	O
hearing	O
loss	O
in	O
the	O
family	O
.	O

In	O
addition	O
,	O
the	O
mutation	O
was	O
absent	O
in	O
100	O
unrelated	O
control	O
DNA	O
samples	O
of	O
Chinese	O
origin	O
.	O

The	O
IVS8+4	B-DNAMutation
A>G	I-DNAMutation
mutation	O
is	O
predicted	O
to	O
create	O
a	O
shift	O
in	O
the	O
reading	O
frame	O
and	O
introduce	O
a	O
stop	O
codon	O
at	O
position	O
372	O
,	O
thereby	O
resulting	O
in	O
a	O
prematurely	O
truncated	O
DFNA5	O
protein	O
.	O

Up	O
to	O
date	O
,	O
a	O
total	O
of	O
four	O
mutations	O
in	O
DFNA5	O
have	O
been	O
reported	O
to	O
lead	O
to	O
hearing	O
impairment	O
,	O
all	O
of	O
them	O
result	O
in	O
skipping	O
of	O
exon	O
8	O
at	O
the	O
mRNA	O
level	O
.	O

Our	O
findings	O
provide	O
further	O
support	O
for	O
the	O
hypothesis	O
that	O
DFNA5-associated	O
hearing	O
loss	O
is	O
caused	O
by	O
a	O
very	O
specific	O
gain-of-function	O
mutation	O
.	O

A	O
novel	O
point	O
mutation	O
in	O
helix	O
11	O
of	O
the	O
ligand-binding	O
domain	O
of	O
the	O
human	O
glucocorticoid	O
receptor	O
gene	O
causing	O
generalized	O
glucocorticoid	O
resistance	O
.	O

BACKGROUND	O
:	O
Generalized	O
glucocorticoid	O
resistance	O
is	O
a	O
rare	O
condition	O
characterized	O
by	O
partial	O
,	O
end-organ	O
insensitivity	O
to	O
glucocorticoids	O
,	O
compensatory	O
elevations	O
in	O
adrenocorticotropic	O
hormone	O
and	O
cortisol	O
secretion	O
,	O
and	O
increased	O
production	O
of	O
adrenal	O
steroids	O
with	O
androgenic	O
and/or	O
mineralocorticoid	O
activity	O
.	O

We	O
have	O
identified	O
a	O
new	O
case	O
of	O
glucocorticoid	O
resistance	O
caused	O
by	O
a	O
novel	O
mutation	O
of	O
the	O
human	O
glucocorticoid	O
receptor	O
(hGR)	O
gene	O
and	O
studied	O
the	O
molecular	O
mechanisms	O
through	O
which	O
the	O
mutant	O
receptor	O
impairs	O
glucocorticoid	O
signal	O
transduction	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
identified	O
a	O
novel	O
,	O
single	O
,	O
heterozygous	O
nucleotide	O
(	B-DNAMutation
T	I-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2209	I-DNAMutation
(	O
exon	O
9alpha	O
)	O
of	O
the	O
hGR	O
gene	O
,	O
which	O
resulted	O
in	O
phenylalanine	O
(F)	O
to	O
leucine	O
(L)	O
substitution	O
at	O
amino	O
acid	O
position	O
737	O
within	O
helix	O
11	O
of	O
the	O
ligand-binding	O
domain	O
of	O
the	O
protein	O
.	O

Compared	O
with	O
the	O
wild-type	O
receptor	O
,	O
the	O
mutant	O
receptor	O
hGRalphaF737L	B-ProteinMutation
demonstrated	O
a	O
significant	O
ligand-exposure	O
time-dependent	O
decrease	O
in	O
its	O
ability	O
to	O
transactivate	O
the	O
glucocorticoid-inducible	O
mouse	O
mammary	O
tumor	O
virus	O
promoter	O
in	O
response	O
to	O
dexamethasone	O
and	O
displayed	O
a	O
2-fold	O
reduction	O
in	O
the	O
affinity	O
for	O
ligand	O
,	O
a	O
12-fold	O
delay	O
in	O
nuclear	O
translocation	O
,	O
and	O
an	O
abnormal	O
interaction	O
with	O
the	O
glucocorticoid	O
receptor-interacting	O
protein	O
1	O
coactivator	O
.	O

The	O
mutant	O
receptor	O
preserved	O
its	O
ability	O
to	O
bind	O
to	O
DNA	O
and	O
exerted	O
a	O
dominant-negative	O
effect	O
on	O
the	O
wild-type	O
hGRalpha	O
only	O
after	O
a	O
short	O
duration	O
of	O
exposure	O
to	O
the	O
ligand	O
.	O

CONCLUSIONS	O
:	O
The	O
mutant	O
receptor	O
hGRalphaF737L	B-ProteinMutation
causes	O
generalized	O
glucocorticoid	O
resistance	O
because	O
of	O
decreased	O
affinity	O
for	O
the	O
ligand	O
,	O
marked	O
delay	O
in	O
nuclear	O
translocation	O
,	O
and/or	O
abnormal	O
interaction	O
with	O
the	O
glucocorticoid	O
receptor-interacting	O
protein	O
1	O
coactivator	O
.	O

These	O
findings	O
confirm	O
the	O
importance	O
of	O
the	O
C	O
terminus	O
of	O
the	O
ligand-binding	O
domain	O
of	O
the	O
receptor	O
in	O
conferring	O
transactivational	O
activity	O
.	O

Common	O
germline	O
genetic	O
variation	O
in	O
antioxidant	O
defense	O
genes	O
and	O
survival	O
after	O
diagnosis	O
of	O
breast	O
cancer	O
.	O

PURPOSE	O
:	O
The	O
prognosis	O
of	O
breast	O
cancer	O
varies	O
considerably	O
among	O
individuals	O
,	O
and	O
inherited	O
genetic	O
factors	O
may	O
help	O
explain	O
this	O
variability	O
.	O

Of	O
particular	O
interest	O
are	O
genes	O
involved	O
in	O
defense	O
against	O
reactive	O
oxygen	O
species	O
(ROS)	O
because	O
ROS	O
are	O
thought	O
to	O
cause	O
DNA	O
damage	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
examined	O
associations	O
between	O
54	O
polymorphisms	O
that	O
tag	O
the	O
known	O
common	O
variants	O
(	O
minor	O
allele	O
frequency	O
>	O
0.05	O
)	O
in	O
10	O
genes	O
involved	O
in	O
oxidative	O
damage	O
repair	O
(	O
CAT	O
,	O
SOD1	O
,	O
SOD2	O
,	O
GPX1	O
,	O
GPX4	O
,	O
GSR	O
,	O
TXN	O
,	O
TXN2	O
,	O
TXNRD1	O
,	O
and	O
TXNRD2	O
)	O
and	O
survival	O
in	O
4,470	O
women	O
with	O
breast	O
cancer	O
.	O

RESULTS	O
:	O
Two	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
GPX4	O
(	O
rs713041	B-SNP
and	O
rs757229	B-SNP
)	O
were	O
associated	O
with	O
all-cause	O
mortality	O
even	O
after	O
adjusting	O
for	O
multiple	O
hypothesis	O
testing	O
(	O
adjusted	O
P	O
=	O
.0041	O
and	O
P	O
=	O
.0035	O
)	O
.	O

These	O
SNPs	O
are	O
correlated	O
with	O
each	O
other	O
(	O
r2	O
=	O
0.61	O
)	O
.	O

GPX4	O
rs713041	B-SNP
is	O
located	O
near	O
the	O
selenocysteine	O
insertion	O
sequence	O
element	O
in	O
the	O
GPX4	O
3'	O
untranslated	O
region	O
,	O
and	O
the	O
rare	O
allele	O
of	O
this	O
SNP	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O
,	O
with	O
a	O
hazard	O
ratio	O
of	O
1.27	O
per	O
rare	O
allele	O
carried	O
(	O
95%	O
CI	O
,	O
1.13	O
to	O
11.43	O
)	O
.	O

This	O
effect	O
was	O
not	O
attenuated	O
after	O
adjusting	O
for	O
tumor	O
stage	O
,	O
grade	O
,	O
or	O
estrogen	O
receptor	O
status	O
.	O

We	O
found	O
that	O
the	O
common	O
allele	O
is	O
preferentially	O
expressed	O
in	O
normal	O
lymphocytes	O
,	O
normal	O
breast	O
,	O
and	O
breast	O
tumors	O
compared	O
with	O
the	O
rare	O
allele	O
,	O
but	O
there	O
were	O
no	O
differences	O
in	O
total	O
levels	O
of	O
GPX4	O
mRNA	O
across	O
genotypes	O
.	O

CONCLUSION	O
:	O
These	O
data	O
provide	O
strong	O
support	O
for	O
the	O
hypothesis	O
that	O
common	O
variation	O
in	O
GPX4	O
is	O
associated	O
with	O
prognosis	O
after	O
a	O
diagnosis	O
of	O
breast	O
cancer	O
.	O

Manganese	O
superoxide	O
dismutase	O
(Mn-SOD)	O
gene	O
polymorphisms	O
in	O
urolithiasis	O
.	O

Polymorphism	O
in	O
manganese	O
superoxide	O
dismutase	O
gene	O
(Mn-SOD)	O
is	O
a	O
new	O
approach	O
to	O
identify	O
its	O
probable	O
association	O
with	O
urolithiasis	O
.	O

Oxidative	O
stress	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
stone	O
formation	O
in	O
the	O
renal	O
system	O
.	O

MnSOD	O
is	O
one	O
of	O
the	O
primary	O
enzymes	O
that	O
directly	O
scavenges	O
potential	O
harmful	O
oxidizing	O
species	O
.	O

A	O
valine	O
(Val)	O
to	O
alanine	O
(Ala)	O
substitution	O
at	O
amino	O
acid	O
16	O
,	O
occurring	O
in	O
the	O
mitochondrial	O
targeting	O
sequence	O
of	O
the	O
MnSOD	O
gene	O
,	O
has	O
been	O
associated	O
with	O
an	O
increase	O
in	O
urolithiasis	O
risk	O
.	O

This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
association	O
of	O
MnSOD	O
gene	O
polymorphism	O
with	O
the	O
risk	O
of	O
urolithiasis	O
.	O

We	O
investigated	O
the	O
MnSOD	O
in	O
66	O
stone-forming	O
adults	O
and	O
72	O
healthy	O
volunteers	O
.	O

DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
and	O
genotyping	O
was	O
performed	O
with	O
PCR-based	O
methods	O
.	O

Then	O
PCR	O
products	O
were	O
cut	O
by	O
BsaW1	O
.	O

Products	O
were	O
run	O
on	O
3%	O
agarose	O
gel	O
,	O
246	O
bp	O
regions	O
were	O
1-Ala-9	O
,	O
164	O
and	O
82	O
bp	O
products	O
were	O
determined	O
as	O
2	O
Val-9	O
.	O

Chi-square	O
test	O
was	O
used	O
for	O
comparison	O
between	O
patients	O
and	O
controls	O
.	O

In	O
the	O
control	O
group	O
the	O
homozygote	O
Ala	O
allele	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
patient	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
distribution	O
of	O
Ala/Val	O
and	O
homozygote	O
Val	O
alleles	O
in	O
the	O
patient	O
group	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

MnSOD	O
genotype	O
determination	O
may	O
provide	O
a	O
tool	O
to	O
identify	O
individuals	O
who	O
are	O
at	O
risk	O
of	O
urolithiasis	O
.	O

This	O
experiment	O
also	O
provides	O
data	O
about	O
antioxidant	O
status	O
and	O
stone	O
formation	O
.	O

A	O
novel	O
"pearl	O
box"	O
cataract	O
associated	O
with	O
a	O
mutation	O
in	O
the	O
connexin	O
46	O
(GJA3)	O
gene	O
.	O

PURPOSE	O
:	O
To	O
undertake	O
mutation	O
screening	O
in	O
the	O
connexin	O
46	O
(GJA3)	O
gene	O
in	O
seven	O
congenital	O
cataract	O
families	O
of	O
Indian	O
origin	O
.	O

METHODS	O
:	O
Seven	O
Indian	O
families	O
with	O
congenital	O
cataract	O
were	O
analyzed	O
by	O
detailed	O
family	O
history	O
and	O
clinical	O
evaluation	O
.	O

Each	O
family	O
had	O
two	O
to	O
five	O
affected	O
members	O
.	O

Mutation	O
screening	O
was	O
carried	O
out	O
in	O
the	O
candidate	O
gene	O
,	O
connexin	O
46	O
(GJA3)	O
,	O
using	O
bidirectional	O
sequencing	O
of	O
amplified	O
products	O
.	O

Segregation	O
of	O
the	O
observed	O
change	O
with	O
the	O
disease	O
phenotype	O
was	O
further	O
tested	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
.	O

RESULTS	O
:	O
Sequencing	O
of	O
the	O
coding	O
region	O
of	O
GJA3	O
showed	O
the	O
presence	O
of	O
a	O
novel	O
,	O
heterozygous	O
C260T	B-DNAMutation
change	O
in	O
one	O
family	O
(CC-472)	O
who	O
had	O
two	O
affected	O
members	O
.	O

The	O
cataract	O
phenotype	O
gave	O
the	O
appearance	O
like	O
a	O
"pearl	O
box"	O
in	O
these	O
two	O
affected	O
individuals	O
of	O
this	O
family	O
.	O

The	O
observed	O
C260T	B-DNAMutation
substitution	O
created	O
a	O
novel	O
restriction	O
enzyme	O
site	O
for	O
NlaIII	O
and	O
resulted	O
in	O
substitution	O
of	O
highly	O
conserved	O
threonine	O
at	O
position	O
87	O
by	O
methionine	O
T87M	B-ProteinMutation
.	O

NlaIII	O
restriction	O
digestion	O
analysis	O
revealed	O
this	O
nucleotide	O
change	O
was	O
not	O
in	O
unaffected	O
members	O
of	O
this	O
family	O
or	O
in	O
100	O
unrelated	O
control	O
subjects	O
(	O
200	O
chromosomes	O
)	O
with	O
the	O
same	O
ethnic	O
background	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
a	O
novel	O
mutation	O
identified	O
in	O
the	O
second	O
transmembrane	O
domain	O
of	O
the	O
connexin	O
46	O
.	O

These	O
findings	O
thus	O
expand	O
the	O
mutation	O
spectrum	O
of	O
the	O
GJA3	O
in	O
association	O
with	O
congenital	O
cataract	O
.	O

Mutations	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
modulate	O
seroreactivity	O
to	O
microbial	O
antigens	O
in	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
A	O
number	O
of	O
antibodies	O
against	O
microbial	O
epitopes	O
or	O
self-antigens	O
have	O
been	O
associated	O
with	O
Crohn's	O
disease	O
.	O

The	O
development	O
of	O
antibodies	O
reflects	O
a	O
loss	O
of	O
tolerance	O
to	O
intestinal	O
bacteria	O
that	O
underlies	O
Crohn's	O
disease	O
,	O
resulting	O
in	O
an	O
exaggerated	O
adaptive	O
immune	O
response	O
to	O
these	O
bacteria	O
.	O

It	O
was	O
hypothesised	O
that	O
the	O
development	O
of	O
antimicrobial	O
antibodies	O
is	O
influenced	O
by	O
the	O
presence	O
of	O
genetic	O
variants	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
therefore	O
to	O
investigate	O
the	O
influence	O
of	O
mutations	O
in	O
these	O
innate	O
immune	O
receptor	O
genes	O
(	O
nucleotide	O
oligomerisation	O
domain	O
(NOD)	O
2/caspase	O
recruitment	O
domain	O
(CARD)	O
15	O
,	O
NOD1/CARD4	O
,	O
TUCAN/CARDINAL/CARD8	O
,	O
Toll-like	O
receptor	O
(TLR)	O
4	O
,	O
TLR2	O
,	O
TLR1	O
and	O
TLR6	O
)	O
on	O
the	O
development	O
of	O
antimicrobial	O
and	O
antiglycan	O
antibodies	O
in	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
.	O

Materials	O
and	O
METHODS	O
:	O
A	O
cohort	O
of	O
1163	O
unrelated	O
patients	O
with	O
IBD	O
(	O
874	O
Crohn's	O
disease	O
,	O
259	O
ulcerative	O
colitis	O
,	O
30	O
indeterminate	O
colitis	O
)	O
and	O
312	O
controls	O
were	O
analysed	O
for	O
anti-Saccharomyces	O
cerevisiae	O
antibodies	O
(gASCA)	O
IgG	O
,	O
anti-laminaribioside	O
antibodies	O
(ALCA)	O
IgG	O
,	O
anti-chitobioside	O
antibodies	O
(ACCA)	O
IgA	O
,	O
anti-mannobioside	O
antibodies	O
(AMCA)	O
IgG	O
and	O
outer	O
membrane	O
porin	O
(Omp)	O
IgA	O
and	O
were	O
genotyped	O
for	O
variants	O
in	O
NOD2/CARD15	O
,	O
TUCAN/CARDINAL/CARD8	O
,	O
NOD1/CARD4	O
,	O
TLR4	O
,	O
TLR1	O
,	O
TLR2	O
and	O
TLR6	O
.	O

RESULTS	O
:	O
When	O
compared	O
with	O
Crohn's	O
disease	O
patients	O
without	O
CARD15	O
mutations	O
,	O
the	O
presence	O
of	O
at	O
least	O
one	O
CARD15	O
variant	O
in	O
Crohn's	O
disease	O
patients	O
more	O
frequently	O
led	O
to	O
gASCA	O
positivity	O
(	O
66.1%	O
versus	O
51.5%	O
,	O
p	O
<	O
0.0001	O
)	O
and	O
ALCA	O
positivity	O
(	O
43.3%	O
versus	O
34.9%	O
,	O
p	O
=	O
0.018	O
)	O
and	O
higher	O
gASCA	O
titers	O
(	O
85.7	O
versus	O
51.8	O
ELISA	O
units	O
,	O
p	O
<	O
0.0001	O
)	O
,	O
independent	O
of	O
ileal	O
involvement	O
.	O

A	O
gene	O
dosage	O
effect	O
,	O
with	O
increasing	O
gASCA	O
and	O
ALCA	O
positivity	O
for	O
patients	O
carrying	O
none	O
,	O
one	O
and	O
two	O
CARD15	O
variants	O
,	O
respectively	O
,	O
was	O
seen	O
for	O
both	O
markers	O
.	O

Similarly	O
,	O
Crohn's	O
disease	O
patients	O
carrying	O
NOD1/CARD4	O
indel	O
had	O
a	O
higher	O
prevalence	O
of	O
gASCA	O
antibodies	O
than	O
wild-type	O
patients	O
(	O
63.8%	O
versus	O
55.2%	O
,	O
p	O
=	O
0.014	O
)	O
,	O
also	O
with	O
a	O
gene	O
dosage	O
effect	O
.	O

An	O
opposite	O
effect	O
was	O
observed	O
for	O
the	O
TLR4	O
D299G	B-ProteinMutation
and	O
TLR2	O
P631H	B-ProteinMutation
variants	O
,	O
with	O
a	O
lower	O
prevalence	O
of	O
ACCA	O
antibodies	O
(	O
23.4%	O
versus	O
35%	O
,	O
p	O
=	O
0.013	O
)	O
and	O
Omp	O
antibodies	O
(	O
20.5%	O
versus	O
34.6%	O
,	O
p	O
=	O
0.009	O
)	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Variants	O
in	O
innate	O
immune	O
receptor	O
genes	O
were	O
found	O
to	O
influence	O
antibody	O
formation	O
against	O
microbial	O
epitopes	O
.	O

In	O
this	O
respect	O
,	O
it	O
is	O
intriguing	O
that	O
an	O
opposite	O
effect	O
of	O
CARD15	O
and	O
TLR4	O
variants	O
was	O
observed	O
.	O

These	O
findings	O
may	O
contribute	O
to	O
an	O
understanding	O
of	O
the	O
aetiology	O
of	O
the	O
seroreactivity	O
observed	O
in	O
IBD	O
.	O

Tenomodulin	O
is	O
associated	O
with	O
obesity	O
and	O
diabetes	O
risk	O
:	O
the	O
Finnish	O
diabetes	O
prevention	O
study	O
.	O

We	O
recently	O
showed	O
that	O
long-term	O
weight	O
reduction	O
changes	O
the	O
gene	O
expression	O
profile	O
of	O
adipose	O
tissue	O
in	O
overweight	O
individuals	O
with	O
impaired	O
glucose	O
tolerance	O
(IGT)	O
.	O

One	O
of	O
the	O
responding	O
genes	O
was	O
X-chromosomal	O
tenomodulin	O
(TNMD)	O
,	O
a	O
putative	O
angiogenesis	O
inhibitor	O
.	O

Our	O
aim	O
was	O
to	O
study	O
the	O
associations	O
of	O
individual	O
single	O
nucleotide	O
polymorphisms	O
and	O
haplotypes	O
with	O
adiposity	O
,	O
glucose	O
metabolism	O
,	O
and	O
the	O
risk	O
of	O
type	O
2	O
diabetes	O
(T2D)	O
.	O

Seven	O
single	O
nucleotide	O
polymorphisms	O
from	O
two	O
different	O
haploblocks	O
were	O
genotyped	O
from	O
507	O
participants	O
of	O
the	O
Finnish	O
Diabetes	O
Prevention	O
Study	O
(DPS)	O
.	O

Sex-specific	O
genotype	O
effects	O
were	O
observed	O
.	O

Three	O
markers	O
of	O
haploblock	O
1	O
were	O
associated	O
with	O
features	O
of	O
adiposity	O
in	O
women	O
(	O
rs5966709	B-SNP
,	O
rs4828037	B-SNP
)	O
and	O
men	O
rs11798018	B-SNP
.	O

Markers	O
rs2073163	B-SNP
and	O
rs1155794	B-SNP
from	O
haploblock	O
2	O
were	O
associated	O
with	O
2-hour	O
plasma	O
glucose	O
levels	O
in	O
men	O
during	O
the	O
3-year	O
follow-up	O
.	O

The	O
same	O
two	O
markers	O
together	O
with	O
rs2073162	B-SNP
associated	O
with	O
the	O
conversion	O
of	O
IGT	O
to	O
T2D	O
in	O
men	O
.	O

The	O
risk	O
of	O
developing	O
T2D	O
was	O
approximately	O
2-fold	O
in	O
individuals	O
with	O
genotypes	O
associated	O
with	O
higher	O
2-hour	O
plasma	O
glucose	O
levels	O
;	O
the	O
hazard	O
ratios	O
were	O
2.192	O
(	O
p	O
=	O
0.025	O
)	O
for	O
rs2073162	B-SNP
-A	O
,	O
2.191	O
(	O
p	O
=	O
0.027	O
)	O
for	O
rs2073163	B-SNP
-C	O
,	O
and	O
1.998	O
(	O
p	O
=	O
0.054	O
)	O
for	O
rs1155974	B-SNP
-T	O
.	O

These	O
results	O
suggest	O
that	O
TNMD	O
polymorphisms	O
are	O
associated	O
with	O
adiposity	O
and	O
also	O
with	O
glucose	O
metabolism	O
and	O
conversion	O
from	O
IGT	O
to	O
T2D	O
in	O
men	O
.	O

Novel	O
mutations	O
in	O
the	O
ZEB1	O
gene	O
identified	O
in	O
Czech	O
and	O
British	O
patients	O
with	O
posterior	O
polymorphous	O
corneal	O
dystrophy	O
.	O

We	O
describe	O
the	O
search	O
for	O
mutations	O
in	O
six	O
unrelated	O
Czech	O
and	O
four	O
unrelated	O
British	O
families	O
with	O
posterior	O
polymorphous	O
corneal	O
dystrophy	O
(PPCD)	O
;	O
a	O
relatively	O
rare	O
eye	O
disorder	O
.	O

Coding	O
exons	O
and	O
intron/exon	O
boundaries	O
of	O
all	O
three	O
genes	O
(	O
VSX1	O
,	O
COL8A2	O
,	O
and	O
ZEB1/TCF8	O
)	O
previously	O
reported	O
to	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
this	O
disorder	O
were	O
screened	O
by	O
DNA	O
sequencing	O
.	O

Four	O
novel	O
pathogenic	O
mutations	O
were	O
identified	O
in	O
four	O
families	O
;	O
two	O
deletions	O
,	O
one	O
nonsense	O
,	O
and	O
one	O
duplication	O
within	O
exon	O
7	O
in	O
the	O
ZEB1	O
gene	O
located	O
at	O
10p11.2	O
.	O

We	O
also	O
genotyped	O
the	O
Czech	O
patients	O
to	O
test	O
for	O
a	O
founder	O
haplotype	O
and	O
lack	O
of	O
disease	O
segregation	O
with	O
the	O
20p11.2	O
locus	O
we	O
previously	O
described	O
.	O

Although	O
a	O
systematic	O
clinical	O
examination	O
was	O
not	O
performed	O
,	O
our	O
investigation	O
does	O
not	O
support	O
an	O
association	O
between	O
ZEB1	O
changes	O
and	O
self	O
reported	O
non-ocular	O
anomalies	O
.	O

In	O
the	O
remaining	O
six	O
families	O
no	O
disease	O
causing	O
mutations	O
were	O
identified	O
thereby	O
indicating	O
that	O
as	O
yet	O
unidentified	O
gene(s)	O
are	O
likely	O
to	O
be	O
responsible	O
for	O
PPCD	O
.	O

3'	O
Mutation	O
of	O
the	O
APC	O
gene	O
and	O
family	O
history	O
of	O
FAP	O
in	O
a	O
patient	O
with	O
apparently	O
sporadic	O
desmoid	O
tumors	O
.	O

Desmoid	O
tumors	O
may	O
occur	O
sporadically	O
or	O
as	O
part	O
of	O
the	O
extraintestinal	O
manifestations	O
of	O
familial	O
adenomatous	O
polyposis	O
.	O

Different	O
phenotypes	O
have	O
been	O
described	O
and	O
some	O
genotype-phenotype	O
correlations	O
have	O
been	O
raised	O
,	O
associated	O
with	O
different	O
sites	O
of	O
germline	O
mutations	O
in	O
the	O
adenomatous	O
polyposis	O
coli	O
(APC)	O
gene	O
.	O

We	O
report	O
on	O
a	O
42-year-old	O
woman	O
ascertained	O
for	O
a	O
large	O
desmoid	O
tumor	O
of	O
the	O
anterior	O
chest	O
wall	O
with	O
pleural	O
involvement	O
,	O
which	O
persistently	O
recurred	O
despite	O
a	O
decade	O
of	O
treatment	O
including	O
hormone	O
therapy	O
,	O
chemotherapy	O
,	O
and	O
surgery	O
.	O

Spontaneous	O
disappearance	O
of	O
the	O
tumor	O
was	O
later	O
noted	O
after	O
1	O
year	O
without	O
any	O
treatment	O
and	O
confirmed	O
after	O
4	O
years	O
of	O
regular	O
follow-up	O
.	O

Repeated	O
colonoscopies	O
were	O
normal	O
in	O
the	O
proband	O
and	O
DNA	O
sequencing	O
showed	O
a	O
frameshift	O
mutation	O
due	O
to	O
a	O
single	O
adenosine	O
deletion	O
at	O
position	O
5772	O
(	O
codon	O
1924	O
)	O
.	O

This	O
mutation	O
,	O
located	O
in	O
the	O
exon	O
15	O
at	O
the	O
3'	O
end	O
of	O
the	O
APC	O
gene	O
,	O
leads	O
to	O
an	O
unusual	O
and	O
late	O
onset	O
phenotype	O
.	O

The	O
pedigree	O
revealed	O
other	O
isolated	O
or	O
familial	O
adenomatous	O
polyposis-associated	O
cases	O
of	O
desmoid	O
tumors	O
.	O

This	O
family	O
report	O
shows	O
that	O
a	O
molecular	O
analysis	O
of	O
the	O
APC	O
gene	O
should	O
be	O
performed	O
in	O
familial	O
desmoid	O
tumors	O
for	O
accurate	O
genetic	O
counseling	O
and	O
follow-up	O
.	O

Atypical	O
Rothmund-Thomson	O
syndrome	O
in	O
a	O
patient	O
with	O
compound	O
heterozygous	O
mutations	O
in	O
RECQL4	O
gene	O
and	O
phenotypic	O
features	O
in	O
RECQL4	O
syndromes	O
.	O

We	O
describe	O
the	O
natural	O
history	O
of	O
the	O
RTSII	O
phenotype	O
in	O
a	O
7-year-old	O
boy	O
who	O
developed	O
intrauterine	O
and	O
postnatal	O
growth	O
retardation	O
,	O
failure	O
to	O
thrive	O
and	O
persisting	O
diarrhoea	O
.	O

The	O
growth	O
hormone	O
stimulation	O
test	O
identified	O
an	O
isolated	O
growth	O
hormone	O
deficiency	O
.	O

Since	O
infancy	O
,	O
the	O
patient	O
manifested	O
skin	O
lesions	O
characterized	O
by	O
a	O
very	O
mild	O
poikilodermic-like	O
appearance	O
on	O
the	O
cheeks	O
only	O
,	O
widespread	O
caf	O
	O
-au-lait	O
spots	O
and	O
the	O
absence	O
of	O
eyebrows	O
and	O
eyelashes	O
.	O

There	O
was	O
no	O
cataract	O
.	O

Orthopaedic	O
and	O
radiologic	O
work-up	O
identified	O
the	O
absence	O
of	O
thumb	O
anomaly	O
and	O
radial	O
head	O
luxation	O
and	O
patellar	O
hypoplasia	O
.	O

Neurologic	O
,	O
cognitive	O
milestones	O
and	O
intelligence	O
were	O
normal	O
.	O

The	O
cytogenetic	O
work-up	O
did	O
not	O
show	O
any	O
anomaly	O
.	O

Based	O
on	O
this	O
clinical	O
presentation	O
,	O
we	O
carried	O
out	O
a	O
sequencing	O
analysis	O
of	O
the	O
RECQL4	O
gene	O
,	O
which	O
is	O
responsible	O
for	O
Rothmund-Thomson	O
,	O
RAPADILINO	O
and	O
Baller-Gerold	O
syndromes	O
and	O
found	O
a	O
splice	O
site	O
mutation	O
IVS10-1G>A	B-DNAMutation
and	O
a	O
nucleotide	O
substitution	O
in	O
exon	O
12	O
L638P	B-ProteinMutation
.	O

The	O
mother	O
was	O
identified	O
as	O
a	O
carrier	O
for	O
the	O
substitution	O
in	O
exon	O
12	O
and	O
the	O
father	O
for	O
the	O
splice	O
site	O
mutation	O
,	O
respectively	O
.	O

An	O
analysis	O
of	O
the	O
transcripts	O
focused	O
on	O
the	O
RECQL4	O
helicase	O
domain	O
:	O
in	O
the	O
proband	O
only	O
those	O
generated	O
from	O
the	O
maternal	O
L638	O
allele	O
were	O
present	O
.	O

This	O
case	O
report	O
emphasizes	O
the	O
clinical	O
overlap	O
between	O
RAPADILINO	O
and	O
Rothmund-Thomson	O
syndromes	O
within	O
a	O
continuum	O
phenotypic	O
spectrum	O
.	O

The	O
distinctive	O
set	O
of	O
clinical	O
signs	O
displayed	O
by	O
the	O
patient	O
may	O
be	O
accounted	O
for	O
by	O
his	O
unique	O
combination	O
of	O
two	O
different	O
RECQL4	O
mutations	O
.	O

The	O
molecular	O
findings	O
provide	O
information	O
that	O
enhances	O
our	O
comprehension	O
of	O
genotype-phenotype	O
correlations	O
in	O
RECQL4	O
diseases	O
,	O
enables	O
a	O
more	O
precise	O
genetic	O
counseling	O
to	O
the	O
parents	O
and	O
facilitates	O
a	O
more	O
appropriate	O
long-term	O
follow-up	O
to	O
the	O
affected	O
child	O
.	O

Genome-wide	O
analysis	O
of	O
neuroblastomas	O
using	O
high-density	O
single	O
nucleotide	O
polymorphism	O
arrays	O
.	O

BACKGROUND	O
:	O
Neuroblastomas	O
are	O
characterized	O
by	O
chromosomal	O
alterations	O
with	O
biological	O
and	O
clinical	O
significance	O
.	O

We	O
analyzed	O
paired	O
blood	O
and	O
primary	O
tumor	O
samples	O
from	O
22	O
children	O
with	O
high-risk	O
neuroblastoma	O
for	O
loss	O
of	O
heterozygosity	O
(LOH)	O
and	O
DNA	O
copy	O
number	O
change	O
using	O
the	O
Affymetrix	O
10K	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
array	O
.	O

FINDINGS	O
:	O
Multiple	O
areas	O
of	O
LOH	O
and	O
copy	O
number	O
gain	O
were	O
seen	O
.	O

The	O
most	O
commonly	O
observed	O
area	O
of	O
LOH	O
was	O
on	O
chromosome	O
arm	O
11q	O
(	O
15/22	O
samples	O
;	O
68%	O
)	O
.	O

Chromosome	O
11q	O
LOH	O
was	O
highly	O
associated	O
with	O
occurrence	O
of	O
chromosome	O
3p	O
LOH	O
:	O
9	O
of	O
the	O
15	O
samples	O
with	O
11q	O
LOH	O
had	O
concomitant	O
3p	O
LOH	O
(	O
P	O
=	O
0.016	O
)	O
.	O

Chromosome	O
1p	O
LOH	O
was	O
seen	O
in	O
one-third	O
of	O
cases	O
.	O

LOH	O
events	O
on	O
chromosomes	O
11q	O
and	O
1p	O
were	O
generally	O
accompanied	O
by	O
copy	O
number	O
loss	O
,	O
indicating	O
hemizygous	O
deletion	O
within	O
these	O
regions	O
.	O

The	O
one	O
exception	O
was	O
on	O
chromosome	O
11p	O
,	O
where	O
LOH	O
in	O
all	O
four	O
cases	O
was	O
accompanied	O
by	O
normal	O
copy	O
number	O
or	O
diploidy	O
,	O
implying	O
uniparental	O
disomy	O
.	O

Gain	O
of	O
copy	O
number	O
was	O
most	O
frequently	O
observed	O
on	O
chromosome	O
arm	O
17q	O
(	O
21/22	O
samples	O
;	O
95%	O
)	O
and	O
was	O
associated	O
with	O
allelic	O
imbalance	O
in	O
six	O
samples	O
.	O

Amplification	O
of	O
MYCN	O
was	O
also	O
noted	O
,	O
and	O
also	O
amplification	O
of	O
a	O
second	O
gene	O
,	O
ALK	O
,	O
in	O
a	O
single	O
case	O
.	O

CONCLUSIONS	O
:	O
This	O
analysis	O
demonstrates	O
the	O
power	O
of	O
SNP	O
arrays	O
for	O
high-resolution	O
determination	O
of	O
LOH	O
and	O
DNA	O
copy	O
number	O
change	O
in	O
neuroblastoma	O
,	O
a	O
tumor	O
in	O
which	O
specific	O
allelic	O
changes	O
drive	O
clinical	O
outcome	O
and	O
selection	O
of	O
therapy	O
.	O

Epstein	O
Barr	O
virus	O
genotypes	O
and	O
LMP-1	O
variants	O
in	O
HIV-infected	O
patients	O
.	O

Two	O
Epstein	O
Barr	O
virus	O
(EBV)	O
genotypes	O
:	O
EBV-1	O
and	O
EBV-2	O
have	O
been	O
described	O
.	O

A	O
30-bp	O
deletion	O
in	O
latent	O
membrane	O
protein-1	O
gene	O
(del-LMP-1)	O
has	O
been	O
identified	O
in	O
various	O
pathologies	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
EBV	O
genotypes	O
and	O
30-bp	O
deletion	O
frequency	O
in	O
HIV-infected	O
patients	O
from	O
Argentina	O
.	O

The	O
study	O
was	O
performed	O
on	O
258	O
individuals	O
:	O
Cases	O
:	O
144	O
HIV-infected	O
patients	O
that	O
included	O
:	O
(a)	O
7	O
AIDS	O
patients	O
with	O
primary	O
central	O
nervous	O
system	O
lymphoma	O
(PCNSL)	O
,	O
(b)	O
62	O
AIDS	O
patients	O
,	O
and	O
(c)	O
75	O
asymptomatic	O
HIV-infected	O
patients	O
.	O

Controls	O
:	O
114	O
HIV-negative	O
individuals	O
.	O

EBV	O
genotypes	O
and	O
variants	O
in	O
LMP-1	O
gene	O
were	O
detected	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)-Southern	O
blot	O
on	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
brain	O
biopsies	O
.	O

In	O
PCNSL	O
,	O
the	O
presence	O
of	O
EBV	O
was	O
confirmed	O
by	O
EBER	O
RNA	O
in	O
situ	O
hybridization	O
,	O
and	O
DNA	O
sequencing	O
of	O
3'	O
end	O
LMP-l	O
gene	O
of	O
PCR	O
products	O
was	O
performed	O
.	O

In	O
HIV-infected	O
patients	O
,	O
EBV-1	O
was	O
detected	O
in	O
48.6%	O
,	O
EBV-2	O
in	O
18.8%	O
,	O
and	O
co-infection	O
with	O
both	O
genotypes	O
in	O
32.6%	O
.	O

In	O
control	O
group	O
,	O
EBV-1	O
was	O
present	O
in	O
74.3%	O
,	O
EBV-2	O
in	O
12.4%	O
,	O
and	O
co-infection	O
in	O
13.3%	O
.	O

Del-LMP-1	O
was	O
found	O
in	O
44.4%	O
of	O
HIV-infected	O
patients	O
samples	O
(	O
20.7%	O
alone	O
and	O
23.7%	O
co-infection	O
with	O
non-deleted	O
form	O
)	O
while	O
it	O
was	O
found	O
in	O
25.3%	O
(	O
6.3%	O
alone	O
and	O
19%	O
with	O
co-infection	O
)	O
in	O
HIV-negative	O
individuals	O
.	O

In	O
HIV-infected	O
patients	O
EBV-2	O
,	O
co-infection	O
and	O
30-bp	O
deletion	O
are	O
more	O
prevalent	O
than	O
in	O
control	O
group	O
.	O

In	O
all	O
,	O
PCNSL	O
brain	O
biopsies	O
samples	O
,	O
del-LMP-1	O
always	O
was	O
detected	O
with	O
EBV-2	O
,	O
but	O
more	O
cases	O
would	O
have	O
to	O
be	O
included	O
to	O
draw	O
definitive	O
conclusions	O
.	O

Retinoblastoma	O
in	O
India	O
:	O
microsatellite	O
analysis	O
and	O
its	O
application	O
in	O
genetic	O
counseling	O
OBJECTIVES	O
:	O
This	O
study	O
was	O
conducted	O
with	O
two	O
objectives	O
.	O

The	O
first	O
was	O
to	O
estimate	O
the	O
frequency	O
of	O
loss	O
of	O
heterozygosity	O
(LOH)	O
of	O
the	O
RB1	O
gene	O
as	O
a	O
mechanism	O
in	O
disease	O
causation	O
in	O
tumors	O
of	O
patients	O
from	O
India	O
.	O

The	O
second	O
objective	O
was	O
to	O
employ	O
RB1	O
molecular	O
deletion	O
and	O
microsatellite-based	O
linkage	O
analysis	O
as	O
laboratory	O
tools	O
,	O
while	O
counseling	O
families	O
with	O
a	O
history	O
of	O
retinoblastoma	O
(RB)	O
.	O

METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
tumors	O
of	O
54	O
RB	O
patients	O
and	O
their	O
relatives	O
.	O

Eight	O
fluorescent	O
microsatellite	O
markers	O
,	O
both	O
intragenic	O
and	O
flanking	O
the	O
RB1	O
gene	O
,	O
were	O
used	O
.	O

After	O
PCR	O
amplification	O
,	O
samples	O
were	O
run	O
on	O
an	O
ABI	O
PRISM	O
310	O
genetic	O
analyzer	O
for	O
LOH	O
,	O
deletion	O
detection	O
,	O
and	O
haplotype	O
generation	O
.	O

RESULTS	O
:	O
LOH	O
was	O
found	O
in	O
conjunction	O
with	O
tumor	O
formation	O
in	O
72.9%	O
of	O
RB	O
patients	O
(	O
39/54	O
patients	O
;	O
p=0.001	O
;	O
95%	O
CI	O
0.6028	O
,	O
0.8417	O
)	O
;	O
however	O
,	O
we	O
could	O
not	O
associate	O
various	O
other	O
clinical	O
parameters	O
of	O
RB	O
patients	O
with	O
the	O
presence	O
or	O
absence	O
of	O
RB1	O
LOH	O
.	O

Seven	O
germline	O
deletions	O
(	O
13%	O
of	O
RB	O
patients	O
)	O
were	O
identified	O
,	O
and	O
the	O
maternal	O
allele	O
was	O
more	O
frequently	O
lost	O
(p=0.01)	O
.	O

A	O
disease	O
co-segregating	O
haplotype	O
was	O
detected	O
in	O
two	O
hereditary	O
autosomal	O
dominant	O
cases	O
.	O

CONCLUSION	O
:	O
LOH	O
of	O
the	O
RB1	O
gene	O
could	O
play	O
an	O
important	O
role	O
in	O
tumor	O
formation	O
.	O

Large	O
deletions	O
involving	O
RB1	O
were	O
observed	O
,	O
and	O
a	O
disease	O
co-segregating	O
haplotype	O
was	O
used	O
for	O
indirect	O
genetic	O
testing	O
.	O

This	O
is	O
the	O
first	O
report	O
from	O
India	O
where	O
molecular	O
testing	O
has	O
been	O
applied	O
for	O
RB	O
families	O
in	O
conjunction	O
with	O
genetic	O
counseling	O
.	O

In	O
tertiary	O
ophthalmic	O
practice	O
in	O
India	O
,	O
there	O
is	O
an	O
emerging	O
trend	O
towards	O
the	O
application	O
of	O
genetical	O
knowledge	O
in	O
clinical	O
practice	O
.	O

The	O
G51S	B-ProteinMutation
purine	O
nucleoside	O
phosphorylase	O
polymorphism	O
is	O
associated	O
with	O
cognitive	O
decline	O
in	O
Alzheimer's	O
disease	O
patients	O
.	O

Alzheimer's	O
disease	O
(AD)	O
is	O
a	O
polygenic	O
and	O
multifactorial	O
complex	O
disease	O
,	O
whose	O
etiopathology	O
is	O
still	O
unclear	O
,	O
however	O
several	O
genetic	O
factors	O
have	O
shown	O
to	O
increase	O
the	O
risk	O
of	O
developing	O
the	O
disease	O
.	O

Purine	O
nucleotides	O
and	O
nucleosides	O
play	O
an	O
important	O
role	O
in	O
the	O
brain	O
.	O

Besides	O
their	O
role	O
in	O
neurotransmission	O
and	O
neuromodulation	O
,	O
they	O
are	O
involved	O
in	O
trophic	O
factor	O
release	O
,	O
apoptosis	O
,	O
and	O
inflammatory	O
responses	O
.	O

These	O
mediators	O
may	O
also	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
control	O
of	O
neurodegenerative	O
processes	O
associated	O
with	O
AD	O
.	O

In	O
this	O
report	O
the	O
distribution	O
of	O
the	O
exonic	O
G/A	B-DNAMutation
single	O
nucleotide	O
polymorphism	O
(SNP)	O
in	O
purine	O
nucleoside	O
phosphorylase	O
(PNP)	O
gene	O
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
serine	O
to	O
glycine	O
at	O
position	O
51	O
G51S	B-ProteinMutation
,	O
was	O
investigated	O
in	O
a	O
large	O
population	O
of	O
AD	O
patients	O
(n=321)	O
and	O
non-demented	O
control	O
(n=208)	O
.	O

The	O
PNP	O
polymorphism	O
distribution	O
was	O
not	O
different	O
between	O
patients	O
and	O
controls	O
.	O

The	O
polymorphism	O
distribution	O
was	O
also	O
analyzed	O
in	O
AD	O
patients	O
stratified	O
according	O
to	O
differential	O
progressive	O
rate	O
of	O
cognitive	O
decline	O
during	O
a	O
2-year	O
follow-up	O
.	O

An	O
increased	O
representation	O
of	O
the	O
PNP	O
AA	O
genotype	O
was	O
observed	O
in	O
AD	O
patients	O
with	O
fast	O
cognitive	O
deterioration	O
in	O
comparison	O
with	O
that	O
from	O
patients	O
with	O
slow	O
deterioration	O
rate	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
G51S	B-ProteinMutation
PNP	O
polymorphism	O
is	O
associated	O
with	O
a	O
faster	O
rate	O
of	O
cognitive	O
decline	O
in	O
AD	O
patients	O
,	O
highlighting	O
the	O
important	O
role	O
of	O
purine	O
metabolism	O
in	O
the	O
progression	O
of	O
this	O
neurodegenerative	O
disorder	O
.	O

Two	O
sites	O
in	O
the	O
MAPT	O
region	O
confer	O
genetic	O
risk	O
for	O
Guam	O
ALS/PDC	O
and	O
dementia	O
.	O

Unusual	O
forms	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
(ALS-G)	O
,	O
Parkinsonism	O
dementia	O
complex	O
(PDC-G)	O
and	O
Guam	O
dementia	O
(GD)	O
are	O
found	O
in	O
Chamorros	O
,	O
the	O
indigenous	O
people	O
of	O
Guam	O
.	O

Neurofibrillary	O
tangles	O
composed	O
of	O
hyperphosphorylated	O
tau	O
are	O
a	O
neuropathologic	O
feature	O
of	O
these	O
closely	O
related	O
disorders	O
.	O

To	O
determine	O
if	O
variation	O
in	O
the	O
gene	O
that	O
encodes	O
microtubule-associated	O
protein	O
tau	O
gene	O
(MAPT)	O
contributes	O
to	O
risk	O
for	O
these	O
disorders	O
,	O
we	O
genotyped	O
nine	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
sites	O
and	O
one	O
insertion/deletion	O
in	O
the	O
5'	O
end	O
of	O
MAPT	O
in	O
54	O
ALS-G	O
,	O
135	O
PDC-G	O
,	O
153	O
GD	O
and	O
258	O
control	O
subjects	O
,	O
all	O
of	O
whom	O
are	O
Chamorros	O
.	O

Variation	O
at	O
three	O
SNPs	O
(	O
sites	O
2	O
,	O
6	O
and	O
9	O
)	O
influenced	O
risk	O
for	O
ALS-G	O
,	O
PDC-G	O
and	O
GD	O
.	O

SNP2	O
acts	O
through	O
a	O
dominant	O
mechanism	O
and	O
is	O
independent	O
of	O
the	O
risk	O
conferred	O
by	O
SNPs	O
6	O
and	O
9	O
,	O
the	O
latter	O
two	O
acting	O
by	O
a	O
recessive	O
mechanism	O
.	O

Persons	O
with	O
the	O
high-risk	O
SNP6	O
and	O
SNP9	O
AC/AC	O
diplotype	O
had	O
an	O
increased	O
risk	O
of	O
3-fold	O
[	O
95%	O
confidence	O
interval	O
(	O
CI)=1.10-8.25	O
]	O
for	O
GD	O
,	O
4-fold	O
(	O
95%	O
CI=1.40-11.64	O
)	O
for	O
PDC-G	O
and	O
6-fold	O
(	O
95%	O
CI=1.44-32.14	O
)	O
for	O
ALS-G	O
,	O
compared	O
to	O
persons	O
with	O
other	O
diplotypes	O
after	O
adjusting	O
for	O
SNP2	O
.	O

Carriers	O
of	O
the	O
SNP2	O
G	O
allele	O
had	O
an	O
increased	O
risk	O
of	O
1.6-fold	O
(	O
95%	O
CI=1.00-2.62	O
)	O
for	O
GD	O
,	O
2-fold	O
(	O
95%	O
CI=1.28-3.66	O
)	O
for	O
PDC-G	O
,	O
and	O
1.5-fold	O
(	O
95%	O
CI=0.74-3.00	O
)	O
for	O
ALS-G	O
,	O
compared	O
to	O
non-carriers	O
after	O
adjusting	O
for	O
SNPs	O
6	O
and	O
9	O
.	O

Others	O
have	O
shown	O
that	O
SNP6	O
is	O
also	O
associated	O
with	O
risk	O
for	O
progressive	O
supranuclear	O
palsy	O
.	O

These	O
two	O
independent	O
cis-acting	O
sites	O
presumably	O
influence	O
risk	O
for	O
Guam	O
neuro-degenerative	O
disorders	O
by	O
regulating	O
MAPT	O
expression	O
.	O

A	O
novel	O
mutation	O
E333D	B-ProteinMutation
in	O
the	O
thyroid	O
hormone	O
beta	O
receptor	O
causing	O
resistance	O
to	O
thyroid	O
hormone	O
syndrome	O
.	O

Resistance	O
to	O
thyroid	O
hormone	O
(RTH)	O
is	O
an	O
inherited	O
syndrome	O
characterized	O
by	O
elevated	O
serum	O
thyroid	O
hormones	O
(TH)	O
,	O
failure	O
to	O
suppress	O
pituitary	O
thyroid	O
stimulating	O
hormone	O
(TSH)	O
secretion	O
,	O
and	O
variable	O
peripheral	O
tissue	O
responsiveness	O
to	O
TH	O
.	O

The	O
disorder	O
is	O
associated	O
with	O
diverse	O
mutations	O
in	O
the	O
thyroid	O
hormone	O
beta	O
receptor	O
(TRbeta)	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
natural	O
RTH	O
mutation	O
E333D	B-ProteinMutation
located	O
in	O
the	O
large	O
carboxy-terminal	O
ligand	O
binding	O
domain	O
of	O
TRbeta	O
.	O

The	O
mutation	O
was	O
identified	O
in	O
a	O
22-year-old	O
French	O
woman	O
coming	O
to	O
medical	O
attention	O
because	O
of	O
an	O
increasing	O
overweight	O
.	O

Biochemical	O
tests	O
showed	O
elevated	O
free	O
thyroxine	O
(	O
T4	O
:	O
20.8	O
pg/ml	O
(	O
normal	O
,	O
8.5-18)	O
)	O
and	O
triiodothyronine	O
(	O
T3	O
:	O
5.7	O
pg/ml	O
(	O
normal	O
,	O
1.4-4)	O
)	O
in	O
the	O
serum	O
,	O
together	O
with	O
an	O
inappropriately	O
nonsuppressed	O
TSH	O
level	O
of	O
4.7	O
mU/ml	O
(	O
normal	O
,	O
0.4-4	O
)	O
.	O

Her	O
father	O
and	O
her	O
brother's	O
serum	O
tests	O
also	O
showed	O
biochemical	O
abnormalities	O
consistent	O
with	O
RTH	O
.	O

Direct	O
sequencing	O
of	O
the	O
TRbeta	O
gene	O
revealed	O
a	O
heterozygous	O
transition	O
1284A>C	B-DNAMutation
in	O
exon	O
9	O
resulting	O
in	O
substitution	O
of	O
glutamic	O
acid	O
333	O
by	O
aspartic	O
acid	O
residue	O
E333D	B-ProteinMutation
.	O

Further	O
functional	O
analyses	O
of	O
the	O
novel	O
TRbeta	O
mutant	O
were	O
conducted	O
.	O

We	O
found	O
that	O
the	O
E333D	B-ProteinMutation
mutation	O
neither	O
significantly	O
affected	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
T3	O
nor	O
modified	O
heterodimer	O
formation	O
with	O
retinoid	O
X	O
receptor	O
(RXR)	O
when	O
bound	O
to	O
DNA	O
.	O

However	O
,	O
in	O
transient	O
transfection	O
assays	O
,	O
the	O
E333D	B-ProteinMutation
TRbeta	O
mutant	O
exhibited	O
impaired	O
transcriptional	O
regulation	O
on	O
two	O
distinct	O
positively	O
regulated	O
thyroid	O
response	O
elements	O
(	O
F2-	O
and	O
DR4-TREs	O
)	O
as	O
well	O
as	O
on	O
the	O
negatively	O
regulated	O
human	O
TSHalpha	O
promoter	O
.	O

Moreover	O
,	O
a	O
dominant	O
inhibition	O
of	O
the	O
wild-type	O
TRbeta	O
counterpart	O
transactivation	O
function	O
was	O
observed	O
on	O
both	O
a	O
positive	O
(F2-TRE)	O
and	O
a	O
negative	O
(TSHalpha)	O
promoter	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
E333D	B-ProteinMutation
TRbeta	O
mutation	O
is	O
responsible	O
for	O
the	O
RTH	O
phenotype	O
in	O
the	O
proposita's	O
family	O
.	O

Homozygous	O
deletion	O
related	O
to	O
Alu	O
repeats	O
in	O
RLBP1	O
causes	O
retinitis	O
punctata	O
albescens	O
.	O

PURPOSE	O
:	O
Retinitis	O
punctata	O
albescens	O
(RPA)	O
is	O
an	O
infrequently	O
occurring	O
form	O
of	O
autosomal	O
recessive	O
(	O
and	O
rarely	O
dominant	O
)	O
retinal	O
dystrophy	O
featuring	O
early-onset	O
severe	O
night	O
blindness	O
and	O
tiny	O
,	O
dotlike	O
,	O
white	O
deposits	O
in	O
the	O
fundus	O
.	O

RPA	O
is	O
associated	O
mostly	O
with	O
mutations	O
in	O
RLBP1	O
and	O
occasionally	O
in	O
RHO	O
,	O
RDS	O
,	O
and	O
RDH5	O
.	O

In	O
this	O
study	O
,	O
mutations	O
were	O
sought	O
in	O
RLBP1	O
,	O
which	O
encodes	O
the	O
retinol	O
binding	O
protein	O
CRALBP	O
in	O
patients	O
with	O
typical	O
RPA	O
.	O

METHODS	O
:	O
Clinical	O
investigation	O
included	O
funduscopy	O
,	O
visual	O
field	O
testing	O
,	O
electroretinogram	O
recording	O
,	O
and	O
adaptometry	O
.	O

The	O
7	O
coding	O
exons	O
(3-9)	O
of	O
RLBP1	O
and	O
the	O
15th	O
(last)	O
exon	O
of	O
ABDH2	O
were	O
PCR	O
amplified	O
and	O
sequenced	O
.	O

Long-distance	O
PCR	O
and	O
cloning	O
of	O
genomic	O
DNA	O
were	O
performed	O
to	O
characterize	O
the	O
deletion	O
.	O

RESULTS	O
:	O
The	O
study	O
involved	O
a	O
24-year-old	O
Moroccan	O
patient	O
with	O
typical	O
RPA	O
,	O
born	O
of	O
first-cousin	O
parents	O
.	O

He	O
carried	O
a	O
7.36-kb	O
homozygous	O
deletion	O
encompassing	O
the	O
last	O
3	O
exons	O
of	O
RLBP1	O
(	O
7	O
,	O
8	O
,	O
and	O
9	O
)	O
and	O
part	O
of	O
the	O
intergenic	O
region	O
between	O
RLBP1	O
and	O
ABHD2	O
,	O
which	O
lies	O
downstream	O
of	O
RLBP1	O
.	O

This	O
deletion	O
abolishes	O
the	O
retinal	O
binding	O
site	O
of	O
CRALBP	O
.	O

The	O
telomeric	O
breakpoint	O
of	O
the	O
deletion	O
(	O
in	O
RLBP1	O
intron	O
6	O
)	O
is	O
embedded	O
in	O
an	O
Alu	O
element	O
,	O
whereas	O
the	O
centromeric	O
breakpoint	O
(	O
in	O
the	O
intergenic	O
region	O
)	O
lies	O
between	O
two	O
Alu	O
elements	O
placed	O
in	O
the	O
opposite	O
orientation	O
.	O

CONCLUSIONS	O
:	O
Because	O
of	O
the	O
high	O
density	O
of	O
Alu	O
elements	O
in	O
RLBP1	O
,	O
a	O
systematic	O
search	O
should	O
be	O
made	O
for	O
deletions	O
in	O
this	O
gene	O
when	O
one	O
or	O
both	O
alleles	O
lack	O
point	O
mutations	O
,	O
in	O
the	O
case	O
of	O
RPA	O
or	O
flecked	O
retinal	O
dystrophy	O
.	O

Monocyte	O
chemotactic	O
protein-1	O
single	O
nucleotide	O
polymorphisms	O
do	O
not	O
confer	O
susceptibility	O
for	O
the	O
development	O
of	O
adult	O
onset	O
polymyositis/dermatomyositis	O
in	O
UK	O
Caucasians	O
.	O

OBJECTIVES	O
:	O
Polymyositis	O
(PM)	O
and	O
dermatomyositis	O
(DM)	O
form	O
part	O
of	O
the	O
idiopathic	O
inflammatory	O
myopathies	O
(IIMs)	O
.	O

The	O
chemokine	O
monocyte	O
chemotactic	O
protein-1	O
(MCP-1)	O
is	O
expressed	O
at	O
sites	O
of	O
the	O
T	O
cell	O
inflammatory	O
response	O
in	O
the	O
IIMs	O
.	O

We	O
thus	O
investigate	O
whether	O
genetic	O
markers	O
in	O
the	O
MCP-1	O
gene	O
confer	O
disease	O
susceptibility	O
for	O
the	O
development	O
of	O
PM	O
and	O
DM	O
.	O

METHODS	O
:	O
DNA	O
samples	O
were	O
analysed	O
from	O
a	O
group	O
of	O
195	O
UK	O
Caucasian	O
IIM	O
patients	O
,	O
comprising	O
103	O
PM	O
and	O
92	O
DM	O
.	O

Their	O
results	O
were	O
compared	O
with	O
those	O
of	O
162	O
ethnically	O
matched	O
controls	O
.	O

The	O
polymorphic	O
positions	O
of	O
three	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
one	O
insertion-deletion	O
sequence	O
within	O
regions	O
coding	O
for	O
MCP-1	O
were	O
tested	O
.	O

The	O
SNPs	O
examined	O
were	O
located	O
in	O
intron	O
1	O
(	O
rs2857657	B-SNP
,	O
C/G	B-DNAMutation
)	O
,	O
exon	O
2	O
(	O
rs4586	B-SNP
,	O
A/G	B-DNAMutation
)	O
and	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
rs13900	B-SNP
,	O
C/T	B-DNAMutation
)	O
.	O

The	O
insertion-deletion	O
sequence	O
was	O
located	O
in	O
intron	O
1	O
(	O
rs3917887	B-SNP
,	O
AGCTCCTCCTTCTC/-	B-DNAMutation
)	O
.	O

Each	O
SNP	O
was	O
tested	O
for	O
Hardy-Weinberg	O
equilibrium	O
and	O
allelic/genotypic	O
associations	O
.	O

Haplotype	O
frequencies	O
were	O
estimated	O
using	O
the	O
Expectation/Maximization	O
algorithm	O
.	O

RESULTS	O
:	O
There	O
was	O
strong	O
linkage	O
disequilibrium	O
present	O
between	O
three	O
out	O
of	O
these	O
four	O
markers	O
.	O

The	O
majority	O
of	O
controls	O
were	O
in	O
Hardy	O
Weinberg	O
equilibrium	O
.	O

No	O
allelic	O
,	O
genotypic	O
or	O
haplotypic	O
associations	O
were	O
detected	O
when	O
comparing	O
PM	O
or	O
DM	O
cases	O
to	O
controls	O
,	O
or	O
when	O
PM	O
and	O
DM	O
were	O
compared	O
with	O
each	O
other	O
.	O

CONCLUSIONS	O
:	O
Genetic	O
markers	O
in	O
the	O
MCP-1	O
gene	O
do	O
not	O
demonstrate	O
significant	O
genetic	O
associations	O
with	O
the	O
IIMs	O
,	O
and	O
do	O
not	O
discriminate	O
PM	O
from	O
DM	O
in	O
a	O
UK	O
Caucasian	O
population	O
.	O

Gene	O
polymorphisms	O
implicated	O
in	O
influencing	O
susceptibility	O
to	O
venous	O
and	O
arterial	O
thromboembolism	O
:	O
frequency	O
distribution	O
in	O
a	O
healthy	O
German	O
population	O
.	O

Evolvement	O
and	O
progression	O
of	O
cardiovascular	O
diseases	O
affecting	O
the	O
venous	O
and	O
arterial	O
system	O
are	O
influenced	O
by	O
a	O
multitude	O
of	O
environmental	O
and	O
hereditary	O
factors	O
.	O

Many	O
of	O
these	O
hereditary	O
factors	O
consist	O
of	O
defined	O
gene	O
polymorphisms	O
,	O
such	O
as	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
or	O
insertion-deletion	O
polymorphisms	O
,	O
which	O
directly	O
or	O
indirectly	O
affect	O
the	O
hemostatic	O
system	O
.	O

The	O
frequencies	O
of	O
individual	O
hemostatic	O
gene	O
polymorphisms	O
in	O
different	O
normal	O
populations	O
are	O
well	O
defined	O
.	O

However	O
,	O
descriptions	O
of	O
patterns	O
of	O
genetic	O
variability	O
of	O
a	O
larger	O
extent	O
of	O
different	O
factors	O
of	O
hereditary	O
hypercoagulability	O
in	O
single	O
populations	O
are	O
scarce	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
i	O
)	O
to	O
give	O
a	O
detailed	O
description	O
of	O
the	O
frequencies	O
of	O
factors	O
of	O
hereditary	O
thrombophilia	O
and	O
their	O
combinations	O
in	O
a	O
German	O
population	O
(	O
n	O
=	O
282	O
)	O
and	O
ii	O
)	O
to	O
compare	O
their	O
distributions	O
with	O
those	O
reported	O
for	O
other	O
regions	O
.	O

Variants	O
of	O
coagulation	O
factors	O
[	O
factor	O
V	O
1691G>A	B-DNAMutation
(	O
factor	O
V	O
Leiden	O
)	O
,	O
factor	O
V	O
4070A>G	B-DNAMutation
(	O
factor	O
V	O
HR2	O
haplotype	O
)	O
,	O
factor	O
VII	O
Arg353Gln	B-ProteinMutation
,	O
factor	O
XIII	O
Val34Leu	B-ProteinMutation
,	O
beta-fibrinogen	O
-455G>A	B-DNAMutation
,	O
prothrombin	O
20210G>A	B-DNAMutation
]	O
,	O
coagulation	O
inhibitors	O
[	O
tissue	O
factor	O
pathway	O
inhibitor	O
536C>T	B-DNAMutation
,	O
thrombomodulin	O
127G>A	B-DNAMutation
]	O
,	O
fibrinolytic	O
factors	O
[	O
angiotensin	O
converting	O
enzyme	O
intron	O
16	O
insertion/deletion	O
,	O
factor	O
VII-activating	O
protease	O
1601G>A	B-DNAMutation
(	O
FSAP	O
Marburg	O
I	O
)	O
,	O
plasminogen	O
activator	O
inhibitor	O
1-675	O
insertion/deletion	O
(5G/4G)	O
,	O
tissue	O
plasminogen	O
activator	O
intron	O
h	O
deletion/insertion	O
]	O
,	O
and	O
other	O
factors	O
implicated	O
in	O
influencing	O
susceptibility	O
to	O
thromboembolic	O
diseases	O
[	O
apolipoprotein	O
E2/E3/E4	O
,	O
glycoprotein	O
Ia	O
807C>T	B-DNAMutation
,	O
methylenetetrahydrofolate	O
reductase	O
677C>T	B-DNAMutation
]	O
were	O
included	O
.	O

The	O
distribution	O
of	O
glycoprotein	O
Ia	O
807C>T	B-DNAMutation
deviated	O
significantly	O
from	O
the	O
Hardy-Weinberg	O
equilibrium	O
,	O
and	O
a	O
comparison	O
with	O
previously	O
published	O
data	O
indicates	O
marked	O
region	O
and	O
ethnicity	O
dependent	O
differences	O
in	O
the	O
genotype	O
distributions	O
of	O
some	O
other	O
factors	O
.	O

Severe	O
prothrombin	O
deficiency	O
caused	O
by	O
prothrombin-Edmonton	O
R-4Q	B-ProteinMutation
combined	O
with	O
a	O
previously	O
undetected	O
deletion	O
.	O

BACKGROUND	O
:	O
During	O
infancy	O
,	O
a	O
male	O
patient	O
experienced	O
several	O
life-threatening	O
bleeding	O
episodes	O
.	O

Standard	O
coagulation	O
tests	O
revealed	O
that	O
the	O
patient's	O
plasma	O
prothrombin	O
activity	O
was	O
8%	O
,	O
while	O
his	O
father's	O
and	O
mother's	O
levels	O
were	O
74%	O
and	O
62%	O
,	O
respectively	O
.	O

OBJECTIVES	O
:	O
A	O
molecular	O
genetic	O
approach	O
was	O
used	O
to	O
determine	O
the	O
molecular	O
basis	O
of	O
prothrombin	O
deficiency	O
within	O
the	O
family	O
.	O

PATIENT/METHODS	O
:	O
Prothrombin	O
genomic	O
DNA	O
fragments	O
were	O
amplified	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

In	O
addition	O
,	O
liver	O
cDNA	O
fragments	O
were	O
amplified	O
from	O
the	O
patient	O
by	O
using	O
reverse	O
transcription	O
(RT)	O
and	O
PCR	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
DNA	O
fragments	O
were	O
determined	O
.	O

RESULTS	O
:	O
A	O
novel	O
,	O
heterozygous	O
point	O
mutation	O
(	O
g.1755	B-DNAMutation
G	I-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
,	O
named	O
prothrombin-Edmonton	O
)	O
was	O
detected	O
in	O
the	O
patient	O
and	O
his	O
mother	O
,	O
resulting	O
in	O
the	O
mutation	O
of	O
Arg-4	O
in	O
the	O
prothrombin	O
propeptide	O
to	O
Gln	O
R-4Q	B-ProteinMutation
.	O

RT-PCR	O
analysis	O
of	O
the	O
patient's	O
liver	O
sample	O
demonstrated	O
the	O
presence	O
of	O
two	O
mRNA	O
transcripts	O
that	O
differed	O
by	O
the	O
presence	O
or	O
absence	O
of	O
exon	O
11	O
.	O

Real-time	O
PCR	O
analysis	O
on	O
genomic	O
DNA	O
and	O
cDNA	O
confirmed	O
a	O
deletion	O
g.10435_10809del	B-DNAMutation
in	O
the	O
paternal	O
allele	O
.	O

CONCLUSIONS	O
:	O
The	O
patient	O
has	O
a	O
maternally-inherited	O
point	O
mutation	O
R-4Q	B-ProteinMutation
and	O
a	O
paternally-inherited	O
deletion	O
.	O

By	O
analogy	O
with	O
the	O
previously	O
reported	O
factor	O
IX	O
San	O
Dimas	O
,	O
the	O
R-4Q	B-ProteinMutation
mutation	O
probably	O
causes	O
under-carboxylation	O
of	O
prothrombin	O
and	O
poor	O
cleavage	O
of	O
the	O
propeptide	O
in	O
the	O
hepatocyte	O
.	O

The	O
deletion	O
probably	O
results	O
in	O
a	O
polypeptide	O
that	O
lacks	O
50	O
amino	O
acids	O
from	O
the	O
protease	O
domain	O
;	O
this	O
is	O
likely	O
to	O
impair	O
folding	O
,	O
secretion	O
,	O
stability	O
and/or	O
activity	O
of	O
the	O
truncated	O
prothrombin	O
.	O

The	O
two	O
mutations	O
combine	O
to	O
give	O
the	O
prothrombin	O
deficiency	O
observed	O
in	O
the	O
patient	O
.	O

A	O
novel	O
His158Arg	B-ProteinMutation
mutation	O
in	O
TIMP3	O
causes	O
a	O
late-onset	O
form	O
of	O
Sorsby	O
fundus	O
dystrophy	O
.	O

PURPOSE	O
:	O
To	O
describe	O
the	O
phenotype	O
and	O
genotype	O
of	O
a	O
family	O
with	O
suspected	O
Sorsby	O
fundus	O
dystrophy	O
(SFD)	O
.	O

DESIGN	O
:	O
Case	O
reports	O
and	O
results	O
of	O
deoxyribonucleic	O
acid	O
(DNA)	O
analysis	O
.	O

METHODS	O
:	O
Clinical	O
features	O
were	O
determined	O
by	O
complete	O
ophthalmologic	O
examination	O
or	O
by	O
review	O
of	O
medical	O
records	O
.	O

Mutational	O
analysis	O
of	O
the	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
(TIMP)3	O
gene	O
was	O
performed	O
by	O
DNA	O
resequencing	O
.	O

Biochemical	O
properties	O
of	O
the	O
mutant	O
TIMP3	O
protein	O
were	O
studied	O
,	O
and	O
phylogenetic	O
and	O
molecular	O
modeling	O
analyses	O
of	O
TIMP	O
proteins	O
were	O
performed	O
.	O

RESULTS	O
:	O
Fundi	O
of	O
four	O
affected	O
family	O
members	O
demonstrated	O
active	O
or	O
regressed	O
bilateral	O
choroidal	O
neovascularization	O
,	O
whereas	O
another	O
affected	O
individual	O
displayed	O
severe	O
diffuse	O
pigmentary	O
degeneration	O
associated	O
with	O
nyctalopia	O
characteristic	O
of	O
SFD	O
.	O

Onset	O
of	O
disease	O
occurred	O
in	O
the	O
fifth	O
to	O
seventh	O
decades	O
of	O
life	O
.	O

A	O
heterozygous	O
His158Arg	B-ProteinMutation
mutation	O
was	O
found	O
in	O
seven	O
affected	O
family	O
members	O
and	O
was	O
absent	O
from	O
an	O
unaffected	O
member	O
and	O
98	O
unrelated	O
controls	O
.	O

Bioinformatic	O
analyses	O
indicate	O
that	O
histidine	O
158	O
is	O
an	O
evolutionarily	O
conserved	O
residue	O
in	O
most	O
vertebrate	O
TIMP	O
homologs	O
and	O
predict	O
that	O
substitution	O
by	O
arginine	O
disrupts	O
TIMP3	O
function	O
.	O

The	O
mutant	O
protein	O
appears	O
to	O
be	O
expressed	O
by	O
fibroblasts	O
from	O
an	O
affected	O
family	O
member	O
.	O

Molecular	O
modeling	O
suggests	O
that	O
TIMP3	O
residue	O
158	O
may	O
be	O
part	O
of	O
a	O
protein-protein	O
interaction	O
interface	O
.	O

CONCLUSION	O
:	O
A	O
novel	O
mutation	O
in	O
TIMP3	O
causes	O
a	O
late-onset	O
form	O
of	O
SFD	O
in	O
this	O
family	O
.	O

His158Arg	B-ProteinMutation
is	O
the	O
first	O
reported	O
TIMP3	O
SFD	O
coding	O
sequence	O
mutation	O
that	O
does	O
not	O
create	O
an	O
unpaired	O
cysteine	O
.	O

Further	O
study	O
of	O
this	O
unusual	O
mutation	O
may	O
provide	O
insight	O
into	O
the	O
mechanism	O
of	O
SFD	O
pathogenesis	O
.	O

Analysis	O
of	O
a	O
missense	O
variant	O
of	O
the	O
human	O
N-formyl	O
peptide	O
receptor	O
that	O
is	O
associated	O
with	O
agonist-independent	O
beta-arrestin	O
association	O
and	O
indices	O
of	O
inflammation	O
.	O

Formyl-Met-Leu-Phe	O
(fMLP)	O
is	O
a	O
potent	O
chemoattractant	O
molecule	O
released	O
from	O
both	O
bacteria	O
and	O
damaged	O
mitochondria	O
that	O
activates	O
fMLP	O
receptors	O
(FPR)	O
leading	O
to	O
neutrophil	O
chemotaxis	O
,	O
degranulation	O
and	O
superoxide	O
production	O
.	O

A	O
common	O
missense	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
human	O
FPR1	O
gene	O
at	O
nucleotide	O
c.32C>T	B-DNAMutation
results	O
in	O
the	O
amino-acid	O
substitution	O
,	O
p.I11T	B-ProteinMutation
,	O
in	O
the	O
FPR1	O
extracellular	O
amino-terminus	O
.	O

The	O
minor	O
(c.32T)	O
allele	O
frequencies	O
were	O
0.25	O
,	O
0.27	O
,	O
0.25	O
,	O
0.15	O
and	O
0.14	O
in	O
healthy	O
Caucasian	O
,	O
African	O
,	O
East	O
Indian	O
,	O
Chinese	O
and	O
Native	O
Canadian	O
individuals	O
,	O
respectively	O
.	O

In	O
subjects	O
homozygous	O
for	O
the	O
p.T11	O
allele	O
,	O
we	O
find	O
elevated	O
serum	O
concentrations	O
of	O
C-reactive	O
protein	O
,	O
increased	O
absolute	O
counts	O
of	O
blood	O
leukocytes	O
and	O
neutrophils	O
,	O
and	O
erythrocyte	O
sedimentation	O
rates	O
.	O

When	O
expressed	O
in	O
HEK	O
293	O
and	O
RBL-2H3	O
cells	O
a	O
substantial	O
proportion	O
of	O
FPR1	O
p.I11T	B-ProteinMutation
variant	O
is	O
retained	O
intracellularly	O
and	O
agonist-independent	O
internalization	O
of	O
the	O
FPR1	O
p.I11T	B-ProteinMutation
variant	O
,	O
but	O
not	O
the	O
wild-type	O
FPR1	O
,	O
is	O
constitutively	O
associated	O
with	O
beta-arrestin2-GFP	O
in	O
vesicles	O
.	O

Moreover	O
,	O
basal	O
N-acetyl-D-glucosaminidase	O
release	O
is	O
increased	O
in	O
primary	O
neutrophils	O
isolated	O
from	O
subjects	O
either	O
heterozygous	O
or	O
homozygous	O
for	O
the	O
FPR1	O
p.T11	O
allele	O
.	O

Taken	O
together	O
,	O
the	O
data	O
suggest	O
an	O
increased	O
receptor	O
activity	O
and	O
phenotypic	O
expression	O
of	O
increased	O
inflammatory	O
indices	O
in	O
subjects	O
with	O
the	O
p.T11	O
allele	O
.	O

Clinical	O
characterization	O
and	O
evaluation	O
of	O
DYT1	O
gene	O
in	O
Indian	O
primary	O
dystonia	O
patients	O
.	O

OBJECTIVES	O
:	O
Dystonia	O
is	O
a	O
common	O
movement	O
disorder	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
examine	O
the	O
relative	O
distribution	O
of	O
the	O
primary	O
dystonia	O
subtypes	O
and	O
identify	O
mutation	O
(s)	O
in	O
the	O
DYT1	O
gene	O
in	O
Indian	O
patients	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Primary	O
dystonia	O
patients	O
(	O
n	O
=	O
178	O
)	O
and	O
controls	O
(	O
n	O
=	O
63	O
)	O
,	O
lacking	O
any	O
symptoms	O
of	O
the	O
disease	O
,	O
were	O
recruited	O
for	O
the	O
study	O
from	O
eastern	O
India	O
.	O

The	O
nucleotide	O
variants	O
in	O
the	O
DYT1	O
gene	O
were	O
identified	O
by	O
carrying	O
out	O
polymerase	O
chain	O
reaction	O
,	O
single	O
stranded	O
conformation	O
polymorphism	O
,	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Unlike	O
other	O
reports	O
,	O
pain	O
and/or	O
tremor	O
was	O
more	O
common	O
in	O
our	O
sporadic	O
patients	O
than	O
in	O
familial	O
cases	O
.	O

Three	O
reported	O
and	O
two	O
novel	O
changes	O
were	O
identified	O
in	O
this	O
gene	O
.	O

The	O
homozygous	O
genotype	O
(G,G)	O
for	O
a	O
missense	O
variant	O
(	O
c.646G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
;	O
Asp216His	B-ProteinMutation
)	O
was	O
significantly	O
over-represented	O
in	O
the	O
patients	O
compared	O
with	O
controls	O
(	O
P	O
<	O
0.05	O
)	O
.	O

However	O
,	O
the	O
commonly	O
reported	O
3	O
bp	O
deletion	O
904-906delGAG	B-DNAMutation
was	O
not	O
detected	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
DYT1	O
gene	O
might	O
have	O
a	O
limited	O
role	O
in	O
causation	O
of	O
dystonia	O
in	O
the	O
Indian	O
population	O
.	O

Two	O
novel	O
mutations	O
in	O
the	O
MEN1	O
gene	O
in	O
subjects	O
with	O
multiple	O
endocrine	O
neoplasia-1	O
.	O

Multiple	O
endocrine	O
neoplasia	O
type	O
1	O
(MEN1)	O
is	O
characterized	O
by	O
parathyroid	O
,	O
enteropancreatic	O
endocrine	O
and	O
pituitary	O
adenomas	O
as	O
well	O
as	O
germline	O
mutation	O
of	O
the	O
MEN1	O
gene	O
.	O

We	O
describe	O
2	O
families	O
with	O
MEN1	O
with	O
novel	O
mutations	O
in	O
the	O
MEN1	O
gene	O
.	O

One	O
family	O
was	O
of	O
Turkish	O
origin	O
,	O
and	O
the	O
index	O
patient	O
had	O
primary	O
hyperparathyroidism	O
(PHPT)	O
plus	O
a	O
prolactinoma	O
;	O
three	O
relatives	O
had	O
PHPT	O
only	O
.	O

The	O
index	O
patient	O
in	O
the	O
second	O
family	O
was	O
a	O
46-yr-old	O
woman	O
of	O
Chinese	O
origin	O
living	O
in	O
Taiwan	O
.	O

This	O
patient	O
presented	O
with	O
a	O
complaint	O
of	O
epigastric	O
pain	O
and	O
watery	O
diarrhea	O
over	O
the	O
past	O
3	O
months	O
,	O
and	O
had	O
undergone	O
subtotal	O
parathyroidectomy	O
and	O
enucleation	O
of	O
pancreatic	O
islet	O
cell	O
tumor	O
about	O
10	O
yr	O
before	O
.	O

There	O
was	O
also	O
a	O
prolactinoma	O
.	O

Sequence	O
analysis	O
of	O
the	O
MEN1	O
gene	O
from	O
leukocyte	O
genomic	O
DNA	O
revealed	O
heterozygous	O
mutations	O
in	O
both	O
probands	O
.	O

The	O
Turkish	O
patient	O
and	O
her	O
affected	O
relatives	O
all	O
had	O
a	O
heterozygous	O
A	O
to	O
G	O
transition	O
at	O
codon	O
557	O
AAG-->GAG	B-DNAMutation
of	O
exon	O
10	O
of	O
MEN1	O
that	O
results	O
in	O
a	O
replacement	O
of	O
lysine	O
by	O
glutamic	O
acid	O
.	O

The	O
Chinese	O
index	O
patient	O
and	O
one	O
of	O
her	O
siblings	O
had	O
a	O
heterozygous	O
mutation	O
at	O
codon	O
418	O
of	O
exon	O
9	O
GAC-->TAT	B-DNAMutation
that	O
results	O
in	O
a	O
substitution	O
of	O
aspartic	O
acid	O
by	O
tyrosine	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
2	O
novel	O
missense	O
mutations	O
in	O
the	O
MEN1	O
gene	O
.	O

Single	O
nucleotide	O
polymorphisms	O
of	O
the	O
HNF4alpha	O
gene	O
are	O
associated	O
with	O
the	O
conversion	O
to	O
type	O
2	O
diabetes	O
mellitus	O
:	O
the	O
STOP-NIDDM	O
trial	O
.	O

Hepatocyte	O
nuclear	O
factor	O
4alpha	O
(HNF4alpha)	O
is	O
a	O
transcription	O
factor	O
,	O
which	O
is	O
necessary	O
for	O
normal	O
function	O
of	O
human	O
liver	O
and	O
pancreatic	O
islets	O
.	O

We	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
of	O
HNF4A	O
,	O
encoding	O
HNF4alpha	O
,	O
influenced	O
the	O
conversion	O
from	O
impaired	O
glucose	O
tolerance	O
(IGT)	O
to	O
type	O
2	O
diabetes	O
mellitus	O
in	O
subjects	O
of	O
the	O
STOP-NIDDM	O
trial	O
.	O

This	O
trial	O
aimed	O
at	O
evaluating	O
the	O
effect	O
of	O
acarbose	O
compared	O
to	O
placebo	O
in	O
the	O
prevention	O
of	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Eight	O
SNPs	O
covering	O
the	O
intragenic	O
and	O
alternate	O
P2	O
promoter	O
regions	O
of	O
HNF4A	O
were	O
genotyped	O
in	O
study	O
samples	O
using	O
the	O
TaqMan	O
Allelic	O
Discrimination	O
Assays	O
.	O

Three	O
SNPs	O
in	O
the	O
P2	O
promoter	O
region	O
(	O
rs4810424	B-SNP
,	O
rs1884614	B-SNP
,	O
and	O
rs2144908	B-SNP
)	O
were	O
in	O
almost	O
complete	O
association	O
(	O
D'>0.97	O
,	O
r	O
(	O
2)>0.95	O
)	O
and	O
,	O
therefore	O
,	O
only	O
rs4810424	B-SNP
was	O
included	O
in	O
further	O
analyses	O
.	O

Female	O
carriers	O
of	O
the	O
less	O
frequent	O
C	O
allele	O
of	O
rs4810424	B-SNP
had	O
a	O
1.7-fold	O
elevated	O
risk	O
[	O
95%	O
confidence	O
interval	O
(CI)	O
1.09-2.66	O
;	O
P=0.020	O
]	O
for	O
the	O
conversion	O
to	O
diabetes	O
compared	O
to	O
women	O
with	O
the	O
common	O
genotype	O
after	O
the	O
adjustment	O
for	O
age	O
,	O
treatment	O
group	O
(	O
placebo	O
or	O
acarbose	O
)	O
,	O
smoking	O
,	O
weight	O
at	O
baseline	O
,	O
and	O
weight	O
change	O
.	O

No	O
association	O
was	O
found	O
in	O
men	O
.	O

Haplotype	O
analysis	O
based	O
on	O
three	O
SNPs	O
(	O
rs4810424	B-SNP
,	O
rs2071197	B-SNP
,	O
and	O
rs3818247	B-SNP
)	O
representing	O
the	O
linkage	O
disequilibrium	O
blocks	O
in	O
our	O
study	O
population	O
indicated	O
that	O
the	O
conversion	O
to	O
type	O
2	O
diabetes	O
mellitus	O
was	O
dependent	O
on	O
the	O
number	O
of	O
risk	O
alleles	O
in	O
different	O
haplotypes	O
in	O
women	O
.	O

Our	O
results	O
suggest	O
that	O
SNPs	O
of	O
HNF4A	O
and	O
their	O
haplotypes	O
predispose	O
to	O
type	O
2	O
diabetes	O
mellitus	O
in	O
female	O
subjects	O
of	O
the	O
STOP-NIDDM	O
study	O
population	O
.	O

Genomic	O
characterization	O
of	O
five	O
deletions	O
in	O
the	O
LDL	O
receptor	O
gene	O
in	O
Danish	O
Familial	O
Hypercholesterolemic	O
subjects	O
.	O

BACKGROUND	O
:	O
Familial	O
Hypercholesterolemia	O
is	O
a	O
common	O
autosomal	O
dominantly	O
inherited	O
disease	O
that	O
is	O
most	O
frequently	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
receptor	O
for	O
low	O
density	O
lipoproteins	O
(LDLR)	O
.	O

Deletions	O
and	O
other	O
major	O
structural	O
rearrangements	O
of	O
the	O
LDLR	O
gene	O
account	O
for	O
approximately	O
5%	O
of	O
the	O
mutations	O
in	O
many	O
populations	O
.	O

METHODS	O
:	O
Five	O
genomic	O
deletions	O
in	O
the	O
LDLR	O
gene	O
were	O
characterized	O
by	O
amplification	O
of	O
mutated	O
alleles	O
and	O
sequencing	O
to	O
identify	O
genomic	O
breakpoints	O
.	O

A	O
diagnostic	O
assay	O
based	O
on	O
duplex	O
PCR	O
for	O
the	O
exon	O
7-8	O
deletion	O
was	O
developed	O
to	O
discriminate	O
between	O
heterozygotes	O
and	O
normals	O
,	O
and	O
bioinformatic	O
analyses	O
were	O
used	O
to	O
identify	O
interspersed	O
repeats	O
flanking	O
the	O
deletions	O
.	O

RESULTS	O
:	O
In	O
one	O
case	O
15	O
bp	O
had	O
been	O
inserted	O
at	O
the	O
site	O
of	O
the	O
deleted	O
DNA	O
,	O
and	O
,	O
in	O
all	O
five	O
cases	O
,	O
Alu	O
elements	O
flanked	O
the	O
sites	O
where	O
deletions	O
had	O
occurred	O
.	O

An	O
assay	O
developed	O
to	O
discriminate	O
the	O
wildtype	O
and	O
the	O
deletion	O
allele	O
in	O
a	O
simple	O
duplex	O
PCR	O
detected	O
three	O
FH	O
patients	O
as	O
heterozygotes	O
,	O
and	O
two	O
individuals	O
with	O
normal	O
lipid	O
values	O
were	O
detected	O
as	O
normal	O
homozygotes	O
.	O

CONCLUSION	O
:	O
The	O
identification	O
of	O
the	O
breakpoints	O
should	O
make	O
it	O
possible	O
to	O
develop	O
specific	O
tests	O
for	O
these	O
mutations	O
,	O
and	O
the	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
role	O
of	O
Alu	O
repeats	O
in	O
intragenic	O
deletions	O
.	O

Ectodermal	O
dysplasia-skin	O
fragility	O
syndrome	O
resulting	O
from	O
a	O
new	O
homozygous	O
mutation	O
,	O
888delC	B-DNAMutation
,	O
in	O
the	O
desmosomal	O
protein	O
plakophilin	O
1	O
.	O

We	O
report	O
an	O
unusual	O
case	O
of	O
an	O
inherited	O
disorder	O
of	O
the	O
desmosomal	O
protein	O
plakophilin	O
1	O
,	O
resulting	O
in	O
ectodermal	O
dysplasia-skin	O
fragility	O
syndrome	O
.	O

The	O
affected	O
6-year-old	O
boy	O
had	O
red	O
skin	O
at	O
birth	O
and	O
subsequently	O
developed	O
skin	O
fragility	O
,	O
progressive	O
plantar	O
keratoderma	O
,	O
nail	O
dystrophy	O
,	O
and	O
alopecia	O
.	O

Skin	O
biopsy	O
revealed	O
widening	O
of	O
intercellular	O
spaces	O
in	O
the	O
epidermis	O
and	O
a	O
reduced	O
number	O
of	O
small	O
,	O
poorly	O
formed	O
desmosomes	O
.	O

Mutation	O
analysis	O
of	O
the	O
plakophilin	O
1	O
gene	O
PKP1	O
revealed	O
a	O
homozygous	O
deletion	O
of	O
C	O
at	O
nucleotide	O
888	O
within	O
exon	O
5	O
.	O

This	O
mutation	O
differs	O
from	O
the	O
PKP1	O
gene	O
pathology	O
reported	O
in	O
8	O
previously	O
published	O
individuals	O
with	O
this	O
rare	O
genodermatosis	O
.	O

However	O
,	O
all	O
cases	O
show	O
similar	O
clinical	O
features	O
,	O
highlighting	O
the	O
importance	O
of	O
functional	O
plakophilin	O
1	O
in	O
maintaining	O
desmosomal	O
adhesion	O
in	O
skin	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
this	O
protein	O
in	O
aspects	O
of	O
ectodermal	O
development	O
.	O

Polymorphisms	O
in	O
thymidylate	O
synthase	O
gene	O
and	O
susceptibility	O
to	O
breast	O
cancer	O
in	O
a	O
Chinese	O
population	O
:	O
a	O
case-control	O
analysis	O
.	O

BACKGROUND	O
:	O
Accumulative	O
evidence	O
suggests	O
that	O
low	O
folate	O
intake	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
breast	O
cancer	O
.	O

Polymorphisms	O
in	O
genes	O
involved	O
in	O
folate	O
metabolism	O
may	O
influence	O
DNA	O
methylation	O
,	O
nucleotide	O
synthesis	O
,	O
and	O
thus	O
individual	O
susceptibility	O
to	O
cancer	O
.	O

Thymidylate	O
synthase	O
(TYMS)	O
is	O
a	O
key	O
enzyme	O
that	O
participates	O
in	O
folate	O
metabolism	O
and	O
catalyzes	O
the	O
conversion	O
of	O
dUMP	O
to	O
dTMP	O
in	O
the	O
process	O
of	O
DNA	O
synthesis	O
.	O

Two	O
potentially	O
functional	O
polymorphisms	O
[	O
a	O
28-bp	O
tandem	O
repeat	O
in	O
the	O
TYMS	O
5'-untranslated	O
enhanced	O
region	O
(TSER)	O
and	O
a	O
6-bp	O
deletion/insertion	O
in	O
the	O
TYMS	O
3'-untranslated	O
region	O
(	O
TS	O
3'-UTR)	O
]	O
were	O
suggested	O
to	O
be	O
correlated	O
with	O
alteration	O
of	O
thymidylate	O
synthase	O
expression	O
and	O
associated	O
with	O
cancer	O
risk	O
.	O

METHODS	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
polymorphisms	O
of	O
the	O
TYMS	O
gene	O
are	O
associated	O
with	O
risk	O
of	O
breast	O
cancer	O
,	O
we	O
genotyped	O
these	O
two	O
polymorphisms	O
in	O
a	O
case-control	O
study	O
of	O
432	O
incident	O
cases	O
with	O
invasive	O
breast	O
cancer	O
and	O
473	O
cancer-free	O
controls	O
in	O
a	O
Chinese	O
population	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
the	O
distribution	O
of	O
TS3'-UTR	O
1494del6	B-DNAMutation
genotype	O
frequencies	O
were	O
significantly	O
different	O
between	O
the	O
cases	O
and	O
controls	O
(	O
P	O
=	O
0.026	O
)	O
.	O

Compared	O
with	O
the	O
TS3'-UTR	O
del6/del6	O
wild-type	O
genotype	O
,	O
a	O
significantly	O
reduced	O
risk	O
was	O
associated	O
with	O
the	O
ins6/ins6	O
homozygous	O
variant	O
genotype	O
(	O
adjusted	O
OR	O
=	O
0.58	O
,	O
95%	O
CI	O
=	O
0.35-0.97	O
)	O
but	O
not	O
the	O
del6/ins6	O
genotype	O
(	O
OR	O
=	O
1.09	O
,	O
95%	O
CI	O
=	O
0.82-1.46	O
)	O
.	O

Furthermore	O
,	O
breast	O
cancer	O
risks	O
associated	O
with	O
the	O
TS3'-UTR	O
del6/del6	O
genotype	O
were	O
more	O
evident	O
in	O
older	O
women	O
,	O
postmenopausal	O
subjects	O
,	O
individuals	O
with	O
a	O
younger	O
age	O
at	O
first-live	O
birth	O
and	O
individuals	O
with	O
an	O
older	O
age	O
at	O
menarche	O
.	O

However	O
,	O
there	O
was	O
no	O
evidence	O
for	O
an	O
association	O
between	O
the	O
TSER	O
polymorphism	O
and	O
breast	O
cancer	O
risks	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
TS3'-UTR	O
del6	O
polymorphism	O
may	O
play	O
a	O
role	O
in	O
the	O
etiology	O
of	O
breast	O
cancer	O
.	O

Further	O
larger	O
population-based	O
studies	O
as	O
well	O
as	O
functional	O
evaluation	O
of	O
the	O
variants	O
are	O
warranted	O
to	O
confirm	O
our	O
findings	O
.	O

Insertion/deletion	O
polymorphism	O
of	O
angiotensin	O
converting	O
enzyme	O
gene	O
in	O
Kawasaki	O
disease	O
.	O

Polymorphism	O
of	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
gene	O
is	O
reported	O
to	O
be	O
associated	O
with	O
ischemic	O
heart	O
disease	O
,	O
hypertrophic	O
cardiomyopathy	O
,	O
and	O
idiopathic	O
dilated	O
cardiomyopathy	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
Kawasaki	O
disease	O
and	O
insertion/deletion	O
polymorphism	O
of	O
ACE	O
gene	O
.	O

Fifty	O
five	O
Kawasaki	O
disease	O
patients	O
and	O
43	O
healthy	O
children	O
were	O
enrolled	O
.	O

ACE	O
genotype	O
was	O
evaluated	O
from	O
each	O
of	O
the	O
subjects'	O
DNA	O
fragments	O
through	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

Frequencies	O
of	O
ACE	O
genotypes	O
(	O
DD	O
,	O
ID	O
,	O
II	O
)	O
were	O
12.7%	O
,	O
60.0%	O
,	O
27.3%	O
in	O
Kawasaki	O
group	O
,	O
and	O
41.9%	O
,	O
30.2%	O
,	O
27.9%	O
in	O
control	O
group	O
respectively	O
,	O
indicating	O
low	O
rate	O
of	O
DD	O
and	O
high	O
rate	O
of	O
ID	O
genotype	O
among	O
Kawasaki	O
patients	O
(p<0.01)	O
.	O

Comparing	O
allelic	O
(	O
I	O
,	O
D	O
)	O
frequencies	O
,	O
I	O
allele	O
was	O
more	O
prevalent	O
in	O
Kawasaki	O
group	O
than	O
in	O
control	O
group	O
(	O
57.3%	O
vs	O
.	O

43.0%	O
,	O
p<0.05	O
)	O
.	O

In	O
Kawasaki	O
group	O
,	O
both	O
genotype	O
and	O
allelic	O
frequencies	O
were	O
not	O
statistically	O
different	O
between	O
those	O
with	O
coronary	O
dilatations	O
and	O
those	O
without	O
.	O

ACE	O
gene	O
I/D	O
polymorphism	O
is	O
thought	O
to	O
be	O
associated	O
with	O
Kawasaki	O
disease	O
but	O
not	O
with	O
the	O
development	O
of	O
coronary	O
dilatations	O
.	O

Tumor	O
thymidylate	O
synthase	O
1494del6	B-DNAMutation
genotype	O
as	O
a	O
prognostic	O
factor	O
in	O
colorectal	O
cancer	O
patients	O
receiving	O
fluorouracil-based	O
adjuvant	O
treatment	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
value	O
of	O
germline	O
and	O
tumor	O
thymidylate	O
synthase	O
(TS)	O
genotyping	O
as	O
a	O
prognostic	O
marker	O
in	O
a	O
series	O
of	O
colorectal	O
cancer	O
patients	O
receiving	O
adjuvant	O
fluorouracil	O
(FU)	O
-based	O
treatment	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
twenty-nine	O
colorectal	O
cancer	O
patients	O
homogeneously	O
treated	O
with	O
FU	O
plus	O
levamisole	O
or	O
leucovorin	O
in	O
the	O
adjuvant	O
setting	O
were	O
included	O
.	O

TS	O
enhancer	O
region	O
,	O
3R	O
G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
single	O
nucleotide	O
polymorphism	O
(SNP)	O
,	O
and	O
TS	O
1494del6	B-DNAMutation
polymorphisms	O
were	O
assessed	O
in	O
both	O
fresh-frozen	O
normal	O
mucosa	O
and	O
tumor	O
.	O

Mutational	O
analyses	O
of	O
TS	O
and	O
allelic	O
imbalances	O
were	O
studied	O
in	O
all	O
primary	O
tumors	O
and	O
in	O
18	O
additional	O
metachronic	O
metastases	O
.	O

TS	O
protein	O
immunostaining	O
was	O
assessed	O
in	O
an	O
expanded	O
series	O
of	O
214	O
tumors	O
.	O

Multivariate	O
Cox	O
models	O
were	O
adjusted	O
for	O
stage	O
,	O
differentiation	O
,	O
and	O
location	O
.	O

RESULTS	O
:	O
Tumor	O
genotyping	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
26%	O
)	O
showed	O
that	O
the	O
3R/3R	O
genotype	O
was	O
associated	O
with	O
a	O
better	O
outcome	O
(	O
hazard	O
ratio	O
[HR]	O
=	O
0.38	O
;	O
95%	O
CI	O
,	O
0.16	O
to	O
0.93	O
;	O
P	O
=	O
.020	O
for	O
the	O
recessive	O
model	O
)	O
.	O

3R	O
G	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
SNP	O
genotyping	O
did	O
not	O
add	O
prognostic	O
information	O
.	O

Tumor	O
TS	O
1494del6	B-DNAMutation
allele	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
36%	O
)	O
was	O
protective	O
(	O
for	O
each	O
allele	O
with	O
the	O
deletion	O
,	O
based	O
on	O
an	O
additive	O
model	O
,	O
HR	O
=	O
0.42	O
;	O
95%	O
CI	O
,	O
0.22	O
to	O
0.82	O
;	O
P	O
=	O
.0034	O
)	O
.	O

Both	O
polymorphisms	O
were	O
in	O
strong	O
linkage	O
disequilibrium	O
(	O
D'	O
=	O
0.71	O
,	O
P	O
<	O
.001	O
)	O
,	O
and	O
the	O
3R/-6	O
base	O
pair	O
(bp)	O
haplotype	O
showed	O
a	O
significant	O
overall	O
survival	O
benefit	O
compared	O
with	O
the	O
most	O
prevalent	O
haplotype	O
2R/+6bp	O
(	O
HR	O
=	O
0.42	O
;	O
95%	O
CI	O
,	O
0.20	O
to	O
0.85	O
;	O
P	O
=	O
.017	O
)	O
.	O

No	O
TS	O
point	O
mutation	O
was	O
detected	O
in	O
primary	O
tumors	O
or	O
metastases	O
.	O

TS	O
protein	O
immunostaining	O
was	O
not	O
associated	O
with	O
survival	O
or	O
any	O
of	O
the	O
genotypes	O
analyzed	O
.	O

CONCLUSION	O
:	O
Tumor	O
TS	O
1494del6	B-DNAMutation
genotype	O
may	O
be	O
a	O
prognostic	O
factor	O
in	O
FU-based	O
adjuvant	O
treatment	O
of	O
colorectal	O
cancer	O
patients	O
.	O

Genetic	O
variation	O
in	O
the	O
COX-2	O
gene	O
and	O
the	O
association	O
with	O
prostate	O
cancer	O
risk	O
.	O

COX-2	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
conversion	O
of	O
arachidonic	O
acid	O
to	O
prostaglandins	O
.	O

The	O
prostaglandins	O
produced	O
by	O
COX-2	O
are	O
involved	O
in	O
inflammation	O
and	O
pain	O
response	O
in	O
different	O
tissues	O
in	O
the	O
body	O
.	O

Accumulating	O
evidence	O
from	O
epidemiologic	O
studies	O
,	O
chemical	O
carcinogen-induced	O
rodent	O
models	O
and	O
clinical	O
trials	O
indicate	O
that	O
COX-2	O
plays	O
a	O
role	O
in	O
human	O
carcinogenesis	O
and	O
is	O
overexpressed	O
in	O
prostate	O
cancer	O
tissue	O
.	O

We	O
examined	O
whether	O
sequence	O
variants	O
in	O
the	O
COX-2	O
gene	O
are	O
associated	O
with	O
prostate	O
cancer	O
risk	O
.	O

We	O
analyzed	O
a	O
large	O
population-based	O
case-control	O
study	O
,	O
cancer	O
prostate	O
in	O
Sweden	O
(CAPS)	O
consisting	O
of	O
1,378	O
cases	O
and	O
782	O
controls	O
.	O

We	O
evaluated	O
16	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
spanning	O
the	O
entire	O
COX-2	O
gene	O
in	O
94	O
subjects	O
of	O
the	O
control	O
group	O
.	O

Five	O
SNPs	O
had	O
a	O
minor	O
allele	O
frequency	O
of	O
more	O
than	O
5%	O
in	O
our	O
study	O
population	O
and	O
these	O
were	O
genotyped	O
in	O
all	O
case	O
patients	O
and	O
control	O
subjects	O
and	O
gene-specific	O
haplotypes	O
were	O
constructed	O
.	O

A	O
statistically	O
significant	O
difference	O
in	O
allele	O
frequency	O
between	O
cases	O
and	O
controls	O
was	O
observed	O
for	O
2	O
of	O
the	O
SNPs	O
(	O
+3100	B-DNAMutation
T/G	I-DNAMutation
and	O
+8365	B-DNAMutation
C/T	I-DNAMutation
)	O
,	O
with	O
an	O
odds	O
ratio	O
of	O
0.78	O
(	O
95%	O
CI=0.64-0.96	O
)	O
and	O
0.65	O
(	O
95%	O
CI=0.45-0.94	O
)	O
respectively	O
.	O

In	O
the	O
haplotype	O
analysis	O
,	O
1	O
haplotype	O
carrying	O
the	O
variant	O
allele	O
from	O
both	O
+3100	B-DNAMutation
T/G	I-DNAMutation
and	O
+8365	B-DNAMutation
C/T	I-DNAMutation
,	O
with	O
a	O
population	O
frequency	O
of	O
3%	O
,	O
was	O
also	O
significantly	O
associated	O
with	O
decreased	O
risk	O
of	O
prostate	O
cancer	O
(	O
p=0.036	O
,	O
global	O
simulated	O
p-value=0.046	O
)	O
.	O

This	O
study	O
supports	O
the	O
hypothesis	O
that	O
inflammation	O
is	O
involved	O
in	O
prostate	O
carcinogenesis	O
and	O
that	O
sequence	O
variation	O
within	O
the	O
COX-2	O
gene	O
influence	O
the	O
risk	O
of	O
prostate	O
cancer	O
.	O

A	O
novel	O
missense	O
mutation	O
,	O
F826Y	B-ProteinMutation
,	O
in	O
the	O
mineralocorticoid	O
receptor	O
gene	O
in	O
Japanese	O
hypertensives	O
:	O
its	O
implications	O
for	O
clinical	O
phenotypes	O
.	O

A	O
gain-of-function	O
mutation	O
resulting	O
in	O
the	O
S810L	B-ProteinMutation
amino	O
acid	O
substitution	O
in	O
the	O
hormone-binding	O
domain	O
of	O
the	O
mineralocorticoid	O
receptor	O
(	O
MR	O
,	O
locus	O
symbol	O
NR3C2	O
)	O
is	O
responsible	O
for	O
early-onset	O
hypertension	O
that	O
is	O
exacerbated	O
in	O
pregnancy	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
test	O
whether	O
other	O
types	O
of	O
missense	O
mutations	O
in	O
the	O
hormone-binding	O
domain	O
could	O
be	O
implicated	O
in	O
hypertension	O
in	O
Japanese	O
.	O

Here	O
,	O
we	O
screened	O
942	O
Japanese	O
patients	O
with	O
hypertension	O
for	O
the	O
S810L	B-ProteinMutation
mutation	O
in	O
exon	O
6	O
in	O
the	O
MR	O
.	O

We	O
did	O
not	O
identify	O
the	O
S810L	B-ProteinMutation
mutation	O
in	O
our	O
hypertensive	O
population	O
,	O
indicating	O
that	O
S810L	B-ProteinMutation
does	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
etiology	O
of	O
essential	O
hypertension	O
in	O
Japanese	O
.	O

However	O
,	O
we	O
identified	O
a	O
novel	O
missense	O
mutation	O
,	O
F826Y	B-ProteinMutation
,	O
in	O
three	O
patients	O
in	O
a	O
heterozygous	O
state	O
,	O
in	O
addition	O
to	O
four	O
single	O
nucleotide	O
polymorphisms	O
,	O
including	O
one	O
synonymous	O
mutation	O
L809L	B-ProteinMutation
.	O

The	O
F826Y	B-ProteinMutation
mutation	O
is	O
present	O
in	O
the	O
MR	O
hormone-binding	O
domain	O
and	O
might	O
affect	O
the	O
ligand	O
affinity	O
.	O

The	O
F826Y	B-ProteinMutation
mutation	O
was	O
also	O
identified	O
in	O
13	O
individuals	O
(	O
5	O
hypertensives	O
and	O
8	O
normotensives	O
)	O
in	O
a	O
Japanese	O
general	O
population	O
(n=3,655)	O
.	O

The	O
allele	O
frequency	O
was	O
0.00178	O
.	O

The	O
frequencies	O
of	O
the	O
F826Y	B-ProteinMutation
mutation	O
in	O
the	O
hypertensive	O
population	O
(3/942)	O
and	O
in	O
the	O
hypertensive	O
group	O
(	O
5/	O
1,480	O
)	O
and	O
the	O
normotensive	O
group	O
(8/2,175)	O
in	O
the	O
general	O
population	O
were	O
not	O
significantly	O
different	O
,	O
suggesting	O
that	O
this	O
mutation	O
does	O
not	O
greatly	O
affect	O
hypertension	O
.	O

Although	O
it	O
is	O
unclear	O
at	O
present	O
whether	O
or	O
not	O
the	O
F826Y	B-ProteinMutation
mutation	O
makes	O
a	O
substantial	O
contribution	O
to	O
the	O
mineralocorticoid	O
receptor	O
activity	O
,	O
this	O
missense	O
mutation	O
may	O
contribute	O
,	O
to	O
some	O
extent	O
,	O
to	O
clinical	O
phenotypes	O
through	O
its	O
effects	O
on	O
MR	O
.	O

Genetic	O
alterations	O
in	O
primary	O
glioblastomas	O
in	O
Japan	O
.	O

Current	O
knowledge	O
of	O
genetic	O
alterations	O
in	O
glioblastomas	O
is	O
based	O
largely	O
on	O
genetic	O
analyses	O
of	O
tumors	O
from	O
mainly	O
caucasian	O
patients	O
in	O
the	O
United	O
States	O
and	O
Europe	O
.	O

In	O
the	O
present	O
study	O
,	O
screening	O
for	O
several	O
key	O
genetic	O
alterations	O
was	O
performed	O
on	O
77	O
primary	O
(	O
de	O
novo	O
)	O
glioblastomas	O
in	O
Japanese	O
patients	O
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
revealed	O
TP53	O
mutations	O
in	O
16	O
of	O
73	O
(22%)	O
glioblastomas	O
and	O
PTEN	O
mutations	O
in	O
13	O
of	O
63	O
(21%)	O
cases	O
analyzed	O
.	O

Polymerase	O
chain	O
reaction	O
(PCR)	O
showed	O
EGFR	O
amplification	O
in	O
25	O
of	O
77	O
(32%)	O
cases	O
and	O
p16	O
homozygous	O
deletion	O
in	O
32	O
of	O
77	O
(42%)	O
cases	O
.	O

Quantitative	O
microsatellite	O
analysis	O
revealed	O
LOH	O
10q	O
in	O
41	O
of	O
59	O
(69%)	O
glioblastomas	O
.	O

The	O
frequencies	O
of	O
these	O
genetic	O
alterations	O
were	O
similar	O
to	O
those	O
reported	O
for	O
primary	O
glioblastomas	O
at	O
the	O
population	O
level	O
in	O
Switzerland	O
.	O

As	O
previously	O
observed	O
for	O
glioblastomas	O
in	O
Europe	O
,	O
there	O
was	O
a	O
positive	O
association	O
between	O
EGFR	O
amplification	O
and	O
p16	O
deletion	O
(p=0.009)	O
,	O
whereas	O
there	O
was	O
an	O
inverse	O
association	O
between	O
TP53	O
mutations	O
and	O
p16	O
deletion	O
(p=0.049)	O
in	O
glioblastomas	O
in	O
Japan	O
.	O

Multivariate	O
analyses	O
showed	O
that	O
radiotherapy	O
was	O
significantly	O
predictive	O
for	O
longer	O
survival	O
of	O
glioblastoma	O
patients	O
(p=0.002)	O
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
of	O
the	O
kinase	O
domain	O
(	O
exons	O
18-21	O
)	O
of	O
the	O
EGFR	O
gene	O
revealed	O
mutations	O
in	O
2	O
ou	O
of	O
69	O
(3%)	O
glioblastomas	O
in	O
Japan	O
and	O
in	O
4	O
of	O
81	O
(5%)	O
glioblastomas	O
in	O
Switzerland	O
.	O

The	O
allele	O
frequencies	O
of	O
polymorphisms	O
at	O
codon	B-DNAMutation
787	I-DNAMutation
CAG/CAA	I-DNAMutation
(Gln/Gln)	O
in	O
glioblastomas	O
in	O
Japan	O
were	O
G/G	O
(82.4%)	O
,	O
G/A	O
(10.8%)	O
,	O
A/A	O
(6.8%)	O
,	O
corresponding	O
to	O
G	O
0.878	O
versus	O
A	O
0.122	O
,	O
significantly	O
different	O
from	O
those	O
in	O
glioblastomas	O
in	O
Switzerland	O
:	O
G/G	O
(27.2%)	O
,	O
G/A	O
(28.4%)	O
,	O
A/A	O
(44.4%)	O
,	O
corresponding	O
to	O
G	O
0.414	O
versus	O
A	O
0.586	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

These	O
results	O
suggest	O
that	O
primary	O
glioblastomas	O
in	O
Japan	O
show	O
genetic	O
alterations	O
similar	O
to	O
those	O
in	O
Switzerland	O
,	O
suggesting	O
a	O
similar	O
molecular	O
basis	O
in	O
caucasians	O
and	O
Asians	O
,	O
despite	O
different	O
genetic	O
backgrounds	O
,	O
including	O
different	O
status	O
of	O
a	O
polymorphism	O
in	O
the	O
EGFR	O
gene	O
.	O

Evidence	O
for	O
alternative	O
candidate	O
genes	O
near	O
RB1	O
involved	O
in	O
clonal	O
expansion	O
of	O
in	O
situ	O
urothelial	O
neoplasia	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
whole-organ	O
histologic	O
and	O
genetic	O
mapping	O
studies	O
using	O
hypervariable	O
DNA	O
markers	O
on	O
chromosome	O
13	O
and	O
then	O
integrate	O
the	O
recombination-	O
and	O
single-nucleotide	O
polymorphic	O
sites	O
(SNPs)-based	O
deletion	O
maps	O
with	O
the	O
annotated	O
genome	O
sequence	O
.	O

Using	O
bladders	O
resected	O
from	O
patients	O
with	O
invasive	O
urothelial	O
carcinoma	O
,	O
we	O
studied	O
allelic	O
patterns	O
of	O
40	O
microsatellite	O
markers	O
mapping	O
to	O
all	O
regions	O
of	O
chromosome	O
13	O
and	O
79	O
SNPs	O
located	O
within	O
the	O
13q14	O
region	O
containing	O
the	O
RB1	O
gene	O
.	O

A	O
whole-organ	O
histologic	O
and	O
genetic	O
mapping	O
strategy	O
was	O
used	O
to	O
identify	O
the	O
evolution	O
of	O
allelic	O
losses	O
on	O
chromosome	O
13	O
during	O
the	O
progression	O
of	O
bladder	O
neoplasia	O
.	O

Markers	O
mapping	O
to	O
chromosomal	O
regions	O
involved	O
in	O
clonal	O
expansion	O
of	O
preneoplastic	O
intraurothelial	O
lesions	O
were	O
subsequently	O
tested	O
in	O
25	O
tumors	O
and	O
21	O
voided	O
urine	O
samples	O
of	O
patients	O
with	O
bladder	O
cancer	O
.	O

Four	O
clusters	O
of	O
allelic	O
losses	O
mapping	O
to	O
distinct	O
regions	O
of	O
chromosome	O
13	O
were	O
identified	O
.	O

Markers	O
mapping	O
to	O
the	O
13q14	O
region	O
that	O
is	O
flanked	O
by	O
D13S263	O
and	O
D13S276	O
,	O
which	O
contains	O
the	O
RB1	O
gene	O
,	O
showed	O
allelic	O
losses	O
associated	O
with	O
early	O
clonal	O
expansion	O
of	O
intraurothelial	O
neoplasia	O
.	O

Such	O
losses	O
could	O
be	O
identified	O
in	O
approximately	O
32%	O
bladder	O
tumor	O
tissue	O
samples	O
and	O
38%	O
of	O
voided	O
urines	O
from	O
patients	O
with	O
bladder	O
cancer	O
.	O

The	O
integration	O
of	O
distribution	O
patterns	O
of	O
clonal	O
allelic	O
losses	O
revealed	O
by	O
the	O
microsatellite	O
markers	O
with	O
those	O
obtained	O
by	O
genotyping	O
of	O
SNPs	O
disclosed	O
that	O
the	O
loss	O
within	O
an	O
approximately	O
4-Mb	O
segment	O
centered	O
around	O
RB1	O
may	O
represent	O
an	O
incipient	O
event	O
in	O
bladder	O
neoplasia	O
.	O

However	O
,	O
the	O
inactivation	O
of	O
RB1	O
occurred	O
later	O
and	O
was	O
associated	O
with	O
the	O
onset	O
of	O
severe	O
dysplasia/carcinoma	O
in	O
situ	O
.	O

Our	O
studies	O
provide	O
evidence	O
for	O
the	O
presence	O
of	O
critical	O
alternative	O
candidate	O
genes	O
mapping	O
to	O
the	O
13q14	O
region	O
that	O
are	O
involved	O
in	O
clonal	O
expansion	O
of	O
neoplasia	O
within	O
the	O
bladder	O
antecedent	O
to	O
the	O
inactivation	O
of	O
the	O
RB1	O
gene	O
.	O

Allele-specific	O
amplification	O
in	O
cancer	O
revealed	O
by	O
SNP	O
array	O
analysis	O
.	O

Amplification	O
,	O
deletion	O
,	O
and	O
loss	O
of	O
heterozygosity	O
of	O
genomic	O
DNA	O
are	O
hallmarks	O
of	O
cancer	O
.	O

In	O
recent	O
years	O
a	O
variety	O
of	O
studies	O
have	O
emerged	O
measuring	O
total	O
chromosomal	O
copy	O
number	O
at	O
increasingly	O
high	O
resolution	O
.	O

Similarly	O
,	O
loss-of-heterozygosity	O
events	O
have	O
been	O
finely	O
mapped	O
using	O
high-throughput	O
genotyping	O
technologies	O
.	O

We	O
have	O
developed	O
a	O
probe-level	O
allele-specific	O
quantitation	O
procedure	O
that	O
extracts	O
both	O
copy	O
number	O
and	O
allelotype	O
information	O
from	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
array	O
data	O
to	O
arrive	O
at	O
allele-specific	O
copy	O
number	O
across	O
the	O
genome	O
.	O

Our	O
approach	O
applies	O
an	O
expectation-maximization	O
algorithm	O
to	O
a	O
model	O
derived	O
from	O
a	O
novel	O
classification	O
of	O
SNP	O
array	O
probes	O
.	O

This	O
method	O
is	O
the	O
first	O
to	O
our	O
knowledge	O
that	O
is	O
able	O
to	O
(a)	O
determine	O
the	O
generalized	O
genotype	O
of	O
aberrant	O
samples	O
at	O
each	O
SNP	O
site	O
(	O
e.g.	O
,	O
CCCCT	O
at	O
an	O
amplified	O
site	O
)	O
,	O
and	O
(b)	O
infer	O
the	O
copy	O
number	O
of	O
each	O
parental	O
chromosome	O
across	O
the	O
genome	O
.	O

With	O
this	O
method	O
,	O
we	O
are	O
able	O
to	O
determine	O
not	O
just	O
where	O
amplifications	O
and	O
deletions	O
occur	O
,	O
but	O
also	O
the	O
haplotype	O
of	O
the	O
region	O
being	O
amplified	O
or	O
deleted	O
.	O

The	O
merit	O
of	O
our	O
model	O
and	O
general	O
approach	O
is	O
demonstrated	O
by	O
very	O
precise	O
genotyping	O
of	O
normal	O
samples	O
,	O
and	O
our	O
allele-specific	O
copy	O
number	O
inferences	O
are	O
validated	O
using	O
PCR	O
experiments	O
.	O

Applying	O
our	O
method	O
to	O
a	O
collection	O
of	O
lung	O
cancer	O
samples	O
,	O
we	O
are	O
able	O
to	O
conclude	O
that	O
amplification	O
is	O
essentially	O
monoallelic	O
,	O
as	O
would	O
be	O
expected	O
under	O
the	O
mechanisms	O
currently	O
believed	O
responsible	O
for	O
gene	O
amplification	O
.	O

This	O
suggests	O
that	O
a	O
specific	O
parental	O
chromosome	O
may	O
be	O
targeted	O
for	O
amplification	O
,	O
whether	O
because	O
of	O
germ	O
line	O
or	O
somatic	O
variation	O
.	O

An	O
R	O
software	O
package	O
containing	O
the	O
methods	O
described	O
in	O
this	O
paper	O
is	O
freely	O
available	O
at	O
http://genome.dfci.harvard.edu/~tlaframb/PLASQ	O
.	O

Tag/anti-tag	O
liquid-phase	O
primer	O
extension	O
array	O
:	O
a	O
flexible	O
and	O
versatile	O
genotyping	O
platform	O
.	O

This	O
study	O
demonstrates	O
an	O
array-based	O
platform	O
to	O
genotype	O
simultaneously	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
some	O
short	O
insertions/deletions	O
(indels)	O
by	O
the	O
integration	O
of	O
the	O
universal	O
tag/anti-tag	O
(TAT)	O
system	O
,	O
liquid-phase	O
primer	O
extension	O
(LIPEX)	O
,	O
and	O
a	O
novel	O
two-color	O
detection	O
strategy	O
on	O
an	O
array	O
format	O
(TATLIPEXA)	O
.	O

The	O
TAT	O
system	O
permits	O
a	O
universal	O
chip	O
to	O
be	O
used	O
for	O
many	O
applications	O
,	O
and	O
the	O
LIPEX	O
simplifies	O
the	O
sample	O
preparation	O
but	O
improves	O
the	O
sensitivity	O
significantly	O
.	O

More	O
importantly	O
,	O
all	O
SNPs	O
and	O
some	O
short	O
indels	O
can	O
be	O
interrogated	O
in	O
a	O
single	O
reaction	O
with	O
only	O
two	O
fluorescent	O
ddNTPs	O
.	O

The	O
concept	O
of	O
TATLIPEXA	O
is	O
demonstrated	O
for	O
nine	O
SNPs	O
(	O
eight	O
point	O
mutations	O
and	O
one	O
single-base	O
insertion	O
)	O
,	O
and	O
genotypes	O
obtained	O
show	O
a	O
remarkable	O
concordance	O
rate	O
of	O
100%	O
with	O
both	O
DNA	O
sequencing	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

Moreover	O
,	O
TATLIPEXA	O
is	O
able	O
to	O
provide	O
quantitative	O
information	O
on	O
allele	O
frequency	O
in	O
pooled	O
DNA	O
samples	O
,	O
which	O
could	O
serve	O
as	O
a	O
rapid	O
screening	O
tool	O
for	O
SNPs	O
associated	O
with	O
diseases	O
.	O

The	O
promoter	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
implicated	O
in	O
glaucoma	O
based	O
on	O
genetic	O
analysis	O
and	O
nuclear	O
factor	O
binding	O
.	O

PURPOSE	O
:	O
Nitric	O
oxide	O
has	O
many	O
beneficial	O
functions	O
in	O
the	O
human	O
body	O
at	O
the	O
right	O
amounts	O
,	O
but	O
it	O
can	O
also	O
be	O
hazardous	O
if	O
it	O
is	O
produced	O
in	O
amounts	O
more	O
than	O
needed	O
and	O
has	O
therefore	O
been	O
studied	O
in	O
relation	O
to	O
several	O
neurological	O
and	O
non-neurological	O
disorders	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
demonstrate	O
a	O
connection	O
between	O
the	O
inducible	O
form	O
of	O
Nitric	O
Oxide	O
Synthase	O
,	O
iNOS	O
,	O
and	O
the	O
neuropathological	O
disorder	O
glaucoma	O
,	O
one	O
of	O
the	O
major	O
causes	O
of	O
blindness	O
in	O
the	O
world	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
establish	O
the	O
genetic	O
association	O
between	O
iNOS	O
and	O
primary	O
open	O
angle	O
glaucoma	O
,	O
POAG	O
,	O
and	O
to	O
find	O
the	O
functional	O
element(s)	O
connected	O
with	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

METHODS	O
:	O
Two	O
microsatellites	O
,	O
1	O
insertion/deletion	O
,	O
and	O
8	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
regulatory	O
region	O
of	O
iNOS	O
were	O
genotyped	O
in	O
200	O
POAG	O
patients	O
and	O
200	O
age-matched	O
controls	O
.	O

Also	O
,	O
the	O
CCTTT-microsatellite	O
was	O
examined	O
for	O
its	O
protein-binding	O
capability	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
EMSA	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
significant	O
difference	O
in	O
allele	O
distribution	O
of	O
the	O
CCTTT-microsatellite	O
,	O
between	O
patients	O
and	O
controls	O
.	O

(CCTTT)14	O
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
a	O
higher	O
activity	O
in	O
a	O
reporter-construct	O
,	O
was	O
significantly	O
more	O
abundant	O
in	O
POAG	O
patients	O
,	O
while	O
(CCTTT)10	O
and	O
(CCTTT)13	O
were	O
less	O
common	O
.	O

In	O
EMSA	O
,	O
the	O
(CCTTT)14	O
allele	O
exhibited	O
specific	O
binding	O
of	O
nuclear	O
proteins	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
,	O
together	O
with	O
other	O
studies	O
on	O
this	O
gene	O
and	O
the	O
CCTTT-microsatellite	O
,	O
establish	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
genetic	O
association	O
of	O
iNOS	O
with	O
POAG	O
and	O
suggest	O
a	O
regulatory	O
function	O
for	O
the	O
microsatellite	O
.	O

Genetic	O
homogeneity	O
for	O
inherited	O
congenital	O
microcoria	O
loci	O
in	O
an	O
Asian	O
Indian	O
pedigree	O
.	O

PURPOSE	O
:	O
Congenital	O
microcoria	O
is	O
a	O
rare	O
autosomal	O
dominant	O
developmental	O
disorder	O
of	O
the	O
iris	O
associated	O
with	O
myopia	O
and	O
juvenile	O
open	O
angle	O
glaucoma	O
.	O

Linkage	O
to	O
the	O
chromosomal	O
locus	O
13q31-q32	O
has	O
previously	O
been	O
reported	O
in	O
a	O
large	O
French	O
family	O
.	O

In	O
the	O
current	O
study	O
,	O
a	O
three	O
generation	O
Asian	O
Indian	O
family	O
with	O
15	O
congenital	O
microcoria	O
(	O
pupils	O
with	O
a	O
diameter	O
<2	O
mm	O
)	O
affected	O
members	O
was	O
studied	O
for	O
linkage	O
to	O
candidate	O
microsatellite	O
markers	O
at	O
the	O
13q31-q32	O
locus	O
.	O

METHODS	O
:	O
Twenty-four	O
members	O
of	O
the	O
family	O
were	O
clinically	O
examined	O
and	O
genomic	O
DNA	O
was	O
extracted	O
.	O

Microsatellite	O
markers	O
at	O
13q31-q32	O
were	O
PCR	O
amplified	O
and	O
run	O
on	O
an	O
ABI	O
Prism	O
310	O
genetic	O
analyzer	O
and	O
genotyped	O
with	O
the	O
GeneScan	O
analysis	O
.	O

Two	O
point	O
and	O
multipoint	O
linkage	O
analyses	O
were	O
performed	O
using	O
the	O
MLINK	O
and	O
SUPERLINK	O
programs	O
.	O

RESULTS	O
:	O
Peak	O
two	O
point	O
LOD	O
scores	O
of	O
3.5	O
,	O
4.7	O
,	O
and	O
5.3	O
were	O
found	O
co-incident	O
with	O
consecutive	O
markers	O
D13S154	O
,	O
DCT	O
,	O
and	O
D13S1280	O
.	O

Multipoint	O
analysis	O
revealed	O
a	O
4	O
cM	O
region	O
encompassing	O
D13S1300	O
to	O
D13S1280	O
where	O
the	O
LOD	O
remains	O
just	O
over	O
6.0	O
Thus	O
we	O
confirm	O
localization	O
of	O
the	O
congenital	O
microcoria	O
locus	O
to	O
chromosomal	O
locus	O
13q31-q32	O
.	O

In	O
addition	O
,	O
eight	O
individuals	O
who	O
had	O
both	O
microcoria	O
and	O
glaucoma	O
were	O
screened	O
for	O
glaucoma	O
genes	O
:	O
myocilin	O
(MYOC)	O
,	O
optineurin	O
(OPTN)	O
and	O
CYP1B1	O
.	O

Using	O
direct	O
sequencing	O
a	O
point	O
mutation	O
(	O
144	B-DNAMutation
G>A	I-DNAMutation
)	O
resulting	O
in	O
a	O
Q48H	B-ProteinMutation
substitution	O
in	O
exon	O
1	O
of	O
the	O
MYOC	O
gene	O
was	O
observed	O
in	O
five	O
of	O
the	O
eight	O
glaucoma	O
patients	O
,	O
but	O
not	O
in	O
unaffected	O
family	O
members	O
and	O
100	O
unrelated	O
controls	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
confirmed	O
the	O
localization	O
of	O
the	O
congenital	O
microcoria	O
locus	O
(MCOR)	O
to	O
13q31-q32	O
in	O
a	O
large	O
Asian	O
Indian	O
family	O
and	O
conclude	O
that	O
current	O
information	O
suggests	O
this	O
is	O
a	O
single	O
locus	O
disorder	O
and	O
genetically	O
homogeneous	O
.	O

When	O
combined	O
with	O
the	O
initial	O
linkage	O
paper	O
our	O
haplotype	O
and	O
linkage	O
data	O
map	O
the	O
MCOR	O
locus	O
to	O
a	O
6-7	O
cM	O
region	O
between	O
D13S265	O
and	O
D13S1280	O
.	O

The	O
DCT	O
locus	O
,	O
a	O
member	O
of	O
the	O
tyrosinase	O
family	O
involved	O
in	O
pigmentation	O
,	O
maps	O
within	O
this	O
region	O
.	O

Data	O
presented	O
here	O
supports	O
the	O
hypothesis	O
that	O
congenital	O
microcoria	O
is	O
a	O
potential	O
risk	O
factor	O
for	O
glaucoma	O
,	O
although	O
this	O
observation	O
is	O
complicated	O
by	O
the	O
partial	O
segregation	O
of	O
MYOC	O
Q48H	B-ProteinMutation
(1q24.3-q25.2)	O
,	O
a	O
mutation	O
known	O
to	O
be	O
associated	O
with	O
glaucoma	O
in	O
India	O
.	O

Fine	O
mapping	O
and	O
candidate	O
gene	O
analysis	O
continues	O
with	O
the	O
hope	O
that	O
characterizing	O
the	O
micocoria	O
gene	O
will	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
microcoria	O
and	O
glaucoma	O
causation	O
.	O

The	O
relationship	O
between	O
microcoria	O
,	O
glaucoma	O
,	O
and	O
the	O
MYOC	O
Q48H	B-ProteinMutation
mutation	O
in	O
this	O
family	O
is	O
discussed	O
.	O

Segregation	O
of	O
a	O
M404V	B-ProteinMutation
mutation	O
of	O
the	O
p62/sequestosome	O
1	O
(p62/SQSTM1)	O
gene	O
with	O
polyostotic	O
Paget's	O
disease	O
of	O
bone	O
in	O
an	O
Italian	O
family	O
.	O

Mutations	O
of	O
the	O
p62/Sequestosome	O
1	O
gene	O
(p62/SQSTM1)	O
account	O
for	O
both	O
sporadic	O
and	O
familial	O
forms	O
of	O
Paget's	O
disease	O
of	O
bone	O
(PDB)	O
.	O

We	O
originally	O
described	O
a	O
methionine-->valine	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
404	I-ProteinMutation
M404V	B-ProteinMutation
of	O
exon	O
8	O
,	O
in	O
the	O
ubiquitin	O
protein-binding	O
domain	O
of	O
p62/SQSTM1	O
gene	O
in	O
an	O
Italian	O
PDB	O
patient	O
.	O

The	O
collection	O
of	O
data	O
from	O
the	O
patient's	O
pedigree	O
provided	O
evidence	O
for	O
a	O
familial	O
form	O
of	O
PDB	O
.	O

Extension	O
of	O
the	O
genetic	O
analysis	O
to	O
other	O
relatives	O
in	O
this	O
family	O
demonstrated	O
segregation	O
of	O
the	O
M404V	B-ProteinMutation
mutation	O
with	O
the	O
polyostotic	O
PDB	O
phenotype	O
and	O
provided	O
the	O
identification	O
of	O
six	O
asymptomatic	O
gene	O
carriers	O
.	O

DNA	O
for	O
mutational	O
analysis	O
of	O
the	O
exon	O
8	O
coding	O
sequence	O
was	O
obtained	O
from	O
22	O
subjects	O
,	O
4	O
PDB	O
patients	O
and	O
18	O
clinically	O
unaffected	O
members	O
.	O

Of	O
the	O
five	O
clinically	O
ascertained	O
affected	O
members	O
of	O
the	O
family	O
,	O
four	O
possessed	O
the	O
M404V	B-ProteinMutation
mutation	O
and	O
exhibited	O
the	O
polyostotic	O
form	O
of	O
PDB	O
,	O
except	O
one	O
patient	O
with	O
a	O
single	O
X-ray-assessed	O
skeletal	O
localization	O
and	O
one	O
with	O
a	O
polyostotic	O
disease	O
who	O
had	O
died	O
several	O
years	O
before	O
the	O
DNA	O
analysis	O
.	O

By	O
both	O
reconstitution	O
and	O
mutational	O
analysis	O
of	O
the	O
pedigree	O
,	O
six	O
unaffected	O
subjects	O
were	O
shown	O
to	O
bear	O
the	O
M404V	B-ProteinMutation
mutation	O
,	O
representing	O
potential	O
asymptomatic	O
gene	O
carriers	O
whose	O
circulating	O
levels	O
of	O
alkaline	O
phosphatase	O
were	O
recently	O
assessed	O
as	O
still	O
within	O
the	O
normal	O
range	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
a	O
genotype-phenotype	O
correlation	O
between	O
the	O
M404V	B-ProteinMutation
mutation	O
in	O
the	O
p62/SQSTM1	O
gene	O
and	O
a	O
polyostotic	O
form	O
of	O
PDB	O
in	O
this	O
family	O
.	O

The	O
high	O
penetrance	O
of	O
the	O
PDB	O
trait	O
in	O
this	O
family	O
together	O
with	O
the	O
study	O
of	O
the	O
asymptomatic	O
gene	O
carriers	O
will	O
allow	O
us	O
to	O
confirm	O
the	O
proposed	O
genotype-phenotype	O
correlation	O
and	O
to	O
evaluate	O
the	O
potential	O
use	O
of	O
mutational	O
analysis	O
of	O
the	O
p62/SQSTM1	O
gene	O
in	O
the	O
early	O
detection	O
of	O
relatives	O
at	O
risk	O
for	O
PDB	O
.	O

HPRTSardinia	O
:	O
a	O
new	O
point	O
mutation	O
causing	O
HPRT	O
deficiency	O
without	O
Lesch-Nyhan	O
disease	O
.	O

Hypoxanthine-guanine	O
phosphoribosyltransferase	O
(HPRT)	O
deficiency	O
always	O
causing	O
hyperuricemia	O
presents	O
various	O
degrees	O
of	O
neurological	O
manifestations	O
,	O
the	O
most	O
severe	O
which	O
is	O
Lesch-Nyhan	O
syndrome	O
.	O

The	O
HPRT	O
gene	O
is	O
situated	O
in	O
the	O
region	O
Xq26-q27.2	O
and	O
consists	O
of	O
9	O
exons	O
.	O

At	O
least	O
300	O
different	O
mutations	O
at	O
different	O
sites	O
in	O
the	O
HPRT	O
coding	O
region	O
from	O
exon	O
1	O
to	O
exon	O
9	O
have	O
been	O
identified	O
.	O

A	O
new	O
mutation	O
in	O
the	O
HPRT	O
gene	O
has	O
been	O
determined	O
in	O
one	O
patient	O
with	O
complete	O
deficiency	O
of	O
erythrocyte	O
activity	O
,	O
with	O
hyperuricemia	O
and	O
gout	O
but	O
without	O
Lesch-Nyhan	O
disease	O
.	O

Analysis	O
of	O
cultured	O
fibroblasts	O
revealed	O
minimal	O
residual	O
HPRT	O
activity	O
mainly	O
when	O
guanine	O
was	O
the	O
substrate	O
.	O

Genomic	O
DNA	O
sequencing	O
demonstrated	O
patient's	O
mother	O
heterozygosity	O
for	O
the	O
mutation	O
and	O
no	O
mutation	O
in	O
her	O
brother	O
.	O

The	O
mutation	O
consists	O
in	O
a	O
C-->T	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
cDNA	I-DNAMutation
base	I-DNAMutation
463	I-DNAMutation
C463T	B-DNAMutation
in	O
exon	O
6	O
,	O
resulting	O
in	O
proline	O
to	O
serine	O
substitution	O
at	O
codon	O
155	O
P155S	B-ProteinMutation
.	O

This	O
mutation	O
had	O
not	O
been	O
reported	O
previously	O
and	O
has	O
been	O
designated	O
HPRT(Sardinia)	O
.	O

The	O
mutation	O
identified	O
in	O
this	O
patient	O
allows	O
some	O
expression	O
of	O
functional	O
enzyme	O
in	O
nucleated	O
cells	O
such	O
as	O
fibroblasts	O
,	O
indicating	O
that	O
such	O
cell	O
type	O
may	O
add	O
further	O
information	O
to	O
conventional	O
blood	O
analysis	O
.	O

A	O
multicentre	O
survey	O
gathering	O
patients	O
with	O
variant	O
neurological	O
forms	O
could	O
contribute	O
to	O
understand	O
the	O
pathophysiology	O
of	O
the	O
neurobehavioral	O
symptoms	O
of	O
HPRT	O
deficiency	O
.	O

Genetic	O
variation	O
in	O
UCP2	O
(	O
uncoupling	O
protein-2	O
)	O
is	O
associated	O
with	O
energy	O
metabolism	O
in	O
Pima	O
Indians	O
.	O

AIMS/HYPOTHESIS	O
:	O
Uncoupling	O
protein-2	O
(UCP2)	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
insulin	O
secretion	O
and	O
the	O
development	O
of	O
obesity	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
genetic	O
variation	O
in	O
UCP2	O
on	O
type	O
2	O
diabetes	O
and	O
obesity	O
,	O
as	O
well	O
as	O
on	O
metabolic	O
phenotypes	O
related	O
to	O
these	O
diseases	O
,	O
in	O
Pima	O
Indians	O
.	O

METHODS	O
:	O
The	O
coding	O
and	O
untranslated	O
regions	O
of	O
UCP2	O
,	O
and	O
approximately	O
1	O
kb	O
of	O
the	O
5'	O
upstream	O
region	O
,	O
were	O
sequenced	O
in	O
DNA	O
samples	O
taken	O
from	O
83	O
extremely	O
obese	O
Pima	O
Indians	O
who	O
were	O
not	O
first-degree	O
relatives	O
.	O

RESULTS	O
:	O
Five	O
variants	O
were	O
identified	O
:	O
(1)	O
a	O
-866G/A	B-DNAMutation
in	O
the	O
5'	O
upstream	O
region	O
;	O
(2)	O
a	O
G/A	B-DNAMutation
in	O
exon	O
2	O
;	O
(3)	O
a	O
C/T	B-DNAMutation
resulting	O
in	O
an	O
Ala55Val	B-ProteinMutation
substitution	O
in	O
exon	O
4	O
;	O
and	O
(	O
4	O
,	O
5	O
)	O
two	O
insertion/deletions	O
(	O
ins/del	O
;	O
45-bp	O
and	O
3-bp	O
)	O
in	O
the	O
3'	O
untranslated	O
region	O
.	O

Among	O
the	O
83	O
subjects	O
whose	O
DNA	O
was	O
sequenced	O
,	O
the	O
-866G/A	B-DNAMutation
was	O
in	O
complete	O
genotypic	O
concordance	O
with	O
the	O
Ala55Val	B-ProteinMutation
and	O
the	O
3-bp	O
ins/del	O
polymorphism	O
.	O

The	O
G/A	B-DNAMutation
polymorphism	O
in	O
exon	O
2	O
was	O
extremely	O
rare	O
.	O

To	O
capture	O
the	O
common	O
variation	O
in	O
this	O
gene	O
for	O
association	O
analyses	O
,	O
the	O
-866G/A	B-DNAMutation
variant	O
(	O
as	O
a	O
representative	O
of	O
Ala55Val	B-ProteinMutation
and	O
the	O
3-bp	O
ins/del	O
polymorphism	O
)	O
and	O
the	O
45-bp	O
ins/del	O
were	O
also	O
genotyped	O
for	O
864	O
full-blooded	O
Pima	O
Indians	O
.	O

Neither	O
of	O
these	O
variants	O
was	O
associated	O
with	O
type	O
2	O
diabetes	O
or	O
body	O
mass	O
index	O
.	O

However	O
,	O
in	O
a	O
subgroup	O
of	O
185	O
subjects	O
who	O
had	O
undergone	O
detailed	O
metabolic	O
measurements	O
,	O
these	O
variants	O
were	O
associated	O
with	O
24-h	O
energy	O
expenditure	O
as	O
measured	O
in	O
a	O
human	O
metabolic	O
chamber	O
(	O
p=0.007	O
for	O
the	O
45-bp	O
ins/del	O
and	O
p=0.03	O
for	O
the	O
-866G/A	B-DNAMutation
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
family	O
membership	O
,	O
fat-free	O
mass	O
and	O
fat	O
mass	O
)	O
.	O

CONCLUSIONS/INTERPRETATION	O
:	O
Our	O
data	O
indicate	O
that	O
variation	O
in	O
UCP2	O
may	O
play	O
a	O
role	O
in	O
energy	O
metabolism	O
,	O
but	O
this	O
gene	O
does	O
not	O
contribute	O
significantly	O
to	O
the	O
aetiology	O
of	O
type	O
2	O
diabetes	O
and/or	O
obesity	O
in	O
Pima	O
Indians	O
.	O

Association	O
of	O
atopy	O
and	O
eczema	O
with	O
polymorphisms	O
in	O
T-cell	O
immunoglobulin	O
domain	O
and	O
mucin	O
domain-IL-2-inducible	O
T-cell	O
kinase	O
gene	O
cluster	O
in	O
chromosome	O
5	O
q	O
33	O
.	O

BACKGROUND	O
:	O
The	O
T-cell	O
immunoglobulin	O
domain	O
and	O
mucin	O
domain	O
(TIM)	O
gene	O
family	O
and	O
the	O
gene	O
for	O
IL-2-inducible	O
T-cell	O
kinase	O
(ITK)	O
,	O
located	O
in	O
chromosome	O
5	O
q	O
33	O
and	O
potentially	O
involved	O
in	O
the	O
T-cell	O
proliferation	O
and	O
differentiation	O
,	O
are	O
good	O
candidate	O
genes	O
for	O
allergic	O
diseases	O
.	O

OBJECTIVE	O
:	O
We	O
assessed	O
the	O
role	O
of	O
polymorphisms	O
in	O
the	O
TIM	O
family	O
genes	O
and	O
ITK	O
in	O
atopy	O
,	O
eczema	O
,	O
and	O
asthma	O
.	O

METHODS	O
:	O
Twenty-one	O
polymorphisms	O
in	O
the	O
TIM-ITK	O
gene	O
cluster	O
were	O
genotyped	O
in	O
564	O
children	O
enrolled	O
in	O
the	O
Tucson	O
Children's	O
Respiratory	O
Study	O
.	O

Skin	O
prick	O
tests	O
to	O
common	O
allergens	O
were	O
performed	O
at	O
age	O
6.1	O
years	O
(n=508)	O
,	O
age	O
10.8	O
years	O
(n=539)	O
,	O
and	O
age	O
16.6	O
years	O
(n=424)	O
.	O

Asthma	O
and	O
eczema	O
were	O
assessed	O
by	O
questionnaire	O
at	O
these	O
3	O
points	O
.	O

Averaged	O
relative	O
risks	O
were	O
estimated	O
.	O

RESULTS	O
:	O
One	O
15-bp	O
insertion/deletion	O
in	O
exon	O
4	O
of	O
TIM	O
1	O
was	O
significantly	O
related	O
to	O
atopy	O
and	O
eczema	O
(	O
relative	O
risk	O
associated	O
with	O
carrying	O
at	O
least	O
1	O
rare	O
allele=1.24	O
[1.07--1.45]	O
,	O
P=.005	O
;	O
and	O
1.43	O
[1.01--2.01]	O
,	O
P=.004	O
,	O
respectively	O
)	O
.	O

The	O
3	O
tested	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
TIM	O
3	O
were	O
significantly	O
related	O
to	O
atopy	O
and	O
eczema	O
.	O

One	O
of	O
them	O
,	O
at	O
position	O
+4259	O
calculated	O
from	O
the	O
translation	O
start	O
site	O
,	O
predicts	O
a	O
putative	O
change	O
in	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
protein	O
,	O
and	O
was	O
the	O
most	O
strongly	O
related	O
to	O
atopy	O
(	O
relative	O
risk=1.28	O
[1.12--1.47]	O
;	O
P=.0003	O
)	O
.	O

SNPs	O
in	O
the	O
5'	O
genomic	O
region	O
in	O
ITK	O
,	O
which	O
show	O
moderate	O
linkage	O
disequilibrium	O
with	O
those	O
in	O
TIM	O
3	O
,	O
had	O
an	O
independent	O
effect	O
on	O
atopy	O
.	O

None	O
of	O
the	O
polymorphisms	O
studied	O
was	O
related	O
to	O
asthma	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
support	O
a	O
potential	O
role	O
for	O
SNPs	O
in	O
TIM	O
1	O
,	O
TIM	O
3	O
,	O
and	O
ITK	O
,	O
independent	O
of	O
each	O
other	O
,	O
in	O
allergic	O
diseases	O
.	O

Carrier	O
frequency	O
of	O
mutation	O
657del5	B-DNAMutation
in	O
the	O
NBS1	O
gene	O
in	O
a	O
population	O
of	O
Polish	O
pediatric	O
patients	O
with	O
sporadic	O
lymphoid	O
malignancies	O
.	O

Nijmegen	O
breakage	O
syndrome	O
(NBS)	O
is	O
a	O
human	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
genomic	O
instability	O
and	O
enhanced	O
cancer	O
predisposition	O
,	O
in	O
particular	O
to	O
lymphoma	O
and	O
leukemia	O
.	O

Recently	O
,	O
significantly	O
higher	O
frequencies	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Slavic	O
founder	O
NBS1	O
mutation	O
,	O
657del5	B-DNAMutation
,	O
were	O
found	O
in	O
Russian	O
children	O
with	O
sporadic	O
lymphoid	O
malignancies	O
,	O
and	O
in	O
Polish	O
adults	O
with	O
non-Hodgkin	O
lymphoma	O
(NHL)	O
.	O

In	O
addition	O
,	O
the	O
substitution	O
643C>T	B-DNAMutation
R215W	B-ProteinMutation
has	O
also	O
been	O
found	O
in	O
excess	O
among	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
.	O

In	O
an	O
attempt	O
to	O
asses	O
the	O
contribution	O
of	O
both	O
mutations	O
to	O
the	O
development	O
of	O
sporadic	O
lymphoid	O
malignancies	O
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
a	O
large	O
group	O
of	O
Polish	O
pediatric	O
patients	O
.	O

The	O
NBS1	O
mutation	O
657del5	B-DNAMutation
on	O
one	O
allele	O
was	O
found	O
in	O
3	O
of	O
270	O
patients	O
with	O
ALL	O
and	O
2	O
of	O
212	O
children	O
and	O
adolescents	O
with	O
NHL	O
;	O
no	O
carrier	O
was	O
found	O
among	O
63	O
patients	O
with	O
Hodgkin	O
lymphoma	O
(HL)	O
.	O

No	O
carriers	O
of	O
the	O
variant	O
R215W	B-ProteinMutation
were	O
detected	O
in	O
any	O
studied	O
group	O
.	O

The	O
relative	O
frequency	O
of	O
the	O
657del5	B-DNAMutation
mutation	O
was	O
calculated	O
from	O
a	O
total	O
of	O
6,984	O
controls	O
matched	O
by	O
place	O
of	O
patient	O
residence	O
,	O
of	O
whom	O
42	O
were	O
found	O
to	O
be	O
carriers	O
(	O
frequency	O
=	O
0.006	O
)	O
.	O

In	O
the	O
analyzed	O
population	O
with	O
malignancies	O
,	O
an	O
increased	O
odds	O
ratio	O
for	O
the	O
occurrence	O
of	O
mutation	O
657del5	B-DNAMutation
was	O
found	O
in	O
comparison	O
with	O
the	O
control	O
Polish	O
population	O
(	O
OR	O
range	O
1.48-1.85	O
,	O
95%	O
confidence	O
interval	O
1.18-2.65	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
the	O
frequency	O
of	O
the	O
mutation	O
carriers	O
was	O
indeed	O
increased	O
in	O
patients	O
with	O
ALL	O
and	O
NHL	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Nonetheless	O
,	O
NBS1	O
gene	O
heterozygosity	O
is	O
not	O
a	O
major	O
risk	O
factor	O
for	O
lymphoid	O
malignancies	O
in	O
childhood	O
and	O
adolescence	O
.	O

Dominant	O
and	O
recessive	O
COL6A1	O
mutations	O
in	O
Ullrich	O
scleroatonic	O
muscular	O
dystrophy	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
five	O
Ullrich	O
scleroatonic	O
muscular	O
dystrophy	O
patients	O
(	O
two	O
Italians	O
,	O
one	O
Belgian	O
,	O
and	O
two	O
Turks	O
)	O
with	O
a	O
clinical	O
phenotype	O
showing	O
different	O
degrees	O
of	O
severity	O
,	O
all	O
carrying	O
mutations	O
localized	O
in	O
COL6A1	O
.	O

We	O
sequenced	O
the	O
three	O
entire	O
COL6	O
complementary	O
DNA	O
.	O

Three	O
of	O
five	O
patients	O
have	O
recessive	O
mutations	O
:	O
two	O
patients	O
(	O
P1and	O
P3	O
)	O
have	O
homozygous	O
single-nucleotide	O
deletions	O
,	O
one	O
in	O
exon	O
9	O
and	O
one	O
in	O
exon	O
22	O
;	O
one	O
patient	O
(P2)	O
has	O
a	O
homozygous	O
single-nucleotide	O
substitution	O
leading	O
to	O
a	O
premature	O
termination	O
codon	O
in	O
exon	O
31	O
.	O

The	O
nonsense	O
mutation	O
of	O
P2	O
also	O
causes	O
a	O
partial	O
skipping	O
of	O
exon	O
31	O
with	O
the	O
formation	O
of	O
a	O
premature	O
termination	O
codon	O
in	O
exon	O
32	O
in	O
15%	O
of	O
the	O
total	O
COL6A1	O
messenger	O
RNA	O
.	O

The	O
remaining	O
two	O
patients	O
carry	O
a	O
heterozygous	O
glycine	O
substitution	O
in	O
exons	O
9	O
and	O
10	O
inside	O
the	O
triple-helix	O
region	O
;	O
both	O
are	O
dominant	O
mutations	O
because	O
the	O
missense	O
mutations	O
are	O
absent	O
in	O
the	O
DNA	O
of	O
their	O
respective	O
parents	O
.	O

As	O
for	O
the	O
three	O
homozygous	O
recessive	O
mutations	O
,	O
the	O
apparently	O
healthy	O
consanguineous	O
parents	O
all	O
carry	O
a	O
heterozygous	O
mutated	O
allele	O
.	O

Here	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
report	O
a	O
genotype-phenotype	O
correlation	O
demonstrating	O
that	O
heterozygous	O
glycine	O
substitutions	O
in	O
the	O
triple-helix	O
domain	O
of	O
COL6A1	O
are	O
dominant	O
and	O
responsible	O
for	O
a	O
milder	O
Ullrich	O
scleroatonic	O
muscular	O
dystrophy	O
phenotype	O
,	O
and	O
that	O
recessive	O
mutations	O
in	O
COL6A1	O
correlate	O
with	O
more	O
severe	O
clinical	O
and	O
biochemical	O
Ullrich	O
scleroatonic	O
muscular	O
dystrophy	O
phenotypes	O
.	O

A	O
single-nucleotide	O
polymorphism	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
hPER2	O
gene	O
is	O
associated	O
with	O
diurnal	O
preference	O
.	O

The	O
PERIOD2	O
(PER2)	O
gene	O
is	O
a	O
key	O
component	O
of	O
the	O
molecular	O
mechanism	O
that	O
generates	O
circadian	O
rhythms	O
in	O
mammals	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
human	O
PER2	O
gene	O
has	O
previously	O
been	O
linked	O
to	O
advanced	O
sleep	O
phase	O
syndrome	O
(ASPS)	O
.	O

We	O
have	O
investigated	O
three	O
other	O
single-nucleotide	O
polymorphisms	O
in	O
the	O
hPER2	O
gene	O
,	O
one	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
C-1228T	B-DNAMutation
,	O
one	O
in	O
exon	O
2	O
in	O
the	O
5'-untranslated	O
region	O
(5'-UTR)	O
C111G	B-DNAMutation
,	O
and	O
one	O
missense	O
mutation	O
G3853A	B-DNAMutation
causing	O
a	O
glycine	O
to	O
glutamine	O
substitution	O
in	O
the	O
predicted	O
protein	O
.	O

Subjects	O
selected	O
from	O
a	O
group	O
of	O
484	O
volunteers	O
for	O
extreme	O
morning	O
or	O
evening	O
preference	O
,	O
or	O
intermediate	O
diurnal	O
preference	O
were	O
genotyped	O
with	O
regard	O
to	O
the	O
three	O
polymorphisms	O
(	O
n=35	O
for	O
each	O
group	O
)	O
.	O

Whereas	O
allele	O
frequencies	O
for	O
the	O
other	O
two	O
polymorphisms	O
did	O
not	O
differ	O
significantly	O
between	O
any	O
of	O
the	O
groups	O
,	O
the	O
111G	O
allele	O
frequency	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
extreme	O
morning	O
preference	O
(0.14)	O
than	O
in	O
subjects	O
with	O
extreme	O
evening	O
preference	O
(0.03)	O
(	O
Fisher's	O
exact	O
test	O
,	O
two-sided	O
P	O
value=0.031	O
,	O
odds	O
ratio=5.67	O
)	O
.	O

No	O
significant	O
difference	O
in	O
111G	O
allele	O
frequency	O
was	O
observed	O
between	O
either	O
of	O
these	O
groups	O
and	O
subjects	O
with	O
intermediate	O
diurnal	O
preference	O
.	O

Computer	O
prediction	O
indicated	O
that	O
the	O
C111G	B-DNAMutation
polymorphism	O
,	O
which	O
occurs	O
12	O
bases	O
upstream	O
from	O
the	O
translation	O
start	O
codon	O
,	O
might	O
alter	O
the	O
secondary	O
structure	O
of	O
the	O
transcript	O
.	O

The	O
PER2	O
111G	O
allele	O
associates	O
with	O
morning	O
preference	O
and	O
is	O
a	O
potential	O
candidate	O
allele	O
for	O
ASPS	O
.	O

Allelic	O
expression	O
imbalance	O
of	O
human	O
mu	O
opioid	O
receptor	O
(OPRM1)	O
caused	O
by	O
variant	O
A118G	B-DNAMutation
.	O

As	O
a	O
primary	O
target	O
for	O
opioid	O
drugs	O
and	O
peptides	O
,	O
the	O
mu	O
opioid	O
receptor	O
(OPRM1)	O
plays	O
a	O
key	O
role	O
in	O
pain	O
perception	O
and	O
addiction	O
.	O

Genetic	O
variants	O
of	O
OPRM1	O
have	O
been	O
implicated	O
in	O
predisposition	O
to	O
drug	O
addiction	O
,	O
in	O
particular	O
the	O
single	O
nucleotide	O
polymorphism	O
A118G	B-DNAMutation
,	O
leading	O
to	O
an	O
N40D	B-ProteinMutation
substitution	O
,	O
with	O
an	O
allele	O
frequency	O
of	O
10-32%	O
,	O
and	O
uncertain	O
functions	O
.	O

We	O
have	O
measured	O
allele-specific	O
mRNA	O
expression	O
of	O
OPRM1	O
in	O
human	O
autopsy	O
brain	O
tissues	O
,	O
using	O
A118G	B-DNAMutation
as	O
a	O
marker	O
.	O

In	O
8	O
heterozygous	O
samples	O
measured	O
,	O
the	O
A118	O
mRNA	O
allele	O
was	O
1.5-2.5-fold	O
more	O
abundant	O
than	O
the	O
G118	O
allele	O
.	O

Transfection	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
of	O
a	O
cDNA	O
representing	O
only	O
the	O
coding	O
region	O
of	O
OPRM1	O
,	O
carrying	O
adenosine	O
,	O
guanosine	O
,	O
cytidine	O
,	O
and	O
thymidine	O
in	O
position	O
118	O
,	O
resulted	O
in	O
1.5-fold	O
lower	O
mRNA	O
levels	O
only	O
for	O
OPRM1-G118	O
,	O
and	O
more	O
than	O
10-fold	O
lower	O
OPRM1	O
protein	O
levels	O
,	O
measured	O
by	O
Western	O
blotting	O
and	O
receptor	O
binding	O
assay	O
.	O

After	O
transfection	O
and	O
inhibition	O
of	O
transcription	O
with	O
actinomycin	O
D	O
,	O
analysis	O
of	O
mRNA	O
turnover	O
failed	O
to	O
reveal	O
differences	O
in	O
mRNA	O
stability	O
between	O
A118	O
and	O
G118	O
alleles	O
,	O
indicating	O
a	O
defect	O
in	O
transcription	O
or	O
mRNA	O
maturation	O
.	O

These	O
results	O
indicate	O
that	O
OPRM1-G118	O
is	O
a	O
functional	O
variant	O
with	O
deleterious	O
effects	O
on	O
both	O
mRNA	O
and	O
protein	O
yield	O
.	O

Clarifying	O
the	O
functional	O
relevance	O
of	O
polymorphisms	O
associated	O
with	O
susceptibility	O
to	O
a	O
complex	O
disorder	O
such	O
as	O
drug	O
addiction	O
provides	O
a	O
foundation	O
for	O
clinical	O
association	O
studies	O
.	O

Identification	O
of	O
a	O
novel	O
WFS1	O
mutation	O
AFF344-345ins	B-ProteinMutation
in	O
Japanese	O
patients	O
with	O
Wolfram	O
syndrome	O
.	O

Wolfram	O
syndrome	O
(WFS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
early	O
onset	O
diabetes	O
mellitus	O
,	O
progressive	O
optic	O
atrophy	O
,	O
sensorineural	O
deafness	O
and	O
diabetes	O
insipidus	O
.	O

Affected	O
individuals	O
may	O
also	O
have	O
renal	O
tract	O
abnormalities	O
as	O
well	O
as	O
neurogical	O
and	O
psychiatric	O
syndromes	O
.	O

WFS1	O
encoding	O
a	O
transmembrane	O
protein	O
was	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
WFS	O
.	O

We	O
report	O
herein	O
a	O
Japanese	O
family	O
,	O
of	O
which	O
two	O
members	O
had	O
this	O
syndrome	O
.	O

In	O
the	O
WFS1	O
gene	O
of	O
these	O
patients	O
,	O
we	O
identified	O
a	O
novel	O
mutation	O
,	O
a	O
nine	O
nucleotide	O
insertion	O
AFF344-345ins	B-ProteinMutation
.	O

In	O
addition	O
,	O
one	O
of	O
these	O
patients	O
had	O
preclinical	O
hypopituitarism	O
,	O
which	O
is	O
an	O
unusual	O
feature	O
of	O
WFS	O
.	O

As	O
only	O
the	O
two	O
family	O
members	O
homozygous	O
for	O
the	O
mutation	O
showed	O
WFS	O
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
this	O
mutation	O
is	O
the	O
cause	O
of	O
WFS	O
.	O

Loss	O
of	O
heterozygosity	O
and	O
transcriptome	O
analyses	O
of	O
a	O
1.2	O
Mb	O
candidate	O
ovarian	O
cancer	O
tumor	O
suppressor	O
locus	O
region	O
at	O
17q25.1-q25.2	O
.	O

Loss	O
of	O
heterozygosity	O
(LOH)	O
analysis	O
was	O
performed	O
in	O
epithelial	O
ovarian	O
cancers	O
(EOC)	O
to	O
further	O
characterize	O
a	O
previously	O
identified	O
candidate	O
tumor	O
suppressor	O
gene	O
(TSG)	O
region	O
encompassing	O
D17S801	O
at	O
chromosomal	O
region	O
17q25.1	O
.	O

LOH	O
of	O
at	O
least	O
one	O
informative	O
marker	O
was	O
observed	O
for	O
100	O
(71%)	O
of	O
140	O
malignant	O
EOC	O
samples	O
in	O
an	O
analysis	O
of	O
6	O
polymorphic	O
markers	O
(cen-D17S1839-D17S785-D17S1817-D17S801-D17S751-D17S722-tel)	O
.	O

The	O
combined	O
LOH	O
analysis	O
revealed	O
a	O
453	O
kilobase	O
(Kb)	O
minimal	O
region	O
of	O
deletion	O
(MRD)	O
bounded	O
by	O
D17S1817	O
and	O
D17S751	O
.	O

Human	O
and	O
mouse	O
genome	O
assemblies	O
were	O
used	O
to	O
resolve	O
marker	O
inconsistencies	O
in	O
the	O
D17S1839-D17S722	O
interval	O
and	O
identify	O
candidates	O
.	O

The	O
region	O
contains	O
32	O
known	O
and	O
strongly	O
predicted	O
genes	O
,	O
9	O
of	O
which	O
overlap	O
the	O
MRD	O
.	O

The	O
reference	O
genomic	O
sequences	O
share	O
nearly	O
identical	O
gene	O
structures	O
and	O
the	O
organization	O
of	O
the	O
region	O
is	O
highly	O
collinear	O
.	O

Although	O
,	O
the	O
region	O
does	O
not	O
show	O
any	O
large	O
internal	O
duplications	O
,	O
a	O
1.5	O
Kb	O
inverted	O
duplicated	O
sequence	O
of	O
87%	O
nucleotide	O
identity	O
was	O
observed	O
in	O
a	O
13	O
Kb	O
region	O
surrounding	O
D17S801	O
.	O

Transcriptome	O
analysis	O
by	O
Affymetrix	O
GeneChip	O
and	O
reverse	O
transcription	O
(RT)-polymerase	O
chain	O
reaction	O
(PCR)	O
methods	O
of	O
3	O
well	O
characterized	O
EOC	O
cell	O
lines	O
and	O
primary	O
cultures	O
of	O
normal	O
ovarian	O
surface	O
epithelial	O
(NOSE)	O
cells	O
was	O
performed	O
with	O
32	O
candidates	O
spanning	O
D17S1839-D17S722	O
interval	O
.	O

RT-PCR	O
analysis	O
of	O
8	O
known	O
or	O
strongly	O
predicted	O
genes	O
residing	O
in	O
the	O
MRD	O
in	O
10	O
EOC	O
samples	O
,	O
that	O
exhibited	O
LOH	O
of	O
the	O
MRD	O
,	O
identified	O
FLJ22341	O
as	O
a	O
strong	O
candidate	O
TSG	O
.	O

The	O
proximal	O
repeat	O
sequence	O
of	O
D17S801	O
occurs	O
8	O
Kb	O
upstream	O
of	O
the	O
putative	O
promoter	O
region	O
of	O
FLJ22341	O
.	O

RT-PCR	O
analysis	O
of	O
the	O
EOC	O
samples	O
and	O
cell	O
lines	O
identified	O
DKFZP434P0316	O
that	O
maps	O
proximal	O
to	O
the	O
MRD	O
,	O
as	O
a	O
candidate	O
.	O

While	O
Affymetrix	O
technology	O
was	O
useful	O
for	O
initially	O
eliminating	O
less	O
promising	O
candidates	O
,	O
subsequent	O
RT-PCR	O
analysis	O
of	O
well-characterized	O
EOC	O
samples	O
was	O
essential	O
to	O
prioritize	O
TSG	O
candidates	O
for	O
further	O
study	O
.	O

Autosomal	O
dominant	O
inheritance	O
of	O
Williams-Beuren	O
syndrome	O
in	O
a	O
father	O
and	O
son	O
with	O
haploinsufficiency	O
for	O
FKBP6	O
.	O

Williams-Beuren	O
syndrome	O
(WBS)	O
is	O
a	O
neurodevelopmental	O
microdeletion	O
disorder	O
that	O
usually	O
occurs	O
sporadically	O
due	O
to	O
its	O
location	O
within	O
a	O
highly	O
repetitive	O
genomic	O
region	O
that	O
is	O
unstable	O
and	O
prone	O
to	O
unequal	O
cross-over	O
during	O
meiosis	O
.	O

The	O
consequential	O
loss	O
of	O
chromosomal	O
material	O
includes	O
approximately	O
1.5	O
Mb	O
of	O
DNA	O
at	O
7q11.23	O
.	O

Whilst	O
cases	O
of	O
dominant	O
inheritance	O
have	O
been	O
described	O
in	O
the	O
literature	O
,	O
there	O
have	O
been	O
few	O
reports	O
of	O
molecular	O
confirmation	O
and	O
none	O
have	O
carried	O
out	O
detailed	O
genotyping	O
.	O

We	O
describe	O
a	O
Bulgarian	O
father	O
and	O
son	O
with	O
WBS	O
detected	O
by	O
fluorescent	O
in	O
situ	O
hybridisation	O
(	O
with	O
an	O
elastin	O
gene	O
probe	O
)	O
and	O
loss	O
of	O
heterozygosity	O
mapping	O
using	O
microsatellite	O
markers	O
located	O
in	O
the	O
critical	O
region	O
.	O

These	O
individuals	O
appear	O
to	O
have	O
a	O
common	O
WBS	O
heterozygous	O
deletion	O
,	O
confirming	O
the	O
expected	O
dominant	O
transmission	O
and	O
adding	O
to	O
the	O
few	O
familial	O
cases	O
reported	O
.	O

The	O
deletion	O
includes	O
the	O
gene	O
FKBP6	O
which	O
has	O
recently	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
homologous	O
chromosome	O
pairing	O
in	O
meiosis	O
and	O
male	O
fertility	O
in	O
mouse	O
models	O
.	O

Homozygous	O
Fkbp6	O
-/-	O
male	O
mice	O
are	O
infertile	O
and	O
our	O
data	O
suggests	O
that	O
haploinsufficiency	O
for	O
FKBP6	O
does	O
not	O
appear	O
to	O
preclude	O
male	O
fertility	O
in	O
WBS	O
,	O
although	O
male	O
infertility	O
involving	O
this	O
gene	O
has	O
the	O
potential	O
to	O
follow	O
the	O
mouse	O
model	O
as	O
a	O
human	O
autosomal	O
recessive	O
condition	O
.	O

Hb	O
zoeterwoude	O
[	O
beta23(B5)Val-->Ala	B-ProteinMutation
)	O
]	O
:	O
a	O
new	O
beta-globin	O
variant	O
found	O
in	O
association	O
with	O
erythrocytosis	O
.	O

We	O
describe	O
the	O
characterization	O
of	O
a	O
new	O
hemoglobin	O
(Hb)	O
variant	O
found	O
in	O
a	O
77-year-old	O
Dutch	O
woman	O
,	O
suspected	O
of	O
hypoxia-mediated	O
erythrocytosis	O
.	O

The	O
typical	O
blood	O
parameters	O
(	O
Hb	O
17.3	O
g/dL	O
;	O
PCV	O
0.525	O
L/L	O
;	O
RBC	O
5.82	O
x	O
10(12)/L	O
)	O
could	O
not	O
be	O
explained	O
by	O
any	O
of	O
the	O
pathological	O
or	O
physiological	O
conditions	O
causing	O
erythrocytosis	O
.	O

The	O
patient	O
was	O
preventively	O
phlebotomized	O
because	O
of	O
intermittent	O
claudication	O
and	O
erythrocytosis	O
.	O

At	O
the	O
hematological	O
and	O
biochemical	O
levels	O
,	O
no	O
anemia	O
or	O
hemolysis	O
were	O
present	O
and	O
no	O
abnormal	O
Hb	O
fractions	O
were	O
detectable	O
on	O
alkaline	O
electrophoresis	O
or	O
high	O
performance	O
liquid	O
chromatography	O
(HPLC)	O
.	O

Molecular	O
analysis	O
revealed	O
intact	O
alpha-globin	O
genes	O
and	O
a	O
heterozygosity	O
for	O
a	O
GTT-->GCT	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
23	I-DNAMutation
of	O
the	O
beta-globin	O
gene	O
,	O
causing	O
a	O
Val-->Ala	B-ProteinMutation
amino	O
acid	O
substitution	O
.	O

The	O
P50	O
measured	O
in	O
full	O
blood	O
indicated	O
that	O
this	O
mutant	O
has	O
an	O
elevated	O
oxygen	O
affinity	O
.	O

This	O
is	O
the	O
fourth	O
single	O
nucleotide	O
substitution	O
at	O
codon	O
23	O
of	O
the	O
beta	O
gene	O
and	O
the	O
second	O
associated	O
with	O
erythrocytosis	O
.	O

Because	O
the	O
family	O
was	O
not	O
available	O
for	O
investigation	O
no	O
information	O
was	O
obtained	O
as	O
to	O
whether	O
the	O
mutation	O
represents	O
a	O
de	O
novo	O
event	O
or	O
was	O
inherited	O
,	O
and	O
might	O
be	O
a	O
more	O
common	O
cause	O
of	O
erythrocytosis	O
in	O
Dutch	O
patients	O
.	O

Considering	O
the	O
relatively	O
high	O
frequency	O
of	O
beta-thalassemia	O
(thal)	O
in	O
the	O
large	O
allochthonous	O
population	O
in	O
The	O
Netherlands	O
,	O
combinations	O
of	O
Hb	O
Zoeterwoude	O
and	O
beta-thal	O
traits	O
may	O
lead	O
to	O
hemizygosity	O
,	O
with	O
severe	O
hypoxia	O
and	O
erythrocytosis	O
from	O
a	O
few	O
months	O
after	O
birth	O
.	O

[	O
Angiotensin	O
converting	O
enzyme	O
gene	O
polymorphisms	O
and	O
coronary	O
risk	O
in	O
a	O
Portuguese	O
population	O
]	O
.	O

BACKGROUND	O
:	O
A	O
family	O
history	O
of	O
coronary	O
heart	O
disease	O
(CHD)	O
is	O
a	O
strong	O
risk	O
marker	O
for	O
the	O
disease	O
,	O
independently	O
of	O
classical	O
risk	O
factors	O
.	O

It	O
could	O
be	O
decoded	O
by	O
recognizing	O
the	O
polymorphisms	O
associated	O
with	O
increased	O
risk	O
.	O

Renin-angiotensin	O
system	O
genes	O
are	O
candidate	O
genes	O
in	O
CHD	O
and	O
the	O
deletion	O
allele	O
of	O
the	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
has	O
been	O
reported	O
as	O
deleterious	O
.	O

However	O
,	O
there	O
is	O
disagreement	O
as	O
to	O
the	O
role	O
of	O
the	O
insertion/deletion	O
polymorphism	O
of	O
the	O
ACE	O
gene	O
in	O
coronary	O
risk	O
.	O

AIM	O
:	O
To	O
evaluate	O
whether	O
ACE	O
gene	O
polymorphisms	O
constitute	O
a	O
CHD	O
risk	O
factor	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
population-based	O
case-control	O
study	O
of	O
301	O
subjects	O
with	O
a	O
history	O
of	O
myocardial	O
infarction	O
or	O
angiographic	O
evidence	O
of	O
coronary	O
heart	O
disease	O
and	O
510	O
age-	O
and	O
gender-matched	O
controls	O
,	O
without	O
CHD	O
,	O
living	O
in	O
a	O
region	O
with	O
high	O
CHD	O
mortality	O
rates	O
.	O

Blood	O
samples	O
were	O
taken	O
,	O
DNA	O
extracted	O
and	O
genotypes	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

Amplification	O
products	O
were	O
identified	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

STATISTICAL	O
ANALYSIS	O
:	O
The	O
Data	O
were	O
evaluated	O
by	O
SPSS	O
for	O
Windows	O
,	O
using	O
the	O
Student's	O
t	O
test	O
,	O
the	O
chi-square	O
test	O
,	O
odds	O
ratios	O
and	O
95%	O
confidence	O
intervals	O
.	O

RESULTS	O
:	O
The	O
prevalence	O
of	O
the	O
DD	O
,	O
ID	O
and	O
II	O
genotype	O
was	O
41.2%	O
,	O
46.3%	O
,	O
12.5%	O
in	O
the	O
cases	O
and	O
28.1%	O
,	O
55.2%	O
and	O
16.7%	O
in	O
the	O
control	O
group	O
.	O

The	O
frequency	O
of	O
the	O
DD	O
genotype	O
was	O
significantly	O
higher	O
in	O
the	O
cases	O
than	O
in	O
the	O
controls	O
(	O
41.2%	O
vs	O
.	O

28.1%	O
,	O
odds	O
ratio	O
1.79	O
,	O
95%	O
CI	O
1.31	O
to	O
2.4	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

By	O
contrast	O
,	O
the	O
ID	O
and	O
II	O
genotypes'	O
prevalence	O
was	O
higher	O
in	O
the	O
control	O
group	O
(	O
55.2%	O
vs	O
.	O

46.3%	O
,	O
p	O
=	O
0.002	O
and	O
16.7	O
vs	O
.	O

12.5%	O
,	O
p	O
=	O
NS	O
,	O
respectively	O
)	O
compared	O
to	O
the	O
case	O
group	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
clearly	O
shows	O
that	O
the	O
ACE	O
DD	O
polymorphism	O
is	O
strongly	O
linked	O
to	O
CHD	O
,	O
and	O
if	O
our	O
data	O
are	O
confirmed	O
in	O
a	O
larger	O
population	O
sample	O
,	O
more	O
aggressive	O
vascular	O
prevention	O
could	O
be	O
justified	O
in	O
patients	O
carrying	O
the	O
DD	O
genotype	O
.	O

DNA	O
repair	O
gene	O
polymorphisms	O
in	O
relation	O
to	O
chromosome	O
aberration	O
frequencies	O
in	O
retired	O
radiation	O
workers	O
.	O

Polymorphic	O
variation	O
in	O
DNA	O
repair	O
genes	O
was	O
examined	O
in	O
a	O
group	O
of	O
retired	O
workers	O
from	O
the	O
British	O
Nuclear	O
Fuels	O
plc	O
facility	O
at	O
Sellafield	O
in	O
relation	O
to	O
previously	O
determined	O
translocation	O
frequencies	O
in	O
peripheral	O
blood	O
lymphocytes	O
.	O

Variation	O
at	O
seven	O
polymorphisms	O
in	O
four	O
genes	O
involved	O
in	O
the	O
base	O
excision	O
repair	O
(	O
XRCC1	O
R194W	B-ProteinMutation
,	O
R399Q	B-ProteinMutation
and	O
a	O
[AC]n	O
microsatellite	O
in	O
the	O
3'	O
UTR	O
)	O
and	O
double	O
strand	O
break	O
repair	O
(	O
XRCC3	O
T241M	B-ProteinMutation
and	O
a	O
[AC]n	O
microsatellite	O
in	O
intron	O
3	O
of	O
XRCC3	O
,	O
XRCC4	O
I134T	B-ProteinMutation
,	O
and	O
a	O
GACTAn	O
microsatellite	O
located	O
120	O
kb	O
5'	O
of	O
XRCC5	O
)	O
pathways	O
was	O
determined	O
for	O
291	O
retired	O
radiation	O
workers	O
who	O
had	O
received	O
cumulative	O
occupational	O
external	O
radiation	O
doses	O
of	O
between	O
0	O
and	O
1873	O
mSv	O
.	O

When	O
the	O
interaction	O
between	O
radiation	O
dose	O
and	O
each	O
DNA	O
repair	O
gene	O
polymorphism	O
was	O
examined	O
in	O
relation	O
to	O
translocation	O
frequency	O
there	O
was	O
no	O
evidence	O
for	O
any	O
of	O
the	O
polymorphisms	O
studied	O
influencing	O
the	O
response	O
to	O
occupational	O
exposure	O
.	O

A	O
positive	O
interaction	O
observed	O
between	O
genotype	O
(	O
individuals	O
with	O
at	O
least	O
one	O
allele	O
>	O
or	O
=20	O
repeat	O
units	O
)	O
at	O
a	O
microsatellite	O
locus	O
in	O
the	O
XRCC3	O
gene	O
and	O
smoking	O
status	O
should	O
be	O
interpreted	O
cautiously	O
because	O
interactions	O
were	O
investigated	O
for	O
seven	O
polymorphisms	O
and	O
two	O
exposures	O
.	O

Nonetheless	O
,	O
further	O
research	O
is	O
warranted	O
to	O
examine	O
whether	O
this	O
DNA	O
repair	O
gene	O
variant	O
might	O
be	O
associated	O
with	O
a	O
sub-optimal	O
repair	O
response	O
to	O
smoking-induced	O
DNA	O
damage	O
and	O
hence	O
an	O
increased	O
frequency	O
of	O
translocations	O
.	O

Primary	O
malignant	O
lymphoma	O
of	O
the	O
brain	O
:	O
frequent	O
abnormalities	O
and	O
inactivation	O
of	O
p14	O
tumor	O
suppressor	O
gene	O
.	O

Ten	O
primary	O
central	O
nervous	O
system	O
lymphomas	O
(	O
PCNSL	O
,	O
brain	O
lymphomas	O
)	O
were	O
examined	O
for	O
p14	O
gene	O
exon	O
1beta	O
deletion	O
,	O
mutation	O
and	O
methylation	O
by	O
Southern	O
blot	O
analysis	O
,	O
nucleotide	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
clones	O
and	O
Southern	O
blot-based	O
methylation	O
assay	O
.	O

In	O
Southern	O
blot	O
analysis	O
,	O
from	O
the	O
signal	O
densities	O
of	O
the	O
hybridized	O
bands	O
and	O
their	O
similarities	O
to	O
those	O
of	O
exons	O
2	O
and	O
3	O
in	O
our	O
previous	O
quantitative	O
study	O
,	O
we	O
found	O
that	O
exon	O
1beta	O
was	O
homozygously	O
deleted	O
in	O
four	O
cases	O
,	O
hemizygously	O
deleted	O
in	O
five	O
cases	O
and	O
not	O
deleted	O
in	O
one	O
case	O
.	O

Thus	O
,	O
the	O
same	O
deletion	O
patterns	O
covered	O
the	O
entire	O
p14	O
gene	O
for	O
all	O
cases	O
except	O
for	O
one	O
case	O
,	O
which	O
suggested	O
the	O
hemizygous	O
deletion	O
of	O
exons	O
1beta	O
and	O
2	O
and	O
homozygous	O
deletion	O
of	O
exon	O
3	O
.	O

In	O
addition	O
,	O
although	O
exon	O
1beta	O
mutation	O
is	O
rare	O
in	O
various	O
tumors	O
,	O
we	O
detected	O
a	O
missense	O
mutation	O
L50R	B-ProteinMutation
in	O
one	O
case	O
with	O
a	O
hemizygous	O
deletion	O
.	O

Methylation	O
of	O
the	O
5'CpG	O
island	O
of	O
the	O
p14	O
gene	O
was	O
not	O
suggested	O
for	O
any	O
case	O
without	O
homozygous	O
deletion	O
.	O

Our	O
observation	O
of	O
frequent	O
p14	O
gene	O
abnormalities	O
(90%)	O
and	O
inactivation	O
(40-60%)	O
was	O
in	O
striking	O
contrast	O
to	O
the	O
same	O
pathological	O
subtype	O
of	O
systemic	O
lymphoma	O
in	O
which	O
p14	O
gene	O
abnormalities	O
and	O
inactivation	O
were	O
infrequent	O
,	O
suggesting	O
a	O
difference	O
in	O
carcinogenesis	O
between	O
PCNSL	O
and	O
systemic	O
lymphoma	O
.	O

Compound	O
heterozygosity	O
for	O
a	O
novel	O
nine-nucleotide	O
deletion	O
and	O
the	O
Asn45Ser	B-ProteinMutation
missense	O
mutation	O
in	O
the	O
glycoprotein	O
IX	O
gene	O
in	O
a	O
patient	O
with	O
Bernard-Soulier	O
syndrome	O
.	O

Bernard-Soulier	O
syndrome	O
(BSS)	O
is	O
a	O
rare	O
inherited	O
bleeding	O
disorder	O
due	O
to	O
quantitative	O
or	O
qualitative	O
abnormalities	O
in	O
the	O
platelet	O
glycoprotein	O
(GP)	O
Ib/IX/V	O
complex	O
,	O
the	O
major	O
von	O
Willebrand	O
factor	O
receptor	O
.	O

The	O
complex	O
comprises	O
four	O
subunits	O
,	O
each	O
encoded	O
by	O
a	O
separate	O
gene	O
.	O

Several	O
mutations	O
have	O
been	O
described	O
for	O
each	O
of	O
the	O
subunits	O
,	O
except	O
for	O
GPV	O
,	O
as	O
a	O
cause	O
of	O
BSS	O
.	O

We	O
describe	O
here	O
the	O
genetic	O
basis	O
of	O
the	O
disorder	O
in	O
a	O
child	O
with	O
BSS	O
.	O

Flow-cytometric	O
analysis	O
of	O
the	O
patient's	O
platelets	O
showed	O
a	O
markedly	O
reduced	O
surface	O
expression	O
of	O
all	O
three	O
glycoproteins	O
of	O
the	O
GPIb/IX/V	O
complex	O
.	O

DNA	O
sequencing	O
analysis	O
showed	O
the	O
patient	O
to	O
be	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
in	O
the	O
GPIX	O
gene	O
,	O
a	O
novel	O
nine-nucleotide	O
deletion	O
starting	O
at	O
position	O
1952	O
of	O
the	O
gene	O
that	O
changes	O
asparagine	O
86	O
for	O
alanine	O
and	O
eliminates	O
amino	O
acids	O
87	O
,	O
88	O
,	O
and	O
89	O
(	O
arginine	O
,	O
threonine	O
,	O
and	O
proline	O
)	O
and	O
a	O
previously	O
reported	O
point	O
mutation	O
that	O
changes	O
the	O
codon	O
asparagine	O
(AAC)	O
for	O
serine	O
(AGC)	O
at	O
residue	O
45	O
.	O

Her	O
mother	O
was	O
heterozygous	O
for	O
the	O
Asn45Ser	B-ProteinMutation
mutation	O
,	O
and	O
her	O
father	O
,	O
for	O
the	O
nine-nucleotide	O
deletion	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
additive	O
effects	O
of	O
both	O
mutations	O
in	O
the	O
GPIX	O
gene	O
are	O
responsible	O
for	O
the	O
BSS	O
phenotype	O
of	O
the	O
patient	O
.	O

Leydig	O
cell	O
hypoplasia	O
due	O
to	O
inactivation	O
of	O
luteinizing	O
hormone	O
receptor	O
by	O
a	O
novel	O
homozygous	O
nonsense	O
truncation	O
mutation	O
in	O
the	O
seventh	O
transmembrane	O
domain	O
.	O

Inactivating	O
mutations	O
in	O
the	O
LH	O
receptor	O
are	O
the	O
predominant	O
cause	O
for	O
male	O
pseudohermaphroditism	O
in	O
subjects	O
with	O
Leydig	O
cell	O
hypoplasia	O
(LCH)	O
.	O

The	O
severity	O
of	O
the	O
mutations	O
,	O
correlates	O
with	O
residual	O
receptor	O
activities	O
.	O

Here	O
,	O
we	O
detail	O
the	O
clinical	O
presentation	O
of	O
one	O
subject	O
with	O
complete	O
male	O
pseudohermaphroditism	O
and	O
LCH	O
.	O

We	O
identify	O
within	O
the	O
proband	O
and	O
her	O
similarly	O
afflicted	O
sibling	O
a	O
homozygous	O
T	O
to	O
G	O
transversion	O
at	O
nucleotide	O
1836	O
in	O
exon	O
11	O
of	O
the	O
LH/CGR	O
gene	O
.	O

This	O
causes	O
conversion	O
of	O
a	O
tyrosine	O
codon	O
into	O
a	O
stop	O
codon	O
at	O
codon	O
612	O
in	O
the	O
seventh	O
transmembrane	O
domain	O
,	O
resulting	O
in	O
a	O
truncated	O
receptor	O
that	O
lacks	O
a	O
cytoplasmic	O
tail	O
.	O

In	O
vitro	O
,	O
in	O
contrast	O
to	O
cells	O
expressing	O
a	O
normal	O
LHR	O
,	O
cells	O
transfected	O
with	O
the	O
mutant	O
cDNA	O
exhibit	O
neither	O
surface	O
binding	O
of	O
radiolabeled	O
hCG	O
nor	O
cAMP	O
generation	O
.	O

In	O
vitro	O
expression	O
under	O
the	O
control	O
of	O
the	O
LHR	O
signal	O
peptide	O
of	O
either	O
a	O
wild	O
type	O
or	O
mutant	O
LHR-GFP	O
fusion	O
protein	O
shows	O
no	O
differences	O
in	O
receptor	O
cellular	O
localization	O
.	O

In	O
conclusion	O
,	O
the	O
in	O
vitro	O
studies	O
suggest	O
that	O
residues	O
in	O
the	O
seventh	O
transmembrane	O
domain	O
and	O
cytoplasmic	O
tail	O
are	O
important	O
for	O
receptor	O
binding	O
and	O
activation	O
without	O
playing	O
a	O
major	O
role	O
in	O
receptor	O
cellular	O
trafficking	O
.	O

Polymorphic	O
forms	O
of	O
prostate	O
specific	O
antigen	O
and	O
their	O
interaction	O
with	O
androgen	O
receptor	O
trinucleotide	O
repeats	O
in	O
prostate	O
cancer	O
.	O

BACKGROUND	O
:	O
Recent	O
data	O
has	O
suggested	O
that	O
polymorphisms	O
in	O
the	O
prostate	O
specific	O
antigen	O
(PSA)	O
may	O
increase	O
prostate	O
cancer	O
(PC)	O
risk	O
.	O

The	O
PSA	O
gene	O
contains	O
a	O
G/A	B-DNAMutation
substitution	O
in	O
the	O
androgen	O
response	O
element	O
(ARE)	O
1	O
region	O
.	O

The	O
androgen	O
receptor	O
(AR)	O
gene	O
has	O
polymorphic	O
regions	O
containing	O
variable	O
length	O
glutamine	O
and	O
glycine	O
repeats	O
and	O
these	O
are	O
believed	O
to	O
be	O
associated	O
with	O
PC	O
risk	O
.	O

The	O
effect	O
on	O
PC	O
risks	O
from	O
PSA	O
polymorphisms	O
alone	O
and	O
synergistically	O
with	O
the	O
AR	O
gene	O
was	O
examined	O
in	O
this	O
report	O
.	O

METHODS	O
:	O
One	O
hundred	O
PC	O
patients	O
and	O
an	O
age	O
matched	O
cohort	O
of	O
79	O
benign	O
prostate	O
hyperplasia	O
and	O
67	O
population	O
controls	O
were	O
entered	O
in	O
this	O
study	O
.	O

DNA	O
was	O
extracted	O
from	O
blood	O
and	O
PSA/ARE	O
promoter	O
region	O
amplified	O
by	O
PCR	O
.	O

PCR	O
products	O
were	O
cut	O
with	O
Nhe	O
1	O
restriction	O
enzyme	O
to	O
distinguish	O
G/A	B-DNAMutation
alleles	O
.	O

AR/CAG	O
and	O
GGC	O
repeat	O
length	O
was	O
detected	O
by	O
automated	O
fluorescence	O
from	O
PCR	O
products	O
.	O

RESULTS	O
:	O
We	O
found	O
a	O
significantly	O
higher	O
PSA/GG	O
distribution	O
in	O
PC	O
(30%)	O
than	O
either	O
benign	O
prostatic	O
hyperplasia	O
(BPH)	O
(18%)	O
or	O
population	O
controls	O
(16%)	O
(	O
P	O
=	O
0.025	O
)	O
.	O

Furthermore	O
the	O
GG	O
distribution	O
within	O
cases	O
was	O
even	O
greater	O
in	O
younger	O
men	O
(	O
<	O
65	O
years	O
;	O
42%	O
;	O
P	O
=	O
0.012	O
)	O
.	O

Additionally	O
,	O
when	O
PSA	O
genotype	O
was	O
cross	O
classified	O
with	O
CAG	O
repeat	O
,	O
significantly	O
more	O
cases	O
than	O
both	O
BPH	O
and	O
population	O
controls	O
were	O
observed	O
to	O
have	O
a	O
short	O
(	O
<	O
22	O
)	O
CAG/GG	O
genotype	O
(	O
P	O
=	O
0.006	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
the	O
PSA/ARE	O
GG	O
genotype	O
confers	O
an	O
increased	O
risk	O
of	O
PC	O
especially	O
among	O
younger	O
men	O
.	O

Moreover	O
,	O
we	O
confirm	O
previous	O
results	O
that	O
a	O
short	O
glutamine	O
repeat	O
in	O
conjunction	O
with	O
GG	O
genotype	O
significantly	O
increases	O
the	O
risk	O
of	O
malignant	O
disease	O
.	O

Genetic	O
linkage	O
of	O
snowflake	O
vitreoretinal	O
degeneration	O
to	O
chromosome	O
2q36	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
chromosomal	O
location	O
of	O
the	O
gene	O
causing	O
snowflake	O
vitreoretinal	O
degeneration	O
(SVD)	O
,	O
an	O
autosomal	O
dominant	O
retinal	O
degeneration	O
characterized	O
by	O
small	O
yellow-white	O
dots	O
in	O
the	O
retina	O
,	O
fibrillar	O
anomaly	O
of	O
the	O
vitreous	O
humor	O
,	O
and	O
retinal	O
detachment	O
.	O

METHODS	O
:	O
Clinical	O
data	O
were	O
collected	O
on	O
31	O
family	O
members	O
by	O
history	O
and	O
examination	O
.	O

Thirteen	O
family	O
members	O
underwent	O
prospective	O
examination	O
.	O

Genotyping	O
was	O
performed	O
using	O
microsatellite	O
markers	O
spaced	O
at	O
approximately	O
10	O
cM	O
intervals	O
.	O

Two-point	O
and	O
multipoint	O
linkage	O
analysis	O
was	O
performed	O
(	O
FASTLINK	O
version	O
of	O
the	O
MLINK	O
program	O
and	O
the	O
VITESSE	O
algorithm	O
,	O
both	O
available	O
at	O
http://linkage.rockefeller.edu/soft/list.html	O
)	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
amplified	O
genomic	O
DNA	O
and	O
mRNA	O
was	O
performed	O
for	O
candidate	O
gene	O
analysis	O
.	O

RESULTS	O
:	O
The	O
SVD	O
locus	O
was	O
linked	O
to	O
markers	O
in	O
a	O
region	O
of	O
chromosome	O
2q36	O
defined	O
by	O
D2S2158	O
and	O
D2S2202	O
,	O
based	O
on	O
meiotic	O
breakpoint	O
mapping	O
of	O
affected	O
individuals	O
.	O

A	O
maximum	O
two-point	O
lod	O
score	O
of	O
5.5	O
was	O
obtained	O
with	O
marker	O
D2S172	O
at	O
theta	O
;	O
=	O
0	O
within	O
this	O
region	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
all	O
52	O
exons	O
of	O
the	O
COL4A3	O
gene	O
revealed	O
no	O
potentially	O
pathogenic	O
coding	O
sequence	O
variation	O
or	O
evidence	O
for	O
deletion	O
.	O

CONCLUSIONS	O
:	O
The	O
genetic	O
locus	O
for	O
SVD	O
lies	O
in	O
a	O
9	O
Mb	O
region	O
flanked	O
by	O
D2S2158	O
and	O
D2S2202	O
.	O

Localization	O
of	O
SVD	O
to	O
a	O
genomic	O
region	O
distinct	O
from	O
both	O
Wagner	O
disease	O
and	O
the	O
Stickler	O
syndromes	O
indicates	O
that	O
SVD	O
is	O
a	O
distinct	O
genetic	O
entity	O
.	O

The	O
absence	O
of	O
coding	O
sequence	O
variation	O
in	O
the	O
only	O
collagen	O
gene	O
within	O
the	O
disease-region	O
,	O
suggests	O
a	O
novel	O
pathogenesis	O
for	O
vitreoretinal	O
degeneration	O
.	O

Snowflake	O
vitreoretinal	O
degeneration	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
families	O
with	O
fibrillar	O
anomaly	O
of	O
the	O
vitreous	O
.	O

Polymorphisms	O
in	O
the	O
MMP1	O
and	O
MMP3	O
promoter	O
and	O
non-small	O
cell	O
lung	O
carcinoma	O
in	O
North	O
China	O
.	O

Matrix	O
metalloproteinases	O
(MMPs)	O
are	O
proteolytic	O
enzymes	O
that	O
regulate	O
various	O
cell	O
behaviors	O
in	O
cancer	O
biology	O
,	O
via	O
their	O
basic	O
function	O
of	O
degradation	O
of	O
proteins	O
.	O

Genetic	O
variations	O
in	O
several	O
MMP	O
promoters	O
may	O
influence	O
transcription	O
and	O
expression	O
of	O
MMPs	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
effects	O
of	O
the	O
two	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
,	O
the	O
guanine	O
insertion	O
polymorphism	O
in	O
the	O
MMP1	O
promoter	O
and	O
the	O
adenosine	O
insertion	O
polymorphism	O
in	O
the	O
MMP3	O
promoter	O
,	O
on	O
risk	O
of	O
the	O
development	O
and	O
lymphatic	O
metastasis	O
of	O
non-small	O
cell	O
lung	O
carcinoma	O
(NSCLC)	O
.	O

The	O
MMP1	O
and	O
MMP3	O
SNPs	O
were	O
genotyped	O
by	O
polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
(PCR-RFLP)	O
analysis	O
in	O
243	O
NSCLC	O
patients	O
and	O
350	O
control	O
subjects	O
in	O
North	O
China	O
.	O

The	O
overall	O
genotype	O
and	O
allelotype	O
distribution	O
of	O
both	O
the	O
variants	O
in	O
cancer	O
patients	O
and	O
controls	O
was	O
not	O
significantly	O
different	O
(	O
all	O
P	O
values	O
are	O
above	O
0.05	O
)	O
.	O

However	O
,	O
stratification	O
analysis	O
showed	O
that	O
smoking	O
individuals	O
with	O
the	O
MMP3	O
5A	O
allele	O
had	O
a	O
>1.5-fold	O
increased	O
risk	O
to	O
develop	O
NSCLC	O
,	O
compared	O
with	O
those	O
harboring	O
the	O
6A	O
homozygous	O
[	O
the	O
age	O
and	O
gender	O
adjusted	O
odds	O
ratio	O
(OR)	O
=	O
1.68	O
,	O
95%	O
confidence	O
interval	O
(CI)	O
=	O
1.04-2.70	O
]	O
.	O

In	O
addition	O
,	O
the	O
frequency	O
of	O
the	O
MMP3	O
5A	O
homozygote	O
in	O
NSCLC	O
patients	O
with	O
lymphatic	O
metastasis	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
lymph	O
node	O
negative	O
ones	O
(	O
5.7	O
versus	O
0%	O
,	O
P	O
=	O
0.04	O
)	O
.	O

Moreover	O
,	O
the	O
MMP	O
1G/5A	O
haplotype	O
significantly	O
increased	O
the	O
risk	O
of	O
lymphatic	O
metastasis	O
(	O
OR	O
=	O
3.36	O
,	O
95%	O
CI	O
=	O
1.42-7.94	O
)	O
,	O
compared	O
with	O
the	O
2G/6A	O
haplotype	O
.	O

The	O
present	O
result	O
suggested	O
that	O
the	O
MMP3	O
promoter	O
polymorphism	O
may	O
modify	O
susceptibility	O
to	O
NSCLC	O
,	O
and	O
the	O
MMP	O
1G/5A	O
haplotype	O
may	O
predicate	O
the	O
risk	O
of	O
lymphatic	O
metastasis	O
of	O
this	O
tumor	O
.	O

Lack	O
of	O
evidence	O
for	O
mutations	O
or	O
deletions	O
in	O
the	O
CDKN2A/p16	O
and	O
CDKN2B/p15	O
genes	O
of	O
Brazilian	O
neuroblastoma	O
patients	O
.	O

Neuroblastoma	O
,	O
the	O
most	O
common	O
extracranial	O
tumor	O
in	O
childhood	O
,	O
has	O
a	O
wide	O
spectrum	O
of	O
clinical	O
and	O
biological	O
features	O
.	O

The	O
loss	O
of	O
heterozygosity	O
within	O
the	O
9p21	O
region	O
has	O
been	O
reported	O
as	O
a	O
prognostic	O
factor	O
.	O

Two	O
tumor	O
suppressor	O
genes	O
located	O
in	O
this	O
region	O
,	O
the	O
CDKN2B/p15	O
and	O
CDKN2A/p16	O
(	O
cyclin-dependent	O
kinase	O
inhibitors	O
2B	O
and	O
2A	O
,	O
respectively	O
)	O
genes	O
,	O
play	O
a	O
critical	O
role	O
in	O
cell	O
cycle	O
progression	O
and	O
are	O
considered	O
to	O
be	O
targets	O
for	O
tumor	O
inactivation	O
.	O

We	O
analyzed	O
CDKN2B/p15	O
and	O
CDKN2A/p16	O
gene	O
alterations	O
in	O
11	O
patients	O
,	O
who	O
ranged	O
in	O
age	O
from	O
4	O
months	O
to	O
13	O
years	O
(	O
male/female	O
ratio	O
was	O
1.2:1	O
)	O
.	O

The	O
most	O
frequent	O
stage	O
of	O
the	O
tumor	O
was	O
stage	O
IV	O
(50%)	O
,	O
followed	O
by	O
stages	O
II	O
and	O
III	O
(20%)	O
and	O
stage	O
I	O
(10%)	O
.	O

The	O
samples	O
were	O
submitted	O
to	O
the	O
multiplex	O
PCR	O
technique	O
for	O
homozygous	O
deletion	O
analysis	O
and	O
to	O
single-strand	O
conformation	O
polymorphism	O
and	O
nucleotide	O
sequencing	O
for	O
mutation	O
analysis	O
.	O

All	O
exons	O
of	O
both	O
genes	O
were	O
analyzed	O
,	O
but	O
no	O
deletion	O
was	O
detected	O
.	O

One	O
sample	O
exhibited	O
shift	O
mobility	O
specific	O
for	O
exon	O
2	O
in	O
the	O
CDKN2B/p15	O
gene	O
,	O
not	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

Homozygous	O
deletions	O
and	O
mutations	O
are	O
not	O
involved	O
in	O
the	O
inactivation	O
mechanism	O
of	O
the	O
CDKN2B/p15	O
and	O
CDKN2A/p16	O
genes	O
in	O
neuroblastoma	O
;	O
however	O
,	O
these	O
two	O
abnormalities	O
do	O
not	O
exclude	O
other	O
inactivation	O
pathways	O
.	O

Recent	O
evidence	O
has	O
shown	O
that	O
the	O
expression	O
of	O
these	O
genes	O
is	O
altered	O
in	O
this	O
disease	O
.	O

Therefore	O
,	O
other	O
mechanisms	O
of	O
inactivation	O
,	O
such	O
as	O
methylation	O
of	O
promoter	O
region	O
and	O
unproperly	O
function	O
of	O
proteins	O
,	O
may	O
be	O
considered	O
in	O
order	O
to	O
estimate	O
the	O
real	O
contribution	O
of	O
these	O
genes	O
to	O
neuroblastoma	O
genesis	O
or	O
disease	O
progression	O
.	O

Fabry	O
disease	O
female	O
proband	O
with	O
clinical	O
manifestations	O
similar	O
to	O
hypertrophic	O
cardiomyopathy	O
.	O

Fabry's	O
disease	O
is	O
an	O
X-linked	O
inborn	O
error	O
of	O
glycosphingolipid	O
catabolism	O
,	O
resulting	O
from	O
a	O
deficiency	O
in	O
alpha-galactosidase	O
A	O
(	O
alpha-Gal	O
A	O
)	O
.	O

A	O
56-year-old	O
Japanese	O
woman	O
was	O
at	O
first	O
suspected	O
of	O
having	O
hypertrophic	O
cardiomyopathy	O
.	O

The	O
patient	O
and	O
her	O
son	O
had	O
alpha-Gal	O
A	O
activity	O
in	O
leukocytes	O
that	O
was	O
remarkably	O
below	O
the	O
limit	O
of	O
controls	O
.	O

DNA	O
analysis	O
of	O
the	O
alpha-Gal	O
A	O
gene	O
revealed	O
a	O
novel	O
missense	O
mutation	O
at	O
codon	O
19	O
in	O
exon	O
1	O
,	O
resulting	O
in	O
leucine-to-proline	O
substitution	O
.	O

As	O
a	O
result	O
she	O
was	O
confirmed	O
as	O
a	O
classic	O
Fabry	O
heterozygote	O
.	O

Recent	O
advances	O
in	O
enzyme	O
replacement	O
therapy	O
can	O
reverse	O
the	O
storage	O
of	O
glycosphingolipids	O
in	O
Fabry's	O
disease	O
.	O

Thus	O
,	O
in	O
patients	O
with	O
cardiac	O
hypertrophy	O
,	O
it	O
is	O
important	O
to	O
differentiate	O
Fabry's	O
disease	O
from	O
other	O
causes	O
of	O
hypertrophy	O
.	O

Therefore	O
,	O
it	O
is	O
necessary	O
to	O
measure	O
alpha-Gal	O
A	O
activity	O
in	O
all	O
suspected	O
cases	O
and	O
to	O
analyze	O
genetic	O
abnormalities	O
in	O
heterozygotes	O
.	O

Genetic	O
variation	O
in	O
apolipoprotein	O
D	O
and	O
Alzheimer's	O
disease	O
.	O

Apolipoprotein	O
D	O
(apoD)	O
is	O
a	O
lipoprotein-associated	O
glycoprotein	O
,	O
structurally	O
unrelated	O
to	O
apoE	O
,	O
that	O
transports	O
small	O
hydrophobic	O
ligands	O
including	O
cholesterol	O
and	O
sterols	O
.	O

Levels	O
are	O
increased	O
in	O
the	O
hippocampus	O
and	O
CSF	O
of	O
Alzheimer's	O
disease	O
(AD)	O
patients	O
.	O

We	O
tested	O
whether	O
variation	O
in	O
the	O
APOD	O
gene	O
affects	O
AD	O
risk	O
.	O

Four	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
investigated	O
(	O
in	O
map	O
order	O
)	O
:	O
exon	O
2	O
,	O
15T-->C	B-DNAMutation
encodes	O
an	O
amino	O
acid	O
substitution	O
Phe-->Ser	B-ProteinMutation
at	I-ProteinMutation
codon	I-ProteinMutation
15	I-ProteinMutation
;	O
intron	B-DNAMutation
2	I-DNAMutation
,	I-DNAMutation
-352G-->A	I-DNAMutation
;	O
intron	B-DNAMutation
3	I-DNAMutation
,	I-DNAMutation
+45C-->T	I-DNAMutation
;	O
intron	B-DNAMutation
4	I-DNAMutation
,	I-DNAMutation
+718C-->T	I-DNAMutation
,	O
determined	O
by	O
SNaPshot	O
assay	O
.	O

SNP	O
frequencies	O
for	O
394	O
eastern	O
Finnish	O
AD	O
patients	O
were	O
compared	O
with	O
those	O
found	O
for	O
470	O
control	O
subjects	O
,	O
dividing	O
subjects	O
also	O
into	O
early-onset	O
AD	O
(	O
EOAD	O
;	O
<	O
or	O
=	O
65	O
years	O
)	O
and	O
late-onset	O
AD	O
(	O
LOAD	O
;	O
>65	O
years	O
)	O
groups	O
.	O

The	O
-352G	O
allele	O
was	O
associated	O
with	O
a	O
significant	O
3-fold	O
increase	O
in	O
the	O
risk	O
of	O
EOAD	O
(	O
OR	O
:	O
2.7	O
;	O
95%	O
CI	O
:	O
1.1-6.5	O
)	O
.	O

The	O
-352G	O
containing	O
haplotypes	O
were	O
more	O
common	O
for	O
EOAD	O
cases	O
(	O
TGCC	O
:	O
0.48	O
vs	O
0.41	O
;	O
TGCT	O
:	O
0.08	O
vs	O
0.01	O
(	O
p	O
=	O
0.002	O
)	O
.	O

In	O
the	O
Grade-of-membership	O
analysis	O
,	O
APOD	O
genotype	O
frequencies	O
at	O
each	O
SNP	O
site	O
and	O
disease	O
status	O
were	O
used	O
to	O
construct	O
two	O
latent	O
groups	O
:	O
the	O
affected	O
group	O
carried	O
-352	O
as	O
GG	O
or	O
GA	O
and	O
+45	O
CC	O
,	O
was	O
often	O
women	O
and	O
enriched	O
in	O
APOE	O
epsilon4	O
.	O

Each	O
method	O
suggested	O
that	O
the	O
-352G	O
allele	O
frequency	O
is	O
higher	O
for	O
EOAD	O
in	O
the	O
eastern	O
Finnish	O
population	O
.	O

Genetic	O
analyses	O
and	O
expression	O
studies	O
identified	O
a	O
novel	O
mutation	O
W486C	B-ProteinMutation
as	O
a	O
molecular	O
basis	O
of	O
congenital	O
coagulation	O
factor	O
XII	O
deficiency	O
.	O

We	O
analyzed	O
the	O
factor	O
XII	O
(FXII)	O
gene	O
of	O
a	O
patient	O
with	O
congenital	O
FXII	O
deficiency	O
and	O
identified	O
a	O
novel	O
amino	O
acid	O
substitution	O
W486C	B-ProteinMutation
in	O
the	O
catalytic	O
domain	O
.	O

The	O
proband	O
was	O
an	O
asymptomatic	O
49-year-old	O
Japanese	O
female	O
with	O
abnormal	O
coagulation	O
test	O
,	O
discovered	O
by	O
chance	O
.	O

The	O
FXII	O
activity	O
and	O
antigen	O
level	O
were	O
both	O
under	O
10%	O
,	O
suggesting	O
a	O
cross-reacting	O
material-negative	O
FXII	O
deficiency	O
.	O

Sequence	O
analysis	O
of	O
the	O
proband's	O
FXII	O
gene	O
revealed	O
a	O
homozygous	O
nucleotide	O
substitution	O
G	B-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
in	O
exon	O
12	O
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
W486C	B-ProteinMutation
in	O
the	O
catalytic	O
domain	O
.	O

We	O
constructed	O
the	O
mutant	O
FXII	O
cDNA	O
in	O
an	O
expression	O
plasmid	O
vector	O
and	O
transfected	O
it	O
into	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

The	O
recombinant	O
wild-type	O
FXII	O
antigen	O
was	O
detected	O
in	O
the	O
culture	O
medium	O
by	O
immunoprecipitation	O
assay	O
,	O
but	O
the	O
mutant	O
FXII	O
W486C	B-ProteinMutation
was	O
not	O
observed	O
.	O

On	O
the	O
other	O
hand	O
,	O
both	O
the	O
wild-type	O
FXII	O
and	O
W486C	B-ProteinMutation
cell	O
lysates	O
contained	O
FXII	O
antigen	O
and	O
FXII	O
mRNA	O
,	O
as	O
estimated	O
by	O
western	O
blotting	O
and	O
quantitative	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
W486C	B-ProteinMutation
substitution	O
of	O
FXII	O
impairs	O
intracellular	O
processing	O
of	O
the	O
protein	O
and/or	O
transport	O
system	O
.	O

Lack	O
of	O
major	O
involvement	O
of	O
human	O
uroplakin	O
genes	O
in	O
vesicoureteral	O
reflux	O
:	O
implications	O
for	O
disease	O
heterogeneity	O
.	O

BACKGROUND	O
:	O
Primary	O
vesicoureteral	O
reflux	O
(VUR)	O
is	O
a	O
hereditary	O
disorder	O
characterized	O
by	O
the	O
retrograde	O
flow	O
of	O
urine	O
into	O
the	O
ureters	O
and	O
kidneys	O
.	O

It	O
affects	O
about	O
1%	O
of	O
the	O
young	O
children	O
and	O
is	O
thus	O
one	O
of	O
the	O
most	O
common	O
hereditary	O
diseases	O
.	O

Its	O
associated	O
nephropathy	O
is	O
an	O
important	O
cause	O
of	O
end-stage	O
renal	O
failure	O
in	O
children	O
and	O
adults	O
.	O

Recent	O
studies	O
indicate	O
that	O
genetic	O
ablation	O
of	O
mouse	O
uroplakin	O
(UP)	O
III	O
gene	O
,	O
which	O
encodes	O
a	O
47	O
kD	O
urothelial-specific	O
integral	O
membrane	O
protein	O
forming	O
urothelial	O
plaques	O
,	O
causes	O
VUR	O
and	O
hydronephrosis	O
.	O

METHODS	O
:	O
To	O
begin	O
to	O
determine	O
whether	O
mutations	O
in	O
UP	O
genes	O
might	O
play	O
a	O
role	O
in	O
human	O
VUR	O
,	O
we	O
genotyped	O
all	O
four	O
UP	O
genes	O
in	O
76	O
patients	O
with	O
radiologically	O
proven	O
primary	O
VUR	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
amplification	O
and	O
sequencing	O
of	O
all	O
their	O
exons	O
plus	O
50	O
to	O
150	O
bp	O
of	O
flanking	O
intronic	O
sequences	O
.	O

RESULTS	O
:	O
Eighteen	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
identified	O
,	O
seven	O
of	O
which	O
were	O
missense	O
,	O
with	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
.	O

Since	O
healthy	O
relatives	O
of	O
the	O
VUR	O
probands	O
are	O
not	O
reliable	O
negative	O
controls	O
for	O
VUR	O
,	O
we	O
used	O
a	O
population	O
of	O
90	O
race-matched	O
,	O
healthy	O
individuals	O
,	O
unrelated	O
to	O
the	O
VUR	O
patients	O
,	O
as	O
controls	O
to	O
perform	O
an	O
association	O
study	O
.	O

Most	O
of	O
the	O
SNPs	O
were	O
not	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
VUR	O
.	O

However	O
,	O
SNP1	O
of	O
UP	O
Ia	O
gene	O
affecting	O
a	O
C	O
to	O
T	O
conversion	O
and	O
an	O
Ala7Val	B-ProteinMutation
change	O
,	O
and	O
SNP7	O
of	O
UP	O
III	O
affecting	O
a	O
C	O
to	O
G	O
conversion	O
and	O
a	O
Pro154Ala	B-ProteinMutation
change	O
,	O
were	O
marginally	O
associated	O
with	O
VUR	O
(	O
both	O
P=	O
0.08	O
)	O
.	O

Studies	O
of	O
additional	O
cases	O
yielded	O
a	O
second	O
set	O
of	O
data	O
that	O
,	O
in	O
combination	O
with	O
the	O
first	O
set	O
,	O
confirmed	O
a	O
weak	O
association	O
of	O
UP	O
III	O
SNP7	O
in	O
VUR	O
(	O
P=	O
0.036	O
adjusted	O
for	O
both	O
subsets	O
of	O
cases	O
vs	O
.	O

controls	O
)	O
.	O

CONCLUSION	O
:	O
Such	O
a	O
weak	O
association	O
and	O
the	O
lack	O
of	O
families	O
with	O
simple	O
dominant	O
Mendelian	O
inheritance	O
suggest	O
that	O
missense	O
changes	O
of	O
uroplakin	O
genes	O
cannot	O
play	O
a	O
dominant	O
role	O
in	O
causing	O
VUR	O
in	O
humans	O
,	O
although	O
they	O
may	O
be	O
weak	O
risk	O
factors	O
contributing	O
to	O
a	O
complex	O
polygenic	O
disease	O
.	O

The	O
fact	O
that	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
have	O
been	O
found	O
in	O
any	O
of	O
the	O
VUR	O
patients	O
,	O
coupled	O
with	O
our	O
recent	O
finding	O
that	O
some	O
breeding	O
pairs	O
of	O
UP	O
III	O
knockout	O
mice	O
yield	O
litters	O
that	O
show	O
not	O
only	O
VUR	O
,	O
but	O
also	O
severe	O
hydronephrosis	O
and	O
neonatal	O
death	O
,	O
raises	O
the	O
possibility	O
that	O
major	O
uroplakin	O
mutations	O
could	O
be	O
embryonically	O
or	O
postnatally	O
lethal	O
in	O
humans	O
.	O

Evaluation	O
of	O
the	O
Lys198Asn	B-ProteinMutation
and	O
-134delA	B-DNAMutation
genetic	O
polymorphisms	O
of	O
the	O
endothelin-1	O
gene	O
.	O

Endothelin-1	O
(ET-1)	O
is	O
a	O
potent	O
vasoconstrictor	O
and	O
shows	O
various	O
pharmacological	O
responses	O
.	O

Two	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ET-1	O
gene	O
(EDN1)	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
blood	O
pressure	O
(BP)	O
.	O

One	O
is	O
the	O
Lys198Asn	B-ProteinMutation
polymorphism	O
,	O
which	O
showed	O
a	O
positive	O
association	O
with	O
BP	O
in	O
overweight	O
people	O
.	O

Another	O
is	O
the	O
3A/4A	O
polymorphism	O
-134delA	B-DNAMutation
located	O
in	O
the	O
5'-untranslated	O
region	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
the	O
Lys198Asn	B-ProteinMutation
polymorphism	O
in	O
ET-1	O
in	O
vitro	O
,	O
as	O
well	O
as	O
the	O
association	O
between	O
either	O
of	O
the	O
two	O
polymorphisms	O
and	O
the	O
plasma	O
ET-1	O
level	O
.	O

We	O
expressed	O
both	O
the	O
major	O
(Lys-type)	O
and	O
minor	O
type	O
(Asn-type)	O
preproET-1	O
in	O
three	O
different	O
cell	O
lines	O
,	O
and	O
measured	O
the	O
levels	O
of	O
ET-1	O
and	O
big	O
ET-1	O
in	O
the	O
culture	O
supernatant	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
ET-1	O
or	O
big	O
ET-1	O
between	O
the	O
Asn-type	O
and	O
Lys-type	O
transfectant	O
.	O

In	O
the	O
association	O
study	O
,	O
the	O
plasma	O
levels	O
of	O
ET-1	O
in	O
54	O
hypertensive	O
patients	O
having	O
an	O
amino	O
acid	O
substitution	O
from	O
Lys	O
to	O
Asn	O
at	O
position	O
198	O
were	O
not	O
different	O
from	O
those	O
of	O
hypertensives	O
without	O
the	O
substitution	O
.	O

However	O
,	O
we	O
found	O
a	O
significant	O
difference	O
in	O
ET-1	O
levels	O
between	O
individuals	O
with	O
the	O
3A/3A	O
and	O
3A/4A	O
genotypes	O
.	O

Our	O
transient	O
expression	O
study	O
indicates	O
that	O
the	O
Lys198Asn	B-ProteinMutation
polymorphism	O
may	O
not	O
directly	O
affect	O
ET-1	O
and	O
big	O
ET-1	O
production	O
.	O

Another	O
variant	O
in	O
the	O
EDN1	O
gene	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
Lys198Asn	B-ProteinMutation
polymorphism	O
may	O
be	O
responsible	O
for	O
the	O
association	O
with	O
BP	O
,	O
or	O
the	O
interaction	O
between	O
the	O
EDN1	O
Lys198Asn	B-ProteinMutation
polymorphism	O
and	O
other	O
factors	O
such	O
as	O
obesity	O
may	O
be	O
involved	O
in	O
the	O
mechanisms	O
elevating	O
BP	O
in	O
vivo	O
.	O

Altered	O
replication	O
timing	O
of	O
the	O
HIRA/Tuple1	O
locus	O
in	O
the	O
DiGeorge	O
and	O
Velocardiofacial	O
syndromes	O
.	O

DiGeorge	O
and	O
Velocardiofacial	O
syndromes	O
(DGS/VCFS)	O
are	O
endowed	O
by	O
a	O
similar	O
complex	O
phenotype	O
including	O
cardiovascular	O
,	O
craniofacial	O
,	O
and	O
thymic	O
malformations	O
,	O
and	O
are	O
associated	O
with	O
heterozygous	O
deletions	O
of	O
22q11	O
chromosomal	O
band	O
.	O

The	O
Typically	O
Deleted	O
Region	O
in	O
the	O
22q11.21	O
subband	O
(	O
here	O
called	O
TDR22	O
)	O
is	O
very	O
gene-dense	O
,	O
and	O
the	O
extent	O
of	O
the	O
deletion	O
has	O
been	O
defined	O
precisely	O
in	O
several	O
studies	O
.	O

However	O
,	O
to	O
date	O
there	O
is	O
no	O
evidence	O
for	O
a	O
mechanism	O
of	O
haploinsufficiency	O
that	O
can	O
fully	O
explain	O
the	O
DGS/VCFS	O
phenotype	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
candidate	O
gene	O
HIRA/Tuple1	O
mapping	O
on	O
the	O
non-deleted	O
TDR22	O
,	O
in	O
DGS/VCFS	O
subjects	O
presents	O
a	O
delayed	O
replication	O
timing	O
.	O

Moreover	O
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
cell	O
ratio	O
showing	O
the	O
HIRA/Tuple1	O
locus	O
localised	O
toward	O
the	O
nuclear	O
periphery	O
.	O

It	O
is	O
known	O
that	O
replication	O
timing	O
and	O
nuclear	O
location	O
are	O
generally	O
correlated	O
to	O
the	O
transcription	O
activity	O
of	O
the	O
relative	O
DNA	O
region	O
.	O

We	O
propose	O
that	O
the	O
alteration	O
in	O
the	O
replication/nuclear	O
location	O
pattern	O
of	O
the	O
non-deleted	O
TDR22	O
indicates	O
an	O
altered	O
gene	O
regulation	O
hence	O
an	O
altered	O
transcritpion	O
in	O
DGS/VCFS	O
.	O

Desmin-related	O
myopathy	O
with	O
Mallory	O
body-like	O
inclusions	O
is	O
caused	O
by	O
mutations	O
of	O
the	O
selenoprotein	O
N	O
gene	O
.	O

Desmin-related	O
myopathies	O
(DRMs)	O
are	O
a	O
heterogeneous	O
group	O
of	O
muscle	O
disorders	O
,	O
morphologically	O
defined	O
by	O
intrasarcoplasmic	O
aggregates	O
of	O
desmin	O
.	O

Mutations	O
in	O
the	O
desmin	O
and	O
the	O
alpha-B	O
crystallin	O
genes	O
account	O
for	O
approximately	O
one	O
third	O
of	O
the	O
DRM	O
cases	O
.	O

The	O
genetic	O
basis	O
of	O
the	O
other	O
forms	O
remain	O
unknown	O
,	O
including	O
the	O
early-onset	O
,	O
recessive	O
form	O
with	O
Mallory	O
body-like	O
inclusions	O
(MB-DRMs)	O
,	O
first	O
described	O
in	O
five	O
related	O
German	O
patients	O
.	O

Recently	O
,	O
we	O
identified	O
the	O
selenoprotein	O
N	O
gene	O
(SEPN1)	O
as	O
responsible	O
for	O
SEPN-related	O
myopathy	O
(SEPN-RM)	O
,	O
a	O
unique	O
early-onset	O
myopathy	O
formerly	O
divided	O
in	O
two	O
different	O
nosological	O
categories	O
:	O
rigid	O
spine	O
muscular	O
dystrophy	O
and	O
the	O
severe	O
form	O
of	O
classical	O
multiminicore	O
disease	O
.	O

The	O
finding	O
of	O
Mallory	O
body-like	O
inclusions	O
in	O
two	O
cases	O
of	O
genetically	O
documented	O
SEPN-RM	O
led	O
us	O
to	O
suspect	O
a	O
relationship	O
between	O
MB-DRM	O
and	O
SEPN1	O
.	O

In	O
the	O
original	O
MB-DRM	O
German	O
family	O
,	O
we	O
demonstrated	O
a	O
linkage	O
of	O
the	O
disease	O
to	O
the	O
SEPN1	O
locus	O
(1p36)	O
,	O
and	O
subsequently	O
a	O
homozygous	O
SEPN1	O
deletion	O
(	O
del	B-DNAMutation
92	I-DNAMutation
nucleotide	I-DNAMutation
-19/+73	I-DNAMutation
)	O
in	O
the	O
affected	O
patients	O
.	O

A	O
comparative	O
reevaluation	O
showed	O
that	O
MB-DRM	O
and	O
SEPN-RM	O
share	O
identical	O
clinical	O
features	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
MB-DRM	O
should	O
be	O
categorized	O
as	O
SEPN-RM	O
.	O

These	O
findings	O
substantiate	O
the	O
molecular	O
heterogeneity	O
of	O
DRM	O
,	O
expand	O
the	O
morphological	O
spectrum	O
of	O
SEPN-RM	O
,	O
and	O
implicate	O
a	O
necessary	O
reassessment	O
of	O
the	O
nosological	O
boundaries	O
in	O
early-onset	O
myopathies	O
.	O

CRYBA3/A1	O
gene	O
mutation	O
associated	O
with	O
suture-sparing	O
autosomal	O
dominant	O
congenital	O
nuclear	O
cataract	O
:	O
a	O
novel	O
phenotype	O
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
genetic	O
defect	O
leading	O
to	O
the	O
congenital	O
nuclear	O
cataract	O
affecting	O
a	O
large	O
five-generation	O
Swiss	O
family	O
.	O

METHODS	O
:	O
Family	O
history	O
and	O
clinical	O
data	O
were	O
recorded	O
.	O

The	O
phenotype	O
was	O
documented	O
by	O
both	O
slit	O
lamp	O
and	O
Scheimpflug	O
photography	O
.	O

One	O
cortical	O
lens	O
was	O
evaluated	O
by	O
electron	O
microscopy	O
after	O
cataract	O
extraction	O
.	O

Lenticular	O
phenotyping	O
and	O
genotyping	O
were	O
performed	O
independently	O
with	O
short	O
tandem	O
repeat	O
polymorphism	O
.	O

Linkage	O
analysis	O
was	O
performed	O
,	O
and	O
candidate	O
genes	O
were	O
PCR	O
amplified	O
and	O
screened	O
for	O
mutations	O
on	O
both	O
strands	O
using	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Affected	O
individuals	O
had	O
a	O
congenital	O
nuclear	O
lactescent	O
cataract	O
in	O
both	O
eyes	O
.	O

Linkage	O
was	O
observed	O
on	O
chromosome	O
17	O
for	O
DNA	O
marker	O
D17S1857	O
(	O
lod	O
score	O
:	O
3.44	O
at	O
theta	O
=	O
0	O
)	O
.	O

Direct	O
sequencing	O
of	O
CRYBA3/A1	O
,	O
which	O
maps	O
to	O
the	O
vicinity	O
,	O
revealed	O
an	O
in-frame	O
3-bp	O
deletion	O
in	O
exon	O
4	O
279delGAG	B-DNAMutation
.	O

This	O
mutation	O
involved	O
a	O
deletion	O
of	O
glycine-91	O
,	O
cosegregated	O
in	O
all	O
affected	O
individuals	O
,	O
and	O
was	O
not	O
observed	O
in	O
unaffected	O
individuals	O
or	O
in	O
250	O
normal	O
control	O
subjects	O
from	O
the	O
same	O
ethnic	O
background	O
.	O

Electron	O
microscopy	O
showed	O
that	O
cortical	O
lens	O
fiber	O
morphology	O
was	O
normal	O
.	O

CONCLUSIONS	O
:	O
The	O
DeltaG91	B-ProteinMutation
mutation	O
in	O
CRYBA3/A1	O
is	O
associated	O
with	O
an	O
autosomal	O
dominant	O
congenital	O
nuclear	O
lactescent	O
cataract	O
.	O

A	O
splice	O
mutation	O
IVS3+1G/A	B-DNAMutation
in	O
this	O
gene	O
has	O
been	O
reported	O
in	O
a	O
zonular	O
cataract	O
with	O
sutural	O
opacities	O
.	O

These	O
results	O
indicate	O
phenotypic	O
heterogeneity	O
related	O
to	O
mutations	O
in	O
this	O
gene	O
.	O

A	O
first	O
Taiwanese	O
Chinese	O
family	O
of	O
type	O
2B	O
von	O
Willebrand	O
disease	O
with	O
R1306W	B-ProteinMutation
mutation	O
.	O

Clinical	O
,	O
laboratory	O
and	O
genetic	O
defect	O
of	O
a	O
Taiwanese	O
family	O
with	O
type	O
2B	O
von	O
Willebrand	O
disease	O
(VWD)	O
were	O
studied	O
.	O

The	O
proband	O
was	O
a	O
55-year-old	O
woman	O
who	O
gave	O
birth	O
to	O
two	O
daughters	O
and	O
one	O
son	O
aged	O
30	O
,	O
29	O
and	O
27	O
,	O
respectively	O
.	O

All	O
had	O
abnormal	O
mucocutaneous	O
bleedings	O
since	O
their	O
childhood	O
.	O

In	O
proband	O
,	O
PT	O
,	O
PTT	O
and	O
platelet	O
count	O
were	O
normal	O
;	O
template	O
bleeding	O
time	O
was	O
14	O
min	O
;	O
VIII:C	O
was	O
51%	O
,	O
von	O
Willebrand	O
factor	O
antigen	O
(VWF:Ag)	O
,	O
42%	O
and	O
von	O
Willerand	O
factor	O
ristocetin-cofactor	O
(	O
VWF:RCo	O
,	O
15%	O
)	O
;	O
ristocetin-induced	O
platelet	O
aggregation	O
(RIPA)	O
at	O
0.3	O
and	O
0.6	O
mg/ml	O
of	O
ristocetin	O
was	O
16%	O
and	O
68%	O
,	O
respectively	O
.	O

The	O
enhanced	O
response	O
to	O
ristocetin	O
was	O
identified	O
to	O
be	O
in	O
plasma	O
,	O
not	O
in	O
platelet	O
itself	O
,	O
by	O
mixing	O
studies	O
.	O

Analysis	O
of	O
von	O
Willebrand	O
factor	O
(VWF)	O
multimer	O
of	O
plasma	O
but	O
not	O
of	O
platelets	O
showed	O
absence	O
of	O
high-molecular	O
weight	O
(HMW)	O
multimer	O
.	O

All	O
three	O
children	O
had	O
similar	O
laboratory	O
findings	O
.	O

Exon	O
28	O
of	O
VWF	O
gene	O
was	O
amplified	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
sequenced	O
.	O

The	O
proband	O
and	O
three	O
children	O
were	O
all	O
found	O
to	O
be	O
heterozygous	O
for	O
C	O
to	O
T	O
transition	O
at	O
nucleotide	O
3916	O
resulting	O
in	O
Arg	B-ProteinMutation
1306	I-ProteinMutation
Trp	I-ProteinMutation
R1306W	B-ProteinMutation
substitution	O
.	O

This	O
mutation	O
in	O
the	O
glycoprotein	O
Ib	O
(GPIb)-binding	O
site	O
has	O
been	O
found	O
to	O
increase	O
the	O
affinity	O
of	O
plasma	O
VWF	O
for	O
platelets	O
,	O
and	O
thus	O
cause	O
loss	O
of	O
HMW	O
multimers	O
and	O
often	O
thrombocytopenia	O
.	O

In	O
conclusion	O
,	O
a	O
first	O
report	O
of	O
type	O
2B	O
VWD	O
in	O
a	O
Taiwanese	O
Chinese	O
family	O
who	O
show	O
R1306W	B-ProteinMutation
mutation	O
in	O
VWF	O
gene	O
was	O
described	O
.	O

Comparison	O
of	O
sequential	O
cytomegalovirus	O
isolates	O
in	O
a	O
patient	O
with	O
lymphoma	O
and	O
failing	O
antiviral	O
therapy	O
.	O

BACKGROUND	O
:	O
Long-term	O
anti-cytomegalovirus	O
(CMV)	O
treatments	O
in	O
immunocompromised	O
patients	O
are	O
hampered	O
by	O
resistance	O
to	O
antiviral	O
drugs	O
.	O

Longitudinal	O
changes	O
in	O
the	O
resistance	O
genotype	O
may	O
depend	O
on	O
changes	O
in	O
selective	O
pressure	O
and	O
the	O
complexity	O
of	O
CMV	O
isolates	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
longitudinal	O
changes	O
in	O
the	O
CMV	O
resistance	O
genotype	O
and	O
phenotype	O
along	O
with	O
strain-specific	O
variability	O
in	O
a	O
patient	O
with	O
non-Hodgkin's	O
lymphoma	O
in	O
whom	O
successive	O
anti-CMV	O
treatments	O
failed	O
.	O

STUDY	O
DESIGN	O
:	O
The	O
resistance	O
phenotype	O
and	O
genotype	O
of	O
seven	O
CMV	O
isolates	O
collected	O
from	O
one	O
patient	O
during	O
a	O
2-year	O
follow-up	O
period	O
were	O
retrospectively	O
analysed	O
.	O

In	O
parallel	O
,	O
we	O
used	O
glycoprotein	O
B	O
(gB)	O
genotyping	O
,	O
and	O
a-	O
and	O
UL10-13-sequence	O
analysis	O
to	O
study	O
CMV	O
interstrain	O
variability	O
.	O

RESULTS	O
:	O
The	O
patient	O
was	O
infected	O
by	O
at	O
least	O
three	O
CMV	O
strains	O
plus	O
variants	O
of	O
the	O
parental	O
strains	O
.	O

Resistance	O
to	O
ganciclovir	O
,	O
cidofovir	O
and	O
foscarnet	O
was	O
successively	O
detected	O
during	O
the	O
follow-up	O
period	O
.	O

UL97	O
protein	O
kinase	O
changes	O
responsible	O
for	O
resistance	O
to	O
ganciclovir	O
were	O
initially	O
detected	O
at	O
residues	O
591	O
and	O
592	O
,	O
and	O
then	O
at	O
position	O
594	O
.	O

Decreased	O
sensitivity	O
to	O
foscarnet	O
coincided	O
with	O
the	O
appearance	O
of	O
amino	O
acid	O
substitution	O
N495K	B-ProteinMutation
in	O
DNA	O
polymerase	O
,	O
whereas	O
cross-resistance	O
to	O
ganciclovir	O
and	O
cidofovir	O
was	O
due	O
to	O
the	O
L501I	B-ProteinMutation
substitution	O
.	O

CONCLUSIONS	O
:	O
The	O
CMV	O
isolates	O
obtained	O
from	O
our	O
patient	O
were	O
complex	O
mixtures	O
of	O
strains	O
.	O

Changes	O
in	O
resistance	O
genotypes	O
depended	O
on	O
resistance	O
selective	O
pressure	O
and	O
were	O
not	O
linked	O
to	O
interstrain	O
variation	O
.	O

Molecular	O
analysis	O
of	O
acute	O
intermittent	O
porphyria	O
:	O
mutation	O
screening	O
in	O
20	O
patients	O
in	O
Germany	O
reveals	O
11	O
novel	O
mutations	O
.	O

Acute	O
intermittent	O
porphyria	O
(AIP)	O
is	O
a	O
very	O
rare	O
autosomal	O
dominant	O
disorder	O
with	O
low	O
penetrance	O
.	O

Mutations	O
in	O
the	O
gene	O
of	O
the	O
porphobilinogen	O
deaminase	O
(PBG-D)	O
,	O
also	O
called	O
hydroxymethylbilane	O
synthase	O
(HMBS)	O
,	O
cause	O
a	O
partial	O
deficiency	O
of	O
this	O
enzyme	O
of	O
the	O
heme	O
biosynthetic	O
pathway	O
.	O

Overstimulation	O
of	O
heme	O
biosynthesis	O
causes	O
clinical	O
symptoms	O
.	O

Because	O
of	O
the	O
variability	O
of	O
the	O
symptoms	O
,	O
diagnosis	O
is	O
often	O
delayed	O
.	O

Using	O
two	O
approaches	O
for	O
genetic	O
analysis	O
,	O
first	O
in	O
a	O
stepwise	O
manner	O
,	O
then	O
sequencing	O
extensive	O
parts	O
of	O
the	O
gene	O
,	O
the	O
screening	O
of	O
the	O
DNA	O
of	O
20	O
unrelated	O
individuals	O
revealed	O
20	O
different	O
mutations	O
,	O
11	O
of	O
which	O
had	O
not	O
been	O
reported	O
previously	O
.	O

The	O
novel	O
mutations	O
affected	O
intron	O
1	O
(	O
33	B-DNAMutation
+	I-DNAMutation
2	I-DNAMutation
T-->C	I-DNAMutation
)	O
,	O
exon	O
5	O
(	O
181	B-DNAMutation
G-->C	I-DNAMutation
)	O
,	O
intron	O
6	O
(	O
267-61	B-DNAMutation
del	I-DNAMutation
8	I-DNAMutation
bp	I-DNAMutation
)	O
,	O
intron	O
7	O
(	O
345-1	B-DNAMutation
G-->C	I-DNAMutation
)	O
,	O
intron	O
9	O
(	O
498	B-DNAMutation
+	I-DNAMutation
15	I-DNAMutation
G-->T	I-DNAMutation
and	O
499-13	B-DNAMutation
Delta-14	I-DNAMutation
bp	I-DNAMutation
indel	I-DNAMutation
TGA	I-DNAMutation
)	O
,	O
intron	O
13	O
(	O
825	B-DNAMutation
+	I-DNAMutation
1	I-DNAMutation
G-->C	I-DNAMutation
and	O
825	B-DNAMutation
+	I-DNAMutation
2	I-DNAMutation
T-->C	I-DNAMutation
)	O
,	O
exon	O
15	O
(	O
962	B-DNAMutation
G-A	I-DNAMutation
,	O
1067	B-DNAMutation
del	I-DNAMutation
A	I-DNAMutation
and	O
1067-1068	B-DNAMutation
ins	I-DNAMutation
5	I-DNAMutation
bp	I-DNAMutation
)	O
.	O

The	O
other	O
nine	O
mutations	O
detected	O
affected	O
intron	O
14	O
,	O
exons	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
(3x)	O
and	O
12	O
.	O

In	O
the	O
majority	O
of	O
AIP	O
patients	O
,	O
the	O
genotype	O
does	O
not	O
predict	O
phenotypic	O
expression	O
.	O

Since	O
the	O
sudden	O
manifestation	O
of	O
the	O
disease	O
maybe	O
prevented	O
by	O
early	O
diagnosis	O
,	O
identification	O
of	O
AIP	O
gene	O
carriers	O
is	O
the	O
best	O
preventive	O
measure	O
.	O

This	O
was	O
performed	O
in	O
five	O
families	O
,	O
revealing	O
10	O
additional	O
AIP	O
gene	O
carriers	O
.	O

Identification	O
of	O
the	O
Kna/Knb	O
polymorphism	O
and	O
a	O
method	O
for	O
Knops	O
genotyping	O
.	O

BACKGROUND	O
:	O
DNA	O
mutations	O
resulting	O
in	O
the	O
McCoy	O
and	O
Swain-Langley	O
polymorphisms	O
have	O
been	O
identified	O
on	O
complement	O
receptor	O
1	O
(CR1)-a	O
ligand	O
for	O
rosetting	O
of	O
Plasmodium	O
falciparum-infected	O
RBCs	O
.	O

The	O
molecular	O
identification	O
of	O
the	O
Kna/Knb	O
polymorphism	O
was	O
sought	O
to	O
develop	O
a	O
genotyping	O
method	O
for	O
use	O
in	O
the	O
study	O
of	O
the	O
Knops	O
blood	O
group	O
and	O
malaria	O
.	O

STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
CR1	O
deletion	O
constructs	O
were	O
used	O
in	O
inhibition	O
studies	O
of	O
anti-Kna	O
.	O

PCR	O
amplification	O
of	O
Exon	O
29	O
was	O
followed	O
by	O
DNA	O
sequencing	O
.	O

A	O
PCR-RFLP	O
was	O
developed	O
with	O
NdeI	O
,	O
BsmI	O
,	O
and	O
MfeI	O
for	O
the	O
detection	O
of	O
Kna/Knb	O
,	O
McCa/McCb	O
,	O
and	O
Sl1/Sl2	O
,	O
respectively	O
.	O

Knops	O
phenotypes	O
were	O
determined	O
with	O
standard	O
serologic	O
techniques	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
310	O
Malian	O
persons	O
were	O
phenotyped	O
for	O
Kna	O
with	O
200	O
(64%)	O
Kn(a+)	O
and	O
110	O
(36%)	O
Kn(a-)	O
.	O

Many	O
of	O
the	O
Kn(a-)	O
exhibited	O
the	O
Knops-null	O
phenotype	O
,	O
that	O
is	O
,	O
Helgeson	O
.	O

The	O
Kna/b	O
DNA	O
polymorphism	O
was	O
identified	O
as	O
a	O
V1561M	B-ProteinMutation
mutation	O
with	O
allele	O
frequencies	O
of	O
Kna	O
(V1561)	O
0.9	O
and	O
Knb	O
(M1561)	O
0.1	O
.	O

CONCLUSION	O
:	O
The	O
high	O
frequency	O
(18%)	O
of	O
Knb	O
in	O
West	O
African	O
persons	O
suggests	O
that	O
it	O
is	O
not	O
solely	O
a	O
Caucasian	O
trait	O
.	O

Furthermore	O
,	O
because	O
of	O
the	O
high	O
incidence	O
of	O
heterozygosity	O
as	O
well	O
as	O
amorphs	O
,	O
accurate	O
Knops	O
typing	O
of	O
donors	O
of	O
African	O
descent	O
is	O
best	O
accomplished	O
by	O
a	O
combination	O
of	O
molecular	O
and	O
serologic	O
techniques	O
.	O

Two	O
novel	O
severe	O
mutations	O
in	O
the	O
pancreatic	O
secretory	O
trypsin	O
inhibitor	O
gene	O
(SPINK1)	O
cause	O
familial	O
and/or	O
hereditary	O
pancreatitis	O
.	O

Mutations	O
in	O
the	O
serine	O
protease	O
inhibitor	O
Kazal	O
type	O
1	O
gene	O
(SPINK1)	O
encoding	O
pancreatic	O
secretory	O
trypsin	O
inhibitor	O
(PSTI)	O
have	O
recently	O
been	O
found	O
to	O
be	O
associated	O
with	O
chronic	O
pancreatitis	O
.	O

Nevertheless	O
,	O
knowledge	O
of	O
severe	O
mutations	O
is	O
particularly	O
scarce	O
,	O
both	O
in	O
terms	O
of	O
number	O
and	O
in	O
the	O
extent	O
of	O
clinical	O
information	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
expand	O
the	O
known	O
spectrum	O
of	O
such	O
mutations	O
.	O

46	O
unrelated	O
families	O
,	O
each	O
including	O
at	O
least	O
two	O
pancreatitis	O
patients	O
and	O
carrying	O
neither	O
cationic	O
trypsinogen	O
(PRSS1)	O
mutations	O
nor	O
the	O
frequent	O
SPINK1	O
N34S	B-ProteinMutation
mutation	O
,	O
participated	O
in	O
this	O
study	O
.	O

The	O
four	O
exons	O
and	O
their	O
flanking	O
sequences	O
of	O
the	O
SPINK1	O
gene	O
were	O
screened	O
by	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
analysis	O
(DHPLC)	O
;	O
and	O
mutations	O
were	O
identified	O
by	O
direct	O
sequencing	O
.	O

A	O
heterozygous	O
microdeletion	O
mutation	O
c.27delC	B-DNAMutation
,	O
which	O
occurs	O
within	O
a	O
symmetric	O
element	O
,	O
was	O
identified	O
in	O
two	O
families	O
.	O

In	O
one	O
family	O
,	O
c.27delC	B-DNAMutation
showed	O
segregation	O
with	O
the	O
disease	O
across	O
two	O
generations	O
,	O
with	O
a	O
penetrance	O
of	O
up	O
to	O
75%	O
.	O

But	O
in	O
the	O
other	O
family	O
,	O
however	O
,	O
the	O
same	O
mutation	O
manifested	O
as	O
a	O
low-penetrance	O
susceptibility	O
factor	O
.	O

In	O
addition	O
,	O
a	O
novel	O
heterozygous	O
splicing	O
mutation	O
,	O
c.87+1G>A	B-DNAMutation
(	O
G>A	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
+1	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
)	O
was	O
found	O
in	O
one	O
family	O
with	O
familial	O
pancreatitis	O
.	O

Our	O
results	O
also	O
helped	O
to	O
resolve	O
the	O
sharply	O
differing	O
views	O
about	O
PSTI's	O
role	O
in	O
pancreatitis	O
.	O

A	O
novel	O
two	O
nucleotide	O
deletion	O
in	O
the	O
apolipoprotein	O
A-I	O
gene	O
,	O
apoA-I	O
Shinbashi	O
,	O
associated	O
with	O
high	O
density	O
lipoprotein	O
deficiency	O
,	O
corneal	O
opacities	O
,	O
planar	O
xanthomas	O
,	O
and	O
premature	O
coronary	O
artery	O
disease	O
.	O

Familial	O
HDL	O
deficiency	O
(FHD)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
lipoprotein	O
disorder	O
.	O

We	O
describe	O
a	O
novel	O
genetic	O
variant	O
of	O
the	O
apolipoprotein	O
A-I	O
(apoA-I)	O
gene	O
resulting	O
in	O
FHD	O
.	O

The	O
proband	O
is	O
a	O
51-year-old	O
woman	O
who	O
was	O
hospitalized	O
due	O
to	O
severe	O
heart	O
failure	O
.	O

Her	O
plasma	O
HDL-cholesterol	O
(C)	O
and	O
apoA-I	O
concentrations	O
were	O
0.08mmol/l	O
and	O
1mg/dl	O
,	O
respectively	O
.	O

She	O
exhibited	O
corneal	O
opacities	O
and	O
planar	O
xanthomas	O
on	O
eyelids	O
and	O
elbows	O
.	O

Coronary	O
angiography	O
demonstrated	O
extensive	O
obstructions	O
in	O
two	O
major	O
vessels	O
.	O

Genomic	O
DNA	O
sequencing	O
of	O
the	O
patient's	O
apoA-I	O
gene	O
revealed	O
a	O
homozygosity	O
for	O
a	O
GC	O
deletion	O
between	O
5	O
GC	O
repeats	O
in	O
exon	O
4	O
,	O
creating	O
a	O
frameshift	O
and	O
a	O
stop	O
codon	O
at	O
residue	O
178	O
.	O

We	O
designated	O
this	O
mutation	O
as	O
apoA-I	O
Shinbashi	O
.	O

The	O
proband's	O
father	O
,	O
son	O
,	O
and	O
daughter	O
were	O
found	O
to	O
be	O
heterozygous	O
for	O
this	O
mutation	O
and	O
their	O
HDL-C	O
and	O
apoA-I	O
levels	O
were	O
about	O
half	O
of	O
normal	O
levels	O
,	O
demonstrating	O
a	O
gene	O
dosage	O
effect	O
.	O

The	O
father	O
underwent	O
coronary	O
bypass	O
surgery	O
at	O
age	O
of	O
70	O
years	O
.	O

Lecithin-cholesterol	O
acyltransferase	O
(LCAT)	O
activity	O
was	O
decreased	O
by	O
63%	O
in	O
the	O
homozygote	O
and	O
31%	O
in	O
heterozygotes	O
,	O
respectively	O
.	O

This	O
new	O
case	O
of	O
apoA-I	O
deficiency	O
,	O
apoA-I	O
Shinbashi	O
,	O
is	O
the	O
first	O
case	O
involving	O
a	O
single	O
gene	O
defect	O
of	O
the	O
apoA-I	O
gene	O
to	O
develop	O
all	O
the	O
characteristics	O
for	O
apoA-I	O
deficiency	O
,	O
including	O
premature	O
coronary	O
heart	O
disease	O
.	O

Gonadal	O
mosaicism	O
in	O
severe	O
Pallister-Hall	O
syndrome	O
.	O

Pallister-Hall	O
syndrome	O
(	O
PHS	O
,	O
MIM	O
#146510	O
)	O
is	O
characterized	O
by	O
central	O
and	O
postaxial	O
polydactyly	O
,	O
hypothalamic	O
hamartoma	O
(HH)	O
,	O
bifid	O
epiglottis	O
,	O
imperforate	O
anus	O
,	O
renal	O
abnormalities	O
,	O
and	O
pulmonary	O
segmentation	O
anomalies	O
.	O

It	O
is	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
.	O

Here	O
,	O
we	O
describe	O
a	O
family	O
with	O
two	O
affected	O
children	O
manifesting	O
severe	O
PHS	O
with	O
mental	O
retardation	O
,	O
behavioral	O
problems	O
,	O
and	O
intractable	O
seizures	O
.	O

Both	O
parents	O
are	O
healthy	O
,	O
with	O
normal	O
intelligence	O
,	O
and	O
have	O
no	O
malformations	O
on	O
physical	O
,	O
laryngoscopic	O
,	O
and	O
cranial	O
MRI	O
exam	O
.	O

The	O
atypical	O
presentation	O
of	O
these	O
children	O
and	O
the	O
absence	O
of	O
parental	O
manifestations	O
suggested	O
an	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
or	O
gonadal	O
mosaicism	O
.	O

Sequencing	O
of	O
GLI3	O
revealed	O
a	O
two	O
nucleotide	O
deletion	O
in	O
exon	O
15	O
c.3385_3386delTT	B-DNAMutation
predicting	O
a	O
frameshift	O
and	O
premature	O
stop	O
at	O
codon	O
1129	O
p.F1129X	B-ProteinMutation
in	O
the	O
children	O
while	O
both	O
parents	O
have	O
wild	O
type	O
alleles	O
.	O

Genotyping	O
with	O
GLI3	O
intragenic	O
markers	O
revealed	O
that	O
both	O
children	O
inherited	O
the	O
abnormal	O
allele	O
from	O
their	O
mother	O
thus	O
supporting	O
gonadal	O
mosaicism	O
as	O
the	O
underlying	O
mechanism	O
of	O
inheritance	O
(	O
paternity	O
was	O
confirmed	O
)	O
.	O

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
gonadal	O
mosaicism	O
in	O
PHS	O
.	O

The	O
severe	O
CNS	O
manifestations	O
of	O
these	O
children	O
are	O
reminiscent	O
of	O
children	O
with	O
non-syndromic	O
HH	O
who	O
often	O
have	O
progressive	O
mental	O
retardation	O
with	O
behavioral	O
problems	O
and	O
intractable	O
seizures	O
.	O

We	O
conclude	O
that	O
the	O
phenotypic	O
spectrum	O
of	O
PHS	O
can	O
include	O
severe	O
CNS	O
manifestations	O
and	O
that	O
recurrence	O
risks	O
for	O
PHS	O
should	O
include	O
a	O
proviso	O
for	O
gonadal	O
mosaicism	O
,	O
though	O
the	O
frequency	O
cannot	O
be	O
calculated	O
from	O
a	O
single	O
case	O
report	O
.	O

Published	O
2003	O
Wiley-Liss	O
,	O
Inc	O
.	O

High-resolution	O
deletion	O
mapping	O
of	O
15q13.2-q21.1	O
in	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
.	O

Deletions	O
found	O
in	O
several	O
types	O
of	O
human	O
tumor	O
,	O
including	O
carcinomas	O
of	O
the	O
colorectum	O
,	O
breast	O
,	O
and	O
lung	O
,	O
suggest	O
the	O
presence	O
of	O
a	O
potential	O
tumor	O
suppressor	O
gene(s)	O
on	O
chromosome	O
15	O
.	O

Common	O
regions	O
of	O
deletion	O
in	O
these	O
tumors	O
are	O
at	O
15q15	O
and	O
15q21	O
.	O

Here	O
,	O
we	O
have	O
analyzed	O
loss	O
of	O
heterozygosity	O
(LOH)	O
on	O
chromosome	O
15	O
to	O
ascertain	O
its	O
potential	O
involvement	O
in	O
the	O
development	O
and	O
progression	O
of	O
transitional	O
cell	O
carcinoma	O
(TCC)	O
of	O
the	O
bladder	O
.	O

A	O
panel	O
of	O
26	O
polymorphic	O
markers	O
,	O
spanning	O
15q12-15q22	O
,	O
were	O
used	O
to	O
map	O
regions	O
of	O
LOH	O
in	O
51	O
TCCs	O
.	O

LOH	O
was	O
found	O
for	O
at	O
least	O
one	O
marker	O
in	O
the	O
region	O
15q14-15q15.3	O
in	O
20	O
of	O
51	O
(39%)	O
tumors	O
.	O

Deletion	O
mapping	O
defined	O
two	O
minimum	O
regions	O
of	O
deletion	O
:	O
a	O
distal	O
region	O
between	O
the	O
markers	O
D15S514	O
and	O
D15S537	O
at	O
15q15.1-15q15.3	O
(	O
estimated	O
as	O
3	O
Mb	O
)	O
and	O
a	O
more	O
proximal	O
region	O
between	O
the	O
markers	O
D15S971	O
and	O
D15S1042	O
at	O
15q14	O
(	O
estimated	O
as	O
1.1	O
Mb	O
)	O
.	O

Analysis	O
of	O
a	O
panel	O
of	O
33	O
bladder	O
tumor	O
cell	O
lines	O
revealed	O
regions	O
of	O
contiguous	O
homozygosity	O
for	O
markers	O
in	O
15q15	O
,	O
indicating	O
likely	O
LOH	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
analysis	O
demonstrated	O
that	O
mitotic	O
recombination	O
is	O
the	O
predicted	O
mechanism	O
of	O
LOH	O
in	O
two	O
of	O
these	O
.	O

These	O
regions	O
of	O
LOH	O
on	O
15q	O
may	O
contain	O
tumor	O
suppressor	O
genes	O
the	O
loss	O
or	O
inactivation	O
of	O
which	O
is	O
associated	O
with	O
TCC	O
development	O
.	O

The	O
DNA	O
repair	O
gene	O
RAD51	O
at	O
15q15.1	O
represents	O
a	O
candidate	O
15q	O
tumor	O
suppressor	O
gene	O
.	O

Expression	O
analysis	O
of	O
rad51	O
protein	O
in	O
tumor	O
cell	O
lines	O
revealed	O
variable	O
levels	O
of	O
expression	O
but	O
no	O
significant	O
loss	O
of	O
expression	O
in	O
cell	O
lines	O
with	O
likely	O
15q	O
LOH	O
.	O

Muscle	O
glycogenosis	O
and	O
mitochondrial	O
hepatopathy	O
in	O
an	O
infant	O
with	O
mutations	O
in	O
both	O
the	O
myophosphorylase	O
and	O
deoxyguanosine	O
kinase	O
genes	O
.	O

OBJECTIVES	O
:	O
To	O
document	O
2	O
apparently	O
incongruous	O
clinical	O
disorders	O
occurring	O
in	O
the	O
same	O
infant	O
:	O
congenital	O
myopathy	O
with	O
myophosphorylase	O
deficiency	O
(	O
McArdle	O
disease	O
)	O
and	O
mitochondrial	O
hepatopathy	O
with	O
liver	O
failure	O
and	O
mitochondrial	O
DNA	O
depletion	O
.	O

METHODS	O
:	O
An	O
infant	O
girl	O
born	O
to	O
consanguineous	O
Moroccan	O
parents	O
had	O
severe	O
congenital	O
hypotonia	O
and	O
hepatomegaly	O
,	O
developed	O
liver	O
failure	O
,	O
and	O
died	O
at	O
5	O
months	O
of	O
age	O
.	O

We	O
studied	O
muscle	O
and	O
liver	O
biopsy	O
specimens	O
histochemically	O
and	O
biochemically	O
,	O
and	O
we	O
sequenced	O
the	O
whole	O
coding	O
regions	O
of	O
the	O
deoxyguanosine	O
kinase	O
(dGK)	O
and	O
myophosphorylase	O
(PYGM)	O
genes	O
.	O

RESULTS	O
:	O
Muscle	O
biopsy	O
specimens	O
showed	O
subsarcolemmal	O
glycogen	O
accumulation	O
and	O
negative	O
histochemical	O
reaction	O
for	O
phosphorylase	O
.	O

Liver	O
biopsy	O
specimens	O
showed	O
micronodular	O
cirrhosis	O
and	O
massive	O
mitochondrial	O
proliferation	O
.	O

Biochemical	O
analysis	O
showed	O
phosphorylase	O
deficiency	O
in	O
muscle	O
and	O
cytochrome	O
c	O
oxidase	O
deficiency	O
in	O
liver	O
.	O

We	O
identified	O
a	O
novel	O
homozygous	O
missense	O
G-to-A	O
mutation	O
at	O
codon	O
456	O
in	O
exon	O
11	O
of	O
PYGM	O
,	O
as	O
well	O
as	O
a	O
homozygous	O
4-base	O
pair	O
GATT	O
duplication	O
(	O
nucleotides	O
763-766	O
)	O
in	O
exon	O
6	O
of	O
dGK	O
,	O
which	O
produces	O
a	O
frame	O
shift	O
and	O
a	O
premature	O
TGA	O
stop	O
codon	O
at	O
nucleotides	O
766	O
to	O
768	O
,	O
resulting	O
in	O
a	O
truncated	O
255-amino	O
acid	O
protein	O
.	O

Both	O
mutations	O
were	O
absent	O
in	O
100	O
healthy	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
further	O
expand	O
the	O
genetic	O
heterogeneity	O
in	O
patients	O
with	O
McArdle	O
disease	O
;	O
confirm	O
the	O
strong	O
relationship	O
between	O
mitochondrial	O
DNA	O
depletion	O
syndrome	O
,	O
liver	O
involvement	O
,	O
and	O
dGK	O
mutations	O
;	O
and	O
suggest	O
that	O
genetic	O
"double	O
trouble"	O
should	O
be	O
considered	O
in	O
patients	O
with	O
unusual	O
severe	O
phenotypes	O
.	O

Association	O
of	O
microsomal	O
epoxide	O
hydrolase	O
polymorphisms	O
and	O
lung	O
cancer	O
risk	O
.	O

Microsomal	O
epoxide	O
hydrolase	O
(mEH)	O
plays	O
a	O
dual	O
role	O
in	O
the	O
detoxification	O
and	O
activation	O
of	O
tobacco	O
procarcinogens	O
.	O

Two	O
polymorphisms	O
affecting	O
enzyme	O
activity	O
have	O
been	O
described	O
in	O
the	O
exons	O
3	O
and	O
4	O
of	O
the	O
mEH	O
gene	O
,	O
which	O
result	O
in	O
the	O
substitution	O
of	O
amino	O
acids	O
histidine	O
to	O
tyrosine	O
at	O
residue	O
113	O
,	O
and	O
arginine	O
to	O
histidine	O
at	O
residue	O
139	O
,	O
respectively	O
.	O

We	O
performed	O
a	O
hospital-based	O
case-control	O
study	O
consisting	O
of	O
277	O
newly	O
diagnosed	O
lung	O
cancer	O
patients	O
and	O
496	O
control	O
subjects	O
to	O
investigate	O
a	O
possible	O
association	O
between	O
these	O
two	O
polymorphisms	O
and	O
lung	O
cancer	O
risk	O
.	O

The	O
polymorphisms	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction/restriction	O
fragment	O
length	O
polymorphism	O
and	O
TaqMan	O
assay	O
using	O
DNA	O
from	O
peripheral	O
white	O
blood	O
cells	O
.	O

Logistic	O
regression	O
was	O
performed	O
to	O
calculate	O
odds	O
ratios	O
(ORs)	O
,	O
confidence	O
limits	O
(CL)	O
and	O
to	O
control	O
for	O
possible	O
confounders	O
.	O

The	O
exon	O
3	O
polymorphism	O
of	O
the	O
mEH	O
gene	O
was	O
associated	O
with	O
a	O
significantly	O
decreased	O
risk	O
of	O
lung	O
cancer	O
.	O

The	O
adjusted	O
OR	O
,	O
calculated	O
relative	O
to	O
subjects	O
with	O
the	O
Tyr113/Tyr113	O
wild	O
type	O
,	O
for	O
the	O
His113/His113	O
genotype	O
was	O
0.38	O
(	O
95%	O
CL	O
0.20-0.75	O
)	O
.	O

An	O
analysis	O
according	O
to	O
histological	O
subtypes	O
revealed	O
a	O
statistically	O
significant	O
association	O
for	O
adenocarcinomas	O
;	O
the	O
adjusted	O
OR	O
for	O
the	O
His113/His113	O
genotype	O
was	O
0.40	O
(	O
95%	O
CL	O
0.17-0.94	O
)	O
.	O

In	O
contrast	O
,	O
no	O
relationship	O
between	O
the	O
exon	O
4	O
polymorphism	O
and	O
lung	O
cancer	O
risk	O
was	O
found	O
.	O

The	O
adjusted	O
OR	O
,	O
calculated	O
relative	O
to	O
the	O
His139/His139	O
wild	O
type	O
,	O
was	O
for	O
the	O
Arg139/Arg139	O
genotype	O
1.83	O
(0.76-4.44)	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
genetically	O
reduced	O
mEH	O
activity	O
may	O
be	O
protective	O
against	O
lung	O
cancer	O
.	O

Detection	O
of	O
PHKA2	O
gene	O
mutation	O
in	O
four	O
Japanese	O
patients	O
with	O
hepatic	O
phosphorylase	O
kinase	O
deficiency	O
.	O

We	O
analyzed	O
the	O
PHKA2	O
gene	O
in	O
four	O
Japanese	O
families	O
with	O
hepatic	O
phosphorylase	O
kinase	O
(PhK)	O
deficiency	O
.	O

Mutational	O
analysis	O
of	O
PHKA2	O
cDNA	O
was	O
performed	O
by	O
reverse-transcribed	O
polymerase	O
chain	O
reaction	O
(RT-PCR)	O
and	O
direct	O
sequencing	O
,	O
and	O
each	O
mutation	O
was	O
confirmed	O
on	O
the	O
genomic	O
DNA	O
.	O

In	O
boys	O
with	O
low	O
erythrocyte	O
PhK	O
activity	O
(	O
i.e.	O
,	O
x-linked	O
liver	O
glycogenosis	O
[XLG]	O
type	O
I	O
)	O
,	O
deletion	O
of	O
exon	O
2	O
(	O
splice	O
site	O
mutation	O
of	O
79-1	B-DNAMutation
G	I-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
)	O
or	O
nonsense	O
mutation	O
of	O
Q1169X	B-ProteinMutation
or	O
R497X	B-ProteinMutation
was	O
identified	O
.	O

However	O
,	O
missense	O
mutation	O
of	O
R295C	B-ProteinMutation
was	O
identified	O
in	O
one	O
boy	O
with	O
normal	O
erythrocyte	O
PhK	O
activity	O
(	O
i.e.	O
,	O
XLG	O
type	O
II	O
)	O
.	O

This	O
mutation	O
was	O
not	O
found	O
in	O
100	O
control	O
alleles	O
,	O
and	O
was	O
considered	O
responsible	O
for	O
presentation	O
of	O
the	O
XLG	O
type	O
II	O
phenotype	O
.	O

Excluding	O
Q1169X	B-ProteinMutation
,	O
all	O
mutations	O
detected	O
in	O
this	O
study	O
represented	O
novel	O
mutations	O
.	O

All	O
mothers	O
were	O
found	O
to	O
be	O
heterozygous	O
carriers	O
of	O
the	O
mutations	O
.	O

Gene	O
analysis	O
was	O
confirmed	O
to	O
represent	O
a	O
useful	O
procedure	O
for	O
diagnosing	O
XLG	O
type	O
II	O
,	O
for	O
which	O
liver	O
biopsy	O
had	O
previously	O
been	O
required	O
to	O
detect	O
hepatic	O
PhK	O
deficiency	O
.	O

Mutation	O
analysis	O
of	O
SLC7A9	O
in	O
cystinuria	O
patients	O
in	O
Sweden	O
.	O

Cystinuria	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
increased	O
urinary	O
excretion	O
of	O
cystine	O
and	O
dibasic	O
amino	O
acids	O
,	O
which	O
cause	O
recurrent	O
stone	O
formation	O
in	O
affected	O
individuals	O
.	O

Three	O
subtypes	O
of	O
cystinuria	O
have	O
been	O
described	O
(	O
type	O
I	O
,	O
II	O
,	O
and	O
III	O
)	O
:	O
type	O
I	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
SLC3A1	O
gene	O
,	O
whereas	O
nontype	O
I	O
(	O
II	O
and	O
III	O
)	O
has	O
been	O
associated	O
with	O
SLC7A9	O
mutations	O
.	O

Of	O
the	O
53	O
patients	O
reported	O
in	O
our	O
previous	O
work	O
,	O
patients	O
that	O
showed	O
SLC7A9	O
mutations	O
in	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
screening	O
and/or	O
either	O
lacked	O
or	O
showed	O
heterozygosity	O
for	O
SLC3A1	O
mutations	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O

The	O
entire	O
coding	O
region	O
and	O
the	O
exon/intron	O
boundaries	O
of	O
the	O
SLC7A9	O
gene	O
were	O
analyzed	O
by	O
means	O
of	O
both	O
SSCP	O
and	O
DNA	O
sequencing	O
in	O
16	O
patients	O
,	O
all	O
but	O
one	O
of	O
which	O
were	O
clinically	O
diagnosed	O
as	O
homozygous	O
cystinurics	O
.	O

Three	O
novel	O
SLC7A9	O
mutations	O
were	O
identified	O
in	O
the	O
patient	O
group	O
:	O
two	O
missense	O
mutations	O
(	O
P261L	B-ProteinMutation
and	O
V330M	B-ProteinMutation
)	O
,	O
and	O
one	O
single	O
base-pair	O
deletion	O
(	O
1009	B-DNAMutation
delA	I-DNAMutation
)	O
.	O

We	O
also	O
detected	O
the	O
previously	O
reported	O
A182T	B-ProteinMutation
and	O
nine	O
novel	O
polymorphisms	O
in	O
the	O
patients	O
.	O

Mutations	O
V330M	B-ProteinMutation
and	O
1009delA	B-DNAMutation
occurred	O
on	O
different	O
alleles	O
in	O
one	O
individual	O
,	O
and	O
we	O
suggest	O
that	O
these	O
mutations	O
cause	O
cystinuria	O
in	O
this	O
patient	O
.	O

One	O
patient	O
that	O
was	O
homozygously	O
mutated	O
in	O
the	O
SLC3A1	O
gene	O
carried	O
the	O
third	O
novel	O
mutation	O
P261L	B-ProteinMutation
.	O

We	O
conclude	O
that	O
SLC3A1	O
is	O
still	O
the	O
major	O
disease	O
gene	O
among	O
Swedish	O
cystinuria	O
patients	O
,	O
with	O
only	O
a	O
minor	O
contribution	O
of	O
SLC7A9	O
mutations	O
as	O
the	O
genetic	O
basis	O
of	O
cystinuria	O
.	O

The	O
absence	O
of	O
SLC3A1	O
and	O
SLC7A9	O
mutations	O
in	O
a	O
substantial	O
proportion	O
of	O
the	O
patients	O
implies	O
that	O
mutations	O
in	O
parts	O
of	O
the	O
genes	O
that	O
were	O
not	O
analyzed	O
may	O
be	O
present	O
,	O
as	O
well	O
as	O
large	O
deletions	O
that	O
escape	O
detection	O
by	O
the	O
methods	O
used	O
.	O

However	O
,	O
our	O
results	O
raise	O
the	O
question	O
of	O
whether	O
other	O
,	O
as	O
yet	O
unknown	O
genes	O
,	O
may	O
also	O
be	O
involved	O
in	O
cystinuria	O
.	O

A	O
cluster	O
of	O
autosomal	O
recessive	O
spondylocostal	O
dysostosis	O
caused	O
by	O
three	O
newly	O
identified	O
DLL3	O
mutations	O
segregating	O
in	O
a	O
small	O
village	O
.	O

In	O
1982	O
,	O
one	O
of	O
us	O
reported	O
a	O
cluster	O
of	O
eight	O
individuals	O
affected	O
by	O
spondylocostal	O
dysostosis	O
(	O
SD	O
,	O
MIM	O
277300	O
)	O
in	O
four	O
nuclear	O
families	O
indigenous	O
to	O
a	O
village	O
from	O
eastern	O
Switzerland	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
the	O
molecular	O
basis	O
for	O
this	O
cluster	O
was	O
segregation	O
of	O
a	O
single	O
mutation	O
in	O
the	O
DLL3	O
gene	O
,	O
recently	O
linked	O
to	O
SD	O
.	O

Marker	O
haplotypes	O
around	O
the	O
DLL3	O
locus	O
contradicted	O
this	O
hypothesis	O
as	O
three	O
different	O
haplotypes	O
were	O
seen	O
in	O
affected	O
individuals	O
,	O
but	O
sequence	O
analysis	O
showed	O
that	O
three	O
unreported	O
DLL3	O
mutations	O
were	O
segregating	O
:	O
a	O
duplication	O
of	O
17	O
bp	O
in	O
exon	O
8	O
c.1285-1301dup	B-DNAMutation
,	O
a	O
single-nucleotide	O
deletion	O
in	O
exon	O
5	O
c.615delC	B-DNAMutation
,	O
and	O
a	O
R238X	B-ProteinMutation
nonsense	O
mutation	O
in	O
exon	O
6	O
.	O

Contrary	O
to	O
our	O
initial	O
assumption	O
of	O
a	O
single	O
allele	O
segregating	O
in	O
this	O
small	O
community	O
,	O
three	O
different	O
pathogenic	O
alleles	O
were	O
observed	O
,	O
with	O
a	O
putative	O
founder	O
mutation	O
occurring	O
at	O
the	O
homozygous	O
state	O
but	O
also	O
compounding	O
with	O
,	O
and	O
thus	O
revealing	O
,	O
two	O
other	O
independent	O
mutations	O
.	O

As	O
all	O
three	O
mutations	O
predict	O
truncation	O
of	O
the	O
DLL3	O
protein	O
and	O
loss	O
of	O
the	O
membrane-attaching	O
domain	O
,	O
the	O
results	O
confirm	O
that	O
autosomal	O
recessive	O
spondylocostal	O
dysostosis	O
represents	O
the	O
null	O
phenotype	O
of	O
DLL3	O
,	O
with	O
remarkable	O
phenotypic	O
consistency	O
across	O
families	O
.	O

A	O
"null	O
allele"	O
mutation	O
is	O
responsible	O
for	O
erythropoietic	O
protoporphyria	O
in	O
an	O
Israeli	O
patient	O
who	O
underwent	O
liver	O
transplantation	O
:	O
relationships	O
among	O
biochemical	O
,	O
clinical	O
,	O
and	O
genetic	O
parameters	O
.	O

Mutations	O
in	O
the	O
human	O
ferrochelatase	O
gene	O
(FECH)	O
are	O
the	O
primary	O
cause	O
of	O
the	O
inborn	O
disorder	O
erythropoietic	O
protoporphyria	O
(EPP)	O
.	O

While	O
the	O
majority	O
of	O
the	O
EPP	O
patients	O
exhibit	O
only	O
photosensitivity	O
,	O
a	O
small	O
percentage	O
of	O
patients	O
(	O
approximately	O
2%	O
)	O
develop	O
liver	O
complications	O
in	O
addition	O
to	O
the	O
cutaneous	O
symptoms	O
.	O

In	O
this	O
study	O
,	O
the	O
FECH	O
gene	O
of	O
an	O
Israeli	O
EPP	O
patient	O
who	O
suffered	O
from	O
EPP-related	O
liver	O
complications	O
was	O
sequenced	O
.	O

A	O
splicing	O
defect	O
IVS10+1	B-DNAMutation
,	I-DNAMutation
g-->t	I-DNAMutation
,	O
which	O
is	O
known	O
to	O
cause	O
the	O
deletion	O
of	O
exon	O
10	O
,	O
was	O
identified	O
in	O
the	O
index	O
patient	O
as	O
well	O
as	O
in	O
his	O
symptomatic	O
older	O
sister	O
and	O
his	O
asymptomatic	O
mother	O
.	O

Like	O
the	O
other	O
12	O
known	O
FECH	O
mutations	O
associated	O
with	O
liver	O
complications	O
,	O
IVS10+1	B-DNAMutation
,	I-DNAMutation
g-->t	I-DNAMutation
is	O
a	O
"null-allele"	O
mutation	O
.	O

Although	O
the	O
two	O
siblings	O
with	O
overt	O
EPP	O
share	O
an	O
identical	O
genotype	O
with	O
respect	O
to	O
both	O
the	O
mutation	O
on	O
one	O
FECH	O
allele	O
and	O
three	O
intragenic	O
single	O
nucleotide	O
polymorphisms	O
,	O
-251G	B-DNAMutation
,	O
IVS1-23T	B-DNAMutation
,	O
and	O
IVS3-48C	B-DNAMutation
on	O
the	O
other	O
allele	O
,	O
the	O
sister	O
of	O
the	O
index	O
patient	O
has	O
so	O
far	O
shown	O
no	O
signs	O
of	O
liver	O
involvement	O
,	O
suggesting	O
that	O
additional	O
factors	O
might	O
account	O
for	O
the	O
liver	O
disease	O
in	O
EPP	O
.	O

A	O
novel	O
compound	O
heterozygous	O
mutation	O
in	O
the	O
CYP17	O
(	O
P450	O
17alpha-hydroxylase	O
)	O
gene	O
leading	O
to	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
.	O

Mutations	O
in	O
the	O
CYP17	O
gene	O
impair	O
steroid	O
biosynthesis	O
in	O
the	O
adrenals	O
and	O
gonads	O
and	O
often	O
cause	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
,	O
leading	O
to	O
amenorrhea	O
,	O
sexual	O
infantilism	O
,	O
and	O
hypokalemic	O
low	O
aldosterone	O
hypertension	O
.	O

Several	O
CYP17	O
mutations	O
resulting	O
in	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
have	O
been	O
reported	O
previously	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
a	O
novel	O
CYP17	O
mutation	O
from	O
the	O
molecular	O
analysis	O
of	O
a	O
Korean	O
patient	O
with	O
primary	O
amenorrhea	O
with	O
a	O
46,XX	O
karyotype	O
,	O
and	O
hypokalemic	O
hypertension	O
.	O

We	O
sequenced	O
all	O
8	O
exons	O
of	O
the	O
CYP17	O
gene	O
that	O
were	O
amplified	O
from	O
patient's	O
genomic	O
DNA	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
found	O
a	O
compound	O
heterozygous	O
mutation	O
in	O
the	O
CYP17	O
structural	O
gene	O
;	O
a	O
1-base	O
deletion	O
and	O
a	O
1-base	O
transversion	O
TAC-->AA	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
,	O
leading	O
to	O
the	O
production	O
of	O
a	O
truncated	O
protein	O
(	O
1-417	O
amino	O
acids	O
)	O
,	O
and	O
a	O
3-base	O
deletion	O
(	O
TCC	O
,	O
either	O
350-351	O
or	O
351-352	O
codon	O
)	O
in	O
the	O
other	O
allele	O
.	O

Restriction	O
enzyme	O
digestion	O
analysis	O
of	O
patient's	O
and	O
parental	O
DNA	O
showed	O
that	O
the	O
1-base	O
deletion	O
and	O
the	O
3-base	O
deletion	O
are	O
inherited	O
from	O
mother	O
and	O
father	O
,	O
respectively	O
.	O

Here	O
we	O
conclude	O
that	O
these	O
novel	O
compound	O
heterozygous	O
mutations	O
might	O
account	O
for	O
the	O
patient's	O
clinical	O
manifestations	O
of	O
17alpha-hydroxylase/17,20-lyase	O
deficiency	O
.	O

Haplotypes	O
extending	O
across	O
ACE	O
are	O
associated	O
with	O
Alzheimer's	O
disease	O
.	O

Numerous	O
genes	O
have	O
been	O
implicated	O
in	O
Alzheimer's	O
disease	O
(AD)	O
,	O
but	O
,	O
with	O
the	O
exception	O
of	O
a	O
demonstrated	O
association	O
with	O
the	O
epsilon	O
4	O
allele	O
of	O
APOE	O
,	O
findings	O
have	O
not	O
been	O
consistently	O
replicated	O
across	O
populations	O
.	O

One	O
of	O
the	O
most	O
widely	O
studied	O
is	O
the	O
gene	O
for	O
angiotensin	O
I	O
converting	O
enzyme	O
(	O
ACE	O
)	O
.	O

A	O
meta-analysis	O
of	O
published	O
data	O
on	O
a	O
common	O
Alu	O
indel	O
polymorphism	O
in	O
ACE	O
was	O
performed	O
which	O
indicated	O
highly	O
significant	O
association	O
of	O
the	O
insertion	O
allele	O
with	O
AD	O
(	O
OR	O
1.30	O
;	O
95%	O
CI	O
1.19	O
-	O
1.41	O
;	O
P=4	O
x	O
10(-8)	O
)	O
.	O

To	O
further	O
explore	O
the	O
influence	O
of	O
ACE	O
on	O
AD	O
,	O
several	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
genotyped	O
in	O
five	O
independent	O
populations	O
represented	O
by	O
over	O
3100	O
individuals	O
.	O

Analyses	O
based	O
upon	O
single	O
markers	O
and	O
haplotypes	O
revealed	O
strong	O
evidence	O
of	O
association	O
in	O
case-control	O
models	O
and	O
also	O
in	O
a	O
model	O
examining	O
the	O
influence	O
of	O
variation	O
in	O
ACE	O
upon	O
cerebrospinal	O
fluid	O
levels	O
of	O
amyloid	O
beta42	O
peptide	O
(Abeta42)	O
.	O

The	O
most	O
significant	O
evidence	O
for	O
association	O
with	O
AD	O
was	O
found	O
for	O
an	O
SNP	O
,	O
A-262T	B-DNAMutation
,	O
located	O
in	O
the	O
ACE	O
promoter	O
(	O
OR	O
1.64	O
;	O
95%	O
CI	O
1.33	O
-1.94	O
;	O
P=2	O
x	O
10(-5)	O
)	O
.	O

Estimates	O
of	O
population	O
attributable	O
risk	O
for	O
the	O
common	O
allele	O
of	O
this	O
SNP	O
suggest	O
that	O
it	O
,	O
or	O
an	O
allele	O
in	O
tight	O
linkage	O
disequilibrium	O
(LD)	O
with	O
it	O
,	O
may	O
contribute	O
to	O
as	O
much	O
as	O
35%	O
of	O
AD	O
in	O
the	O
general	O
population	O
.	O

Results	O
support	O
a	O
model	O
whereby	O
decreased	O
ACE	O
activity	O
may	O
influence	O
AD	O
susceptibility	O
by	O
a	O
mechanism	O
involving	O
beta-amyloid	O
metabolism	O
.	O

Identification	O
of	O
new	O
polymorphisms	O
in	O
the	O
CACNA1S	O
gene	O
.	O

We	O
identified	O
four	O
novel	O
polymorphisms	O
in	O
the	O
CACNA1S	O
gene	O
that	O
encodes	O
the	O
alpha1-subunit	O
of	O
the	O
dihydropyridine	O
receptor	O
.	O

Mutations	O
in	O
this	O
gene	O
are	O
associated	O
with	O
two	O
genetic	O
diseases	O
:	O
malignant	O
hyperthermia	O
and	O
hypokalemic	O
periodic	O
paralysis	O
.	O

The	O
nucleotide	O
substitutions	O
c2403T	B-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
and	O
c5398T	B-DNAMutation
-->	I-DNAMutation
C	I-DNAMutation
did	O
not	O
result	O
in	O
amino	O
acid	O
replacement	O
,	O
the	O
nucleotide	O
substitution	O
c4475C	B-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
caused	O
the	O
replacement	O
of	O
the	O
Ala1492	O
with	O
an	O
Asp	O
residue	O
and	O
an	O
A	O
insertion	O
was	O
identified	O
in	O
intron	O
36	O
.	O

By	O
using	O
methods	O
based	O
on	O
digestion	O
with	O
restriction	O
enzymes	O
we	O
calculated	O
the	O
frequencies	O
of	O
these	O
novel	O
polymorphisms	O
,	O
as	O
well	O
as	O
heterozygosity	O
,	O
in	O
normal	O
subjects	O
from	O
southern	O
Italy	O
.	O

Association	O
of	O
an	O
IL-1A	O
3'UTR	O
polymorphism	O
with	O
end-stage	O
renal	O
disease	O
and	O
IL-1	O
alpha	O
expression	O
.	O

BACKGROUND	O
:	O
We	O
evaluated	O
polymorphisms	O
in	O
the	O
interleukin-1	O
alpha	O
3'-untranslated	O
region	O
(	O
IL-1A	O
3'[UTR]	O
)	O
for	O
association	O
with	O
type	O
2	O
diabetes-associated	O
(DM)	O
and	O
nondiabetic-associated	O
(non-DM)	O
end-stage	O
renal	O
disease	O
(ESRD)	O
in	O
two	O
ethnic	O
groups	O
.	O

METHODS	O
:	O
IL-1A	O
3'UTR	O
polymorphisms	O
were	O
identified	O
by	O
alignment	O
of	O
overlapping	O
human	O
expressed	O
sequence	O
tags	O
(ESTs)	O
.	O

Sequence	O
ambiguities	O
were	O
experimentally	O
confirmed	O
and	O
variants	O
genotyped	O
to	O
test	O
for	O
association	O
with	O
ESRD	O
in	O
75	O
unrelated	O
Caucasians	O
with	O
DM	O
ESRD	O
,	O
95	O
unrelated	O
Caucasian	O
controls	O
and	O
,	O
in	O
a	O
parallel	O
study	O
,	O
92	O
unrelated	O
African	O
Americans	O
with	O
type	O
2	O
DM	O
ESRD	O
,	O
95	O
unrelated	O
African	O
Americans	O
with	O
non-DM	O
ESRD	O
,	O
and	O
86	O
unrelated	O
African	O
American	O
controls	O
.	O

IL-1A	O
3'	O
UTR	O
genotype	O
and	O
lipopolysaccharide	O
(LPS)-stimulated	O
IL-1	O
alpha	O
protein	O
levels	O
were	O
measured	O
in	O
healthy	O
Caucasians	O
(	O
N	O
=	O
112	O
)	O
and	O
African	O
Americans	O
(	O
N	O
=	O
101	O
)	O
to	O
evaluate	O
association	O
between	O
genotype	O
and	O
protein	O
level	O
.	O

RESULTS	O
:	O
A	O
polymorphism	O
in	O
the	O
3'	O
UTR	O
of	O
the	O
human	O
IL-1A	O
gene	O
was	O
associated	O
with	O
ESRD	O
and	O
IL-1	O
alpha	O
protein	O
expression	O
.	O

The	O
polymorphism	O
consists	O
of	O
two	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
an	O
insertion/deletion	O
generating	O
four	O
different	O
haplotypes	O
:	O
TN7TTCAA	O
,	O
AN7TTCAA	O
,	O
TN7TTCAG	O
and	O
an	O
allele	O
deleted	O
for	O
four	O
internal	O
bases	O
,	O
TN7(delTTCA)A	B-DNAMutation
.	O

The	O
4	O
bp	O
deletion	O
allele	O
,	O
TN7(delTTCA)A	B-DNAMutation
,	O
was	O
significantly	O
less	O
common	O
among	O
Caucasian	O
DM	O
ESRD	O
and	O
African	O
American	O
non-DM	O
ESRD	O
patients	O
(	O
recessive	O
model	O
;	O
P	O
=	O
0.0364	O
and	O
P	O
=	O
0.0293	O
,	O
respectively	O
)	O
.	O

In	O
vitro	O
,	O
this	O
polymorphism	O
is	O
associated	O
with	O
the	O
amount	O
of	O
IL-1	O
alpha	O
protein	O
synthesized	O
in	O
LPS-stimulated	O
lymphocytes	O
from	O
healthy	O
subjects	O
(	O
P	O
=	O
0.0013	O
,	O
additive	O
model	O
)	O
,	O
with	O
the	O
TN7(delTTCA)A	B-DNAMutation
haplotype	O
associated	O
with	O
higher	O
levels	O
of	O
stimulated	O
IL-1	O
alpha	O
.	O

CONCLUSION	O
:	O
The	O
association	O
of	O
the	O
TN7(delTTCA)A	B-DNAMutation
haplotype	O
with	O
higher	O
levels	O
of	O
IL-1	O
alpha	O
expression	O
and	O
reduced	O
risk	O
for	O
ESRD	O
is	O
consistent	O
with	O
involvement	O
of	O
cytokines	O
in	O
risk	O
for	O
developing	O
nephropathy	O
.	O

The	O
association	O
between	O
GJB2	O
mutation	O
and	O
GJB6	O
gene	O
in	O
non	O
syndromic	O
hearing	O
loss	O
school	O
children	O
.	O

Recently	O
,	O
molecular	O
testing	O
for	O
GJB2	O
mutations	O
has	O
become	O
the	O
standard	O
of	O
care	O
for	O
the	O
diagnosis	O
of	O
patients	O
with	O
non	O
syndromic	O
hearing	O
impairment	O
of	O
unknown	O
cause	O
.	O

The	O
aims	O
of	O
this	O
study	O
are	O
to	O
determine	O
the	O
association	O
between	O
GJB2	O
mutation	O
and	O
GJB6	O
and	O
to	O
report	O
the	O
variation	O
of	O
mutations	O
in	O
deaf	O
students	O
who	O
have	O
heterozygous	O
GJB2	O
.	O

This	O
retrospective	O
study	O
was	O
conducted	O
at	O
Universiti	O
Kebangsaan	O
Malaysia	O
Medical	O
Center	O
(UKMMC)	O
.	O

Data	O
was	O
collected	O
from	O
previous	O
files	O
and	O
records	O
from	O
Tissue	O
Engineering	O
and	O
Human	O
Genetic	O
Research	O
Group	O
Laboratory	O
.	O

Approval	O
from	O
Ethical	O
Committee	O
was	O
obtained	O
prior	O
to	O
the	O
study	O
.	O

A	O
total	O
of	O
138	O
students	O
have	O
been	O
screened	O
in	O
previous	O
studies	O
in	O
UKMMC	O
for	O
the	O
presence	O
of	O
GJB2	O
mutations	O
as	O
a	O
cause	O
for	O
hearing	O
loss	O
.	O

Thirty	O
four	O
of	O
the	O
138	O
subjects	O
have	O
GJB2	O
mutations	O
;	O
2	O
showed	O
homozygous	O
mutations	O
whereas	O
another	O
32	O
were	O
heterozygous	O
for	O
GJB2	O
gene	O
mutation	O
.	O

Only	O
31	O
DNA	O
samples	O
of	O
students	O
presented	O
with	O
sensorineural	O
hearing	O
loss	O
with	O
heterozygous	O
mutation	O
in	O
GJB2	O
gene	O
were	O
included	O
in	O
this	O
study	O
.	O

The	O
sequencing	O
results	O
obtained	O
were	O
analyzed	O
.	O

The	O
degree	O
of	O
hearing	O
loss	O
of	O
those	O
students	O
with	O
association	O
between	O
GJB2	O
mutation	O
and	O
GJB6	O
mutation	O
will	O
be	O
discussed	O
.	O

Five	O
out	O
of	O
31	O
subjects	O
(16.2%)	O
have	O
mutations	O
in	O
their	O
GJB6	O
gene	O
,	O
suggesting	O
a	O
digenic	O
inheritance	O
of	O
GJB2/GJB6	O
mutation	O
.	O

In	O
total	O
,	O
four	O
novel	O
mutations	O
were	O
identified	O
;	O
E137D	B-ProteinMutation
(n=1)	O
,	O
R32Q	B-ProteinMutation
(n=1)	O
,	O
E101K	B-ProteinMutation
(n=1)	O
and	O
Y156H	B-ProteinMutation
(n=1)	O
and	O
one	O
mutation	O
deletion	O
;	O
366delT	B-DNAMutation
(n=1)	O
.	O

All	O
students	O
with	O
association	O
GJB2	O
mutation	O
and	O
GJB6	O
showed	O
severe	O
to	O
profound	O
hearing	O
loss	O
in	O
both	O
ears	O
.	O

Interestingly	O
this	O
study	O
not	O
detected	O
the	O
large	O
deletion	O
of	O
342	O
kb	O
in	O
GJB6	O
gene	O
suggesting	O
that	O
the	O
mutation	O
is	O
very	O
rare	O
in	O
this	O
region	O
compared	O
to	O
certain	O
parts	O
of	O
the	O
world	O
.	O

Homozygously	O
deleted	O
gene	O
DACH1	O
regulates	O
tumor-initiating	O
activity	O
of	O
glioma	O
cells	O
.	O

Loss	O
or	O
reduction	O
in	O
function	O
of	O
tumor	O
suppressor	O
genes	O
contributes	O
to	O
tumorigenesis	O
.	O

Here	O
,	O
by	O
allelic	O
DNA	O
copy	O
number	O
analysis	O
using	O
single-nucleotide	O
polymorphism	O
genotyping	O
array	O
and	O
mass	O
spectrometry	O
,	O
we	O
report	O
homozygous	O
deletion	O
in	O
glioblastoma	O
multiformes	O
at	O
chromosome	O
13q21	O
,	O
where	O
DACH1	O
gene	O
is	O
located	O
.	O

We	O
found	O
decreased	O
cell	O
proliferation	O
of	O
a	O
series	O
of	O
glioma	O
cell	O
lines	O
by	O
forced	O
expression	O
of	O
DACH1	O
.	O

We	O
then	O
generated	O
U87TR-Da	O
glioma	O
cells	O
,	O
where	O
DACH1	O
expression	O
could	O
be	O
activated	O
by	O
exposure	O
of	O
the	O
cells	O
to	O
doxycycline	O
.	O

Both	O
ex	O
vivo	O
cellular	O
proliferation	O
and	O
in	O
vivo	O
growth	O
of	O
s.c	O
.	O

transplanted	O
tumors	O
in	O
mice	O
are	O
reduced	O
in	O
U87TR-Da	O
cells	O
with	O
DACH1	O
expression	O
(U87-DACH1-high)	O
,	O
compared	O
with	O
DACH1-nonexpressing	O
U87TR-Da	O
cells	O
(U87-DACH1-low)	O
.	O

U87-DACH1-low	O
cells	O
form	O
spheroids	O
with	O
CD133	O
and	O
Nestin	O
expression	O
in	O
serum-free	O
medium	O
but	O
U87-DACH1-high	O
cells	O
do	O
not	O
.	O

Compared	O
with	O
spheroid-forming	O
U87-DACH1-low	O
cells	O
,	O
adherent	O
U87-DACH1-high	O
cells	O
display	O
lower	O
tumorigenicity	O
,	O
indicating	O
DACH1	O
decreases	O
the	O
number	O
of	O
tumor-initiating	O
cells	O
.	O

Gene	O
expression	O
analysis	O
and	O
chromatin	O
immunoprecipitation	O
assay	O
reveal	O
that	O
fibroblast	O
growth	O
factor	O
2	O
(FGF2/bFGF)	O
is	O
transcriptionally	O
repressed	O
by	O
DACH1	O
,	O
especially	O
in	O
cells	O
cultured	O
in	O
serum-free	O
medium	O
.	O

Exogenous	O
bFGF	O
rescues	O
spheroid-forming	O
activity	O
and	O
tumorigenicity	O
of	O
the	O
U87-DACH1-high	O
cells	O
,	O
suggesting	O
that	O
loss	O
of	O
DACH1	O
increases	O
the	O
number	O
of	O
tumor-initiating	O
cells	O
through	O
transcriptional	O
activation	O
of	O
bFGF	O
.	O

These	O
results	O
illustrate	O
that	O
DACH1	O
is	O
a	O
distinctive	O
tumor	O
suppressor	O
,	O
which	O
does	O
not	O
only	O
suppress	O
growth	O
of	O
tumor	O
cells	O
but	O
also	O
regulates	O
bFGF-mediated	O
tumor-initiating	O
activity	O
of	O
glioma	O
cells	O
.	O

PTCH1	O
gene	O
mutations	O
in	O
exon	O
17	O
and	O
loss	O
of	O
heterozygosity	O
on	O
D9S180	O
microsatellite	O
in	O
sporadic	O
and	O
inherited	O
human	O
basal	O
cell	O
carcinomas	O
.	O

BACKGROUND	O
:	O
Basal	O
cell	O
carcinomas	O
(BCCs)	O
are	O
the	O
most	O
frequent	O
human	O
cancer	O
that	O
results	O
from	O
malignant	O
transformation	O
of	O
basal	O
cells	O
in	O
the	O
epidermis	O
.	O

Gorlin	O
syndrome	O
is	O
a	O
rare	O
inherited	O
autosomal	O
dominant	O
disease	O
that	O
predisposes	O
with	O
multiple	O
BCCs	O
and	O
other	O
birth	O
defects	O
.	O

Both	O
sporadic	O
and	O
inherited	O
BCCs	O
are	O
associated	O
with	O
mutations	O
in	O
the	O
tumor	O
suppressor	O
gene	O
PTCH1	O
,	O
but	O
there	O
is	O
still	O
uncertainty	O
on	O
the	O
role	O
of	O
its	O
homolog	O
PTCH2	O
.	O

OBJECTIVES	O
:	O
To	O
search	O
for	O
mutations	O
and	O
genomic	O
instability	O
in	O
sporadic	O
and	O
inherited	O
BCCs	O
.	O

METHODS	O
:	O
DNA	O
obtained	O
from	O
leukocytes	O
and	O
tumor	O
cells	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
regarding	O
five	O
exons	O
of	O
PTCH1	O
and	O
PTCH2	O
and	O
neighboring	O
microsatellites	O
.	O

Exons	O
were	O
sequenced	O
and	O
compared	O
with	O
the	O
GenBank	O
database	O
.	O

RESULTS	O
:	O
Only	O
D9S180	O
,	O
of	O
six	O
microsatellites	O
,	O
showed	O
loss	O
of	O
heterozygosity	O
in	O
three	O
BCCs	O
(	O
two	O
sporadic	O
and	O
one	O
inherited	O
)	O
.	O

One	O
sporadic	O
BCC	O
presented	O
the	O
mutation	O
g.2885G>C	B-DNAMutation
in	O
exon	O
17	O
of	O
PTCH1	O
,	O
which	O
predicts	O
the	O
substitution	O
p.R962T	B-ProteinMutation
in	O
an	O
external	O
domain	O
of	O
the	O
protein	O
.	O

In	O
addition	O
,	O
the	O
leukocytes	O
and	O
tumor	O
cells	O
of	O
one	O
patient	O
with	O
Gorlin	O
syndrome	O
showed	O
the	O
mutation	O
g.2839T>G	B-DNAMutation
in	O
the	O
same	O
exon	O
and	O
gene	O
,	O
which	O
predicts	O
a	O
p.E947stop	B-ProteinMutation
and	O
truncated	O
protein	O
.	O

All	O
control	O
and	O
tumor	O
samples	O
presented	O
IVS9	B-DNAMutation
+	I-DNAMutation
217T	I-DNAMutation
in	O
intron	O
9	O
of	O
PTCH1	O
.	O

CONCLUSION	O
:	O
Mutations	O
found	O
in	O
the	O
PTCH1	O
gene	O
and	O
neighboring	O
repetitive	O
sequences	O
may	O
have	O
contributed	O
to	O
the	O
development	O
of	O
the	O
studied	O
BCCs	O
.	O

Chasing	O
the	O
ubiquitous	O
RET	O
proto-oncogene	O
in	O
South	O
African	O
MEN2	O
families--implications	O
for	O
the	O
surgeon	O
.	O

The	O
RET	O
proto-oncogene	O
(	O
REarranged	O
during	O
Transfection	O
;	O
RET	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
causation	O
of	O
many	O
thyroid	O
tumours	O
.	O

Germline	O
RET	O
proto-oncogene	O
missense	O
mutations	O
have	O
been	O
clearly	O
linked	O
to	O
medullary	O
thyroid	O
carcinoma	O
(MTC)	O
and	O
the	O
inherited	O
cancer	O
syndrome	O
multiple	O
endocrine	O
neoplasia	O
type	O
2	O
(	O
MEN2A	O
,	O
MEN2B	O
)	O
.	O

METHODS	O
:	O
We	O
investigated	O
a	O
cohort	O
of	O
MEN2-related	O
patients	O
referred	O
to	O
Tygerberg	O
Hospital	O
,	O
W	O
Cape	O
(2003-2009)	O
.	O

The	O
study	O
cohort	O
was	O
divided	O
into	O
three	O
groups	O
based	O
on	O
pathology	O
(	O
viz	O
.	O

MEN/MTC	O
,	O
phaeochromocytoma	O
,	O
and	O
a	O
miscellaneous	O
group	O
of	O
MEN	O
pathologies	O
)	O
.	O

Families	O
with	O
identified	O
high-risk	O
factors	O
were	O
recalled	O
.	O

Serum	O
calcitonin	O
levels	O
were	O
monitored	O
where	O
indicated	O
.	O

DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
by	O
standard	O
techniques	O
and	O
polymerase	O
chain	O
reaction	O
(PCR)	O
products	O
screened	O
for	O
RET	O
gene	O
variations	O
by	O
heteroduplex	O
single-strand	O
duplication	O
techniques	O
(	O
heteroduplex	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
)	O
being	O
validated	O
with	O
automated	O
sequencing	O
techniques	O
showing	O
conformational	O
variants	O
in	O
acrylamide	O
gel	O
.	O

RESULTS	O
:	O
We	O
screened	O
40	O
persons	O
,	O
male/female	O
ratio	O
1:1.5	O
.	O

Three	O
ethnic	O
groups	O
were	O
represented	O
(	O
white	O
(12)	O
,	O
black	O
(11)	O
and	O
mixed	O
race	O
(	O
17	O
)	O
)	O
.	O

Nine	O
were	O
index	O
MTC	O
cases	O
,	O
5	O
phaeochromocytoma	O
,	O
3	O
Hirschsprung's	O
disease-MEN	O
associations	O
and	O
2	O
miscellaneous	O
(	O
1	O
neuroblastoma	O
,	O
1	O
intestinal	O
neuronal	O
dysplasia	O
)	O
,	O
while	O
1	O
fell	O
into	O
the	O
MEN2B	O
category	O
.	O

The	O
remaining	O
19	O
were	O
unaffected	O
relatives	O
screened	O
for	O
carrier	O
status	O
,	O
among	O
whom	O
afamilial	O
recurrence	O
was	O
observed	O
in	O
7	O
.	O

On	O
genetic	O
testing	O
,	O
an	O
RET	O
point	O
mutation	O
at	O
the	O
high-risk	O
634	O
cysteine	O
allele	O
was	O
identified	O
in	O
11	O
cases	O
.	O

A	O
further	O
cysteine	O
radical	O
mutation	O
at	O
the	O
620	O
position	O
was	O
related	O
to	O
MEN2	O
in	O
3	O
families	O
plus	O
1	O
other	O
family	O
referred	O
from	O
elsewhere	O
.	O

Other	O
less-recognised	O
gene	O
variations	O
were	O
detected	O
throughout	O
the	O
RET	O
gene	O
in	O
70%	O
of	O
cases	O
and	O
included	O
the	O
691	O
position	O
on	O
codon	O
11	O
(	O
11	O
cases	O
)	O
;	O
the	O
432	O
position	O
(	O
4	O
cases	O
,	O
1	O
homozygous	O
)	O
intronic	O
mutations	O
on	O
exon	O
4	O
(	O
1	O
case	O
)	O
;	O
and	O
an	O
IVS19-37G/C	B-DNAMutation
and	O
a	O
D1017N	B-ProteinMutation
variation	O
in	O
exon	O
19	O
in	O
2	O
MEN	O
families	O
.	O

Fifteen	O
MTC	O
patients	O
have	O
had	O
thyroidectomies	O
,	O
of	O
which	O
2	O
were	O
prophylactic	O
(	O
C-cell	O
hyperplasia	O
;	O
early	O
occult	O
MTC	O
)	O
.	O

A	O
further	O
3	O
are	O
awaiting	O
prophylactic	O
surgery	O
.	O

CONCLUSION	O
:	O
RET	O
gene	O
mutation	O
carries	O
a	O
risk	O
of	O
MEN2	O
and	O
MTC	O
in	O
all	O
ethnic	O
groups	O
in	O
South	O
Africa	O
.	O

Prophylactic	O
surgery	O
may	O
prevent	O
MTC	O
,	O
so	O
genetic	O
screening	O
is	O
important	O
to	O
identify	O
and	O
treat	O
high-risk	O
patients	O
.	O

Autosomal	O
dominant	O
mutation	O
in	O
the	O
signal	O
peptide	O
of	O
renin	O
in	O
a	O
kindred	O
with	O
anemia	O
,	O
hyperuricemia	O
,	O
and	O
CKD	O
.	O

Homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
renin	O
(REN)	O
cause	O
renal	O
tubular	O
dysgenesis	O
,	O
which	O
is	O
characterized	O
by	O
death	O
in	O
utero	O
due	O
to	O
kidney	O
failure	O
and	O
pulmonary	O
hypoplasia	O
.	O

The	O
phenotype	O
resembles	O
the	O
fetopathy	O
caused	O
by	O
angiotensin-converting	O
enzyme	O
inhibitor	O
or	O
angiotensin	O
receptor	O
blocker	O
intake	O
during	O
pregnancy	O
.	O

Recently	O
,	O
heterozygous	O
REN	O
mutations	O
were	O
shown	O
to	O
result	O
in	O
early-onset	O
hyperuricemia	O
,	O
anemia	O
,	O
and	O
chronic	O
kidney	O
disease	O
(CKD)	O
.	O

To	O
date	O
,	O
only	O
3	O
different	O
heterozygous	O
REN	O
mutations	O
have	O
been	O
published	O
.	O

We	O
report	O
mutation	O
analysis	O
of	O
the	O
REN	O
gene	O
in	O
39	O
kindreds	O
with	O
hyperuricemia	O
and	O
CKD	O
who	O
previously	O
tested	O
negative	O
for	O
mutations	O
in	O
the	O
UMOD	O
(uromodulin)	O
and	O
HNF1B	O
(	O
hepatocyte	O
nuclear	O
factor	O
1b	O
)	O
genes	O
.	O

We	O
identified	O
one	O
kindred	O
with	O
a	O
novel	O
thymidine	O
to	O
cytosine	O
mutation	O
at	O
position	O
28	O
in	O
the	O
REN	O
complementary	O
DNA	O
,	O
corresponding	O
to	O
a	O
tryptophan	O
to	O
arginine	O
substitution	O
at	O
amino	O
acid	O
10	O
,	O
which	O
is	O
found	O
within	O
the	O
signal	O
sequence	O
(	O
c.28T>C	B-DNAMutation
;	O
p.W10R	B-ProteinMutation
)	O
.	O

On	O
this	O
basis	O
,	O
we	O
conclude	O
that	O
REN	O
mutations	O
are	O
rare	O
events	O
in	O
patients	O
with	O
CKD	O
.	O

Within	O
the	O
kindred	O
,	O
we	O
found	O
affected	O
individuals	O
over	O
4	O
generations	O
who	O
carried	O
the	O
novel	O
REN	O
mutation	O
and	O
were	O
characterized	O
by	O
significant	O
anemia	O
,	O
hyperuricemia	O
,	O
and	O
CKD	O
.	O

Anemia	O
was	O
severe	O
and	O
disproportional	O
to	O
the	O
degree	O
of	O
decreased	O
kidney	O
function	O
.	O

Because	O
all	O
heterozygous	O
REN	O
mutations	O
that	O
have	O
been	O
described	O
are	O
localized	O
in	O
the	O
signal	O
sequence	O
,	O
screening	O
of	O
the	O
REN	O
gene	O
for	O
patients	O
with	O
CKD	O
with	O
hyperuricemia	O
and	O
anemia	O
may	O
best	O
be	O
focused	O
on	O
sequencing	O
of	O
exon	O
1	O
,	O
which	O
encodes	O
the	O
signal	O
peptide	O
.	O

Detection	O
of	O
possible	O
restriction	O
sites	O
for	O
type	O
II	O
restriction	O
enzymes	O
in	O
DNA	O
sequences	O
.	O

In	O
order	O
to	O
make	O
a	O
step	O
forward	O
in	O
the	O
knowledge	O
of	O
the	O
mechanism	O
operating	O
in	O
complex	O
polygenic	O
disorders	O
such	O
as	O
diabetes	O
and	O
obesity	O
,	O
this	O
paper	O
proposes	O
a	O
new	O
algorithm	O
(	O
PRSD	O
-possible	O
restriction	O
site	O
detection	O
)	O
and	O
its	O
implementation	O
in	O
Applied	O
Genetics	O
software	O
.	O

This	O
software	O
can	O
be	O
used	O
for	O
in	O
silico	O
detection	O
of	O
potential	O
(hidden)	O
recognition	O
sites	O
for	O
endonucleases	O
and	O
for	O
nucleotide	O
repeats	O
identification	O
.	O

The	O
recognition	O
sites	O
for	O
endonucleases	O
may	O
result	O
from	O
hidden	O
sequences	O
through	O
deletion	O
or	O
insertion	O
of	O
a	O
specific	O
number	O
of	O
nucleotides	O
.	O

Tests	O
were	O
conducted	O
on	O
DNA	O
sequences	O
downloaded	O
from	O
NCBI	O
servers	O
using	O
specific	O
recognition	O
sites	O
for	O
common	O
type	O
II	O
restriction	O
enzymes	O
introduced	O
in	O
the	O
software	O
database	O
(	O
n	O
=	O
126	O
)	O
.	O

Each	O
possible	O
recognition	O
site	O
indicated	O
by	O
the	O
PRSD	O
algorithm	O
implemented	O
in	O
Applied	O
Genetics	O
was	O
checked	O
and	O
confirmed	O
by	O
NEBcutter	O
V2.0	O
and	O
Webcutter	O
2.0	O
software	O
.	O

In	O
the	O
sequence	O
NG_008724.1	O
(	O
which	O
includes	O
63632	O
nucleotides	O
)	O
we	O
found	O
a	O
high	O
number	O
of	O
potential	O
restriction	O
sites	O
for	O
ECO	O
R1	O
that	O
may	O
be	O
produced	O
by	O
deletion	O
(	O
n	O
=	O
43	O
sites	O
)	O
or	O
insertion	O
(	O
n	O
=	O
591	O
sites	O
)	O
of	O
one	O
nucleotide	O
.	O

The	O
second	O
module	O
of	O
Applied	O
Genetics	O
has	O
been	O
designed	O
to	O
find	O
simple	O
repeats	O
sizes	O
with	O
a	O
real	O
future	O
in	O
understanding	O
the	O
role	O
of	O
SNPs	O
(	O
Single	O
Nucleotide	O
Polymorphisms	O
)	O
in	O
the	O
pathogenesis	O
of	O
the	O
complex	O
metabolic	O
disorders	O
.	O

We	O
have	O
tested	O
the	O
presence	O
of	O
simple	O
repetitive	O
sequences	O
in	O
five	O
DNA	O
sequence	O
.	O

The	O
software	O
indicated	O
exact	O
position	O
of	O
each	O
repeats	O
detected	O
in	O
the	O
tested	O
sequences	O
.	O

Future	O
development	O
of	O
Applied	O
Genetics	O
can	O
provide	O
an	O
alternative	O
for	O
powerful	O
tools	O
used	O
to	O
search	O
for	O
restriction	O
sites	O
or	O
repetitive	O
sequences	O
or	O
to	O
improve	O
genotyping	O
methods	O
.	O

Carboxy-terminal	O
sequence	O
variation	O
of	O
LMP1	O
gene	O
in	O
Epstein-Barr-virus-associated	O
mononucleosis	O
and	O
tumors	O
from	O
Serbian	O
patients	O
.	O

Seven	O
strains	O
of	O
Epstein-Barr	O
virus	O
(EBV)	O
are	O
defined	O
based	O
on	O
C-terminal	O
sequence	O
variations	O
of	O
the	O
latent	O
membrane	O
protein	O
1	O
(LMP1)	O
.	O

Some	O
strains	O
,	O
especially	O
those	O
with	O
a	O
30-bp	O
deletion	O
,	O
are	O
thought	O
to	O
be	O
related	O
to	O
tumorigenic	O
activity	O
and	O
geographical	O
localization	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
determine	O
the	O
prevalence	O
of	O
different	O
LMP1	O
strains	O
and	O
to	O
investigate	O
sequence	O
variation	O
in	O
the	O
C-terminal	O
region	O
of	O
LMP1	O
in	O
Serbian	O
isolates	O
.	O

This	O
study	O
included	O
53	O
EBV-DNA-positive	O
plasma	O
and	O
tissue	O
block	O
samples	O
from	O
patients	O
with	O
mononucleosis	O
syndrome	O
,	O
renal	O
transplantation	O
,	O
and	O
tumors	O
,	O
mostly	O
nasopharyngeal	O
carcinoma	O
.	O

The	O
sequence	O
of	O
the	O
506-bp	O
fragment	O
of	O
LMP1	O
	O
	O
C	O
terminus	O
was	O
used	O
for	O
phylogenetic	O
analyses	O
and	O
identification	O
of	O
LMP1	O
strains	O
,	O
deletions	O
,	O
and	O
mutations	O
.	O

The	O
majority	O
of	O
isolates	O
were	O
non-deleted	O
(66%)	O
,	O
and	O
the	O
rest	O
had	O
30-bp	O
,	O
rare	O
69-bp	O
,	O
or	O
yet	O
unknown	O
27-bp	O
deletions	O
,	O
which	O
were	O
not	O
related	O
to	O
malignant	O
or	O
non-malignant	O
isolate	O
origin	O
.	O

However	O
,	O
the	O
majority	O
of	O
69-bp	O
deletion	O
isolates	O
were	O
derived	O
from	O
patients	O
with	O
nasopharyngeal	O
carcinoma	O
.	O

Less	O
than	O
five	O
33-bp	O
repeats	O
were	O
found	O
in	O
the	O
majority	O
of	O
non-deleted	O
isolates	O
(68.6%)	O
,	O
whereas	O
most	O
69-bp	O
deletion	O
isolates	O
(75%)	O
had	O
five	O
or	O
six	O
repeats	O
.	O

Serbian	O
isolates	O
were	O
assigned	O
to	O
four	O
LMP1	O
strains	O
:	O
B95-8	O
(32.1%)	O
,	O
China	O
1	O
(24.5%)	O
,	O
North	O
Carolina	O
(	O
NC	O
;	O
18.9%	O
)	O
,	O
and	O
Mediterranean	O
(	O
Med	O
;	O
24.5%	O
)	O
.	O

In	O
NC	O
isolates	O
,	O
three	O
new	O
mutations	O
unique	O
for	O
this	O
strain	O
were	O
identified	O
.	O

EBV	O
EBNA2	O
genotypes	O
1	O
and	O
2	O
were	O
both	O
found	O
,	O
with	O
dominance	O
of	O
genotype	O
1	O
(90.7%)	O
.	O

This	O
study	O
demonstrated	O
noticeable	O
geographical-associated	O
characteristics	O
in	O
the	O
LMP1	O
C	O
terminus	O
of	O
investigated	O
isolates	O
.	O

Roles	O
of	O
G1359A	O
polymorphism	O
of	O
the	O
cannabinoid	O
receptor	O
gene	O
(CNR1)	O
on	O
weight	O
loss	O
and	O
adipocytokines	O
after	O
a	O
hypocaloric	O
diet	O
.	O

BACKGROUND	O
:	O
A	O
intragenic	O
biallelic	O
polymorphism	O
(	O
1359	B-DNAMutation
G/A	I-DNAMutation
)	O
of	O
the	O
CB1	O
gene	O
resulting	O
in	O
the	O
substitution	O
of	O
the	O
G	O
to	O
A	O
at	O
nucleotide	O
position	O
1359	O
in	O
codon	O
435	O
(Thr)	O
,	O
was	O
reported	O
as	O
a	O
common	O
polymorphism	O
in	O
Caucasian	O
populations	O
.	O

Intervention	O
studies	O
with	O
this	O
polymorphism	O
have	O
not	O
been	O
realized	O
.	O

OBJECTIVE	O
:	O
We	O
decided	O
to	O
investigate	O
the	O
role	O
of	O
the	O
polymorphism	O
(G1359A)	O
of	O
CB1	O
receptor	O
gene	O
on	O
adipocytokines	O
response	O
and	O
weight	O
loss	O
secondary	O
to	O
a	O
lifestyle	O
modification	O
(	O
Mediterranean	O
hypocaloric	O
diet	O
and	O
exercise	O
)	O
in	O
obese	O
patients	O
.	O

DESIGN	O
:	O
A	O
population	O
of	O
94	O
patients	O
with	O
obesity	O
was	O
analyzed	O
.	O

Before	O
and	O
after	O
3	O
months	O
on	O
a	O
hypocaloric	O
diet	O
,	O
an	O
anthropometric	O
evaluation	O
,	O
an	O
assessment	O
of	O
nutritional	O
intake	O
and	O
a	O
biochemical	O
analysis	O
were	O
performed	O
.	O

The	O
statistical	O
analysis	O
was	O
performed	O
for	O
the	O
combined	O
G1359A	O
and	O
A1359A	O
as	O
a	O
group	O
and	O
wild	O
type	O
G1359G	O
as	O
second	O
group	O
,	O
with	O
a	O
dominant	O
model	O
.	O

Results	O
:	O
Forty	O
seven	O
patients	O
(50%)	O
had	O
the	O
genotype	O
G1359G	O
(	O
wild	O
type	O
group	O
)	O
and	O
47	O
(50%)	O
patients	O
G1359A	O
(	O
41	O
patients	O
,	O
43.6%	O
)	O
or	O
A1359A	O
(	O
6	O
patients	O
,	O
6.4%	O
)	O
(	O
mutant	O
type	O
group	O
)	O
had	O
the	O
genotype	O
.	O

In	O
wild	O
and	O
mutant	O
type	O
groups	O
,	O
weight	O
,	O
body	O
mass	O
index	O
,	O
fat	O
mass	O
,	O
waist	O
circumference	O
and	O
systolic	O
blood	O
pressure	O
decreased	O
.	O

In	O
mutant	O
type	O
group	O
,	O
resistin	O
(	O
4.15	O
	O
	O
	O
1.7	O
ng/ml	O
vs	O
.	O

3.90	O
	O
	O
	O
2.1	O
ng/ml	O
:	O
P	O
<	O
0.05	O
)	O
,	O
leptin	O
(	O
78.4	O
	O
	O
	O
69	O
ng/ml	O
vs	O
66.2	O
	O
	O
	O
32	O
ng/ml	O
:	O
P	O
<	O
0.05	O
)	O
and	O
IL-6	O
(	O
1.40	O
	O
	O
	O
1.9	O
pg/ml	O
vs	O
0.81	O
	O
	O
	O
1.5	O
pg/ml	O
:	O
P	O
<	O
0.05	O
)	O
levels	O
decreased	O
after	O
dietary	O
treatment	O
.	O

CONCLUSION	O
:	O
The	O
novel	O
finding	O
of	O
this	O
study	O
is	O
the	O
association	O
of	O
the	O
mutant	O
allele	O
(A1359)	O
with	O
a	O
decrease	O
of	O
resistin	O
,	O
leptin	O
and	O
interleukin-6	O
secondary	O
to	O
weight	O
loss	O
.	O

Large	O
contiguous	O
gene	O
deletions	O
in	O
Sj	O
	O
gren-Larsson	O
syndrome	O
.	O

Sj	O
	O
gren-Larsson	O
syndrome	O
(SLS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
ichthyosis	O
,	O
mental	O
retardation	O
,	O
spasticity	O
and	O
mutations	O
in	O
the	O
ALDH3A2	O
gene	O
for	O
fatty	O
aldehyde	O
dehydrogenase	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
fatty	O
aldehyde	O
to	O
fatty	O
acid	O
.	O

More	O
than	O
70	O
mutations	O
have	O
been	O
identified	O
in	O
SLS	O
patients	O
,	O
including	O
small	O
deletions	O
or	O
insertions	O
,	O
missense	O
mutations	O
,	O
splicing	O
defects	O
and	O
complex	O
nucleotide	O
changes	O
.	O

We	O
now	O
describe	O
2	O
SLS	O
patients	O
whose	O
disease	O
is	O
caused	O
by	O
large	O
contiguous	O
gene	O
deletions	O
of	O
the	O
ALDH3A2	O
locus	O
on	O
17p11.2	O
.	O

The	O
deletions	O
were	O
defined	O
using	O
long	O
distance	O
inverse	O
PCR	O
and	O
microarray-based	O
comparative	O
genomic	O
hybridization	O
.	O

A	O
24-year-old	O
SLS	O
female	O
was	O
homozygous	O
for	O
a	O
352-kb	O
deletion	O
involving	O
ALDH3A2	O
and	O
4	O
contiguous	O
genes	O
including	O
ALDH3A1	O
,	O
which	O
codes	O
for	O
the	O
major	O
soluble	O
protein	O
in	O
cornea	O
.	O

Although	O
lacking	O
corneal	O
disease	O
,	O
she	O
showed	O
severe	O
symptoms	O
of	O
SLS	O
with	O
uncommon	O
deterioration	O
in	O
oral	O
motor	O
function	O
and	O
loss	O
of	O
ambulation	O
.	O

The	O
other	O
19-month-old	O
female	O
patient	O
was	O
a	O
compound	O
heterozygote	O
for	O
a	O
1.44-Mb	O
contiguous	O
gene	O
deletion	O
and	O
a	O
missense	O
mutation	O
(	O
c.407C>T	B-DNAMutation
,	O
P136L	B-ProteinMutation
)	O
in	O
ALDH3A2	O
.	O

These	O
studies	O
suggest	O
that	O
large	O
gene	O
deletions	O
may	O
account	O
for	O
up	O
to	O
5%	O
of	O
the	O
mutant	O
alleles	O
in	O
SLS	O
.	O

Geneticists	O
should	O
consider	O
the	O
possibility	O
of	O
compound	O
heterozygosity	O
for	O
large	O
deletions	O
in	O
patients	O
with	O
SLS	O
and	O
other	O
inborn	O
errors	O
of	O
metabolism	O
,	O
which	O
has	O
implications	O
for	O
carrier	O
testing	O
and	O
prenatal	O
diagnosis	O
.	O

OPA1	O
mutations	O
in	O
Japanese	O
patients	O
suspected	O
to	O
have	O
autosomal	O
dominant	O
optic	O
atrophy	O
.	O

PURPOSE	O
:	O
To	O
report	O
three	O
types	O
of	O
heterozygous	O
mutations	O
in	O
the	O
OPA1	O
gene	O
in	O
five	O
patients	O
from	O
three	O
families	O
with	O
autosomal	O
dominant	O
optic	O
atrophy	O
(	O
ADOA	O
,	O
MIM#165500	O
)	O
.	O

METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
the	O
leukocytes	O
of	O
the	O
peripheral	O
blood	O
.	O

For	O
mtDNA	O
,	O
mutations	O
were	O
examined	O
at	O
positions	O
11778	O
,	O
3460	O
and	O
14484	O
.	O

For	O
the	O
OPA1	O
gene	O
,	O
the	O
exons	O
were	O
amplified	O
by	O
PCR	O
and	O
mutations	O
were	O
detected	O
by	O
restriction	O
enzymes	O
or	O
the	O
dye	O
terminator	O
method	O
.	O

RESULTS	O
:	O
We	O
detected	O
three	O
types	O
of	O
OPA1	O
mutation	O
but	O
no	O
mtDNA	O
mutations	O
.	O

In	O
the	O
OPA1	O
gene	O
,	O
heterozygous	O
frameshift	O
mutations	O
from	O
codon	O
903	O
due	O
to	O
a	O
four-base	O
pair	O
deletion	O
in	O
exon	O
27	O
were	O
detected	O
in	O
three	O
patients	O
from	O
one	O
family	O
(	O
c.2708_2711delTTAG	B-DNAMutation
,	O
p.V903GfsX905	B-ProteinMutation
)	O
.	O

A	O
heterozygous	O
mutation	O
due	O
to	O
a	O
three-base	O
pair	O
deletion	O
in	O
exon	O
17	O
,	O
leading	O
to	O
a	O
one-amino	O
acid	O
deletion	O
(	O
c.1618_1620delACT	B-DNAMutation
,	O
p.T540del	B-ProteinMutation
)	O
,	O
and	O
a	O
heterozygous	O
mutation	O
due	O
to	O
a	O
one-base	O
substitution	O
in	O
exon	O
11	O
,	O
leading	O
to	O
a	O
stop	O
codon	O
(	O
c.1084G>T	B-DNAMutation
,	O
p.E362X	B-ProteinMutation
)	O
,	O
were	O
detected	O
in	O
sporadic	O
cases	O
.	O

CONCLUSION	O
:	O
OPA1	O
mutations	O
existed	O
in	O
three	O
Japanese	O
families	O
with	O
ADOA	O
.	O

After	O
a	O
detailed	O
clinical	O
assessment	O
of	O
the	O
proband	O
,	O
the	O
screening	O
of	O
the	O
OPA1	O
gene	O
may	O
be	O
helpful	O
for	O
precise	O
diagnosis	O
of	O
ADOA	O
,	O
provided	O
the	O
relevant	O
information	O
of	O
the	O
family	O
members	O
is	O
limited	O
.	O

Interleukin-17F	O
gene	O
polymorphism	O
in	O
patients	O
with	O
chronic	O
immune	O
thrombocytopenia	O
.	O

INTRODUCTION	O
:	O
IL-17F	O
is	O
a	O
novel	O
inflammatory	O
cytokine	O
and	O
plays	O
an	O
important	O
role	O
in	O
some	O
autoimmune	O
diseases	O
.	O

We	O
investigated	O
the	O
association	O
between	O
chronic	O
ITP	O
and	O
the	O
frequency	O
of	O
the	O
single-nucleotide	O
polymorphism	O
rs763780	B-SNP
7488T/C	B-DNAMutation
,	O
which	O
causes	O
a	O
His-to-Arg	O
substitution	O
at	O
amino	O
acid	O
161	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
We	O
examined	O
102	O
patients	O
(	O
men/women	O
,	O
40/62	O
;	O
median	O
age	O
,	O
42	O
)	O
diagnosed	O
with	O
chronic	O
ITP	O
and	O
188	O
healthy	O
controls	O
(	O
men/women	O
,	O
78/110	O
;	O
median	O
age	O
,	O
38	O
)	O
.	O

Genotyping	O
was	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
(PCR-RFLP)	O
technique	O
.	O

RESULTS	O
:	O
Compared	O
with	O
the	O
control	O
group	O
,	O
patients	O
with	O
chronic	O
ITP	O
had	O
a	O
significantly	O
lower	O
frequency	O
of	O
the	O
IL-17F	O
7488CC	O
genotype	O
(	O
0%	O
vs	O
.	O

4.8%	O
,	O
P<0.05	O
)	O
.	O

The	O
number	O
of	O
IL-17F	O
7488C	O
alleles	O
among	O
the	O
patients	O
with	O
chronic	O
ITP	O
was	O
also	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
(	O
8.7%	O
vs	O
.	O

15.2%	O
OR=0.48	O
,	O
95%CI=0.27-0.84	O
,	O
P=0.016	O
)	O
.	O

Furthermore	O
,	O
patients	O
with	O
the	O
IL-17F	O
7488TT	O
genotype	O
showed	O
a	O
severe	O
thrombocytopenic	O
state	O
(	O
platelet	O
count<10	O
10(9)	O
/L	O
)	O
at	O
diagnosis	O
than	O
those	O
with	O
the	O
IL-17F	O
7488TC	O
genotype	O
(	O
20.9%	O
vs	O
.	O

0%	O
,	O
P=0.04	O
)	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
IL-17F	O
7488	O
T	O
allele	O
is	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
chronic	O
ITP	O
,	O
suggesting	O
a	O
role	O
for	O
IL-17F	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
ITP	O
.	O

Loss-of-function	O
mutations	O
in	O
PTPN11	O
cause	O
metachondromatosis	O
,	O
but	O
not	O
Ollier	O
disease	O
or	O
Maffucci	O
syndrome	O
.	O

Metachondromatosis	O
(MC)	O
is	O
a	O
rare	O
,	O
autosomal	O
dominant	O
,	O
incompletely	O
penetrant	O
combined	O
exostosis	O
and	O
enchondromatosis	O
tumor	O
syndrome	O
.	O

MC	O
is	O
clinically	O
distinct	O
from	O
other	O
multiple	O
exostosis	O
or	O
multiple	O
enchondromatosis	O
syndromes	O
and	O
is	O
unlinked	O
to	O
EXT1	O
and	O
EXT2	O
,	O
the	O
genes	O
responsible	O
for	O
autosomal	O
dominant	O
multiple	O
osteochondromas	O
(MO)	O
.	O

To	O
identify	O
a	O
gene	O
for	O
MC	O
,	O
we	O
performed	O
linkage	O
analysis	O
with	O
high-density	O
SNP	O
arrays	O
in	O
a	O
single	O
family	O
,	O
used	O
a	O
targeted	O
array	O
to	O
capture	O
exons	O
and	O
promoter	O
sequences	O
from	O
the	O
linked	O
interval	O
in	O
16	O
participants	O
from	O
11	O
MC	O
families	O
,	O
and	O
sequenced	O
the	O
captured	O
DNA	O
using	O
high-throughput	O
parallel	O
sequencing	O
technologies	O
.	O

DNA	O
capture	O
and	O
parallel	O
sequencing	O
identified	O
heterozygous	O
putative	O
loss-of-function	O
mutations	O
in	O
PTPN11	O
in	O
4	O
of	O
the	O
11	O
families	O
.	O

Sanger	O
sequence	O
analysis	O
of	O
PTPN11	O
coding	O
regions	O
in	O
a	O
total	O
of	O
17	O
MC	O
families	O
identified	O
mutations	O
in	O
10	O
of	O
them	O
(	O
5	O
frameshift	O
,	O
2	O
nonsense	O
,	O
and	O
3	O
splice-site	O
mutations	O
)	O
.	O

Copy	O
number	O
analysis	O
of	O
sequencing	O
reads	O
from	O
a	O
second	O
targeted	O
capture	O
that	O
included	O
the	O
entire	O
PTPN11	O
gene	O
identified	O
an	O
additional	O
family	O
with	O
a	O
15	O
kb	O
deletion	O
spanning	O
exon	O
7	O
of	O
PTPN11	O
.	O

Microdissected	O
MC	O
lesions	O
from	O
two	O
patients	O
with	O
PTPN11	O
mutations	O
demonstrated	O
loss-of-heterozygosity	O
for	O
the	O
wild-type	O
allele	O
.	O

We	O
next	O
sequenced	O
PTPN11	O
in	O
DNA	O
samples	O
from	O
54	O
patients	O
with	O
the	O
multiple	O
enchondromatosis	O
disorders	O
Ollier	O
disease	O
or	O
Maffucci	O
syndrome	O
,	O
but	O
found	O
no	O
coding	O
sequence	O
PTPN11	O
mutations	O
.	O

We	O
conclude	O
that	O
heterozygous	O
loss-of-function	O
mutations	O
in	O
PTPN11	O
are	O
a	O
frequent	O
cause	O
of	O
MC	O
,	O
that	O
lesions	O
in	O
patients	O
with	O
MC	O
appear	O
to	O
arise	O
following	O
a	O
"second	O
hit,"	O
that	O
MC	O
may	O
be	O
locus	O
heterogeneous	O
since	O
1	O
familial	O
and	O
5	O
sporadically	O
occurring	O
cases	O
lacked	O
obvious	O
disease-causing	O
PTPN11	O
mutations	O
,	O
and	O
that	O
PTPN11	O
mutations	O
are	O
not	O
a	O
common	O
cause	O
of	O
Ollier	O
disease	O
or	O
Maffucci	O
syndrome	O
.	O

The	O
TREX1	O
exonuclease	O
R114H	B-ProteinMutation
mutation	O
in	O
Aicardi-Gouti	O
	O
res	O
syndrome	O
and	O
lupus	O
reveals	O
dimeric	O
structure	O
requirements	O
for	O
DNA	O
degradation	O
activity	O
.	O

Mutations	O
in	O
the	O
TREX1	O
gene	O
cause	O
Aicardi-Gouti	O
	O
res	O
syndrome	O
(AGS)	O
and	O
are	O
linked	O
to	O
the	O
autoimmune	O
disease	O
systemic	O
lupus	O
erythematosus	O
.	O

The	O
TREX1	O
protein	O
is	O
a	O
dimeric	O
3'	O
DNA	O
exonuclease	O
that	O
degrades	O
DNA	O
to	O
prevent	O
inappropriate	O
immune	O
activation	O
.	O

One	O
of	O
the	O
most	O
common	O
TREX1	O
mutations	O
,	O
R114H	B-ProteinMutation
,	O
causes	O
AGS	O
as	O
a	O
homozygous	O
and	O
compound	O
heterozygous	O
mutation	O
and	O
is	O
found	O
as	O
a	O
heterozygous	O
mutation	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

The	O
TREX1	O
proteins	O
containing	O
R114H	B-ProteinMutation
and	O
the	O
insertion	O
mutations	O
aspartate	O
at	O
position	O
201	O
D201ins	B-ProteinMutation
and	O
alanine	O
at	O
position	O
124	O
A124ins	B-ProteinMutation
,	O
found	O
in	O
compound	O
heterozygous	O
AGS	O
with	O
R114H	B-ProteinMutation
,	O
were	O
prepared	O
and	O
the	O
DNA	O
degradation	O
activities	O
were	O
tested	O
.	O

The	O
homodimer	O
TREX1(R114H/R114H)	B-ProteinMutation
exhibits	O
a	O
23-fold	O
reduced	O
single-stranded	O
DNA	O
(ssDNA)	O
exonuclease	O
activity	O
relative	O
to	O
TREX1(WT)	O
.	O

The	O
TREX1(D201ins/D201ins)	B-ProteinMutation
and	O
TREX1(A124ins/A124ins)	B-ProteinMutation
exhibit	O
more	O
than	O
10,000-fold	O
reduced	O
ssDNA	O
degradation	O
activities	O
.	O

However	O
,	O
the	O
TREX1(R114H/D201ins)	B-ProteinMutation
and	O
TREX1(R114H/A124ins)	B-ProteinMutation
compound	O
heterodimers	O
exhibit	O
activities	O
10-fold	O
greater	O
than	O
the	O
TREX1(R114H/R114H)	B-ProteinMutation
homodimer	O
during	O
ssDNA	O
and	O
double-stranded	O
DNA	O
(dsDNA)	O
degradation	O
.	O

These	O
higher	O
levels	O
of	O
activities	O
measured	O
in	O
the	O
TREX1(R114H/D201ins)	B-ProteinMutation
and	O
TREX1(R114H/A124ins)	B-ProteinMutation
compound	O
heterodimers	O
are	O
attributed	O
to	O
Arg-114	O
residues	O
of	O
TREX1(D201ins)	B-ProteinMutation
and	O
TREX1(A124ins)	B-ProteinMutation
positioned	O
at	O
the	O
dimer	O
interface	O
contributing	O
to	O
the	O
active	O
sites	O
of	O
the	O
opposing	O
TREX1(R114H)	B-ProteinMutation
protomer	O
.	O

This	O
interpretation	O
is	O
further	O
supported	O
by	O
exonuclease	O
activities	O
measured	O
for	O
TREX1	O
enzymes	O
containing	O
R114A	B-ProteinMutation
and	O
R114K	B-ProteinMutation
mutations	O
.	O

These	O
biochemical	O
data	O
provide	O
direct	O
evidence	O
for	O
TREX1	O
residues	O
in	O
one	O
protomer	O
contributing	O
to	O
DNA	O
degradation	O
catalyzed	O
in	O
the	O
opposing	O
protomer	O
and	O
help	O
to	O
explain	O
the	O
dimeric	O
TREX1	O
structure	O
required	O
for	O
full	O
catalytic	O
competency	O
.	O

Genetic	O
polymorphism	O
of	O
the	O
glutathione-S-transferase	O
P1	O
gene	O
(GSTP1)	O
and	O
susceptibility	O
to	O
prostate	O
cancer	O
in	O
the	O
Kashmiri	O
population	O
.	O

Glutathione-S-transferase	O
P1	O
(GSTP1)	O
is	O
a	O
critical	O
enzyme	O
of	O
the	O
phase	O
II	O
detoxification	O
pathway	O
.	O

One	O
of	O
the	O
common	O
functional	O
polymorphisms	O
of	O
GSTP1	O
is	O
A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
313	I-DNAMutation
,	O
which	O
results	O
in	O
an	O
amino	O
acid	O
substitution	O
Ile105Val	B-ProteinMutation
at	O
the	O
substrate	O
binding	O
site	O
of	O
GSTP1	O
and	O
reduces	O
catalytic	O
activity	O
of	O
GSTP1	O
.	O

To	O
investigate	O
the	O
GSTP1	O
Ile105Val	B-ProteinMutation
genotype	O
frequency	O
in	O
prostate	O
cancer	O
cases	O
in	O
the	O
Kashmiri	O
population	O
,	O
we	O
designed	O
a	O
case-control	O
study	O
,	O
in	O
which	O
50	O
prostate	O
cancer	O
cases	O
and	O
45	O
benign	O
prostate	O
hyperplasia	O
cases	O
were	O
studied	O
for	O
GSTP1	O
Ile105Val	B-ProteinMutation
polymorphism	O
,	O
compared	O
to	O
80	O
controls	O
taken	O
from	O
the	O
general	O
population	O
,	O
employing	O
the	O
PCR-RFLP	O
technique	O
.	O

We	O
found	O
the	O
frequency	O
of	O
the	O
three	O
different	O
genotypes	O
of	O
GSTP1	O
Ile105Val	B-ProteinMutation
in	O
our	O
ethnic	O
Kashmir	O
population	O
,	O
i.e.	O
,	O
Ile/Ile	O
,	O
Ile/Val	O
and	O
Val/Val	O
,	O
to	O
be	O
52.4	O
,	O
33.3	O
and	O
14.3%	O
among	O
prostate	O
cancer	O
cases	O
,	O
48.5	O
,	O
37.5	O
and	O
14%	O
among	O
benign	O
prostate	O
hyperplasia	O
cases	O
and	O
73.8	O
,	O
21.3	O
and	O
5%	O
in	O
the	O
control	O
population	O
,	O
respectively	O
.	O

There	O
was	O
a	O
significant	O
association	O
between	O
the	O
GSTP1	O
Ile/Val	O
genotype	O
and	O
the	O
advanced	O
age	O
group	O
among	O
the	O
cases	O
.	O

We	O
conclude	O
that	O
GSTP1	O
Ile/Val	O
polymorphism	O
is	O
involved	O
in	O
the	O
risk	O
of	O
prostate	O
cancer	O
development	O
in	O
our	O
population	O
.	O

Identification	O
of	O
LIPH	O
gene	O
mutation	O
in	O
a	O
consanguineous	O
family	O
segregating	O
the	O
woolly	O
hair/hypotrichosis	O
phenotype	O
.	O

OBJECTIVE	O
:	O
To	O
identify	O
the	O
disease	O
causing	O
gene	O
in	O
a	O
four	O
generation	O
consanguineous	O
family	O
in	O
which	O
eleven	O
family	O
members	O
were	O
suffering	O
from	O
Woolly	O
hair/hypotrichosis	O
phenotype	O
.	O

METHODS	O
:	O
Linkage	O
analysis	O
was	O
carried	O
out	O
to	O
identify	O
the	O
disease-causing	O
gene	O
in	O
this	O
family	O
.	O

Genomic	O
DNA	O
of	O
all	O
the	O
available	O
family	O
members	O
was	O
genotyped	O
for	O
the	O
microsatellite	O
markers	O
for	O
all	O
the	O
known	O
woolly	O
hair/hypotrichosis	O
loci.Automated	O
DNA	O
sequencing	O
of	O
the	O
candidate	O
gene	O
was	O
performed	O
to	O
identify	O
the	O
disease-causing	O
mutation	O
.	O

RESULTS	O
:	O
By	O
using	O
homozygosity	O
linkage	O
analysis	O
we	O
have	O
mapped	O
the	O
family	O
on	O
chromosome	O
3q27.3	O
with	O
a	O
two	O
point	O
LOD	O
score	O
of	O
4.04	O
,	O
Mutation	O
screening	O
of	O
the	O
LIPH	O
gene	O
revealed	O
a	O
homozygous	O
c.659_660delTA	B-DNAMutation
deletion	O
mutation	O
segregating	O
with	O
the	O
disease	O
phenotype	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
the	O
c.659_660delTA	B-DNAMutation
mutation	O
in	O
the	O
LIPH	O
gene	O
cause	O
autosomal	O
recessive	O
WH/hypotrichosis	O
phenotype	O
in	O
this	O
family	O
.	O

This	O
mutation	O
has	O
been	O
reported	O
in	O
several	O
Pakistani	O
and	O
Guyanese	O
families	O
suggesting	O
a	O
founder	O
mutation	O
in	O
the	O
LIPH	O
gene	O
in	O
Indo-Pak	O
sub-continent	O
.	O

Familial	O
glucocorticoid	O
receptor	O
haploinsufficiency	O
by	O
non-sense	O
mediated	O
mRNA	O
decay	O
,	O
adrenal	O
hyperplasia	O
and	O
apparent	O
mineralocorticoid	O
excess	O
.	O

Primary	O
glucocorticoid	O
resistance	O
(	O
OMIM	O
138040	O
)	O
is	O
a	O
rare	O
hereditary	O
disease	O
that	O
causes	O
a	O
generalized	O
partial	O
insensitivity	O
to	O
glucocorticoid	O
action	O
,	O
due	O
to	O
genetic	O
alterations	O
of	O
the	O
glucocorticoid	O
receptor	O
(GR)	O
.	O

Investigation	O
of	O
adrenal	O
incidentalomas	O
led	O
to	O
the	O
discovery	O
of	O
a	O
family	O
(	O
eight	O
affected	O
individuals	O
spanning	O
three	O
generations	O
)	O
,	O
prone	O
to	O
cortisol	O
resistance	O
,	O
bilateral	O
adrenal	O
hyperplasia	O
,	O
arterial	O
hypertension	O
and	O
hypokalemia	O
.	O

This	O
phenotype	O
exacerbated	O
over	O
time	O
,	O
cosegregates	O
with	O
the	O
first	O
heterozygous	O
nonsense	O
mutation	O
p.R469[R,X]	B-ProteinMutation
reported	O
to	O
date	O
for	O
the	O
GR	O
,	O
replacing	O
an	O
arginine	O
(CGA)	O
by	O
a	O
stop	O
(TGA)	O
at	O
amino-acid	O
469	O
in	O
the	O
second	O
zinc	O
finger	O
of	O
the	O
DNA-binding	O
domain	O
of	O
the	O
receptor	O
.	O

In	O
vitro	O
,	O
this	O
mutation	O
leads	O
to	O
a	O
truncated	O
50-kDa	O
GR	O
lacking	O
hormone	O
and	O
DNA	O
binding	O
capacity	O
,	O
devoid	O
of	O
hormone-dependent	O
nuclear	O
translocation	O
and	O
transactivation	O
properties	O
.	O

In	O
the	O
proband's	O
fibroblasts	O
,	O
we	O
provided	O
evidence	O
for	O
the	O
lack	O
of	O
expression	O
of	O
the	O
defective	O
allele	O
in	O
vivo	O
.	O

The	O
absence	O
of	O
detectable	O
mutated	O
GR	O
mRNA	O
was	O
accompanied	O
by	O
a	O
50%	O
reduction	O
in	O
wild	O
type	O
GR	O
transcript	O
and	O
protein	O
.	O

This	O
reduced	O
GR	O
expression	O
leads	O
to	O
a	O
significantly	O
below-normal	O
induction	O
of	O
glucocorticoid-induced	O
target	O
genes	O
,	O
FKBP5	O
in	O
fibroblasts	O
.	O

We	O
demonstrated	O
that	O
the	O
molecular	O
mechanisms	O
of	O
glucocorticoid	O
signaling	O
dysfunction	O
involved	O
GR	O
haploinsufficiency	O
due	O
to	O
the	O
selective	O
degradation	O
of	O
the	O
mutated	O
GR	O
transcript	O
through	O
a	O
nonsense-mediated	O
mRNA	O
Decay	O
that	O
was	O
experimentally	O
validated	O
on	O
emetine-treated	O
propositus'	O
fibroblasts	O
.	O

GR	O
haploinsufficiency	O
leads	O
to	O
hypertension	O
due	O
to	O
illicit	O
occupation	O
of	O
renal	O
mineralocorticoid	O
receptor	O
by	O
elevated	O
cortisol	O
rather	O
than	O
to	O
increased	O
mineralocorticoid	O
production	O
reported	O
in	O
primary	O
glucocorticoid	O
resistance	O
.	O

Indeed	O
,	O
apparent	O
mineralocorticoid	O
excess	O
was	O
demonstrated	O
by	O
a	O
decrease	O
in	O
urinary	O
tetrahydrocortisone-tetrahydrocortisol	O
ratio	O
in	O
affected	O
patients	O
,	O
revealing	O
reduced	O
glucocorticoid	O
degradation	O
by	O
renal	O
activity	O
of	O
the	O
11b-hydroxysteroid	O
dehydrogenase	O
type	O
2	O
,	O
a	O
GR	O
regulated	O
gene	O
.	O

We	O
propose	O
thus	O
that	O
GR	O
haploinsufficiency	O
compromises	O
glucocorticoid	O
sensitivity	O
and	O
may	O
represent	O
a	O
novel	O
genetic	O
cause	O
of	O
subclinical	O
hypercortisolism	O
,	O
incidentally	O
revealed	O
bilateral	O
adrenal	O
hyperplasia	O
and	O
mineralocorticoid-independent	O
hypertension	O
.	O

cAMP	O
sensitivity	O
of	O
HCN	O
pacemaker	O
channels	O
determines	O
basal	O
heart	O
rate	O
but	O
is	O
not	O
critical	O
for	O
autonomic	O
rate	O
control	O
.	O

BACKGROUND	O
:	O
HCN	O
channels	O
activate	O
the	O
pacemaker	O
current	O
I(f)	O
,	O
which	O
is	O
thought	O
to	O
contribute	O
significantly	O
to	O
generation	O
and	O
regulation	O
of	O
heart	O
rhythm	O
.	O

HCN4	O
represents	O
the	O
dominant	O
isotype	O
in	O
the	O
sinoatrial	O
node	O
and	O
binding	O
of	O
cAMP	O
was	O
suggested	O
to	O
be	O
necessary	O
for	O
autonomic	O
heart	O
rate	O
regulation	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
a	O
candidate	O
gene	O
approach	O
,	O
a	O
heterozygous	O
insertion	O
of	O
13	O
nucleotides	O
in	O
exon	O
6	O
of	O
the	O
HCN4	O
gene	O
leading	O
to	O
a	O
truncated	O
cyclic	O
nucleotide-binding	O
domain	O
was	O
identified	O
in	O
a	O
45-year-old	O
woman	O
with	O
sinus	O
bradycardia	O
.	O

Biophysical	O
properties	O
determined	O
by	O
whole-cell	O
patch-clamp	O
recording	O
of	O
HEK293	O
cells	O
demonstrated	O
that	O
mutant	O
subunits	O
(HCN4-695X)	O
were	O
insensitive	O
to	O
cAMP	O
.	O

Heteromeric	O
channels	O
composed	O
of	O
wild-type	O
and	O
mutant	O
subunits	O
failed	O
to	O
respond	O
to	O
cAMP-like	O
homomeric	O
mutant	O
channels	O
,	O
indicating	O
a	O
dominant-negative	O
suppression	O
of	O
cAMP-induced	O
channel	O
activation	O
by	O
mutant	O
subunits	O
.	O

Pedigree	O
analysis	O
identified	O
7	O
additional	O
living	O
carriers	O
showing	O
similar	O
clinical	O
phenotypes	O
,	O
that	O
is	O
,	O
sinus	O
node	O
dysfunction	O
with	O
mean	O
resting	O
heart	O
rate	O
of	O
45.9	O
	O
4.6	O
bpm	O
(n=8)	O
compared	O
with	O
66.5	O
	O
9.1	O
bpm	O
of	O
unaffected	O
relatives	O
(	O
n=6	O
;	O
P<0.01	O
)	O
.	O

Clinical	O
evaluation	O
revealed	O
no	O
ischemic	O
or	O
structural	O
heart	O
disease	O
in	O
any	O
family	O
member	O
.	O

Importantly	O
,	O
mutant	O
carriers	O
exhibited	O
normal	O
heart	O
rate	O
variance	O
and	O
full	O
ability	O
to	O
accelerate	O
heart	O
rate	O
under	O
physical	O
activity	O
or	O
pharmacological	O
stimulation	O
.	O

Moreover	O
,	O
mutant	O
carriers	O
displayed	O
distinctive	O
sinus	O
arrhythmias	O
and	O
premature	O
beats	O
linked	O
to	O
adrenergic	O
stress	O
.	O

CONCLUSIONS	O
:	O
In	O
humans	O
,	O
cAMP	O
responsiveness	O
of	O
I(f)	O
determines	O
basal	O
heart	O
rate	O
but	O
is	O
not	O
critical	O
for	O
maximum	O
heart	O
rate	O
,	O
heart	O
rate	O
variability	O
,	O
or	O
chronotropic	O
competence	O
.	O

Furthermore	O
,	O
cAMP-activated	O
I(f)	O
may	O
stabilize	O
heart	O
rhythm	O
during	O
chronotropic	O
response	O
.	O

A	O
novel	O
homozygous	O
splice	O
site	O
mutation	O
in	O
COL7A1	O
in	O
a	O
Chinese	O
patient	O
with	O
severe	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
and	O
squamous	O
cell	O
carcinoma	O
.	O

BACKGROUND	O
:	O
Recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
(RDEB)	O
is	O
an	O
inherited	O
blistering	O
skin	O
disorder	O
caused	O
by	O
mutations	O
in	O
COL7A1	O
gene	O
encoding	O
type	O
VII	O
collagen	O
,	O
the	O
major	O
component	O
of	O
anchoring	O
fibrils	O
in	O
the	O
dermo-epidermal	O
junction	O
.	O

The	O
development	O
of	O
cutaneous	O
squamous	O
cell	O
carcinoma	O
(SCC)	O
is	O
one	O
of	O
the	O
most	O
serious	O
complications	O
of	O
this	O
disease	O
.	O

We	O
report	O
herein	O
a	O
Chinese	O
patient	O
with	O
the	O
severe	O
generalized	O
subtype	O
of	O
RDEB	O
(	O
RDEB-sev	O
gen	O
)	O
complicated	O
by	O
SCC	O
.	O

METHODS	O
:	O
Skin	O
biopsies	O
were	O
examined	O
for	O
histology	O
,	O
basement	O
membrane	O
ultrastructure	O
,	O
and	O
type	O
VII	O
collagen	O
expression	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
peripheral	O
blood	O
samples	O
and	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
direct	O
automated	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Histopathological	O
examination	O
of	O
the	O
patient's	O
skin	O
revealed	O
an	O
undetectable	O
expression	O
of	O
type	O
VII	O
collagen	O
polypeptides	O
in	O
the	O
basement	O
membrane	O
zone	O
.	O

Mutation	O
analysis	O
identified	O
a	O
novel	O
splice	O
site	O
mutation	O
in	O
intron	O
64	O
IVS64+5g->a	B-DNAMutation
of	O
COL7A1	O
gene	O
,	O
which	O
resulted	O
in	O
an	O
in-frame	O
deletion	O
of	O
exon	O
64	O
in	O
both	O
alleles	O
.	O

CONCLUSIONS	O
:	O
This	O
report	O
contributes	O
to	O
the	O
expanding	O
database	O
of	O
COL7A1	O
mutations	O
and	O
emphasizes	O
the	O
need	O
to	O
elucidate	O
the	O
underlying	O
genetic	O
mechanisms	O
associated	O
with	O
the	O
increased	O
incidence	O
of	O
SCC	O
in	O
RDEB	O
patients	O
.	O

Molecular	O
diagnosis	O
of	O
46,XY	O
DSD	O
and	O
identification	O
of	O
a	O
novel	O
8	O
nucleotide	O
deletion	O
in	O
exon	O
1	O
of	O
the	O
SRD5A2	O
gene	O
.	O

Phenotypic	O
presentation	O
of	O
46,XY	O
DSD	O
depends	O
on	O
the	O
underlying	O
defects	O
.	O

Defect	O
in	O
androgen	O
action	O
on	O
the	O
target	O
tissues	O
or	O
production	O
of	O
active	O
metabolite	O
share	O
common	O
morphological	O
features	O
.	O

Molecular	O
study	O
may	O
help	O
differentiating	O
these	O
abnormalities	O
with	O
precision	O
.	O

Mutational	O
analysis	O
of	O
androgen	O
receptor	O
(AR)	O
and	O
SRD5A2	O
genes	O
was	O
performed	O
in	O
29	O
patients	O
with	O
46,XY	O
DSD	O
,	O
by	O
PCR-SSCP	O
.	O

The	O
amplicons	O
that	O
showed	O
an	O
aberrant	O
migration	O
in	O
SSCP	O
were	O
subjected	O
to	O
sequencing	O
.	O

Interestingly	O
,	O
six	O
patients	O
from	O
4	O
unrelated	O
families	O
(	O
a	O
pair	O
of	O
sibs	O
,	O
uncle/nephew	O
and	O
other	O
two	O
isolated	O
)	O
were	O
identified	O
with	O
mutations	O
in	O
SRD5A2	O
gene	O
.	O

In	O
five	O
patients	O
p.R246Q	B-ProteinMutation
missense	O
mutation	O
was	O
detected	O
,	O
of	O
which	O
four	O
were	O
homozygous	O
and	O
one	O
was	O
compound	O
heterozygous	O
:	O
g.80_87delT	B-DNAMutation
CGCGAAG	I-DNAMutation
p.A27fsX132	B-ProteinMutation
and	O
p.R246Q	B-ProteinMutation
.	O

Another	O
patient	O
with	O
isolated	O
micropenis	O
harbored	O
a	O
heterozygous	O
p.G196S	B-ProteinMutation
missense	O
mutation	O
.	O

No	O
AR	O
gene	O
mutation	O
was	O
detected	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
suggests	O
that	O
p.R246Q	B-ProteinMutation
mutation	O
is	O
common	O
amongst	O
patients	O
with	O
SRD5A2	O
gene	O
defect	O
from	O
the	O
Northern	O
states	O
of	O
India	O
.	O

Also	O
,	O
it	O
records	O
a	O
novel	O
deletion	O
in	O
exon	O
1	O
of	O
SRD5A2	O
gene	O
in	O
a	O
patient	O
with	O
severe	O
hypospadias	O
.	O

A	O
novel	O
mutation	O
screening	O
system	O
for	O
Ehlers-Danlos	O
Syndrome	O
,	O
vascular	O
type	O
by	O
high-resolution	O
melting	O
curve	O
analysis	O
in	O
combination	O
with	O
small	O
amplicon	O
genotyping	O
using	O
genomic	O
DNA	O
.	O

Ehlers-Danlos	O
syndrome	O
,	O
vascular	O
type	O
(vEDS)	O
(	O
MIM	O
#130050	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
caused	O
by	O
type	O
III	O
procollagen	O
gene	O
(COL3A1)	O
mutations	O
.	O

Most	O
COL3A1	O
mutations	O
are	O
detected	O
by	O
using	O
total	O
RNA	O
from	O
patient-derived	O
fibroblasts	O
,	O
which	O
requires	O
an	O
invasive	O
skin	O
biopsy	O
.	O

High-resolution	O
melting	O
curve	O
analysis	O
(hrMCA)	O
has	O
recently	O
been	O
developed	O
as	O
a	O
post-PCR	O
mutation	O
scanning	O
method	O
which	O
enables	O
simple	O
,	O
rapid	O
,	O
cost-effective	O
,	O
and	O
highly	O
sensitive	O
mutation	O
screening	O
of	O
large	O
genes	O
.	O

We	O
established	O
a	O
hrMCA	O
method	O
to	O
screen	O
for	O
COL3A1	O
mutations	O
using	O
genomic	O
DNA	O
.	O

PCR	O
primers	O
pairs	O
for	O
COL3A1	O
(	O
52	O
amplicons	O
)	O
were	O
designed	O
to	O
cover	O
all	O
coding	O
regions	O
of	O
the	O
52	O
exons	O
,	O
including	O
the	O
splicing	O
sites	O
.	O

We	O
used	O
15	O
DNA	O
samples	O
(	O
8	O
validation	O
samples	O
and	O
7	O
samples	O
of	O
clinically	O
suspected	O
vEDS	O
patients	O
)	O
in	O
this	O
study	O
.	O

The	O
eight	O
known	O
COL3A1	O
mutations	O
in	O
validation	O
samples	O
were	O
all	O
successfully	O
detected	O
by	O
the	O
hrMCA	O
.	O

In	O
addition	O
,	O
we	O
identified	O
five	O
novel	O
COL3A1	O
mutations	O
,	O
including	O
one	O
deletion	O
c.2187delA	B-DNAMutation
and	O
one	O
nonsense	O
mutation	O
c.2992C>T	B-DNAMutation
that	O
could	O
not	O
be	O
determined	O
by	O
the	O
conventional	O
total	O
RNA	O
method	O
.	O

Furthermore	O
,	O
we	O
established	O
a	O
small	O
amplicon	O
genotyping	O
(SAG)	O
method	O
for	O
detecting	O
three	O
high	O
frequency	O
coding-region	O
SNPs	O
(	O
rs1800255	B-SNP
:	O
G>A	B-DNAMutation
,	O
rs1801184	B-SNP
:	O
T>C	B-DNAMutation
,	O
and	O
rs2271683	B-SNP
:	O
A>G	B-DNAMutation
)	O
in	O
COL3A1	O
to	O
differentiate	O
mutations	O
before	O
sequencing	O
.	O

The	O
use	O
of	O
hrMCA	O
in	O
combination	O
with	O
SAG	O
from	O
genomic	O
DNA	O
enables	O
rapid	O
detection	O
of	O
COL3A1	O
mutations	O
with	O
high	O
efficiency	O
and	O
specificity	O
.	O

A	O
better	O
understanding	O
of	O
the	O
genotype-phenotype	O
correlation	O
in	O
COL3A1	O
using	O
this	O
method	O
will	O
lead	O
to	O
improve	O
in	O
diagnosis	O
and	O
treatment	O
.	O

Identification	O
of	O
a	O
frameshift	O
mutation	O
in	O
Osterix	O
in	O
a	O
patient	O
with	O
recessive	O
osteogenesis	O
imperfecta	O
.	O

Osteogenesis	O
imperfecta	O
,	O
or	O
"brittle	O
bone	O
disease,"	O
is	O
a	O
type	O
I	O
collagen-related	O
condition	O
associated	O
with	O
osteoporosis	O
and	O
increased	O
risk	O
of	O
bone	O
fractures	O
.	O

Using	O
a	O
combination	O
of	O
homozygosity	O
mapping	O
and	O
candidate	O
gene	O
approach	O
,	O
we	O
have	O
identified	O
a	O
homozygous	O
single	O
base	O
pair	O
deletion	O
c.1052delA	B-DNAMutation
in	O
SP7/Osterix	O
(OSX)	O
in	O
an	O
Egyptian	O
child	O
with	O
recessive	O
osteogenesis	O
imperfecta	O
.	O

The	O
clinical	O
findings	O
from	O
this	O
patient	O
include	O
recurrent	O
fractures	O
,	O
mild	O
bone	O
deformities	O
,	O
delayed	O
tooth	O
eruption	O
,	O
normal	O
hearing	O
,	O
and	O
white	O
sclera	O
.	O

OSX	O
encodes	O
a	O
transcription	O
factor	O
containing	O
three	O
Cys2-His2	O
zinc-finger	O
DNA-binding	O
domains	O
at	O
its	O
C	O
terminus	O
,	O
which	O
,	O
in	O
mice	O
,	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
bone	O
formation	O
.	O

The	O
frameshift	O
caused	O
by	O
the	O
c.1052delA	B-DNAMutation
deletion	O
removes	O
the	O
last	O
81	O
amino	O
acids	O
of	O
the	O
protein	O
,	O
including	O
the	O
third	O
zinc-finger	O
motif	O
.	O

This	O
finding	O
adds	O
another	O
locus	O
to	O
the	O
spectrum	O
of	O
genes	O
associated	O
with	O
osteogenesis	O
imperfecta	O
and	O
reveals	O
that	O
SP7/OSX	O
also	O
plays	O
a	O
key	O
role	O
in	O
human	O
bone	O
development	O
.	O

A	O
Taiwanese	O
boy	O
with	O
congenital	O
generalized	O
lipodystrophy	O
caused	O
by	O
homozygous	O
Ile262fs	B-ProteinMutation
mutation	O
in	O
the	O
BSCL2	O
gene	O
.	O

Congenital	O
generalized	O
lipodystrophy	O
(CGL)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disease	O
that	O
is	O
characterized	O
by	O
a	O
near-complete	O
absence	O
of	O
adipose	O
tissue	O
from	O
birth	O
or	O
early	O
infancy	O
.	O

Mutations	O
in	O
the	O
BSCL2	O
gene	O
are	O
known	O
to	O
result	O
in	O
CGL2	O
,	O
a	O
more	O
severe	O
phenotype	O
than	O
CGL1	O
,	O
with	O
earlier	O
onset	O
,	O
more	O
extensive	O
fat	O
loss	O
and	O
biochemical	O
changes	O
,	O
more	O
severe	O
intellectual	O
impairment	O
,	O
and	O
more	O
severe	O
cardiomyopathy	O
.	O

We	O
report	O
a	O
3-month-old	O
Taiwanese	O
boy	O
with	O
initial	O
presentation	O
of	O
a	O
lack	O
of	O
subcutaneous	O
fat	O
,	O
prominent	O
musculature	O
,	O
generalized	O
eruptive	O
xanthomas	O
,	O
and	O
extreme	O
hypertriglyceridemia	O
.	O

Absence	O
of	O
mechanical	O
adipose	O
tissue	O
in	O
the	O
orbits	O
and	O
scalp	O
was	O
revealed	O
by	O
head	O
magnetic	O
resonance	O
imaging	O
.	O

Hepatomegaly	O
was	O
noticed	O
,	O
and	O
histological	O
examination	O
of	O
a	O
liver	O
biopsy	O
specimen	O
suggested	O
severe	O
hepatic	O
steatosis	O
and	O
periportal	O
necrosis	O
.	O

However	O
,	O
echocardiography	O
indicated	O
no	O
sign	O
of	O
cardiomyopathy	O
and	O
he	O
showed	O
no	O
distinct	O
intellectual	O
impairment	O
that	O
interfered	O
with	O
daily	O
life	O
.	O

About	O
1	O
year	O
later	O
,	O
abdominal	O
computed	O
tomography	O
revealed	O
enlargement	O
of	O
kidneys	O
.	O

He	O
had	O
a	O
homozygous	O
insertion	O
of	O
a	O
nucleotide	O
,	O
783insG	B-DNAMutation
(	O
Ile262fs	B-ProteinMutation
mutation	O
)	O
,	O
in	O
exon	O
7	O
of	O
the	O
BSCL2	O
gene	O
.	O

We	O
reviewed	O
the	O
genotype	O
of	O
CGL	O
cases	O
from	O
Japan	O
,	O
India	O
,	O
China	O
and	O
Taiwan	O
,	O
and	O
found	O
that	O
BSCL2	O
is	O
a	O
major	O
causative	O
gene	O
for	O
CGL	O
in	O
Asian	O
.	O

8q24	O
allelic	O
imbalance	O
and	O
MYC	O
gene	O
copy	O
number	O
in	O
primary	O
prostate	O
cancer	O
.	O

Four	O
independent	O
regions	O
within	O
8q24	O
near	O
the	O
MYC	O
gene	O
are	O
associated	O
with	O
risk	O
for	O
prostate	O
cancer	O
(Pca)	O
.	O

Here	O
,	O
we	O
investigated	O
allelic	O
imbalance	O
(AI)	O
at	O
8q24	O
risk	O
variants	O
and	O
MYC	O
gene	O
DNA	O
copy	O
number	O
(CN)	O
in	O
27	O
primary	O
Pcas	O
.	O

Heterozygotes	O
were	O
observed	O
in	O
24	O
of	O
27	O
patients	O
at	O
one	O
or	O
more	O
8q24	O
markers	O
and	O
27%	O
of	O
the	O
loci	O
exhibited	O
AI	O
in	O
tumor	O
DNA	O
.	O

The	O
8q24	O
risk	O
alleles	O
were	O
preferentially	O
favored	O
in	O
the	O
tumors	O
.	O

Increased	O
MYC	O
gene	O
CN	O
was	O
observed	O
in	O
33%	O
of	O
tumors	O
,	O
and	O
the	O
co-existence	O
of	O
increased	O
MYC	O
gene	O
CN	O
with	O
AI	O
at	O
risk	O
loci	O
was	O
observed	O
in	O
86%	O
(	O
P<0.004	O
exact	O
binomial	O
test	O
)	O
of	O
the	O
informative	O
tumors	O
.	O

No	O
AI	O
was	O
observed	O
in	O
tumors	O
,	O
which	O
did	O
not	O
reveal	O
increased	O
MYC	O
gene	O
CN	O
.	O

Higher	O
Gleason	O
score	O
was	O
associated	O
with	O
tumors	O
exhibiting	O
AI	O
(P=0.04)	O
and	O
also	O
with	O
increased	O
MYC	O
gene	O
CN	O
(P=0.02)	O
.	O

Our	O
results	O
suggest	O
that	O
AI	O
at	O
8q24	O
and	O
increased	O
MYC	O
gene	O
CN	O
may	O
both	O
be	O
related	O
to	O
high	O
Gleason	O
score	O
in	O
Pca	O
.	O

Our	O
findings	O
also	O
suggest	O
that	O
these	O
two	O
somatic	O
alterations	O
may	O
be	O
due	O
to	O
the	O
same	O
preferential	O
chromosomal	O
duplication	O
event	O
during	O
prostate	O
tumorigenesis	O
.	O

Lack	O
of	O
p16	O
gene	O
mutations	O
in	O
gastric	O
cancers	O
in	O
Kashmir	O
.	O

BACKGROUND	O
AND	O
AIM	O
:	O
The	O
focus	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
frequencies	O
of	O
homozygous	O
deletions	O
and	O
mutations	O
of	O
p16	O
gene	O
in	O
gastric	O
carcinomas	O
in	O
the	O
Kashmiri	O
population	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
84	O
gastric	O
carcinoma	O
patients	O
were	O
screened	O
by	O
the	O
single	O
strand	O
conformation	O
polymorphism	O
(SSCP)	O
technique	O
and	O
later	O
by	O
DNA	O
sequencing	O
to	O
detect	O
mutations	O
of	O
the	O
p16	O
gene	O
.	O

Also	O
PCR	O
was	O
applied	O
further	O
to	O
further	O
detect	O
any	O
homozygous	O
deletions	O
.	O

RESULTS	O
:	O
SSCP	O
and	O
DNA	O
sequencing	O
performed	O
encompassing	O
all	O
the	O
three	O
exons	O
of	O
p16	O
gene	O
could	O
not	O
detect	O
any	O
mutations	O
in	O
any	O
ofl	O
84	O
cases	O
.	O

Though	O
we	O
could	O
observe	O
mobility	O
shifts	O
in	O
SSCP	O
of	O
two	O
samples	O
,	O
subsequent	O
DNA	O
sequencing	O
did	O
not	O
show	O
any	O
mutation	O
.	O

Further	O
PCR	O
could	O
not	O
detect	O
any	O
homozygous	O
deletion	O
in	O
P16	O
in	O
any	O
case	O
.	O

CONCLUSION	O
:	O
Though	O
Kashmir	O
is	O
a	O
high	O
incidence	O
area	O
of	O
gastric	O
carcinomas	O
,	O
p16gene	O
mutations	O
/or	O
deletions	O
do	O
not	O
appear	O
to	O
be	O
involved	O
.	O

Clinical	O
and	O
genetic	O
characterization	O
of	O
manifesting	O
carriers	O
of	O
DMD	O
mutations	O
.	O

Manifesting	O
carriers	O
of	O
DMD	O
gene	O
mutations	O
may	O
present	O
diagnostic	O
challenges	O
,	O
particularly	O
in	O
the	O
absence	O
of	O
a	O
family	O
history	O
of	O
dystrophinopathy	O
.	O

We	O
review	O
the	O
clinical	O
and	O
genetic	O
features	O
in	O
15	O
manifesting	O
carriers	O
identified	O
among	O
860	O
subjects	O
within	O
the	O
United	O
Dystrophinopathy	O
Project	O
,	O
a	O
large	O
clinical	O
dystrophinopathy	O
cohort	O
whose	O
members	O
undergo	O
comprehensive	O
DMD	O
mutation	O
analysis	O
.	O

We	O
defined	O
manifesting	O
carriers	O
as	O
females	O
with	O
significant	O
weakness	O
,	O
excluding	O
those	O
with	O
only	O
myalgias/cramps	O
.	O

DNA	O
extracted	O
from	O
peripheral	O
blood	O
was	O
used	O
to	O
study	O
X-chromosome	O
inactivation	O
patterns	O
.	O

Among	O
these	O
manifesting	O
carriers	O
,	O
age	O
at	O
symptom	O
onset	O
ranged	O
from	O
2	O
to	O
47	O
years	O
.	O

Seven	O
had	O
no	O
family	O
history	O
and	O
eight	O
had	O
male	O
relatives	O
with	O
Duchenne	O
muscular	O
dystrophy	O
(DMD)	O
.	O

Clinical	O
severity	O
among	O
the	O
manifesting	O
carriers	O
varied	O
from	O
a	O
DMD-like	O
progression	O
to	O
a	O
very	O
mild	O
Becker	O
muscular	O
dystrophy-like	O
phenotype	O
.	O

Eight	O
had	O
exonic	O
deletions	O
or	O
duplications	O
and	O
six	O
had	O
point	O
mutations	O
.	O

One	O
patient	O
had	O
two	O
mutations	O
(	O
an	O
exonic	O
deletion	O
and	O
a	O
splice	O
site	O
mutation	O
)	O
,	O
consistent	O
with	O
a	O
heterozygous	O
compound	O
state	O
.	O

The	O
X-chromosome	O
inactivation	O
pattern	O
was	O
skewed	O
toward	O
non-random	O
in	O
four	O
out	O
of	O
seven	O
informative	O
deletions	O
or	O
duplications	O
but	O
was	O
random	O
in	O
all	O
cases	O
with	O
nonsense	O
mutations	O
.	O

We	O
present	O
the	O
results	O
of	O
DMD	O
mutation	O
analysis	O
in	O
this	O
manifesting	O
carrier	O
cohort	O
,	O
including	O
the	O
first	O
example	O
of	O
a	O
presumably	O
compound	O
heterozygous	O
DMD	O
mutation	O
.	O

Our	O
results	O
demonstrate	O
that	O
improved	O
molecular	O
diagnostic	O
methods	O
facilitate	O
the	O
identification	O
of	O
DMD	O
mutations	O
in	O
manifesting	O
carriers	O
,	O
and	O
confirm	O
the	O
heterogeneity	O
of	O
mutational	O
mechanisms	O
as	O
well	O
as	O
the	O
wide	O
spectrum	O
of	O
phenotypes	O
.	O

Detection	O
of	O
EGFR	O
mutations	O
in	O
plasma	O
DNA	O
from	O
lung	O
cancer	O
patients	O
by	O
mass	O
spectrometry	O
genotyping	O
is	O
predictive	O
of	O
tumor	O
EGFR	O
status	O
and	O
response	O
to	O
EGFR	O
inhibitors	O
.	O

AIMS	O
:	O
EGFR	O
mutations	O
now	O
guide	O
the	O
clinical	O
use	O
of	O
EGFR-targeted	O
therapy	O
in	O
lung	O
cancer	O
.	O

However	O
,	O
standard	O
EGFR	O
mutation	O
analysis	O
requires	O
a	O
minimum	O
amount	O
of	O
tumor	O
tissue	O
,	O
which	O
may	O
not	O
be	O
available	O
in	O
certain	O
situations	O
.	O

In	O
this	O
study	O
,	O
we	O
combined	O
a	O
mass	O
spectrometry	O
genotyping	O
assay	O
(Sequenom)	O
with	O
a	O
mutant-enriched	O
PCR	O
(ME-PCR)	O
to	O
detect	O
EGFR	O
mutations	O
in	O
free	O
plasma	O
DNA	O
from	O
patients	O
with	O
lung	O
cancer	O
.	O

METHOD	O
:	O
DNAs	O
were	O
extracted	O
from	O
31	O
plasma	O
samples	O
from	O
31	O
patients	O
and	O
analyzed	O
by	O
both	O
methods	O
for	O
EGFR	O
Exon	O
19	O
deletion	O
and	O
EGFR	O
L858R	B-ProteinMutation
mutation	O
.	O

Results	O
in	O
plasma	O
DNA	O
samples	O
were	O
compared	O
with	O
EGFR	O
mutation	O
status	O
obtained	O
in	O
tumor	O
DNA	O
(	O
18/31	O
EGFR	O
mutant	O
)	O
.	O

The	O
relationship	O
of	O
EGFR	O
mutation	O
status	O
in	O
tumor	O
and/or	O
plasma	O
samples	O
to	O
overall	O
survival	O
was	O
assessed	O
.	O

RESULTS	O
:	O
The	O
EGFR	O
mutation	O
status	O
in	O
plasma	O
DNA	O
was	O
identical	O
to	O
the	O
primary	O
tumor	O
in	O
61%	O
of	O
patients	O
(19/31)	O
.	O

By	O
mass	O
spectrometry	O
genotyping	O
,	O
the	O
plasma	O
samples	O
contained	O
mutant	O
DNA	O
corresponding	O
to	O
5/14	O
EGFR	O
Exon	O
19	O
deletions	O
and	O
3/4	O
EGFR	O
L858R	B-ProteinMutation
mutations	O
previously	O
diagnosed	O
in	O
the	O
matched	O
tumors	O
.	O

Two	O
samples	O
were	O
positive	O
in	O
plasma	O
DNA	O
but	O
negative	O
in	O
primary	O
tumor	O
tissue	O
.	O

Results	O
were	O
similar	O
for	O
samples	O
studied	O
by	O
ME-PCR	O
.	O

For	O
patients	O
treated	O
with	O
erlotinib	O
,	O
overall	O
survival	O
was	O
correlated	O
with	O
the	O
presence	O
of	O
EGFR	O
mutation	O
in	O
plasma	O
and/or	O
tumor	O
tissue	O
(p=0.002)	O
,	O
with	O
the	O
two	O
patients	O
positive	O
only	O
in	O
plasma	O
DNA	O
showing	O
responses	O
and	O
favorable	O
outcomes	O
.	O

CONCLUSION	O
:	O
The	O
detection	O
of	O
EGFR	O
mutations	O
in	O
plasma	O
DNA	O
samples	O
by	O
mass	O
spectrometry	O
genotyping	O
and	O
ME-PCR	O
is	O
feasible	O
.	O

A	O
positive	O
EGFR	O
result	O
in	O
plasma	O
DNA	O
has	O
a	O
high	O
predictive	O
value	O
for	O
tumor	O
EGFR	O
status	O
and	O
for	O
favorable	O
clinical	O
course	O
on	O
EGFR-targeted	O
therapy	O
and	O
could	O
therefore	O
be	O
useful	O
in	O
guiding	O
clinical	O
decisions	O
in	O
patients	O
with	O
insufficient	O
or	O
unavailable	O
tumor	O
specimens	O
.	O

Recombinant	O
phenotyping	O
of	O
cytomegalovirus	O
sequence	O
variants	O
detected	O
after	O
200	O
or	O
100	O
days	O
of	O
valganciclovir	O
prophylaxis	O
.	O

BACKGROUND	O
:	O
In	O
a	O
phase	O
III	O
controlled	O
trial	O
IMproved	O
Protection	O
Against	O
Cytomegalovirus	O
in	O
Transplantation	O
(IMPACT)	O
comparing	O
200	O
with	O
100	O
days	O
of	O
valganciclovir	O
prophylaxis	O
in	O
318	O
cytomegalovirus	O
D+/R-	O
kidney	O
transplant	O
recipients	O
,	O
an	O
equal	O
number	O
of	O
patients	O
(	O
n=3	O
per	O
arm	O
)	O
had	O
known	O
ganciclovir	O
resistance	O
mutations	O
detected	O
during	O
viral	O
breakthrough	O
.	O

In	O
addition	O
,	O
many	O
other	O
viral	O
sequence	O
variants	O
were	O
observed	O
that	O
were	O
of	O
unknown	O
significance	O
for	O
ganciclovir	O
resistance	O
.	O

Recombinant	O
phenotyping	O
was	O
performed	O
to	O
determine	O
whether	O
the	O
previously	O
uncharacterized	O
genotypic	O
changes	O
affected	O
ganciclovir	O
susceptibility	O
,	O
especially	O
in	O
those	O
receiving	O
the	O
longer	O
duration	O
of	O
prophylaxis	O
.	O

METHODS	O
:	O
Sequences	O
encoding	O
individual	O
amino	O
acid	O
substitutions	O
in	O
the	O
UL97	O
kinase	O
or	O
UL54	O
DNA	O
polymerase	O
gene	O
were	O
transferred	O
by	O
recombination	O
into	O
a	O
cloned	O
cytomegalovirus	O
laboratory	O
strain	O
,	O
followed	O
by	O
reporter-based	O
yield	O
reduction	O
phenotypic	O
assay	O
of	O
the	O
resulting	O
virus	O
for	O
ganciclovir	O
susceptibility	O
.	O

RESULTS	O
:	O
Twenty-six	O
uncharacterized	O
amino	O
acid	O
substitutions	O
were	O
detected	O
,	O
2	O
in	O
UL97	O
and	O
24	O
in	O
UL54	O
.	O

All	O
10	O
substitutions	O
in	O
the	O
200-day	O
arm	O
and	O
9	O
of	O
17	O
substitutions	O
in	O
the	O
100-day	O
arm	O
(	O
prioritized	O
based	O
on	O
location	O
and	O
conservation	O
)	O
were	O
selected	O
for	O
phenotyping	O
;	O
one	O
substitution	O
was	O
detected	O
in	O
both	O
subsets	O
.	O

Results	O
were	O
generated	O
for	O
nine	O
of	O
ten	O
200-day	O
and	O
eight	O
of	O
nine	O
100-day	O
substitutions	O
,	O
with	O
no	O
substitution	O
demonstrating	O
a	O
significant	O
reduction	O
in	O
ganciclovir	O
susceptibility	O
.	O

The	O
two	O
remaining	O
amino	O
acid	O
substitutions	O
,	O
both	O
in	O
UL54	O
,	O
were	O
not	O
evaluated	O
because	O
of	O
poor	O
viral	O
viability	O
.	O

CONCLUSION	O
:	O
Phenotypic	O
evaluation	O
of	O
previously	O
uncharacterized	O
viral	O
genotypes	O
in	O
the	O
200-day	O
valganciclovir	O
prophylaxis	O
group	O
showed	O
no	O
evidence	O
of	O
an	O
increased	O
incidence	O
of	O
genotypic	O
ganciclovir	O
resistance	O
when	O
compared	O
with	O
those	O
in	O
the	O
100-day	O
prophylaxis	O
group	O
.	O

Monoallelic	O
thyroid	O
peroxidase	O
gene	O
mutation	O
in	O
a	O
patient	O
with	O
congenital	O
hypothyroidism	O
with	O
total	O
iodide	O
organification	O
defect	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
genetic	O
defect	O
of	O
a	O
patient	O
with	O
dyshormonogenetic	O
congenital	O
hypothyroidisms	O
(CH)	O
with	O
total	O
iodide	O
organification	O
defect	O
(TIOD)	O
.	O

A	O
male	O
child	O
diagnosed	O
with	O
CH	O
during	O
neonatal	O
screening	O
.	O

Laboratory	O
tests	O
confirmed	O
the	O
permanent	O
and	O
severe	O
CH	O
with	O
TIOD	O
(	O
99%	O
perchlorate	O
release	O
)	O
.	O

The	O
coding	O
sequence	O
of	O
TPO	O
,	O
DUOX2	O
,	O
and	O
DUOXA2	O
genes	O
and	O
2957	O
base	O
pairs	O
(bp)	O
of	O
the	O
TPO	O
promoter	O
were	O
sequenced	O
.	O

Molecular	O
analysis	O
of	O
patient's	O
DNA	O
identified	O
the	O
heterozygous	O
duplication	O
GGCC	O
c.1186_1187insGGCC	B-DNAMutation
in	O
exon	O
8	O
of	O
the	O
TPO	O
gene	O
.	O

No	O
additional	O
mutation	O
was	O
detected	O
either	O
in	O
the	O
TPO	O
gene	O
,	O
TPO	O
promoter	O
,	O
DUOX2	O
or	O
DUOXA2	O
genes	O
.	O

We	O
have	O
described	O
a	O
patient	O
with	O
a	O
clear	O
TIOD	O
causing	O
severe	O
goitrous	O
CH	O
due	O
to	O
a	O
monoallelic	O
TPO	O
mutation	O
.	O

A	O
plausible	O
explanation	O
for	O
the	O
association	O
between	O
an	O
autosomal	O
recessive	O
disorder	O
with	O
a	O
single	O
TPO-mutated	O
allele	O
is	O
the	O
presence	O
of	O
monoallelic	O
TPO	O
expression	O
.	O

The	O
M235T	B-ProteinMutation
polymorphism	O
of	O
the	O
angiotensinogen	O
gene	O
in	O
South	O
Indian	O
patients	O
of	O
hypertrophic	O
cardiomyopathy	O
.	O

INTRODUCTION	O
:	O
Hypertrophic	O
cardiomyopathy	O
(HCM)	O
is	O
a	O
complex	O
disorder	O
and	O
genetically	O
transmitted	O
cardiac	O
disease	O
with	O
a	O
diverse	O
clinical	O
course	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
association	O
of	O
the	O
T704C	B-DNAMutation
polymorphism	O
of	O
exon	O
2	O
of	O
the	O
angiotensinogen	O
(AGT)	O
gene	O
with	O
HCM	O
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O

Subjects	O
and	O
methods	O
.	O

One-hundred	O
and	O
fifty	O
HCM	O
(	O
90	O
sporadic	O
hypertrophic	O
cardiomyopathy	O
[SHCM]	O
and	O
60	O
familial	O
hypertrophic	O
cardiomyopathy	O
[	O
FHCM	O
]	O
)	O
patients	O
and	O
165	O
age-	O
and	O
sex-matched	O
normal	O
healthy	O
controls	O
without	O
known	O
hypertension	O
and	O
left	O
ventricular	O
hypertrophy	O
were	O
included	O
in	O
the	O
study	O
.	O

DNA	O
was	O
isolated	O
from	O
peripheral	O
leukocytes	O
and	O
the	O
region	O
of	O
interest	O
in	O
the	O
AGT	O
gene	O
bearing	O
a	O
missense	O
mutation	O
methionine	O
to	O
threonine	O
substitution	O
at	O
codon	O
235	O
M235T	B-ProteinMutation
of	O
exon	O
2	O
,	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

The	O
PCR	O
products	O
were	O
subjected	O
to	O
restriction	O
digestion	O
with	O
the	O
enzyme	O
SfaNI	O
.	O

RESULTS	O
:	O
Significant	O
differences	O
were	O
detected	O
in	O
genotypic	O
distribution	O
(	O
p	O
=	O
0.04	O
)	O
as	O
well	O
as	O
the	O
allelic	O
frequency	O
(	O
p	O
=	O
0.003	O
)	O
between	O
the	O
SHCM	O
patients	O
and	O
controls	O
.	O

The	O
polymorphism	O
did	O
not	O
show	O
any	O
association	O
with	O
FHCM	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
T	O
allele	O
of	O
the	O
AGT	O
gene	O
is	O
significantly	O
associated	O
with	O
SHCM	O
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O

However	O
,	O
we	O
did	O
not	O
find	O
significant	O
association	O
of	O
this	O
polymorphism	O
with	O
FHCM	O
.	O

Atypical	O
GH	O
insensitivity	O
syndrome	O
and	O
severe	O
insulin-like	O
growth	O
factor-I	O
deficiency	O
resulting	O
from	O
compound	O
heterozygous	O
mutations	O
of	O
the	O
GH	O
receptor	O
,	O
including	O
a	O
novel	O
frameshift	O
mutation	O
affecting	O
the	O
intracellular	O
domain	O
.	O

BACKGROUND/AIMS	O
:	O
GH	O
insensitivity	O
and	O
IGF	O
deficiency	O
may	O
result	O
from	O
aberrations	O
of	O
the	O
GH	O
receptor	O
(GHR)	O
.	O

We	O
describe	O
a	O
4-year-old	O
child	O
with	O
modest	O
growth	O
failure	O
and	O
normal	O
serum	O
concentrations	O
of	O
GH-binding	O
protein	O
(GHBP)	O
,	O
but	O
clinical	O
evidence	O
of	O
GH	O
insensitivity	O
.	O

METHOD	O
:	O
Serum	O
and	O
DNA	O
samples	O
from	O
the	O
proband	O
and	O
his	O
parents	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
child	O
had	O
a	O
height	O
of	O
-4	O
SD	O
,	O
elevated	O
serum	O
GH	O
concentrations	O
,	O
abnormally	O
low	O
serum	O
IGF-I	O
and	O
IGFBP-3	O
concentrations	O
and	O
normal	O
GHBP	O
concentrations	O
.	O

DNA	O
analysis	O
revealed	O
compound	O
heterozygosity	O
for	O
mutations	O
of	O
GHR	O
,	O
including	O
a	O
previously	O
reported	O
R211H	B-ProteinMutation
mutation	O
and	O
a	O
novel	O
duplication	O
of	O
a	O
nucleotide	O
in	O
exon	O
9	O
899dupC	B-DNAMutation
,	O
the	O
latter	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
stop	O
codon	O
.	O

Treatment	O
with	O
recombinant	O
DNA-derived	O
IGF-I	O
resulted	O
in	O
growth	O
acceleration	O
.	O

CONCLUSION	O
:	O
Mutations	O
affecting	O
the	O
intracellular	O
domain	O
of	O
the	O
GHR	O
can	O
result	O
in	O
GH	O
insensitivity	O
and	O
IGF	O
deficiency	O
,	O
despite	O
normal	O
serum	O
concentrations	O
of	O
GHBP	O
.	O

The	O
presence	O
of	O
clinical	O
and	O
biochemical	O
evidence	O
of	O
GH	O
resistance	O
is	O
sufficient	O
to	O
consider	O
the	O
possibility	O
of	O
aberrations	O
of	O
the	O
GHR	O
,	O
even	O
in	O
the	O
presence	O
of	O
normal	O
serum	O
GHBP	O
concentrations	O
.	O

Alteration	O
in	O
the	O
gene	O
encoding	O
protein	O
tyrosine	O
phosphatase	O
nonreceptor	O
type	O
6	O
(PTPN6/SHP1)	O
may	O
contribute	O
to	O
neutrophilic	O
dermatoses	O
.	O

We	O
have	O
found	O
a	O
B2	O
repeat	O
insertion	O
in	O
the	O
gene	O
encoding	O
protein	O
tyrosine	O
phosphatase	O
nonreceptor	O
type	O
6	O
(PTPN6)	O
in	O
a	O
mouse	O
that	O
developed	O
a	O
skin	O
disorder	O
with	O
clinical	O
and	O
histopathological	O
features	O
resembling	O
those	O
seen	O
in	O
human	O
neutrophilic	O
dermatoses	O
.	O

Neutrophilic	O
dermatoses	O
are	O
a	O
group	O
of	O
complex	O
heterogeneous	O
autoinflammatory	O
diseases	O
that	O
all	O
demonstrate	O
excessive	O
neutrophil	O
infiltration	O
of	O
the	O
skin	O
.	O

Therefore	O
,	O
we	O
tested	O
the	O
cDNA	O
and	O
genomic	O
DNA	O
sequences	O
of	O
PTPN6	O
from	O
patients	O
with	O
Sweet's	O
syndrome	O
(SW)	O
and	O
pyoderma	O
gangrenosum	O
and	O
found	O
numerous	O
novel	O
splice	O
variants	O
in	O
different	O
combinations	O
.	O

Isoforms	O
resulting	O
from	O
deletions	O
of	O
exons	O
2	O
,	O
5	O
,	O
11	O
,	O
and	O
15	O
and	O
retention	O
of	O
intron	O
1	O
or	O
5	O
were	O
the	O
most	O
common	O
in	O
a	O
patients	O
with	O
a	O
familial	O
case	O
of	O
SW	O
,	O
who	O
had	O
a	O
neonatal	O
onset	O
of	O
an	O
inflammatory	O
disorder	O
with	O
skin	O
lesions	O
and	O
a	O
biopsy	O
specimen	O
consistent	O
with	O
SW	O
.	O

These	O
isoforms	O
were	O
associated	O
with	O
a	O
heterozygous	O
E441G	B-ProteinMutation
mutation	O
and	O
a	O
heterozygous	O
1.7-kbp	O
deletion	O
in	O
the	O
promoter	O
region	O
of	O
the	O
PTPN6	O
gene	O
.	O

Although	O
full-length	O
PTPN6	O
was	O
detected	O
in	O
all	O
other	O
patients	O
with	O
either	O
pyoderma	O
gangrenosum	O
or	O
SW	O
,	O
it	O
was	O
always	O
associated	O
with	O
splice	O
variants	O
:	O
a	O
partial	O
deletion	O
of	O
exon	O
4	O
with	O
the	O
complete	O
deletion	O
of	O
exon	O
5	O
,	O
alterations	O
that	O
were	O
not	O
detected	O
in	O
healthy	O
controls	O
.	O

The	O
defect	O
in	O
transcriptional	O
regulation	O
of	O
the	O
hematopoietic	O
PTPN6	O
appears	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
certain	O
subsets	O
of	O
the	O
heterogeneous	O
group	O
of	O
neutrophilic	O
dermatoses	O
.	O

Novel	O
and	O
recurrent	O
TRPV4	O
mutations	O
and	O
their	O
association	O
with	O
distinct	O
phenotypes	O
within	O
the	O
TRPV4	O
dysplasia	O
family	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
TRPV4	O
,	O
a	O
gene	O
that	O
encodes	O
a	O
Ca(2+)	O
permeable	O
non-selective	O
cation	O
channel	O
,	O
have	O
recently	O
been	O
found	O
in	O
a	O
spectrum	O
of	O
skeletal	O
dysplasias	O
that	O
includes	O
brachyolmia	O
,	O
spondylometaphyseal	O
dysplasia	O
,	O
Kozlowski	O
type	O
(SMDK)	O
and	O
metatropic	O
dysplasia	O
(MD)	O
.	O

Only	O
a	O
total	O
of	O
seven	O
missense	O
mutations	O
were	O
detected	O
,	O
however	O
.	O

The	O
full	O
spectrum	O
of	O
TRPV4	O
mutations	O
and	O
their	O
phenotypes	O
remained	O
unclear	O
.	O

OBJECTIVES	O
AND	O
METHODS	O
:	O
To	O
examine	O
TRPV4	O
mutation	O
spectrum	O
and	O
phenotype-genotype	O
association	O
,	O
we	O
searched	O
for	O
TRPV4	O
mutations	O
by	O
PCR-direct	O
sequencing	O
from	O
genomic	O
DNA	O
in	O
22	O
MD	O
and	O
20	O
SMDK	O
probands	O
.	O

RESULTS	O
:	O
TRPV4	O
mutations	O
were	O
found	O
in	O
all	O
but	O
one	O
MD	O
subject	O
.	O

In	O
total	O
,	O
19	O
different	O
heterozygous	O
mutations	O
were	O
identified	O
in	O
41	O
subjects	O
;	O
two	O
were	O
recurrent	O
and	O
17	O
were	O
novel	O
.	O

In	O
MD	O
,	O
a	O
recurrent	O
P799L	B-ProteinMutation
mutation	O
was	O
identified	O
in	O
nine	O
subjects	O
,	O
as	O
well	O
as	O
10	O
novel	O
mutations	O
including	O
F471del	B-ProteinMutation
,	O
the	O
first	O
deletion	O
mutation	O
of	O
TRPV4	O
.	O

In	O
SMDK	O
,	O
a	O
recurrent	O
R594H	B-ProteinMutation
mutation	O
was	O
identified	O
in	O
12	O
subjects	O
and	O
seven	O
novel	O
mutations	O
.	O

An	O
association	O
between	O
the	O
position	O
of	O
mutations	O
and	O
the	O
disease	O
phenotype	O
was	O
also	O
observed	O
.	O

Thus	O
,	O
P799	O
in	O
exon	O
15	O
is	O
a	O
hot	O
codon	O
for	O
MD	O
mutations	O
,	O
as	O
four	O
different	O
amino	O
acid	O
substitutions	O
have	O
been	O
observed	O
at	O
this	O
codon	O
;	O
while	O
R594	O
in	O
exon	O
11	O
is	O
a	O
hotspot	O
for	O
SMDK	O
mutations	O
.	O

CONCLUSION	O
:	O
The	O
TRPV4	O
mutation	O
spectrum	O
in	O
MD	O
and	O
SMDK	O
,	O
which	O
showed	O
genotype-phenotype	O
correlation	O
and	O
potential	O
functional	O
significance	O
of	O
mutations	O
that	O
are	O
non-randomly	O
distributed	O
over	O
the	O
gene	O
,	O
was	O
presented	O
in	O
this	O
study	O
.	O

The	O
results	O
would	O
help	O
diagnostic	O
laboratories	O
establish	O
efficient	O
screening	O
strategies	O
for	O
genetic	O
diagnosis	O
of	O
the	O
TRPV4	O
dysplasia	O
family	O
diseases	O
.	O

Association	O
of	O
obesity	O
risk	O
SNPs	O
in	O
PCSK1	O
with	O
insulin	O
sensitivity	O
and	O
proinsulin	O
conversion	O
.	O

BACKGROUND	O
:	O
Prohormone	O
convertase	O
1	O
is	O
involved	O
in	O
maturation	O
of	O
peptides	O
.	O

Rare	O
mutations	O
in	O
gene	O
PCSK1	O
,	O
encoding	O
this	O
enzyme	O
,	O
cause	O
childhood	O
obesity	O
and	O
abnormal	O
glucose	O
homeostasis	O
with	O
elevated	O
proinsulin	O
concentrations	O
.	O

Common	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
within	O
this	O
gene	O
,	O
rs6232	B-SNP
and	O
rs6235	B-SNP
,	O
are	O
associated	O
with	O
obesity	O
.	O

We	O
studied	O
whether	O
these	O
SNPs	O
influence	O
the	O
prediabetic	O
traits	O
insulin	O
resistance	O
,	O
beta-cell	O
dysfunction	O
,	O
or	O
glucose	O
intolerance	O
.	O

METHODS	O
:	O
We	O
genotyped	O
1498	O
German	O
subjects	O
for	O
SNPs	O
rs6232	B-SNP
and	O
rs6235	B-SNP
within	O
PCSK1	O
.	O

The	O
subjects	O
were	O
metabolically	O
characterized	O
by	O
oral	O
glucose	O
tolerance	O
test	O
with	O
glucose	O
,	O
insulin	O
,	O
proinsulin	O
,	O
and	O
C-peptide	O
measurements	O
.	O

A	O
subgroup	O
of	O
512	O
subjects	O
underwent	O
a	O
hyperinsulinemic-euglycemic	O
clamp	O
.	O

RESULTS	O
:	O
The	O
minor	O
allele	O
frequencies	O
were	O
25.8%	O
for	O
SNP	O
rs6235	B-SNP
and	O
6.0%	O
for	O
rs6232	B-SNP
.	O

After	O
adjustment	O
for	O
sex	O
and	O
age	O
,	O
we	O
found	O
no	O
association	O
of	O
SNPs	O
rs6235	B-SNP
and	O
rs6232	B-SNP
with	O
BMI	O
or	O
other	O
weight-related	O
traits	O
(	O
all	O
p	O
>or=	O
0.07	O
)	O
.	O

Both	O
minor	O
alleles	O
,	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
BMI	O
and	O
insulin	O
sensitivity	O
were	O
associated	O
with	O
elevated	O
AUCproinsulin	O
and	O
AUCproinsulin/AUCinsulin	O
(	O
rs6235	B-SNP
:	O
p(additive)	O
model	O
<or=	O
0.009	O
,	O
effect	O
sizes	O
8/8%	O
,	O
rs6232	B-SNP
:	O
pdominant	O
model	O
<or=	O
0.01	O
,	O
effect	O
sizes	O
10/21%	O
)	O
.	O

Insulin	O
secretion	O
was	O
not	O
affected	O
by	O
the	O
variants	O
(	O
different	O
secretion	O
parameters	O
,	O
all	O
p	O
>or=	O
0.08	O
)	O
.	O

The	O
minor	O
allele	O
of	O
SNP	O
rs6232	B-SNP
was	O
additionally	O
associated	O
with	O
15%	O
higher	O
OGTT-derived	O
and	O
19%	O
higher	O
clamp-derived	O
insulin	O
sensitivity	O
(	O
pdom	O
<or=	O
0.0047	O
)	O
,	O
4.5%	O
lower	O
HOMAIR	O
(	O
pdom	O
=	O
0.02	O
)	O
and	O
3.5%	O
lower	O
120-min	O
glucose	O
(	O
pdom	O
=	O
0.0003	O
)	O
independently	O
of	O
BMI	O
and	O
proinsulin	O
conversion	O
.	O

SNP	O
rs6235	B-SNP
was	O
not	O
associated	O
with	O
parameters	O
of	O
glucose	O
metabolism	O
.	O

CONCLUSIONS	O
:	O
Like	O
rare	O
mutations	O
in	O
PCSK1	O
,	O
the	O
more	O
common	O
variants	O
tested	O
determine	O
glucose-stimulated	O
proinsulin	O
conversion	O
,	O
but	O
not	O
insulin	O
secretion	O
.	O

In	O
addition	O
,	O
rs6232	B-SNP
,	O
encoding	O
the	O
amino	O
acid	O
exchange	O
N221D	B-ProteinMutation
,	O
influences	O
insulin	O
sensitivity	O
and	O
glucose	O
homeostasis	O
.	O

Correlation	O
between	O
thymidylate	O
synthase	O
gene	O
variants	O
,	O
RNA	O
and	O
protein	O
levels	O
in	O
primary	O
colorectal	O
adenocarcinomas	O
.	O

This	O
study	O
was	O
designed	O
to	O
compare	O
thymidylate	O
synthase	O
(TS)	O
genotype	O
,	O
mRNA	O
and	O
protein	O
levels	O
in	O
primary	O
colorectal	O
adenocarcinoma	O
,	O
and	O
to	O
examine	O
the	O
correlation	O
between	O
microsatellite	O
instability	O
(MSI)	O
and	O
TS	O
expression	O
.	O

The	O
TS	O
genotype	O
of	O
68	O
patients	O
with	O
colorectal	O
cancer	O
was	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
tumour	O
tissue	O
.	O

The	O
TS	O
mRNA	O
levels	O
in	O
tumour	O
tissue	O
were	O
measured	O
by	O
reverse-transcription	O
PCR	O
,	O
and	O
TS	O
protein	O
levels	O
and	O
MSI	O
status	O
were	O
assessed	O
using	O
immunohistochemistry	O
.	O

Significantly	O
higher	O
mRNA	O
and	O
protein	O
levels	O
were	O
observed	O
in	O
patients	O
with	O
the	O
TS	O
3R/3R	O
versus	O
the	O
2R/2R	O
and	O
2R/3R	O
genotypes	O
.	O

There	O
was	O
no	O
correlation	O
between	O
TS	O
single	O
nucleotide	O
polymorphism	O
and	O
TS	O
expression	O
.	O

Individuals	O
homozygous	O
for	O
the	O
six	O
base-pair	O
insertion	O
in	O
the	O
3'-untranslated	O
region	O
had	O
significantly	O
higher	O
TS	O
mRNA	O
levels	O
than	O
heterozygous	O
and	O
homozygous	O
wild	O
type	O
individuals	O
.	O

The	O
TS	O
mRNA	O
and	O
protein	O
levels	O
were	O
significantly	O
higher	O
in	O
microsatellite	O
unstable	O
tumours	O
compared	O
with	O
microsatellite	O
stable	O
tumours	O
.	O

There	O
was	O
a	O
significant	O
association	O
between	O
the	O
number	O
of	O
TS	O
enhancer	O
region	O
repeats	O
(	O
in	O
blood	O
)	O
and	O
intratumoural	O
TS	O
mRNA	O
and	O
protein	O
levels	O
.	O

A	O
larger	O
case	O
series	O
investigating	O
the	O
role	O
of	O
TS	O
gene	O
polymorphisms	O
as	O
predictors	O
of	O
sensitivity	O
to	O
5-fluorouracil-based	O
chemotherapy	O
is	O
required	O
.	O

A	O
functional	O
polymorphism	O
in	O
the	O
disrupted-in	O
schizophrenia	O
1	O
gene	O
is	O
associated	O
with	O
chronic	O
fatigue	O
syndrome	O
.	O

AIMS	O
:	O
Disrupted-in	O
schizophrenia	O
1	O
(DISC1)	O
,	O
identified	O
in	O
a	O
pedigree	O
with	O
a	O
familial	O
psychosis	O
with	O
the	O
chromosome	O
translocation	O
(1:11)	O
,	O
is	O
a	O
putative	O
susceptibility	O
gene	O
for	O
psychoses	O
such	O
as	O
schizophrenia	O
and	O
major	O
depressive	O
disorder	O
(MDD)	O
.	O

Patients	O
with	O
chronic	O
fatigue	O
syndrome	O
(CFS)	O
report	O
having	O
continuous	O
severe	O
fatigue	O
and	O
many	O
overlapping	O
symptoms	O
with	O
MDD	O
;	O
however	O
,	O
the	O
mechanism	O
and	O
effective	O
treatment	O
of	O
CFS	O
are	O
still	O
unclear	O
.	O

We	O
focused	O
on	O
the	O
overlapping	O
symptoms	O
between	O
CFS	O
and	O
MDD	O
and	O
performed	O
an	O
association	O
study	O
of	O
the	O
functional	O
single-nucleotide	O
polymorphism	O
(SNP)	O
in	O
the	O
DISC1	O
gene	O
with	O
CFS	O
.	O

MAIN	O
METHODS	O
:	O
Venous	O
blood	O
was	O
drawn	O
from	O
CFS	O
patients	O
and	O
controls	O
and	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
whole	O
blood	O
according	O
to	O
standard	O
procedures	O
.	O

Ser704Cys	B-ProteinMutation
DISC1	O
SNP	O
was	O
genotyped	O
using	O
the	O
TaqMan	O
5'-exonuclease	O
allelic	O
discrimination	O
assay	O
.	O

KEY	O
FINDINGS	O
:	O
We	O
found	O
that	O
the	O
Cys704	O
allele	O
of	O
Ser704Cys	B-ProteinMutation
SNP	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
CFS	O
development	O
compared	O
with	O
the	O
Ser704	O
allele	O
.	O

SIGNIFICANCE	O
:	O
DISC1	O
Ser704Cys	B-ProteinMutation
might	O
be	O
a	O
functional	O
variant	O
that	O
affects	O
one	O
of	O
the	O
mechanisms	O
implicated	O
in	O
the	O
biology	O
of	O
CFS	O
.	O

Some	O
patients	O
with	O
CFS	O
showed	O
a	O
phenotype	O
similar	O
to	O
that	O
of	O
patients	O
with	O
MDD	O
,	O
but	O
further	O
studies	O
are	O
needed	O
to	O
clarify	O
the	O
biological	O
mechanism	O
,	O
because	O
this	O
study	O
is	O
of	O
a	O
rather	O
preliminary	O
nature	O
.	O

Despite	O
the	O
variety	O
of	O
patients	O
with	O
CFS	O
,	O
DISC1	O
Ser704Cys	B-ProteinMutation
has	O
an	O
association	O
with	O
CFS	O
,	O
which	O
may	O
also	O
suggest	O
that	O
DISC1	O
plays	O
a	O
central	O
role	O
in	O
the	O
induction	O
of	O
various	O
psychiatric	O
diseases	O
.	O

Large	O
deletion	O
involving	O
exon	O
5	O
of	O
the	O
arylsulfatase	O
B	O
gene	O
caused	O
apparent	O
homozygosity	O
in	O
a	O
mucopolysaccharidosis	O
type	O
VI	O
patient	O
.	O

Apparent	O
homozygosity	O
for	O
the	O
mutation	O
p.R315X	B-ProteinMutation
present	O
on	O
exon	O
5	O
of	O
the	O
arylsulfatase	O
B	O
(ARSB)	O
gene	O
in	O
a	O
mucopolysaccharidosis	O
type	O
VI	O
patient	O
was	O
solved	O
in	O
this	O
study	O
by	O
further	O
testing	O
for	O
a	O
second	O
mutation	O
.	O

Patient	O
cDNA	O
analysis	O
revealed	O
that	O
the	O
entire	O
exon	O
5	O
of	O
the	O
ARSB	O
gene	O
was	O
lacking	O
;	O
this	O
new	O
mutation	O
was	O
identified	O
as	O
c.899-1142del	B-DNAMutation
.	O

As	O
the	O
genomic	O
DNA	O
sequencing	O
excluded	O
the	O
presence	O
of	O
splicing	O
mutations	O
,	O
polymerase	O
chain	O
reaction	O
analysis	O
was	O
performed	O
for	O
polymorphisms	O
listed	O
in	O
the	O
NCBI	O
SNP	O
database	O
for	O
the	O
ARSB	O
gene	O
.	O

This	O
allowed	O
the	O
mutation	O
at	O
the	O
genomic	O
DNA	O
level	O
to	O
be	O
identified	O
as	O
g.99367-102002del	B-DNAMutation
;	O
this	O
gross	O
deletion	O
,	O
involving	O
the	O
entire	O
exon	O
5	O
of	O
the	O
gene	O
and	O
parts	O
of	O
introns	O
4	O
and	O
5	O
led	O
to	O
a	O
frameshift	O
starting	O
at	O
amino	O
acid	O
300	O
and	O
resulting	O
in	O
a	O
protein	O
with	O
39%	O
amino	O
acids	O
different	O
from	O
the	O
normal	O
enzyme	O
.	O

We	O
stress	O
that	O
extensive	O
DNA	O
analysis	O
needs	O
to	O
be	O
performed	O
in	O
case	O
of	O
apparent	O
homozygosity	O
to	O
avoid	O
potential	O
errors	O
in	O
genetic	O
counseling	O
.	O

The	O
six-nucleotide	O
deletion/insertion	O
variant	O
in	O
the	O
CASP8	O
promoter	O
region	O
is	O
inversely	O
associated	O
with	O
risk	O
of	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
.	O

Caspase	O
8	O
(CASP8)	O
is	O
an	O
apoptosis-related	O
cysteine	O
peptidase	O
involved	O
in	O
the	O
death	O
receptor	O
pathway	O
and	O
likely	O
in	O
the	O
mitochondrial	O
pathway	O
.	O

A	O
CASP8	O
promoter	O
region	O
six-nucleotide	O
deletion/insertion	O
(	O
-652	B-DNAMutation
6N	I-DNAMutation
ins/del	I-DNAMutation
)	O
variant	O
and	O
a	O
coding	O
region	O
D302H	B-ProteinMutation
polymorphism	O
are	O
reportedly	O
important	O
in	O
cancer	O
development	O
,	O
but	O
no	O
reported	O
study	O
has	O
assessed	O
the	O
associations	O
of	O
these	O
genetic	O
variations	O
with	O
risk	O
of	O
head	O
and	O
neck	O
cancer	O
.	O

In	O
a	O
hospital-based	O
study	O
of	O
non-Hispanic	O
whites	O
,	O
we	O
genotyped	O
CASP8	O
-652	B-DNAMutation
6N	I-DNAMutation
del	I-DNAMutation
and	O
302H	O
variants	O
in	O
1,023	O
patients	O
with	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
(SCCHN)	O
and	O
1,052	O
cancer-free	O
controls	O
.	O

Crude	O
and	O
adjusted	O
odds	O
ratios	O
(OR)	O
and	O
95%	O
confidence	O
intervals	O
(CI)	O
were	O
estimated	O
using	O
unconditional	O
logistic	O
regression	O
models	O
.	O

The	O
CASP8	O
-652	B-DNAMutation
6N	I-DNAMutation
del	I-DNAMutation
variant	O
genotypes	O
or	O
haplotypes	O
were	O
inversely	O
associated	O
with	O
SCCHN	O
risk	O
(	O
adjusted	O
OR	O
,	O
0.70	O
;	O
95%	O
CI	O
,	O
0.57-0.85	O
for	O
the	O
ins/del	O
+	O
del/del	O
genotypes	O
compared	O
with	O
the	O
ins/ins	O
genotype	O
;	O
adjusted	O
OR	O
,	O
0.73	O
;	O
95%	O
CI	O
,	O
0.55-0.97	O
for	O
the	O
del-D	O
haplotype	O
compared	O
with	O
the	O
ins-D	O
haplotype	O
)	O
.	O

Furthermore	O
,	O
the	O
number	O
of	O
the	O
CASP8	O
-652	B-DNAMutation
6N	I-DNAMutation
del	I-DNAMutation
(	O
but	O
not	O
302H	O
)	O
variant	O
allele	O
tended	O
to	O
correlate	O
with	O
increased	O
levels	O
of	O
camptothecin-induced	O
p53-mediated	O
apoptosis	O
in	O
T	O
lymphocytes	O
from	O
170	O
cancer-free	O
controls	O
.	O

We	O
concluded	O
that	O
the	O
CASP8	O
-652	B-DNAMutation
6N	I-DNAMutation
del	I-DNAMutation
variant	O
allele	O
may	O
contribute	O
to	O
the	O
risk	O
of	O
developing	O
SCCHN	O
in	O
non-Hispanic	O
white	O
populations	O
.	O

Further	O
validation	O
by	O
population-based	O
case-control	O
studies	O
and	O
rigorous	O
mechanistic	O
studies	O
is	O
warranted	O
.	O

Angiotensin-converting	O
enzyme	O
insertion/deletion	O
and	O
angiotensin	O
type	O
1	O
receptor	O
A1166C	B-DNAMutation
polymorphisms	O
as	O
genetic	O
risk	O
factors	O
in	O
benign	O
prostatic	O
hyperplasia	O
and	O
prostate	O
cancer	O
.	O

INTRODUCTION	O
:	O
Prostate	O
cancer	O
is	O
one	O
of	O
the	O
most	O
common	O
malignant	O
neoplasias	O
in	O
developed	O
countries	O
.	O

In	O
2003	O
,	O
6,536	O
new	O
cases	O
and	O
4,602	O
related	O
deaths	O
were	O
reported	O
in	O
Mexico	O
.	O

The	O
renin-angiotensin	O
system	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
prostate	O
cancer	O
pathology	O
.	O

Two	O
previous	O
studies	O
investigated	O
the	O
association	O
of	O
prostate	O
cancer	O
with	O
the	O
insertion/deletion	O
(I/D)	O
polymorphism	O
in	O
the	O
angiotensin-converting	O
enzyme	O
(ACE)	O
gene	O
;	O
both	O
studies	O
reported	O
an	O
association	O
between	O
prostate	O
cancer	O
and	O
the	O
DD	O
genotype	O
.	O

The	O
present	O
study	O
was	O
aimed	O
at	O
searching	O
for	O
an	O
association	O
of	O
prostate	O
cancer	O
and	O
benign	O
prostatic	O
hyperplasia	O
with	O
the	O
I/D	O
polymorphism	O
in	O
the	O
ACE	O
gene	O
and	O
the	O
A1166C	B-DNAMutation
polymorphism	O
in	O
the	O
angiotensin	O
type	O
1	O
receptor	O
(AGT1R)	O
gene	O
and	O
at	O
comparing	O
allele	O
frequencies	O
between	O
both	O
groups	O
and	O
the	O
general	O
population	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
20	O
samples	O
from	O
individuals	O
with	O
a	O
prostate	O
cancer	O
diagnosis	O
and	O
from	O
20	O
samples	O
from	O
individuals	O
with	O
a	O
benign	O
prostatic	O
hyperplasia	O
diagnosis	O
.	O

Genotyping	O
was	O
performed	O
by	O
PCR-RFLP	O
analysis	O
.	O

Polymorphism	O
frequency	O
results	O
obtained	O
for	O
the	O
test	O
groups	O
were	O
compared	O
with	O
the	O
frequencies	O
in	O
66	O
individuals	O
from	O
the	O
general	O
population	O
,	O
which	O
were	O
previously	O
obtained	O
at	O
the	O
same	O
molecular	O
medicine	O
laboratory	O
in	O
the	O
context	O
of	O
other	O
studies	O
.	O

RESULTS	O
:	O
The	O
comparative	O
analysis	O
of	O
the	O
three	O
groups	O
revealed	O
significant	O
differences	O
for	O
allele	O
frequencies	O
in	O
the	O
two	O
genes	O
in	O
patients	O
groups	O
(	O
prostate	O
cancer	O
and	O
benign	O
prostatic	O
hyperplasia	O
)	O
versus	O
the	O
general	O
population	O
.	O

The	O
D	O
allele	O
in	O
the	O
ACE	O
gene	O
was	O
closely	O
associated	O
with	O
a	O
significant	O
higher	O
risk	O
of	O
developing	O
both	O
benign	O
prostatic	O
hyperplasia	O
(	O
odds	O
ratio	O
[OR]=21.87	O
;	O
95%	O
confidence	O
interval	O
[	O
CI]=2.314-206.479	O
)	O
or	O
prostate	O
cancer	O
(	O
OR=31.66	O
;	O
95%	O
CI=0.091-1.272	O
)	O
,	O
and	O
the	O
AGT1R	O
A1166	O
allele	O
in	O
the	O
homozygote	O
state	O
was	O
identified	O
as	O
a	O
risk	O
genotype	O
for	O
benign	O
prostatic	O
hyperplasia	O
(OR=56.07)	O
.	O

CONCLUSIONS	O
:	O
Genotypes	O
in	O
ACE	O
and	O
AGT1R	O
polymorphisms	O
could	O
be	O
considered	O
as	O
genetic	O
risk	O
markers	O
for	O
benign	O
prostatic	O
hyperplasia	O
or	O
prostate	O
cancer	O
.	O

Molecular	O
analysis	O
of	O
gamma-globin	O
promoters	O
,	O
HS-111	O
and	O
3'HS1	O
,	O
in	O
beta-thalassemia	O
intermedia	O
patients	O
associated	O
with	O
high	O
levels	O
of	O
Hb	O
F	O
.	O

The	O
nucleotide	O
(nt)	O
variations	O
in	O
the	O
promoter	O
region	O
of	O
the	O
gamma-globin	O
genes	O
,	O
HS-111	O
and	O
3'HS1	O
regions	O
,	O
were	O
studied	O
in	O
Iranian	O
patients	O
with	O
beta-thalassemia	O
intermedia	O
(beta-TI)	O
,	O
beta-thalassemia	O
major	O
(beta-TM)	O
and	O
healthy	O
individuals	O
.	O

Of	O
the	O
five	O
nt	O
variations	O
at	O
the	O
5'	O
end	O
of	O
the	O
(A)gamma-globin	O
gene	O
,	O
-369	B-DNAMutation
(C>G)	I-DNAMutation
,	O
-611	B-DNAMutation
(-T)	I-DNAMutation
and	O
-603/604	B-DNAMutation
(GA>AG)	I-DNAMutation
were	O
found	O
in	O
all	O
samples	O
,	O
whereas	O
-588	B-DNAMutation
(A>G)	I-DNAMutation
and	O
-AAGC	B-DNAMutation
at	I-DNAMutation
-222	I-DNAMutation
to	I-DNAMutation
-225	I-DNAMutation
were	O
found	O
at	O
different	O
frequencies	O
in	O
the	O
studied	O
groups	O
.	O

Therefore	O
,	O
the	O
-369	O
,	O
-611	O
and	O
-603/604	O
variations	O
were	O
considered	O
common	O
mutations	O
in	O
this	O
population	O
,	O
and	O
the	O
difference	O
with	O
respect	O
to	O
the	O
-AAGC	O
deletion	O
was	O
not	O
significant	O
.	O

However	O
,	O
the	O
A	O
allele	O
of	O
the	O
-588	O
variation	O
and	O
[+]	O
allele	O
of	O
the	O
XmnI	O
polymorphism	O
were	O
more	O
frequent	O
in	O
beta-TI	O
patients	O
,	O
especially	O
those	O
who	O
had	O
the	O
IVS-II-1(G>A)	B-DNAMutation
/	O
IVS-II-1(G>A)	B-DNAMutation
genotype	O
.	O

The	O
+	O
allele	O
of	O
XmnI	O
also	O
had	O
complete	O
correlation	O
with	O
the	O
A	O
allele	O
of	O
-588	O
variation	O
.	O

The	O
HS-111	O
(	O
-21	O
A	O
)	O
variation	O
also	O
showed	O
association	O
with	O
beta-TI	O
patients	O
who	O
had	O
high	O
levels	O
of	O
Hb	O
F	O
.	O

Bearing	O
in	O
mind	O
that	O
the	O
-588	O
variation	O
lies	O
within	O
the	O
postulated	O
adult-specific	O
silencer	O
region	O
and	O
that	O
the	O
majority	O
of	O
beta-TI	O
patients	O
had	O
allele	O
A	O
,	O
then	O
it	O
can	O
be	O
envisaged	O
that	O
this	O
allele	O
could	O
have	O
a	O
role	O
in	O
altering	O
the	O
repressor	O
function	O
at	O
this	O
region	O
.	O

Therefore	O
,	O
the	O
A	O
allele	O
of	O
-588	O
,	O
[+]	O
allele	O
of	O
XmnI	O
and	O
HS-111	O
(	O
-21	O
A	O
)	O
variation	O
are	O
useful	O
genetic	O
markers	O
to	O
differentiate	O
between	O
beta-TM	O
and	O
beta-TI	O
patients	O
.	O

However	O
,	O
these	O
nt	O
changes	O
alone	O
may	O
not	O
be	O
the	O
only	O
elements	O
raising	O
the	O
level	O
of	O
Hb	O
F	O
,	O
other	O
regulatory	O
and	O
modifying	O
factors	O
also	O
play	O
a	O
role	O
in	O
Hb	O
F	O
production	O
.	O

Multiple	O
trichoepitheliomas--a	O
novel	O
mutation	O
in	O
the	O
CYLD	O
gene	O
.	O

BACKGROUND	O
:	O
Trichoepitheliomas	O
are	O
benign	O
neoplasms	O
with	O
follicular	O
differentiation	O
.	O

They	O
may	O
present	O
as	O
a	O
solitary	O
lesion	O
or	O
as	O
multiple	O
lesions	O
.	O

Multiple	O
trichoepitheliomas	O
are	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
within	O
families	O
,	O
with	O
both	O
variable	O
penetrance	O
and	O
expressivity	O
.	O

Recent	O
investigations	O
support	O
that	O
mutations	O
in	O
CYLD	O
,	O
the	O
gene	O
affected	O
in	O
familial	O
cylindromatosis	O
as	O
well	O
as	O
in	O
Brooke-Spiegler	O
syndrome	O
,	O
are	O
also	O
responsible	O
for	O
multiple	O
trichoepitheliomas	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
report	O
the	O
case	O
of	O
a	O
9-year-old	O
African	O
girl	O
with	O
multiple	O
facial	O
trichoepitheliomas	O
in	O
whom	O
a	O
mutation	O
in	O
the	O
CYLD	O
gene	O
was	O
hypothesised	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
After	O
genomic	O
DNA	O
extraction	O
from	O
the	O
peripheral	O
blood	O
,	O
a	O
molecular	O
analysis	O
of	O
the	O
CYLD	O
gene	O
was	O
performed	O
by	O
PCR	O
,	O
DHPLC	O
and	O
automated	O
sequencing	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
mutation	O
in	O
exon	O
18	O
of	O
the	O
CYLD	O
gene	O
c.2449delT	B-DNAMutation
was	O
identified	O
,	O
with	O
a	O
deletion	O
of	O
one	O
nucleotide	O
resulting	O
in	O
a	O
premature	O
translational	O
termination	O
codon	O
at	O
amino	O
acid	O
position	O
831	O
on	O
the	O
affected	O
allele	O
(	O
p.Cys817Valfs	B-ProteinMutation
X15	I-ProteinMutation
)	O
.	O

CONCLUSIONS	O
:	O
The	O
predominating	O
tumours	O
define	O
the	O
classification	O
of	O
these	O
three	O
entities	O
.	O

Nevertheless	O
,	O
studies	O
suggest	O
that	O
they	O
can	O
simply	O
represent	O
phenotypic	O
variations	O
of	O
the	O
same	O
disease	O
spectrum	O
,	O
sharing	O
common	O
genetic	O
mutations	O
.	O

FGFR4	O
Gly388Arg	B-ProteinMutation
polymorphism	O
and	O
prostate	O
cancer	O
risk	O
in	O
Scottish	O
men	O
.	O

Fibroblast	O
growth	O
factor	O
receptor	O
4	O
(FGFR4)	O
,	O
a	O
member	O
of	O
the	O
fibroblast	O
growth	O
receptor	O
family	O
,	O
was	O
recently	O
reported	O
to	O
be	O
more	O
abundantly	O
expressed	O
in	O
malignant	O
than	O
benign	O
prostate	O
cells	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
at	O
position	O
388	O
of	O
the	O
FGFR4	O
amino-acid	O
sequence	O
results	O
in	O
the	O
substitution	O
of	O
glycine	O
(Gly)	O
with	O
arginine	O
(Arg)	O
and	O
higher	O
frequency	O
of	O
the	O
ArgArg	O
genotype	O
was	O
previously	O
found	O
in	O
prostate	O
cancer	O
patients	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
blood	O
drawn	O
from	O
399	O
prostate	O
cancer	O
patients	O
,	O
150	O
BPH	O
patients	O
and	O
294	O
healthy	O
community	O
controls	O
.	O

Polymerase	O
chain	O
reaction	O
was	O
carried	O
out	O
and	O
single	O
nucleotide	O
polymorphisms	O
of	O
FGFR4	O
were	O
identified	O
by	O
restriction	O
enzyme	O
digestion	O
.	O

No	O
overall	O
association	O
is	O
detectable	O
between	O
the	O
Arg	O
allele	O
and	O
increased	O
prostate	O
cancer	O
risk	O
.	O

Subgroup	O
analysis	O
shows	O
a	O
higher	O
incidence	O
of	O
the	O
heterozygous	O
ArgGly	O
genotype	O
in	O
cancer	O
cases	O
than	O
in	O
the	O
combined	O
group	O
of	O
BPH	O
and	O
controls	O
(P<0.05)	O
;	O
this	O
difference	O
is	O
statistically	O
significant	O
between	O
cancer	O
and	O
BPH	O
patients	O
but	O
not	O
between	O
cancer	O
cases	O
and	O
community	O
controls	O
.	O

The	O
single	O
nucleotide	O
polymorphism	O
Gly(388)Arg	B-ProteinMutation
in	O
FGFR4	O
is	O
not	O
associated	O
with	O
increased	O
risk	O
of	O
prostate	O
cancer	O
in	O
Scottish	O
men	O
.	O

This	O
observation	O
is	O
in	O
contrast	O
with	O
results	O
from	O
two	O
previous	O
studies	O
conducted	O
in	O
the	O
USA	O
and	O
Japan	O
.	O

Polymorphisms	O
in	O
the	O
FOXP3	O
gene	O
in	O
Han	O
Chinese	O
psoriasis	O
patients	O
.	O

BACKGROUND	O
:	O
Psoriasis	O
is	O
a	O
common	O
dermatological	O
disorder	O
,	O
in	O
which	O
autoimmunity	O
plays	O
an	O
important	O
role	O
.	O

CD4(+)CD25(+)	O
regulatory	O
T	O
cells	O
(T-regs)	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
some	O
autoimmune	O
diseases	O
.	O

T-regs	O
express	O
the	O
fork	O
head/winged	O
helix	O
transcription	O
factor	O
,	O
FOXP3	O
,	O
which	O
appears	O
to	O
be	O
of	O
key	O
importance	O
in	O
the	O
development	O
and	O
function	O
of	O
T-regs	O
.	O

Studies	O
have	O
found	O
that	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	O
FOXP3	O
gene	O
contribute	O
to	O
susceptibility	O
to	O
some	O
autoimmune	O
disorders	O
.	O

However	O
,	O
information	O
about	O
FOXP3	O
gene	O
in	O
psoriasis	O
is	O
limited	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
evaluated	O
the	O
association	O
between	O
FOXP3	O
gene	O
SNPs	O
and	O
susceptibility	O
to	O
psoriasis	O
in	O
a	O
Han	O
Chinese	O
population	O
.	O

METHODS	O
:	O
In	O
a	O
hospital-based	O
case-control	O
study	O
,	O
524	O
patients	O
with	O
psoriasis	O
and	O
549	O
psoriasis-free	O
controls	O
were	O
recruited	O
according	O
to	O
age	O
and	O
gender	O
.	O

We	O
investigated	O
four	O
SNPs	O
in	O
the	O
FOXP3	O
gene	O
(	O
-6054	B-DNAMutation
,	I-DNAMutation
deletion/ATT	I-DNAMutation
;	O
-3279	B-DNAMutation
,	I-DNAMutation
A/C	I-DNAMutation
;	O
-924	B-DNAMutation
,	I-DNAMutation
A/G	I-DNAMutation
;	O
IVS9+459	B-DNAMutation
,	I-DNAMutation
A/G	I-DNAMutation
)	O
in	O
psoriatic	O
patients	O
,	O
and	O
assessed	O
allele	O
and	O
genotype	O
frequencies	O
in	O
psoriatic	O
patients	O
(	O
237	O
females	O
,	O
287	O
males	O
)	O
and	O
normal	O
controls	O
(	O
272	O
females	O
,	O
277	O
males	O
)	O
.	O

The	O
polymorphisms	O
were	O
genotyped	O
using	O
the	O
PCR	O
sequence-specific	O
primer	O
(PCR-SSP)	O
technique	O
and	O
PCR-restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
analysis	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
increased	O
risk	O
of	O
psoriasis	O
was	O
associated	O
with	O
the	O
FOXP3	O
-3279	O
AC	O
genotype	O
(	O
adjusted	O
OR	O
,	O
1.32	O
;	O
95%	O
CI	O
,	O
1.01-1.74	O
)	O
and	O
the	O
combined	O
AC+AA	O
genotype	O
(	O
adjusted	O
OR	O
,	O
1.38	O
;	O
95%	O
CI	O
,	O
1.07-1.78	O
)	O
,	O
compared	O
with	O
the	O
-3279	O
CC	O
genotype	O
.	O

We	O
also	O
found	O
that	O
an	O
increased	O
risk	O
of	O
psoriasis	O
was	O
associated	O
with	O
the	O
FOXP3	O
IVS9+459	O
GG	O
genotype	O
(	O
adjusted	O
OR	O
,	O
2.24	O
;	O
95%	O
CI	O
,	O
1.41-3.58	O
)	O
.	O

However	O
,	O
the	O
combined	O
GA+GG	O
genotype	O
showed	O
no	O
such	O
tendency	O
(	O
adjusted	O
OR=1.28	O
;	O
95%	O
CI	O
,	O
1.00-1.64	O
)	O
,	O
compared	O
with	O
the	O
IVS9+459	O
AA	O
genotype	O
.	O

There	O
was	O
no	O
evidence	O
of	O
an	O
increased	O
risk	O
associated	O
with	O
the	O
FOXP3-6054	B-DNAMutation
deletion/ATT	I-DNAMutation
or	O
FOXP3-924	B-DNAMutation
A/G	I-DNAMutation
genotype	O
.	O

In	O
combined	O
genotype	O
analyses	O
,	O
the	O
FOXP3-3279	O
AC+AA	O
genotype	O
was	O
more	O
obviously	O
associated	O
in	O
males	O
(	O
adjusted	O
OR=1.60	O
,	O
95%	O
CI=1.11-2.31	O
)	O
and	O
severe	O
psoriasis	O
patients	O
(	O
PASI	O
score	O
>20	O
;	O
adjusted	O
OR=1.97	O
,	O
95%	O
CI=1.41-2.75	O
)	O
.	O

Meanwhile	O
,	O
the	O
FOXP3	O
IVS9+459	O
GA+GG	O
genotype	O
was	O
also	O
associated	O
with	O
severe	O
psoriasis	O
patients	O
(	O
adjusted	O
OR=1.69	O
,	O
95%	O
CI=1.21-2.36	O
)	O
.	O

CONCLUSIONS	O
:	O
FOXP3	O
polymorphisms	O
appear	O
to	O
contribute	O
to	O
the	O
risk	O
of	O
psoriasis	O
in	O
a	O
Han	O
Chinese	O
population	O
.	O

Larger	O
studies	O
are	O
needed	O
to	O
confirm	O
these	O
findings	O
.	O

A	O
LDR-PCR	O
approach	O
for	O
multiplex	O
polymorphisms	O
genotyping	O
of	O
severely	O
degraded	O
DNA	O
with	O
fragment	O
sizes	O
<100	O
bp	O
.	O

Reducing	O
amplicon	O
sizes	O
has	O
become	O
a	O
major	O
strategy	O
for	O
analyzing	O
degraded	O
DNA	O
typical	O
of	O
forensic	O
samples	O
.	O

However	O
,	O
amplicon	O
sizes	O
in	O
current	O
mini-short	O
tandem	O
repeat-polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
mini-sequencing	O
assays	O
are	O
still	O
not	O
suitable	O
for	O
analysis	O
of	O
severely	O
degraded	O
DNA	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
multiplex	O
typing	O
method	O
that	O
couples	O
ligase	O
detection	O
reaction	O
with	O
PCR	O
that	O
can	O
be	O
used	O
to	O
identify	O
single	O
nucleotide	O
polymorphisms	O
and	O
small-scale	O
insertion/deletions	O
in	O
a	O
sample	O
of	O
severely	O
fragmented	O
DNA	O
.	O

This	O
method	O
adopts	O
thermostable	O
ligation	O
for	O
allele	O
discrimination	O
and	O
subsequent	O
PCR	O
for	O
signal	O
enhancement	O
.	O

In	O
this	O
study	O
,	O
four	O
polymorphic	O
loci	O
were	O
used	O
to	O
assess	O
the	O
ability	O
of	O
this	O
technique	O
to	O
discriminate	O
alleles	O
in	O
an	O
artificially	O
degraded	O
sample	O
of	O
DNA	O
with	O
fragment	O
sizes	O
<100	O
bp	O
.	O

Our	O
results	O
showed	O
clear	O
allelic	O
discrimination	O
of	O
single	O
or	O
multiple	O
loci	O
,	O
suggesting	O
that	O
this	O
method	O
might	O
aid	O
in	O
the	O
analysis	O
of	O
extremely	O
degraded	O
samples	O
in	O
which	O
allelic	O
drop	O
out	O
of	O
larger	O
fragments	O
is	O
observed	O
.	O

A	O
MANBA	O
mutation	O
resulting	O
in	O
residual	O
beta-mannosidase	O
activity	O
associated	O
with	O
severe	O
leukoencephalopathy	O
:	O
a	O
possible	O
pseudodeficiency	O
variant	O
.	O

BACKGROUND	O
:	O
beta-Mannosidosis	O
(	O
OMIM	O
248510	O
)	O
is	O
a	O
rare	O
inborn	O
lysosomal	O
storage	O
disorder	O
caused	O
by	O
the	O
deficient	O
activity	O
of	O
beta-mannosidase	O
,	O
an	O
enzyme	O
encoded	O
by	O
a	O
single	O
gene	O
(MANBA)	O
located	O
on	O
chromosome	O
4q22-25	O
.	O

To	O
date	O
,	O
only	O
20	O
cases	O
of	O
this	O
autosomal	O
recessive	O
disorder	O
have	O
been	O
described	O
and	O
14	O
different	O
MANBA	O
mutations	O
were	O
incriminated	O
in	O
the	O
disease	O
.	O

These	O
are	O
all	O
null	O
mutations	O
or	O
missense	O
mutations	O
that	O
abolish	O
beta-mannosidase	O
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
the	O
molecular	O
defect	O
of	O
a	O
new	O
case	O
of	O
beta-mannosidosis	O
,	O
presenting	O
with	O
a	O
severe	O
neurological	O
disorder	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
leukocytes	O
of	O
the	O
patient	O
to	O
allow	O
MANBA	O
sequencing	O
.	O

The	O
identified	O
mutation	O
was	O
engineered	O
by	O
site-directed	O
mutagenesis	O
and	O
the	O
mutant	O
protein	O
was	O
expressed	O
through	O
transient	O
transfection	O
in	O
HEK293T	O
cells	O
.	O

The	O
beta-mannosidase	O
expression	O
and	O
activity	O
were	O
respectively	O
assessed	O
by	O
Western	O
blot	O
and	O
fluorometric	O
assay	O
in	O
both	O
leukocytes	O
and	O
HEK293T	O
cells	O
.	O

RESULTS	O
:	O
A	O
missense	O
disease-associated	O
mutation	O
,	O
c.1922G>A	B-DNAMutation
p.Arg641His	B-ProteinMutation
,	O
was	O
identified	O
for	O
which	O
the	O
patient	O
was	O
homozygous	O
.	O

In	O
contrast	O
to	O
previously	O
described	O
missense	O
mutations	O
,	O
this	O
substitution	O
does	O
not	O
totally	O
abrogate	O
the	O
enzyme	O
activity	O
but	O
led	O
to	O
a	O
residual	O
activity	O
of	O
about	O
7%	O
in	O
the	O
patient's	O
leukocytes	O
,	O
11%	O
in	O
lymphoblasts	O
and	O
14%	O
in	O
plasma	O
.	O

Expression	O
studies	O
in	O
transfected	O
cells	O
also	O
resulted	O
in	O
7%	O
residual	O
activity	O
.	O

CONCLUSION	O
:	O
Correlations	O
between	O
MANBA	O
mutations	O
,	O
residual	O
activity	O
of	O
beta-mannosidase	O
and	O
the	O
severity	O
of	O
the	O
ensuing	O
neurological	O
disorder	O
are	O
discussed	O
.	O

Whether	O
the	O
c.1922G>A	B-DNAMutation
mutation	O
is	O
responsible	O
for	O
a	O
yet	O
undescribed	O
pseudodeficiency	O
of	O
beta-mannosidase	O
is	O
also	O
discussed	O
.	O

Screening	O
of	O
the	O
LIX1	O
gene	O
in	O
Japanese	O
and	O
Malaysian	O
patients	O
with	O
SMA	O
and/or	O
SMA-like	O
disorder	O
.	O

BACKGROUND	O
:	O
The	O
majority	O
of	O
spinal	O
muscular	O
atrophy	O
(SMA)	O
patients	O
showed	O
homozygous	O
deletion	O
or	O
other	O
mutations	O
of	O
SMN1	O
.	O

However	O
,	O
the	O
genetic	O
etiology	O
of	O
a	O
significant	O
number	O
of	O
SMA	O
patients	O
has	O
not	O
been	O
clarified	O
.	O

Recently	O
,	O
mutation	O
in	O
the	O
gene	O
underlying	O
cat	O
SMA	O
,	O
limb	O
expression	O
1	O
(LIX1)	O
,	O
has	O
been	O
reported	O
.	O

Similarity	O
in	O
clinical	O
and	O
pathological	O
features	O
of	O
cat	O
and	O
human	O
SMA	O
may	O
give	O
an	O
insight	O
into	O
possible	O
similarity	O
of	O
the	O
genetic	O
etiology	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
screened	O
for	O
a	O
mutation	O
in	O
LIX1	O
using	O
direct	O
DNA	O
sequencing	O
in	O
our	O
SMA	O
and/or	O
SMA-like	O
patients	O
who	O
retained	O
SMN1	O
.	O

A	O
total	O
of	O
33	O
patients	O
were	O
enrolled	O
in	O
this	O
study	O
,	O
of	O
which	O
22	O
were	O
Japanese	O
and	O
11	O
were	O
Malaysians	O
.	O

All	O
these	O
patients	O
possessed	O
at	O
least	O
two	O
copies	O
of	O
SMN1	O
.	O

RESULTS	O
:	O
We	O
did	O
not	O
identify	O
any	O
pathogenic	O
mutations	O
in	O
the	O
coding	O
regions	O
or	O
splice	O
sites	O
of	O
LIX1	O
in	O
the	O
patients	O
.	O

In	O
addition	O
,	O
we	O
described	O
a	O
polymorphism	O
within	O
LIX1	O
intron	O
3	O
,	O
c.387+107A>T	B-DNAMutation
.	O

We	O
found	O
that	O
A-allele	O
is	O
significantly	O
more	O
frequent	O
in	O
SMA	O
patients	O
compared	O
to	O
normal	O
individuals	O
.	O

CONCLUSION	O
:	O
Molecular	O
genetic	O
analysis	O
of	O
our	O
SMA	O
and/or	O
SMA-like	O
patients	O
suggests	O
that	O
LIX1	O
is	O
not	O
associated	O
with	O
the	O
development	O
of	O
their	O
disorders	O
.	O

However	O
,	O
the	O
number	O
of	O
patients	O
analyzed	O
in	O
this	O
study	O
was	O
very	O
limited	O
,	O
and	O
a	O
larger	O
study	O
with	O
bigger	O
sample	O
size	O
is	O
needed	O
to	O
confirm	O
this	O
result	O
.	O

Single	O
nucleotide	O
polymorphism	O
discovery	O
in	O
TBX1	O
in	O
individuals	O
with	O
and	O
without	O
22q11.2	O
deletion	O
syndrome	O
.	O

BACKGROUND	O
:	O
Children	O
with	O
22q11.2	O
deletion	O
syndrome	O
(22q11.2DS)	O
have	O
a	O
wide	O
range	O
of	O
clinical	O
features	O
.	O

TBX1	O
has	O
been	O
proposed	O
as	O
a	O
candidate	O
gene	O
for	O
some	O
of	O
the	O
features	O
in	O
this	O
condition	O
.	O

Polymorphisms	O
in	O
the	O
nondeleted	O
TBX1	O
,	O
which	O
may	O
affect	O
the	O
function	O
of	O
the	O
sole	O
TBX1	O
gene	O
in	O
individuals	O
with	O
the	O
22q11.2DS	O
,	O
may	O
be	O
a	O
key	O
to	O
understanding	O
the	O
phenotypic	O
variability	O
among	O
individuals	O
with	O
a	O
shared	O
deletion	O
.	O

Comprehensive	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
discovery	O
by	O
resequencing	O
candidate	O
genes	O
can	O
identify	O
genetic	O
variants	O
that	O
influence	O
a	O
given	O
phenotype	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
further	O
characterize	O
the	O
sequence	O
variability	O
in	O
TBX1	O
by	O
identifying	O
all	O
common	O
SNPs	O
in	O
this	O
gene	O
.	O

METHODS	O
:	O
We	O
resequenced	O
TBX1	O
in	O
29	O
children	O
with	O
a	O
documented	O
22q11.2	O
deletion	O
and	O
95	O
nondeleted	O
,	O
healthy	O
individuals	O
.	O

We	O
estimated	O
allele	O
frequencies	O
,	O
performed	O
tagSNP	O
selection	O
,	O
and	O
inferred	O
haplotypes	O
.	O

We	O
also	O
compared	O
SNP	O
frequencies	O
between	O
22q11.2DS	O
and	O
control	O
samples	O
.	O

RESULTS	O
:	O
We	O
identified	O
355	O
biallelic	O
markers	O
among	O
the	O
190	O
chromosomes	O
resequenced	O
in	O
the	O
control	O
panel	O
.	O

The	O
vast	O
majority	O
of	O
the	O
markers	O
identified	O
were	O
SNPs	O
(	O
n	O
=	O
331	O
)	O
,	O
and	O
the	O
remainder	O
indels	O
(	O
n	O
=	O
24	O
)	O
.	O

We	O
did	O
not	O
identify	O
SNPs	O
or	O
indels	O
in	O
the	O
cis-	O
regulatory	O
element	O
(	O
FOX-binding	O
site	O
)	O
upstream	O
of	O
TBX1	O
.	O

In	O
children	O
with	O
22q11.2DS	O
we	O
detected	O
187	O
biallelic	O
markers	O
,	O
six	O
of	O
which	O
were	O
indels	O
.	O

Four	O
of	O
the	O
seven	O
coding	O
SNPs	O
identified	O
in	O
the	O
controls	O
were	O
identified	O
in	O
children	O
with	O
22q11.2DS	O
.	O

CONCLUSIONS	O
:	O
This	O
comprehensive	O
SNP	O
discovery	O
data	O
can	O
be	O
used	O
to	O
select	O
SNPs	O
to	O
genotype	O
for	O
future	O
association	O
studies	O
assessing	O
the	O
role	O
of	O
TBX1	O
and	O
phenotypic	O
variability	O
in	O
individuals	O
with	O
22q11.2DS	O
.	O

Matriptase-2	O
mutations	O
in	O
iron-refractory	O
iron	O
deficiency	O
anemia	O
patients	O
provide	O
new	O
insights	O
into	O
protease	O
activation	O
mechanisms	O
.	O

Mutations	O
leading	O
to	O
abrogation	O
of	O
matriptase-2	O
proteolytic	O
activity	O
in	O
humans	O
are	O
associated	O
with	O
an	O
iron-refractory	O
iron	O
deficiency	O
anemia	O
(IRIDA)	O
due	O
to	O
elevated	O
hepcidin	O
levels	O
.	O

Here	O
we	O
describe	O
two	O
novel	O
heterozygous	O
mutations	O
within	O
the	O
matriptase-2	O
(TMPRSS6)	O
gene	O
of	O
monozygotic	O
twin	O
girls	O
exhibiting	O
an	O
IRIDA	O
phenotype	O
.	O

The	O
first	O
is	O
the	O
frameshift	O
mutation	O
P686fs	B-ProteinMutation
caused	O
by	O
the	O
insertion	O
of	O
the	O
four	O
nucleotides	O
CCCC	O
in	O
exon	O
16	O
2172_2173insCCCC	B-DNAMutation
that	O
is	O
predicted	O
to	O
terminate	O
translation	O
before	O
the	O
catalytic	O
serine	O
.	O

The	O
second	O
mutation	O
is	O
the	O
di-nucleotide	O
substitution	O
c.467C>A	B-DNAMutation
and	O
c.468C>T	B-DNAMutation
in	O
exon	O
3	O
that	O
causes	O
the	O
missense	O
mutation	O
A118D	B-ProteinMutation
in	O
the	O
SEA	O
domain	O
of	O
the	O
extracellular	O
stem	O
region	O
of	O
matriptase-2	O
.	O

Functional	O
analysis	O
of	O
both	O
variant	O
matriptase-2	O
proteases	O
has	O
revealed	O
that	O
they	O
lead	O
to	O
ineffective	O
suppression	O
of	O
hepcidin	O
transcription	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
A118D	B-ProteinMutation
SEA	O
domain	O
mutation	O
causes	O
an	O
intra-molecular	O
structural	O
imbalance	O
that	O
impairs	O
matriptase-2	O
activation	O
.	O

Collectively	O
,	O
these	O
results	O
extend	O
the	O
pattern	O
of	O
TMPRSS6	O
mutations	O
associated	O
with	O
IRIDA	O
and	O
functionally	O
demonstrate	O
that	O
mutations	O
affecting	O
protease	O
regions	O
other	O
than	O
the	O
catalytic	O
domain	O
may	O
have	O
a	O
profound	O
impact	O
in	O
the	O
regulatory	O
role	O
of	O
matriptase-2	O
during	O
iron	O
deficiency	O
.	O

Serotonin	O
transporter	O
gene	O
polymorphic	O
element	O
5-HTTLPR	O
increases	O
the	O
risk	O
of	O
sporadic	O
Parkinson's	O
disease	O
in	O
Italy	O
.	O

Parkinson's	O
disease	O
(PD)	O
is	O
a	O
neurodegenerative	O
disorder	O
causing	O
muscular	O
rigidity	O
,	O
resting	O
tremor	O
and	O
bradykinesia	O
.	O

We	O
conducted	O
an	O
association	O
study	O
assessing	O
how	O
PD	O
risk	O
in	O
Italy	O
was	O
influenced	O
by	O
the	O
serotonin	O
transporter	O
gene	O
(SLC6A4)	O
polymorphic	O
region	O
5-HTTLPR	O
,	O
consisting	O
of	O
an	O
insertion/deletion	O
(	O
long	O
allele-L/short	O
allele-S	O
)	O
of	O
43	O
bp	O
in	O
the	O
SLC6A4	O
promoter	O
region	O
.	O

The	O
SLC6A4	O
promoter	O
single	O
nucleotide	O
polymorphism	O
rs25531	B-SNP
A-->G	B-DNAMutation
was	O
evaluated	O
too	O
.	O

We	O
collected	O
837	O
independent	O
subjects	O
(	O
393	O
PD	O
,	O
444	O
controls	O
)	O
.	O

An	O
association	O
between	O
the	O
5-HTTLPR	O
polymorphism	O
and	O
risk	O
of	O
PD	O
(	O
S/S	O
genotype	O
OR	O
[	O
95%	O
CI	O
]	O
:	O
1.7[1.2-2.5]	O
,	O
p	O
=	O
0.002	O
)	O
was	O
found	O
.	O

The	O
rs25531	B-SNP
and	O
the	O
haplotype	O
5-HTTLPR/	O
rs25531	B-SNP
did	O
not	O
associate	O
with	O
risk	O
of	O
PD	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
5-HTTLPR	O
polymorphic	O
element	O
within	O
the	O
SLC6A4	O
promoter	O
may	O
govern	O
the	O
genetic	O
risk	O
of	O
PD	O
in	O
Italians	O
.	O

Angiotensin	O
converting	O
enzyme	O
gene	O
polymorphism	O
in	O
Turkish	O
asthmatic	O
patients	O
.	O

Asthma	O
is	O
a	O
chronic	O
inflammatory	O
disease	O
of	O
the	O
airways	O
.	O

Several	O
candidate	O
genes	O
have	O
been	O
identified	O
with	O
a	O
potential	O
role	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
,	O
including	O
the	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
gene	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
frequency	O
of	O
an	O
ACE	O
gene	O
polymorphism	O
in	O
Turkish	O
asthmatic	O
patients	O
and	O
to	O
determine	O
its	O
impact	O
on	O
clinical	O
parameters	O
and	O
disease	O
severity	O
.	O

Ninety-seven	O
asthmatic	O
patients	O
(	O
M/F	O
25/72	O
,	O
mean	O
age	O
39	O
+/-	O
13	O
years	O
)	O
and	O
96	O
healthy	O
subjects	O
(	O
M/F	O
26/70	O
,	O
mean	O
age	O
38	O
+/-	O
12	O
years	O
)	O
were	O
included	O
.	O

At	O
baseline	O
,	O
all	O
participants	O
completed	O
a	O
questionnaire	O
on	O
demographics	O
,	O
symptoms	O
,	O
triggering	O
factors	O
,	O
severity	O
of	O
asthma	O
,	O
and	O
the	O
presence	O
of	O
atopism	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
all	O
patients	O
and	O
genomic	O
DNA	O
was	O
isolated	O
.	O

The	O
frequency	O
of	O
the	O
ACE	O
genotypes	O
(	O
I	O
=	O
insertion	O
and	O
D	O
=	O
deletion	O
)	O
among	O
asthmatics	O
and	O
controls	O
were	O
compared	O
:	O
asthmatics	O
showed	O
a	O
40.2%	O
prevalence	O
of	O
the	O
DD	O
genotype	O
(	O
n	O
=	O
39	O
)	O
,	O
ID	O
was	O
45.4%	O
(	O
n	O
=	O
44	O
)	O
,	O
and	O
II	O
was	O
14.4%	O
(	O
n	O
=	O
14.4	O
)	O
.	O

In	O
the	O
control	O
subjects	O
,	O
the	O
frequency	O
of	O
DD	O
was	O
18.8%	O
(	O
n	O
=	O
18	O
)	O
,	O
ID	O
was	O
50%	O
(	O
n	O
=	O
48	O
)	O
and	O
II	O
was	O
31.3%	O
(	O
n	O
=	O
30	O
)	O
.	O

The	O
DD	O
ACE	O
genotype	O
was	O
significantly	O
more	O
frequent	O
in	O
asthmatics	O
compared	O
with	O
controls	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Asthmatics	O
with	O
the	O
ID	O
ACE	O
genotype	O
showed	O
a	O
higher	O
frequency	O
of	O
drug	O
allergies	O
,	O
although	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.08	O
)	O
.	O

Asthmatics	O
with	O
the	O
DD	O
genotype	O
appeared	O
to	O
have	O
a	O
higher	O
incidence	O
of	O
asthmatic	O
episode	O
exacerbations	O
due	O
to	O
viral	O
infections	O
,	O
but	O
again	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.08	O
)	O
.	O

Patients	O
with	O
mild	O
or	O
moderate-severe	O
asthma	O
had	O
similar	O
frequencies	O
of	O
these	O
mutations	O
.	O

We	O
found	O
a	O
higher	O
frequency	O
of	O
the	O
ACE	O
DD	O
gene	O
mutation	O
in	O
Turkish	O
asthmatic	O
patients	O
compared	O
with	O
non-asthmatics	O
,	O
suggesting	O
that	O
this	O
ACE	O
gene	O
polymorphism	O
may	O
be	O
a	O
risk	O
factor	O
for	O
asthma	O
but	O
does	O
not	O
increase	O
the	O
severity	O
of	O
the	O
disease	O
.	O

The	O
role	O
of	O
the	O
CCR5	O
Delta32	B-DNAMutation
polymorphism	O
in	O
abdominal	O
aortic	O
aneurysms	O
.	O

BACKGROUND	O
:	O
C-C	O
chemokine	O
receptor	O
5	O
(CCR5)	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
inflammatory	O
response	O
.	O

Abdominal	O
aortic	O
aneurysms	O
(AAA)	O
may	O
arise	O
as	O
the	O
result	O
of	O
a	O
chronic	O
inflammatory	O
process	O
which	O
is	O
influenced	O
by	O
genetic	O
predisposition	O
.	O

The	O
CCR5	O
gene	O
is	O
associated	O
with	O
a	O
32	O
base	O
pair	O
deletion	O
(	O
the	O
Delta32	B-DNAMutation
polymorphism	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
CCR5	O
Delta32	B-DNAMutation
polymorphism	O
in	O
the	O
development	O
of	O
AAA	O
.	O

METHODS	O
:	O
A	O
case-control	O
study	O
was	O
conducted	O
including	O
285	O
patients	O
with	O
AAA	O
and	O
273	O
control	O
subjects	O
.	O

A	O
blood	O
sample	O
was	O
taken	O
from	O
each	O
individual	O
and	O
DNA	O
was	O
extracted	O
.	O

CCR5	O
genotype	O
was	O
determined	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

Flow	O
cytometry	O
was	O
used	O
to	O
investigate	O
the	O
biological	O
activity	O
of	O
the	O
Delta32	B-DNAMutation
polymorphism	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
AAA	O
and	O
the	O
control	O
group	O
in	O
relation	O
to	O
the	O
Delta32	B-DNAMutation
allele	O
frequency	O
(	O
AAA	O
group	O
10%	O
,	O
control	O
group	O
=	O
12%	O
,	O
P	O
=	O
0.82	O
,	O
chi-squared	O
analysis	O
)	O
.	O

Genotype	O
analysis	O
revealed	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
(	O
AAA	O
vs	O
.	O

controls	O
,	O
wild-type	O
homozygotes	O
=	O
82%	O
vs	O
.	O

77%	O
,	O
heterozygotes	O
=	O
16%	O
vs	O
.	O

21%	O
,	O
vs	O
.	O

Delta32	B-DNAMutation
homozygotes	O
=	O
2%	O
and	O
2%	O
,	O
respectively	O
,	O
P	O
=	O
0.33	O
,	O
chi-squared	O
analysis	O
)	O
.	O

The	O
polymorphism	O
was	O
shown	O
to	O
be	O
biologically	O
active	O
with	O
the	O
number	O
of	O
Delta32	B-DNAMutation
alleles	O
correlating	O
with	O
cell	O
expression	O
of	O
ccr5	O
as	O
detected	O
with	O
flow	O
cytometry	O
(	O
P	O
<	O
or	O
=	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
the	O
ccr5	O
Delta32	B-DNAMutation
is	O
a	O
biologically	O
active	O
genetic	O
polymorphism	O
;	O
however	O
,	O
there	O
is	O
no	O
association	O
between	O
this	O
polymorphism	O
and	O
AAA	O
.	O

Marked	O
high	O
density	O
lipoprotein	O
deficiency	O
due	O
to	O
apolipoprotein	O
A-I	O
Tomioka	O
(	O
codon	O
138	O
deletion	O
)	O
.	O

We	O
report	O
a	O
novel	O
apolipoprotein	O
A-I	O
(apoA-I)	O
mutation	O
identified	O
in	O
a	O
64-year-old	O
patient	O
with	O
marked	O
plasma	O
high	O
density	O
lipoprotein	O
(HDL)	O
cholesterol	O
(	O
4	O
mg/dl	O
)	O
and	O
apoA-I	O
(5mg/dl)	O
deficiency	O
,	O
prior	O
myocardial	O
infarction	O
,	O
and	O
moderate	O
corneal	O
opacities	O
.	O

Coronary	O
angiography	O
revealed	O
extensive	O
atherosclerosis	O
in	O
all	O
three	O
major	O
vessels	O
.	O

Genomic	O
DNA	O
sequencing	O
of	O
the	O
proband	O
revealed	O
a	O
homozygous	O
novel	O
deletion	O
of	O
two	O
successive	O
adenine	O
residues	O
in	O
codon	O
138	O
in	O
the	O
apoA-I	O
gene	O
,	O
resulting	O
in	O
a	O
frameshift	O
mutation	O
at	O
amino	O
acid	O
residues	O
138-178	O
,	O
which	O
we	O
have	O
designated	O
as	O
apoA-I	O
Tomioka	O
.	O

His	O
elder	O
brother	O
was	O
also	O
homozygous	O
for	O
apoA-I	O
Tomioka	O
with	O
marked	O
HDL	O
cholesterol	O
and	O
apoA-I	O
deficiency	O
,	O
but	O
had	O
no	O
clinical	O
evidence	O
of	O
coronary	O
heart	O
disease	O
.	O

Other	O
family	O
members	O
including	O
three	O
siblings	O
and	O
two	O
sons	O
were	O
heterozygous	O
for	O
the	O
mutation	O
,	O
and	O
had	O
approximately	O
50%	O
of	O
normal	O
plasma	O
HDL	O
cholesterol	O
,	O
and	O
apoA-I	O
.	O

Analysis	O
of	O
apoA-I-containing	O
HDL	O
particles	O
by	O
two-dimensional	O
gel	O
electrophoresis	O
revealed	O
undetectable	O
apoA-I	O
HDL	O
particles	O
in	O
the	O
homozygotes	O
,	O
while	O
in	O
heterozygotes	O
,	O
the	O
mean	O
concentrations	O
of	O
apoA-I	O
in	O
large	O
alpha-1	O
and	O
very	O
small	O
prebeta-1	O
HDL	O
subpopulations	O
were	O
significantly	O
decreased	O
at	O
about	O
35%	O
of	O
normal	O
.	O

Thus	O
,	O
apoA-I	O
Tomioka	O
,	O
a	O
novel	O
deletion	O
mutation	O
in	O
codon	O
138	O
of	O
the	O
apoA-I	O
gene	O
,	O
is	O
the	O
causative	O
defect	O
in	O
this	O
case	O
of	O
HDL	O
deficiency	O
.	O

Correlation	O
of	O
polymorphism	O
of	O
the	O
coding	O
region	O
of	O
glutathione	O
S-	O
transferase	O
M1	O
to	O
susceptibility	O
of	O
nasopharyngeal	O
carcinoma	O
in	O
South	O
China	O
population	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Glutathione	O
S-transferase	O
M1	O
(GSTM1)	O
deficiency	O
may	O
increase	O
the	O
risk	O
of	O
nasopharyngeal	O
carcinoma	O
(NPC)	O
.	O

This	O
study	O
was	O
to	O
evaluate	O
the	O
correlation	O
of	O
the	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
in	O
the	O
coding	O
region	O
of	O
GSTM1	O
gene	O
to	O
NPC	O
susceptibility	O
in	O
southern	O
China	O
population	O
.	O

METHODS	O
:	O
In	O
total	O
239	O
NPC	O
patients	O
and	O
286	O
age-matched	O
healthy	O
controls	O
were	O
entered	O
into	O
the	O
study	O
.	O

Among	O
them	O
,	O
225	O
out	O
of	O
239	O
NPC	O
patients	O
and	O
273	O
out	O
of	O
286	O
controls	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O

SNP	O
screening	O
of	O
all	O
exons	O
,	O
relevant	O
intron-exon	O
boundaries	O
,	O
and	O
the	O
promoter	O
region	O
of	O
GSTM1	O
,	O
in	O
total	O
4739bp	O
,	O
was	O
performed	O
by	O
PCR	O
direct	O
sequencing	O
.	O

The	O
loci	O
T1270533G	B-DNAMutation
and	O
C1256088C	O
were	O
selected	O
for	O
the	O
case-control	O
study	O
using	O
the	O
tetra-Primer	O
ARMS-PCR	O
,	O
as	O
well	O
as	O
the	O
sequencing	O
method	O
.	O

RESULTS	O
:	O
In	O
total	O
29	O
SNPs	O
of	O
GSTM1	O
were	O
identified	O
by	O
sequencing	O
.	O

Missense	O
mutation	O
occurred	O
in	O
the	O
polymorphic	O
loci	O
of	O
T1270533G	B-DNAMutation
and	O
C1256088C	O
.	O

However	O
,	O
no	O
evident	O
relationships	O
between	O
the	O
variants	O
of	O
T1270533G	B-DNAMutation
and	O
clinical	O
phenotypes	O
of	O
NPC	O
were	O
observed	O
in	O
the	O
NPC	O
group	O
and	O
healthy	O
control	O
group	O
(	O
OR	O
=	O
0.170	O
,	O
95%CI	O
=	O
0.95-0.306	O
for	O
homozygote	O
TT	O
)	O
.	O

The	O
deletion	O
frequency	O
of	O
C1256088C	O
was	O
45%	O
(45/100)	O
for	O
NPC	O
patients	O
and	O
42%	O
(42/100)	O
for	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
polymorphism	O
of	O
T1270533G	B-DNAMutation
does	O
not	O
affect	O
the	O
detoxification	O
function	O
of	O
GSTM1	O
.	O

The	O
T1270533G	B-DNAMutation
locus	O
has	O
no	O
apparent	O
association	O
with	O
genetic	O
susceptibility	O
to	O
NPC	O
in	O
the	O
southern	O
China	O
population	O
.	O

The	O
loss	O
rate	O
of	O
C1256088C	O
is	O
high	O
in	O
this	O
study	O
.	O

High-resolution	O
genomic	O
copy	O
number	O
profiling	O
of	O
glioblastoma	O
multiforme	O
by	O
single	O
nucleotide	O
polymorphism	O
DNA	O
microarray	O
.	O

Glioblastoma	O
multiforme	O
(GBM)	O
is	O
an	O
extremely	O
malignant	O
brain	O
tumor	O
.	O

To	O
identify	O
new	O
genomic	O
alterations	O
in	O
GBM	O
,	O
genomic	O
DNA	O
of	O
tumor	O
tissue/explants	O
from	O
55	O
individuals	O
and	O
6	O
GBM	O
cell	O
lines	O
were	O
examined	O
using	O
single	O
nucleotide	O
polymorphism	O
DNA	O
microarray	O
(SNP-Chip)	O
.	O

Further	O
gene	O
expression	O
analysis	O
relied	O
on	O
an	O
additional	O
56	O
GBM	O
samples	O
.	O

SNP-Chip	O
results	O
were	O
validated	O
using	O
several	O
techniques	O
,	O
including	O
quantitative	O
PCR	O
(Q-PCR)	O
,	O
nucleotide	O
sequencing	O
,	O
and	O
a	O
combination	O
of	O
Q-PCR	O
and	O
detection	O
of	O
microsatellite	O
markers	O
for	O
loss	O
of	O
heterozygosity	O
with	O
normal	O
copy	O
number	O
[	O
acquired	O
uniparental	O
disomy	O
(	O
AUPD	O
)	O
]	O
.	O

Whole	O
genomic	O
DNA	O
copy	O
number	O
in	O
each	O
GBM	O
sample	O
was	O
profiled	O
by	O
SNP-Chip	O
.	O

Several	O
signaling	O
pathways	O
were	O
frequently	O
abnormal	O
.	O

Either	O
the	O
p16(INK4A)/p15(INK4B)-CDK4/6-pRb	O
or	O
p14(ARF)-MDM2/4-p53	O
pathways	O
were	O
abnormal	O
in	O
89%	O
(	O
49	O
of	O
55	O
)	O
of	O
cases	O
.	O

Simultaneous	O
abnormalities	O
of	O
both	O
pathways	O
occurred	O
in	O
84%	O
(	O
46	O
of	O
55	O
)	O
samples	O
.	O

The	O
phosphoinositide	O
3-kinase	O
pathway	O
was	O
altered	O
in	O
71%	O
(	O
39	O
of	O
55	O
)	O
GBMs	O
either	O
by	O
deletion	O
of	O
PTEN	O
or	O
amplification	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
and/or	O
vascular	O
endothelial	O
growth	O
factor	O
receptor/platelet-derived	O
growth	O
factor	O
receptor	O
alpha	O
.	O

Deletion	O
of	O
chromosome	O
6q26-27	O
often	O
occurred	O
(	O
16	O
of	O
55	O
samples	O
)	O
.	O

The	O
minimum	O
common	O
deleted	O
region	O
included	O
PARK2	O
,	O
PACRG	O
,	O
QKI	O
,	O
and	O
PDE10A	O
genes	O
.	O

Further	O
reverse	O
transcription	O
Q-PCR	O
studies	O
showed	O
that	O
PARK2	O
expression	O
was	O
decreased	O
in	O
another	O
collection	O
of	O
GBMs	O
at	O
a	O
frequency	O
of	O
61%	O
(	O
34	O
of	O
56	O
)	O
of	O
samples	O
.	O

The	O
1p36.23	O
region	O
was	O
deleted	O
in	O
35%	O
(	O
19	O
of	O
55	O
)	O
of	O
samples	O
.	O

Notably	O
,	O
three	O
samples	O
had	O
homozygous	O
deletion	O
encompassing	O
this	O
site	O
.	O

Also	O
,	O
a	O
novel	O
internal	O
deletion	O
of	O
a	O
putative	O
tumor	O
suppressor	O
gene	O
,	O
LRP1B	O
,	O
was	O
discovered	O
causing	O
an	O
aberrant	O
protein	O
.	O

AUPDs	O
occurred	O
in	O
58%	O
(	O
32	O
of	O
55	O
)	O
of	O
the	O
GBM	O
samples	O
and	O
five	O
of	O
six	O
GBM	O
cell	O
lines	O
.	O

A	O
common	O
AUPD	O
was	O
found	O
at	O
chromosome	O
17p13.3-12	O
(	O
included	O
p53	O
gene	O
)	O
in	O
13	O
of	O
61	O
samples	O
and	O
cell	O
lines	O
.	O

Single-strand	O
conformational	O
polymorphism	O
and	O
nucleotide	O
sequencing	O
showed	O
that	O
9	O
of	O
13	O
of	O
these	O
samples	O
had	O
homozygous	O
p53	O
mutations	O
,	O
suggesting	O
that	O
mitotic	O
recombination	O
duplicated	O
the	O
abnormal	O
p53	O
gene	O
,	O
probably	O
providing	O
a	O
growth	O
advantage	O
to	O
these	O
cells	O
.	O

A	O
significantly	O
shortened	O
survival	O
time	O
was	O
found	O
in	O
patients	O
with	O
13q14	O
(RB)	O
deletion	O
or	O
17p13.1	O
(p53)	O
deletion/AUPD	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
this	O
technique	O
is	O
a	O
rapid	O
,	O
robust	O
,	O
and	O
inexpensive	O
method	O
to	O
profile	O
genome-wide	O
abnormalities	O
in	O
GBM	O
.	O

A	O
large	O
Swiss	O
family	O
with	O
Bernard-Soulier	O
syndrome	O
-	O
Correlation	O
phenotype	O
and	O
genotype	O
.	O

Bernard-Soulier	O
syndrome	O
(BSS)	O
is	O
a	O
rare	O
,	O
autosomal	O
recessive	O
inherited	O
bleeding	O
disorder	O
associated	O
with	O
thrombocytopenia	O
,	O
thrombocytopathy	O
and	O
giant	O
platelets	O
.	O

BSS	O
is	O
caused	O
by	O
genetic	O
alterations	O
of	O
the	O
glycoprotein	O
(GP)	O
Ib/V/IX	O
complex	O
.	O

We	O
report	O
on	O
a	O
large	O
Swiss	O
family	O
of	O
whom	O
four	O
family	O
members	O
suffer	O
from	O
BSS	O
.	O

Here	O
,	O
a	O
homozygous	O
missense	O
mutation	O
in	O
position	O
1829	O
(A(R)G)	O
of	O
the	O
GPIX	O
gene	O
constituting	O
a	O
N45S	B-ProteinMutation
substitution	O
is	O
the	O
cause	O
for	O
the	O
bleeding	O
symptoms	O
.	O

A	O
total	O
of	O
38	O
family	O
members	O
within	O
two	O
generations	O
were	O
analyzed	O
regarding	O
the	O
N45S	B-ProteinMutation
mutation	O
by	O
DNA	O
sequencing	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

The	O
laboratory	O
parameters	O
which	O
are	O
characteristically	O
for	O
BSS	O
such	O
as	O
platelet	O
count	O
,	O
platelet	O
volume	O
and	O
the	O
expression	O
of	O
CD42a	O
(GPIX)	O
,	O
CD42b	O
(GPIbalpha)	O
and	O
CD41	O
(GPIIb)	O
were	O
measured	O
for	O
all	O
38	O
individuals	O
.	O

The	O
four	O
homozygous	O
patients	O
showed	O
bleeding	O
symptoms	O
,	O
thrombocytopenia	O
and	O
giant	O
platelets	O
.	O

In	O
these	O
patients	O
,	O
the	O
expression	O
of	O
CD42a	O
(GPIX)	O
,	O
CD42b	O
(GPIbalpha)	O
was	O
diminished	O
.	O

Interestingly	O
,	O
the	O
intensity	O
of	O
the	O
bleeding	O
symptoms	O
of	O
the	O
4	O
homozygous	O
family	O
members	O
seemed	O
to	O
vary	O
although	O
they	O
carry	O
the	O
same	O
mutation	O
.	O

The	O
24	O
heterozygous	O
carriers	O
did	O
not	O
differ	O
significantly	O
from	O
their	O
10	O
wildtype	O
family	O
members	O
regarding	O
bleeding	O
symptoms	O
and	O
laboratory	O
analysis	O
.	O

Identification	O
and	O
molecular	O
characterization	O
of	O
six	O
novel	O
mutations	O
in	O
the	O
UDP-N-acetylglucosamine-1-phosphotransferase	O
gamma	O
subunit	O
(GNPTG)	O
gene	O
in	O
patients	O
with	O
mucolipidosis	O
III	O
gamma	O
.	O

Mucolipidosis	O
type	O
III	O
(MLIII)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
affecting	O
lysosomal	O
hydrolase	O
trafficking	O
.	O

In	O
a	O
study	O
of	O
10	O
patients	O
from	O
seven	O
families	O
with	O
a	O
clinical	O
phenotype	O
and	O
enzymatic	O
diagnosis	O
of	O
MLIII	O
,	O
six	O
novel	O
GNPTG	O
gene	O
mutations	O
were	O
identified	O
.	O

These	O
included	O
missense	O
p.T286M	B-ProteinMutation
and	O
nonsense	O
p.W111X	B-ProteinMutation
mutations	O
and	O
a	O
transition	O
in	O
the	O
obligate	O
AG-dinucleotide	O
of	O
the	O
intron	O
8	O
acceptor	O
splice	O
site	O
c.610-2A>G	B-DNAMutation
.	O

Three	O
microdeletions	O
were	O
also	O
identified	O
,	O
two	O
of	O
which	O
(	O
c.611delG	B-DNAMutation
and	O
c.640_667del28	B-DNAMutation
)	O
were	O
located	O
within	O
the	O
coding	O
region	O
whereas	O
one	O
c.609+28_610-16del	B-DNAMutation
was	O
located	O
entirely	O
within	O
intron	O
8	O
.	O

RT-PCR	O
analysis	O
of	O
the	O
c.610-2A>G	B-DNAMutation
transition	O
demonstrated	O
that	O
the	O
change	O
altered	O
splicing	O
,	O
leading	O
to	O
the	O
production	O
of	O
two	O
distinct	O
aberrantly	O
spliced	O
forms	O
,	O
viz	O
.	O

the	O
skipping	O
of	O
exon	O
9	O
p.G204_K247del	B-ProteinMutation
or	O
the	O
retention	O
of	O
introns	O
8	O
and	O
9	O
p.G204VfsX28	B-ProteinMutation
.	O

RT-PCR	O
analysis	O
,	O
performed	O
on	O
a	O
patient	O
homozygous	O
for	O
the	O
intronic	O
deletion	O
c.609+28_610-16del	B-DNAMutation
,	O
failed	O
to	O
detect	O
any	O
GNPTG	O
RNA	O
transcripts	O
.	O

To	O
determine	O
whether	O
c.609+28_610-16del	B-DNAMutation
allele-derived	O
transcripts	O
were	O
subject	O
to	O
nonsense-mediated	O
mRNA	O
decay	O
(NMD)	O
,	O
patient	O
fibroblasts	O
were	O
incubated	O
with	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O

An	O
RT-PCR	O
fragment	O
retaining	O
43	O
bp	O
of	O
intron	O
8	O
was	O
consistently	O
detected	O
suggesting	O
that	O
the	O
33-bp	O
genomic	O
deletion	O
had	O
elicited	O
NMD	O
.	O

Quantitative	O
real-time	O
PCR	O
and	O
GNPTG	O
western	O
blot	O
analysis	O
confirmed	O
that	O
the	O
homozygous	O
microdeletion	O
p.G204VfsX17	B-ProteinMutation
had	O
elicited	O
NMD	O
resulting	O
in	O
failure	O
to	O
synthesize	O
GNPTG	O
protein	O
.	O

Analysis	O
of	O
the	O
sequences	O
surrounding	O
the	O
microdeletion	O
breakpoints	O
revealed	O
either	O
intrinsic	O
repetitivity	O
of	O
the	O
deleted	O
region	O
or	O
short	O
direct	O
repeats	O
adjacent	O
to	O
the	O
breakpoint	O
junctions	O
.	O

This	O
is	O
consistent	O
with	O
these	O
repeats	O
having	O
mediated	O
the	O
microdeletions	O
via	O
replication	O
slippage	O
and	O
supports	O
the	O
view	O
that	O
the	O
mutational	O
spectrum	O
of	O
the	O
GNPTG	O
gene	O
is	O
strongly	O
influenced	O
by	O
the	O
properties	O
of	O
the	O
local	O
DNA	O
sequence	O
environment	O
.	O

Pure	O
monosomy	O
and	O
pure	O
trisomy	O
of	O
13q21.2-31.1	O
consequent	O
to	O
a	O
familial	O
insertional	O
translocation	O
:	O
exclusion	O
of	O
PCDH9	O
as	O
the	O
responsible	O
gene	O
for	O
autosomal	O
dominant	O
auditory	O
neuropathy	O
(AUNA1)	O
.	O

Insertional	O
translocations	O
(IT)	O
are	O
rare	O
structural	O
rearrangements	O
.	O

Offspring	O
of	O
IT	O
balanced	O
carriers	O
are	O
at	O
high	O
risk	O
to	O
have	O
either	O
pure	O
partial	O
trisomy	O
or	O
monosomy	O
for	O
the	O
inserted	O
segment	O
as	O
manifested	O
by	O
"pure"	O
phenotypes	O
.	O

We	O
describe	O
an	O
IT	O
between	O
chromosomes	O
3	O
and	O
13	O
segregating	O
in	O
a	O
three-generation	O
pedigree	O
.	O

Short	O
tandem	O
repeat	O
(STR)	O
segregation	O
analysis	O
and	O
array-comparative	O
genomic	O
hybridization	O
were	O
used	O
to	O
define	O
the	O
IT	O
as	O
a	O
25.1	O
Mb	O
segment	O
spanning	O
13q21.2-q31.1	O
.	O

The	O
phenotype	O
of	O
pure	O
monosomy	O
included	O
deafness	O
,	O
duodenal	O
stenosis	O
,	O
developmental	O
and	O
growth	O
delay	O
,	O
vertebral	O
anomalies	O
,	O
and	O
facial	O
dysmorphisms	O
;	O
the	O
trisomy	O
was	O
manifested	O
by	O
only	O
minor	O
dysmorphisms	O
.	O

As	O
the	O
AUNA1	O
deafness	O
locus	O
on	O
13q14-21	O
overlaps	O
the	O
IT	O
in	O
the	O
PCDH9	O
(protocadherin-9)	O
gene	O
region	O
,	O
PCDH9	O
was	O
investigated	O
as	O
a	O
candidate	O
gene	O
for	O
deafness	O
in	O
both	O
families	O
.	O

Genotyping	O
of	O
STRs	O
and	O
single	O
nucleotide	O
polymorphisms	O
defined	O
the	O
AUNA1	O
breakpoint	O
as	O
35	O
kb	O
5'	O
to	O
PCDH9	O
,	O
with	O
a	O
2.4	O
Mb	O
area	O
of	O
overlap	O
with	O
the	O
IT	O
.	O

DNA	O
sequencing	O
of	O
coding	O
regions	O
in	O
the	O
AUNA1	O
family	O
and	O
in	O
the	O
retained	O
homologue	O
chromosome	O
in	O
the	O
monosomic	O
patient	O
revealed	O
no	O
mutations	O
.	O

We	O
conclude	O
that	O
AUNA1	O
deafness	O
does	O
not	O
share	O
a	O
common	O
etiology	O
with	O
deafness	O
associated	O
with	O
monosomy	O
13q21.2-q31.3	O
;	O
deafness	O
may	O
result	O
from	O
monosomy	O
of	O
PCHD9	O
or	O
another	O
gene	O
in	O
the	O
IT	O
,	O
as	O
has	O
been	O
demonstrated	O
in	O
contiguous	O
gene	O
deletion	O
syndromes	O
.	O

Precise	O
characterization	O
of	O
the	O
breakpoints	O
of	O
the	O
translocated	O
region	O
is	O
useful	O
to	O
identify	O
which	O
genes	O
may	O
be	O
contributing	O
to	O
the	O
phenotype	O
,	O
either	O
through	O
haploinsufficiency	O
or	O
extra	O
dosage	O
effects	O
,	O
in	O
order	O
to	O
define	O
genotype-phenotype	O
correlations	O
.	O

A	O
simple	O
multiplex	O
real-time	O
PCR	O
methodology	O
for	O
the	O
SMN1	O
gene	O
copy	O
number	O
quantification	O
.	O

Spinal	O
muscular	O
atrophy	O
(SMA)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
caused	O
,	O
in	O
about	O
95%	O
of	O
SMA	O
cases	O
,	O
by	O
homozygous	O
deletion	O
of	O
the	O
survival	O
motor	O
neuron	O
1	O
(SMN1)	O
gene	O
or	O
its	O
conversion	O
to	O
the	O
highly	O
homologous	O
SMN2	O
gene	O
.	O

The	O
molecular	O
diagnosis	O
of	O
SMA	O
is	O
usually	O
carried	O
out	O
by	O
a	O
PCR-Restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
approach	O
.	O

However	O
,	O
this	O
approach	O
is	O
not	O
useful	O
for	O
identification	O
of	O
healthy	O
deletion	O
carriers	O
.	O

TaqMan	O
technology	O
is	O
one	O
of	O
the	O
most	O
reliable	O
and	O
widely	O
adopted	O
techniques	O
for	O
the	O
SMN1	O
copy	O
number	O
evaluation	O
.	O

However	O
,	O
several	O
limitations	O
of	O
this	O
technique	O
have	O
been	O
described	O
.	O

Particularly	O
,	O
DNA	O
extraction	O
methods	O
and	O
accurate	O
template	O
quantification	O
have	O
been	O
shown	O
to	O
be	O
critical	O
for	O
reliable	O
results	O
.	O

In	O
this	O
work	O
,	O
we	O
set	O
up	O
a	O
reliable	O
,	O
highly	O
reproducible	O
,	O
and	O
easy-to-perform	O
TaqMan	O
technology-based	O
protocol	O
to	O
obtain	O
the	O
SMN1	O
gene	O
copy	O
number	O
assessment	O
.	O

We	O
demonstrate	O
that	O
PCR	O
amplification	O
of	O
both	O
target	O
gene	O
and	O
reference	O
gene	O
in	O
the	O
same	O
reaction	O
mix	O
,	O
instead	O
of	O
separated	O
mixes	O
,	O
greatly	O
reduces	O
reported	O
criticisms	O
of	O
simplex	O
TaqMan	O
technology	O
.	O

The	O
multiplex	O
real-time	O
PCR	O
we	O
describe	O
allows	O
interlaboratory	O
samples	O
and	O
data	O
exchange	O
,	O
without	O
the	O
need	O
to	O
equalize	O
the	O
DNA	O
isolation	O
technique	O
.	O

Further	O
,	O
the	O
protocol	O
described	O
below	O
requires	O
fewer	O
replica	O
tests	O
than	O
the	O
simplex	O
methodology	O
does	O
,	O
leading	O
to	O
reduced	O
overall	O
cost	O
for	O
the	O
diagnostic	O
assay	O
.	O

Phosphatidylinositol	O
3-kinase	O
p85alpha	O
regulatory	O
subunit	O
gene	O
Met326Ile	B-ProteinMutation
polymorphism	O
in	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
.	O

BACKGROUND	O
:	O
Insulin	O
resistance	O
is	O
a	O
core	O
feature	O
of	O
polycystic	O
ovary	O
syndrome	O
(PCOS)	O
.	O

Phosphatidylinositol	O
(PI)	O
3-kinase	O
is	O
an	O
important	O
enzyme	O
in	O
the	O
early	O
insulin	O
signaling	O
cascade	O
and	O
plays	O
a	O
key	O
role	O
in	O
insulin-mediated	O
glucose	O
transport	O
.	O

In	O
its	O
regulatory	O
subunit	O
,	O
p85alpha	O
,	O
there	O
is	O
a	O
common	O
amino	O
acid	O
substitution	O
(	O
the	O
Met326Ile	B-ProteinMutation
polymorphism	O
)	O
,	O
and	O
this	O
amino	O
acid	O
may	O
be	O
crucial	O
for	O
the	O
function	O
of	O
the	O
p85alpha	O
regulatory	O
subunit	O
and	O
PI3-kinase	O
.	O

METHODS	O
:	O
Analysis	O
of	O
the	O
Met326Ile	B-ProteinMutation
polymorphism	O
was	O
carried	O
out	O
on	O
DNA	O
samples	O
from	O
256	O
PCOS	O
patients	O
and	O
283	O
controls	O
.	O

Clinical	O
and	O
biochemical	O
profiles	O
of	O
participants	O
were	O
also	O
compared	O
.	O

RESULTS	O
:	O
The	O
genotype	O
distribution	O
of	O
the	O
Met326Ile	B-ProteinMutation
polymorphism	O
in	O
the	O
PCOS	O
group	O
was	O
not	O
different	O
from	O
that	O
of	O
the	O
controls	O
(	O
Met326Met/Met326Ile/Ile326Ile	B-ProteinMutation
rates	O
were	O
73.4%/23.4%/3.2%	O
and	O
70.3%/26.1%/3.6%	O
for	O
the	O
PCOS	O
and	O
control	O
groups	O
,	O
respectively	O
,	O
P	O
=	O
0.72	O
)	O
.	O

The	O
PCOS	O
group	O
was	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
the	O
presence	O
of	O
the	O
variant	O
326Ile	O
allele	O
.	O

Compared	O
with	O
those	O
carrying	O
at	O
least	O
one	O
variant	O
326Ile	O
allele	O
,	O
carriers	O
with	O
the	O
Met326Met	O
genotype	O
had	O
higher	O
serum	O
17-hydroxyprogesterone	O
(17-OHP)	O
{1.1	O
[	O
95%	O
confidence	O
interval	O
(CI)	O
1.1-1.3	O
]	O
ng/ml	O
in	O
those	O
with	O
the	O
Met326Met	O
genotype	O
versus	O
0.8	O
(	O
95%	O
CI	O
0.7-1.0	O
)	O
ng/ml	O
in	O
those	O
with	O
Ile326Ile	O
and	O
Met326Ile	B-ProteinMutation
genotypes	O
,	O
P	O
=	O
0.0073}	O
and	O
free	O
testosterone	O
levels	O
[	O
1.2	O
(	O
95%	O
CI	O
1.1-1.4	O
)	O
pg/ml	O
for	O
Met326Met	O
genotype	O
versus	O
0.9	O
(	O
95%	O
CI	O
0.6-1.3	O
)	O
pg/ml	O
for	O
Ile326Ile	O
and	O
Met326Ile	B-ProteinMutation
genotypes	O
,	O
P	O
=	O
0.038	O
]	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
PI3-kinase	O
gene	O
Met326Ile	B-ProteinMutation
polymorphism	O
may	O
not	O
be	O
a	O
major	O
determinant	O
for	O
the	O
development	O
of	O
PCOS	O
,	O
but	O
it	O
may	O
modulate	O
the	O
concentrations	O
of	O
serum	O
17-OHP	O
or	O
free	O
testosterone	O
in	O
PCOS	O
patients	O
.	O

Identification	O
of	O
newly	O
polymorphic	O
intron	O
40	O
markers	O
of	O
the	O
von	O
Willebrand	O
factor	O
gene	O
in	O
a	O
Japanese	O
population	O
.	O

We	O
investigated	O
a	O
region	O
of	O
repetitive	O
DNA	O
located	O
in	O
intron	O
40	O
of	O
the	O
von	O
Willebrand	O
factor	O
(vWF)	O
gene	O
(	O
nucleotides	O
[nt]	O
1639-2404	O
;	O
i.e.	O
,	O
F8VWF	O
)	O
.	O

We	O
identified	O
13	O
alleles	O
and	O
33	O
genotypes	O
in	O
49	O
unrelated	O
Japanese	O
individuals	O
.	O

The	O
heterozygosity	O
of	O
the	O
region	O
was	O
0.897	O
.	O

Direct	O
sequence	O
analyses	O
revealed	O
five	O
single-base	O
substitutions	O
,	O
one	O
tetranucleotide	O
(TTAT)	O
insertion	O
,	O
and	O
seven	O
short	O
tandem	O
repeats	O
(STRs)	O
in	O
the	O
intron	O
;	O
four	O
of	O
the	O
STRs	O
and	O
one	O
single-base	O
substitution	O
had	O
been	O
reported	O
previously	O
.	O

The	O
four	O
new	O
base	O
substitutions	O
we	O
identified	O
were	O
1849T>A	B-DNAMutation
,	O
2122C>T	B-DNAMutation
,	O
2180C>T	B-DNAMutation
,	O
and	O
2192C>T	B-DNAMutation
.	O

The	O
novel	O
TTAT	O
tetranucleotide	O
was	O
inserted	O
between	O
nt	O
2057	O
and	O
2058	O
.	O

The	O
three	O
newly	O
identified	O
STRs	O
were	O
1978(TATC)(1-2)	B-DNAMutation
,	O
2193(ATCT)(5-13)	B-DNAMutation
,	O
and	O
2234(TGTA)(5-7)	B-DNAMutation
.	O

The	O
five	O
single-base	O
substitutions	O
and	O
the	O
TTAT	O
insertion	O
were	O
identified	O
only	O
with	O
3'	O
downstream	O
of	O
vWA	O
allele	O
14	O
.	O

Neurofibromin	O
1	O
(NF1)	O
defects	O
are	O
common	O
in	O
human	O
ovarian	O
serous	O
carcinomas	O
and	O
co-occur	O
with	O
TP53	O
mutations	O
.	O

Ovarian	O
serous	O
carcinoma	O
(OSC)	O
is	O
the	O
most	O
common	O
and	O
lethal	O
histologic	O
type	O
of	O
ovarian	O
epithelial	O
malignancy	O
.	O

Mutations	O
of	O
TP53	O
and	O
dysfunction	O
of	O
the	O
Brca1	O
and/or	O
Brca2	O
tumor-suppressor	O
proteins	O
have	O
been	O
implicated	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
a	O
large	O
fraction	O
of	O
OSCs	O
,	O
but	O
frequent	O
somatic	O
mutations	O
in	O
other	O
well-established	O
tumor-suppressor	O
genes	O
have	O
not	O
been	O
identified	O
.	O

Using	O
a	O
genome-wide	O
screen	O
of	O
DNA	O
copy	O
number	O
alterations	O
in	O
36	O
primary	O
OSCs	O
,	O
we	O
identified	O
two	O
tumors	O
with	O
apparent	O
homozygous	O
deletions	O
of	O
the	O
NF1	O
gene	O
.	O

Subsequently	O
,	O
18	O
ovarian	O
carcinoma-derived	O
cell	O
lines	O
and	O
41	O
primary	O
OSCs	O
were	O
evaluated	O
for	O
NF1	O
alterations	O
.	O

Markedly	O
reduced	O
or	O
absent	O
expression	O
of	O
Nf1	O
protein	O
was	O
observed	O
in	O
6	O
of	O
the	O
18	O
cell	O
lines	O
,	O
and	O
using	O
the	O
protein	O
truncation	O
test	O
and	O
sequencing	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
,	O
NF1	O
mutations	O
resulting	O
in	O
deletion	O
of	O
exons	O
and/or	O
aberrant	O
splicing	O
of	O
NF1	O
transcripts	O
were	O
detected	O
in	O
5	O
of	O
the	O
6	O
cell	O
lines	O
with	O
loss	O
of	O
NF1	O
expression	O
.	O

Similarly	O
,	O
NF1	O
alterations	O
including	O
homozygous	O
deletions	O
and	O
splicing	O
mutations	O
were	O
identified	O
in	O
9	O
(22%)	O
of	O
41	O
primary	O
OSCs	O
.	O

As	O
expected	O
,	O
tumors	O
and	O
cell	O
lines	O
with	O
NF1	O
defects	O
lacked	O
mutations	O
in	O
KRAS	O
or	O
BRAF	O
but	O
showed	O
Ras	O
pathway	O
activation	O
based	O
on	O
immunohistochemical	O
detection	O
of	O
phosphorylated	O
MAPK	O
(	O
primary	O
tumors	O
)	O
or	O
increased	O
levels	O
of	O
GTP-bound	O
Ras	O
(	O
cell	O
lines	O
)	O
.	O

The	O
TP53	O
tumor-suppressor	O
gene	O
was	O
mutated	O
in	O
all	O
OSCs	O
with	O
documented	O
NF1	O
mutation	O
,	O
suggesting	O
that	O
the	O
pathways	O
regulated	O
by	O
these	O
two	O
tumor-suppressor	O
proteins	O
often	O
cooperate	O
in	O
the	O
development	O
of	O
ovarian	O
carcinomas	O
with	O
serous	O
differentiation	O
.	O

The	O
influence	O
of	O
interstitial	O
collagenase-1	O
genotype	O
polymorphism	O
on	O
colorectal	O
cancer	O
risk	O
in	O
Iranian	O
population	O
.	O

Interstitial	O
collagenase-1	O
degrades	O
a	O
variety	O
of	O
extracellular	O
matrix	O
components	O
.	O

A	O
single	O
guanine	O
insertion	O
polymorphism	O
in	O
the	O
promoter	O
has	O
been	O
found	O
that	O
influences	O
on	O
the	O
transcription	O
and	O
expression	O
level	O
of	O
the	O
gene	O
.	O

It	O
is	O
suggested	O
that	O
this	O
polymorphism	O
may	O
enhance	O
susceptibility	O
to	O
some	O
types	O
of	O
cancer	O
.	O

Therefore	O
,	O
this	O
case-control	O
study	O
evaluated	O
the	O
association	O
of	O
this	O
genotype	O
polymorphism	O
with	O
susceptibility	O
to	O
initiation	O
and	O
invasion	O
of	O
colorectal	O
cancer	O
.	O

For	O
this	O
reason	O
,	O
whole	O
blood	O
samples	O
were	O
obtained	O
from	O
150	O
CRC	O
patients	O
and	O
100	O
control	O
subjects	O
in	O
Tehran	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
and	O
genotyped	O
by	O
PCR-RFLP	O
method	O
.	O

We	O
showed	O
that	O
2G	O
allele	O
and	O
2G/2G	O
genotype	O
had	O
higher	O
frequencies	O
in	O
patients	O
(	O
60%	O
and	O
39%	O
,	O
respectively	O
)	O
than	O
in	O
controls	O
(	O
47%	O
and	O
23%	O
,	O
respectively	O
)	O
.	O

The	O
CRC	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
with	O
metastasis	O
(M+)	O
and	O
without	O
metastasis	O
(M-)	O
groups	O
.	O

The	O
2G	O
allele	O
was	O
more	O
frequent	O
in	O
M+	O
group	O
compared	O
with	O
control	O
group	O
.	O

However	O
,	O
no	O
significantly	O
difference	O
was	O
observed	O
between	O
M-group	O
and	O
control	O
(	O
chi(2	O
)	O
=	O
0.48	O
,	O
P	O
=	O
0.78	O
for	O
2G/2G	O
genotype	O
)	O
.	O

Further	O
stratification	O
analyses	O
showed	O
that	O
only	O
gender	O
(	O
OR	O
=	O
2.58	O
,	O
95%	O
CI	O
=	O
0.89-7.52	O
for	O
women	O
and	O
OR	O
=	O
4.12	O
,	O
95%	O
CI	O
=	O
1.62-10.42	O
for	O
men	O
)	O
and	O
smoking	O
(	O
OR	O
=	O
3.03	O
,	O
95%	O
CI	O
=	O
1.28-7.16	O
for	O
non-smokers	O
and	O
OR	O
=	O
4.09	O
,	O
95%	O
CI	O
=	O
1.18-4.15	O
for	O
smoker	O
)	O
may	O
modify	O
the	O
risk	O
of	O
colorectal	O
invasion	O
related	O
to	O
2G/2G	O
genotype	O
.	O

Furthermore	O
,	O
individual	O
with	O
2G/2G	O
genotype	O
seems	O
to	O
spread	O
metastasis	O
,	O
3	O
years	O
earlier	O
than	O
those	O
who	O
were	O
1G/1G	O
and	O
1G/2G	O
.	O

In	O
conclusion	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
present	O
epidemiological	O
study	O
for	O
the	O
first	O
time	O
indicates	O
the	O
relationship	O
of	O
2G/2G	O
genotype	O
polymorphism	O
with	O
invasion	O
risk	O
of	O
colorectal	O
cancer	O
in	O
subgroups	O
of	O
gender	O
and	O
smoking	O
,	O
especially	O
in	O
smoker	O
men	O
.	O

A	O
case	O
of	O
Bernard-Soulier	O
Syndrome	O
due	O
to	O
a	O
homozygous	O
four	O
bases	O
deletion	O
(TGAG)	O
of	O
GPIbalpha	O
gene	O
:	O
lack	O
of	O
GPIbalpha	O
but	O
absence	O
of	O
bleeding	O
.	O

More	O
than	O
20	O
DNA	O
mutations	O
with	O
different	O
inheritance	O
pattern	O
have	O
been	O
described	O
in	O
patients	O
with	O
Bernard-Soulier	O
Syndrome	O
(BSS)	O
,	O
leading	O
to	O
abnormal	O
or	O
absent	O
synthesis	O
and/or	O
expression	O
of	O
GPIbalpha	O
.	O

Clinical	O
phenotype	O
shows	O
considerable	O
variation	O
between	O
individuals	O
,	O
such	O
as	O
bleeding	O
,	O
platelet	O
count	O
and	O
the	O
percentage	O
of	O
large	O
platelets	O
.	O

We	O
describe	O
in	O
a	O
BSS	O
patient	O
the	O
first	O
case	O
of	O
homozygous	O
four	O
bases	O
deletion	O
(TGAG)	O
in	O
the	O
gpIbalpha	O
gene	O
coding	O
sequence	O
,	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
.	O

In	O
the	O
propositus	O
,	O
blood	O
smears	O
revealed	O
giant	O
platelets	O
(	O
30	O
x	O
10(9)	O
platelets/L	O
)	O
,	O
and	O
platelet	O
agglutination	O
to	O
ristocetin	O
was	O
absent	O
.	O

Propositus'	O
parents	O
are	O
consanguineous	O
.	O

His	O
father	O
and	O
paternal	O
grandmother	O
showed	O
a	O
mild	O
thrombocytopenia	O
(	O
108	O
x	O
10(9)/L	O
and	O
120	O
x	O
10(9)/L	O
platelets	O
respectively	O
)	O
while	O
mothers	O
and	O
sister's	O
referred	O
normal	O
platelet	O
counts	O
.	O

The	O
surface	O
expression	O
of	O
GPIbalpha	O
was	O
practically	O
undetectable	O
by	O
flow-cytometry	O
and	O
western	O
blot	O
in	O
the	O
patient	O
and	O
was	O
reduced	O
in	O
the	O
father	O
.	O

Proband's	O
DNA	O
analysis	O
revealed	O
a	O
homozygous	O
four-base-pair	O
deletion	O
(TGAG)	O
,	O
starting	O
from	O
the	O
last	O
base	O
of	O
the	O
codon	O
for	O
Ser39	O
,	O
leading	O
to	O
a	O
coding	O
frame	O
shift	O
with	O
a	O
new	O
termination	O
codon	O
after	O
11	O
novel	O
amino	O
acids	O
.	O

The	O
same	O
mutation	O
was	O
seen	O
in	O
heterozygosis	O
in	O
both	O
parents	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
GPIbalpha	O
TGAG	O
deletion	O
in	O
homozygous	O
state	O
even	O
if	O
the	O
defect	O
has	O
already	O
been	O
described	O
in	O
a	O
case	O
of	O
compound	O
heterozygosis	O
.	O

Surprisingly	O
,	O
the	O
propositus	O
does	O
not	O
report	O
any	O
spontaneous	O
bleeding	O
tendency	O
.	O

Is	O
the	O
European	O
spatial	O
distribution	O
of	O
the	O
HIV-1-resistant	O
CCR5-Delta32	B-DNAMutation
allele	O
formed	O
by	O
a	O
breakdown	O
of	O
the	O
pathocenosis	O
due	O
to	O
the	O
historical	O
Roman	O
expansion	O
.	O

We	O
studied	O
the	O
possible	O
effects	O
of	O
the	O
expansion	O
of	O
ancient	O
Mediterranean	O
civilizations	O
during	O
the	O
five	O
centuries	O
before	O
and	O
after	O
Christ	O
on	O
the	O
European	O
distribution	O
of	O
the	O
mutant	O
allele	O
for	O
the	O
chemokine	O
receptor	O
gene	O
CCR5	O
which	O
has	O
a	O
32-bp	O
deletion	O
CCR5-Delta32	B-DNAMutation
.	O

There	O
is	O
a	O
strong	O
evidence	O
for	O
the	O
unitary	O
origin	O
of	O
the	O
CCR5-Delta32	B-DNAMutation
mutation	O
,	O
this	O
it	O
is	O
found	O
principally	O
in	O
Europe	O
and	O
Western	O
Asia	O
,	O
with	O
generally	O
a	O
north-south	O
downhill	O
cline	O
frequency	O
.	O

Homozygous	O
carriers	O
of	O
this	O
mutation	O
show	O
a	O
resistance	O
to	O
HIV-1	O
infection	O
and	O
a	O
slower	O
progression	O
towards	O
AIDS	O
.	O

However	O
,	O
HIV	O
has	O
clearly	O
emerged	O
too	O
recently	O
to	O
have	O
been	O
the	O
selective	O
force	O
on	O
CCR5	O
.	O

Our	O
analyses	O
showed	O
strong	O
negative	O
correlations	O
in	O
Europe	O
between	O
the	O
allele	O
frequency	O
and	O
two	O
historical	O
parameters	O
,	O
i.e	O
.	O

the	O
first	O
colonization	O
dates	O
by	O
the	O
great	O
ancient	O
Mediterranean	O
civilizations	O
,	O
and	O
the	O
distances	O
from	O
the	O
Northern	O
frontiers	O
of	O
the	O
Roman	O
Empire	O
in	O
its	O
greatest	O
expansion	O
.	O

Moreover	O
,	O
other	O
studies	O
have	O
shown	O
that	O
the	O
deletion	O
frequencies	O
in	O
both	O
German	O
Bronze	O
Age	O
and	O
Swedish	O
Neolithic	O
populations	O
were	O
similar	O
to	O
those	O
found	O
in	O
the	O
corresponding	O
modern	O
populations	O
,	O
and	O
this	O
deletion	O
has	O
been	O
found	O
in	O
ancient	O
DNA	O
of	O
around	O
7000	O
years	O
ago	O
,	O
suggesting	O
that	O
in	O
the	O
past	O
,	O
the	O
deletion	O
frequency	O
could	O
have	O
been	O
relatively	O
high	O
in	O
European	O
populations	O
.	O

In	O
addition	O
,	O
in	O
West	O
Nile	O
virus	O
pathogenesis	O
,	O
CCR5	O
plays	O
an	O
antimicrobial	O
role	O
showing	O
that	O
host	O
genetic	O
factors	O
are	O
highly	O
pathogen-specific	O
.	O

Our	O
results	O
added	O
to	O
all	O
these	O
previous	O
data	O
suggest	O
that	O
the	O
actual	O
European	O
allele	O
frequency	O
distribution	O
might	O
not	O
be	O
due	O
to	O
genes	O
spreading	O
,	O
but	O
to	O
a	O
negative	O
selection	O
resulting	O
in	O
the	O
spread	O
of	O
pathogens	O
principally	O
during	O
Roman	O
expansion	O
.	O

Indeed	O
,	O
as	O
gene	O
flows	O
from	O
colonizers	O
to	O
European	O
native	O
populations	O
were	O
extremely	O
low	O
,	O
the	O
mutational	O
changes	O
might	O
be	O
associated	O
with	O
vulnerability	O
to	O
imported	O
infections	O
.	O

To	O
date	O
,	O
the	O
nature	O
of	O
the	O
parasites	O
remains	O
unknown	O
;	O
however	O
,	O
zoonoses	O
could	O
be	O
incriminated	O
.	O

Expanding	O
clinical	O
spectrum	O
of	O
non-autoimmune	O
hyperthyroidism	O
due	O
to	O
an	O
activating	O
germline	O
mutation	O
,	O
p.M453T	B-ProteinMutation
,	O
in	O
the	O
thyrotropin	O
receptor	O
gene	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
clinical	O
and	O
genetic	O
features	O
of	O
a	O
Thai	O
family	O
with	O
non-autoimmune	O
hyperthyroidism	O
(NAH)	O
caused	O
by	O
an	O
activating	O
germline	O
mutation	O
in	O
the	O
thyrotropin	O
receptor	O
(TSHR)	O
gene	O
.	O

PATIENTS	O
:	O
Three	O
affected	O
individuals	O
from	O
the	O
same	O
family	O
(	O
a	O
father	O
and	O
his	O
two	O
children	O
)	O
were	O
studied	O
.	O

Clinical	O
and	O
imaging	O
findings	O
were	O
reviewed	O
and	O
compared	O
.	O

GENETIC	O
ANALYSIS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
and	O
mutation	O
analysis	O
of	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
TSHR	O
gene	O
was	O
performed	O
in	O
both	O
children	O
and	O
their	O
parents	O
by	O
direct	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
germline	O
T	O
to	O
C	O
transition	O
in	O
exon	O
10	O
of	O
the	O
TSHR	O
gene	O
c.1358T-->C	B-DNAMutation
resulting	O
in	O
the	O
substitution	O
of	O
methionine	O
(ATG)	O
by	O
threonine	O
(ACG)	O
at	O
codon	O
453	O
p.M453T	B-ProteinMutation
was	O
identified	O
in	O
the	O
father	O
and	O
his	O
two	O
children	O
.	O

They	O
presented	O
with	O
different	O
clinical	O
severity	O
and	O
variable	O
age	O
of	O
onset	O
.	O

In	O
addition	O
to	O
hyperthyroidism	O
,	O
ventriculomegaly	O
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
were	O
consistently	O
found	O
in	O
all	O
affected	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Ventriculomegaly	O
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
might	O
be	O
characteristic	O
features	O
of	O
NAH	O
because	O
of	O
an	O
activating	O
TSHR	O
germline	O
mutation	O
.	O

In	O
addition	O
,	O
the	O
shortening	O
of	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
has	O
never	O
been	O
previously	O
described	O
,	O
expanding	O
the	O
phenotypic	O
spectrum	O
of	O
the	O
disease	O
.	O

Identification	O
of	O
rifampin-resistant	O
genotypes	O
in	O
Mycobacterium	O
tuberculosis	O
by	O
PCR-reverse	O
dot	O
blot	O
hybridization	O
.	O

A	O
PCR-reverse	O
dot	O
blot	O
hybridization	O
(RDBH)	O
assay	O
was	O
developed	O
for	O
rapid	O
identification	O
of	O
rifampin	O
(RFP)-resistant	O
genotypes	O
in	O
Mycobacterium	O
tuberculosis	O
clinical	O
isolates	O
.	O

The	O
assay	O
used	O
the	O
rpoB	O
gene	O
as	O
target	O
and	O
was	O
used	O
to	O
evaluate	O
148	O
clinical	O
isolates	O
(	O
97	O
RFP-resistant	O
isolates	O
and	O
51	O
RFP-susceptible	O
isolates	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
isolates	O
were	O
subjected	O
to	O
DNA	O
sequencing	O
and	O
conventional	O
drug	O
susceptibility	O
test	O
.	O

One	O
hundred	O
and	O
forty	O
one	O
(95.3%)	O
and	O
136	O
(91.9%)	O
of	O
the	O
148	O
strains	O
were	O
correctly	O
identified	O
by	O
DNA	O
sequencing	O
and	O
RDBH	O
assay	O
,	O
respectively	O
.	O

None	O
of	O
the	O
51	O
RFP-susceptible	O
isolates	O
examined	O
had	O
alterations	O
in	O
rpoB	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
DNA	O
sequencing	O
were	O
92.8%	O
and	O
100%	O
,	O
and	O
the	O
positive	O
predictive	O
value	O
(PPV)	O
and	O
negative	O
predictive	O
value	O
(NPV)	O
were	O
100%	O
and	O
87.9%	O
,	O
respectively	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
the	O
RDBH	O
assay	O
were	O
87.6%	O
and	O
100%	O
,	O
and	O
the	O
PPV	O
and	O
NPV	O
were	O
100%	O
and	O
81.0%	O
,	O
respectively	O
.	O

Codons	O
531	O
and	O
526	O
of	O
the	O
rpoB	O
were	O
found	O
to	O
be	O
the	O
most	O
common	O
sites	O
of	O
nucleotide	O
substitutions	O
.	O

Mutations	O
at	O
codons	O
511	O
,	O
513	O
,	O
515	O
,	O
516	O
,	O
517	O
,	O
518	O
,	O
and	O
533	O
were	O
also	O
found	O
.	O

There	O
were	O
two-codon	O
mutations	O
in	O
four	O
isolates	O
.	O

No	O
deletion	O
and	O
insertion	O
was	O
found	O
in	O
the	O
rpoB	O
gene	O
.	O

These	O
results	O
indicate	O
that	O
the	O
RDBH	O
assay	O
is	O
a	O
rapid	O
,	O
simple	O
,	O
and	O
reliable	O
method	O
for	O
routine	O
identification	O
of	O
RFP	O
resistance	O
in	O
M	O
.	O

tuberculosis	O
.	O

Molecular	O
and	O
clinical	O
characterization	O
of	O
a	O
novel	O
SCN5A	O
mutation	O
associated	O
with	O
atrioventricular	O
block	O
and	O
dilated	O
cardiomyopathy	O
.	O

BACKGROUND	O
:	O
Increased	O
susceptibility	O
to	O
dilated	O
cardiomyopathy	O
has	O
been	O
observed	O
in	O
patients	O
carrying	O
mutations	O
in	O
the	O
SCN5A	O
gene	O
,	O
but	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
and	O
characterized	O
,	O
both	O
in	O
vitro	O
and	O
clinically	O
,	O
an	O
SCN5A	O
mutation	O
associated	O
with	O
familial	O
progressive	O
atrioventricular	O
block	O
of	O
adult	O
onset	O
and	O
dilated	O
cardiomyopathy	O
in	O
a	O
Chinese	O
family	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Among	O
32	O
family	O
members	O
,	O
5	O
were	O
initially	O
diagnosed	O
with	O
atrioventricular	O
block	O
after	O
age	O
30	O
;	O
4	O
were	O
studied	O
,	O
3	O
of	O
whom	O
later	O
developed	O
dilated	O
cardiomyopathy	O
.	O

We	O
found	O
a	O
heterozygous	O
single-nucleotide	O
mutation	O
resulting	O
in	O
an	O
amino	O
acid	O
substitution	O
A1180V	B-ProteinMutation
in	O
all	O
studied	O
patients	O
and	O
in	O
6	O
other	O
younger	O
unaffected	O
members	O
but	O
not	O
in	O
200	O
control	O
chromosomes	O
.	O

When	O
expressed	O
with	O
the	O
beta1	O
subunit	O
,	O
the	O
mutated	O
channels	O
exhibited	O
a	O
-4.5-mV	O
shift	O
of	O
inactivation	O
with	O
slower	O
recovery	O
leading	O
to	O
a	O
rate-dependent	O
Na(+)	O
current	O
reduction	O
and	O
a	O
moderate	O
increase	O
in	O
late	O
Na(+)	O
current	O
.	O

Clinical	O
study	O
revealed	O
that	O
although	O
QRS	O
duration	O
decreased	O
with	O
increasing	O
heart	O
rate	O
in	O
noncarrier	O
family	O
members	O
,	O
this	O
change	O
was	O
blunted	O
in	O
unaffected	O
carriers	O
whose	O
ECG	O
and	O
heart	O
function	O
were	O
normal	O
.	O

Resting	O
corrected	O
QT	O
interval	O
of	O
unaffected	O
carriers	O
was	O
significantly	O
longer	O
than	O
that	O
of	O
noncarriers	O
,	O
even	O
though	O
it	O
was	O
still	O
within	O
the	O
normal	O
range	O
.	O

CONCLUSIONS	O
:	O
A1180V	B-ProteinMutation
expresses	O
a	O
mild	O
Na(+)	O
channel	O
phenotype	O
in	O
vitro	O
and	O
a	O
corresponding	O
clinical	O
phenotype	O
in	O
unaffected	O
mutation	O
carriers	O
,	O
implying	O
that	O
A1180V	B-ProteinMutation
caused	O
structural	O
heart	O
disease	O
in	O
affected	O
carriers	O
by	O
disturbing	O
Na(+)	O
influx	O
and	O
,	O
hence	O
,	O
cellular	O
Na(+)	O
homeostasis	O
.	O

The	O
high	O
penetrance	O
of	O
A1180V	B-ProteinMutation
suggests	O
this	O
phenotype	O
as	O
a	O
high	O
risk	O
factor	O
for	O
dilated	O
cardiomyopathy	O
with	O
preceding	O
atrioventricular	O
block	O
.	O

Anticipation	O
in	O
familial	O
lattice	O
corneal	O
dystrophy	O
type	O
I	O
with	O
R124C	B-ProteinMutation
mutation	O
in	O
the	O
TGFBI	O
(BIGH3)	O
gene	O
.	O

PURPOSE	O
:	O
To	O
report	O
the	O
clinical	O
,	O
ophthalmic	O
,	O
and	O
genetic	O
characteristics	O
for	O
lattice	O
corneal	O
dystrophy	O
type	O
I	O
(LCDI)	O
in	O
a	O
Chilean	O
family	O
.	O

METHODS	O
:	O
Six	O
affected	O
family	O
members	O
were	O
examined	O
clinically	O
including	O
visual	O
acuity	O
,	O
color	O
cornea	O
photography	O
,	O
applanation	O
tonography	O
,	O
and	O
fundoscopy	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
from	O
six	O
affected	O
and	O
three	O
unaffected	O
members	O
of	O
a	O
family	O
with	O
lattice	O
corneal	O
dystrophy	O
type	O
I	O
.	O

Exon	O
4	O
of	O
the	O
transforming	O
growth	O
factor-induced	O
gene	O
(TGFBI)	O
was	O
screened	O
for	O
the	O
most	O
frequent	O
mutation	O
,	O
R124C	B-ProteinMutation
,	O
in	O
the	O
proband	O
by	O
sequencing	O
.	O

We	O
also	O
designed	O
a	O
rapid	O
polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
(PCR-RFLP)	O
method	O
to	O
analyze	O
the	O
same	O
mutation	O
,	O
amplifying	O
exon	O
4	O
and	O
digesting	O
with	O
PstI	O
restriction	O
enzyme	O
.	O

Using	O
this	O
strategy	O
,	O
we	O
analyzed	O
the	O
mutation	O
in	O
six	O
affected	O
and	O
three	O
healthy	O
family	O
members	O
.	O

RESULTS	O
:	O
Three	O
generations	O
of	O
family	O
members	O
were	O
positively	O
diagnosed	O
with	O
lattice	O
corneal	O
dystrophy	O
.	O

Six	O
participants	O
demonstrated	O
LCD1	O
in	O
both	O
eyes	O
,	O
most	O
of	O
whom	O
were	O
symmetric	O
.	O

Age	O
at	O
onset	O
of	O
symptoms	O
was	O
variable	O
(	O
3-42	O
years	O
old	O
)	O
.	O

Moreover	O
,	O
in	O
this	O
family	O
,	O
the	O
age	O
of	O
onset	O
of	O
the	O
disease	O
decreased	O
in	O
succeeding	O
generations	O
,	O
which	O
could	O
be	O
interpreted	O
as	O
anticipation	O
.	O

Visual	O
acuity	O
varied	O
from	O
1.0	O
to	O
0.13	O
.	O

Two	O
patients	O
,	O
ages	O
69	O
and	O
44	O
years	O
old	O
,	O
demonstrated	O
a	O
degree	O
of	O
severity	O
"Bad"	O
according	O
to	O
best-corrected	O
vision	O
and	O
corneal	O
commitment	O
.	O

The	O
exon	O
4	O
sequence	O
of	O
TGFBI	O
of	O
the	O
proband	O
exhibits	O
the	O
heterozygous	O
single-nucleotide	O
mutation	O
,	O
C417T	B-DNAMutation
,	O
leading	O
to	O
amino	O
acid	O
substitution	O
R124C	B-ProteinMutation
in	O
the	O
encoded	O
TGF-induced	O
protein	O
.	O

Using	O
PCR-RFLP	O
,	O
we	O
confirmed	O
the	O
heterozygous	O
mutation	O
in	O
six	O
affected	O
family	O
members	O
and	O
excluded	O
it	O
in	O
three	O
healthy	O
members	O
.	O

CONCLUSIONS	O
:	O
The	O
R124C	B-ProteinMutation
mutation	O
in	O
TGFBI	O
cosegregated	O
with	O
LCD	O
type	O
I	O
in	O
the	O
investigated	O
family	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
molecular	O
analysis	O
of	O
LCD	O
type	O
I	O
in	O
Chilean	O
patients	O
.	O

The	O
early	O
onset	O
affected	O
persons	O
in	O
the	O
fourth	O
generation	O
raises	O
the	O
possibility	O
of	O
anticipation	O
.	O

Genetic	O
polymorphisms	O
in	O
the	O
carbonyl	O
reductase	O
3	O
gene	O
CBR3	O
and	O
the	O
NAD(P)H:quinone	O
oxidoreductase	O
1	O
gene	O
NQO1	O
in	O
patients	O
who	O
developed	O
anthracycline-related	O
congestive	O
heart	O
failure	O
after	O
childhood	O
cancer	O
.	O

BACKGROUND	O
:	O
Exposure	O
to	O
anthracyclines	O
as	O
part	O
of	O
cancer	O
therapy	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
congestive	O
heart	O
failure	O
(CHF)	O
.	O

The	O
potential	O
role	O
of	O
genetic	O
risk	O
factors	O
in	O
anthracycline-related	O
CHF	O
remains	O
to	O
be	O
defined	O
.	O

Thus	O
,	O
in	O
this	O
study	O
,	O
the	O
authors	O
examined	O
whether	O
common	O
polymorphisms	O
in	O
candidate	O
genes	O
involved	O
in	O
the	O
pharmacodynamics	O
of	O
anthracyclines	O
(	O
in	O
particular	O
,	O
the	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate:quinone	O
oxidoreductase	O
1	O
gene	O
NQO1	O
and	O
the	O
carbonyl	O
reductase	O
3	O
gene	O
CBR3	O
)	O
had	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline-related	O
CHF	O
.	O

METHODS	O
:	O
A	O
nested	O
case-control	O
study	O
was	O
conducted	O
within	O
a	O
cohort	O
of	O
1979	O
patients	O
enrolled	O
in	O
the	O
Childhood	O
Cancer	O
Survivor	O
Study	O
who	O
received	O
treatment	O
with	O
anthracyclines	O
and	O
had	O
available	O
DNA	O
.	O

Thirty	O
patients	O
with	O
CHF	O
(cases)	O
and	O
115	O
matched	O
controls	O
were	O
genotyped	O
for	O
polymorphisms	O
in	O
NQO1	O
(NQO1*2)	O
and	O
CBR3	O
(	O
the	O
CBR3	O
valine	O
[V]	O
to	O
methionine	O
[M]	O
substitution	O
at	O
position	O
244	O
[	O
V244M	B-ProteinMutation
]	O
)	O
.	O

Enzyme	O
activity	O
assays	O
with	O
recombinant	O
CBR3	O
isoforms	O
(	O
CBR3	O
V244	O
and	O
CBR3	O
M244	O
)	O
and	O
the	O
anthracycline	O
substrate	O
doxorubicin	O
were	O
used	O
to	O
investigate	O
the	O
functional	O
impact	O
of	O
the	O
CBR3	O
V244M	B-ProteinMutation
polymorphism	O
.	O

RESULTS	O
:	O
Multivariate	O
analyses	O
adjusted	O
for	O
sex	O
and	O
primary	O
disease	O
recurrence	O
were	O
used	O
to	O
test	O
for	O
associations	O
between	O
the	O
candidate	O
genetic	O
polymorphisms	O
(	O
NQO1*2	O
and	O
CBR3	O
V244M	B-ProteinMutation
)	O
and	O
the	O
risk	O
of	O
CHF	O
.	O

Analyses	O
indicated	O
no	O
association	O
between	O
the	O
NQO1*2	O
polymorphism	O
and	O
the	O
risk	O
of	O
anthracycline-related	O
CHF	O
(	O
odds	O
ratio	O
[OR]	O
,	O
1.04	O
;	O
P=.97	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
the	O
CBR3	O
V244M	B-ProteinMutation
polymorphism	O
and	O
the	O
risk	O
of	O
CHF	O
(	O
OR	O
,	O
8.16	O
;	O
P=.056	O
for	O
G/G	O
vs	O
A/A	O
;	O
OR	O
,	O
5.44	O
;	O
P=.092	O
for	O
G/A	O
vs	O
A/A	O
)	O
.	O

In	O
line	O
,	O
recombinant	O
CBR3	O
V244	O
(	O
G	O
allele	O
)	O
synthesized	O
2.6-fold	O
more	O
cardiotoxic	O
doxorubicinol	O
per	O
unit	O
of	O
time	O
than	O
CBR3	O
M244	O
(	O
A	O
allele	O
;	O
CBR3	O
V244	O
[	O
8.26+/-3.57	O
nmol/hour.mg	O
]	O
vs	O
CBR3	O
M244	O
[	O
3.22+/-0.67	O
nmol/hour.mg	O
]	O
;	O
P=.01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
functional	O
CBR3	O
V244M	B-ProteinMutation
polymorphism	O
may	O
have	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline-related	O
CHF	O
among	O
childhood	O
cancer	O
survivors	O
by	O
modulating	O
the	O
intracardiac	O
formation	O
of	O
cardiotoxic	O
anthracycline	O
alcohol	O
metabolites	O
.	O

Larger	O
confirmatory	O
case-control	O
studies	O
are	O
warranted	O
.	O

Association	O
between	O
promoter	O
-1607	O
polymorphism	O
of	O
MMP1	O
and	O
lumbar	O
disc	O
disease	O
in	O
Southern	O
Chinese	O
.	O

BACKGROUND	O
:	O
Matrix	O
metalloproteinases	O
(MMPs)	O
are	O
involved	O
in	O
the	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
of	O
the	O
intervertebral	O
disc	O
.	O

A	O
SNP	O
for	O
guanine	O
insertion/deletion	O
G/D	B-DNAMutation
,	O
the	O
-1607	O
promoter	O
polymorphism	O
,	O
of	O
the	O
MMP1	O
gene	O
was	O
found	O
significantly	O
affecting	O
promoter	O
activity	O
and	O
corresponding	O
transcription	O
level	O
.	O

Hence	O
it	O
is	O
a	O
good	O
candidate	O
for	O
genetic	O
studies	O
in	O
DDD	O
.	O

METHODS	O
:	O
Southern	O
Chinese	O
volunteers	O
between	O
18	O
and	O
55	O
years	O
were	O
recruited	O
from	O
the	O
population	O
.	O

DDD	O
in	O
the	O
lumbar	O
spine	O
was	O
defined	O
by	O
MRI	O
using	O
Schneiderman's	O
classification	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
leukocytes	O
and	O
genotyping	O
was	O
performed	O
using	O
the	O
Sequenom	O
platform	O
.	O

Association	O
and	O
Hardy-Weinberg	O
equilibrium	O
checking	O
were	O
assessed	O
by	O
Chi-square	O
test	O
and	O
Mann-Whitney	O
U	O
test	O
.	O

RESULTS	O
:	O
Our	O
results	O
showed	O
substantial	O
evidence	O
of	O
association	O
between	O
-1607	O
promoter	O
polymorphism	O
of	O
MMP1	O
and	O
DDD	O
in	O
the	O
Southern	O
Chinese	O
subjects	O
.	O

D	O
allelic	O
was	O
significantly	O
associated	O
with	O
DDD	O
(	O
p	O
value	O
=	O
0.027	O
,	O
odds	O
ratio	O
=	O
1.41	O
with	O
95%	O
CI	O
=	O
1.04-1.90	O
)	O
while	O
Genotypic	O
association	O
on	O
the	O
presence	O
of	O
D	O
allele	O
was	O
also	O
significantly	O
associated	O
with	O
DDD	O
(	O
p	O
value	O
=	O
0.046	O
,	O
odds	O
ratio	O
=	O
1.50	O
with	O
95%	O
CI	O
=	O
1.01-2.24	O
)	O
.	O

Further	O
age	O
stratification	O
showed	O
significant	O
genotypic	O
as	O
well	O
as	O
allelic	O
association	O
in	O
the	O
group	O
of	O
over	O
40	O
years	O
(	O
genotypic	O
:	O
p	O
value	O
=	O
0.035	O
,	O
odds	O
ratio	O
=	O
1.617	O
with	O
95%	O
CI	O
=	O
1.033-2.529	O
;	O
allelic	O
:	O
p	O
value	O
=	O
0.033	O
,	O
odds	O
ratio	O
=	O
1.445	O
with	O
95%	O
CI	O
=	O
1.029-2.029	O
)	O
.	O

Disc	O
bulge	O
,	O
annular	O
tears	O
and	O
the	O
Schmorl's	O
nodes	O
were	O
not	O
associated	O
with	O
the	O
D	O
allele	O
.	O

CONCLUSION	O
:	O
We	O
demonstrated	O
that	O
individuals	O
with	O
the	O
presence	O
of	O
D	O
allele	O
for	O
the	O
-1607	O
promoter	O
polymorphism	O
of	O
MMP1	O
are	O
about	O
1.5	O
times	O
more	O
susceptible	O
to	O
develop	O
DDD	O
when	O
compared	O
with	O
those	O
having	O
G	O
allele	O
only	O
.	O

Further	O
association	O
was	O
identified	O
in	O
individuals	O
over	O
40	O
years	O
of	O
age	O
.	O

Disc	O
bulge	O
,	O
annular	O
tear	O
as	O
well	O
as	O
Schmorl's	O
nodes	O
were	O
not	O
associated	O
with	O
this	O
polymorphism	O
.	O

Association	O
between	O
gynecomastia	O
and	O
aromatase	O
(CYP19)	O
polymorphisms	O
.	O

OBJECTIVE	O
:	O
Aromatase	O
cytochrome	O
P45019	O
(CYP19)	O
is	O
a	O
key	O
enzyme	O
in	O
estrogen	O
biosynthesis	O
,	O
and	O
polymorphisms	O
within	O
its	O
gene	O
are	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
estrogen-dependent	O
diseases	O
.	O

Enhanced	O
estrogen	O
stimulation	O
of	O
breast	O
tissue	O
in	O
men	O
may	O
lead	O
to	O
gynecomastia	O
.	O

We	O
assessed	O
whether	O
intron	O
4	O
(TTTA)n	O
repeat	O
and	O
TCT	O
deletion/insertion	O
polymorphisms	O
and	O
an	O
exon	O
10	O
(3'-UTR)	O
C/T	B-DNAMutation
single	O
nucleotide	O
polymorphism	O
of	O
CYP19	O
are	O
associated	O
with	O
gynecomastia	O
.	O

DESIGN/METHODS	O
:	O
We	O
performed	O
a	O
genetic	O
association	O
study	O
of	O
100	O
patients	O
referred	O
to	O
the	O
endocrinological	O
outpatient	O
clinic	O
with	O
breast	O
glandular	O
tissue	O
enlargement	O
confirmed	O
by	O
clinical	O
and	O
ultrasound	O
examinations	O
and	O
99	O
healthy	O
volunteers	O
without	O
gynecomastia	O
.	O

Microsatellite	O
(TTTA)n	O
and	O
insertion/deletion	O
polymorphisms	O
were	O
studied	O
using	O
capillary	O
electrophoresis	O
,	O
and	O
the	O
C/T	B-DNAMutation
polymorphism	O
in	O
the	O
3'-UTR	O
was	O
analyzed	O
using	O
the	O
TaqMan	O
assay	O
.	O

RESULTS	O
:	O
Significantly	O
increased	O
risk	O
of	O
gynecomastia	O
was	O
found	O
in	O
subjects	O
carrying	O
a	O
CYP19	O
exon	O
10	O
T	O
allele	O
that	O
was	O
previously	O
related	O
to	O
the	O
high	O
aromatase	O
activity	O
.	O

Frequency	O
of	O
the	O
TT	O
genotype	O
was	O
significantly	O
higher	O
in	O
patients	O
when	O
compared	O
with	O
controls	O
(	O
40.6	O
vs	O
26.3%	O
;	O
TT	O
versus	O
CT	O
and	O
CC	O
genotypes	O
;	O
P(c)<0.05	O
)	O
.	O

We	O
found	O
strong	O
linkage	O
disequilibrium	O
between	O
the	O
alleles	O
of	O
studied	O
polymorphic	O
loci	O
.	O

T	O
allele	O
in	O
the	O
3'-UTR	O
was	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
long	O
alleles	O
of	O
the	O
intron	O
4	O
polymorphism	O
,	O
mainly	O
(TTTA)11	O
.	O

However	O
,	O
our	O
findings	O
did	O
not	O
show	O
significant	O
correlation	O
of	O
alleles	O
having	O
more	O
than	O
nine	O
TTTA	O
repeats	O
with	O
gynecomastia	O
.	O

CONCLUSIONS	O
:	O
The	O
CYP19	O
polymorphisms	O
might	O
contribute	O
to	O
the	O
incidence	O
of	O
gynecomastia	O
,	O
but	O
further	O
studies	O
in	O
larger	O
groups	O
are	O
needed	O
to	O
confirm	O
these	O
results	O
.	O

Aryl	O
hydrocarbon	O
receptor	O
interacting	O
protein	O
(AIP)	O
gene	O
mutation	O
analysis	O
in	O
children	O
and	O
adolescents	O
with	O
sporadic	O
pituitary	O
adenomas	O
.	O

OBJECTIVE	O
:	O
Pituitary	O
adenomas	O
occur	O
rarely	O
in	O
childhood	O
and	O
adolescence	O
.	O

Pituitary	O
adenoma	O
predisposition	O
(PAP)	O
has	O
been	O
recently	O
associated	O
with	O
germline	O
mutations	O
in	O
the	O
aryl	O
hydrocarbon	O
receptor	O
interacting	O
protein	O
(AIP)	O
gene	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
proportion	O
of	O
germline	O
AIP	O
mutations	O
in	O
apparently	O
sporadic	O
paediatric	O
pituitary	O
adenomas	O
.	O

DESIGN	O
:	O
Genomic	O
DNA	O
was	O
analysed	O
for	O
mutations	O
in	O
the	O
AIP	O
gene	O
,	O
by	O
PCR	O
amplification	O
and	O
direct	O
sequencing	O
.	O

PATIENTS	O
:	O
A	O
population-based	O
cohort	O
consisting	O
of	O
36	O
apparently	O
sporadic	O
paediatric	O
pituitary	O
adenoma	O
patients	O
,	O
referred	O
to	O
two	O
medical	O
centres	O
in	O
Italy	O
,	O
was	O
included	O
in	O
the	O
study	O
.	O

Patients	O
were	O
either	O
less	O
than	O
18	O
years	O
at	O
diagnosis	O
,	O
or	O
showed	O
clinical	O
evidence	O
of	O
adenoma	O
development	O
before	O
the	O
age	O
of	O
18	O
years	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
in-frame	O
deletion	O
Y248del	B-ProteinMutation
c.742_744delTAC	B-DNAMutation
was	O
identified	O
in	O
one	O
GH-secreting	O
adenoma	O
patient	O
.	O

Loss	O
of	O
heterozygosity	O
(LOH)	O
analysis	O
of	O
tumour	O
DNA	O
revealed	O
the	O
loss	O
of	O
the	O
wild-type	O
allele	O
.	O

First	O
degree	O
relatives	O
carrying	O
the	O
mutation	O
were	O
clinically	O
unaffected	O
.	O

CONCLUSIONS	O
:	O
While	O
mutations	O
were	O
absent	O
in	O
non-GH-secreting	O
adenoma	O
patients	O
,	O
germline	O
AIP	O
mutations	O
can	O
be	O
found	O
in	O
children	O
and	O
adolescents	O
with	O
GH-secreting	O
tumours	O
,	O
even	O
in	O
the	O
absence	O
of	O
family	O
history	O
.	O

The	O
present	O
study	O
reports	O
the	O
AIP	O
mutation	O
analysis	O
results	O
on	O
patients	O
of	O
a	O
single	O
ethnic	O
origin	O
.	O

Clearly	O
,	O
further	O
studies	O
are	O
needed	O
to	O
improve	O
our	O
knowledge	O
on	O
the	O
role	O
of	O
AIP	O
in	O
paediatric	O
pituitary	O
adenomas	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
IRF5	O
promoter	O
region	O
is	O
associated	O
with	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
in	O
the	O
Japanese	O
population	O
.	O

OBJECTIVES	O
:	O
Interferon	O
regulatory	O
factor	O
5	O
(IRF5)	O
is	O
a	O
member	O
of	O
the	O
IRF	O
family	O
of	O
transcription	O
factors	O
,	O
which	O
regulate	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
.	O

Polymorphisms	O
in	O
the	O
IRF5	O
gene	O
have	O
been	O
associated	O
with	O
susceptibility	O
to	O
systemic	O
lupus	O
erythaematosus	O
(SLE)	O
in	O
Caucasian	O
and	O
Asian	O
populations	O
,	O
but	O
their	O
involvement	O
in	O
other	O
autoimmune	O
diseases	O
is	O
still	O
uncertain	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
genetic	O
role	O
of	O
IRF5	O
in	O
susceptibility	O
to	O
rheumatoid	O
arthritis	O
(RA)	O
in	O
Japanese	O
subjects	O
.	O

METHODS	O
:	O
We	O
selected	O
13	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
and	O
a	O
CGGGG	O
insertion-deletion	O
polymorphism	O
in	O
the	O
IRF5	O
gene	O
.	O

We	O
performed	O
2	O
sets	O
of	O
case-control	O
comparisons	O
using	O
Japanese	O
subjects	O
(	O
first	O
set	O
:	O
830	O
patients	O
with	O
RA	O
and	O
658	O
controls	O
;	O
second	O
set	O
:	O
1112	O
patients	O
with	O
RA	O
and	O
940	O
controls	O
)	O
,	O
and	O
then	O
performed	O
a	O
stratified	O
analysis	O
using	O
human	O
leukocyte	O
antigen	O
(HLA)-DRB1	O
shared	O
epitope	O
(SE)	O
status	O
.	O

We	O
genotyped	O
the	O
SNPs	O
using	O
TaqMan	O
assays	O
.	O

RESULTS	O
:	O
A	O
significant	O
association	O
of	O
the	O
rs729302	B-SNP
A	O
allele	O
with	O
RA	O
susceptibility	O
was	O
found	O
in	O
both	O
sets	O
(	O
odds	O
ratio	O
(OR)	O
1.22	O
,	O
95%	O
CI	O
1.09	O
to	O
1.35	O
,	O
p<0.001	O
in	O
the	O
combined	O
analysis	O
)	O
.	O

When	O
the	O
patients	O
were	O
stratified	O
by	O
the	O
SE	O
,	O
the	O
rs729302	B-SNP
A	O
allele	O
was	O
found	O
to	O
confer	O
increased	O
risk	O
to	O
RA	O
in	O
patients	O
that	O
were	O
SE	O
negative	O
(	O
OR	O
1.50	O
,	O
95%	O
CI	O
1.17	O
to	O
1.92	O
,	O
p	O
=	O
0.001	O
)	O
as	O
compared	O
with	O
patients	O
carrying	O
the	O
SE	O
(	O
OR	O
1.11	O
,	O
95%	O
CI	O
0.93	O
to	O
1.33	O
,	O
p	O
=	O
0.24	O
)	O
.	O

In	O
both	O
sets	O
,	O
no	O
genotyped	O
polymorphisms	O
were	O
significantly	O
associated	O
with	O
RA	O
susceptibility	O
,	O
but	O
rs729302	B-SNP
was	O
significantly	O
associated	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
the	O
promoter	O
polymorphism	O
of	O
IRF5	O
is	O
a	O
genetic	O
factor	O
conferring	O
predisposition	O
to	O
RA	O
,	O
and	O
that	O
it	O
contributes	O
considerably	O
to	O
disease	O
pathogenesis	O
in	O
patients	O
that	O
were	O
SE	O
negative	O
.	O

Functional	O
inactivation	O
of	O
the	O
WTX	O
gene	O
is	O
not	O
a	O
frequent	O
event	O
in	O
Wilms'	O
tumors	O
.	O

For	O
many	O
years	O
the	O
precise	O
genetic	O
etiology	O
of	O
the	O
majority	O
of	O
Wilms'	O
tumors	O
has	O
remained	O
unexplained	O
.	O

Recently	O
,	O
the	O
WTX	O
gene	O
,	O
mapped	O
to	O
chromosome	O
Xq11.1	O
,	O
has	O
been	O
reported	O
to	O
be	O
lost	O
or	O
mutated	O
in	O
approximately	O
one-third	O
of	O
Wilms'	O
tumors	O
.	O

Moreover	O
,	O
in	O
female	O
cases	O
,	O
the	O
somatically	O
inactivated	O
alleles	O
were	O
found	O
to	O
invariantly	O
derive	O
from	O
the	O
active	O
chromosome	O
X	O
.	O

Consequently	O
,	O
WTX	O
has	O
been	O
proposed	O
as	O
a	O
'one-hit'	O
tumor	O
suppressor	O
gene	O
.	O

To	O
provide	O
further	O
insights	O
on	O
the	O
contribution	O
of	O
WTX	O
to	O
the	O
development	O
of	O
the	O
disease	O
,	O
we	O
have	O
examined	O
102	O
Wilms'	O
tumors	O
,	O
obtained	O
from	O
43	O
male	O
and	O
57	O
female	O
patients	O
.	O

Quantitative	O
PCR	O
analyses	O
detected	O
WTX	O
deletions	O
in	O
5	O
of	O
45	O
(11%)	O
tumors	O
from	O
males	O
,	O
whereas	O
loss	O
of	O
heterozygosity	O
at	O
WTX-linked	O
microsatellites	O
was	O
observed	O
in	O
9	O
tumors	O
from	O
50	O
informative	O
females	O
(19%)	O
.	O

However	O
,	O
in	O
the	O
latter	O
group	O
,	O
using	O
a	O
combination	O
of	O
HUMARA	O
assay	O
and	O
bisulfite-modified	O
DNA	O
sequencing	O
,	O
we	O
found	O
that	O
the	O
deletion	O
affected	O
the	O
active	O
chromosome	O
X	O
only	O
in	O
two	O
cases	O
(4%)	O
.	O

Sequence	O
analyses	O
detected	O
an	O
inactivating	O
somatic	O
mutation	O
of	O
WTX	O
in	O
a	O
single	O
tumor	O
,	O
in	O
which	O
a	O
strongly	O
reduced	O
expression	O
of	O
the	O
mutant	O
allele	O
respect	O
to	O
the	O
wild-type	O
allele	O
was	O
observed	O
,	O
a	O
finding	O
not	O
consistent	O
with	O
its	O
localization	O
on	O
the	O
active	O
chromosome	O
X	O
.	O

Overall	O
,	O
a	O
functional	O
somatic	O
nullizygosity	O
of	O
the	O
WTX	O
gene	O
was	O
ascertained	O
only	O
in	O
seven	O
of	O
the	O
Wilms'	O
tumors	O
included	O
in	O
the	O
study	O
(	O
approximately	O
7%	O
)	O
.	O

Our	O
findings	O
indicate	O
that	O
previously	O
reported	O
estimates	O
on	O
the	O
proportion	O
of	O
Wilms'	O
tumors	O
due	O
to	O
WTX	O
alterations	O
should	O
be	O
reconsidered	O
.	O

Identification	O
of	O
novel	O
mutations	O
and	O
sequence	O
variants	O
in	O
the	O
SOX2	O
and	O
CHX10	O
genes	O
in	O
patients	O
with	O
anophthalmia/microphthalmia	O
.	O

PURPOSE	O
:	O
Mutations	O
in	O
the	O
SOX2	O
and	O
CHX10	O
genes	O
have	O
been	O
reported	O
in	O
patients	O
with	O
anophthalmia	O
and/or	O
microphthalmia	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
34	O
anophthalmic/microphthalmic	O
patient	O
DNA	O
samples	O
(	O
two	O
sets	O
of	O
siblings	O
included	O
)	O
for	O
mutations	O
and	O
sequence	O
variants	O
in	O
SOX2	O
and	O
CHX10	O
.	O

METHODS	O
:	O
Conformational	O
sensitive	O
gel	O
electrophoresis	O
(CSGE)	O
was	O
used	O
for	O
the	O
initial	O
SOX2	O
and	O
CHX10	O
screening	O
of	O
34	O
affected	O
individuals	O
(	O
two	O
sets	O
of	O
siblings	O
)	O
,	O
five	O
unaffected	O
family	O
members	O
,	O
and	O
80	O
healthy	O
controls	O
.	O

Patient	O
samples	O
containing	O
heteroduplexes	O
were	O
selected	O
for	O
sequence	O
analysis	O
.	O

Base	O
pair	O
changes	O
in	O
SOX2	O
and	O
CHX10	O
were	O
confirmed	O
by	O
sequencing	O
bidirectionally	O
in	O
patient	O
samples	O
.	O

RESULTS	O
:	O
Two	O
novel	O
heterozygous	O
mutations	O
and	O
two	O
sequence	O
variants	O
(	O
one	O
known	O
)	O
in	O
SOX2	O
were	O
identified	O
in	O
this	O
cohort	O
.	O

Mutation	O
c.310	B-DNAMutation
G>T	I-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
Glu104X	I-ProteinMutation
)	O
,	O
found	O
in	O
one	O
patient	O
,	O
was	O
in	O
the	O
region	O
encoding	O
the	O
high	O
mobility	O
group	O
(HMG)	O
DNA-binding	O
domain	O
and	O
resulted	O
in	O
a	O
change	O
from	O
glutamic	O
acid	O
to	O
a	O
stop	O
codon	O
.	O

The	O
second	O
mutation	O
,	O
noted	O
in	O
two	O
affected	O
siblings	O
,	O
was	O
a	O
single	O
nucleotide	O
deletion	O
c.549delC	B-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
Pro184ArgfsX19	I-ProteinMutation
)	O
in	O
the	O
region	O
encoding	O
the	O
activation	O
domain	O
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
the	O
coding	O
sequence	O
.	O

The	O
shortened	O
protein	O
products	O
may	O
result	O
in	O
the	O
loss	O
of	O
function	O
.	O

In	O
addition	O
,	O
a	O
novel	O
nucleotide	O
substitution	O
c.*557G>A	B-DNAMutation
was	O
identified	O
in	O
the	O
3'-untranslated	O
region	O
in	O
one	O
patient	O
.	O

The	O
relationship	O
between	O
the	O
nucleotide	O
change	O
and	O
the	O
protein	O
function	O
is	O
indeterminate	O
.	O

A	O
known	O
single	O
nucleotide	O
polymorphism	O
(	O
c	B-DNAMutation
.	I-DNAMutation
*469	I-DNAMutation
C>A	I-DNAMutation
,	O
SNP	O
rs11915160	B-SNP
)	O
was	O
also	O
detected	O
in	O
2	O
of	O
the	O
34	O
patients	O
.	O

Screening	O
of	O
CHX10	O
identified	O
two	O
synonymous	O
sequence	O
variants	O
,	O
c.471	B-DNAMutation
C>T	I-DNAMutation
(	O
p.Ser157Ser	B-ProteinMutation
,	O
rs35435463	B-SNP
)	O
and	O
c.579	B-DNAMutation
G>A	I-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
Gln193Gln	I-ProteinMutation
,	O
novel	O
SNP	O
)	O
,	O
and	O
one	O
non-synonymous	O
sequence	O
variant	O
,	O
c.871	B-DNAMutation
G>A	I-DNAMutation
(	O
p	B-ProteinMutation
.	I-ProteinMutation
Asp291Asn	I-ProteinMutation
,	O
novel	O
SNP	O
)	O
.	O

The	O
non-synonymous	O
polymorphism	O
was	O
also	O
present	O
in	O
healthy	O
controls	O
,	O
suggesting	O
non-causality	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
support	O
the	O
role	O
of	O
SOX2	O
in	O
ocular	O
development	O
.	O

Loss	O
of	O
SOX2	O
function	O
results	O
in	O
severe	O
eye	O
malformation	O
.	O

CHX10	O
was	O
not	O
implicated	O
with	O
microphthalmia/anophthalmia	O
in	O
our	O
patient	O
cohort	O
.	O

Co-inheritance	O
of	O
a	O
PKD1	O
mutation	O
and	O
homozygous	O
PKD2	O
variant	O
:	O
a	O
potential	O
modifier	O
in	O
autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
.	O

BACKGROUND	O
:	O
Autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
(ADPKD)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
polycystins	O
1	O
(PC1)	O
and	O
2	O
(PC2)	O
,	O
is	O
one	O
of	O
the	O
most	O
commonly	O
inherited	O
renal	O
diseases	O
,	O
affecting	O
~1	O
:	O
1000	O
Caucasians	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
screened	O
Greek	O
ADPKD	O
patients	O
with	O
the	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE)	O
assay	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
patient	O
homozygous	O
for	O
a	O
nucleotide	O
change	O
c.1445T	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
,	O
resulting	O
in	O
a	O
novel	O
homozygous	O
substitution	O
of	O
the	O
non-polar	O
hydrophobic	O
phenylalanine	O
to	O
the	O
polar	O
hydrophilic	O
cysteine	O
in	O
exon	O
6	O
at	O
codon	O
482	O
p.F482C	B-ProteinMutation
of	O
the	O
PKD2	O
gene	O
and	O
a	O
de-novo	O
PKD1	O
splice-site	O
variant	O
IVS21-2delAG	B-DNAMutation
.	O

We	O
did	O
not	O
find	O
this	O
PKD2	O
variant	O
in	O
a	O
screen	O
of	O
280	O
chromosomes	O
of	O
healthy	O
subjects	O
,	O
supporting	O
its	O
pathogenicity	O
.	O

The	O
proband's	O
parents	O
did	O
not	O
have	O
the	O
PKD1	O
mutation	O
.	O

Real-time	O
PCR	O
of	O
the	O
PKD2	O
transcript	O
from	O
a	O
skin	O
biopsy	O
revealed	O
20-fold	O
higher	O
expression	O
in	O
the	O
patient	O
than	O
in	O
a	O
healthy	O
subject	O
and	O
was	O
higher	O
in	O
the	O
patient's	O
peripheral	O
blood	O
mononuclear	O
cells	O
(PBMCs)	O
than	O
in	O
those	O
of	O
her	O
heterozygote	O
daughter	O
and	O
a	O
healthy	O
subject	O
.	O

The	O
greater	O
gene	O
expression	O
was	O
also	O
supported	O
by	O
Western	O
blotting	O
.	O

Inner	O
medullar	O
collecting	O
duct	O
(IMCD)	O
cells	O
transfected	O
with	O
the	O
mutant	O
PKD2	O
mouse	O
gene	O
presented	O
a	O
perinuclear	O
and	O
diffuse	O
cytoplasmic	O
localization	O
compared	O
with	O
the	O
wild	O
type	O
ER	O
localization	O
.	O

Patch-clamping	O
of	O
PBMCs	O
from	O
the	O
p.F482C	B-ProteinMutation
homozygous	O
and	O
heterozygous	O
subjects	O
revealed	O
lower	O
polycystin-2	O
channel	O
function	O
than	O
in	O
controls	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
for	O
the	O
first	O
time	O
a	O
patient	O
with	O
ADPKD	O
who	O
is	O
heterozygous	O
for	O
a	O
de	O
novo	O
PKD1	O
variant	O
and	O
homozygous	O
for	O
a	O
novel	O
PKD2	O
mutation	O
.	O

A	O
human	O
phospholamban	O
promoter	O
polymorphism	O
in	O
dilated	O
cardiomyopathy	O
alters	O
transcriptional	O
regulation	O
by	O
glucocorticoids	O
.	O

Depressed	O
calcium	O
handling	O
by	O
the	O
sarcoplasmic	O
reticulum	O
(SR)	O
Ca-ATPase	O
and	O
its	O
regulator	O
phospholamban	O
(PLN)	O
is	O
a	O
key	O
characteristic	O
of	O
human	O
and	O
experimental	O
heart	O
failure	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
increases	O
in	O
the	O
relative	O
levels	O
of	O
PLN	O
to	O
Ca-ATPase	O
in	O
failing	O
hearts	O
and	O
resulting	O
inhibition	O
of	O
Ca	O
sequestration	O
during	O
diastole	O
,	O
impairs	O
contractility	O
.	O

Here	O
,	O
we	O
identified	O
a	O
genetic	O
variant	O
in	O
the	O
PLN	O
promoter	O
region	O
,	O
which	O
increases	O
its	O
expression	O
and	O
may	O
serve	O
as	O
a	O
genetic	O
modifier	O
in	O
dilated	O
cardiomyopathy	O
(DCM)	O
.	O

The	O
variant	O
AF177763.1:g.203A>C	B-DNAMutation
(	O
at	O
position	O
-36	O
bp	O
relative	O
to	O
the	O
PLN	O
transcriptional	O
start	O
site	O
)	O
was	O
found	O
only	O
in	O
the	O
heterozygous	O
form	O
in	O
1	O
out	O
of	O
296	O
normal	O
subjects	O
and	O
in	O
22	O
out	O
of	O
381	O
cardiomyopathy	O
patients	O
(	O
heart	O
failure	O
at	O
age	O
of	O
18-44	O
years	O
,	O
ejection	O
fraction=22+/-9%	O
)	O
.	O

In	O
vitro	O
analysis	O
,	O
using	O
luciferase	O
as	O
a	O
reporter	O
gene	O
in	O
rat	O
neonatal	O
cardiomyocytes	O
,	O
indicated	O
that	O
the	O
PLN-variant	O
increased	O
activity	O
by	O
24%	O
compared	O
to	O
the	O
wild	O
type	O
.	O

Furthermore	O
,	O
the	O
g.203A>C	B-DNAMutation
substitution	O
altered	O
the	O
specific	O
sequence	O
of	O
the	O
steroid	O
receptor	O
for	O
the	O
glucocorticoid	O
nuclear	O
receptor	O
(GR)/transcription	O
factor	O
in	O
the	O
PLN	O
promoter	O
,	O
resulting	O
in	O
enhanced	O
binding	O
to	O
the	O
mutated	O
DNA	O
site	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
g.203A>C	B-DNAMutation
genetic	O
variant	O
in	O
the	O
human	O
PLN	O
promoter	O
may	O
contribute	O
to	O
depressed	O
contractility	O
and	O
accelerate	O
functional	O
deterioration	O
in	O
heart	O
failure	O
.	O

Cone	O
dystrophy	O
with	O
supernormal	O
rod	O
response	O
is	O
strictly	O
associated	O
with	O
mutations	O
in	O
KCNV2	O
.	O

PURPOSE	O
:	O
Cone	O
dystrophy	O
with	O
supernormal	O
rod	O
response	O
(CDSRR)	O
is	O
a	O
retinal	O
disorder	O
characterized	O
by	O
reduced	O
visual	O
acuity	O
,	O
color	O
vision	O
defects	O
,	O
and	O
specific	O
alterations	O
of	O
ERG	O
responses	O
that	O
feature	O
elevated	O
scotopic	O
b-wave	O
amplitudes	O
at	O
high	O
luminance	O
intensities	O
.	O

Mutations	O
in	O
PDE6H	O
and	O
in	O
KCNV2	O
have	O
been	O
described	O
in	O
CDSRR	O
.	O

A	O
combined	O
clinical	O
and	O
genetic	O
study	O
was	O
conducted	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
CDSRR	O
,	O
to	O
substantiate	O
these	O
prior	O
RESULTS	O
:	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
	O
<AbstractText	O
Label="METHODS"	O
NlmCategory="METHODS">Seventeen	O
patients	O
from	O
13	O
families	O
underwent	O
a	O
detailed	O
ophthalmic	O
examination	O
including	O
color	O
vision	O
testing	O
,	O
Goldmann	O
visual	O
fields	O
,	O
fundus	O
photography	O
,	O
Ganzfeld	O
and	O
multifocal	O
ERGs	O
,	O
and	O
optical	O
coherence	O
tomography	O
.	O

The	O
coding	O
sequences	O
and	O
flanking	O
intron/UTR	O
sequences	O
of	O
PDE6C	O
and	O
KCNV2	O
were	O
screened	O
for	O
mutations	O
by	O
means	O
of	O
DHPLC	O
and	O
direct	O
DNA	O
sequencing	O
of	O
PCR-amplified	O
genomic	O
DNA	O
.	O

results	O
.	O

Whereas	O
no	O
mutations	O
were	O
detected	O
in	O
the	O
PDE6H	O
gene	O
,	O
mutations	O
in	O
KCNV2	O
were	O
identified	O
in	O
all	O
patients	O
,	O
in	O
either	O
the	O
homozygous	O
or	O
compound	O
heterozygous	O
state	O
.	O

Ten	O
of	O
the	O
11	O
identified	O
mutations	O
were	O
novel	O
,	O
including	O
three	O
missense	O
and	O
six	O
truncating	O
mutations	O
and	O
one	O
gross	O
deletion	O
.	O

The	O
mutations	O
concordantly	O
segregate	O
in	O
all	O
available	O
families	O
according	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O

The	O
CDSRR	O
phenotype	O
was	O
associated	O
with	O
reduced	O
visual	O
acuity	O
of	O
variable	O
degree	O
and	O
color	O
vision	O
defects	O
.	O

Macular	O
defects	O
ranging	O
from	O
mild	O
pigmentary	O
changes	O
to	O
distinct	O
foveal	O
atrophy	O
were	O
present	O
in	O
nine	O
patients	O
.	O

Progression	O
of	O
the	O
disease	O
was	O
observed	O
in	O
only	O
three	O
of	O
seven	O
patients	O
with	O
follow-up	O
data	O
.	O

CONCLUSIONS	O
:	O
The	O
phenotype	O
of	O
cone	O
dystrophy	O
with	O
supernormal	O
rod	O
response	O
is	O
tightly	O
linked	O
with	O
mutations	O
in	O
KCNV2	O
.	O

SnoRNA	O
U50	O
is	O
a	O
candidate	O
tumor-suppressor	O
gene	O
at	O
6q14.3	O
with	O
a	O
mutation	O
associated	O
with	O
clinically	O
significant	O
prostate	O
cancer	O
.	O

Deletion	O
of	O
chromosome	O
6q14-q22	O
is	O
common	O
in	O
multiple	O
human	O
cancers	O
including	O
prostate	O
cancer	O
,	O
and	O
chromosome	O
6	O
transferred	O
into	O
cancer	O
cells	O
induces	O
senescence	O
and	O
reduces	O
cell	O
growth	O
,	O
tumorigenicity	O
and	O
metastasis	O
,	O
indicating	O
the	O
existence	O
of	O
one	O
or	O
more	O
tumor-suppressor	O
genes	O
in	O
6q	O
.	O

To	O
identify	O
the	O
6q	O
tumor-suppressor	O
gene	O
,	O
we	O
first	O
narrowed	O
the	O
common	O
region	O
of	O
deletion	O
to	O
a	O
2.5	O
Mb	O
interval	O
at	O
6q14-15	O
.	O

Of	O
the	O
11	O
genes	O
located	O
in	O
this	O
minimal	O
deletion	O
region	O
and	O
expressed	O
in	O
normal	O
prostates	O
,	O
only	O
snoRNA	O
U50	O
was	O
mutated	O
,	O
demonstrated	O
transcriptional	O
downregulation	O
and	O
inhibited	O
colony	O
formation	O
in	O
prostate	O
cancer	O
cells	O
.	O

The	O
mutation	O
,	O
a	O
homozygous	O
2	O
bp	O
(TT)	O
deletion	O
,	O
was	O
found	O
in	O
two	O
of	O
30	O
prostate	O
cancer	O
cell	O
lines/xenografts	O
and	O
nine	O
of	O
89	O
localized	O
prostate	O
cancers	O
(	O
eleven	O
of	O
119	O
or	O
9%	O
cancers	O
)	O
.	O

Two	O
of	O
89	O
(2%)	O
patients	O
with	O
prostate	O
cancer	O
also	O
showed	O
the	O
same	O
mutation	O
in	O
their	O
germline	O
DNA	O
,	O
but	O
none	O
of	O
104	O
cancer-free	O
control	O
men	O
did	O
.	O

The	O
homozygous	O
deletion	O
abolished	O
U50	O
function	O
in	O
a	O
colony	O
formation	O
assay	O
.	O

Analysis	O
of	O
1371	O
prostate	O
cancer	O
cases	O
and	O
1371	O
matched	O
control	O
men	O
from	O
a	O
case-control	O
study	O
nested	O
in	O
a	O
prospective	O
cohort	O
showed	O
that	O
,	O
although	O
a	O
germline	O
heterozygous	O
genotype	O
of	O
the	O
deletion	O
was	O
detected	O
in	O
both	O
patients	O
and	O
controls	O
at	O
similar	O
frequencies	O
,	O
the	O
homozygosity	O
of	O
the	O
deletion	O
was	O
significantly	O
associated	O
with	O
clinically	O
significant	O
prostate	O
cancer	O
(	O
odds	O
ratio	O
2.9	O
;	O
95%	O
confidence	O
interval	O
1.17-7.21	O
)	O
.	O

These	O
findings	O
establish	O
snoRNA	O
U50	O
as	O
a	O
reasonable	O
candidate	O
for	O
the	O
6q	O
tumor-suppressor	O
gene	O
in	O
prostate	O
cancer	O
and	O
likely	O
in	O
other	O
types	O
of	O
cancers	O
.	O

Identification	O
of	O
novel	O
susceptibility	O
genes	O
in	O
childhood-onset	O
systemic	O
lupus	O
erythematosus	O
using	O
a	O
uniquely	O
designed	O
candidate	O
gene	O
pathway	O
platform	O
.	O

OBJECTIVE	O
:	O
Childhood-onset	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
presents	O
a	O
unique	O
subgroup	O
of	O
patients	O
for	O
genetic	O
study	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
identify	O
susceptibility	O
genes	O
contributing	O
to	O
SLE	O
,	O
using	O
a	O
novel	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
to	O
investigate	O
gene	O
expression	O
in	O
patients	O
with	O
childhood-onset	O
SLE	O
and	O
both	O
of	O
their	O
parents	O
.	O

METHODS	O
:	O
Utilizing	O
bioinformatic	O
tools	O
,	O
a	O
platform	O
of	O
9,412	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
from	O
1,204	O
genes	O
was	O
designed	O
and	O
validated	O
.	O

Molecular	O
inversion	O
probes	O
and	O
high-throughput	O
SNP	O
technologies	O
were	O
used	O
for	O
assay	O
development	O
.	O

Seven	O
hundred	O
fifty	O
three	O
subjects	O
,	O
corresponding	O
to	O
251	O
full	O
trios	O
of	O
childhood-onset	O
SLE	O
families	O
,	O
were	O
genotyped	O
and	O
analyzed	O
using	O
transmission	O
disequilibrium	O
testing	O
(TDT)	O
and	O
multitest	O
corrections	O
.	O

RESULTS	O
:	O
Family-based	O
TDT	O
showed	O
a	O
significant	O
association	O
of	O
SLE	O
with	O
a	O
N673S	B-ProteinMutation
polymorphism	O
in	O
the	O
P-selectin	O
gene	O
(SELP)	O
(	O
P	O
=	O
5.74	O
x	O
10(-6)	O
)	O
and	O
a	O
C203S	B-ProteinMutation
polymorphism	O
in	O
the	O
interleukin-1	O
receptor-associated	O
kinase	O
1	O
gene	O
(IRAK1)	O
(	O
P	O
=	O
9.58	O
x	O
10(-6)	O
)	O
.	O

These	O
2	O
SNPs	O
had	O
a	O
false	O
discovery	O
rate	O
for	O
multitest	O
correction	O
of	O
<0.05	O
,	O
and	O
therefore	O
a	O
>95%	O
probability	O
of	O
being	O
considered	O
as	O
proven	O
.	O

Furthermore	O
,	O
7	O
additional	O
SNPs	O
showed	O
q	O
values	O
of	O
<0.5	O
,	O
suggesting	O
association	O
with	O
SLE	O
and	O
providing	O
a	O
direction	O
for	O
followup	O
studies	O
.	O

These	O
additional	O
genes	O
notably	O
included	O
TNFRSF6	O
(Fas)	O
and	O
IRF5	O
,	O
supporting	O
previous	O
findings	O
of	O
their	O
association	O
with	O
SLE	O
pathogenesis	O
.	O

CONCLUSION	O
:	O
SELP	O
and	O
IRAK1	O
were	O
identified	O
as	O
novel	O
SLE-associated	O
genes	O
with	O
a	O
high	O
degree	O
of	O
significance	O
,	O
suggesting	O
new	O
directions	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
SLE	O
.	O

The	O
overall	O
design	O
and	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
the	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
used	O
provides	O
a	O
novel	O
and	O
powerful	O
approach	O
that	O
is	O
generally	O
applicable	O
in	O
identifying	O
genetic	O
foundations	O
of	O
complex	O
diseases	O
.	O

Screening	O
of	O
Iranian	O
thalassemic	O
families	O
for	O
the	O
most	O
common	O
deletions	O
of	O
the	O
beta-globin	O
gene	O
cluster	O
.	O

Deltabeta-thalassemia	O
(thal)	O
is	O
a	O
disorder	O
,	O
characterized	O
by	O
increased	O
levels	O
of	O
fetal	O
hemoglobin	O
(	O
Hb	O
F	O
)	O
in	O
adult	O
life	O
.	O

A	O
considerable	O
number	O
of	O
deletions	O
of	O
variable	O
size	O
and	O
position	O
in	O
the	O
beta-globin	O
gene	O
cluster	O
are	O
associated	O
with	O
the	O
clinical	O
manifestation	O
of	O
deltabeta-thal	O
.	O

In	O
this	O
study	O
we	O
have	O
determined	O
the	O
presence	O
of	O
the	O
eight	O
most	O
common	O
deletions	O
in	O
Iranian	O
patients	O
.	O

Thirty-two	O
patients	O
from	O
19	O
families	O
were	O
referred	O
to	O
the	O
Kariminejad-Najmabadi	O
Pathology	O
and	O
Genetics	O
Center	O
,	O
Tehran	O
,	O
Iran	O
(	O
a	O
private	O
genetics	O
center	O
)	O
,	O
within	O
the	O
past	O
3	O
years	O
with	O
elevated	O
levels	O
of	O
Hb	O
F	O
and	O
low	O
mean	O
corpuscular	O
volume	O
(MCV)	O
.	O

After	O
obtaining	O
their	O
informed	O
consent	O
,	O
DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
by	O
the	O
salting-out	O
method	O
.	O

Detection	O
of	O
eight	O
deletions	O
was	O
performed	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

These	O
deletions	O
included	O
the	O
hereditary	O
persistence	O
of	O
fetal	O
Hb	O
(HPFH)	O
1	O
(Black)	O
and	O
3	O
(Indian)	O
,	O
Spanish	O
(	O
-114	O
kb	O
)	O
,	O
Sicilian	O
(	O
-13,377	O
bp	O
)	O
,	O
Chinese	O
(G)gamma((A)gammadeltabeta)(0)-thal	O
(	O
-100	O
kb	O
)	O
,	O
Asian-Indian	O
inversion-deletion	O
(G)gamma((A)gammadeltabeta)(0)-thal	O
,	O
and	O
the	O
Turkish	O
form	O
of	O
inversion-deletion	O
(deltabeta)(0)-thal	O
,	O
as	O
well	O
as	O
the	O
Hbs	O
Lepore	O
,	O
which	O
are	O
characterized	O
by	O
unequal	O
crossovers	O
between	O
the	O
delta-	O
and	O
beta-globin	O
genes	O
.	O

We	O
found	O
the	O
Sicilian	O
(	O
-13,377	O
bp	O
)	O
and	O
Hb	O
Lepore	O
deletions	O
as	O
well	O
as	O
the	O
Asian-Indian	O
(G)gamma((A)gammadeltabeta)(0)-thal	O
in	O
11	O
(57.89%)	O
,	O
three	O
(15.78%)	O
and	O
five	O
(26.31%)	O
families	O
,	O
respectively	O
.	O

None	O
of	O
the	O
aforementioned	O
deletions	O
were	O
found	O
in	O
one	O
of	O
the	O
patients	O
.	O

This	O
is	O
the	O
first	O
study	O
of	O
the	O
deletions	O
involved	O
in	O
deltabeta-thal	O
in	O
Iranian	O
patients	O
.	O

Our	O
study	O
highlights	O
the	O
importance	O
of	O
detecting	O
these	O
mutations	O
for	O
prenatal	O
diagnosis	O
carrier	O
detection	O
and	O
genotype/phenotype	O
prediction	O
.	O

Clinical	O
and	O
molecular	O
characterization	O
of	O
Italian	O
patients	O
affected	O
by	O
Cohen	O
syndrome	O
.	O

Cohen	O
syndrome	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
with	O
variability	O
in	O
the	O
clinical	O
manifestations	O
,	O
characterized	O
by	O
developmental	O
delay	O
,	O
visual	O
disability	O
,	O
facial	O
dysmorphisms	O
and	O
intermittent	O
neutropenia	O
.	O

We	O
described	O
a	O
cohort	O
of	O
10	O
patients	O
affected	O
by	O
Cohen	O
syndrome	O
from	O
nine	O
Italian	O
families	O
ranging	O
from	O
5	O
to	O
52	O
years	O
at	O
assessment	O
.	O

Characteristic	O
age	O
related	O
facial	O
changes	O
were	O
well	O
documented	O
.	O

Visual	O
anomalies	O
,	O
namely	O
retinopathy	O
and	O
myopia	O
,	O
were	O
present	O
in	O
9/10	O
patients	O
(	O
retinopathy	O
in	O
9/10	O
and	O
myopia	O
in	O
8/10	O
)	O
.	O

Truncal	O
obesity	O
has	O
been	O
described	O
in	O
all	O
patients	O
older	O
than	O
6	O
years	O
(8/8)	O
.	O

DNA	O
samples	O
from	O
all	O
patients	O
were	O
analyzed	O
for	O
mutations	O
in	O
COH1	O
by	O
DHPLC	O
.	O

We	O
detected	O
15	O
COH1	O
alterations	O
most	O
of	O
them	O
were	O
truncating	O
mutations	O
,	O
only	O
one	O
being	O
a	O
missense	O
change	O
.	O

Partial	O
gene	O
deletions	O
have	O
been	O
found	O
in	O
two	O
families	O
.	O

Most	O
mutations	O
were	O
private	O
.	O

Two	O
were	O
already	O
reported	O
in	O
the	O
literature	O
just	O
once	O
.	O

A	O
single	O
base	O
deletion	O
leading	O
to	O
p.T3708fs3769	B-ProteinMutation
,	O
never	O
reported	O
before	O
,	O
was	O
found	O
in	O
three	O
apparently	O
unrelated	O
families	O
deriving	O
from	O
a	O
restricted	O
area	O
of	O
the	O
Veneto's	O
lowland	O
,	O
between	O
Padova	O
town	O
and	O
Tagliamento	O
river	O
,	O
in	O
heterozygous	O
state	O
.	O

Given	O
the	O
geographical	O
conformation	O
of	O
this	O
region	O
,	O
which	O
is	O
neither	O
geographically	O
or	O
culturally	O
isolated	O
,	O
a	O
recent	O
origin	O
of	O
the	O
mutation	O
could	O
be	O
hypothesized	O
.	O

Skewed	O
X	O
inactivation	O
in	O
an	O
X	O
linked	O
nystagmus	O
family	O
resulted	O
from	O
a	O
novel	O
,	O
p.R229G	B-ProteinMutation
,	O
missense	O
mutation	O
in	O
the	O
FRMD7	O
gene	O
.	O

AIMS	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
underlying	O
genetic	O
defect	O
of	O
a	O
large	O
Turkish	O
X	O
linked	O
nystagmus	O
(NYS)	O
family	O
.	O

METHODS	O
:	O
Both	O
Xp11	O
and	O
Xq26	O
loci	O
were	O
tested	O
by	O
linkage	O
analysis	O
.	O

The	O
12	O
exons	O
and	O
intron-exon	O
junctions	O
of	O
the	O
FRMD7	O
gene	O
were	O
screened	O
by	O
direct	O
sequencing	O
.	O

X	O
chromosome	O
inactivation	O
analysis	O
was	O
performed	O
by	O
enzymatic	O
predigestion	O
of	O
DNA	O
with	O
a	O
methylation-sensitive	O
enzyme	O
,	O
followed	O
by	O
PCR	O
of	O
the	O
polymorphic	O
CAG	O
repeat	O
of	O
the	O
androgen	O
receptor	O
gene	O
.	O

RESULTS	O
:	O
The	O
family	O
contained	O
162	O
individuals	O
,	O
among	O
whom	O
28	O
had	O
NYS	O
.	O

Linkage	O
analysis	O
confirmed	O
the	O
Xq26	O
locus	O
.	O

A	O
novel	O
missense	O
c.686C>G	B-DNAMutation
mutation	O
,	O
which	O
causes	O
the	O
substitution	O
of	O
a	O
conserved	O
arginine	O
at	O
amino	O
acid	O
position	O
229	O
by	O
glycine	O
p.R229G	B-ProteinMutation
in	O
exon	O
8	O
of	O
the	O
FRMD7	O
gene	O
,	O
was	O
observed	O
.	O

This	O
change	O
was	O
not	O
documented	O
in	O
120	O
control	O
individuals	O
.	O

The	O
clinical	O
findings	O
in	O
a	O
female	O
who	O
was	O
homozygous	O
for	O
the	O
mutation	O
were	O
not	O
different	O
from	O
those	O
of	O
affected	O
heterozygous	O
females	O
.	O

Skewed	O
X	O
inactivation	O
was	O
remarkable	O
in	O
the	O
affected	O
females	O
of	O
the	O
family	O
.	O

CONCLUSIONS	O
:	O
A	O
novel	O
p.R229G	B-ProteinMutation
mutation	O
in	O
the	O
FRMD7	O
gene	O
causes	O
the	O
NYS	O
phenotype	O
,	O
and	O
skewed	O
X	O
inactivation	O
influences	O
the	O
manifestation	O
of	O
the	O
disease	O
in	O
X	O
linked	O
NYS	O
females	O
.	O

Polymorphic	O
MLH1	O
and	O
risk	O
of	O
cancer	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	O
lymphoma	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Methylating	O
agents	O
are	O
effective	O
chemotherapy	O
agents	O
for	O
Hodgkin	O
lymphoma	O
,	O
but	O
are	O
associated	O
with	O
the	O
development	O
of	O
second	O
primary	O
cancers	O
.	O

Cytotoxicity	O
of	O
methylating	O
agents	O
is	O
mediated	O
primarily	O
by	O
the	O
DNA	O
mismatch	O
repair	O
(MMR)	O
system	O
.	O

Loss	O
of	O
MLH1	O
,	O
a	O
major	O
component	O
of	O
DNA	O
MMR	O
,	O
results	O
in	O
tolerance	O
to	O
the	O
cytotoxic	O
effects	O
of	O
methylating	O
agents	O
and	O
persistence	O
of	O
mutagenised	O
cells	O
at	O
high	O
risk	O
of	O
malignant	O
transformation	O
.	O

We	O
hypothesised	O
that	O
a	O
common	O
substitution	O
in	O
the	O
basal	O
promoter	O
of	O
MLH1	O
(	O
position	O
-93	O
,	O
rs1800734	B-SNP
)	O
modifies	O
the	O
risk	O
of	O
cancer	O
after	O
methylating	O
chemotherapy	O
.	O

METHODS	O
:	O
133	O
patients	O
who	O
developed	O
cancer	O
following	O
chemotherapy	O
and/or	O
radiotherapy	O
(	O
n	O
=	O
133	O
)	O
,	O
420	O
patients	O
diagnosed	O
with	O
de	O
novo	O
myeloid	O
leukaemia	O
,	O
242	O
patients	O
diagnosed	O
with	O
primary	O
Hodgkin	O
lymphoma	O
,	O
and	O
1177	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
MLH1	O
-93	O
polymorphism	O
by	O
allelic	O
discrimination	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
.	O

Odds	O
ratios	O
and	O
95%	O
confidence	O
intervals	O
for	O
cancer	O
risk	O
by	O
MLH1	O
-93	O
polymorphism	O
status	O
,	O
and	O
stratified	O
by	O
previous	O
exposure	O
to	O
methylating	O
chemotherapy	O
,	O
were	O
calculated	O
using	O
unconditional	O
logistic	O
regression	O
.	O

RESULTS	O
:	O
Carrier	O
frequency	O
of	O
the	O
MLH1	O
-93	O
variant	O
was	O
higher	O
in	O
patients	O
who	O
developed	O
therapy	O
related	O
acute	O
myeloid	O
leukaemia	O
(t-AML)	O
(	O
75.0%	O
,	O
n	O
=	O
12	O
)	O
or	O
breast	O
cancer	O
(	O
53.3%	O
.	O

n	O
=	O
15	O
)	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	O
lymphoma	O
compared	O
to	O
patients	O
without	O
previous	O
methylating	O
exposure	O
(	O
t-AML	O
,	O
30.4%	O
,	O
n	O
=	O
69	O
;	O
breast	O
cancer	O
patients	O
,	O
27.2%	O
,	O
n	O
=	O
22	O
)	O
.	O

The	O
MLH1	O
-93	O
variant	O
allele	O
was	O
also	O
over-represented	O
in	O
t-AML	O
cases	O
when	O
compared	O
to	O
de	O
novo	O
AML	O
cases	O
(	O
36.9%	O
,	O
n	O
=	O
420	O
)	O
and	O
healthy	O
controls	O
(	O
36.3%	O
,	O
n	O
=	O
952	O
)	O
,	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
developing	O
t-AML	O
(	O
odds	O
ratio	O
5.31	O
,	O
95%	O
confidence	O
interval	O
1.40	O
to	O
20.15	O
)	O
,	O
but	O
only	O
in	O
patients	O
previously	O
treated	O
with	O
a	O
methylating	O
agent	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
common	O
polymorphism	O
at	O
position	O
-93	O
in	O
the	O
core	O
promoter	O
of	O
MLH1	O
defines	O
a	O
risk	O
allele	O
for	O
the	O
development	O
of	O
cancer	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	O
lymphoma	O
.	O

However	O
,	O
replication	O
of	O
this	O
finding	O
in	O
larger	O
studies	O
is	O
suggested	O
.	O

A	O
novel	O
missense	O
mutation	O
in	O
the	O
paired	O
domain	O
of	O
human	O
PAX9	O
causes	O
oligodontia	O
.	O

PAX9	O
and	O
MSX1	O
are	O
transcription	O
factors	O
that	O
play	O
essential	O
roles	O
in	O
craniofacial	O
and	O
limb	O
development	O
.	O

In	O
humans	O
,	O
mutations	O
in	O
both	O
genes	O
are	O
associated	O
with	O
nonsyndromic	O
and	O
syndromic	O
oligodontia	O
,	O
respectively	O
.	O

We	O
screened	O
one	O
family	O
with	O
nonsyndromic	O
oligodontia	O
for	O
mutations	O
in	O
PAX9	O
and	O
MSX1	O
.	O

Single	O
stranded	O
conformational	O
polymorphism	O
(SSCP)	O
analysis	O
and	O
sequencing	O
revealed	O
a	O
novel	O
heterozygous	O
C139T	B-DNAMutation
transition	O
in	O
PAX9	O
in	O
the	O
affected	O
members	O
of	O
the	O
family	O
.	O

There	O
were	O
no	O
mutations	O
detected	O
in	O
the	O
entire	O
coding	O
sequence	O
of	O
MSX1	O
.	O

The	O
C139T	B-DNAMutation
mutation	O
,	O
predicted	O
to	O
result	O
in	O
the	O
substitution	O
of	O
an	O
arginine	O
by	O
a	O
tryptophan	O
R47W	B-ProteinMutation
in	O
the	O
N-terminal	O
subdomain	O
,	O
affected	O
conserved	O
residues	O
in	O
the	O
PAX9	O
paired	O
domain	O
.	O

To	O
elucidate	O
the	O
pathogenic	O
mechanism	O
producing	O
oligodontia	O
phenotype	O
caused	O
by	O
this	O
mutation	O
,	O
we	O
analyzed	O
the	O
binding	O
of	O
wild-type	O
and	O
mutant	O
PAX9	O
paired	O
domain	O
protein	O
to	O
double-stranded	O
DNA	O
targets	O
.	O

The	O
R47W	B-ProteinMutation
mutation	O
dramatically	O
reduced	O
DNA	O
binding	O
suggesting	O
that	O
the	O
mutant	O
protein	O
with	O
consequent	O
haploinsufficiency	O
results	O
in	O
a	O
clinical	O
phenotype	O
.	O

Role	O
of	O
homozygous	O
DC-SIGNR	O
5/5	O
tandem	O
repeat	O
polymorphism	O
in	O
HIV-1	O
exposed	O
seronegative	O
North	O
Indian	O
individuals	O
.	O

Despite	O
multiple	O
sexual	O
exposures	O
to	O
HIV-1	O
virus	O
,	O
some	O
individuals	O
remain	O
HIV-1	O
seronegative	O
.	O

Although	O
several	O
genetic	O
factors	O
have	O
been	O
related	O
to	O
HIV-1	O
resistance	O
,	O
the	O
homozygosity	O
for	O
a	O
mutation	O
in	O
CCR5	O
gene	O
(	O
the	O
32-bp	O
deletion	O
,	O
i.e.	O
,	O
CCR5-Delta32	B-DNAMutation
allele	O
)	O
is	O
presently	O
considered	O
the	O
most	O
relevant	O
one	O
.	O

The	O
C-type	O
lectins	O
,	O
DC-SIGN	O
(	O
present	O
on	O
dendritic	O
cells	O
and	O
macrophages	O
)	O
and	O
DC-SIGNR	O
(	O
present	O
on	O
endothelial	O
cells	O
in	O
liver	O
and	O
lymph	O
nodes	O
)	O
efficiently	O
bind	O
and	O
transmit	O
HIV-1	O
to	O
susceptible	O
cell	O
in	O
trans	O
,	O
thereby	O
augmenting	O
the	O
infection	O
.	O

A	O
potential	O
association	O
of	O
the	O
DC-SIGN	O
and	O
DC-SIGNR	O
neck	O
domain	O
repeat	O
polymorphism	O
and	O
risk	O
of	O
HIV-1	O
infection	O
is	O
currently	O
under	O
debate	O
.	O

To	O
determine	O
the	O
influence	O
of	O
host	O
genetic	O
factors	O
on	O
HIV-1	O
resistance	O
,	O
we	O
conducted	O
genetic	O
risk	O
association	O
study	O
in	O
HIV-1-exposed	O
seronegative	O
(	O
n	O
=	O
47	O
)	O
individuals	O
,	O
HIV-1	O
seronegative	O
(	O
n	O
=	O
262	O
)	O
healthy	O
control	O
,	O
and	O
HIV-1-infected	O
seropositive	O
patients	O
(	O
n	O
=	O
168	O
)	O
for	O
polymorphism	O
in	O
neck	O
domain	O
of	O
DC-SIGN	O
and	O
DC-SIGNR	O
genes	O
.	O

The	O
DC-SIGN	O
and	O
DC-SIGNR	O
genotypes	O
were	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
method	O
in	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
and	O
confirmed	O
by	O
sequencing	O
.	O

Fisher	O
exact	O
or	O
chi	O
(2)	O
test	O
was	O
used	O
for	O
static	O
analysis	O
.	O

DC-SIGN	O
genotype	O
and	O
allele	O
distribution	O
was	O
fairly	O
similar	O
in	O
HIV-1-exposed	O
seronegative	O
,	O
HIV-1	O
seropositive	O
,	O
and	O
HIV-1	O
seronegative	O
control	O
.	O

There	O
was	O
no	O
statistical	O
significance	O
in	O
the	O
differences	O
in	O
the	O
distribution	O
of	O
DC-SIGN	O
genotypes	O
.	O

A	O
total	O
of	O
13	O
genotypes	O
were	O
found	O
in	O
DC-SIGNR	O
neck	O
repeat	O
region	O
polymorphism	O
.	O

Among	O
all	O
the	O
genotypes	O
,	O
only	O
5/5	O
homozygous	O
showed	O
significant	O
reduced	O
risk	O
of	O
HIV-1	O
infection	O
in	O
HIV-1-exposed	O
seronegative	O
individuals	O
(	O
p	O
=	O
0.009	O
)	O
.	O

A	O
unique	O
genotype	O
8/5	O
heterozygous	O
was	O
also	O
found	O
in	O
HIV-1	O
seropositive	O
individual	O
,	O
which	O
is	O
not	O
reported	O
elsewhere	O
.	O

Angiotensin-converting	O
enzyme	O
insertion/deletion	O
(	O
ACE	O
I/D	O
)	O
and	O
angiotensin	O
II	O
type	O
1	O
receptor	O
(AT1R)	O
gene	O
polymorphism	O
and	O
its	O
association	O
with	O
preeclampsia	O
in	O
Chinese	O
women	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
whether	O
polymorphisms	O
of	O
angiotensin	O
converting	O
enzyme	O
gene	O
(ACE)	O
and	O
angiotensin	O
II	O
receptor	O
type	O
1	O
gene	O
(AT1R)	O
are	O
associated	O
with	O
etiology	O
of	O
preeclampsia	O
and	O
renal	O
impact	O
in	O
women	O
with	O
preeclampsia	O
.	O

METHODS	O
:	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
of	O
133	O
patients	O
with	O
preeclampsia	O
and	O
105	O
healthy	O
pregnant	O
women	O
.	O

The	O
I/D	O
polymorphism	O
of	O
the	O
ACE	O
gene	O
was	O
assessed	O
by	O
polymerase	O
chain	O
reaction	O
,	O
and	O
the	O
A1166C	B-DNAMutation
polymorphism	O
of	O
the	O
AT(1)R	O
gene	O
was	O
additionally	O
assessed	O
by	O
DdeI	O
digestion	O
.	O

The	O
level	O
of	O
proteinuria	O
,	O
fasting	O
serum	O
urea	O
,	O
creatinine	O
and	O
uric	O
acid	O
were	O
investigated	O
according	O
to	O
different	O
genotypes	O
of	O
ACE	O
and	O
AT1R	O
genes	O
.	O

RESULTS	O
:	O
The	O
frequency	O
of	O
genotypes	O
of	O
the	O
ACE	O
gene	O
and	O
the	O
AT1R	O
gene	O
was	O
similar	O
in	O
preeclampsia	O
and	O
normal	O
pregnancy	O
.	O

DD	O
and	O
ID	O
genotype	O
predominated	O
in	O
patients	O
with	O
severe	O
proteinuria	O
,	O
as	O
well	O
as	O
increased	O
serum	O
urea	O
and	O
uric	O
acid	O
.	O

Serum	O
creatinine	O
was	O
also	O
increased	O
,	O
but	O
no	O
significant	O
difference	O
was	O
found	O
among	O
three	O
genotypes	O
.	O

The	O
level	O
of	O
proteinuria	O
,	O
serum	O
uric	O
acid	O
,	O
urea	O
,	O
and	O
creatinine	O
did	O
not	O
vary	O
between	O
different	O
AT1R	O
genotypes	O
.	O

Compared	O
with	O
patients	O
without	O
renal	O
dysfunction	O
,	O
the	O
frequency	O
of	O
DD	O
and	O
ID	O
genotypes	O
of	O
ACE	O
gene	O
was	O
much	O
higher	O
in	O
those	O
with	O
renal	O
dysfunction	O
,	O
but	O
AC	O
and	O
CC	O
genotypes	O
of	O
AT1R	O
gene	O
were	O
not	O
.	O

CONCLUSION	O
:	O
We	O
found	O
no	O
association	O
of	O
the	O
two	O
gene	O
polymorphisms	O
with	O
preeclampsia	O
.	O

However	O
,	O
ACE	O
gene	O
I/D	O
polymorphisms	O
were	O
associated	O
with	O
the	O
severe	O
proteinuria	O
and	O
renal	O
dysfunction	O
seen	O
in	O
preeclampsia	O
.	O

Preeclampsia	O
patients	O
carrying	O
the	O
D	O
allele	O
may	O
be	O
susceptible	O
to	O
renal	O
dysfunction	O
.	O

An	O
improved	O
tetra-primer	O
PCR	O
approach	O
for	O
the	O
detection	O
of	O
the	O
FGFR3	O
G380R	B-ProteinMutation
mutation	O
responsible	O
for	O
achondroplasia	O
.	O

Achondroplasia	O
is	O
the	O
most	O
common	O
form	O
of	O
dwarfism	O
and	O
has	O
an	O
incidence	O
of	O
approximately	O
1/7500	O
.	O

In	O
more	O
than	O
98%	O
of	O
cases	O
,	O
the	O
disease	O
is	O
associated	O
with	O
a	O
G	O
to	O
A	O
or	O
G	O
to	O
C	O
substitution	O
at	O
nucleotide	O
position	O
1138	O
p.G380R	B-ProteinMutation
of	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
(FGFR3)	O
gene	O
.	O

We	O
have	O
developed	O
a	O
sensitive	O
single	O
tube	O
tetra-primer	O
PCR	O
assay	O
to	O
detect	O
both	O
the	O
c.1138G>A	B-DNAMutation
and	O
c.1138G>C	B-DNAMutation
mutations	O
and	O
can	O
successfully	O
distinguish	O
DNA	O
samples	O
that	O
are	O
homozygous	O
and	O
heterozygous	O
for	O
the	O
c.1138G>A	B-DNAMutation
mutation	O
.	O

Titration	O
studies	O
showed	O
that	O
the	O
assay	O
could	O
reliably	O
detect	O
one	O
copy	O
of	O
the	O
mutant	O
allele	O
in	O
a	O
mix	O
of	O
100	O
wild-type	O
alleles	O
.	O

The	O
assay	O
has	O
been	O
tested	O
in	O
50	O
healthy	O
controls	O
,	O
3	O
known	O
patients	O
with	O
achondroplasia	O
,	O
and	O
5	O
amniotic	O
fluids	O
suspected	O
of	O
having	O
achondroplasia	O
and	O
for	O
whom	O
we	O
had	O
previously	O
determined	O
the	O
genotypes	O
for	O
the	O
c.1138G>A	B-DNAMutation
mutation	O
by	O
PCR-RFLP	O
.	O

We	O
have	O
observed	O
complete	O
concordance	O
between	O
methods	O
.	O

Our	O
tetra-primer	O
PCR	O
assay	O
is	O
sensitive	O
,	O
low-cost	O
,	O
and	O
easy	O
to	O
use	O
method	O
for	O
FGFR3	O
p.G380R	B-ProteinMutation
genotyping	O
,	O
which	O
could	O
be	O
used	O
even	O
in	O
"low-tech"	O
laboratories	O
.	O

Association	O
study	O
between	O
Gilles	O
de	O
la	O
Tourette	O
Syndrome	O
and	O
two	O
genes	O
in	O
the	O
Robo-Slit	O
pathway	O
located	O
in	O
the	O
chromosome	O
11q24	O
linked/associated	O
region	O
.	O

Gilles	O
de	O
la	O
Tourette	O
Syndrome	O
(GTS)	O
is	O
an	O
inherited	O
neuropsychiatric	O
disorder	O
characterized	O
by	O
the	O
presence	O
of	O
motor	O
and	O
phonic	O
tics	O
.	O

Previous	O
genetic	O
studies	O
have	O
identified	O
linkage	O
and	O
association	O
between	O
GTS	O
and	O
the	O
11q24	O
chromosomal	O
region	O
.	O

We	O
selected	O
for	O
study	O
,	O
within	O
this	O
region	O
,	O
two	O
possible	O
susceptibility	O
genes	O
for	O
GTS	O
,	O
the	O
ROBO3	O
and	O
ROBO4	O
genes	O
.	O

These	O
two	O
genes	O
were	O
selected	O
because	O
of	O
the	O
recent	O
identification	O
of	O
SLITRK1	O
as	O
a	O
potential	O
susceptibility	O
gene	O
for	O
GTS	O
based	O
on	O
a	O
translocation	O
breakpoint	O
and	O
the	O
further	O
finding	O
of	O
two	O
mutations	O
in	O
the	O
SLITRK1	O
gene	O
in	O
three	O
patients	O
with	O
GTS	O
.	O

While	O
thus	O
far	O
,	O
the	O
SLITRK1	O
gene	O
appears	O
to	O
account	O
for	O
only	O
a	O
few	O
cases	O
of	O
GTS	O
,	O
these	O
findings	O
,	O
if	O
confirmed	O
,	O
point	O
to	O
other	O
genes	O
in	O
these	O
pathways	O
that	O
may	O
contribute	O
to	O
GTS	O
.	O

Based	O
on	O
this	O
,	O
we	O
examined	O
two	O
genes	O
in	O
the	O
Slit-Robo	O
pathway	O
involved	O
in	O
cell	O
migration	O
,	O
axonal	O
pathfinding	O
,	O
and/or	O
neuronal	O
differentiation	O
because	O
of	O
their	O
location	O
in	O
11q24	O
,	O
a	O
region	O
previously	O
identified	O
as	O
linked	O
and	O
associated	O
with	O
GTS	O
.	O

We	O
selected	O
six	O
haplotype	O
tagging	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
for	O
ROBO3	O
and	O
four	O
for	O
ROBO4	O
and	O
genotyped	O
them	O
in	O
our	O
sample	O
of	O
trios	O
and	O
sibpair	O
families	O
diagnosed	O
with	O
GTS	O
.	O

Based	O
on	O
155	O
nuclear	O
families	O
with	O
255	O
affected	O
children	O
,	O
we	O
did	O
not	O
find	O
evidence	O
for	O
association	O
between	O
GTS	O
and	O
either	O
the	O
ROBO3	O
or	O
ROBO4	O
genes	O
.	O

Thus	O
,	O
these	O
two	O
genes	O
are	O
unlikely	O
to	O
be	O
the	O
susceptibility	O
genes	O
contributing	O
to	O
GTS	O
on	O
11q24	O
.	O

Coincidence	O
of	O
mutations	O
in	O
different	O
connexin	O
genes	O
in	O
Hungarian	O
patients	O
.	O

Mutations	O
in	O
the	O
GJB2	O
gene	O
are	O
the	O
most	O
common	O
cause	O
of	O
hereditary	O
prelingual	O
sensorineural	O
hearing	O
impairment	O
in	O
Europe	O
.	O

Several	O
studies	O
indicate	O
that	O
different	O
members	O
of	O
the	O
connexin	O
protein	O
family	O
interact	O
to	O
form	O
gap	O
junctions	O
in	O
the	O
inner	O
ear	O
.	O

Mutations	O
in	O
different	O
connexin	O
genes	O
may	O
accumulate	O
and	O
,	O
consequently	O
lead	O
to	O
hearing	O
impairment	O
.	O

Therefore	O
,	O
we	O
screened	O
47	O
Hungarian	O
GJB2-	O
heterozygous	O
(	O
one	O
mutation	O
in	O
coding	O
exon	O
of	O
the	O
GJB2	O
gene	O
)	O
patients	O
with	O
hearing	O
impairment	O
for	O
DNA	O
changes	O
in	O
two	O
further	O
connexin	O
genes	O
(	O
GJB6	O
and	O
GJB3	O
)	O
and	O
in	O
the	O
5'	O
non-coding	O
region	O
of	O
GJB2	O
including	O
the	O
splice	O
sites	O
.	O

Eleven	O
out	O
of	O
47	O
GJB2-heterozygous	O
patients	O
analyzed	O
carried	O
the	O
splice	O
site	O
mutation	O
-3170G>A	B-DNAMutation
in	O
the	O
5'UTR	O
region	O
of	O
GJB2	O
.	O

One	O
out	O
of	O
these	O
11	O
patients	O
showed	O
homozygous	O
-3170G>A	B-DNAMutation
genotype	O
in	O
combination	O
with	O
p.R127H	B-ProteinMutation
.	O

Next	O
to	O
the	O
GJB2	O
mutations	O
we	O
noted	O
2	O
cases	O
of	O
deletion	O
in	O
GJB6	O
[Delta(GJB6-D13S1830)]	O
and	O
3	O
(	O
2	O
new	O
and	O
1	O
described	O
)	O
base	O
substitutions	O
in	O
GJB3	O
[	O
c.357C>T	B-DNAMutation
,	O
c.798C>T	B-DNAMutation
and	O
c.94C>T	B-DNAMutation
(	O
p.R32W	B-ProteinMutation
)	O
]	O
which	O
are	O
unlikely	O
disease-causing	O
.	O

Our	O
results	O
suggest	O
the	O
importance	O
of	O
routine	O
screening	O
for	O
the	O
rather	O
frequent	O
-3170G>A	B-DNAMutation
mutation	O
(	O
in	O
addition	O
to	O
c.35delG	B-DNAMutation
)	O
in	O
patients	O
with	O
hearing	O
impairment	O
.	O

Characterisation	O
of	O
a	O
large	O
complex	O
intragenic	O
re-arrangement	O
in	O
the	O
FVII	O
gene	O
(F7)	O
avoiding	O
misdiagnosis	O
in	O
inherited	O
factor	O
VII	O
deficiency	O
.	O

Inherited	O
factor	O
VII	O
(FVII)	O
deficiency	O
is	O
a	O
rare	O
autosomal	O
recessive	O
bleeding	O
disorder	O
mostly	O
caused	O
by	O
point	O
mutations	O
.	O

Large	O
genomic	O
re-arrangements	O
at	O
F7	O
locus	O
could	O
account	O
for	O
a	O
fraction	O
of	O
mutant	O
alleles	O
that	O
remain	O
unidentified	O
after	O
DNA	O
sequencing	O
,	O
because	O
they	O
escape	O
conventional	O
polymerase	O
chain	O
reaction	O
(PCR)-based	O
techniques	O
.	O

We	O
report	O
the	O
first	O
systematic	O
screening	O
of	O
F7	O
for	O
large	O
re-arrangements	O
,	O
by	O
semi-quantitative	O
multiplex	O
PCR	O
of	O
fluorescent	O
fragments	O
targeting	O
the	O
9	O
exons	O
and	O
the	O
promoter	O
region	O
.	O

A	O
well-characterised	O
cohort	O
of	O
43	O
unrelated	O
patients	O
either	O
apparently	O
homozygous	O
for	O
a	O
F7	O
point	O
mutation	O
or	O
carrying	O
at	O
least	O
one	O
unidentified	O
F7	O
mutant	O
allele	O
participated	O
in	O
this	O
study	O
.	O

Two	O
large	O
F7	O
re-arrangements	O
were	O
identified	O
in	O
two	O
FVII-deficient	O
pedigrees	O
,	O
including	O
a	O
discontinuous	O
deletion	O
involving	O
two	O
distinct	O
portions	O
of	O
F7	O
whose	O
proximal	O
and	O
distal	O
end	O
junctions	O
were	O
characterised	O
.	O

A	O
simple	O
and	O
efficient	O
method	O
for	O
the	O
routine	O
detection	O
of	O
gross	O
alterations	O
of	O
F7	O
,	O
which	O
accounted	O
for	O
2.3%	O
of	O
mutant	O
alleles	O
in	O
our	O
sample	O
,	O
is	O
now	O
available	O
in	O
inherited	O
FVII	O
deficiency	O
.	O

This	O
test	O
should	O
complement	O
conventional	O
PCR-based	O
techniques	O
not	O
only	O
in	O
unsolved	O
cases	O
,	O
but	O
also	O
where	O
inheritance	O
pattern	O
analysis	O
is	O
not	O
achievable	O
.	O

A	O
novel	O
IRF6	O
nonsense	O
mutation	O
Y67X	B-ProteinMutation
in	O
a	O
German	O
family	O
with	O
Van	O
der	O
Woude	O
syndrome	O
.	O

Van	O
der	O
Woude	O
syndrome	O
(VWS)	O
is	O
the	O
most	O
common	O
type	O
of	O
syndromic	O
orofacial	O
cleft	O
,	O
which	O
accounts	O
for	O
approximately	O
2%	O
of	O
all	O
cleft	O
lip	O
and	O
palate	O
cases	O
.	O

It	O
is	O
characterised	O
by	O
variable	O
association	O
of	O
lower	O
lip	O
pits	O
,	O
cleft	O
lip	O
and	O
cleft	O
palate	O
,	O
and	O
hypodontia	O
.	O

VWS	O
arises	O
as	O
the	O
result	O
of	O
mutations	O
in	O
the	O
gene	O
encoding	O
interferon	O
regulatory	O
factor	O
6	O
(IRF6)	O
.	O

The	O
disorder	O
is	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
,	O
with	O
high	O
penetrance	O
and	O
variable	O
expressivity	O
.	O

Very	O
recently	O
,	O
mutations	O
of	O
the	O
IRF6	O
gene	O
in	O
exons	O
2-9	O
have	O
been	O
found	O
in	O
VWS	O
patients	O
,	O
suggesting	O
that	O
this	O
gene	O
plays	O
an	O
important	O
role	O
in	O
orofacial	O
development	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
IRF6	O
gene	O
in	O
a	O
German	O
family	O
.	O

Five	O
out	O
of	O
the	O
12	O
persons	O
affected	O
were	O
able	O
to	O
be	O
investigated	O
.	O

The	O
mutation	O
produced	O
a	O
stop	O
codon	O
within	O
exon	O
4	O
of	O
the	O
IRF6	O
gene	O
.	O

All	O
5	O
patients	O
were	O
heterozygous	O
for	O
a	O
base	O
substitution	O
c.201C>A	B-DNAMutation
changing	O
the	O
tyrosine	O
codon	O
at	O
amino	O
acid	O
position	O
67	O
into	O
a	O
stop	O
codon	O
p.Y67X	B-ProteinMutation
in	O
exon	O
4	O
.	O

The	O
premature	O
stop	O
codon	O
was	O
responsible	O
for	O
a	O
truncated	O
protein	O
lacking	O
parts	O
of	O
the	O
DNA-	O
binding	O
domain	O
and	O
the	O
complete	O
Smad-interferon	O
regulatory	O
factor-binding	O
domain	O
probably	O
essential	O
for	O
interactions	O
with	O
the	O
Smad	O
transcription	O
factors	O
.	O

Subfertility	O
in	O
mice	O
harboring	O
a	O
mutation	O
in	O
betaB2-crystallin	O
.	O

PURPOSE	O
:	O
betaB2-crystallin	O
is	O
one	O
of	O
the	O
most	O
abundant	O
proteins	O
of	O
the	O
adult	O
ocular	O
lens	O
of	O
mammals	O
although	O
it	O
is	O
expressed	O
at	O
lower	O
levels	O
in	O
several	O
extralenticular	O
locations	O
.	O

While	O
mutations	O
in	O
betaB2-crystallin	O
are	O
known	O
to	O
result	O
in	O
lens	O
opacities	O
,	O
alterations	O
in	O
tissues	O
besides	O
the	O
lens	O
have	O
not	O
been	O
previously	O
investigated	O
in	O
these	O
mutants	O
.	O

Since	O
we	O
found	O
mice	O
harboring	O
the	O
Crybb2Phil	O
mutation	O
bred	O
poorly	O
,	O
here	O
we	O
assess	O
the	O
contribution	O
of	O
betaB2-crystallin	O
to	O
mouse	O
fertility	O
and	O
determine	O
the	O
expression	O
pattern	O
of	O
betaB2-crystallin	O
in	O
the	O
testis	O
.	O

METHODS	O
:	O
The	O
expression	O
pattern	O
of	O
betaB2-crystallin	O
in	O
the	O
testis	O
was	O
analyzed	O
by	O
rt-PCR	O
,	O
western	O
blotting	O
,	O
and	O
immunohistochemistry	O
.	O

The	O
fecundity	O
of	O
wildtype	O
and	O
Crybb2Phil	O
mice	O
was	O
analyzed	O
by	O
quantitative	O
fertility	O
testing	O
.	O

The	O
morphology	O
of	O
testes	O
and	O
ovaries	O
was	O
assessed	O
by	O
hematoxylin	O
and	O
eosin	O
staining	O
.	O

RESULTS	O
:	O
In	O
the	O
mouse	O
testis	O
,	O
betaB2-crystallin	O
mRNA	O
is	O
found	O
at	O
low	O
levels	O
at	O
birth	O
,	O
but	O
its	O
expression	O
upregulates	O
in	O
this	O
tissue	O
as	O
the	O
testis	O
is	O
primed	O
to	O
initiate	O
spermatogenesis	O
.	O

Western	O
blotting	O
detected	O
betaB2-crystallin	O
protein	O
in	O
sperm	O
obtained	O
from	O
mice	O
,	O
cattle	O
,	O
and	O
humans	O
while	O
immunolocalization	O
detected	O
this	O
protein	O
in	O
developing	O
sperm	O
from	O
the	O
spermatocyte	O
stage	O
onward	O
.	O

Male	O
and	O
female	O
mice	O
homozygous	O
for	O
a	O
12	O
nucleotide	O
inframe	O
deletion	O
mutation	O
in	O
betaB2-crystallin	O
are	O
subfertile	O
when	O
analyzed	O
on	O
a	O
Swiss	O
Webster	O
derived	O
background	O
due	O
to	O
defects	O
in	O
egg	O
and	O
sperm	O
production	O
.	O

However	O
,	O
mice	O
harboring	O
the	O
same	O
mutation	O
on	O
the	O
C57Bl/6	O
genetic	O
background	O
did	O
not	O
exhibit	O
any	O
defects	O
in	O
reproductive	O
function	O
.	O

CONCLUSIONS	O
:	O
betaB2-crystallin	O
is	O
expressed	O
in	O
developing	O
and	O
mature	O
sperm	O
and	O
mice	O
of	O
both	O
sexes	O
harboring	O
the	O
Philly	O
mutation	O
in	O
the	O
betaB2-crystallin	O
gene	O
are	O
subfertile	O
when	O
analyzed	O
on	O
a	O
Swiss	O
Webster	O
genetic	O
background	O
.	O

While	O
these	O
data	O
are	O
suggestive	O
of	O
a	O
role	O
for	O
betaB2-crystallin	O
in	O
fertility	O
,	O
definitive	O
determination	O
of	O
this	O
will	O
await	O
the	O
creation	O
of	O
a	O
betaB2-crystallin	O
null	O
mouse	O
.	O

Monitoring	O
the	O
isochromosome	O
i(7)(q10)	O
in	O
the	O
bone	O
marrow	O
of	O
patients	O
with	O
Shwachman	O
syndrome	O
by	O
real-time	O
quantitative	O
PCR	O
.	O

Clonal	O
chromosome	O
anomalies	O
may	O
be	O
found	O
in	O
the	O
bone	O
marrow	O
(BM)	O
of	O
patients	O
with	O
Shwachman	O
syndrome	O
,	O
who	O
are	O
at	O
risk	O
to	O
develop	O
myelodysplastic	O
syndromes	O
and/or	O
acute	O
myeloid	O
leukemias	O
.	O

In	O
particular	O
,	O
an	O
isochromosome	O
i(7)(q10)	O
is	O
frequent	O
,	O
and	O
is	O
usually	O
monitored	O
by	O
chromosome	O
analyses	O
.	O

We	O
tested	O
an	O
approach	O
by	O
real-time	O
quantitative	O
polymerase	O
chain	O
reaction	O
(RQ-PCR)	O
on	O
a	O
chromosome	O
7	O
polymorphism	O
.	O

Five	O
DNA	O
samples	O
of	O
2	O
Shwachman	O
syndrome	O
patients	O
with	O
clonal	O
i(7)(q10)	O
in	O
the	O
BM	O
were	O
used	O
.	O

Both	O
were	O
heterozygous	O
for	O
the	O
diallelic	O
indel	O
polymorphism	O
MID1064	O
,	O
which	O
maps	O
in	O
7q35	O
.	O

The	O
percentage	O
of	O
i(7)(q10)-positive	O
cells	O
was	O
extrapolated	O
from	O
the	O
ratio	O
of	O
the	O
2	O
alleles	O
measured	O
by	O
means	O
of	O
an	O
allele-specific	O
RQ-PCR	O
assay	O
.	O

The	O
results	O
were	O
compared	O
with	O
cytogenetic	O
analyses	O
on	O
the	O
same	O
material	O
used	O
for	O
RQ-PCR	O
.	O

In	O
1	O
patient	O
,	O
the	O
RQ-PCR	O
results	O
matched	O
well	O
with	O
those	O
of	O
chromosome	O
analyses	O
,	O
whereas	O
in	O
the	O
other	O
one	O
RQ-PCR	O
showed	O
that	O
around	O
40%	O
of	O
the	O
BM	O
cells	O
were	O
abnormal	O
,	O
while	O
they	O
resulted	O
to	O
be	O
nearly	O
80%	O
with	O
conventional	O
monitoring	O
assays	O
.	O

As	O
the	O
results	O
obtained	O
by	O
RQ-PCR	O
refer	O
to	O
the	O
DNA	O
of	O
around	O
128,000	O
BM	O
cells	O
,	O
our	O
method	O
proved	O
to	O
be	O
feasible	O
and	O
more	O
efficient	O
in	O
the	O
quantitative	O
evaluation	O
of	O
the	O
i(7)(q10)-positive	O
clone	O
than	O
conventional	O
ones	O
.	O

DFF45/ICAD	O
restores	O
cisplatin-induced	O
nuclear	O
fragmentation	O
but	O
not	O
DNA	O
cleavage	O
in	O
DFF45-deficient	O
neuroblastoma	O
cells	O
.	O

We	O
have	O
previously	O
defined	O
a	O
homozygously	O
deleted	O
region	O
at	O
chromosome	O
1p36.2-p36.3	O
in	O
human	O
neuroblastoma	O
cell	O
lines	O
,	O
NB-1	O
and	O
NB-C201	O
,	O
and	O
identified	O
six	O
genes	O
including	O
DFF45/ICAD	O
within	O
this	O
region	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
NB-C201	O
cells	O
are	O
much	O
more	O
resistant	O
to	O
various	O
genotoxic	O
stresses	O
such	O
as	O
cisplatin	O
(CDDP)	O
than	O
CHP134	O
and	O
SH-SY5Y	O
cells	O
that	O
do	O
not	O
have	O
the	O
homozygous	O
deletion	O
.	O

To	O
examine	O
a	O
role(s)	O
of	O
DFF45	O
in	O
the	O
regulation	O
of	O
apoptosis	O
in	O
response	O
to	O
CDDP	O
,	O
we	O
have	O
established	O
stably	O
DFF45-expressing	O
NB-C201	O
cell	O
clones	O
(	O
DFF45-1	O
and	O
DFF45-3	O
)	O
and	O
a	O
control	O
cell	O
clone	O
(NB-C201-C)	O
using	O
a	O
retrovirus-mediated	O
gene	O
transfer	O
.	O

In	O
contrast	O
to	O
NB-C201-C	O
cells	O
,	O
DFF45-3	O
cells	O
displayed	O
apoptotic	O
nuclear	O
fragmentation	O
in	O
response	O
to	O
CDDP	O
.	O

Although	O
CDDP-induced	O
proteolytic	O
cleavage	O
of	O
procaspase-3	O
and	O
DFF45	O
in	O
DFF45-3	O
cells	O
,	O
we	O
could	O
not	O
detect	O
a	O
typical	O
apoptotic	O
DNA	O
fragmentation	O
.	O

Additionally	O
,	O
deletion	O
analysis	O
revealed	O
that	O
C-terminal	O
region	O
of	O
DFF45	O
is	O
required	O
for	O
inducing	O
nuclear	O
fragmentation	O
.	O

Unexpectedly	O
,	O
(	O
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium	O
bromide	O
(MTT)	O
assays	O
demonstrated	O
that	O
DFF45	O
has	O
undetectable	O
effect	O
on	O
CDDP	O
sensitivity	O
of	O
NB-C201	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
present	O
results	O
suggest	O
that	O
DFF45/DFF40	O
system	O
may	O
be	O
sufficient	O
for	O
CDDP-induced	O
nuclear	O
fragmentation	O
but	O
not	O
DNA	O
cleavage	O
.	O

Molecular	O
analysis	O
of	O
the	O
CYP2F1	O
gene	O
:	O
identification	O
of	O
a	O
frequent	O
non-functional	O
allelic	O
variant	O
.	O

The	O
CYP2F1	O
is	O
a	O
human	O
cytochrome	O
P450	O
that	O
is	O
selectively	O
expressed	O
in	O
lung	O
tissue	O
and	O
involved	O
in	O
the	O
metabolism	O
of	O
various	O
pneumotoxicants	O
with	O
potential	O
carcinogenic	O
effects	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
first	O
systematic	O
investigation	O
of	O
the	O
genetic	O
polymorphism	O
of	O
this	O
enzyme	O
.	O

We	O
analyzed	O
the	O
nucleotidic	O
sequence	O
of	O
the	O
CYP2F1	O
gene	O
in	O
DNA	O
samples	O
from	O
90	O
French	O
Caucasians	O
consisting	O
in	O
44	O
patients	O
with	O
lung	O
cancer	O
and	O
46	O
control	O
individuals	O
,	O
using	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
of	O
PCR	O
products	O
(PCR-SSCP)	O
.	O

We	O
identified	O
24	O
novel	O
mutations	O
distributed	O
in	O
the	O
promoter	O
region	O
of	O
the	O
gene	O
,	O
as	O
well	O
as	O
in	O
the	O
coding	O
regions	O
and	O
their	O
flanking	O
intronic	O
sequences	O
.	O

In	O
addition	O
to	O
the	O
wild-type	O
CYP2F1*1	O
allele	O
,	O
seven	O
allelic	O
variant	O
,	O
CYP2F1*2A	O
,	O
*2B	O
,	O
*3	O
,	O
*4	O
,	O
*5A	O
,	O
*5B	O
and	O
*6	O
,	O
were	O
characterized	O
.	O

The	O
most	O
frequent	O
allelic	O
variant	O
,	O
CYP2F1*2A	O
(25.6%)	O
,	O
harbors	O
a	O
combination	O
of	O
9	O
mutations	O
,	O
including	O
2	O
missense	O
mutations	O
(	O
Asp218Asn	B-ProteinMutation
and	O
Gln266His	B-ProteinMutation
)	O
and	O
a	O
1-bp	O
insertion	O
c.14_15insC	B-DNAMutation
that	O
creates	O
a	O
premature	O
stop	O
codon	O
in	O
exon	O
2	O
,	O
probably	O
leading	O
to	O
the	O
synthesis	O
of	O
a	O
severely	O
truncated	O
protein	O
with	O
no	O
catalytic	O
activity	O
.	O

The	O
identification	O
of	O
around	O
7%	O
of	O
homozygotes	O
for	O
the	O
frameshift	O
mutation	O
in	O
our	O
Caucasian	O
population	O
suggests	O
the	O
existence	O
of	O
an	O
interindividual	O
variation	O
of	O
the	O
CYP2F1	O
activity	O
and	O
,	O
consequently	O
,	O
the	O
possibility	O
of	O
interindividual	O
differences	O
in	O
the	O
toxic	O
response	O
to	O
some	O
pneumotoxicants	O
and	O
in	O
the	O
susceptibility	O
to	O
certain	O
chemically	O
induced	O
diseases	O
.	O

However	O
,	O
our	O
preliminary	O
results	O
did	O
not	O
show	O
any	O
evidence	O
that	O
the	O
CYP2F1	O
genetic	O
polymorphism	O
has	O
implications	O
in	O
the	O
pathogenesis	O
of	O
lung	O
cancer	O
.	O

Human	O
TBX1	O
missense	O
mutations	O
cause	O
gain	O
of	O
function	O
resulting	O
in	O
the	O
same	O
phenotype	O
as	O
22q11.2	O
deletions	O
.	O

Deletion	O
22q11.2	O
syndrome	O
is	O
the	O
most	O
frequent	O
known	O
microdeletion	O
syndrome	O
and	O
is	O
associated	O
with	O
a	O
highly	O
variable	O
phenotype	O
,	O
including	O
DiGeorge	O
and	O
Shprintzen	O
(velocardiofacial)	O
syndromes	O
.	O

Although	O
haploinsufficiency	O
of	O
the	O
T-box	O
transcription	O
factor	O
gene	O
TBX1	O
is	O
thought	O
to	O
cause	O
the	O
phenotype	O
,	O
to	O
date	O
,	O
only	O
four	O
different	O
point	O
mutations	O
in	O
TBX1	O
have	O
been	O
reported	O
in	O
association	O
with	O
six	O
of	O
the	O
major	O
features	O
of	O
22q11.2	O
deletion	O
syndrome	O
.	O

Although	O
,	O
for	O
the	O
two	O
truncating	O
mutations	O
,	O
loss	O
of	O
function	O
was	O
previously	O
shown	O
,	O
the	O
pathomechanism	O
of	O
the	O
missense	O
mutations	O
remains	O
unknown	O
.	O

We	O
report	O
a	O
novel	O
heterozygous	O
missense	O
mutation	O
,	O
H194Q	B-ProteinMutation
,	O
in	O
a	O
familial	O
case	O
of	O
Shprintzen	O
syndrome	O
and	O
show	O
that	O
this	O
and	O
the	O
two	O
previously	O
reported	O
missense	O
mutations	O
result	O
in	O
gain	O
of	O
function	O
,	O
possibly	O
through	O
stabilization	O
of	O
the	O
protein	O
dimer	O
DNA	O
complex	O
.	O

We	O
therefore	O
conclude	O
that	O
TBX1	O
gain-of-function	O
mutations	O
can	O
result	O
in	O
the	O
same	O
phenotypic	O
spectrum	O
as	O
haploinsufficiency	O
caused	O
by	O
loss-of-function	O
mutations	O
or	O
deletions	O
.	O

A	O
possible	O
bichromatid	O
mutation	O
in	O
a	O
male	O
gamete	O
giving	O
rise	O
to	O
a	O
female	O
mosaic	O
for	O
two	O
different	O
mutations	O
in	O
the	O
X-linked	O
gene	O
WAS	O
.	O

In	O
genetic	O
disorders	O
caused	O
by	O
point	O
mutations	O
or	O
small	O
frameshift	O
mutations	O
,	O
affected	O
members	O
of	O
the	O
same	O
family	O
are	O
expected	O
to	O
have	O
the	O
same	O
mutation	O
in	O
the	O
causative	O
gene	O
.	O

We	O
have	O
recently	O
evaluated	O
a	O
family	O
in	O
which	O
this	O
was	O
not	O
the	O
case	O
.	O

Maternal	O
cousins	O
with	O
Wiskott-Aldrich	O
syndrome	O
(	O
WAS	O
;	O
MIM	O
301000	O
)	O
had	O
two	O
different	O
but	O
contiguous	O
single	O
base	O
pair	O
deletions	O
in	O
WAS	O
.	O

The	O
proband	O
had	O
an	O
A	O
deletion	O
in	O
codon	O
242	O
in	O
exon	O
7	O
of	O
WAS	O
;	O
his	O
two	O
cousins	O
had	O
a	O
C	O
deletion	O
in	O
codon	O
241	O
.	O

The	O
mother	O
of	O
the	O
proband	O
was	O
heterozygous	O
for	O
the	O
A	O
deletion	O
allele	O
,	O
but	O
her	O
three	O
sisters	O
,	O
including	O
the	O
mother	O
of	O
the	O
affected	O
cousins	O
,	O
were	O
heterozygous	O
for	O
the	O
C	O
deletion	O
.	O

Both	O
deletions	O
occurred	O
on	O
the	O
haplotype	O
from	O
the	O
unaffected	O
maternal	O
great-grandfather	O
.	O

The	O
maternal	O
grandmother	O
,	O
who	O
was	O
a	O
carrier	O
of	O
WAS	O
,	O
based	O
on	O
a	O
non-random	O
pattern	O
of	O
X	O
chromosome	O
inactivation	O
in	O
T	O
cells	O
,	O
was	O
mosaic	O
for	O
both	O
deletions	O
.	O

These	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
mutations	O
originating	O
in	O
a	O
male	O
gamete	O
with	O
different	O
mutations	O
on	O
the	O
two	O
strands	O
of	O
DNA	O
,	O
a	O
bichromatid	O
mutation	O
.	O

A	O
novel	O
mutation	O
at	O
the	O
DFNA36	O
hearing	O
loss	O
locus	O
reveals	O
a	O
critical	O
function	O
and	O
potential	O
genotype-phenotype	O
correlation	O
for	O
amino	O
acid-572	O
of	O
TMC1	O
.	O

We	O
ascertained	O
a	O
North	O
American	O
Caucasian	O
family	O
(LMG248)	O
segregating	O
autosomal	O
dominant	O
,	O
non-syndromic	O
,	O
post-lingual	O
,	O
progressive	O
sensorineural	O
hearing	O
loss	O
.	O

The	O
hearing	O
loss	O
begins	O
in	O
the	O
second	O
decade	O
of	O
life	O
and	O
initially	O
affects	O
high	O
frequencies	O
.	O

It	O
progresses	O
to	O
profound	O
deafness	O
at	O
all	O
frequencies	O
by	O
the	O
fourth	O
or	O
fifth	O
decade	O
.	O

The	O
phenotype	O
co-segregates	O
with	O
short-tandem	O
repeat	O
markers	O
flanking	O
the	O
TMC1	O
gene	O
at	O
the	O
DFNA36	O
locus	O
on	O
chromosome	O
9q31-q21	O
.	O

The	O
affected	O
individuals	O
carry	O
a	O
novel	O
missense	O
substitution	O
,	O
p.D572H	B-ProteinMutation
c.G1714C	B-DNAMutation
,	O
of	O
the	O
TMC1	O
gene	O
.	O

This	O
mutation	O
is	O
at	O
the	O
same	O
nucleotide	O
and	O
amino	O
acid	O
position	O
as	O
the	O
only	O
other	O
reported	O
DFNA36	O
mutation	O
,	O
p.D572N	B-ProteinMutation
c.G1714A	B-DNAMutation
.	O

Our	O
observations	O
implicate	O
a	O
critical	O
function	O
for	O
amino	O
acid-572	O
for	O
wild-type	O
TMC1	O
function	O
or	O
the	O
pathogenesis	O
of	O
DFNA36	O
hearing	O
loss	O
.	O

The	O
slower	O
progression	O
of	O
hearing	O
loss	O
associated	O
with	O
p.D572H	B-ProteinMutation
,	O
in	O
comparison	O
with	O
that	O
caused	O
by	O
p.D572N	B-ProteinMutation
,	O
may	O
reflect	O
a	O
correlation	O
of	O
DFNA36	O
phenotype	O
with	O
TMC1	O
genotype	O
.	O

Cytochrome	O
p4501A1	O
gene	O
variants	O
as	O
susceptibility	O
marker	O
for	O
prostate	O
cancer	O
.	O

CYP1A1	O
activates	O
environmental	O
procarcinogens	O
and	O
catalyzes	O
oxidative	O
metabolism	O
of	O
estrogens	O
and	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
prostate	O
cancer	O
.	O

To	O
evaluate	O
this	O
phenomenon	O
,	O
the	O
association	O
between	O
two	O
single	O
nucleotide	O
polymorphisms	O
(	O
A	O
to	O
G	O
transition	O
in	O
exon7	O
leading	O
to	O
amino	O
acid	O
substitution	O
Ile462Val	B-ProteinMutation
and	O
T3801C	B-DNAMutation
at	O
3'UTR	O
)	O
of	O
CYP1A1	O
gene	O
in	O
prostate	O
cancer	O
were	O
analyzed	O
in	O
a	O
case-control	O
study	O
of	O
100	O
individuals	O
in	O
South	O
Indian	O
population	O
.	O

The	O
estimated	O
relative	O
risk	O
was	O
significantly	O
high	O
for	O
individuals	O
with	O
w1/m1	O
genotype	O
at	O
3'UTR	O
of	O
CYP1A1	O
gene	O
(	O
OR-4.64	O
;	O
95%CI	O
=	O
1.51-14.86	O
;	O
P	O
<	O
0.01	O
)	O
whereas	O
the	O
CYP1A1	O
Ile/Val	O
genotype	O
(w2/m2)	O
on	O
exon	O
7	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
decreased	O
risk	O
for	O
prostate	O
cancer	O
(	O
OR-0.17	O
;	O
95%CI	O
=	O
0.02-0.89	O
;	O
P=0.03	O
)	O
.	O

A	O
Stratified	O
analysis	O
of	O
the	O
genotypes	O
with	O
age	O
of	O
onset	O
and	O
tumor	O
grade	O
showed	O
the	O
w1/m1	O
genotype	O
to	O
be	O
significantly	O
associated	O
with	O
an	O
early	O
age	O
of	O
onset	O
;	O
however	O
the	O
tumor	O
grades	O
did	O
not	O
have	O
significant	O
association	O
with	O
the	O
variant	O
genotypes	O
.	O

Thus	O
the	O
present	O
study	O
indicates	O
that	O
individuals	O
with	O
the	O
variant	O
w1/m1	O
genotype	O
exhibit	O
an	O
increased	O
risk	O
while	O
those	O
with	O
w2/m2	O
genotype	O
exhibit	O
a	O
decreased	O
risk	O
for	O
prostate	O
cancer	O
.	O

Multipoint	O
interphase	O
FISH	O
in	O
childhood	O
T-acute	O
lymphoblastic	O
leukemia	O
detects	O
subpopulations	O
that	O
carry	O
different	O
chromosome	O
3	O
aberrations	O
.	O

We	O
examined	O
chromosome	O
3	O
in	O
32	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(ALL)	O
bone	O
marrow	O
samples	O
.	O

Using	O
interphase	O
multipoint	O
FISH	O
(mp-FISH)	O
,	O
which	O
was	O
developed	O
by	O
our	O
group	O
,	O
with	O
42	O
chromosome	O
3-specific	O
probes	O
,	O
we	O
detected	O
clonal	O
chromosome	O
3	O
aberrations	O
in	O
4	O
T-cell	O
ALL	O
(T-ALL)	O
cases	O
.	O

Four	O
out	O
of	O
seven	O
T-ALL	O
cases	O
carried	O
3q	O
trisomies	O
.	O

One	O
T-ALL	O
case	O
carried	O
either	O
trisomy	O
3	O
(	O
in	O
15%	O
of	O
the	O
cells	O
)	O
or	O
a	O
23-megabase	O
(Mb)	O
3p13	O
approximately	O
p12	O
deletion	O
in	O
a	O
different	O
subpopulation	O
of	O
cells	O
of	O
32%	O
.	O

Another	O
T-ALL	O
case	O
had	O
either	O
3q	O
trisomy	O
in	O
11%	O
or	O
a	O
12-Mb	O
3p12	O
approximately	O
p13	O
deletion	O
in	O
19%	O
of	O
the	O
cells	O
.	O

The	O
deletions	O
were	O
overlapping	O
.	O

In	O
both	O
cases	O
,	O
the	O
majority	O
of	O
the	O
bone	O
marrow	O
cells	O
(	O
47	O
and	O
70%	O
,	O
respectively	O
)	O
were	O
normal	O
chromosome	O
3	O
disomics	O
.	O

The	O
interstitial	O
deletions	O
detected	O
harbor	O
a	O
known	O
homozygous	O
deletion	O
region	O
between	O
72.6	O
and	O
78.8	O
Mb	O
,	O
which	O
has	O
been	O
described	O
in	O
lung	O
and	O
breast	O
tumors	O
and	O
contains	O
the	O
DUTT1/ROBO1	O
tumor	O
suppressor	O
gene	O
.	O

These	O
deletions	O
detected	O
by	O
mp-FISH	O
would	O
have	O
remained	O
unnoticed	O
by	O
conventional	O
cytogenetics	O
and	O
multiplex	O
FISH	O
,	O
as	O
well	O
as	O
by	O
current	O
methods	O
based	O
on	O
total	O
tumor	O
DNA	O
analysis	O
such	O
as	O
comparative	O
genomic	O
hybridization	O
(CGH)	O
,	O
array	O
CGH	O
,	O
and	O
loss	O
of	O
heterozygosity	O
(LOH)	O
.	O

Single-base	O
substitution	O
at	O
the	O
last	O
nucleotide	O
of	O
exon	O
6	O
c.671G>A	B-DNAMutation
,	O
resulting	O
in	O
the	O
skipping	O
of	O
exon	O
6	O
,	O
and	O
exons	O
6	O
and	O
7	O
in	O
human	O
succinyl-CoA:3-ketoacid	O
CoA	O
transferase	O
(SCOT)	O
gene	O
.	O

Succinyl-CoA:3-ketoacid	O
CoA	O
transferase	O
(	O
SCOT	O
,	O
EC	O
2.8.3.5	O
)	O
is	O
the	O
key	O
enzyme	O
for	O
ketone	O
body	O
utilization	O
.	O

Hereditary	O
SCOT	O
deficiency	O
(	O
MIM	O
245050	O
)	O
causes	O
episodes	O
of	O
severe	O
ketoacidosis	O
.	O

We	O
identified	O
a	O
homozygous	O
point	O
mutation	O
c.671G>A	B-DNAMutation
,	O
which	O
is	O
a	O
single-base	O
substitution	O
at	O
the	O
last	O
nucleotide	O
of	O
exon	O
6	O
,	O
in	O
a	O
Turkish	O
patient	O
(GS12)	O
with	O
SCOT	O
deficiency	O
.	O

This	O
point	O
mutation	O
resulted	O
in	O
the	O
skipping	O
of	O
exon	O
6	O
,	O
and	O
exons	O
6	O
and	O
7	O
in	O
human	O
SCOT	O
genes	O
.	O

To	O
understand	O
why	O
the	O
c.671G>A	B-DNAMutation
causes	O
exons	O
6	O
and	O
7	O
skipping	O
,	O
nuclear	O
RNA	O
was	O
separated	O
from	O
cytoplasmic	O
RNA	O
and	O
both	O
were	O
analyzed	O
by	O
RT-PCR	O
.	O

In	O
nuclear	O
RNA	O
,	O
SCOT	O
mRNA	O
with	O
exon	O
6	O
skipping	O
was	O
predominant	O
and	O
mRNA	O
with	O
exons	O
6	O
and	O
7	O
skipping	O
was	O
hardly	O
detected	O
,	O
whereas	O
the	O
latter	O
became	O
one	O
of	O
major	O
mRNA	O
species	O
in	O
cytoplasmic	O
RNA	O
.	O

This	O
discrepancy	O
was	O
interpreted	O
as	O
follows	O
:	O
exon	O
6	O
skipping	O
causes	O
a	O
frameshift	O
and	O
nonsense-mediated	O
RNA	O
decay	O
in	O
the	O
cytosol	O
,	O
so	O
mRNA	O
with	O
exon	O
6	O
skipping	O
was	O
unstable	O
.	O

On	O
the	O
other	O
hand	O
,	O
SCOT	O
mRNA	O
with	O
exons	O
6	O
and	O
7	O
is	O
a	O
minor	O
transcript	O
but	O
it	O
retains	O
the	O
reading-frame	O
and	O
is	O
stable	O
in	O
cytosol	O
.	O

As	O
a	O
result	O
,	O
the	O
latter	O
mRNA	O
is	O
more	O
abundant	O
under	O
steady-state	O
conditions	O
as	O
compared	O
to	O
the	O
former	O
mRNA	O
.	O

Genetic	O
polymorphism	O
of	O
the	O
binding	O
domain	O
of	O
surfactant	O
protein-A2	O
increases	O
susceptibility	O
to	O
meningococcal	O
disease	O
.	O

BACKGROUND	O
:	O
Meningococcal	O
disease	O
occurs	O
after	O
colonization	O
of	O
the	O
nasopharynx	O
with	O
Neisseria	O
meningitidis	O
.	O

Surfactant	O
protein	O
(SP)-A	O
and	O
SP-D	O
are	O
pattern-recognition	O
molecules	O
of	O
the	O
respiratory	O
tract	O
that	O
activate	O
inflammatory	O
and	O
phagocytic	O
defences	O
after	O
binding	O
to	O
microbial	O
sugars	O
.	O

Variation	O
in	O
the	O
genes	O
of	O
the	O
surfactant	O
proteins	O
affects	O
the	O
expression	O
and	O
function	O
of	O
these	O
molecules	O
.	O

METHODS	O
:	O
Allele	O
frequencies	O
of	O
SP-A1	O
,	O
SP-A2	O
,	O
and	O
SP-D	O
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
in	O
303	O
patients	O
with	O
microbiologically	O
proven	O
meningococcal	O
disease	O
,	O
including	O
18	O
patients	O
who	O
died	O
,	O
and	O
222	O
healthy	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Homozygosity	O
of	O
allele	O
1A1	O
of	O
SP-A2	O
increased	O
the	O
risk	O
of	O
meningococcal	O
disease	O
(	O
odds	O
ratio	O
[OR]	O
,	O
7.4	O
;	O
95%	O
confidence	O
interval	O
[CI]	O
,	O
1.3-42.4	O
)	O
;	O
carriage	O
of	O
1A5	O
reduced	O
the	O
risk	O
(	O
OR	O
,	O
0.3	O
;	O
95%	O
CI	O
,	O
0.1-0.97	O
)	O
.	O

An	O
analysis	O
of	O
the	O
multiple	O
single-nucleotide	O
polymorphisms	O
in	O
SP-A	O
demonstrated	O
that	O
homozygosity	O
for	O
alleles	O
encoding	O
lysine	O
(	O
in	O
1A1	O
)	O
rather	O
than	O
glutamine	O
(	O
in	O
1A5	O
)	O
at	O
amino	O
acid	O
223	O
in	O
the	O
carbohydrate	O
recognition	O
domain	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
meningococcal	O
disease	O
(	O
OR	O
,	O
6.7	O
;	O
95%	O
CI	O
,	O
1.4-31.5	O
)	O
.	O

Carriage	O
of	O
alleles	O
encoding	O
lysine	O
at	O
residue	O
223	O
was	O
found	O
in	O
61%	O
of	O
patients	O
who	O
died	O
,	O
compared	O
with	O
35%	O
of	O
those	O
who	O
survived	O
(	O
OR	O
adjusted	O
for	O
age	O
,	O
2.9	O
;	O
95%	O
CI	O
,	O
1.1-7.7	O
)	O
.	O

Genetic	O
variation	O
of	O
SP-A1	O
and	O
SP-D	O
was	O
not	O
associated	O
with	O
meningococcal	O
disease	O
.	O

CONCLUSIONS	O
:	O
Gene	O
polymorphism	O
resulting	O
in	O
the	O
substitution	O
of	O
glutamine	O
with	O
lysine	O
at	O
residue	O
223	O
in	O
the	O
carbohydrate	O
recognition	O
domain	O
of	O
SP-A2	O
increases	O
susceptibility	O
to	O
meningococcal	O
disease	O
,	O
as	O
well	O
as	O
the	O
risk	O
of	O
death	O
.	O

Nucleotide	O
change	O
of	O
codon	O
38	O
in	O
the	O
X	O
gene	O
of	O
hepatitis	O
B	O
virus	O
genotype	O
C	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
hepatocellular	O
carcinoma	O
.	O

BACKGROUND/AIMS	O
:	O
The	O
hepatitis	O
B	O
virus	O
(HBV)	O
genotype	O
C	O
is	O
associated	O
with	O
the	O
development	O
of	O
hepatocellular	O
carcinoma	O
(HCC)	O
.	O

In	O
addition	O
,	O
the	O
HBV	O
X	O
gene	O
,	O
which	O
encodes	O
the	O
pleiotropic	O
transactivator	O
HBx	O
,	O
has	O
also	O
been	O
associated	O
with	O
the	O
development	O
of	O
HCC	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
nucleotide	O
changes	O
in	O
the	O
X	O
gene	O
of	O
genotype	O
C	O
are	O
associated	O
with	O
the	O
development	O
of	O
HCC	O
.	O

METHODS/RESULTS	O
:	O
We	O
sequenced	O
the	O
X	O
gene	O
in	O
age-	O
and	O
sex-matched	O
39	O
HBV-infected	O
patients	O
with	O
HCC	O
and	O
36	O
HBV-infected	O
patients	O
without	O
HCC	O
.	O

A	O
novel	O
nucleotide	O
change	O
that	O
resulted	O
in	O
a	O
proline	O
to	O
serine	O
substitution	O
at	O
codon	O
38	O
in	O
HBx	O
(	O
codon-38	O
change	O
)	O
was	O
preferentially	O
found	O
in	O
patients	O
with	O
HCC	O
.	O

Then	O
,	O
sera	O
were	O
collected	O
from	O
a	O
new	O
group	O
of	O
age-	O
and	O
sex-matched	O
52	O
patients	O
with	O
HCC	O
and	O
51	O
patients	O
without	O
HCC	O
.	O

In	O
this	O
cohort	O
also	O
,	O
the	O
codon-38	O
change	O
was	O
associated	O
with	O
HCC	O
.	O

Multiple	O
logistic	O
regression	O
analysis	O
showed	O
the	O
prevalence	O
of	O
the	O
codon-38	O
change	O
was	O
significantly	O
associated	O
with	O
HCC	O
in	O
all	O
patients	O
(	O
P=0.001	O
,	O
odds	O
ratio	O
:	O
4.89	O
)	O
.	O

CONCLUSION	O
:	O
The	O
codon-38	O
change	O
in	O
genotype	O
C	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
the	O
development	O
of	O
HCC	O
and	O
may	O
serve	O
as	O
a	O
useful	O
molecular	O
marker	O
for	O
predicting	O
the	O
clinical	O
outcomes	O
in	O
patients	O
infected	O
with	O
HBV	O
.	O

No	O
independent	O
role	O
of	O
the	O
-1123	B-DNAMutation
G>C	I-DNAMutation
and+2740	B-DNAMutation
A>G	I-DNAMutation
variants	O
in	O
the	O
association	O
of	O
PTPN22	O
with	O
type	O
1	O
diabetes	O
and	O
juvenile	O
idiopathic	O
arthritis	O
in	O
two	O
Caucasian	O
populations	O
.	O

INTRODUCTION	O
:	O
The	O
PTPN22	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
T	O
cell	O
response	O
.	O

Its	O
+1858C>T	B-DNAMutation
R620W	B-ProteinMutation
polymorphism	O
has	O
been	O
shown	O
to	O
associate	O
with	O
a	O
risk	O
for	O
multiple	O
autoimmune	O
diseases	O
,	O
including	O
type	O
1	O
diabetes	O
(T1D)	O
and	O
juvenile	O
idiopathic	O
arthritis	O
(JIA)	O
.	O

The	O
minor	O
(susceptibility)	O
allele	O
is	O
absent	O
in	O
Asian	O
populations	O
,	O
but	O
a	O
recent	O
study	O
suggested	O
an	O
independent	O
involvement	O
of	O
another	O
polymorphism	O
located	O
within	O
the	O
promoter	O
-1123	O
nucleotides	O
relative	O
to	O
the	O
translational	O
start	O
site	O
.	O

AIMS	O
:	O
We	O
aimed	O
to	O
analyse	O
the	O
association	O
of	O
three	O
PTPN22	O
polymorphisms	O
in	O
two	O
distinct	O
Caucasian	O
populations	O
,	O
the	O
Czechs	O
(	O
with	O
T1D	O
and	O
with	O
JIA	O
)	O
and	O
Azeri	O
(	O
with	O
T1D	O
)	O
.	O

METHODS	O
:	O
The	O
single	O
nucleotide	O
polymorphisms	O
(SNP)	O
at	O
positions	O
-1123	O
rs2488457	B-SNP
,	O
+1858	O
(	O
rs2476601	B-SNP
,	O
the	O
R620W	B-ProteinMutation
substitution	O
)	O
,	O
and	O
+2740	O
rs1217412	B-SNP
were	O
genotyped	O
using	O
TaqMan	O
assays	O
in	O
372	O
subjects	O
with	O
childhood-onset	O
T1D	O
,	O
130	O
subjects	O
with	O
JIA	O
,	O
and	O
400	O
control	O
subjects	O
of	O
Czech	O
origin	O
,	O
and	O
in	O
160	O
subjects	O
with	O
T1D	O
and	O
271	O
healthy	O
controls	O
of	O
Azeri	O
origin	O
.	O

RESULTS	O
:	O
In	O
the	O
Czechs	O
,	O
all	O
three	O
SNPs	O
were	O
in	O
a	O
tight	O
linkage	O
disequlibrium	O
,	O
while	O
in	O
the	O
Azeri	O
,	O
the	O
linkage	O
disequlibrium	O
was	O
limited	O
to	O
between	O
the	O
promoter	O
and	O
3'-UTR	O
polymorphism	O
,	O
D'(-1123	O
,	O
+2740)=0.99	O
,	O
r(2)=0.72	O
.	O

Haplotype	O
reconstruction	O
via	O
the	O
expectation-maximization	O
algorithm	O
showed	O
in	O
both	O
populations	O
that	O
only	O
the	O
haplotype	O
containing	O
the	O
minor	O
(W)	O
allele	O
at	O
codon	O
620	O
was	O
associated	O
with	O
T1D	O
(	O
OR=2.26	O
,	O
95%	O
CI	O
1.68-3.02	O
in	O
Czechs	O
,	O
OR=14.8	O
,	O
95%	O
CI	O
2.0-651	O
in	O
Azeri	O
)	O
or	O
JIA	O
(	O
OR=2.43	O
,	O
95%	O
CI	O
1.66-3.56	O
in	O
Czechs	O
)	O
.	O

The	O
haplotypes	O
having	O
the	O
wild-type	O
(R)	O
allele	O
at	O
codon	O
620	O
and	O
minor	O
alleles	O
at	O
-1123	O
and/or	O
+2740	O
were	O
neutral	O
as	O
to	O
the	O
risk	O
of	O
autoimmune	O
conditions	O
in	O
both	O
populations	O
.	O

CONCLUSIONS	O
:	O
In	O
two	O
different	O
Caucasian	O
populations	O
,	O
the	O
Czechs	O
and	O
the	O
Azeri	O
,	O
no	O
independent	O
contribution	O
can	O
be	O
detected	O
either	O
of	O
the	O
-1123	O
promoter	O
SNP	O
or	O
the	O
+2740	O
3'-UTR	O
SNP	O
,	O
and	O
only	O
the	O
minor	O
allele	O
at	O
PTPN22	O
codon	O
620	O
contributes	O
to	O
the	O
risk	O
of	O
autoimmunity	O
.	O

Mutations	O
in	O
the	O
NDP	O
gene	O
:	O
contribution	O
to	O
Norrie	O
disease	O
,	O
familial	O
exudative	O
vitreoretinopathy	O
and	O
retinopathy	O
of	O
prematurity	O
.	O

BACKGROUND	O
:	O
To	O
examine	O
the	O
contribution	O
of	O
mutations	O
within	O
the	O
Norrie	O
disease	O
(NDP)	O
gene	O
to	O
the	O
clinically	O
similar	O
retinal	O
diseases	O
Norrie	O
disease	O
,	O
X-linked	O
familial	O
exudative	O
vitreoretinopathy	O
(FEVR)	O
,	O
Coat's	O
disease	O
and	O
retinopathy	O
of	O
prematurity	O
(ROP)	O
.	O

METHODS	O
:	O
A	O
dataset	O
comprising	O
13	O
Norrie-FEVR	O
,	O
one	O
Coat's	O
disease	O
,	O
31	O
ROP	O
patients	O
and	O
90	O
ex-premature	O
babies	O
of	O
<32	O
weeks'	O
gestation	O
underwent	O
an	O
ophthalmologic	O
examination	O
and	O
were	O
screened	O
for	O
mutations	O
within	O
the	O
NDP	O
gene	O
by	O
direct	O
DNA	O
sequencing	O
,	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
or	O
gel	O
electrophoresis	O
.	O

Controls	O
were	O
only	O
screened	O
using	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
and	O
gel	O
electrophoresis	O
.	O

Confirmation	O
of	O
mutations	O
identified	O
was	O
obtained	O
by	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Evidence	O
for	O
two	O
novel	O
mutations	O
in	O
the	O
NDP	O
gene	O
was	O
presented	O
:	O
Leu103Val	B-ProteinMutation
in	O
one	O
FEVR	O
patient	O
and	O
His43Arg	B-ProteinMutation
in	O
monozygotic	O
twin	O
Norrie	O
disease	O
patients	O
.	O

Furthermore	O
,	O
a	O
previously	O
described	O
14-bp	O
deletion	O
located	O
in	O
the	O
5'	O
unstranslated	O
region	O
of	O
the	O
NDP	O
gene	O
was	O
detected	O
in	O
three	O
cases	O
of	O
regressed	O
ROP	O
.	O

A	O
second	O
heterozygotic	O
14-bp	O
deletion	O
was	O
detected	O
in	O
an	O
unaffected	O
ex-premature	O
girl	O
.	O

Only	O
two	O
of	O
the	O
13	O
Norrie-FEVR	O
index	O
cases	O
had	O
the	O
full	O
features	O
of	O
Norrie	O
disease	O
with	O
deafness	O
and	O
mental	O
retardation	O
.	O

CONCLUSION	O
:	O
Two	O
novel	O
mutations	O
within	O
the	O
coding	O
region	O
of	O
the	O
NDP	O
gene	O
were	O
found	O
,	O
one	O
associated	O
with	O
a	O
severe	O
disease	O
phenotypes	O
of	O
Norrie	O
disease	O
and	O
the	O
other	O
with	O
FEVR	O
.	O

A	O
deletion	O
within	O
the	O
non-coding	O
region	O
was	O
associated	O
with	O
only	O
mild-regressed	O
ROP	O
,	O
despite	O
the	O
presence	O
of	O
low	O
birthweight	O
,	O
prematurity	O
and	O
exposure	O
to	O
oxygen	O
.	O

In	O
full-term	O
children	O
with	O
retinal	O
detachment	O
only	O
15%	O
appear	O
to	O
have	O
the	O
full	O
features	O
of	O
Norrie	O
disease	O
and	O
this	O
is	O
important	O
for	O
counselling	O
parents	O
on	O
the	O
possible	O
long-term	O
outcome	O
.	O

Intronic	O
deletions	O
in	O
the	O
SLC34A3	O
gene	O
cause	O
hereditary	O
hypophosphatemic	O
rickets	O
with	O
hypercalciuria	O
.	O

CONTEXT	O
:	O
Hereditary	O
hypophosphatemic	O
rickets	O
with	O
hypercalciuria	O
(HHRH)	O
is	O
a	O
rare	O
metabolic	O
disorder	O
,	O
characterized	O
by	O
hypophosphatemia	O
and	O
rickets/osteomalacia	O
with	O
increased	O
serum	O
1,25-dihydroxyvitamin	O
D	O
[1,25-(OH)(2)D]	O
resulting	O
in	O
hypercalciuria	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
determine	O
whether	O
mutations	O
in	O
the	O
SLC34A3	O
gene	O
,	O
which	O
encodes	O
sodium-phosphate	O
cotransporter	O
type	O
IIc	O
,	O
are	O
responsible	O
for	O
the	O
occurrence	O
of	O
HHRH	O
.	O

DESIGN	O
AND	O
SETTING	O
:	O
Mutation	O
analysis	O
of	O
exons	O
and	O
adjacent	O
introns	O
in	O
the	O
SLC34A3	O
gene	O
was	O
conducted	O
at	O
an	O
academic	O
research	O
laboratory	O
and	O
medical	O
center	O
.	O

PATIENTS	O
OR	O
OTHER	O
PARTICIPANTS	O
:	O
Members	O
of	O
two	O
unrelated	O
families	O
with	O
HHRH	O
participated	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
Two	O
affected	O
siblings	O
in	O
one	O
family	O
were	O
homozygous	O
for	O
a	O
101-bp	O
deletion	O
in	O
intron	O
9	O
.	O

Haplotype	O
analysis	O
of	O
the	O
SLC34A3	O
locus	O
in	O
the	O
family	O
showed	O
that	O
the	O
two	O
deletions	O
are	O
on	O
different	O
haplotypes	O
.	O

An	O
unrelated	O
individual	O
with	O
HHRH	O
was	O
a	O
compound	O
heterozygote	O
for	O
an	O
85-bp	O
deletion	O
in	O
intron	O
10	O
and	O
a	O
G-to-A	O
substitution	O
at	O
the	O
last	O
nucleotide	O
in	O
exon	O
7	O
.	O

The	O
intron	O
9	O
deletion	O
(	O
and	O
likely	O
the	O
other	O
two	O
mutations	O
)	O
identified	O
in	O
this	O
study	O
causes	O
aberrant	O
RNA	O
splicing	O
.	O

Sequence	O
analysis	O
of	O
the	O
deleted	O
regions	O
revealed	O
the	O
presence	O
of	O
direct	O
repeats	O
of	O
homologous	O
sequences	O
.	O

CONCLUSION	O
:	O
HHRH	O
is	O
caused	O
by	O
biallelic	O
mutations	O
in	O
the	O
SLC34A3	O
gene	O
.	O

Haplotype	O
analysis	O
suggests	O
that	O
the	O
two	O
intron	O
9	O
deletions	O
arose	O
independently	O
.	O

The	O
identification	O
of	O
three	O
independent	O
deletions	O
in	O
introns	O
9	O
and	O
10	O
suggests	O
that	O
the	O
SLC34A3	O
gene	O
may	O
be	O
susceptible	O
to	O
unequal	O
crossing	O
over	O
because	O
of	O
sequence	O
misalignment	O
during	O
meiosis	O
.	O

DNA	O
damage	O
and	O
repair	O
in	O
gastric	O
cancer--a	O
correlation	O
with	O
the	O
hOGG1	O
and	O
RAD51	O
genes	O
polymorphisms	O
.	O

The	O
cell's	O
susceptibility	O
to	O
mutagens	O
and	O
its	O
ability	O
to	O
repair	O
DNA	O
lesions	O
are	O
important	O
for	O
cancer	O
induction	O
,	O
promotion	O
and	O
progression	O
.	O

Both	O
the	O
mutagens'	O
sensitivity	O
and	O
the	O
efficacy	O
of	O
DNA	O
repair	O
may	O
be	O
affected	O
by	O
variation	O
in	O
several	O
genes	O
,	O
including	O
DNA	O
repair	O
genes	O
.	O

The	O
hOGG1	O
gene	O
encodes	O
glycosylase	O
of	O
base	O
excision	O
repair	O
and	O
RAD51	O
specifies	O
a	O
key	O
protein	O
in	O
homologues	O
recombination	O
repair	O
.	O

Both	O
can	O
be	O
involved	O
in	O
the	O
repair	O
of	O
oxidative	O
DNA	O
lesions	O
,	O
which	O
can	O
contribute	O
to	O
stomach	O
cancer	O
.	O

In	O
the	O
present	O
work	O
we	O
determined	O
the	O
level	O
of	O
basal	O
and	O
oxidative	O
DNA	O
damage	O
and	O
the	O
kinetics	O
of	O
removal	O
of	O
DNA	O
damage	O
induced	O
by	O
hydrogen	O
peroxide	O
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
30	O
gastric	O
cancer	O
patients	O
and	O
30	O
healthy	O
individuals	O
.	O

The	O
metrics	O
from	O
DNA	O
damage	O
and	O
repair	O
study	O
were	O
correlated	O
with	O
the	O
genotypes	O
of	O
common	O
polymorphisms	O
of	O
the	O
hOGG1	O
and	O
RAD51	O
genes	O
:	O
a	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
1245	I-DNAMutation
position	I-DNAMutation
of	O
the	O
hOGG1	O
gene	O
producing	O
a	O
Ser-->Cys	B-ProteinMutation
substitution	I-ProteinMutation
at	I-ProteinMutation
the	I-ProteinMutation
codon	I-ProteinMutation
326	I-ProteinMutation
(	O
the	O
Ser326Cys	B-ProteinMutation
polymorphism	O
)	O
and	O
a	O
G-->C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
135	I-DNAMutation
(	O
5'-untranslated	O
region	O
)	O
of	O
the	O
RAD51	O
gene	O
(	O
the	O
G135C	B-DNAMutation
polymorphism	O
)	O
.	O

DNA	O
damage	O
and	O
repair	O
were	O
evaluated	O
by	O
alkaline	O
single	O
cell	O
gel	O
electrophoresis	O
(	O
comet	O
assay	O
)	O
assisted	O
by	O
DNA	O
repair	O
enzymes	O
:	O
endonuclease	O
III	O
(Nth)	O
and	O
formamidopyrimidine-DNA	O
glycosylase	O
(Fpg)	O
,	O
preferentially	O
recognizing	O
oxidized	O
DNA	O
bases	O
.	O

The	O
genotypes	O
of	O
the	O
polymorphism	O
were	O
determined	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
PCR	O
.	O

We	O
observed	O
a	O
strong	O
association	O
between	O
gastric	O
cancer	O
occurrence	O
,	O
impaired	O
DNA	O
repair	O
in	O
human	O
lymphocytes	O
and	O
the	O
G/C	O
genotype	O
of	O
the	O
G135C	B-DNAMutation
polymorphism	O
of	O
the	O
RAD51	O
gene	O
.	O

Moreover	O
,	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
that	O
genotype	O
and	O
stomach	O
cancer	O
occurrence	O
in	O
subjects	O
with	O
high	O
level	O
of	O
oxidatively	O
damaged	O
DNA	O
.	O

We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
the	O
Ser1245Cys	B-ProteinMutation
polymorphism	O
of	O
the	O
hOGG1	O
gene	O
and	O
gastric	O
cancer	O
,	O
including	O
subjects	O
with	O
impaired	O
DNA	O
repair	O
and/or	O
high	O
levels	O
of	O
endogenous	O
oxidative	O
DNA	O
lesions	O
.	O

Therefore	O
,	O
our	O
result	O
suggest	O
that	O
the	O
G135C	B-DNAMutation
polymorphism	O
of	O
the	O
RAD51	O
gene	O
may	O
be	O
linked	O
with	O
gastric	O
cancer	O
by	O
the	O
modulation	O
of	O
the	O
cellular	O
response	O
to	O
oxidative	O
stress	O
and	O
this	O
polymorphism	O
may	O
be	O
a	O
useful	O
additional	O
marker	O
in	O
this	O
disease	O
along	O
with	O
the	O
genetic	O
or/and	O
environmental	O
indicators	O
of	O
oxidative	O
stress	O
.	O

Genotyping	O
of	O
five	O
chinese	O
patients	O
with	O
17alpha-hydroxylase	O
deficiency	O
diagnosed	O
through	O
high-performance	O
liquid	O
chromatography	O
serum	O
adrenal	O
profile	O
:	O
identification	O
of	O
two	O
novel	O
CYP17	O
mutations	O
.	O

CONTEXT	O
:	O
17alpha-Hydroxylase	O
deficiency	O
is	O
a	O
rare	O
form	O
of	O
congenital	O
adrenal	O
hyperplasia	O
caused	O
by	O
CYP17	O
gene	O
mutations	O
.	O

OBJECTIVE	O
:	O
Five	O
Chinese	O
patients	O
with	O
17alpha-hydroxylase	O
deficiency	O
were	O
genotyped	O
.	O

PATIENTS	O
:	O
The	O
five	O
patients	O
derived	O
from	O
four	O
families	O
living	O
in	O
Shandong	O
Province	O
,	O
China	O
.	O

The	O
diagnosis	O
of	O
17alpha-hydroxylase	O
deficiency	O
was	O
initially	O
established	O
through	O
HPLC	O
serum	O
adrenal	O
profiles	O
in	O
Qilu	O
Hospital	O
,	O
China	O
,	O
from	O
1983-1993	O
.	O

RESULTS	O
:	O
Three	O
CYP17	O
gene	O
mutations	O
were	O
identified	O
from	O
these	O
patients	O
.	O

Among	O
them	O
,	O
V311fs	B-ProteinMutation
and	O
Y329fs	B-ProteinMutation
are	O
two	O
novel	O
frame-shifting	O
mutations	O
.	O

V311fs	B-ProteinMutation
is	O
an	O
8-bp	O
nucleotide	O
(TTAAATGG)	O
deletion	O
in	O
exon	O
5	O
.	O

Y329fs	B-ProteinMutation
is	O
a	O
deletion-insertion	O
combined	O
mutation	O
TAC-->AA	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
329	I-DNAMutation
in	O
exon	O
6	O
.	O

Two	O
homozygotes	O
for	O
Y329fs	B-ProteinMutation
and	O
one	O
compound	O
heterozygote	O
for	O
Y329fs	B-ProteinMutation
and	O
V311fs	B-ProteinMutation
were	O
identified	O
from	O
three	O
different	O
families	O
.	O

Two	O
homozygous	O
sisters	O
for	O
the	O
D487_S488_F489	O
deletion	O
were	O
identified	O
.	O

CONCLUSION	O
:	O
The	O
results	O
confirmed	O
the	O
diagnostic	O
value	O
of	O
the	O
HPLC	O
serum	O
adrenal	O
profile	O
for	O
17alpha-hydroxylase	O
deficiency	O
.	O

The	O
D487_S488_F489	O
deletion	O
had	O
been	O
identified	O
in	O
two	O
previously	O
genotyped	O
Chinese	O
families	O
.	O

In	O
our	O
present	O
study	O
,	O
a	O
third	O
Chinese	O
family	O
with	O
this	O
mutation	O
was	O
identified	O
,	O
suggesting	O
that	O
this	O
mutation	O
is	O
a	O
prevalent	O
CYP17	O
mutation	O
in	O
the	O
Chinese	O
population	O
.	O

The	O
identification	O
of	O
Y329fs	B-ProteinMutation
mutation	O
in	O
addition	O
to	O
three	O
previously	O
identified	O
mutations	O
at	O
codon	O
329	O
suggests	O
that	O
codon	O
329	O
is	O
an	O
unstable	O
point	O
of	O
the	O
CYP17	O
gene	O
.	O

The	O
mutations	O
identified	O
from	O
our	O
five	O
patients	O
appear	O
to	O
be	O
random	O
,	O
but	O
the	O
recurrence	O
of	O
the	O
Y329fs	B-ProteinMutation
mutation	O
may	O
be	O
attributed	O
to	O
a	O
founder	O
effect	O
.	O

Our	O
studies	O
suggest	O
that	O
17alpha-hydroxylase	O
deficiency	O
may	O
not	O
be	O
rare	O
in	O
the	O
Chinese	O
population	O
.	O

A	O
novel	O
multidrug-resistance	O
protein	O
2	O
gene	O
mutation	O
identifies	O
a	O
subgroup	O
of	O
patients	O
with	O
primary	O
biliary	O
cirrhosis	O
and	O
pruritus	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
characterized	O
by	O
the	O
substitution	O
of	O
valine	O
for	O
glutamate	O
V1188E	B-ProteinMutation
in	O
exon	O
25	O
of	O
the	O
multidrug	O
resistance	O
protein	O
2	O
gene	O
was	O
found	O
in	O
a	O
group	O
of	O
patients	O
with	O
primary	O
biliary	O
cirrhosis	O
.	O

This	O
heterozygous	O
mutation	O
was	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
pruritus	O
.	O

Genetic	O
heterogeneity	O
of	O
the	O
GLDC	O
gene	O
in	O
28	O
unrelated	O
patients	O
with	O
glycine	O
encephalopathy	O
.	O

Glycine	O
encephalopathy	O
,	O
or	O
nonketotic	O
hyperglycinaemia	O
(	O
NKH	O
;	O
Mckusick	O
238300	O
)	O
is	O
a	O
severe	O
autosomal	O
recessive	O
disease	O
due	O
to	O
a	O
defect	O
in	O
the	O
glycine	O
cleavage	O
system	O
(GCS)	O
,	O
which	O
is	O
a	O
complex	O
of	O
four	O
subunits	O
:	O
P-	O
,	O
T-	O
,	O
H-	O
and	O
L-proteins	O
.	O

A	O
P-protein	O
(	O
glycine	O
decarboxylase	O
or	O
GLDC	O
)	O
deficiency	O
was	O
reported	O
in	O
about	O
80%	O
of	O
NKH	O
patients	O
.	O

We	O
performed	O
mutation	O
analysis	O
of	O
the	O
complete	O
coding	O
sequence	O
of	O
the	O
GLDC	O
gene	O
in	O
28	O
unrelated	O
patients	O
with	O
neonatal	O
NKH	O
using	O
denaturing	O
high-performance	O
liquid	O
chromatography	O
(DHPLC)	O
and	O
sequencing	O
.	O

Forty	O
different	O
gene	O
alterations	O
were	O
identified	O
,	O
confirming	O
the	O
large	O
molecular	O
heterogeneity	O
of	O
the	O
GLDC	O
gene	O
.	O

Eighteen	O
alterations	O
were	O
clearly	O
disease-causing	O
:	O
two	O
large	O
deletions	O
,	O
four	O
one-base	O
deletions	O
(	O
c.28delC	B-DNAMutation
,	O
c.1175delC	B-DNAMutation
,	O
c.2186delC	B-DNAMutation
,	O
c.2422delA	B-DNAMutation
)	O
,	O
one	O
1-base	O
insertion	O
c.1002_1003insT	B-DNAMutation
,	O
one	O
4-base	O
insertion	O
c.1285_1286insCAAA	B-DNAMutation
,	O
one	O
insertion/deletion	O
c.2153_2155delinsTCCTGGTTTA	B-DNAMutation
,	O
five	O
nonsense	O
mutations	O
(	O
p.E153X	B-ProteinMutation
,	O
p.R236X	B-ProteinMutation
,	O
p.E270X	B-ProteinMutation
,	O
p.R337X	B-ProteinMutation
,	O
p.R424X	B-ProteinMutation
)	O
and	O
four	O
splice	O
site	O
mutations	O
(	O
c.861+1G	B-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
,	O
c.1402-1C	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
,	O
c.2316-1G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
,	O
c.2919+1G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	O
.	O

Additionally	O
,	O
we	O
identified	O
one	O
intronic	O
mutation	O
outside	O
the	O
consensus	O
splice	O
sites	O
(	O
c.2838+5G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	O
and	O
21	O
nucleotide	O
substitutions	O
leading	O
to	O
amino	O
acid	O
change	O
(	O
including	O
three	O
previously	O
described	O
mutations	O
:	O
p.T269M	B-ProteinMutation
,	O
p.R461Q	B-ProteinMutation
,	O
p.G771R	B-ProteinMutation
)	O
,	O
the	O
pathogenicity	O
of	O
which	O
should	O
be	O
confirmed	O
by	O
expression	O
studies	O
(	O
p.S132W	B-ProteinMutation
,	O
p.Y138F	B-ProteinMutation
,	O
p.G171A	B-ProteinMutation
,	O
p.T187K	B-ProteinMutation
,	O
p.R212K	B-ProteinMutation
,	O
p.T269M	B-ProteinMutation
,	O
p.R373W	B-ProteinMutation
,	O
p.I440N	B-ProteinMutation
,	O
p.R461Q	B-ProteinMutation
,	O
p.N533Y	B-ProteinMutation
,	O
p.C644F	B-ProteinMutation
,	O
p.H651R	B-ProteinMutation
,	O
p.V705M	B-ProteinMutation
,	O
p.N732K	B-ProteinMutation
,	O
p.G771R	B-ProteinMutation
,	O
p.H775R	B-ProteinMutation
,	O
p.T830M	B-ProteinMutation
,	O
p.A841P	B-ProteinMutation
,	O
p.D880V	B-ProteinMutation
,	O
p.S957P	B-ProteinMutation
and	O
p.R966G	B-ProteinMutation
)	O
.	O

Mutation	O
analysis	O
allowed	O
us	O
to	O
identify	O
sequence	O
alterations	O
in	O
both	O
alleles	O
for	O
19	O
patients	O
and	O
in	O
one	O
allele	O
for	O
7	O
patients	O
One	O
patient	O
was	O
carrying	O
three	O
mutations	O
(	O
p.Y138F	B-ProteinMutation
,	O
p.T269M	B-ProteinMutation
and	O
p.E153X	B-ProteinMutation
)	O
and	O
one	O
patient	O
was	O
carrying	O
two	O
amino	O
acid	O
substitutions	O
on	O
the	O
same	O
allele	O
(	O
p.V705M	B-ProteinMutation
and	O
p.R212K	B-ProteinMutation
)	O
and	O
an	O
unidentified	O
mutation	O
on	O
the	O
other	O
allele	O
.	O

No	O
mutation	O
could	O
be	O
found	O
in	O
two	O
patients	O
,	O
suggesting	O
possible	O
defects	O
in	O
the	O
H-protein	O
or	O
gene	O
alterations	O
that	O
could	O
not	O
be	O
identified	O
by	O
our	O
technique	O
.	O

The	O
potential	O
use	O
of	O
genotype	O
determination	O
for	O
prenatal	O
diagnosis	O
is	O
emphasized	O
.	O

Genetic	O
investigation	O
of	O
the	O
TSPYL1	O
gene	O
in	O
sudden	O
infant	O
death	O
syndrome	O
.	O

BACKGROUND	O
:	O
Sudden	O
infant	O
death	O
syndrome	O
(SIDS)	O
constitutes	O
the	O
most	O
frequent	O
cause	O
of	O
death	O
in	O
the	O
postperinatal	O
period	O
in	O
Germany	O
.	O

Recently	O
,	O
a	O
lethal	O
phenotype	O
characterized	O
by	O
sudden	O
infant	O
death	O
with	O
dysgenesis	O
of	O
the	O
testes	O
syndrome	O
(SIDDT)	O
was	O
identified	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
TSPYL1	O
gene	O
.	O

PURPOSE	O
:	O
The	O
study's	O
purpose	O
was	O
to	O
reveal	O
a	O
possible	O
role	O
of	O
TSPYL1	O
in	O
SIDS	O
.	O

METHODS	O
:	O
DNA	O
samples	O
of	O
126	O
SIDS	O
cases	O
and	O
261	O
controls	O
were	O
investigated	O
.	O

RESULTS	O
:	O
We	O
found	O
five	O
sequence	O
variations	O
,	O
each	O
of	O
them	O
causing	O
an	O
amino	O
acid	O
substitution	O
.	O

No	O
Hardy	O
Weinberg	O
disequilibrium	O
and	O
no	O
significant	O
difference	O
in	O
allele	O
frequencies	O
between	O
patients	O
and	O
controls	O
were	O
observed	O
for	O
any	O
variation	O
.	O

In	O
one	O
female	O
patient	O
a	O
p.F366L	B-ProteinMutation
amino	O
acid	O
polymorphism	O
was	O
found	O
heterozygous	O
,	O
which	O
could	O
not	O
be	O
displayed	O
in	O
controls	O
.	O

A	O
pathogenic	O
implication	O
of	O
this	O
substitution	O
,	O
which	O
is	O
conserved	O
in	O
primates	O
and	O
rodents	O
,	O
cannot	O
be	O
ruled	O
out	O
completely	O
.	O

Because	O
SIDDT	O
is	O
the	O
result	O
of	O
homozygous	O
TSPYL1	O
mutations	O
,	O
this	O
heterozygous	O
exchange	O
cannot	O
solely	O
explain	O
the	O
sudden	O
death	O
in	O
this	O
child	O
.	O

The	O
reported	O
mutation	O
associated	O
with	O
SIDDT	O
457_458insG	B-DNAMutation
was	O
not	O
detectable	O
in	O
our	O
cohort	O
.	O

CONCLUSION	O
:	O
No	O
association	O
of	O
sequence	O
variations	O
in	O
the	O
TSPYL1	O
gene	O
and	O
SIDS	O
has	O
been	O
found	O
in	O
a	O
German	O
cohort	O
.	O

Genetic	O
analysis	O
of	O
TSPYL1	O
seems	O
to	O
be	O
of	O
limited	O
significance	O
in	O
the	O
differential	O
diagnosis	O
of	O
SIDS	O
without	O
dysgenesis	O
of	O
the	O
testes	O
.	O

Indirect	O
CFTR	O
mutation	O
identification	O
by	O
PCR/OLA	O
anomalous	O
electropherograms	O
.	O

Mutations	O
of	O
CFTR	O
gene	O
are	O
responsible	O
for	O
cystic	O
fibrosis	O
(CF)	O
and	O
other	O
clinical	O
conditions	O
such	O
as	O
congenital	O
absence	O
of	O
the	O
vas	O
deferens	O
(CAVD)	O
,	O
chronic	O
pancreatitis	O
(IP)	O
,	O
and	O
idiopathic	O
disseminated	O
bronchiectasis	O
(DBE)	O
classified	O
as	O
CFTR-related	O
disorders	O
.	O

The	O
PCR/OLA	O
assay	O
is	O
designed	O
to	O
detect	O
31	O
known	O
mutations	O
including	O
the	O
24	O
most	O
common	O
CF	O
mutations	O
worldwide	O
,	O
as	O
identified	O
by	O
the	O
CF	O
Consortium	O
.	O

In	O
order	O
to	O
define	O
the	O
CFTR	O
genotype	O
a	O
series	O
of	O
1812	O
individuals	O
from	O
central-southern	O
Italy	O
with	O
and	O
without	O
CF	O
manifestations	O
were	O
screened	O
by	O
using	O
the	O
PCR/OLA	O
assay	O
.	O

Here	O
we	O
report	O
the	O
description	O
of	O
five	O
cases	O
of	O
anomalous	O
electropherograms	O
obtained	O
after	O
PCR/OLA	O
analysis	O
,	O
that	O
led	O
to	O
the	O
identification	O
,	O
in	O
the	O
homozygous	O
state	O
,	O
of	O
two	O
point	O
mutations	O
(	O
D110H	B-ProteinMutation
and	O
S589N	B-ProteinMutation
)	O
not	O
included	O
in	O
the	O
assay	O
test	O
panel	O
,	O
a	O
large	O
gene	O
deletion	O
CFTRdel14b_17b	B-DNAMutation
,	O
and	O
an	O
exonic	O
polymorphism	O
(	O
c.4002A	B-DNAMutation
>	I-DNAMutation
G	I-DNAMutation
)	O
.	O

Haplotype	O
and	O
real	O
time	O
PCR	O
analysis	O
were	O
also	O
performed	O
in	O
the	O
subject	O
carrying	O
the	O
large	O
CFTR	O
deletion	O
.	O

The	O
study	O
demonstrates	O
that	O
the	O
PCR/OLA	O
assay	O
,	O
besides	O
being	O
an	O
efficient	O
and	O
user-friendly	O
method	O
to	O
screen	O
known	O
mutations	O
in	O
the	O
CFTR	O
gene	O
,	O
may	O
also	O
function	O
as	O
a	O
mutation/polymorphism-scanning	O
assay	O
,	O
at	O
least	O
for	O
certain	O
nucleotide	O
changes	O
located	O
in	O
some	O
critical	O
regions	O
of	O
the	O
gene	O
.	O

Congenital	O
disorder	O
of	O
glycosylation	O
Ic	O
due	O
to	O
a	O
de	O
novo	O
deletion	O
and	O
an	O
hALG-6	O
mutation	O
.	O

We	O
describe	O
a	O
new	O
cause	O
of	O
congenital	O
disorder	O
of	O
glycosylation-Ic	O
(CDG-Ic)	O
in	O
a	O
young	O
girl	O
with	O
a	O
rather	O
mild	O
CDG	O
phenotype	O
.	O

Her	O
cells	O
accumulated	O
lipid-linked	O
oligosaccharides	O
lacking	O
three	O
glucose	O
residues	O
,	O
and	O
sequencing	O
of	O
the	O
ALG6	O
gene	O
showed	O
what	O
initially	O
appeared	O
to	O
be	O
a	O
homozygous	O
novel	O
point	O
mutation	O
338G>A	B-DNAMutation
.	O

However	O
,	O
haplotype	O
analysis	O
showed	O
that	O
the	O
patient	O
does	O
not	O
carry	O
any	O
paternal	O
DNA	O
markers	O
extending	O
33kb	O
in	O
the	O
telomeric	O
direction	O
from	O
the	O
ALG6	O
region	O
,	O
and	O
microsatellite	O
analysis	O
extended	O
the	O
abnormal	O
region	O
to	O
at	O
least	O
2.5Mb	O
.	O

We	O
used	O
high-resolution	O
karyotyping	O
to	O
confirm	O
a	O
deletion	O
(10-12Mb)	O
[del(1)(p31.2p32.3)]	O
and	O
found	O
no	O
structural	O
abnormalities	O
in	O
the	O
father	O
,	O
suggesting	O
a	O
de	O
novo	O
event	O
.	O

Our	O
findings	O
extend	O
the	O
causes	O
of	O
CDG	O
to	O
larger	O
DNA	O
deletions	O
and	O
identify	O
the	O
first	O
Japanese	O
CDG-Ic	O
mutation	O
.	O

A	O
novel	O
single-nucleotide	O
substitution	O
,	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
,	O
in	O
the	O
leukotriene	O
C4	O
synthase	O
gene	O
associated	O
with	O
allergic	O
diseases	O
.	O

Cysteinyl	O
leukotrienes	O
(cysLTs)	O
play	O
important	O
roles	O
in	O
bronchial	O
asthma	O
,	O
and	O
can	O
mediate	O
bronchial	O
smooth	O
muscle	O
constriction	O
and	O
increase	O
mucous	O
secretion	O
,	O
vascular	O
permeability	O
and	O
cellular	O
infiltration	O
.	O

We	O
identified	O
a	O
novel	O
heterozygous	O
single-nucleotide	O
substitution	O
10G>A	B-DNAMutation
(	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
)	O
in	O
the	O
first	O
exon	O
of	O
the	O
leukotriene	O
C4	O
synthase	O
gene	O
(LTC4S)	O
.	O

This	O
substitution	O
was	O
detected	O
in	O
5	O
of	O
141	O
allergic	O
patients	O
,	O
but	O
not	O
in	O
110	O
nonallergic	O
subjects	O
.	O

There	O
was	O
a	O
difference	O
in	O
the	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
frequency	O
between	O
the	O
allergic	O
patients	O
and	O
nonallergic	O
subjects	O
(	O
Fisher's	O
exact	O
test	O
,	O
p=0.0460	O
)	O
.	O

The	O
five	O
patients	O
with	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
had	O
allergic	O
diseases	O
such	O
as	O
bronchial	O
asthma	O
and/or	O
allergic	O
dermatitis	O
.	O

Furthermore	O
,	O
a	O
familial	O
analysis	O
of	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
revealed	O
a	O
link	O
with	O
allergic	O
diseases	O
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
Glu	B-ProteinMutation
4	I-ProteinMutation
Lys	I-ProteinMutation
in	O
the	O
LTC4S	O
might	O
be	O
associated	O
with	O
allergic	O
diseases	O
.	O

A	O
genetic	O
analysis	O
of	O
serotonergic	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
in	O
migraine	O
using	O
a	O
DNA	O
pooling	O
approach	O
.	O

Migraine	O
is	O
a	O
common	O
debilitating	O
primary	O
headache	O
disorder	O
with	O
significant	O
mental	O
,	O
physical	O
and	O
social	O
health	O
implications	O
.	O

The	O
brain	O
neurotransmitter	O
5-hydroxytryptamine	O
(	O
5-HT	O
;	O
serotonin	O
)	O
is	O
involved	O
in	O
nociceptive	O
pathways	O
and	O
has	O
been	O
implicated	O
in	O
the	O
pathophysiology	O
of	O
migraine	O
.	O

With	O
few	O
genetic	O
studies	O
investigating	O
biosynthetic	O
and	O
metabolic	O
enzymes	O
governing	O
the	O
rate	O
of	O
5-HT	O
activity	O
and	O
their	O
relationship	O
to	O
migraine	O
,	O
it	O
was	O
the	O
objective	O
of	O
this	O
study	O
to	O
assess	O
genetic	O
variants	O
within	O
the	O
human	O
tryptophan	O
hydroxylase	O
(TPH)	O
,	O
amino	O
acid	O
decarboxylase	O
(AADC)	O
and	O
monoamine	O
oxidase	O
A	O
(MAOA)	O
genes	O
in	O
migraine	O
susceptibility	O
.	O

This	O
objective	O
was	O
undertaken	O
using	O
a	O
high-throughput	O
DNA	O
pooling	O
experimental	O
design	O
,	O
which	O
proved	O
to	O
be	O
a	O
very	O
accurate	O
,	O
sensitive	O
and	O
specific	O
method	O
of	O
estimating	O
allele	O
frequencies	O
for	O
single	O
nucleotide	O
polymorphism	O
,	O
insertion	O
deletion	O
and	O
variable	O
number	O
tandem	O
repeat	O
loci	O
.	O

Application	O
of	O
DNA	O
pooling	O
to	O
a	O
wide	O
array	O
of	O
genetic	O
loci	O
provides	O
greater	O
scope	O
in	O
the	O
assessment	O
of	O
population-based	O
genetic	O
association	O
study	O
designs	O
.	O

Despite	O
the	O
application	O
of	O
this	O
high-throughput	O
genotyping	O
method	O
,	O
negative	O
results	O
from	O
the	O
two-stage	O
DNA	O
pooling	O
design	O
used	O
to	O
screen	O
loci	O
within	O
the	O
TPH	O
,	O
AADC	O
and	O
MAOA	O
genes	O
did	O
not	O
support	O
their	O
role	O
in	O
migraine	O
susceptibility	O
.	O

A	O
Cys	B-ProteinMutation
23-Ser	I-ProteinMutation
23	I-ProteinMutation
substitution	O
in	O
the	O
5-HT(2C)	O
receptor	O
gene	O
influences	O
body	O
weight	O
regulation	O
in	O
females	O
with	O
seasonal	O
affective	O
disorder	O
:	O
an	O
Austrian-Canadian	O
collaborative	O
study	O
.	O

Most	O
females	O
with	O
seasonal	O
affective	O
disorder	O
(SAD)	O
exhibit	O
atypical	O
vegetative	O
symptoms	O
such	O
as	O
overeating	O
,	O
and	O
weight	O
gain	O
when	O
depressed	O
.	O

The	O
serotonin	O
2C	O
receptor	O
(5-HT(2C))	O
plays	O
a	O
key	O
role	O
in	O
control	O
of	O
appetite	O
and	O
satiety	O
.	O

A	O
5-HT(2C)	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
substitution	O
,	O
coded	O
for	O
by	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
)	O
within	O
the	O
5-HT(2C)	O
gene	O
,	O
has	O
been	O
shown	O
to	O
influence	O
5-HT(2C)	O
function	O
.	O

We	O
hypothesized	O
that	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
influences	O
weight	O
regulation	O
in	O
females	O
with	O
SAD	O
.	O

Two	O
independent	O
samples	O
from	O
Austria	O
(	O
162	O
females	O
with	O
SAD	O
,	O
119	O
controls	O
)	O
,	O
and	O
Canada	O
(	O
90	O
females	O
with	O
SAD	O
,	O
42	O
controls	O
)	O
were	O
genotyped	O
for	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
.	O

Influence	O
on	O
weight	O
regulation	O
was	O
analyzed	O
within	O
patients	O
with	O
atypical	O
features	O
.	O

In	O
Austrians	O
,	O
genotype	O
distribution	O
differed	O
between	O
patients	O
and	O
controls	O
(p=0.044)	O
and	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
was	O
associated	O
with	O
weight	O
(p=0.039)	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
;	O
p=0.038	O
)	O
,	O
and	O
seasonal	O
appetite	O
change	O
(p=0.031)	O
.	O

All	O
values	O
were	O
highest	O
in	O
Cys/Cys	O
,	O
intermediate	O
in	O
Cys/Ser	O
,	O
and	O
lowest	O
in	O
Ser/Ser	O
carriers	O
.	O

In	O
Canadian	O
patients	O
,	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
was	O
associated	O
with	O
minimum	O
lifetime	O
BMI	O
(p=0.046)	O
,	O
with	O
lowest	O
values	O
in	O
Ser/Ser	O
carriers	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
mediates	O
severity	O
of	O
weight	O
regulation	O
disturbances	O
in	O
females	O
with	O
SAD	O
,	O
and	O
the	O
gene-dose	O
effect-like	O
differences	O
suggest	O
a	O
direct	O
functional	O
role	O
of	O
Cys	B-ProteinMutation
23	I-ProteinMutation
Ser	I-ProteinMutation
in	O
the	O
behavioral	O
regulation	O
of	O
body	O
weight	O
.	O

Two	O
novel	O
mutations	O
in	O
SRY	O
gene	O
form	O
Chinese	O
sex	O
reversal	O
XY	O
females	O
.	O

The	O
SRY	O
gene	O
(	O
sex	O
determining	O
region	O
on	O
Y	O
chromosome	O
)	O
acts	O
as	O
TDF	O
and	O
is	O
required	O
for	O
regulating	O
male	O
sex	O
determination	O
.	O

SRY	O
represents	O
a	O
transcription	O
factor	O
belonging	O
to	O
the	O
superfamily	O
of	O
genes	O
sharing	O
the	O
HMG-box	O
motif	O
(	O
high-mobility	O
group-box	O
)	O
,	O
which	O
acts	O
as	O
DNA	O
binding	O
region	O
.	O

Deletion	O
and	O
inactivating	O
mutations	O
of	O
SRY	O
are	O
among	O
the	O
known	O
causes	O
of	O
XY	O
sex	O
reversal	O
.	O

Here	O
,	O
we	O
described	O
the	O
screening	O
of	O
10	O
patients	O
who	O
presented	O
with	O
46,XY	O
sex	O
reversal	O
for	O
mutations	O
in	O
open	O
reading	O
frame	O
(ORF)	O
of	O
SRY	O
gene	O
.	O

DNA	O
was	O
isolated	O
from	O
blood	O
samples	O
using	O
standard	O
techniques	O
.	O

A	O
609	O
bp	O
fragment	O
from	O
the	O
central	O
portion	O
of	O
the	O
SRY	O
gene	O
was	O
amplified	O
,	O
using	O
primers	O
XES-2	O
and	O
XES-7	O
.	O

The	O
amplified	O
PCR	O
fragments	O
were	O
cloned	O
into	O
the	O
pUCm-T	O
vectors	O
,	O
and	O
direct	O
sequencing	O
were	O
carried	O
out	O
on	O
an	O
ABI	O
377-3	O
automated	O
DNA	O
sequencer	O
to	O
detect	O
the	O
mutation	O
.	O

PCR-restriction	O
enzyme	O
digestion	O
was	O
applied	O
to	O
detect	O
the	O
results	O
of	O
DNA	O
sequencing	O
.	O

In	O
two	O
patients,de	O
novo	O
mutations	O
led	O
to	O
an	O
amino	O
acid	O
substitution	O
.	O

An	O
A	O
was	O
replaced	O
by	O
a	O
G	O
in	O
codon	O
38	O
upstream	O
of	O
the	O
5'	O
border	O
outside	O
the	O
HMG	O
box	O
of	O
the	O
SRY	O
gene	O
,	O
resulting	O
in	O
the	O
replacement	O
of	O
the	O
amino	O
acid	O
glutamate	O
by	O
glycine	O
.	O

Another	O
heterozygous	O
T	O
to	O
A	O
transition	O
at	O
the	O
nucleotide	O
position	O
+387	O
which	O
encodes	O
for	O
a	O
Tyrosine	O
(Tyr)	O
instead	O
of	O
a	O
Term	O
,	O
whereas	O
her	O
father	O
was	O
proven	O
to	O
have	O
the	O
wild-type	O
sequence	O
.	O

These	O
point	O
mutations	O
have	O
been	O
confirmed	O
with	O
PCR-restrict	O
enzyme	O
method	O
.	O

As	O
demonstrated	O
by	O
the	O
Human	O
Gene	O
Mutation	O
Database	O
analysis,homology	O
search	O
,	O
and	O
review	O
of	O
the	O
literature	O
,	O
these	O
two	O
mutations	O
were	O
not	O
described	O
previously	O
and	O
brought	O
the	O
total	O
number	O
of	O
SRY	O
gene	O
nucleotide	O
substitutions	O
(missense/nonsense)	O
to	O
45	O
.	O

These	O
findings	O
indicated	O
that	O
these	O
amino	O
acid	O
substitutions	O
may	O
be	O
responsible	O
for	O
the	O
sex	O
reversal,not	O
only	O
inside	O
the	O
HMG-box	O
but	O
also	O
outside	O
the	O
HMG-box	O
.	O

The	O
two	O
novel	O
mutations	O
in	O
SRY	O
gene	O
provided	O
valuable	O
information	O
for	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
the	O
patient	O
with	O
46,XY	O
female	O
sex	O
reversal	O
.	O

Successful	O
therapy	O
with	O
argatroban	O
for	O
superior	O
mesenteric	O
vein	O
thrombosis	O
in	O
a	O
patient	O
with	O
congenital	O
antithrombin	O
deficiency	O
.	O

A	O
38-year-old	O
woman	O
was	O
admitted	O
with	O
superior	O
mesenteric	O
vein	O
(SMV)	O
thrombosis	O
,	O
which	O
was	O
refractory	O
to	O
anticoagulation	O
therapy	O
.	O

The	O
plasma	O
antithrombin	O
activity	O
was	O
decreased	O
and	O
hardly	O
compensated	O
by	O
concentrated	O
antithrombin	O
preparation	O
due	O
to	O
high	O
consumption	O
rate	O
.	O

However	O
,	O
successful	O
anticoagulation	O
was	O
achieved	O
by	O
administration	O
of	O
direct	O
thrombin	O
inhibitor	O
,	O
argatroban	O
.	O

Family	O
studies	O
of	O
antithrombin	O
activity	O
revealed	O
that	O
she	O
had	O
type	O
I	O
congenital	O
antithrombin	O
deficiency	O
.	O

A	O
novel	O
heterozygous	O
mutation	O
in	O
the	O
gene	O
for	O
antithrombin	O
(	O
single	O
nucleotide	O
T	O
insertion	O
at	O
7916	O
and	O
7917	O
,	O
Glu	B-ProteinMutation
272	I-ProteinMutation
to	I-ProteinMutation
stop	I-ProteinMutation
in	O
exon	O
4	O
)	O
was	O
identified	O
.	O

Argatroban	O
administration	O
would	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
congenital	O
antithrombin	O
deficiency	O
with	O
SMV	O
thrombosis	O
.	O

Mild	O
glycine	O
encephalopathy	O
(NKH)	O
in	O
a	O
large	O
kindred	O
due	O
to	O
a	O
silent	O
exonic	O
GLDC	O
splice	O
mutation	O
.	O

BACKGROUND	O
:	O
Classic	O
neonatal-onset	O
glycine	O
encephalopathy	O
(GE)	O
is	O
devastating	O
and	O
life	O
threatening	O
.	O

Milder	O
,	O
later	O
onset	O
variants	O
have	O
been	O
reported	O
but	O
were	O
usually	O
sporadic	O
and	O
incompletely	O
defined	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
clinical	O
and	O
biochemical	O
phenotype	O
and	O
molecular	O
basis	O
of	O
mild	O
GE	O
in	O
nine	O
children	O
from	O
a	O
consanguineous	O
Israeli	O
Bedouin	O
kindred	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
screened	O
for	O
GLDC	O
,	O
AMT	O
,	O
and	O
GCSH	O
gene	O
mutations	O
.	O

GLDC	O
expression	O
in	O
lymphoblasts	O
was	O
studied	O
by	O
Northern	O
blot	O
and	O
reverse	O
transcriptase	O
PCR	O
analysis	O
.	O

RESULTS	O
:	O
Clinical	O
features	O
included	O
hypotonia	O
,	O
abnormal	O
movements	O
,	O
convulsions	O
,	O
and	O
moderate	O
mental	O
retardation	O
with	O
relative	O
sparing	O
of	O
gross	O
motor	O
function	O
,	O
activities	O
of	O
daily	O
living	O
skills	O
,	O
and	O
receptive	O
language	O
.	O

Aggression	O
and	O
irritability	O
were	O
prominent	O
.	O

CSF-to-plasma	O
glycine	O
ratio	O
was	O
mildly	O
to	O
moderately	O
elevated	O
.	O

All	O
nine	O
patients	O
were	O
homozygous	O
and	O
their	O
parents	O
heterozygous	O
for	O
a	O
novel	O
,	O
translationally	O
silent	O
GLDC	O
exon	O
22	O
transversion	O
c.2607C>A	B-DNAMutation
.	O

Lymphoblast	O
GLDC	O
mRNA	O
levels	O
were	O
considerably	O
reduced	O
.	O

Three	O
aberrantly	O
spliced	O
cDNA	O
species	O
were	O
identified	O
:	O
exon	O
22	O
and	O
exon	O
22	O
to	O
23	O
skipping	O
,	O
and	O
insertion	O
of	O
an	O
87-base	O
pair	O
cryptic	O
exon	O
.	O

Homozygosity	O
for	O
c.2607C>A	B-DNAMutation
was	O
also	O
identified	O
in	O
an	O
unrelated	O
but	O
haplotypically	O
identical	O
patient	O
with	O
an	O
unusually	O
favorable	O
outcome	O
despite	O
severe	O
neonatal-onset	O
GE	O
.	O

Mutation	O
analysis	O
enabled	O
prenatal	O
diagnosis	O
of	O
three	O
unaffected	O
and	O
one	O
affected	O
pregnancies	O
.	O

CONCLUSIONS	O
:	O
The	O
mutation	O
in	O
this	O
kindred	O
led	O
to	O
missplicing	O
and	O
reduced	O
GLDC	O
(	O
glycine	O
decarboxylase	O
)	O
expression	O
.	O

The	O
4	O
to	O
6%	O
of	O
normally	O
spliced	O
GLDC	O
mRNA	O
in	O
the	O
patients	O
may	O
account	O
for	O
their	O
relatively	O
favorable	O
clinical	O
outcome	O
compared	O
with	O
patients	O
with	O
classic	O
glycine	O
encephalopathy	O
.	O

Activating	O
mutation	O
in	O
the	O
tyrosine	O
kinase	O
JAK2	O
in	O
polycythemia	O
vera	O
,	O
essential	O
thrombocythemia	O
,	O
and	O
myeloid	O
metaplasia	O
with	O
myelofibrosis	O
.	O

Polycythemia	O
vera	O
(PV)	O
,	O
essential	O
thrombocythemia	O
(ET)	O
,	O
and	O
myeloid	O
metaplasia	O
with	O
myelofibrosis	O
(MMM)	O
are	O
clonal	O
disorders	O
arising	O
from	O
hematopoietic	O
progenitors	O
.	O

An	O
internet-based	O
protocol	O
was	O
used	O
to	O
collect	O
clinical	O
information	O
and	O
biological	O
specimens	O
from	O
patients	O
with	O
these	O
diseases	O
.	O

High-throughput	O
DNA	O
resequencing	O
identified	O
a	O
recurrent	O
somatic	O
missense	O
mutation	O
JAK2V617F	O
in	O
granulocyte	O
DNA	O
samples	O
of	O
121	O
of	O
164	O
PV	O
patients	O
,	O
of	O
which	O
41	O
had	O
homozygous	O
and	O
80	O
had	O
heterozygous	O
mutations	O
.	O

Molecular	O
and	O
cytogenetic	O
analyses	O
demonstrated	O
that	O
homozygous	O
mutations	O
were	O
due	O
to	O
duplication	O
of	O
the	O
mutant	O
allele	O
.	O

JAK2V617F	O
was	O
also	O
identified	O
in	O
granulocyte	O
DNA	O
samples	O
from	O
37	O
of	O
115	O
ET	O
and	O
16	O
of	O
46	O
MMM	O
patients	O
,	O
but	O
was	O
not	O
observed	O
in	O
269	O
normal	O
individuals	O
.	O

In	O
vitro	O
analysis	O
demonstrated	O
that	O
JAK2V617F	O
is	O
a	O
constitutively	O
active	O
tyrosine	O
kinase	O
.	O

Severe	O
growth	O
hormone	O
insensitivity	O
resulting	O
from	O
total	O
absence	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5b	O
.	O

CONTEXT	O
:	O
The	O
central	O
clinical	O
feature	O
of	O
GH	O
insensitivity	O
(GHI)	O
is	O
severe	O
growth	O
failure	O
associated	O
with	O
elevated	O
serum	O
concentrations	O
of	O
GH	O
and	O
abnormally	O
low	O
serum	O
levels	O
of	O
IGF-I	O
.	O

GHI	O
can	O
be	O
the	O
result	O
of	O
an	O
abnormality	O
in	O
the	O
GH	O
receptor	O
or	O
aberrancies	O
downstream	O
of	O
the	O
GH	O
receptor	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
GH-IGF-I	O
axis	O
in	O
a	O
young	O
female	O
GHI	O
subject	O
who	O
presented	O
with	O
a	O
height	O
of	O
114	O
cm	O
(	O
-7.8	O
sd	O
score	O
)	O
at	O
age	O
16.4	O
yr	O
.	O

PATIENT	O
:	O
The	O
subject	O
,	O
from	O
a	O
consanguineous	O
pedigree	O
,	O
had	O
circulating	O
levels	O
of	O
GH	O
and	O
GH-binding	O
protein	O
that	O
were	O
normal	O
to	O
elevated	O
,	O
whereas	O
IGF-I	O
(	O
7.2	O
ng/ml	O
;	O
normal	O
,	O
242-600	O
)	O
,	O
IGF-binding	O
protein-3	O
(	O
543	O
ng/ml	O
;	O
normal	O
,	O
2500-4800	O
)	O
,	O
and	O
acid-labile	O
subunit	O
(	O
1.22	O
microg/ml	O
;	O
normal	O
,	O
5.6-16	O
)	O
levels	O
were	O
abnormally	O
low	O
and	O
failed	O
to	O
increase	O
during	O
an	O
IGF-I	O
generation	O
test	O
.	O

DESIGN	O
:	O
Dermal	O
fibroblast	O
cultures	O
were	O
established	O
with	O
the	O
consent	O
of	O
the	O
patient	O
and	O
family	O
.	O

Immunoblot	O
analysis	O
of	O
cell	O
lysates	O
and	O
DNA	O
sequencing	O
of	O
her	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5b	O
(STAT5b)	O
,	O
a	O
critical	O
intermediate	O
of	O
the	O
GH-IGF-I	O
axis	O
,	O
were	O
performed	O
.	O

RESULTS	O
:	O
Sequencing	O
of	O
the	O
STAT5b	O
gene	O
revealed	O
a	O
novel	O
homozygous	O
insertion	O
of	O
a	O
single	O
nucleotide	O
in	O
exon	O
10	O
.	O

The	O
insertion	O
resulted	O
in	O
a	O
frame	O
shift	O
,	O
leading	O
to	O
early	O
protein	O
termination	O
and	O
consequent	O
lack	O
of	O
immunodetectable	O
STAT5b	O
protein	O
.	O

CONCLUSION	O
:	O
The	O
identification	O
of	O
a	O
second	O
case	O
of	O
severe	O
growth	O
failure	O
associated	O
with	O
STAT5b	O
mutation	O
implicates	O
a	O
unique	O
and	O
critical	O
role	O
for	O
STAT5b	O
in	O
GH	O
stimulation	O
of	O
IGF-I	O
gene	O
expression	O
and	O
statural	O
growth	O
.	O

Association	O
of	O
sporadic	O
chondrocalcinosis	O
with	O
a	O
-4-basepair	O
G-to-A	O
transition	O
in	O
the	O
5'-untranslated	O
region	O
of	O
ANKH	O
that	O
promotes	O
enhanced	O
expression	O
of	O
ANKH	O
protein	O
and	O
excess	O
generation	O
of	O
extracellular	O
inorganic	O
pyrophosphate	O
.	O

OBJECTIVE	O
:	O
Certain	O
mutations	O
in	O
ANKH	O
,	O
which	O
encodes	O
a	O
multiple-pass	O
transmembrane	O
protein	O
that	O
regulates	O
inorganic	O
pyrophosphate	O
(PPi)	O
transport	O
,	O
are	O
linked	O
to	O
autosomal-dominant	O
familial	O
chondrocalcinosis	O
.	O

This	O
study	O
investigated	O
the	O
potential	O
for	O
ANKH	O
sequence	O
variants	O
to	O
promote	O
sporadic	O
chondrocalcinosis	O
.	O

METHODS	O
:	O
ANKH	O
variants	O
identified	O
by	O
genomic	O
sequencing	O
were	O
screened	O
for	O
association	O
with	O
chondrocalcinosis	O
in	O
128	O
patients	O
with	O
severe	O
sporadic	O
chondrocalcinosis	O
or	O
pseudogout	O
and	O
in	O
ethnically	O
matched	O
healthy	O
controls	O
.	O

The	O
effects	O
of	O
specific	O
variants	O
on	O
expression	O
of	O
common	O
markers	O
were	O
evaluated	O
by	O
in	O
vitro	O
transcription/translation	O
.	O

The	O
function	O
of	O
these	O
variants	O
was	O
studied	O
in	O
transfected	O
human	O
immortalized	O
CH-8	O
articular	O
chondrocytes	O
.	O

RESULTS	O
:	O
Sporadic	O
chondrocalcinosis	O
was	O
associated	O
with	O
a	O
G-to-A	O
transition	O
in	O
the	O
ANKH	O
5'-untranslated	O
region	O
(5'-UTR)	O
at	O
4	O
bp	O
upstream	O
of	O
the	O
start	O
codon	O
(	O
in	O
homozygotes	O
of	O
the	O
minor	O
allele	O
,	O
genotype	O
relative	O
risk	O
6.0	O
,	O
P	O
=	O
0.0006	O
;	O
overall	O
genotype	O
association	O
P	O
=	O
0.02	O
)	O
.	O

This	O
-4-bp	O
transition	O
,	O
as	O
well	O
as	O
2	O
mutations	O
previously	O
linked	O
with	O
familial	O
and	O
sporadic	O
chondrocalcinosis	O
(	O
+14	O
bp	O
C-to-T	O
and	O
C-terminal	O
GAG	O
deletion	O
,	O
respectively	O
)	O
,	O
but	O
not	O
the	O
French	O
familial	O
chondrocalcinosis	O
kindred	O
143-bp	O
T-to-C	O
mutation	O
,	O
increased	O
reticulocyte	O
ANKH	O
transcription/ANKH	O
translation	O
in	O
vitro	O
.	O

Transfection	O
of	O
complementary	O
DNA	O
for	O
both	O
the	O
wild-type	O
ANKH	O
and	O
the	O
-4-bp	O
ANKH	O
protein	O
variant	O
promoted	O
increased	O
extracellular	O
PPi	O
in	O
CH-8	O
cells	O
,	O
but	O
unexpectedly	O
,	O
these	O
ANKH	O
mutants	O
had	O
divergent	O
effects	O
on	O
the	O
expression	O
of	O
extracellular	O
PPi	O
and	O
the	O
chondrocyte	O
hypertrophy	O
marker	O
,	O
type	O
X	O
collagen	O
.	O

CONCLUSION	O
:	O
A	O
subset	O
of	O
sporadic	O
chondrocalcinosis	O
appears	O
to	O
be	O
heritable	O
via	O
a	O
-4-bp	O
G-to-A	O
ANKH	O
5'-UTR	O
transition	O
that	O
up-regulates	O
expression	O
of	O
ANKH	O
and	O
extracellular	O
PPi	O
in	O
chondrocyte	O
cells	O
.	O

Distinct	O
ANKH	O
mutations	O
associated	O
with	O
heritable	O
chondrocalcinosis	O
may	O
promote	O
disease	O
by	O
divergent	O
effects	O
on	O
extracellular	O
PPi	O
and	O
chondrocyte	O
hypertrophy	O
,	O
which	O
is	O
likely	O
to	O
mediate	O
differences	O
in	O
the	O
clinical	O
phenotypes	O
and	O
severity	O
of	O
the	O
disease	O
.	O

The	O
number	O
of	O
lymph	O
node	O
metastases	O
in	O
gastric	O
cancer	O
correlates	O
with	O
the	O
angiotensin	O
I-converting	O
enzyme	O
gene	O
insertion/deletion	O
polymorphism	O
.	O

PURPOSE	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
substantiate	O
the	O
putative	O
significance	O
of	O
angiotensin	O
I-converting	O
enzyme	O
(ACE)	O
on	O
gastric	O
cancer	O
biology	O
by	O
investigating	O
the	O
influence	O
of	O
its	O
gene	O
polymorphism	O
on	O
gastric	O
cancer	O
progression	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
purified	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
tissue	O
specimens	O
.	O

Amplified	O
ACE	O
gene	O
fragments	O
were	O
separated	O
on	O
agarose	O
gels	O
.	O

D	O
or	O
I	O
alleles	O
were	O
identified	O
by	O
the	O
presence	O
of	O
190-	O
or	O
490-bp	O
fragments	O
,	O
respectively	O
.	O

Local	O
expression	O
of	O
ACE	O
was	O
investigated	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Twenty-four	O
of	O
113	O
(21%)	O
gastric	O
cancer	O
patients	O
had	O
the	O
II	O
,	O
57	O
(51%)	O
the	O
ID	O
,	O
and	O
32	O
(28%)	O
the	O
DD	O
genotype	O
.	O

The	O
distribution	O
of	O
the	O
ACE	O
genotypes	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
control	O
group	O
of	O
189	O
patients	O
without	O
gastric	O
cancer	O
.	O

However	O
,	O
the	O
ACE	O
genotypes	O
correlated	O
with	O
the	O
number	O
of	O
lymph	O
node	O
metastases	O
and	O
the	O
Unio	O
Internationale	O
Contra	O
Cancrum	O
(UICC)	O
tumor	O
stage	O
.	O

Patients	O
with	O
the	O
II	O
genotype	O
had	O
a	O
highly	O
significantly	O
smaller	O
number	O
of	O
lymph	O
node	O
metastases	O
(	O
P	O
<	O
0.001	O
)	O
and	O
a	O
significantly	O
lower	O
UICC	O
tumor	O
stage	O
(	O
P	O
=	O
0.01	O
)	O
than	O
patients	O
with	O
the	O
DD	O
genotype	O
.	O

No	O
correlation	O
was	O
found	O
between	O
tumor	O
type	O
,	O
tumor	O
location	O
,	O
local	O
tumor	O
growth	O
,	O
distant	O
metastases	O
,	O
and	O
the	O
ACE	O
genotype	O
.	O

The	O
expression	O
of	O
ACE	O
in	O
gastric	O
cancer	O
was	O
investigated	O
by	O
immunohistochemistry	O
in	O
100	O
of	O
113	O
patients	O
.	O

ACE	O
was	O
expressed	O
by	O
endothelial	O
cells	O
in	O
all	O
(100%)	O
specimens	O
and	O
by	O
tumor	O
cells	O
in	O
56	O
(56%)	O
specimens	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
shows	O
that	O
ACE	O
is	O
expressed	O
locally	O
in	O
gastric	O
cancer	O
and	O
that	O
the	O
gene	O
polymorphism	O
influences	O
metastatic	O
behavior	O
.	O

Identification	O
of	O
novel	O
type	O
VII	O
collagen	O
gene	O
mutations	O
resulting	O
in	O
severe	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
the	O
proband	O
in	O
a	O
small	O
nuclear	O
family	O
of	O
Chinese	O
and	O
Dutch/German	O
descent	O
and	O
identified	O
two	O
novel	O
mutations	O
in	O
the	O
type	O
VII	O
collagen	O
gene	O
leading	O
to	O
recessive	O
dystrophic	O
epidermolysis	O
bullosa	O
,	O
Hallopeau-Siemens	O
variant	O
(HS-RDEB)	O
.	O

The	O
maternal	O
mutation	O
is	O
a	O
single	O
base	O
pair	O
deletion	O
of	O
a	O
cytosine	O
nucleotide	O
in	O
exon	O
26	O
,	O
designated	O
3472delC	B-DNAMutation
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
termination	O
codon	O
(PTC)	O
within	O
the	O
same	O
exon	O
,	O
7	O
bp	O
downstream	O
of	O
the	O
site	O
of	O
the	O
mutation	O
.	O

The	O
paternal	O
mutation	O
is	O
a	O
G-->A	B-DNAMutation
transition	O
located	O
at	O
the	O
5'	O
donor	O
splice	O
site	O
within	O
intron	O
51	O
,	O
designated	O
IVS51	B-DNAMutation
+	I-DNAMutation
1G-->A	I-DNAMutation
.	O

This	O
mutation	O
leads	O
to	O
the	O
activation	O
of	O
a	O
cryptic	O
splice	O
site	O
,	O
32	O
bp	O
downstream	O
of	O
the	O
mutation	O
site	O
and	O
to	O
subsequent	O
aberrant	O
out-of-frame	O
splicing	O
,	O
resulting	O
in	O
two	O
alternative	O
mRNA	O
transcripts	O
and	O
a	O
downstream	O
PTC	O
.	O

To	O
our	O
knowledge	O
,	O
these	O
two	O
mutations	O
have	O
not	O
been	O
previously	O
reported	O
.	O

These	O
findings	O
extend	O
the	O
body	O
of	O
evidence	O
for	O
compound	O
heterozygous	O
mutations	O
leading	O
to	O
HS-RDEB	O
and	O
provide	O
the	O
basis	O
for	O
prenatal	O
diagnosis	O
in	O
this	O
family	O
.	O

Adult	O
onset	O
metachromatic	O
leukodystrophy	O
without	O
electroclinical	O
peripheral	O
nervous	O
system	O
involvement	O
:	O
a	O
new	O
mutation	O
in	O
the	O
ARSA	O
gene	O
.	O

BACKGROUND	O
:	O
Metachromatic	O
leukodystrophy	O
(MLD)	O
is	O
a	O
lysosomal	O
storage	O
disease	O
caused	O
by	O
the	O
deficiency	O
of	O
arylsulfatase	O
A	O
(ARSA)	O
.	O

Clinically	O
,	O
the	O
disease	O
is	O
heterogeneous	O
with	O
respect	O
to	O
the	O
age	O
of	O
onset	O
,	O
affection	O
of	O
peripheral	O
and	O
central	O
nervous	O
systems	O
,	O
and	O
progression	O
.	O

OBJECTIVES	O
:	O
To	O
analyze	O
mutations	O
in	O
the	O
ARSA	O
gene	O
of	O
a	O
patient	O
with	O
adult-onset	O
MLD	O
with	O
no	O
signs	O
of	O
peripheral	O
polyneuropathy	O
and	O
to	O
emphasize	O
the	O
clinical	O
,	O
neuroradiologic	O
,	O
neuropathologic	O
,	O
and	O
genetic	O
features	O
of	O
the	O
disease	O
.	O

DESIGN	O
:	O
Case	O
study	O
of	O
a	O
patient	O
clinically	O
presenting	O
with	O
rapidly	O
progressive	O
dementia	O
and	O
behavioral	O
abnormalities	O
.	O

We	O
report	O
the	O
findings	O
of	O
clinical	O
evaluation	O
and	O
neurophysiologic	O
and	O
neuropathologic	O
studies	O
of	O
peripheral	O
nerves	O
;	O
we	O
also	O
performed	O
DNA	O
sequence	O
analysis	O
,	O
transfections	O
,	O
metabolic	O
labeling	O
,	O
and	O
immunoprecipitation	O
of	O
mutant	O
ARSA	O
polypeptides	O
.	O

SETTING	O
:	O
Genetic	O
research	O
and	O
clinical	O
unit	O
,	O
university	O
hospital	O
.	O

RESULTS	O
:	O
Genetic	O
analysis	O
revealed	O
homozygosity	O
for	O
a	O
novel	O
mutation	O
in	O
exon	O
3	O
of	O
ARSA	O
F219V	B-ProteinMutation
.	O

This	O
substitution	O
leads	O
to	O
a	O
misfolded	O
unstable	O
enzyme	O
with	O
a	O
specific	O
activity	O
less	O
than	O
1%	O
of	O
normal	O
.	O

There	O
were	O
no	O
clinical	O
or	O
neurophysiologic	O
signs	O
of	O
peripheral	O
nervous	O
system	O
dysfunction	O
.	O

Typical	O
neuropathologic	O
signs	O
for	O
MLD	O
were	O
absent	O
from	O
nerve	O
biopsy	O
specimens	O
.	O

CONCLUSIONS	O
:	O
This	O
novel	O
mutation	O
is	O
associated	O
with	O
progressive	O
psychocognitive	O
impairment	O
without	O
clinical	O
or	O
electrophysiologic	O
signs	O
and	O
only	O
minor	O
morphologic	O
signs	O
of	O
peripheral	O
nerve	O
affection	O
.	O

The	O
F219V	B-ProteinMutation
substitution	O
causes	O
reduction	O
in	O
enzyme	O
activity	O
to	O
an	O
extent	O
unexpected	O
for	O
an	O
adult	O
patient	O
with	O
MLD	O
.	O

Parkin	O
mutations	O
and	O
early-onset	O
parkinsonism	O
in	O
a	O
Taiwanese	O
cohort	O
.	O

BACKGROUND	O
:	O
Loss	O
of	O
function	O
of	O
the	O
parkin	O
gene	O
(PRKN)	O
is	O
the	O
predominant	O
genetic	O
cause	O
of	O
juvenile	O
and	O
early-onset	O
parkinsonism	O
in	O
Japan	O
,	O
Europe	O
,	O
and	O
the	O
United	O
States	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
frequency	O
of	O
PRKN	O
mutations	O
in	O
Taiwanese	O
(	O
ethnic	O
Chinese	O
)	O
patients	O
with	O
early-onset	O
parkinsonism	O
and	O
to	O
explore	O
genotype-phenotype	O
correlations	O
.	O

DESIGN	O
:	O
Clinical	O
assessment	O
included	O
medical	O
,	O
neurologic	O
,	O
and	O
psychiatric	O
evaluation	O
.	O

Genomic	O
DNA	O
sequencing	O
and	O
quantitative	O
polymerase	O
chain	O
reaction	O
were	O
performed	O
to	O
identify	O
PRKN	O
mutations	O
.	O

Gene	O
expression	O
was	O
examined	O
in	O
patient	O
lymphoblastoid	O
cell	O
lines	O
,	O
in	O
which	O
PRKN	O
mutations	O
were	O
identified	O
.	O

PATIENTS	O
:	O
Forty-one	O
Taiwanese	O
patients	O
with	O
early-onset	O
parkinsonism	O
(	O
aged	O
<50	O
years	O
at	O
onset	O
)	O
.	O

RESULTS	O
:	O
Four	O
of	O
41	O
probands	O
had	O
PRKN	O
mutations	O
.	O

One	O
proband	O
had	O
compound	O
heterozygous	O
mutations	O
,	O
with	O
a	O
PRKN	O
exon	O
2	O
deletion	O
and	O
an	O
exon	O
7	O
G284R	B-ProteinMutation
substitution	O
.	O

The	O
phenotype	O
resembled	O
typical	O
Parkinson	O
disease	O
.	O

Three	O
patients	O
were	O
mutation	O
carriers	O
.	O

One	O
proband	O
had	O
PRKN	O
exon	O
2	O
and	O
exon	O
3	O
deletions	O
in	O
the	O
same	O
allele	O
.	O

However	O
,	O
this	O
patient's	O
phenotype	O
was	O
that	O
of	O
classic	O
"parkin-proven"	O
autosomal	O
recessive	O
juvenile	O
parkinsonism	O
,	O
characterized	O
by	O
symmetrical	O
foot	O
dystonia	O
at	O
onset	O
,	O
gait	O
disturbance	O
,	O
diurnal	O
change	O
,	O
and	O
very	O
slow	O
progression	O
.	O

The	O
2	O
remaining	O
carriers	O
had	O
novel	O
heterozygous	O
exon	O
11	O
R396G	B-ProteinMutation
substitutions	O
.	O

Patients	O
with	O
PRKN	O
mutations	O
were	O
younger	O
at	O
onset	O
than	O
those	O
without	O
mutations	O
,	O
and	O
they	O
required	O
a	O
lower	O
dose	O
of	O
levodopa	O
despite	O
longer	O
disease	O
duration	O
.	O

CONCLUSIONS	O
:	O
Mutations	O
in	O
PRKN	O
are	O
a	O
rare	O
cause	O
of	O
early-onset	O
parkinsonism	O
in	O
Taiwanese	O
individuals	O
.	O

The	O
overall	O
mutation	O
frequency	O
,	O
adjusted	O
for	O
age	O
at	O
onset	O
,	O
was	O
comparable	O
with	O
that	O
reported	O
for	O
white	O
cohorts	O
;	O
however	O
,	O
the	O
point	O
mutations	O
identified	O
seem	O
to	O
be	O
population	O
specific	O
.	O

TGFBI	O
gene	O
mutations	O
causing	O
lattice	O
and	O
granular	O
corneal	O
dystrophies	O
in	O
Indian	O
patients	O
.	O

PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
TGFBI	O
gene	O
in	O
Indian	O
patients	O
with	O
lattice	O
corneal	O
dystrophy	O
(LCD)	O
or	O
granular	O
corneal	O
dystrophy	O
(GCD)	O
and	O
to	O
look	O
for	O
genotype-phenotype	O
correlations	O
.	O

METHODS	O
:	O
Thirty-seven	O
unrelated	O
patients	O
were	O
studied	O
,	O
18	O
with	O
LCD	O
and	O
19	O
with	O
GCD	O
.	O

The	O
diagnosis	O
of	O
LCD	O
or	O
GCD	O
was	O
made	O
on	O
the	O
basis	O
of	O
clinical	O
and/or	O
histopathological	O
evaluation	O
.	O

Exons	O
and	O
flanking	O
intron	O
sequences	O
of	O
the	O
TGFBI	O
gene	O
were	O
amplified	O
by	O
PCR	O
with	O
specific	O
primers	O
.	O

PCR	O
products	O
were	O
screened	O
by	O
the	O
method	O
of	O
single-strand	O
conformation	O
polymorphism	O
followed	O
by	O
sequencing	O
.	O

Mutations	O
were	O
confirmed	O
by	O
screening	O
at	O
least	O
100	O
unrelated	O
normal	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Mutations	O
were	O
identified	O
in	O
14	O
of	O
18	O
patients	O
with	O
LCD	O
and	O
in	O
all	O
19	O
patients	O
with	O
GCD	O
.	O

In	O
LCD	O
,	O
three	O
novel	O
heterozygous	O
mutations	O
found	O
were	O
glycine-594-valine	B-ProteinMutation
Gly594Val	B-ProteinMutation
in	O
2	O
of	O
18	O
patients	O
,	O
valine-539-aspartic	B-ProteinMutation
acid	O
Val539Asp	B-ProteinMutation
in	O
1	O
patient	O
,	O
and	O
deletion	O
of	O
valine	O
624	O
,	O
valine	O
625	O
Val624-Val625del	B-ProteinMutation
in	O
1	O
patient	O
.	O

In	O
addition	O
,	O
mutation	O
of	O
arginine	B-ProteinMutation
124-to-cysteine	I-ProteinMutation
Arg124Cys	B-ProteinMutation
was	O
found	O
in	O
8	O
of	O
18	O
patients	O
and	O
histidine	B-ProteinMutation
626-to-arginine	I-ProteinMutation
His626Arg	B-ProteinMutation
in	O
2	O
of	O
18	O
patients	O
.	O

Atypical	O
clinical	O
features	O
for	O
LCD	O
were	O
noted	O
in	O
patients	O
with	O
the	O
Gly594Val	B-ProteinMutation
and	O
Val624-Val625del	B-ProteinMutation
mutations	O
.	O

In	O
GCD	O
,	O
18	O
patients	O
with	O
GCD	O
type	O
I	O
had	O
a	O
mutation	O
of	O
arginine	B-ProteinMutation
555-to-tryptophan	I-ProteinMutation
Arg555Trp	B-ProteinMutation
and	O
1	O
patient	O
with	O
GCD	O
type	O
III	O
(	O
Reis-Bucklers	O
dystrophy	O
)	O
,	O
had	O
the	O
Arg124Leu	B-ProteinMutation
mutation	O
.	O

Seven	O
novel	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
also	O
found	O
,	O
of	O
which	O
a	O
change	O
of	O
leucine	B-ProteinMutation
269	I-ProteinMutation
to	I-ProteinMutation
phenylalanine	I-ProteinMutation
Leu269Phe	B-ProteinMutation
was	O
found	O
in	O
12	O
of	O
18	O
patients	O
with	O
the	O
Arg555Trp	B-ProteinMutation
mutation	O
.	O

CONCLUSIONS	O
:	O
Arg124Cys	B-ProteinMutation
and	O
Arg555Trp	B-ProteinMutation
appear	O
to	O
be	O
the	O
predominant	O
mutations	O
causing	O
LCD	O
and	O
GCD	O
,	O
respectively	O
,	O
in	O
the	O
population	O
studied	O
.	O

The	O
novel	O
mutations	O
identified	O
in	O
this	O
study	O
are	O
associated	O
with	O
distinct	O
phenotypes	O
.	O

Two	O
new	O
beta-chain	O
variants	O
:	O
Hb	O
Tripoli	O
beta26(B8)Glu-->Ala	B-ProteinMutation
and	O
Hb	O
Tizi-Ouzou	O
beta29(B11)Gly-->Ser	B-ProteinMutation
.	O

Two	O
new	O
beta-globin	O
chain	O
variants	O
:	O
Hb	O
Tripoli	O
:	O
codon	B-DNAMutation
26	I-DNAMutation
,	I-DNAMutation
GAG-->GCG	I-DNAMutation
beta26(B8)Glu-->Ala	B-ProteinMutation
and	O
Hb	O
Tizi-Ouzou	O
:	O
codon	B-DNAMutation
29	I-DNAMutation
,	I-DNAMutation
GGC-->AGC	I-DNAMutation
beta29(B11)Gly-->Ser	B-ProteinMutation
are	O
described	O
on	O
the	O
first	O
exon	O
of	O
the	O
beta-globin	O
gene	O
.	O

The	O
two	O
variants	O
are	O
characterized	O
by	O
DNA	O
sequencing	O
and	O
mass	O
spectrometry	O
(MS)	O
.	O

Hematological	O
abnormalities	O
were	O
found	O
in	O
the	O
two	O
carriers	O
.	O

The	O
presence	O
of	O
microcytosis	O
and	O
hypochromia	O
is	O
explained	O
by	O
an	O
additional	O
homozygous	O
3.7	O
kb	O
alpha(+)	O
thalassemic	O
deletion	O
for	O
the	O
carrier	O
of	O
Hb	O
Tizi-Ouzou	O
.	O

Hb	O
Tizi-Ouzou	O
showed	O
a	O
slight	O
instability	O
in	O
vitro	O
.	O

The	O
same	O
hematological	O
abnormalities	O
associated	O
with	O
anemia	O
are	O
difficult	O
to	O
explain	O
for	O
Hb	O
Tripoli's	O
carrier	O
in	O
the	O
absence	O
of	O
an	O
alpha-globin	O
genes	O
abnormality	O
and	O
could	O
suggest	O
a	O
possible	O
abnormal	O
splicing	O
.	O

CD72	O
polymorphisms	O
associated	O
with	O
alternative	O
splicing	O
modify	O
susceptibility	O
to	O
human	O
systemic	O
lupus	O
erythematosus	O
through	O
epistatic	O
interaction	O
with	O
FCGR2B	O
.	O

We	O
previously	O
reported	O
association	O
of	O
FCGR2B-Ile232Thr	B-ProteinMutation
with	O
systemic	O
lupus	O
erythematosus	O
(SLE)	O
in	O
three	O
Asian	O
populations	O
.	O

Because	O
polymorphism	O
of	O
CD72	O
,	O
another	O
inhibitory	O
receptor	O
of	O
B	O
cells	O
,	O
was	O
associated	O
with	O
murine	O
SLE	O
,	O
we	O
identified	O
human	O
CD72	O
polymorphisms	O
,	O
tested	O
their	O
association	O
with	O
SLE	O
and	O
examined	O
genetic	O
interaction	O
with	O
FCGR2B	O
in	O
the	O
Japanese	O
(	O
160	O
SLE	O
,	O
277	O
controls	O
)	O
,	O
Thais	O
(	O
87	O
SLE	O
,	O
187	O
controls	O
)	O
and	O
Caucasians	O
(	O
94	O
families	O
containing	O
SLE	O
members	O
)	O
.	O

Four	O
polymorphisms	O
and	O
six	O
rare	O
variations	O
were	O
detected	O
.	O

The	O
former	O
constituted	O
two	O
major	O
haplotypes	O
that	O
contained	O
one	O
or	O
two	O
repeats	O
of	O
13	O
nucleotides	O
in	O
intron	O
8	O
(	O
designated	O
as	O
*1	O
and	O
*2	O
,	O
respectively	O
)	O
.	O

Although	O
association	O
with	O
susceptibility	O
to	O
SLE	O
was	O
not	O
detected	O
,	O
the	O
*1	O
allele	O
was	O
significantly	O
associated	O
with	O
nephritis	O
among	O
the	O
Japanese	O
patients	O
(P=0.024)	O
.	O

RT-PCR	O
identified	O
a	O
novel	O
alternatively	O
spliced	O
(AS)	O
transcript	O
that	O
was	O
expressed	O
at	O
the	O
protein	O
level	O
in	O
COS-7	O
transfectants	O
.	O

The	O
ratio	O
of	O
AS/common	O
isoforms	O
was	O
strikingly	O
increased	O
in	O
individuals	O
with	O
*2/*2	O
genotype	O
when	O
compared	O
with	O
*1/*1	O
(P=0.000038)	O
or	O
*1/*2	O
(P=0.0085)	O
genotypes	O
.	O

Using	O
the	O
two	O
Asian	O
cohorts	O
,	O
significant	O
association	O
of	O
FCGR2B-232Thr/Thr	O
with	O
SLE	O
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
CD72-*1/*1	O
genotype	O
(	O
OR	O
4.63	O
,	O
95%	O
CI	O
1.47-14.6	O
,	O
P=0.009	O
versus	O
FCGR2B-232Ile/Ile	O
plus	O
CD72-*2/*2	O
)	O
.	O

Minigene	O
assays	O
demonstrated	O
that	O
the	O
13-nucleotide	O
repeat	O
and	O
4	O
bp	O
deletion	O
within	O
the	O
same	O
haplotype	O
of	O
intron	O
8	O
could	O
regulate	O
alternative	O
splicing	O
.	O

The	O
AS	O
isoform	O
lacks	O
exon	O
8	O
,	O
and	O
is	O
deduced	O
to	O
contain	O
49	O
amino	O
acid	O
changes	O
in	O
the	O
membrane-distal	O
portion	O
of	O
the	O
extracellular	O
domain	O
,	O
where	O
considerable	O
amino	O
acid	O
changes	O
are	O
known	O
in	O
CD72(c)	O
allele	O
associated	O
with	O
murine	O
SLE	O
.	O

These	O
results	O
indicated	O
that	O
the	O
presence	O
of	O
CD72-*2	O
allele	O
decreases	O
risk	O
for	O
human	O
SLE	O
conferred	O
by	O
FCGR2B-232Thr	O
,	O
possibly	O
by	O
increasing	O
the	O
AS	O
isoform	O
of	O
CD72	O
.	O

Features	O
of	O
epidermolysis	O
bullosa	O
simplex	O
due	O
to	O
mutations	O
in	O
the	O
ectodomain	O
of	O
type	O
XVII	O
collagen	O
.	O

BACKGROUND	O
:	O
Mutations	O
in	O
COL17A1	O
,	O
coding	O
for	O
type	O
XVII	O
collagen	O
,	O
cause	O
junctional	O
epidermolysis	O
bullosa	O
with	O
an	O
ultrastructural	O
plane	O
of	O
cleavage	O
through	O
the	O
lamina	O
lucida	O
of	O
the	O
epidermal	O
basement	O
membrane	O
.	O

OBJECTIVES	O
:	O
To	O
identify	O
the	O
COL17A1	O
mutations	O
in	O
a	O
child	O
with	O
reduced	O
type	O
XVII	O
collagen	O
expression	O
and	O
intraepidermal	O
blister	O
formation	O
.	O

PATIENT	O
AND	O
METHODS	O
:	O
Protein	O
expression	O
and	O
level	O
of	O
tissue	O
separation	O
were	O
studied	O
by	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O

The	O
mutations	O
were	O
identified	O
by	O
analysing	O
the	O
patient's	O
DNA	O
and	O
mRNA	O
.	O

RESULTS	O
:	O
Immunofluorescence	O
microscopy	O
performed	O
on	O
nonlesional	O
skin	O
demonstrated	O
absence	O
of	O
the	O
type	O
XVII	O
collagen	O
endodomain	O
and	O
presence	O
,	O
although	O
reduced	O
,	O
of	O
the	O
shed	O
ectodomain	O
.	O

Electron	O
microscopy	O
showed	O
that	O
the	O
plane	O
of	O
cleavage	O
was	O
through	O
the	O
basal	O
cells	O
,	O
not	O
through	O
the	O
lamina	O
lucida	O
.	O

Two	O
heterozygous	O
mutations	O
were	O
identified	O
in	O
COL17A1	O
:	O
a	O
new	O
3'-acceptor	O
splice-site	O
mutation	O
in	O
intron	O
21	O
1877-2A-->C	B-DNAMutation
,	O
and	O
a	O
deletion	O
in	O
exon	O
48	O
3432delT	B-DNAMutation
.	O

The	O
splice-site	O
mutation	O
in	O
intron	O
21	O
results	O
in	O
alternative	O
transcripts	O
of	O
which	O
two	O
are	O
in-frame	O
,	O
with	O
deletions	O
of	O
the	O
first	O
nine	O
codons	O
of	O
exon	O
22	O
and	O
the	O
entire	O
exon	O
22	O
,	O
respectively	O
.	O

By	O
Western	O
blot	O
analysis	O
,	O
a	O
type	O
XVII	O
collagen	O
molecule	O
was	O
detected	O
that	O
was	O
slightly	O
smaller	O
than	O
normal	O
.	O

CONCLUSIONS	O
:	O
Occasionally	O
mutations	O
in	O
the	O
COL17A1	O
gene	O
may	O
result	O
in	O
split	O
levels	O
suggesting	O
epidermolysis	O
bullosa	O
simplex	O
rather	O
than	O
junctional	O
epidermolysis	O
bullosa	O
.	O

Deletion	O
of	O
mouse	O
rad9	O
causes	O
abnormal	O
cellular	O
responses	O
to	O
DNA	O
damage	O
,	O
genomic	O
instability	O
,	O
and	O
embryonic	O
lethality	O
.	O

The	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
rad9	O
gene	O
promotes	O
cell	O
survival	O
through	O
activation	O
of	O
cell	O
cycle	O
checkpoints	O
induced	O
by	O
DNA	O
damage	O
.	O

Mouse	O
embryonic	O
stem	O
cells	O
with	O
a	O
targeted	O
deletion	O
of	O
Mrad9	O
,	O
the	O
mouse	O
ortholog	O
of	O
this	O
gene	O
,	O
were	O
created	O
to	O
evaluate	O
its	O
function	O
in	O
mammals	O
.	O

Mrad9(-/-)	O
cells	O
demonstrated	O
a	O
marked	O
increase	O
in	O
spontaneous	O
chromosome	O
aberrations	O
and	O
HPRT	O
mutations	O
,	O
indicating	O
a	O
role	O
in	O
the	O
maintenance	O
of	O
genomic	O
integrity	O
.	O

These	O
cells	O
were	O
also	O
extremely	O
sensitive	O
to	O
UV	O
light	O
,	O
gamma	O
rays	O
,	O
and	O
hydroxyurea	O
,	O
and	O
heterozygotes	O
were	O
somewhat	O
sensitive	O
to	O
the	O
last	O
two	O
agents	O
relative	O
to	O
Mrad9(+/+)	O
controls	O
.	O

Mrad9(-/-)	O
cells	O
could	O
initiate	O
but	O
not	O
maintain	O
gamma-ray-induced	O
G(2)	O
delay	O
and	O
retained	O
the	O
ability	O
to	O
delay	O
DNA	O
synthesis	O
rapidly	O
after	O
UV	O
irradiation	O
,	O
suggesting	O
that	O
checkpoint	O
abnormalities	O
contribute	O
little	O
to	O
the	O
radiosensitivity	O
observed	O
.	O

Ectopic	O
expression	O
of	O
Mrad9	O
or	O
human	O
HRAD9	O
complemented	O
Mrad9(-/-)	O
cell	O
defects	O
,	O
indicating	O
that	O
the	O
gene	O
has	O
radioresponse	O
and	O
genomic	O
maintenance	O
functions	O
that	O
are	O
evolutionarily	O
conserved	O
.	O

Mrad9(+/-)	O
mice	O
were	O
generated	O
,	O
but	O
heterozygous	O
intercrosses	O
failed	O
to	O
yield	O
Mrad9(-/-)	O
pups	O
,	O
since	O
embryos	O
died	O
at	O
midgestation	O
.	O

Furthermore	O
,	O
Mrad9(-/-)	O
mouse	O
embryo	O
fibroblasts	O
were	O
not	O
viable	O
.	O

These	O
investigations	O
establish	O
Mrad9	O
as	O
a	O
key	O
mammalian	O
genetic	O
element	O
of	O
pathways	O
that	O
regulate	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
,	O
maintenance	O
of	O
genomic	O
integrity	O
,	O
and	O
proper	O
embryonic	O
development	O
.	O

Genetics	O
of	O
endometriosis	O
:	O
a	O
role	O
for	O
the	O
progesterone	O
receptor	O
gene	O
polymorphism	O
PROGINS	O
.	O

OBJECTIVE	O
:	O
Endometriosis	O
is	O
a	O
steroid-dependent	O
disease	O
with	O
a	O
particular	O
genetic	O
background	O
,	O
but	O
the	O
locations	O
of	O
possible	O
genomic	O
aberrations	O
are	O
still	O
poorly	O
clarified	O
.	O

We	O
have	O
investigated	O
the	O
potential	O
association	O
between	O
endometriosis	O
and	O
the	O
PROGINS	O
306	O
base	O
pair	O
insertion	O
polymorphism	O
in	O
intron	O
G	O
of	O
the	O
progesterone	O
receptor	O
(PR)	O
gene	O
,	O
which	O
has	O
been	O
reported	O
previously	O
to	O
segregate	O
with	O
this	O
disease	O
.	O

DESIGN	O
:	O
In	O
a	O
case-control	O
study	O
,	O
we	O
examined	O
the	O
PROGINS	O
polymorphism	O
of	O
the	O
progesterone	O
receptor	O
gene	O
in	O
131	O
Italian	O
women	O
affected	O
by	O
endometriosis	O
diagnosed	O
according	O
to	O
published	O
criteria	O
for	O
the	O
definition	O
of	O
the	O
definite	O
disease	O
.	O

Control	O
subjects	O
were	O
represented	O
by	O
127	O
Italian	O
women	O
without	O
laparoscopic	O
evidence	O
of	O
the	O
disease	O
.	O

MEASUREMENTS	O
:	O
Peripheral	O
blood	O
samples	O
,	O
DNA	O
extraction	O
and	O
polymerase	O
chain	O
reaction	O
(PCR)	O
were	O
used	O
to	O
genotype	O
women	O
for	O
the	O
presence	O
of	O
the	O
PROGINS	O
polymorphism	O
.	O

RESULTS	O
:	O
We	O
found	O
a	O
statistically	O
significant	O
difference	O
in	O
the	O
distribution	O
of	O
PROGINS	O
genotypes	O
between	O
patients	O
with	O
and	O
without	O
endometriosis	O
.	O

The	O
frequency	O
of	O
the	O
PROGINS	O
allele	O
T2	O
was	O
17.2%	O
and	O
11%	O
,	O
respectively	O
,	O
in	O
affected	O
women	O
and	O
in	O
controls	O
[	O
odds	O
ratio	O
(OR)	O
=	O
1.7	O
,	O
95%	O
confidence	O
interval	O
(CI)	O
1.0-2.8	O
]	O
.	O

This	O
association	O
was	O
stronger	O
in	O
patients	O
with	O
more	O
severe	O
forms	O
of	O
endometriosis	O
,	O
such	O
as	O
an	O
infiltrating	O
disease	O
or	O
a	O
disease	O
characterized	O
by	O
severe	O
pelvic	O
adhesions	O
(	O
OR	O
2.4	O
,	O
95%	O
CI	O
1.2-4.8	O
;	O
and	O
OR	O
2.7	O
,	O
95%	O
CI	O
1.4-5.3	O
,	O
respectively	O
)	O
.	O

Combination	O
of	O
the	O
results	O
from	O
an	O
earlier	O
study	O
and	O
the	O
current	O
data	O
indicates	O
that	O
carrying	O
the	O
allele	O
variant	O
T2	O
is	O
associated	O
with	O
a	O
twofold	O
increase	O
in	O
the	O
risk	O
of	O
developing	O
endometriosis	O
(	O
OR	O
2.0	O
,	O
95%	O
CI	O
1.3-2.9	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
further	O
support	O
the	O
idea	O
that	O
the	O
PROGINS	O
polymorphism	O
of	O
the	O
progesterone	O
receptor	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
endometriosis	O
.	O

Mre11	O
deficiency	O
in	O
Arabidopsis	O
is	O
associated	O
with	O
chromosomal	O
instability	O
in	O
somatic	O
cells	O
and	O
Spo11-dependent	O
genome	O
fragmentation	O
during	O
meiosis	O
.	O

The	O
Mre11/Rad50/Nbs1	O
complex	O
is	O
involved	O
in	O
many	O
aspects	O
of	O
chromosome	O
metabolism	O
.	O

Aberrant	O
function	O
of	O
the	O
complex	O
is	O
associated	O
with	O
defects	O
in	O
the	O
DNA	O
checkpoint	O
,	O
double-strand	O
break	O
repair	O
,	O
meiosis	O
,	O
and	O
telomere	O
maintenance	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
the	O
consequences	O
of	O
Mre11	O
dysfunction	O
for	O
the	O
stability	O
of	O
mitotic	O
and	O
meiotic	O
chromosomes	O
in	O
Arabidopsis	O
thaliana	O
.	O

Although	O
plants	O
homozygous	O
for	O
a	O
T-DNA	O
insertion	O
in	O
a	O
conserved	O
region	O
of	O
the	O
MRE11	O
gene	O
are	O
viable	O
,	O
they	O
exhibit	O
growth	O
defects	O
and	O
are	O
infertile	O
.	O

Analysis	O
of	O
mitotic	O
chromosomes	O
prepared	O
from	O
the	O
mutant	O
plants	O
revealed	O
abundant	O
dicentric	O
chromosomes	O
and	O
chromosomal	O
fragments	O
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
showed	O
that	O
anaphase	O
bridges	O
are	O
often	O
formed	O
by	O
homologous	O
chromosome	O
arms	O
.	O

The	O
frequency	O
of	O
chromosome	O
fusions	O
was	O
not	O
reduced	O
in	O
mre11	O
ku70	O
double	O
mutants	O
,	O
suggesting	O
that	O
plants	O
possess	O
DNA	O
end-joining	O
activities	O
independent	O
of	O
the	O
Ku70/80	O
and	O
Mre11	O
complexes	O
.	O

Cytogenetic	O
examination	O
of	O
pollen	O
mother	O
cells	O
revealed	O
massive	O
chromosome	O
fragmentation	O
and	O
the	O
absence	O
of	O
synapsis	O
in	O
the	O
initial	O
stages	O
of	O
meiosis	O
.	O

The	O
fragmentation	O
was	O
substantially	O
suppressed	O
in	O
mre11	O
spo11-1	O
double	O
mutants	O
,	O
indicating	O
that	O
Mre11	O
is	O
required	O
for	O
repair	O
but	O
not	O
for	O
the	O
induction	O
of	O
Spo11-dependent	O
meiotic	O
DNA	O
breaks	O
in	O
Arabidopsis	O
.	O

Severe	O
form	O
of	O
thyroid	O
hormone	O
resistance	O
in	O
a	O
patient	O
with	O
homozygous/hemizygous	O
mutation	O
of	O
T3	O
receptor	O
gene	O
.	O

Resistance	O
to	O
thyroid	O
hormone	O
syndrome	O
(RTH)	O
is	O
a	O
rare	O
disorder	O
,	O
usually	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

Patients	O
with	O
RTH	O
are	O
usually	O
euthyroid	O
but	O
can	O
occasionally	O
present	O
with	O
signs	O
and	O
symptoms	O
of	O
thyrotoxicosis	O
or	O
rarely	O
with	O
hypothyroidism	O
.	O

Affected	O
individuals	O
are	O
usually	O
heterozygous	O
for	O
mutations	O
in	O
the	O
thyroid	O
hormone	O
receptor	O
beta	O
gene	O
(TR-beta)	O
.	O

We	O
present	O
a	O
patient	O
with	O
RTH	O
found	O
to	O
be	O
homo-/hemizygous	O
for	O
a	O
mutation	O
in	O
the	O
TR-beta	O
gene	O
.	O

The	O
single	O
nucleotide	O
substitution	O
I280S	B-ProteinMutation
1123T-->G	B-DNAMutation
was	O
present	O
either	O
on	O
both	O
alleles	O
or	O
in	O
a	O
hemizygous	O
form	O
with	O
complete	O
deletion	O
of	O
the	O
second	O
allele	O
.	O

The	O
I280S	B-ProteinMutation
mutation	O
was	O
recently	O
reported	O
in	O
a	O
heterozygous	O
patient	O
.	O

The	O
severe	O
phenotype	O
with	O
seriously	O
impaired	O
intellectual	O
development	O
,	O
hyperkinetic	O
behaviour	O
,	O
tachycardia	O
,	O
hearing	O
and	O
visual	O
impairment	O
is	O
probably	O
due	O
to	O
the	O
dominant	O
negative	O
effect	O
of	O
the	O
I280S	B-ProteinMutation
mutant	O
protein	O
and	O
the	O
absence	O
of	O
any	O
functional	O
TR-beta	O
.	O

Microevolution	O
between	O
paired	O
antral	O
and	O
paired	O
antrum	O
and	O
corpus	O
Helicobacter	O
pylori	O
isolates	O
recovered	O
from	O
individual	O
patients	O
.	O

Sequence	O
variations	O
located	O
at	O
the	O
signal	O
sequence	O
and	O
mid-region	O
within	O
the	O
vacA	O
gene	O
,	O
the	O
3'-end	O
of	O
the	O
cagA	O
gene	O
,	O
the	O
indel	O
motifs	O
at	O
the	O
3'-end	O
of	O
the	O
cag	O
pathogenicity	O
island	O
and	O
the	O
regions	O
upstream	O
of	O
the	O
vacA	O
and	O
ribA	O
genes	O
were	O
determined	O
by	O
PCR	O
in	O
19	O
paired	O
antral	O
or	O
antrum	O
and	O
corpus	O
Helicobacter	O
pylori	O
isolates	O
obtained	O
at	O
the	O
same	O
endoscopic	O
session	O
,	O
and	O
three	O
antral	O
pairs	O
taken	O
sequentially	O
.	O

Random	O
amplification	O
of	O
polymorphic	O
DNA	O
(RAPD)-PCR	O
and	O
fluorescent	O
amplified	O
fragment	O
length	O
polymorphism	O
(FAFLP)-PCR	O
fingerprinting	O
were	O
applied	O
to	O
these	O
paired	O
clinical	O
isolates	O
.	O

The	O
FAFLP-PCR	O
profiles	O
generated	O
were	O
phylogenetically	O
analysed	O
.	O

For	O
the	O
22	O
paired	O
isolates	O
there	O
were	O
no	O
differences	O
within	O
pairs	O
at	O
five	O
of	O
the	O
genetic	O
loci	O
studied	O
.	O

However	O
,	O
six	O
pairs	O
of	O
isolates	O
(27%)	O
,	O
of	O
which	O
four	O
were	O
antrum	O
and	O
corpus	O
pairs	O
,	O
showed	O
differences	O
in	O
the	O
numbers	O
of	O
repeats	O
located	O
at	O
the	O
3'-end	O
of	O
the	O
cagA	O
gene	O
.	O

RAPD-PCR	O
fingerprinting	O
showed	O
that	O
16	O
(73%)	O
pairs	O
,	O
nine	O
of	O
which	O
were	O
antrum	O
and	O
corpus	O
pairs	O
,	O
possessed	O
identical	O
profiles	O
,	O
while	O
six	O
(27%)	O
displayed	O
distinctly	O
different	O
profiles	O
,	O
indicating	O
mixed	O
infections	O
.	O

Three	O
of	O
the	O
six	O
pairs	O
showing	O
differences	O
at	O
the	O
3'-end	O
of	O
the	O
cagA	O
gene	O
yielded	O
identical	O
RAPD-PCR	O
fingerprints	O
.	O

FAFLP-PCR	O
fingerprinting	O
and	O
phylogenetic	O
analysis	O
revealed	O
that	O
all	O
16	O
pairs	O
that	O
displayed	O
identical	O
RAPD-PCR	O
profiles	O
had	O
highly	O
similar	O
,	O
but	O
not	O
identical	O
,	O
fingerprints	O
,	O
demonstrating	O
that	O
these	O
pairs	O
were	O
ancestrally	O
related	O
but	O
had	O
undergone	O
minor	O
genomic	O
alterations	O
.	O

Two	O
antrum	O
and	O
corpus	O
pairs	O
of	O
isolates	O
,	O
within	O
the	O
latter	O
group	O
,	O
were	O
isolates	O
obtained	O
from	O
two	O
siblings	O
from	O
the	O
same	O
family	O
.	O

This	O
analysis	O
demonstrated	O
that	O
each	O
sibling	O
was	O
colonized	O
by	O
ancestrally	O
related	O
strains	O
that	O
exhibited	O
differences	O
in	O
vacA	O
genotype	O
characteristics	O
.	O

A	O
novel	O
arginine	O
substitution	O
mutation	O
in	O
1A	O
domain	O
and	O
a	O
novel	O
27	O
bp	O
insertion	O
mutation	O
in	O
2B	O
domain	O
of	O
keratin	O
12	O
gene	O
associated	O
with	O
Meesmann's	O
corneal	O
dystrophy	O
.	O

AIM	O
:	O
To	O
determine	O
the	O
disease	O
causing	O
gene	O
defects	O
in	O
two	O
patients	O
with	O
Meesmann's	O
corneal	O
dystrophy	O
.	O

METHODS	O
:	O
Mutational	O
analysis	O
of	O
domains	O
1A	O
and	O
2B	O
of	O
the	O
keratin	O
3	O
(K3)	O
and	O
keratin	O
12	O
(K12)	O
genes	O
from	O
two	O
patients	O
with	O
Meesmann's	O
corneal	O
dystrophy	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Novel	O
mutations	O
of	O
the	O
K12	O
gene	O
were	O
identified	O
in	O
both	O
patients	O
.	O

In	O
one	O
patient	O
a	O
heterozygous	O
point	O
mutation	O
(	O
429A-->C	B-DNAMutation
=	O
Arg135Ser	B-ProteinMutation
)	O
was	O
found	O
in	O
the	O
1A	O
domain	O
of	O
the	O
K12	O
gene	O
.	O

This	O
mutation	O
was	O
confirmed	O
by	O
restriction	O
digestion	O
.	O

In	O
the	O
second	O
patient	O
a	O
heterozygous	O
27	O
bp	O
duplication	O
was	O
found	O
inserted	O
in	O
the	O
2B	O
domain	O
at	O
nucleotide	O
position	O
1222	O
1222ins27	B-DNAMutation
of	O
the	O
K12	O
gene	O
.	O

This	O
mutation	O
was	O
confirmed	O
by	O
gel	O
electrophoresis	O
.	O

The	O
mutations	O
were	O
not	O
present	O
in	O
unaffected	O
controls	O
.	O

CONCLUSION	O
:	O
Novel	O
K12	O
mutations	O
were	O
linked	O
to	O
Meesmann's	O
corneal	O
dystrophy	O
in	O
two	O
different	O
patients	O
.	O

A	O
missense	O
mutation	O
replacing	O
a	O
highly	O
conserved	O
arginine	O
residue	O
in	O
the	O
beginning	O
of	O
the	O
helix	O
initiation	O
motif	O
was	O
found	O
in	O
one	O
patient	O
,	O
and	O
an	O
insertion	O
mutation	O
,	O
consisting	O
of	O
a	O
duplication	O
of	O
27	O
nucleotides	O
,	O
was	O
found	O
before	O
the	O
helix	O
termination	O
motif	O
in	O
the	O
other	O
.	O

A	O
new	O
but	O
frequent	O
mutation	O
of	O
apoB-100-apoB	O
His3543Tyr	B-ProteinMutation
.	O

ApolipoproteinB	O
100	O
(apoB-100)	O
is	O
an	O
important	O
component	O
of	O
atherogenic	O
lipoproteins	O
such	O
as	O
LDL	O
and	O
serves	O
as	O
a	O
ligand	O
for	O
the	O
LDL-receptor	O
.	O

Familial	O
defective	O
apolipoproteinB	O
100	O
(FDB)	O
is	O
caused	O
by	O
a	O
R3500Q	B-ProteinMutation
mutation	O
of	O
the	O
apoB	O
gene	O
and	O
results	O
in	O
decreased	O
binding	O
of	O
LDL	O
to	O
the	O
LDL-receptor	O
.	O

So	O
far	O
FDB	O
is	O
the	O
most	O
frequent	O
and	O
best	O
studied	O
alteration	O
of	O
apoB-100	O
.	O

Apart	O
from	O
this	O
,	O
three	O
other	O
apoB	O
mutations	O
,	O
R3500W	B-ProteinMutation
,	O
R3531C	B-ProteinMutation
and	O
R3480W	B-ProteinMutation
,	O
affecting	O
binding	O
to	O
the	O
LDL-receptor	O
are	O
known	O
to	O
date	O
.	O

We	O
screened	O
the	O
apoB	O
gene	O
segment	O
of	O
codons	O
3448-3561	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE)	O
analysis	O
in	O
a	O
total	O
of	O
853	O
consecutively	O
sampled	O
German	O
patients	O
undergoing	O
diagnostic	O
coronary	O
angiography	O
for	O
suspected	O
CAD	O
.	O

By	O
this	O
,	O
a	O
new	O
single	O
base	O
mutation	O
was	O
detected	O
and	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

The	O
mutation	O
,	O
CAC(3543)TAC	B-DNAMutation
results	O
in	O
a	O
His3543Tyr	B-ProteinMutation
substitution	O
in	O
apoB-100	O
H3543Y	B-ProteinMutation
.	O

The	O
prevalence	O
of	O
heterozygotes	O
for	O
H3543Y	B-ProteinMutation
in	O
the	O
study	O
population	O
was	O
0.47%	O
compared	O
to	O
0.12%	O
for	O
the	O
known	O
Arg	B-ProteinMutation
3500	I-ProteinMutation
Gln	I-ProteinMutation
R3500Q	B-ProteinMutation
mutation	O
.	O

In	O
conclusion	O
,	O
the	O
new	O
mutation	O
is	O
four	O
times	O
more	O
frequent	O
than	O
"classical"	O
FDB	O
and	O
thus	O
appears	O
to	O
be	O
the	O
most	O
common	O
apoB	O
mutation	O
in	O
Germany	O
.	O

POLG	O
mutations	O
associated	O
with	O
Alpers'	O
syndrome	O
and	O
mitochondrial	O
DNA	O
depletion	O
.	O

Alpers'	O
syndrome	O
is	O
a	O
fatal	O
neurogenetic	O
disorder	O
first	O
described	O
more	O
than	O
70	O
years	O
ago	O
.	O

It	O
is	O
an	O
autosomal	O
recessive	O
,	O
developmental	O
mitochondrial	O
DNA	O
depletion	O
disorder	O
characterized	O
by	O
deficiency	O
in	O
mitochondrial	O
DNA	O
polymerase	O
gamma	O
(POLG)	O
catalytic	O
activity	O
,	O
refractory	O
seizures	O
,	O
neurodegeneration	O
,	O
and	O
liver	O
disease	O
.	O

In	O
two	O
unrelated	O
pedigrees	O
of	O
Alpers'	O
syndrome	O
,	O
each	O
affected	O
child	O
was	O
found	O
to	O
carry	O
a	O
homozygous	O
mutation	O
in	O
exon	O
17	O
of	O
the	O
POLG	O
locus	O
that	O
led	O
to	O
a	O
Glu873Stop	B-ProteinMutation
mutation	O
just	O
upstream	O
of	O
the	O
polymerase	O
domain	O
of	O
the	O
protein	O
.	O

In	O
addition	O
,	O
each	O
affected	O
child	O
was	O
heterozygous	O
for	O
the	O
G1681A	B-DNAMutation
mutation	O
in	O
exon	O
7	O
that	O
led	O
to	O
an	O
Ala467Thr	B-ProteinMutation
substitution	O
in	O
POLG	O
,	O
within	O
the	O
linker	O
region	O
of	O
the	O
protein	O
.	O

Identification	O
of	O
three	O
F5	O
gene	O
mutations	O
associated	O
with	O
inherited	O
coagulation	O
factor	O
V	O
deficiency	O
in	O
two	O
Chinese	O
pedigrees	O
.	O

To	O
investigate	O
the	O
molecular	O
defects	O
in	O
two	O
Chinese	O
pedigrees	O
with	O
inherited	O
factor	O
V	O
(FV)	O
deficiency	O
.	O

A	O
37-year-old	O
male	O
(	O
proband	O
1	O
)	O
and	O
an	O
18-month-old	O
boy	O
(	O
proband	O
2	O
)	O
were	O
diagnosed	O
as	O
inherited	O
coagulation	O
FV	O
deficiency	O
by	O
severely	O
reduced	O
plasma	O
levels	O
of	O
FV	O
activity	O
and	O
antigen	O
.	O

All	O
25	O
exons	O
and	O
their	O
flanking	O
sequence	O
of	O
F5	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
for	O
both	O
probands	O
and	O
the	O
PCR	O
products	O
were	O
directly	O
sequenced	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
the	O
peripheral	O
lymphocytes	O
of	O
proband	O
1	O
for	O
detecting	O
the	O
changes	O
at	O
mRNA	O
level	O
.	O

The	O
homozygous	O
deletion	O
IVS8	B-DNAMutation
-2A>G	I-DNAMutation
was	O
identified	O
in	O
the	O
F5	O
gene	O
of	O
proband	O
1	O
and	O
complementary	O
DNA	O
(cDNA)	O
analysis	O
revealed	O
the	O
abolishment	O
of	O
the	O
canonical	O
splicing	O
site	O
by	O
the	O
mutation	O
and	O
the	O
activation	O
of	O
the	O
cryptic	O
acceptor	O
site	O
24	O
bp	O
upstream	O
instead	O
.	O

The	O
insertion	O
introduced	O
eight	O
additional	O
amino	O
acids	O
(AA)	O
into	O
the	O
FV	O
protein	O
.	O

Two	O
heterozygous	O
mutations	O
of	O
F5	O
gene	O
were	O
discovered	O
in	O
proband	O
2	O
.	O

The	O
2238-9del	B-DNAMutation
AG	I-DNAMutation
in	O
exon	O
13	O
introduced	O
a	O
premature	O
termination	O
code	O
at	O
689	O
AA	O
and	O
the	O
substitution	O
of	O
G6410	B-DNAMutation
by	I-DNAMutation
T	I-DNAMutation
in	O
exon	O
23	O
lead	O
to	O
the	O
missense	O
mutation	O
Gly2079Val	B-ProteinMutation
.	O

Three	O
F5	O
gene	O
mutations	O
,	O
IVS8	B-DNAMutation
-2A>G	I-DNAMutation
,	O
2238-9del	B-DNAMutation
AG	I-DNAMutation
and	O
G6410T	B-DNAMutation
,	O
have	O
been	O
identified	O
in	O
two	O
Chinese	O
pedigree	O
with	O
congenital	O
FV	O
deficiency	O
,	O
respectively	O
.	O

Four	O
novel	O
mutations	O
in	O
the	O
thiazide-sensitive	O
Na-Cl	O
co-transporter	O
gene	O
in	O
Japanese	O
patients	O
with	O
Gitelman's	O
syndrome	O
.	O

BACKGROUND	O
:	O
Gitelman's	O
syndrome	O
(GS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
resulting	O
from	O
inactivating	O
mutations	O
in	O
the	O
thiazide-sensitive	O
Na-Cl	O
co-transporter	O
(NCCT)	O
gene	O
.	O

To	O
date	O
,	O
almost	O
90	O
mutations	O
have	O
been	O
identified	O
.	O

It	O
is	O
possible	O
that	O
there	O
is	O
a	O
population-specific	O
distribution	O
of	O
mutations	O
.	O

In	O
this	O
study	O
,	O
we	O
analysed	O
mutations	O
in	O
the	O
NCCT	O
gene	O
of	O
seven	O
Japanese	O
patients	O
with	O
GS	O
.	O

METHODS	O
:	O
Peripheral	O
blood	O
mononuclear	O
cells	O
were	O
isolated	O
from	O
patients	O
with	O
GS	O
,	O
their	O
family	O
members	O
and	O
healthy	O
control	O
subjects	O
.	O

A	O
mutation	O
analysis	O
of	O
the	O
NCCT	O
gene	O
was	O
performed	O
completely	O
by	O
direct	O
automated	O
sequencing	O
of	O
polymerase	O
chain	O
reaction-amplified	O
DNA	O
products	O
.	O

In	O
patients	O
with	O
a	O
deletion	O
or	O
splice	O
site	O
mutation	O
,	O
we	O
undertook	O
cDNA	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
We	O
identified	O
nine	O
mutations	O
.	O

Five	O
of	O
them	O
[	O
c.185C>T	B-DNAMutation
Thr60Met	B-ProteinMutation
,	O
c.1712C>T	B-DNAMutation
Ala569Val	B-ProteinMutation
,	O
c.1930C>T	B-DNAMutation
Arg642Cys	B-ProteinMutation
,	O
c.2552T>A	B-DNAMutation
Leu849His	B-ProteinMutation
and	O
c.1932delC	B-DNAMutation
]	O
have	O
been	O
reported	O
in	O
Japanese	O
patients	O
,	O
but	O
not	O
in	O
GS	O
patients	O
from	O
other	O
ethnic	O
groups	O
.	O

The	O
remaining	O
four	O
mutations	O
[	O
c.7A>T	B-DNAMutation
Met1Leu	B-ProteinMutation
,	O
c.1181_1186+20del26	B-DNAMutation
,	O
c.1811_1812delAT	B-DNAMutation
and	O
IVS16+1G>A	B-DNAMutation
]	O
were	O
novel	O
.	O

In	O
cDNA	O
derived	O
from	O
a	O
patient	O
with	O
c.1181_1186+20del26	B-DNAMutation
,	O
a	O
deletion	O
of	O
exon	O
9	O
and	O
a	O
frameshift	O
at	O
the	O
start	O
of	O
exon	O
10	O
were	O
observed	O
.	O

In	O
cDNA	O
derived	O
from	O
patients	O
with	O
IVS16+1G>A	B-DNAMutation
,	O
an	O
additional	O
96	O
bp	O
insertion	O
between	O
exons	O
16	O
and	O
17	O
was	O
observed	O
.	O

Six	O
out	O
of	O
seven	O
patients	O
were	O
compound	O
heterozygotes	O
,	O
and	O
the	O
remaining	O
one	O
carried	O
a	O
single	O
heterozygous	O
mutation	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
four	O
novel	O
mutations	O
in	O
the	O
NCCT	O
gene	O
in	O
seven	O
Japanese	O
patients	O
with	O
GS	O
.	O

Moreover	O
,	O
our	O
study	O
suggests	O
that	O
the	O
distribution	O
of	O
mutations	O
in	O
the	O
NCCT	O
gene	O
in	O
Japanese	O
GS	O
patients	O
potentially	O
differs	O
from	O
that	O
in	O
other	O
populations	O
.	O

Compound	O
heterozygous	O
mutations	O
in	O
the	O
SRD5A2	O
gene	O
exon	O
4	O
in	O
a	O
male	O
pseudohermaphrodite	O
patient	O
of	O
Chinese	O
origin	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
perform	O
5-alpha-reductase	O
type	O
2	O
gene	O
(SRD5A2)	O
analysis	O
in	O
a	O
male	O
pseudohermaphrodite	O
(MPH)	O
patient	O
with	O
normal	O
testosterone	O
(T)	O
production	O
and	O
normal	O
androgen	O
receptor	O
(AR)	O
gene	O
coding	O
sequences	O
.	O

A	O
patient	O
of	O
Chinese	O
origin	O
with	O
ambiguous	O
genitalia	O
at	O
14	O
months	O
,	O
a	O
46,XY	O
karyotype	O
,	O
and	O
normal	O
T	O
secretion	O
under	O
human	O
chorionic	O
gonadotropin	O
(hCG)	O
stimulation	O
underwent	O
a	O
gonadectomy	O
at	O
20	O
months	O
.	O

Exons	O
1-8	O
of	O
the	O
AR	O
gene	O
and	O
exons	O
1-5	O
of	O
the	O
SRD5A2	O
gene	O
were	O
sequenced	O
from	O
peripheral	O
blood	O
DNA	O
.	O

AR	O
gene	O
coding	O
sequences	O
were	O
normal	O
.	O

SRD5A2	O
gene	O
analysis	O
revealed	O
2	O
consecutive	O
mutations	O
in	O
exon	O
4	O
,	O
each	O
located	O
in	O
a	O
different	O
allele	O
:	O
1	O
)	O
a	O
T	O
nucleotide	O
deletion	O
,	O
which	O
predicts	O
a	O
frameshift	O
mutation	O
from	O
codon	O
219	O
,	O
and	O
2	O
)	O
a	O
missense	O
mutation	O
at	O
codon	O
227	O
,	O
where	O
the	O
substitution	O
of	O
guanine	O
(CGA)	O
by	O
adenine	O
(CAA)	O
predicts	O
a	O
glutamine	O
replacement	O
of	O
arginine	O
R227Q	B-ProteinMutation
.	O

Testes	O
located	O
in	O
the	O
inguinal	O
canal	O
showed	O
a	O
normal	O
morphology	O
for	O
age	O
.	O

The	O
patient	O
was	O
a	O
compound	O
heterozygote	O
for	O
SRD5A2	O
mutations	O
,	O
carrying	O
2	O
mutations	O
in	O
exon	O
4	O
.	O

The	O
patient	O
showed	O
an	O
R227Q	B-ProteinMutation
mutation	O
that	O
has	O
been	O
described	O
in	O
an	O
Asian	O
population	O
and	O
MPH	O
patients	O
,	O
along	O
with	O
a	O
novel	O
frameshift	O
mutation	O
,	O
Tdel219	B-DNAMutation
.	O

Testis	O
morphology	O
showed	O
that	O
,	O
during	O
early	O
infancy	O
,	O
the	O
5-alpha-reductase	O
enzyme	O
deficiency	O
may	O
not	O
have	O
affected	O
interstitial	O
or	O
tubular	O
development	O
.	O

Single-strand	O
conformation	O
polymorphism	O
analysis	O
of	O
the	O
FMR1	O
gene	O
in	O
autistic	O
and	O
mentally	O
retarded	O
children	O
in	O
Japan	O
.	O

Fragile	O
X	O
syndrome	O
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
mental	O
retardation	O
in	O
males	O
,	O
and	O
patients	O
with	O
fragile	O
X	O
syndrome	O
occasionally	O
develop	O
autism	O
.	O

It	O
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
the	O
trinucleotide	O
repeat	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
FMR1	O
gene	O
,	O
but	O
in	O
a	O
small	O
number	O
of	O
patients	O
deletions	O
and	O
point	O
mutations	O
have	O
been	O
identified	O
.	O

We	O
screened	O
all	O
17	O
exons	O
of	O
the	O
FMR1	O
gene	O
for	O
mutations	O
in	O
90	O
autistic	O
or	O
mentally	O
retarded	O
children	O
using	O
polymerase	O
chain	O
reaction	O
(PCR)-single	O
strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
.	O

No	O
mutations	O
were	O
found	O
in	O
76	O
male	O
patients	O
.	O

However	O
,	O
one	O
female	O
patient	O
was	O
heterozygous	O
for	O
a	O
normal	O
allele	O
and	O
a	O
mutant	O
allele	O
with	O
an	O
A	O
to	O
C	O
substitution	O
at	O
nucleotide	O
879	O
in	O
exon	O
9	O
.	O

This	O
mutation	O
was	O
not	O
found	O
in	O
50	O
controls	O
.	O

Reverse	O
transcription-PCR	O
revealed	O
that	O
a	O
large	O
proportion	O
of	O
the	O
mutant	O
transcripts	O
were	O
spliced	O
aberrantly	O
,	O
causing	O
premature	O
termination	O
of	O
the	O
protein	O
synthesis	O
.	O

Although	O
uncommon	O
,	O
point	O
mutations	O
in	O
the	O
FMR1	O
gene	O
may	O
be	O
a	O
cause	O
of	O
autism	O
and	O
mental	O
retardation	O
in	O
Japanese	O
patients	O
.	O

Expression	O
mapping	O
at	O
12p12-13	O
in	O
advanced	O
prostate	O
carcinoma	O
.	O

We	O
have	O
previously	O
mapped	O
a	O
putative	O
prostate	O
cancer	O
tumor-suppressor	O
gene	O
to	O
a	O
1-2	O
Mb	O
region	O
of	O
12p12-13	O
.	O

Initial	O
work	O
to	O
identify	O
the	O
tumor	O
suppressor	O
at	O
this	O
locus	O
focused	O
on	O
candidates	O
previously	O
implicated	O
in	O
malignancy	O
;	O
however	O
,	O
mutational	O
and	O
methylation	O
analyses	O
failed	O
to	O
identify	O
significant	O
genomic	O
events	O
.	O

An	O
alternative	O
approach	O
is	O
to	O
use	O
expression	O
analysis	O
to	O
prioritize	O
the	O
genes	O
within	O
the	O
region	O
of	O
interest	O
.	O

This	O
experimental	O
design	O
is	O
based	O
on	O
the	O
hypothesis	O
that	O
tumor-suppressor	O
genes	O
demonstrate	O
decreased	O
expression	O
in	O
tumors	O
compared	O
to	O
normals	O
.	O

Herein	O
,	O
we	O
narrow	O
the	O
region	O
of	O
interest	O
using	O
deletion	O
mapping	O
data	O
and	O
employ	O
expression	O
analysis	O
to	O
prioritize	O
the	O
genes	O
in	O
the	O
minimal	O
deleted	O
region	O
.	O

Highly	O
informative	O
polymorphic	O
markers	O
spanning	O
our	O
region	O
were	O
used	O
to	O
assess	O
for	O
loss	O
of	O
heterozygosity	O
in	O
99	O
tumor	O
and	O
normal	O
DNA	O
pairs	O
.	O

The	O
minimal	O
region	O
of	O
deletion	O
was	O
determined	O
to	O
be	O
approximately	O
500	O
kb	O
bounded	O
by	O
D12S391	O
and	O
A002Q26	O
.	O

Publically	O
available	O
databases	O
place	O
7	O
genes	O
within	O
this	O
minimal	O
deletion	O
region	O
.	O

An	O
additional	O
3	O
genes	O
lie	O
just	O
outside	O
this	O
minimal	O
deletion	O
region	O
and	O
could	O
possibly	O
be	O
inactivated	O
by	O
deletion	O
of	O
promoter	O
,	O
3'-untranslated	O
region	O
sequences	O
or	O
alternative	O
splice	O
variants	O
.	O

Relative	O
levels	O
of	O
expression	O
of	O
these	O
10	O
candidate	O
genes	O
were	O
determined	O
in	O
6	O
normal	O
prostates	O
,	O
5	O
local	O
prostate	O
tumors	O
,	O
9	O
prostate	O
lymph	O
node	O
metastases	O
,	O
6	O
prostate	O
cancer	O
cell	O
lines	O
and	O
12	O
prostate	O
cancer	O
xenografts	O
using	O
quantitative	O
RT-PCR	O
.	O

DUSP16	O
,	O
FLJ10298	O
and	O
BCLG	O
were	O
significantly	O
downregulated	O
in	O
both	O
clinical	O
tumors	O
and	O
cultured	O
prostate	O
cancer	O
tissue	O
,	O
indicating	O
that	O
one	O
or	O
all	O
may	O
be	O
critical	O
to	O
initiation	O
or	O
progression	O
of	O
prostate	O
carcinoma	O
.	O

The	O
Arg753GLn	B-ProteinMutation
polymorphism	O
of	O
the	O
human	O
toll-like	O
receptor	O
2	O
gene	O
in	O
tuberculosis	O
disease	O
.	O

Toll-like	O
receptor	O
2	O
(TLR2)	O
,	O
a	O
member	O
of	O
the	O
Toll-like	O
receptor	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
recognition	O
of	O
,	O
and	O
subsequent	O
immune	O
response	O
activation	O
against	O
,	O
mycobacteria	O
.	O

The	O
genetic	O
polymorphism	O
of	O
TLR2	O
(	O
arginine	O
to	O
glutamine	O
substitution	O
at	O
residue	O
753	O
(	O
Arg753Gln	B-ProteinMutation
)	O
)	O
has	O
been	O
associated	O
with	O
a	O
negative	O
influence	O
on	O
TLR2	O
function	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
determine	O
the	O
innate	O
host	O
response	O
to	O
mycobacteria	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
Arg753Gln	B-ProteinMutation
single	O
nucleotide	O
polymorphism	O
of	O
the	O
TLR2	O
gene	O
in	O
tuberculosis	O
(TB)	O
patients	O
compared	O
to	O
healthy	O
controls	O
.	O

A	O
retrospective	O
case/control	O
study	O
was	O
carried	O
out	O
.	O

The	O
Arg753Gln	B-ProteinMutation
polymorphism	O
of	O
the	O
TLR2	O
gene	O
was	O
studied	O
in	O
151	O
TB	O
patients	O
compared	O
to	O
116	O
ethnically	O
and	O
age-matched	O
healthy	O
control	O
subjects	O
.	O

The	O
TLR2	O
polymorphism	O
(	O
adenine	O
(A)	O
allele	O
)	O
was	O
observed	O
in	O
17.9	O
and	O
7.7%	O
of	O
TB	O
patients	O
and	O
controls	O
,	O
respectively	O
.	O

When	O
the	O
ratios	O
of	O
the	O
three	O
genotypes	O
were	O
compared	O
between	O
the	O
two	O
groups	O
,	O
the	O
AA	O
genotype	O
was	O
found	O
to	O
be	O
more	O
significantly	O
associated	O
with	O
TB	O
.	O

Allele	O
frequencies	O
for	O
guanine	O
(G)	O
and	O
A	O
were	O
found	O
to	O
be	O
0.95	O
and	O
0.05	O
in	O
the	O
control	O
group	O
and	O
0.86	O
and	O
0.14	O
in	O
the	O
TB	O
patient	O
group	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
developing	O
TB	O
disease	O
was	O
increased	O
6.04-	O
and	O
1.60-fold	O
for	O
carriers	O
of	O
the	O
AA	O
and	O
GA	O
genotypes	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
data	O
suggest	O
that	O
the	O
arginine	O
to	O
glutamine	O
substitution	O
at	O
residue	O
753	O
polymorphism	O
of	O
the	O
Toll-like	O
receptor	O
2	O
gene	O
influences	O
the	O
risk	O
of	O
developing	O
tuberculosis	O
.	O

Homozygous	O
deletions	O
within	O
the	O
11q13	O
cervical	O
cancer	O
tumor-suppressor	O
locus	O
in	O
radiation-induced	O
,	O
neoplastically	O
transformed	O
human	O
hybrid	O
cells	O
.	O

Studies	O
on	O
nontumorigenic	O
and	O
tumorigenic	O
human	O
cell	O
hybrids	O
derived	O
from	O
the	O
fusion	O
of	O
HeLa	O
(	O
a	O
cervical	O
cancer	O
cell	O
line	O
)	O
with	O
GM00077	O
(	O
a	O
normal	O
skin	O
fibroblast	O
cell	O
line	O
)	O
have	O
demonstrated	O
"functional"	O
tumor-suppressor	O
activity	O
on	O
chromosome	O
11	O
.	O

It	O
has	O
been	O
shown	O
that	O
several	O
of	O
the	O
neoplastically	O
transformed	O
radiation-induced	O
hybrid	O
cells	O
called	O
GIMs	O
(	O
gamma	O
ray	O
induced	O
mutants	O
)	O
,	O
isolated	O
from	O
the	O
nontumorigenic	O
CGL1	O
cells	O
,	O
have	O
lost	O
one	O
copy	O
of	O
the	O
fibroblast	O
chromosome	O
11	O
.	O

We	O
hypothesized	O
,	O
therefore	O
,	O
that	O
the	O
remaining	O
copy	O
of	O
the	O
gene	O
might	O
be	O
mutated	O
in	O
the	O
cytogenetically	O
intact	O
copy	O
of	O
fibroblast	O
chromosome	O
11	O
.	O

Because	O
a	O
cervical	O
cancer	O
tumor	O
suppressor	O
locus	O
has	O
been	O
localized	O
to	O
chromosome	O
band	O
11q13	O
,	O
we	O
performed	O
deletion-mapping	O
analysis	O
of	O
eight	O
different	O
GIMs	O
using	O
a	O
total	O
of	O
32	O
different	O
polymorphic	O
and	O
microsatellite	O
markers	O
on	O
the	O
long	O
arm	O
(	O
q	O
arm	O
)	O
of	O
chromosome	O
11	O
.	O

Four	O
irradiated	O
,	O
nontumorigenic	O
hybrid	O
cell	O
lines	O
,	O
called	O
CONs	O
,	O
were	O
also	O
analyzed	O
.	O

Allelic	O
deletion	O
was	O
ascertained	O
by	O
the	O
loss	O
of	O
a	O
fibroblast	O
allele	O
in	O
the	O
hybrid	O
cell	O
lines	O
.	O

The	O
analysis	O
confirmed	O
the	O
loss	O
of	O
a	O
fibroblast	O
chromosome	O
11	O
in	O
five	O
of	O
the	O
GIMs	O
.	O

Further	O
,	O
homozygous	O
deletion	O
(	O
complete	O
loss	O
)	O
of	O
chromosome	O
band	O
11q13	O
band	O
sequences	O
,	O
including	O
that	O
of	O
D11S913	O
,	O
was	O
observed	O
in	O
two	O
of	O
the	O
GIMs	O
.	O

Detailed	O
mapping	O
with	O
genomic	O
sequences	O
localized	O
the	O
homozygous	O
deletion	O
to	O
a	O
5.7-kb	O
interval	O
between	O
EST	O
AW167735	O
and	O
EST	O
F05086	O
.	O

Southern	O
blot	O
hybridization	O
using	O
genomic	O
DNA	O
probes	O
from	O
the	O
D11S913	O
locus	O
confirmed	O
the	O
existence	O
of	O
homozygous	O
deletion	O
in	O
the	O
two	O
GIM	O
cell	O
lines	O
.	O

Additionally	O
,	O
PCR	O
analysis	O
showed	O
a	O
reduction	O
in	O
signal	O
intensity	O
for	O
a	O
marker	O
mapped	O
31	O
kb	O
centromeric	O
of	O
D11S913	O
in	O
four	O
other	O
GIMs	O
.	O

Finally	O
,	O
Northern	O
blot	O
hybridization	O
with	O
the	O
genomic	O
probes	O
revealed	O
the	O
presence	O
of	O
a	O
novel	O
>15-kb	O
transcript	O
in	O
six	O
of	O
the	O
GIMs	O
.	O

These	O
transcripts	O
were	O
not	O
observed	O
in	O
the	O
nontumorigenic	O
hybrid	O
cell	O
lines	O
.	O

Because	O
the	O
chromosome	O
11q13	O
band	O
deletions	O
in	O
the	O
tumorigenic	O
hybrid	O
cell	O
lines	O
overlapped	O
with	O
the	O
minimal	O
deletion	O
in	O
cervical	O
cancer	O
,	O
the	O
data	O
suggest	O
that	O
the	O
same	O
gene	O
may	O
be	O
involved	O
in	O
the	O
development	O
of	O
cervical	O
cancer	O
and	O
in	O
radiation-induced	O
carcinogenesis	O
.	O

We	O
propose	O
that	O
a	O
gene	O
localized	O
in	O
proximity	O
to	O
the	O
homozygous	O
deletion	O
is	O
the	O
candidate	O
tumor-suppressor	O
gene	O
.	O

Structural	O
and	O
biochemical	O
basis	O
for	O
novel	O
mutations	O
in	O
homozygous	O
Israeli	O
maple	O
syrup	O
urine	O
disease	O
patients	O
:	O
a	O
proposed	O
mechanism	O
for	O
the	O
thiamin-responsive	O
phenotype	O
.	O

Maple	O
syrup	O
urine	O
disease	O
(MSUD)	O
results	O
from	O
mutations	O
affecting	O
different	O
subunits	O
of	O
the	O
mitochondrial	O
branched-chain	O
alpha-ketoacid	O
dehydrogenase	O
complex	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
seven	O
novel	O
mutations	O
in	O
MSUD	O
patients	O
from	O
Israel	O
.	O

These	O
include	O
C219W-alpha	B-ProteinMutation
(	O
TGC	O
to	O
TGG	O
)	O
in	O
the	O
E1alpha	O
subunit	O
;	O
H156Y-beta	B-ProteinMutation
(	O
CAT	O
to	O
TAT	O
)	O
,	O
V69G-beta	B-ProteinMutation
(	O
GTT	O
to	O
GGT	O
)	O
,	O
IVS	B-DNAMutation
9	I-DNAMutation
del[-7:-4]	I-DNAMutation
,	O
and	O
1109	B-DNAMutation
ins	I-DNAMutation
8bp	I-DNAMutation
(	O
exon	O
10	O
)	O
in	O
the	O
E1beta	O
subunit	O
;	O
and	O
H391R	B-ProteinMutation
(	O
CAC	O
to	O
CGC	O
)	O
and	O
S133stop	B-ProteinMutation
(	O
TCA	O
to	O
TGA	O
)	O
affecting	O
the	O
E2	O
subunit	O
of	O
the	O
branched-chain	O
alpha-ketoacid	O
dehydrogenase	O
complex	O
.	O

Recombinant	O
E1	O
proteins	O
carrying	O
the	O
C219W-alpha	B-ProteinMutation
or	O
H156Y-beta	B-ProteinMutation
mutation	O
show	O
no	O
catalytic	O
activity	O
with	O
defective	O
subunit	O
assembly	O
and	O
reduced	O
binding	O
affinity	O
for	O
cofactor	O
thiamin	O
diphosphate	O
.	O

The	O
mutant	O
E1	O
harboring	O
the	O
V69G-beta	B-ProteinMutation
substitution	O
cannot	O
be	O
expressed	O
,	O
suggesting	O
aberrant	O
folding	O
caused	O
by	O
this	O
mutation	O
.	O

These	O
E1	O
mutations	O
are	O
ubiquitously	O
associated	O
with	O
the	O
classic	O
phenotype	O
in	O
homozygous-affected	O
patients	O
.	O

The	O
H391R	B-ProteinMutation
substitution	O
in	O
the	O
E2	O
subunit	O
abolishes	O
the	O
key	O
catalytic	O
residue	O
that	O
functions	O
as	O
a	O
general	O
base	O
in	O
the	O
acyltransfer	O
reaction	O
,	O
resulting	O
in	O
a	O
completely	O
inactive	O
E2	O
component	O
.	O

However	O
,	O
wild-type	O
E1	O
activity	O
is	O
enhanced	O
by	O
E1	O
binding	O
to	O
this	O
full-length	O
mutant	O
E2	O
in	O
vitro	O
.	O

We	O
propose	O
that	O
the	O
augmented	O
E1	O
activity	O
is	O
responsible	O
for	O
robust	O
thiamin	O
responsiveness	O
in	O
homozygous	O
patients	O
carrying	O
the	O
H391R	B-ProteinMutation
E2	O
mutation	O
and	O
that	O
the	O
presence	O
of	O
a	O
full-length	O
mutant	O
E2	O
is	O
diagnostic	O
of	O
this	O
MSUD	O
phenotype	O
.	O

The	O
present	O
results	O
offer	O
a	O
structural	O
and	O
biochemical	O
basis	O
for	O
these	O
novel	O
mutations	O
and	O
will	O
facilitate	O
DNA-based	O
diagnosis	O
for	O
MSUD	O
in	O
the	O
Israeli	O
population	O
.	O

Haplotypes	O
and	O
DNA	O
sequence	O
variation	O
within	O
and	O
surrounding	O
the	O
transthyretin	O
gene	O
:	O
genotype-phenotype	O
correlations	O
in	O
familial	O
amyloid	O
polyneuropathy	O
V30M	B-ProteinMutation
in	O
Portugal	O
and	O
Sweden	O
.	O

Familial	O
amyloid	O
polyneuropathy	O
(FAP)	O
is	O
a	O
lethal	O
autosomal	O
dominant	O
disorder	O
in	O
which	O
fibrils	O
derived	O
from	O
mutant	O
forms	O
of	O
transthyretin	O
(TTR)	O
,	O
the	O
normal	O
plasma	O
carrier	O
of	O
thyroxine	O
(T(4))	O
and	O
retinol-binding	O
protein	O
,	O
are	O
deposited	O
in	O
tissues	O
.	O

Over	O
80	O
TTR	O
sequence	O
variants	O
are	O
associated	O
with	O
FAP	O
,	O
but	O
the	O
amino-acid	O
substitutions	O
alone	O
do	O
not	O
completely	O
explain	O
the	O
variability	O
in	O
disease	O
penetrance	O
,	O
pathology	O
and	O
clinical	O
course	O
.	O

To	O
analyze	O
the	O
factors	O
possibly	O
contributing	O
to	O
this	O
phenotypic	O
variability	O
,	O
we	O
characterized	O
the	O
variations	O
within	O
the	O
wild-type	O
and	O
mutant	O
Val30Met	B-ProteinMutation
TTR	O
genes	O
and	O
their	O
flanking	O
sequences	O
by	O
performing	O
extended	O
microsatellite	O
haplotype	O
analyses	O
,	O
sequencing	O
and	O
single-nucleotide	O
polymorphism	O
haplotyping	O
of	O
genomic	O
DNA	O
from	O
Portuguese	O
and	O
Swedish	O
carriers	O
of	O
V30M	B-ProteinMutation
.	O

We	O
identified	O
10	O
new	O
polymorphisms	O
in	O
the	O
TTR	O
untranslated	O
regions	O
,	O
eight	O
resulting	O
from	O
single-base	O
substitutions	O
and	O
two	O
arising	O
from	O
insertion/deletions	O
in	O
dinucleotide	O
repeat	O
sequences	O
.	O

The	O
data	O
suggest	O
that	O
the	O
onset	O
of	O
symptoms	O
of	O
FAP	O
V30M	B-ProteinMutation
may	O
be	O
modulated	O
by	O
an	O
interval	O
downstream	O
of	O
TTR	O
on	O
the	O
accompanying	O
noncarrier	O
chromosome	O
(	O
defined	O
by	O
microsatellites	O
D18S457	O
and	O
D18S456	O
)	O
,	O
but	O
not	O
by	O
the	O
immediately	O
5'-	O
and	O
3'-flanking	O
sequences	O
of	O
TTR	O
.	O

During	O
the	O
course	O
of	O
these	O
studies	O
,	O
we	O
also	O
encountered	O
the	O
first	O
instance	O
in	O
which	O
the	O
previously	O
described	O
intragenic	O
haplotype	O
III	O
may	O
be	O
associated	O
with	O
V30M	B-ProteinMutation
FAP	O
in	O
the	O
Portuguese	O
population	O
.	O

Germline	O
deletions	O
of	O
EXO1	O
do	O
not	O
cause	O
colorectal	O
tumors	O
and	O
lesions	O
which	O
are	O
null	O
for	O
EXO1	O
do	O
not	O
have	O
microsatellite	O
instability	O
.	O

Exonuclease	O
1	O
(EXO1)	O
is	O
a	O
candidate	O
gene	O
for	O
colorectal	O
tumor	O
susceptibility	O
because	O
it	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
mismatch	O
repair	O
.	O

There	O
have	O
been	O
several	O
studies	O
investigating	O
the	O
role	O
of	O
EXO1	O
in	O
mismatch	O
repair	O
but	O
few	O
investigating	O
its	O
role	O
in	O
causing	O
clinical	O
disease	O
.	O

In	O
one	O
recent	O
study	O
,	O
germline	O
variants	O
of	O
EXO1	O
were	O
reported	O
to	O
be	O
associated	O
with	O
predisposition	O
to	O
colorectal	O
cancer	O
in	O
families	O
with	O
phenotypes	O
similar	O
to	O
hereditary	O
nonpolyposis	O
colon	O
cancer	O
(HNPCC)	O
.	O

We	O
recently	O
identified	O
nine	O
individuals	O
from	O
two	O
British	O
families	O
with	O
multiple	O
cutaneous	O
and	O
uterine	O
leiomyomatosis	O
with	O
independently	O
arising	O
heterozygous	O
germline	O
deletions	O
of	O
1q42.3	O
approximately	O
q43	O
encompassing	O
not	O
only	O
FH	O
,	O
the	O
multiple	O
leiomyomatosis-associated	O
gene	O
,	O
but	O
also	O
several	O
flanking	O
genes	O
,	O
including	O
EXO1	O
.	O

We	O
investigated	O
these	O
families	O
for	O
any	O
indication	O
of	O
predisposition	O
to	O
colorectal	O
cancer	O
or	O
other	O
HNPCC	O
spectrum	O
cancers	O
by	O
means	O
of	O
detailed	O
questionnaires	O
,	O
interviews	O
,	O
and	O
examination	O
of	O
EXO1-null	O
skin	O
leiomyomata	O
for	O
microsatellite	O
instability	O
(MSI)	O
.	O

No	O
individual	O
in	O
these	O
families	O
had	O
developed	O
colorectal	O
cancer	O
or	O
known	O
colorectal	O
adenomas	O
,	O
and	O
none	O
had	O
any	O
symptoms	O
warranting	O
gastrointestinal	O
or	O
other	O
investigation	O
.	O

EXO1-null	O
tumors	O
showed	O
no	O
evidence	O
of	O
MSI	O
.	O

This	O
study	O
questions	O
the	O
functional	O
significance	O
of	O
previously	O
reported	O
variants	O
of	O
EXO1	O
reported	O
in	O
HNPCC-like	O
families	O
and	O
suggests	O
that	O
in	O
humans	O
there	O
may	O
be	O
other	O
as	O
yet	O
undiscovered	O
proteins	O
that	O
have	O
exonuclease	O
function	O
overlapping	O
with	O
that	O
of	O
EXO1	O
in	O
DNA	O
mismatch	O
repair	O
.	O

Also	O
of	O
interest	O
is	O
the	O
absence	O
of	O
phenotypic	O
abnormality	O
apart	O
from	O
multiple	O
leiomyomatosis	O
in	O
any	O
deletion	O
carrier	O
even	O
though	O
the	O
adjacent	O
genes	O
RGS7	O
,	O
KMO	O
,	O
CHML	O
,	O
and	O
OPN3	O
were	O
also	O
deleted	O
.	O

Beta-thalassemia	O
in	O
association	O
with	O
a	O
new	O
delta-chain	O
hemoglobin	O
variant	O
delta116(g18)Arg-->Leu	B-ProteinMutation
:	O
implications	O
for	O
carrier	O
screening	O
and	O
prenatal	O
diagnosis	O
.	O

We	O
describe	O
a	O
complicated	O
genetic	O
counseling	O
and	O
prenatal	O
diagnostic	O
case	O
involving	O
an	O
East	O
Indian	O
couple	O
that	O
had	O
lost	O
two	O
consecutive	O
pregnancies	O
.	O

Hemoglobinopathy	O
screening	O
was	O
conducted	O
to	O
investigate	O
the	O
possibility	O
of	O
Hb	O
Bart's	O
hydrops	O
fetalis	O
or	O
Hb	O
H	O
hydrops	O
fetalis	O
.	O

The	O
initial	O
work-up	O
indicated	O
that	O
alpha-thalassemia	O
was	O
not	O
a	O
contributing	O
factor	O
,	O
with	O
both	O
parents	O
being	O
carriers	O
of	O
single	O
gene	O
deletions	O
(-alpha(3.7)/alphaalpha)	O
.	O

However	O
,	O
the	O
Hb	O
electrophoresis	O
results	O
indicated	O
that	O
the	O
couple	O
might	O
be	O
at	O
risk	O
for	O
having	O
children	O
with	O
Hb	O
E/Hb	O
Lepore	O
disease	O
.	O

Subsequent	O
DNA	O
testing	O
demonstrated	O
that	O
the	O
father	O
carried	O
the	O
Hb	O
E	O
mutation	O
,	O
but	O
failed	O
to	O
confirm	O
that	O
the	O
mother	O
carries	O
the	O
Hb	O
Lepore	O
deletion	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
mother	O
was	O
heterozygous	O
for	O
a	O
common	O
East	O
Indian	O
beta(0)-thalassemia	O
mutation	O
,	O
yet	O
had	O
a	O
normal	O
level	O
of	O
Hb	O
A(2)	O
.	O

The	O
mother	O
also	O
carried	O
a	O
previously	O
unreported	O
missense	O
mutation	O
of	O
the	O
delta-globin	O
gene	O
,	O
in	O
cis	O
with	O
the	O
beta(0)-thalassemia	O
mutation	O
,	O
which	O
gave	O
rise	O
to	O
the	O
minor	O
Hb	O
variant	O
originally	O
misidentified	O
as	O
Hb	O
Lepore	O
.	O

This	O
case	O
illustrates	O
the	O
importance	O
of	O
comprehensive	O
molecular	O
analyses	O
for	O
accurate	O
assessment	O
of	O
genetic	O
risks	O
for	O
hemoglobinopathy	O
syndromes	O
.	O

Novel	O
polypyrimidine	O
variation	O
(	O
IVS46	B-DNAMutation
:	I-DNAMutation
del	I-DNAMutation
T	I-DNAMutation
-39...-46	I-DNAMutation
)	O
in	O
ABCA1	O
causes	O
exon	O
skipping	O
and	O
contributes	O
to	O
HDL	O
cholesterol	O
deficiency	O
in	O
a	O
family	O
with	O
premature	O
coronary	O
disease	O
.	O

Recent	O
studies	O
have	O
implicated	O
mutations	O
in	O
the	O
ATP-binding	O
cassette	O
transporter	O
A1	O
,	O
ABCA1	O
,	O
as	O
a	O
cause	O
of	O
Tangier	O
disease	O
(TD)	O
and	O
familial	O
hypoalphalipoproteinemia	O
(FHA)	O
.	O

We	O
investigated	O
a	O
proband	O
with	O
very	O
low	O
levels	O
of	O
high-density	O
lipoprotein	O
cholesterol	O
(	O
HDL-C	O
,	O
6	O
mg/dL	O
)	O
and	O
a	O
history	O
of	O
premature	O
coronary	O
heart	O
disease	O
(CHD)	O
.	O

Sequencing	O
of	O
the	O
ABCA1	O
gene	O
revealed	O
2	O
distinct	O
variants	O
.	O

The	O
first	O
mutation	O
was	O
a	O
G5947A	B-DNAMutation
substitution	O
R1851Q	B-ProteinMutation
.	O

The	O
second	O
mutation	O
was	O
a	O
single-nucleotide	O
deletion	O
of	O
thymidine	O
in	O
a	O
polypyrimidine	O
tract	O
located	O
33	O
to	O
46	O
bps	O
upstream	O
to	O
the	O
start	O
of	O
exon	O
47	O
.	O

This	O
mutation	O
does	O
not	O
involve	O
the	O
3'	O
acceptor	O
splice	O
site	O
and	O
is	O
outside	O
the	O
lariat	O
branchpoint	O
sequence	O
(	O
IVS46	B-DNAMutation
:	I-DNAMutation
del	I-DNAMutation
T	I-DNAMutation
-39...-46	I-DNAMutation
)	O
.	O

Amplification	O
of	O
cDNA	O
obtained	O
in	O
cultured	O
fibroblasts	O
of	O
the	O
proband	O
and	O
affected	O
family	O
member	O
revealed	O
an	O
abnormally	O
spliced	O
cDNA	O
sequence	O
with	O
skipping	O
of	O
exon	O
47	O
.	O

These	O
variants	O
were	O
not	O
identified	O
in	O
over	O
400	O
chromosomes	O
of	O
healthy	O
whites	O
.	O

Compound	O
heterozygotes	O
(n=4)	O
exhibited	O
the	O
lowest	O
HDL-C	O
(	O
11+/-5	O
mg/dL	O
)	O
and	O
ApoA-I	O
(	O
35+/-15	O
mg/dL	O
)	O
compared	O
with	O
wild-type	O
(n=25)	O
(	O
HDL-C	O
51+/-14	O
mg/dL	O
;	O
ApoA-I	O
133+/-21	O
mg/dL	O
)	O
(P<0.0005)	O
or	O
subjects	O
affected	O
with	O
either	O
R1851Q	B-ProteinMutation
(n=6)	O
(	O
HDL-C	O
36+/-8	O
;	O
ApoA-I	O
117+/-19	O
)	O
or	O
IVS46	B-DNAMutation
:	I-DNAMutation
del	I-DNAMutation
T	I-DNAMutation
-39...-46	I-DNAMutation
(n=5)	O
(	O
HDL-C	O
31+9	O
;	O
ApoA-I	O
115+28	O
(P<0.01)	O
.	O

These	O
data	O
suggest	O
that	O
polypyrimidine	O
tract	O
variation	O
may	O
represent	O
a	O
novel	O
mechanism	O
for	O
altered	O
splicing	O
and	O
exon	O
skipping	O
that	O
is	O
independent	O
of	O
traditional	O
intronic	O
variants	O
as	O
previously	O
identified	O
in	O
acceptor/donor	O
splice	O
regions	O
or	O
the	O
lariat	O
branchpoint	O
domain	O
.	O

Frequency	O
of	O
polymorphisms	O
of	O
genes	O
coding	O
for	O
HIV-1	O
co-receptors	O
CCR5	O
and	O
CCR2	O
in	O
a	O
Brazilian	O
population	O
.	O

Entry	O
of	O
human	O
immunodeficiency	O
type	O
1	O
virus	O
(HIV-1)	O
into	O
target	O
cells	O
requires	O
both	O
CD(4)and	O
one	O
of	O
the	O
chemokine	O
receptors	O
.	O

Viruses	O
predominantly	O
use	O
one	O
,	O
or	O
occasionally	O
both	O
,	O
of	O
the	O
major	O
co-receptors	O
CCR5	O
and	O
CXCR4	O
,	O
although	O
other	O
receptors	O
,	O
including	O
CCR2B	O
and	O
CCR3	O
,	O
function	O
as	O
minor	O
co-receptors	O
.	O

A	O
32-nucleotide	O
deletion	O
(D32)	O
within	O
the	O
b-chemokine	O
receptor	O
5	O
gene	O
(CCR5)	O
has	O
been	O
described	O
in	O
subjects	O
who	O
remain	O
uninfected	O
despite	O
extensive	O
exposition	O
to	O
HIV-1	O
.	O

The	O
heterozygous	O
genotype	O
delays	O
disease	O
progression	O
.	O

This	O
allele	O
is	O
common	O
among	O
Caucasians	O
,	O
but	O
has	O
not	O
been	O
found	O
in	O
people	O
of	O
African	O
or	O
Asian	O
ancestry	O
.	O

A	O
more	O
common	O
transition	O
involving	O
a	O
valine	O
to	O
isoleucine	O
switch	O
in	O
transmembrane	O
domain	O
I	O
of	O
CCR2B	O
(64I)	O
,	O
with	O
unknown	O
functional	O
consequences	O
,	O
was	O
found	O
to	O
delay	O
disease	O
progression	O
but	O
not	O
to	O
reduce	O
infection	O
risk	O
.	O

As	O
the	O
Brazilian	O
population	O
consists	O
of	O
a	O
mixture	O
of	O
several	O
ethnic	O
groups	O
,	O
we	O
decided	O
to	O
examine	O
the	O
genotype	O
frequency	O
of	O
these	O
polymorphisms	O
in	O
this	O
country	O
.	O

There	O
were	O
11.5%	O
CCR5	O
heterozygotes	O
among	O
the	O
HIV-1	O
infected	O
population	O
and	O
12.5%	O
among	O
uninfected	O
individuals	O
,	O
similar	O
to	O
data	O
from	O
North	O
America	O
and	O
Western	O
Europe	O
.	O

The	O
prevalence	O
of	O
CCR2-64I	O
homozygotes	O
and	O
heterozygotes	O
was	O
0.06	O
and	O
15.2%	O
,	O
respectively	O
,	O
also	O
similar	O
to	O
what	O
is	O
known	O
for	O
North	O
America	O
and	O
Western	O
Europe	O
.	O

Progressive	O
decline	O
of	O
vasopressin	O
secretion	O
in	O
familial	O
autosomal	O
dominant	O
neurohypophyseal	O
diabetes	O
insipidus	O
presenting	O
a	O
novel	O
mutation	O
in	O
the	O
vasopressin-neurophysin	O
II	O
gene	O
.	O

OBJECTIVE	O
:	O
Familial	O
autosomal	O
dominant	O
neurohypophyseal	O
diabetes	O
insipidus	O
(FNDI)	O
is	O
a	O
rare	O
form	O
of	O
central	O
diabetes	O
insipidus	O
(DI)	O
,	O
which	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
vasopressin-neurophysin	O
II	O
(AVP-NPII)	O
gene	O
.	O

The	O
present	O
study	O
evaluated	O
the	O
AVP	O
secretion	O
over	O
time	O
and	O
analysed	O
the	O
structure	O
of	O
the	O
AVP-NPII	O
gene	O
in	O
a	O
Brazilian	O
family	O
with	O
FNDI	O
.	O

SUBJECTS	O
AND	O
DESIGN	O
:	O
Four	O
affected	O
members	O
and	O
one	O
nonaffected	O
member	O
from	O
one	O
Brazilian	O
family	O
with	O
FNDI	O
were	O
studied	O
.	O

The	O
diagnosis	O
of	O
central	O
DI	O
was	O
established	O
by	O
fluid	O
deprivation	O
test	O
and	O
hypertonic	O
saline	O
infusion	O
.	O

Two	O
affected	O
members	O
were	O
assessed	O
twice	O
within	O
a	O
6-year	O
interval	O
.	O

For	O
molecular	O
analysis	O
,	O
genomic	O
DNA	O
was	O
extracted	O
and	O
the	O
AVP-NPII	O
gene	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
.	O

RESULTS	O
:	O
The	O
functional	O
assessment	O
of	O
patients	O
with	O
FNDI	O
over	O
time	O
confirmed	O
a	O
progressive	O
loss	O
in	O
AVP	O
secretion	O
.	O

Two	O
patients	O
were	O
first	O
diagnosed	O
as	O
partial	O
central	O
DI	O
and	O
,	O
several	O
years	O
later	O
,	O
they	O
developed	O
severe	O
central	O
DI	O
.	O

Sequencing	O
analysis	O
revealed	O
a	O
heterozygous	O
new	O
point	O
mutation	O
in	O
the	O
nucleotide	O
1892	O
in	O
the	O
coding	O
sequence	O
for	O
neurophysin-II	O
of	O
the	O
AVP-NPII	O
gene	O
1892G>C	B-DNAMutation
predicting	O
an	O
amino	O
acid	O
substitution	O
A68P	B-ProteinMutation
in	O
all	O
affected	O
members	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
demonstrate	O
a	O
gradual	O
vasopressinergic	O
deficiency	O
due	O
to	O
a	O
novel	O
mutation	O
in	O
the	O
AVP-NPII	O
gene	O
in	O
a	O
Brazilian	O
family	O
with	O
FNDI	O
.	O

The	O
accumulation	O
of	O
A68P	B-ProteinMutation
mutated	O
precursor	O
might	O
have	O
a	O
cytotoxicity	O
effect	O
,	O
leading	O
to	O
a	O
gradual	O
death	O
of	O
magnocellular	O
neurones	O
,	O
and	O
a	O
progressive	O
decline	O
in	O
AVP	O
secretion	O
.	O

Congenital	O
hypothyroidism	O
due	O
to	O
a	O
new	O
deletion	O
in	O
the	O
sodium/iodide	O
symporter	O
protein	O
.	O

OBJECTIVE	O
:	O
Iodide	O
transport	O
defect	O
(ITD)	O
is	O
a	O
rare	O
disorder	O
characterised	O
by	O
an	O
inability	O
of	O
the	O
thyroid	O
to	O
maintain	O
an	O
iodide	O
gradient	O
across	O
the	O
basolateral	O
membrane	O
of	O
thyroid	O
follicular	O
cells	O
,	O
that	O
often	O
results	O
in	O
congenital	O
hypothyroidism	O
.	O

When	O
present	O
the	O
defect	O
is	O
also	O
found	O
in	O
the	O
salivary	O
glands	O
and	O
gastric	O
mucosa	O
and	O
it	O
has	O
been	O
shown	O
to	O
arise	O
from	O
abnormalities	O
of	O
the	O
sodium/iodide	O
symporter	O
(NIS)	O
.	O

PATIENT	O
:	O
We	O
describe	O
a	O
woman	O
with	O
hypothyroidism	O
identified	O
at	O
the	O
3rd	O
month	O
of	O
life	O
.	O

The	O
diagnosis	O
of	O
ITD	O
was	O
suspected	O
because	O
of	O
nodular	O
goitre	O
,	O
and	O
little	O
if	O
any	O
iodide	O
uptake	O
by	O
the	O
thyroid	O
and	O
salivary	O
glands	O
.	O

Treatment	O
with	O
iodide	O
partially	O
corrected	O
the	O
hypothyroidism	O
;	O
however	O
,	O
long-term	O
substitution	O
therapy	O
with	O
L-thyroxine	O
was	O
started	O
.	O

MEASUREMENTS	O
:	O
Thyroid	O
radioiodide	O
uptake	O
was	O
only	O
1.4%	O
and	O
0.3%	O
at	O
1	O
and	O
24	O
h	O
after	O
the	O
administration	O
of	O
recombinant	O
human	O
TSH	O
.	O

The	O
saliva	O
to	O
plasma	O
I-	O
ratio	O
was	O
1.1	O
indicating	O
that	O
the	O
inability	O
of	O
the	O
thyroid	O
gland	O
to	O
concentrate	O
I-	O
was	O
also	O
present	O
in	O
the	O
salivary	O
glands	O
.	O

RESULTS	O
:	O
Analysis	O
of	O
the	O
patient's	O
NIS	O
gene	O
revealed	O
a	O
15	O
nucleotide	O
(nt)	O
deletion	O
of	O
the	O
coding	O
sequence	O
(	O
nt	O
1314	O
through	O
nt	O
1328	O
)	O
and	O
the	O
insertion	O
of	O
15	O
nt	O
duplicating	O
the	O
first	O
15	O
nt	O
of	O
the	O
adjacent	O
intron	O
.	O

The	O
patient	O
was	O
homozygous	O
for	O
this	O
insertion/deletion	O
,	O
while	O
both	O
consanguineous	O
parents	O
were	O
heterozygous	O
.	O

This	O
deletion	O
predicts	O
the	O
production	O
of	O
a	O
protein	O
lacking	O
the	O
five	O
terminal	O
amino	O
acids	O
of	O
exon	O
XI	O
(439-443)	O
which	O
are	O
located	O
in	O
the	O
6th	O
intracellular	O
loop	O
.	O

COS-7	O
cells	O
transfected	O
with	O
a	O
vector	O
expressing	O
the	O
mutant	O
del-(439-443)	B-DNAMutation
NIS	O
failed	O
to	O
concentrate	O
iodide	O
,	O
suggesting	O
that	O
the	O
mutation	O
was	O
the	O
direct	O
cause	O
of	O
the	O
ITD	O
in	O
this	O
patient	O
.	O

CONCLUSION	O
:	O
In	O
conclusion	O
we	O
describe	O
the	O
first	O
Italian	O
case	O
of	O
congenital	O
hypothyroidism	O
due	O
to	O
a	O
new	O
deletion	O
in	O
the	O
NIS	O
gene	O
.	O

Cdx-2	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
vitamin	O
D	O
receptor	O
gene	O
determines	O
susceptibility	O
to	O
fracture	O
in	O
the	O
elderly	O
.	O

A	O
Cdx-2	O
binding	O
site	O
polymorphism	O
(	O
G	O
to	O
A	O
)	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
vitamin	O
D	O
receptor	O
gene	O
was	O
reported	O
.	O

In	O
an	O
ecological	O
study	O
in	O
eight	O
ethnic	O
groups	O
and	O
an	O
association	O
study	O
in	O
2848	O
elderly	O
whites	O
,	O
we	O
found	O
the	O
A-allele	O
to	O
be	O
associated	O
with	O
decreased	O
fracture	O
risk	O
.	O

Our	O
findings	O
expand	O
previous	O
similar	O
findings	O
in	O
a	O
Japanese	O
study	O
to	O
whites	O
and	O
show	O
a	O
relationship	O
with	O
fracture	O
risk	O
of	O
this	O
functional	O
polymorphism	O
.	O

INTRODUCTION	O
:	O
A	O
single	O
nucleotide	O
polymorphism	O
(SNP)	O
within	O
a	O
binding	O
site	O
of	O
the	O
intestinal-specific	O
transcription	O
factor	O
Cdx-2	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
vitamin	O
D	O
receptor	O
(VDR)	O
gene	O
was	O
previously	O
reported	O
.	O

It	O
was	O
found	O
to	O
modulate	O
the	O
transcription	O
of	O
the	O
hVDR	O
gene	O
and	O
to	O
be	O
associated	O
with	O
decreased	O
bone	O
mineral	O
density	O
in	O
a	O
small	O
group	O
of	O
postmenopausal	O
Japanese	O
women	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
relationship	O
between	O
the	O
VDR	O
Cdx-2	O
genotype	O
and	O
risk	O
of	O
fracture	O
.	O

METHODS	O
:	O
We	O
first	O
determined	O
the	O
location	O
of	O
this	O
SNP	O
in	O
the	O
VDR	O
gene	O
by	O
sequencing	O
analysis	O
,	O
and	O
we	O
developed	O
an	O
allele-specific	O
multiplex	O
polymerase	O
chain	O
reaction	O
test	O
to	O
determine	O
the	O
Cdx-2	O
genotype	O
.	O

We	O
then	O
performed	O
an	O
ecological	O
study	O
in	O
eight	O
ethnic	O
groups	O
and	O
an	O
association	O
analysis	O
in	O
a	O
large	O
epidemiological	O
cohort	O
of	O
2848	O
Dutch	O
white	O
men	O
and	O
women	O
,	O
>	O
or	O
=	O
55	O
years	O
old	O
.	O

RESULTS	O
AND	O
CONCLUSIONS	O
:	O
The	O
location	O
of	O
the	O
G	O
to	O
A	O
substitution	O
was	O
found	O
in	O
the	O
promoter	O
region	O
of	O
exon	O
le	O
(le-G-1739A)	O
of	O
the	O
VDR	O
gene	O
.	O

By	O
comparing	O
the	O
frequency	O
of	O
the	O
A-allele	O
in	O
eight	O
different	O
ethnic	O
groups	O
,	O
we	O
observed	O
a	O
negative	O
correlation	O
between	O
prevalence	O
of	O
the	O
A-allele	O
and	O
published	O
hip	O
fracture	O
incidence	O
rates	O
in	O
these	O
ethnic	O
groups	O
(	O
p	O
=	O
0.006	O
for	O
men	O
and	O
p	O
=	O
0.02	O
for	O
women	O
)	O
,	O
suggesting	O
a	O
protective	O
effect	O
of	O
this	O
allele	O
on	O
fracture	O
risk	O
.	O

Subsequently	O
,	O
in	O
the	O
association	O
study	O
,	O
the	O
A-allele	O
(	O
population	O
frequency	O
19%	O
)	O
was	O
observed	O
to	O
have	O
a	O
protective	O
effect	O
on	O
occurrence	O
of	O
osteoporotic	O
fractures	O
,	O
especially	O
for	O
nonvertebral	O
fracture	O
in	O
women	O
(	O
relative	O
risk	O
of	O
AA	O
versus	O
GG	O
genotype	O
is	O
0.2	O
;	O
95%	O
CI	O
,	O
0.05-0.8	O
)	O
.	O

This	O
effect	O
remained	O
after	O
adjustment	O
for	O
age	O
,	O
weight	O
,	O
and	O
bone	O
mineral	O
density	O
.	O

We	O
conclude	O
that	O
the	O
A-allele	O
of	O
the	O
VDR	O
Cdx-2	O
polymorphism	O
is	O
present	O
in	O
whites	O
,	O
albeit	O
at	O
low	O
frequency	O
,	O
and	O
show	O
a	O
protective	O
effect	O
of	O
this	O
allele	O
on	O
risk	O
of	O
fracture	O
.	O

A	O
glycine	O
to	O
aspartic	O
acid	O
substitution	O
of	O
COL2A1	O
in	O
a	O
family	O
with	O
the	O
Strudwick	O
variant	O
of	O
spondyloepimetaphyseal	O
dysplasia	O
.	O

BACKGROUND	O
:	O
Spondyloepimetaphyseal	O
dysplasia	O
(SEMD)	O
is	O
one	O
of	O
a	O
clinically	O
heterogeneous	O
group	O
of	O
skeletal	O
disorders	O
,	O
characterized	O
by	O
defective	O
growth	O
and	O
modelling	O
of	O
the	O
spine	O
and	O
long	O
bones	O
.	O

Common	O
clinical	O
features	O
include	O
disproportionate	O
short	O
stature	O
,	O
malformed	O
vertebrae	O
and	O
abnormal	O
epiphyses	O
or	O
metaphyses	O
.	O

Some	O
cases	O
have	O
been	O
associated	O
with	O
mutations	O
in	O
the	O
COL2A1	O
gene	O
.	O

AIM	O
:	O
To	O
determine	O
whether	O
the	O
autosomal	O
dominant	O
Strudwick-type	O
SEMD	O
in	O
a	O
three-generation	O
family	O
,	O
showing	O
specific	O
phenotypical	O
features	O
such	O
as	O
chest	O
deformity	O
,	O
limb	O
shortening	O
,	O
myopia	O
and	O
early-onset	O
degenerative	O
osteoarthrosis	O
,	O
might	O
be	O
caused	O
by	O
a	O
novel	O
COL2A1	O
mutation	O
.	O

DESIGN	O
:	O
Genetic	O
testing	O
and	O
clinical	O
examination	O
of	O
family	O
members	O
.	O

METHODS	O
:	O
Direct	O
sequencing	O
of	O
PCR-amplified	O
genomic	O
DNA	O
from	O
the	O
COL2A1	O
gene	O
.	O

RESULTS	O
:	O
A	O
point	O
mutation	O
within	O
exon	O
20	O
of	O
the	O
COL2A1	O
gene	O
was	O
identified	O
that	O
substituted	O
a	O
glycine	O
for	O
an	O
aspartic	O
acid	O
residue	O
at	O
codon	O
262	O
.	O

DISCUSSION	O
:	O
All	O
previously	O
reported	O
autosomal	O
dominant	O
mutations	O
causing	O
SEMD	O
have	O
substituted	O
an	O
obligate	O
glycine	O
within	O
the	O
triple	O
helix	O
,	O
in	O
particular	O
at	O
codons	O
292	O
,	O
304	O
and	O
709	O
in	O
the	O
three	O
reported	O
Strudwick-type	O
patients	O
.	O

Additionally	O
,	O
a	O
recurrent	O
glycine	O
substitution	O
at	O
codon	O
154	O
has	O
been	O
identified	O
in	O
two	O
unrelated	O
Finnish	O
cases	O
with	O
radiological	O
features	O
consistent	O
with	O
the	O
Strudwick	O
subtype	O
.	O

Our	O
sixth	O
helical	O
glycine	O
substitution	O
extends	O
the	O
mutational	O
spectrum	O
and	O
genotype/phenotype	O
correlations	O
of	O
Strudwick-type	O
SEMD	O
.	O

Genetic	O
polymorphisms	O
of	O
renin-angiotensin	O
system	O
and	O
progression	O
of	O
interstitial	O
nephritis	O
.	O

Genes	O
of	O
the	O
renin-angiotensin	O
system	O
(RAS)	O
are	O
involved	O
in	O
the	O
progression	O
of	O
renal	O
failure	O
.	O

Among	O
them	O
,	O
the	O
angiotensin-converting	O
enzyme	O
(ACE)	O
,	O
angiotensinogen	O
(AGT)	O
and	O
angiotensin	O
II	O
type	O
1	O
receptor	O
(AT1R)	O
genes	O
are	O
of	O
particular	O
interest	O
.	O

We	O
examined	O
polymorphisms	O
of	O
these	O
three	O
genes	O
for	O
association	O
with	O
the	O
development	O
of	O
interstitial	O
nephritis	O
and	O
progression	O
to	O
end-stage	O
renal	O
failure	O
.	O

The	O
allele	O
frequency	O
and	O
genotype	O
distribution	O
were	O
compared	O
in	O
90	O
patients	O
with	O
interstitial	O
nephritis	O
and	O
200	O
healthy	O
controls	O
.	O

DNA	O
samples	O
were	O
genotyped	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
.	O

We	O
did	O
not	O
find	O
statistically	O
significant	O
differences	O
between	O
groups	O
in	O
the	O
insertion/deletion	O
polymorphism	O
of	O
the	O
ACE	O
gene	O
.	O

An	O
involvement	O
of	O
M235T	B-ProteinMutation
polymorphism	O
of	O
the	O
AGT	O
gene	O
in	O
renal	O
disease	O
was	O
observed	O
in	O
our	O
study	O
.	O

The	O
frequency	O
of	O
the	O
T	O
allele	O
was	O
higher	O
in	O
patients	O
than	O
in	O
controls	O
(	O
32%	O
vs	O
.	O

24%	O
)	O
.	O

In	O
the	O
A1166C	B-DNAMutation
AT1R	O
polymorphism	O
the	O
homozygous	O
CC	O
genotype	O
was	O
also	O
more	O
frequent	O
in	O
interstitial	O
nephritis	O
patients	O
(	O
7%	O
vs	O
.	O

3.5%	O
)	O
.	O

In	O
patients	O
carrying	O
the	O
C	O
allele	O
,	O
an	O
average	O
time	O
to	O
ESRD	O
was	O
significantly	O
shorter	O
than	O
in	O
subjects	O
with	O
the	O
AA	O
genotype	O
.	O

Our	O
study	O
shows	O
the	O
association	O
of	O
the	O
AGT	O
and	O
AT1R	O
gene	O
polymorphisms	O
with	O
the	O
development	O
and	O
progression	O
of	O
interstitial	O
nephritis	O
.	O

The	O
C	O
allele	O
of	O
the	O
A1166C	B-DNAMutation
polymorphism	O
appears	O
to	O
be	O
a	O
risk	O
factor	O
for	O
faster	O
disease	O
progression	O
.	O

Epidemiology	O
of	O
tuberculosis	O
on	O
Gran	O
Canaria	O
:	O
a	O
4	O
year	O
population	O
study	O
using	O
traditional	O
and	O
molecular	O
approaches	O
.	O

BACKGROUND	O
:	O
In	O
recent	O
years	O
several	O
population	O
based	O
studies	O
using	O
restriction	O
fragment	O
length	O
polymorphism	O
(RFLP)	O
analysis	O
have	O
shown	O
a	O
higher	O
rate	O
of	O
recent	O
transmission	O
of	O
tuberculosis	O
than	O
previously	O
thought	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
transmission	O
patterns	O
of	O
tuberculosis	O
and	O
the	O
potential	O
causes	O
of	O
recent	O
transmission	O
on	O
the	O
island	O
of	O
Gran	O
Canaria	O
(Spain)	O
.	O

METHODS	O
:	O
The	O
strains	O
of	O
all	O
patients	O
diagnosed	O
with	O
tuberculosis	O
confirmed	O
by	O
culture	O
between	O
1	O
January	O
1993	O
and	O
31	O
December	O
1996	O
were	O
typed	O
by	O
RFLP	O
using	O
the	O
insertion	O
sequence	O
IS6110	O
.	O

A	O
cluster	O
was	O
defined	O
as	O
two	O
or	O
more	O
isolates	O
with	O
an	O
identical	O
RFLP	O
pattern	O
.	O

Epidemiological	O
linkage	O
through	O
contact	O
tracing	O
was	O
investigated	O
.	O

RESULTS	O
:	O
Of	O
the	O
total	O
of	O
719	O
patients	O
,	O
153	O
(21.3%)	O
were	O
excluded	O
because	O
there	O
was	O
inadequate	O
bacterial	O
DNA	O
for	O
genotyping	O
(n=129)	O
or	O
the	O
isolates	O
of	O
Mycobacterium	O
tuberculosis	O
had	O
less	O
than	O
five	O
copies	O
of	O
IS6110	O
(n=24)	O
.	O

The	O
isolates	O
from	O
409	O
patients	O
(72.3%)	O
were	O
grouped	O
into	O
78	O
different	O
clusters	O
with	O
an	O
estimated	O
58.5%	O
of	O
the	O
cases	O
being	O
due	O
to	O
recent	O
transmission	O
.	O

Young	O
age	O
was	O
the	O
only	O
significant	O
predictor	O
of	O
clustering	O
.	O

Only	O
in	O
147	O
(35.9%)	O
of	O
the	O
409	O
patients	O
belonging	O
to	O
a	O
cluster	O
could	O
an	O
epidemiological	O
link	O
be	O
found	O
.	O

111	O
patients	O
(19.6%)	O
were	O
identified	O
as	O
having	O
had	O
previous	O
contact	O
with	O
a	O
tuberculosis	O
patient	O
and	O
81	O
of	O
them	O
(72.9%)	O
belonged	O
to	O
a	O
cluster	O
.	O

The	O
three	O
largest	O
clusters	O
included	O
75	O
,	O
49	O
and	O
20	O
patients	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Recent	O
transmission	O
is	O
frequent	O
among	O
patients	O
with	O
tuberculosis	O
on	O
Gran	O
Canaria	O
and	O
could	O
be	O
associated	O
with	O
certain	O
aspects	O
of	O
control	O
measures	O
.	O

Some	O
of	O
the	O
clusters	O
described	O
in	O
the	O
study	O
could	O
be	O
due	O
to	O
the	O
prevalence	O
of	O
particular	O
strains	O
of	O
M	O
tuberculosis	O
on	O
the	O
island	O
.	O

Spectrum	O
of	O
mutations	O
in	O
the	O
arylsulfatase	O
A	O
gene	O
in	O
a	O
Canadian	O
DNA	O
collection	O
including	O
two	O
novel	O
frameshift	O
mutations	O
,	O
a	O
new	O
missense	O
mutation	O
C488R	B-ProteinMutation
and	O
an	O
MLD	O
mutation	O
R84Q	B-ProteinMutation
in	O
cis	O
with	O
a	O
pseudodeficiency	O
allele	O
.	O

We	O
describe	O
three	O
novel	O
mutations	O
in	O
the	O
human	O
arylsulfatase	O
A	O
gene	O
in	O
three	O
patients	O
with	O
MLD	O
,	O
an	O
autosomal	O
recessive	O
lysosomal	O
storage	O
disorder	O
.	O

An	O
insertion	O
,	O
2590_2591insCCCC	B-DNAMutation
in	O
exon	O
8	O
and	O
a	O
deletion	O
,	O
752_758delGCCGGCC	B-DNAMutation
,	O
in	O
exon	O
3	O
will	O
both	O
result	O
in	O
frameshifts	O
.	O

A	O
mutation	O
in	O
exon	O
8	O
,	O
2566T-->C	B-DNAMutation
,	O
results	O
in	O
a	O
missense	O
mutation	O
C488R	B-ProteinMutation
,	O
disrupting	O
an	O
unusual	O
cysteine-knot	O
at	O
the	O
C-terminal	O
end	O
of	O
the	O
protein	O
.	O

All	O
three	O
mutations	O
are	O
heterozygous	O
with	O
previously	O
documented	O
mutations	O
.	O

A	O
previously	O
reported	O
mutation	O
,	O
R84Q	B-ProteinMutation
was	O
identified	O
on	O
a	O
pseudodeficiency	O
allele	O
.	O

These	O
mutations	O
are	O
part	O
of	O
a	O
heterogeneous	O
spectrum	O
of	O
mutations	O
found	O
in	O
a	O
collection	O
of	O
DNA	O
samples	O
from	O
MLD	O
patients	O
from	O
across	O
Canada	O
and	O
the	O
USA	O
.	O

The	O
molecular	O
basis	O
for	O
the	O
thalassaemias	O
in	O
Sri	O
Lanka	O
.	O

The	O
beta-globin	O
gene	O
mutations	O
and	O
the	O
alpha-globin	O
genes	O
of	O
620	O
patients	O
with	O
the	O
phenotype	O
of	O
severe	O
to	O
moderate	O
thalassaemia	O
from	O
seven	O
centres	O
in	O
Sri	O
Lanka	O
were	O
analysed	O
.	O

Twenty-four	O
beta-globin	O
gene	O
mutations	O
were	O
identified	O
,	O
three	O
accounting	O
for	O
84.5%	O
of	O
the	O
1240	O
alleles	O
studied	O
:	O
IVSI-5	B-DNAMutation
(G-->C)	I-DNAMutation
56.2%	O
;	O
IVSI-1	B-DNAMutation
(G-->A)	I-DNAMutation
15.2%	O
;	O
and	O
haemoglobin	O
E	O
(	O
codon	B-DNAMutation
(CD)26	I-DNAMutation
GAG-->GAA	I-DNAMutation
)	O
13.1%	O
.	O

Three	O
new	O
mutations	O
were	O
found	O
;	O
a	O
13-bp	O
deletion	O
removing	O
the	O
last	O
nucleotide	O
in	O
CD6	O
to	O
CD10	O
inclusively	O
,	O
IVSI-129	B-DNAMutation
(A-->C)	I-DNAMutation
in	O
the	O
consensus	O
splice	O
site	O
,	O
and	O
a	O
frame	O
shift	O
,	O
CD55	O
(-A)	O
.	O

The	O
allele	O
frequency	O
of	O
alpha+	O
thalassaemia	O
was	O
6.5%	O
and	O
1.1%	O
for	O
-alpha3.7	O
and	O
-alpha4.2	O
deletions	O
respectively	O
.	O

Non-deletion	O
alpha-thalassaemia	O
was	O
not	O
observed	O
.	O

Triplicate	O
or	O
quadruplicate	O
alpha-globin	O
genes	O
were	O
unusually	O
common	O
.	O

In	O
1.5%	O
of	O
cases	O
it	O
was	O
impossible	O
to	O
identify	O
beta-thalassaemia	O
alleles	O
,	O
but	O
in	O
Kurunegala	O
detailed	O
family	O
studies	O
led	O
to	O
an	O
explanation	O
for	O
the	O
severe	O
thalassaemia	O
phenotype	O
in	O
every	O
case	O
,	O
including	O
a	O
previously	O
unreported	O
instance	O
of	O
homozygosity	O
for	O
a	O
quadruplicated	O
alpha-globin	O
gene	O
together	O
with	O
beta-thalassaemia	O
trait	O
.	O

These	O
findings	O
have	O
implications	O
for	O
the	O
control	O
of	O
thalassaemia	O
in	O
high-frequency	O
populations	O
with	O
complex	O
ethnic	O
histories	O
.	O

Pacemaker	O
channel	O
dysfunction	O
in	O
a	O
patient	O
with	O
sinus	O
node	O
disease	O
.	O

The	O
cardiac	O
pacemaker	O
current	O
I(f)	O
is	O
a	O
major	O
determinant	O
of	O
diastolic	O
depolarization	O
in	O
sinus	O
nodal	O
cells	O
and	O
has	O
a	O
key	O
role	O
in	O
heartbeat	O
generation	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
some	O
forms	O
of	O
"idiopathic"	O
sinus	O
node	O
dysfunction	O
(SND)	O
are	O
related	O
to	O
inherited	O
dysfunctions	O
of	O
cardiac	O
pacemaker	O
ion	O
channels	O
.	O

In	O
a	O
candidate	O
gene	O
approach	O
,	O
a	O
heterozygous	O
1-bp	O
deletion	O
1631delC	B-DNAMutation
in	O
exon	O
5	O
of	O
the	O
human	O
HCN4	O
gene	O
was	O
detected	O
in	O
a	O
patient	O
with	O
idiopathic	O
SND	O
.	O

The	O
mutant	O
HCN4	O
protein	O
(HCN4-573X)	O
had	O
a	O
truncated	O
C-terminus	O
and	O
lacked	O
the	O
cyclic	O
nucleotide-binding	O
domain	O
.	O

COS-7	O
cells	O
transiently	O
transfected	O
with	O
HCN4-573X	O
cDNA	O
indicated	O
normal	O
intracellular	O
trafficking	O
and	O
membrane	O
integration	O
of	O
HCN4-573X	O
subunits	O
.	O

Patch-clamp	O
experiments	O
showed	O
that	O
HCN4-573X	O
channels	O
mediated	O
I(f)-like	O
currents	O
that	O
were	O
insensitive	O
to	O
increased	O
cellular	O
cAMP	O
levels	O
.	O

Coexpression	O
experiments	O
showed	O
a	O
dominant-negative	O
effect	O
of	O
HCN4-573X	O
subunits	O
on	O
wild-type	O
subunits	O
.	O

These	O
data	O
indicate	O
that	O
the	O
cardiac	O
I(f)	O
channels	O
are	O
functionally	O
expressed	O
but	O
with	O
altered	O
biophysical	O
properties	O
.	O

Taken	O
together	O
,	O
the	O
clinical	O
,	O
genetic	O
,	O
and	O
in	O
vitro	O
data	O
provide	O
a	O
likely	O
explanation	O
for	O
the	O
patient's	O
sinus	O
bradycardia	O
and	O
the	O
chronotropic	O
incompetence	O
.	O

Genetic	O
changes	O
and	O
expression	O
of	O
the	O
mannose	O
6-phosphate/insulin-like	O
growth	O
factor	O
II	O
receptor	O
gene	O
in	O
human	O
hepatitis	O
B	O
virus-associated	O
hepatocellular	O
carcinoma	O
.	O

It	O
was	O
reported	O
that	O
60-70%	O
of	O
hepatitis	O
B	O
virus	O
(HBV)-negative	O
hepatocellular	O
carcinoma	O
(HCC)	O
had	O
loss	O
of	O
heterozygosity	O
(LOH)	O
at	O
the	O
mannose	O
6-phosphate/insulin-like	O
growth	O
factor	O
II	O
receptor	O
(M6P/IGF2R)	O
locus	O
and	O
this	O
gene	O
was	O
mutated	O
in	O
55%	O
of	O
these	O
patients	O
with	O
LOH	O
.	O

In	O
this	O
study	O
,	O
genomic	O
DNA	O
from	O
29	O
pairs	O
of	O
HBV-positive	O
HCC	O
and	O
corresponding	O
non-tumor	O
tissues	O
was	O
used	O
to	O
analyze	O
LOH	O
at	O
the	O
M6P/IGF2R	O
locus	O
and	O
single	O
deoxyguanosine	O
deletion	O
in	O
this	O
gene	O
by	O
PCR	O
.	O

Total	O
RNA	O
from	O
19	O
of	O
the	O
29	O
patients	O
was	O
utilized	O
to	O
determine	O
a	O
192	O
bp	O
insert	O
in	O
the	O
M6P/IGF2R	O
mRNA	O
and	O
expression	O
of	O
this	O
gene	O
by	O
RT-PCR	O
.	O

Twenty-eight	O
of	O
29	O
(97%)	O
HBV-positive	O
HCC	O
were	O
found	O
to	O
be	O
informative	O
at	O
the	O
M6P/IGF2R	O
locus	O
but	O
LOH	O
at	O
this	O
region	O
was	O
only	O
detected	O
in	O
4/28	O
(14%)	O
informative	O
patients	O
.	O

Neither	O
single	O
deoxyguanosine	O
deletion	O
in	O
this	O
gene	O
nor	O
192	O
bp	O
insert	O
in	O
its	O
mRNA	O
occurred	O
in	O
these	O
patients	O
.	O

Compared	O
with	O
corresponding	O
non-tumor	O
tissues	O
,	O
expression	O
of	O
the	O
M6P/IGF2R	O
mRNA	O
was	O
decreased	O
in	O
13/19	O
(68%)	O
HBV-positive	O
HCC	O
tissues	O
,	O
suggesting	O
that	O
M6P/IGF2R	O
may	O
be	O
involved	O
in	O
HBV-associated	O
hepatocarcinogenesis	O
by	O
the	O
regulation	O
of	O
its	O
expression	O
level	O
.	O

In	O
the	O
development	O
of	O
HBV-associated	O
HCC	O
,	O
M6P/IGF2R	O
mutation	O
may	O
not	O
be	O
a	O
major	O
agent	O
.	O

NRAMP1	O
genetic	O
polymorphisms	O
as	O
a	O
risk	O
factor	O
of	O
tuberculous	O
pleurisy	O
.	O

SETTING	O
:	O
Nrampl	O
encoded	O
by	O
the	O
NRAMP1	O
gene	O
influences	O
the	O
phagolysosomal	O
function	O
of	O
alveolar	O
macrophage	O
against	O
Mycobacterium	O
tuberculosis	O
.	O

Genetic	O
polymorphisms	O
of	O
NRAMP1	O
affect	O
innate	O
host	O
resistance	O
through	O
the	O
defective	O
production	O
and	O
function	O
of	O
Nrampl	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
this	O
relationship	O
,	O
the	O
NRAMP1	O
polymorphisms	O
in	O
patients	O
with	O
tuberculous	O
pleurisy	O
were	O
determined	O
.	O

DESIGN	O
:	O
Pleural	O
biopsy	O
proven	O
56	O
patients	O
were	O
designated	O
to	O
the	O
pleurisy	O
group	O
and	O
45	O
healthy	O
adults	O
were	O
designated	O
to	O
the	O
healthy	O
control	O
group	O
.	O

Three	O
NRAMP1	O
polymorphisms	O
such	O
as	O
single	O
nucleotide	O
change	O
in	O
intron	O
4(469	B-DNAMutation
+	I-DNAMutation
14G/C	I-DNAMutation
,	O
INT4	O
)	O
,	O
a	O
non-conservative	O
single-base	O
substitution	O
at	O
codon	O
543(D543N)	B-ProteinMutation
and	O
TGTG	O
deletion	O
in	O
the	O
3'	O
untranslated	O
region	O
(	O
1729	B-DNAMutation
+	I-DNAMutation
55del4	I-DNAMutation
,	O
3'UTR	O
)	O
were	O
determined	O
.	O

RESULTS	O
:	O
The	O
frequencies	O
of	O
mutant	O
genotypes	O
of	O
INT4	O
and	O
3'UTR	O
were	O
significantly	O
high	O
in	O
the	O
pleurisy	O
group	O
(	O
P	O
=	O
0.01	O
,	O
P	O
=	O
0.02	O
)	O
,	O
but	O
the	O
frequencies	O
of	O
D543N	B-ProteinMutation
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Odds	O
ratios	O
(OR)	O
,	O
which	O
are	O
a	O
comparison	O
of	O
the	O
wild	O
with	O
the	O
mutant	O
genotype	O
,	O
were	O
8.02	O
(	O
95%CI	O
2.42	O
approximately	O
26.57	O
)	O
for	O
INT4	O
and	O
5.73	O
(	O
95%CI	O
1.14	O
approximately	O
28.92	O
)	O
for	O
3'UTR	O
which	O
were	O
statistically	O
significant	O
.	O

In	O
the	O
combined	O
analysis	O
of	O
the	O
INT4	O
and	O
3'UTR	O
,	O
the	O
ORs	O
were	O
6.00	O
(	O
95%CI	O
1.46	O
approximately	O
24.64	O
)	O
for	O
GC/++	O
genotype	O
and	O
14.00	O
(	O
95%CI	O
1.61	O
approximately	O
121.75	O
)	O
for	O
GC/+del	O
when	O
compared	O
with	O
GG/++	O
;	O
these	O
differences	O
were	O
statistically	O
significant	O
.	O

CONCLUSION	O
:	O
The	O
NRAMP1	O
genetic	O
polymorphisms	O
,	O
especially	O
INT4	O
and	O
3'UTR	O
,	O
were	O
closely	O
related	O
to	O
tuberculous	O
pleurisy	O
.	O

A	O
novel	O
CACNA1F	O
mutation	O
in	O
a	O
french	O
family	O
with	O
the	O
incomplete	O
type	O
of	O
X-linked	O
congenital	O
stationary	O
night	O
blindness	O
.	O

PURPOSE	O
:	O
To	O
describe	O
a	O
French	O
family	O
with	O
the	O
incomplete	O
type	O
of	O
X-linked	O
congenital	O
stationary	O
night	O
blindness	O
(CSNB2)	O
associated	O
with	O
a	O
novel	O
mutation	O
in	O
the	O
retina-specific	O
calcium	O
channel	O
alpha(1)	O
subunit	O
gene	O
(CACNA1F)	O
.	O

DESIGN	O
:	O
Interventional	O
case	O
report	O
.	O

METHODS	O
:	O
Two	O
family	O
members	O
with	O
a	O
history	O
of	O
nonprogressive	O
night	O
blindness	O
and	O
subnormal	O
visual	O
acuity	O
were	O
clinically	O
examined	O
and	O
the	O
genotype	O
determined	O
by	O
molecular	O
genetic	O
analysis	O
.	O

RESULT	O
:	O
Both	O
patients	O
had	O
clinical	O
manifestations	O
characteristic	O
of	O
CSNB2	O
.	O

Electrophysiologically	O
,	O
we	O
found	O
a	O
predominant	O
reduction	O
of	O
the	O
ERG	O
B-wave	O
in	O
the	O
maximal	O
response	O
.	O

Both	O
rod	O
and	O
cone	O
function	O
were	O
subnormal	O
,	O
with	O
the	O
latter	O
tending	O
to	O
be	O
more	O
attenuated	O
.	O

We	O
identified	O
a	O
C	O
deletion	O
at	O
nucleotide	O
position	O
4548	O
,	O
resulting	O
in	O
a	O
frameshift	O
with	O
a	O
predicted	O
premature	O
termination	O
at	O
codon	O
1524	O
.	O

CONCLUSIONS	O
:	O
The	O
clinical	O
and	O
genetic	O
study	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
CACNA1F	O
gene	O
adds	O
further	O
support	O
to	O
the	O
contention	O
that	O
CSNB2	O
represents	O
a	O
genetically	O
distinct	O
retinal	O
disorder	O
of	O
a	O
calcium	O
channel	O
.	O

Analysis	O
of	O
the	O
G/C	B-DNAMutation
polymorphism	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
RAD51	O
gene	O
in	O
breast	O
cancer	O
.	O

The	O
breast	O
cancer	O
suppressor	O
proteins	O
BRCA1	O
and	O
BRCA2	O
interact	O
with	O
RAD51	O
,	O
a	O
protein	O
essential	O
for	O
maintaining	O
genomic	O
stability	O
by	O
playing	O
a	O
central	O
role	O
in	O
homology-dependent	O
recombinational	O
repair	O
of	O
the	O
DNA	O
double-strand	O
breaks	O
.	O

Therefore	O
,	O
genetic	O
variability	O
in	O
the	O
RAD51	O
gene	O
may	O
contribute	O
to	O
the	O
appearance	O
and/or	O
progression	O
of	O
breast	O
cancer	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
5'-	O
untranslated	O
region	O
of	O
RAD51	O
(	O
a	O
G	O
to	O
C	O
substitution	O
at	O
position	O
135	O
,	O
the	O
G/C	B-DNAMutation
polymorphism	O
)	O
is	O
reported	O
to	O
modulate	O
breast	O
cancer	O
risk	O
.	O

We	O
investigated	O
the	O
distribution	O
of	O
genotypes	O
and	O
frequency	O
of	O
alleles	O
of	O
the	O
G/C	B-DNAMutation
polymorphism	O
in	O
breast	O
cancer	O
.	O

Tumor	O
tissues	O
were	O
obtained	O
from	O
postmenopausal	O
women	O
with	O
node-negative	O
and	O
node-positive	O
breast	O
carcinoma	O
with	O
uniform	O
tumor	O
size	O
.	O

Blood	O
samples	O
from	O
age	O
matched	O
healthy	O
women	O
served	O
as	O
control	O
.	O

The	O
G/C	B-DNAMutation
polymorphism	O
was	O
determined	O
by	O
PCR-based	O
MvaI	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

The	O
distribution	O
of	O
the	O
genotypes	O
of	O
the	O
G/C	B-DNAMutation
polymorphism	O
did	O
not	O
differ	O
significantly	O
(	O
P	O
>	O
0.05	O
)	O
from	O
those	O
predicted	O
by	O
the	O
Hardy-Weinberg	O
distribution	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
genotype	O
distribution	O
and	O
allele	O
frequencies	O
between	O
node-positive	O
and	O
node-negative	O
patients	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
distributions	O
of	O
the	O
genotypes	O
in	O
subgroups	O
assigned	O
to	O
histological	O
grades	O
according	O
to	O
Scarf-Bloom-Richardson	O
criteria	O
and	O
the	O
distribution	O
predicted	O
by	O
Hardy-Weinberg	O
equilibrium	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Our	O
study	O
implies	O
that	O
the	O
G/C	B-DNAMutation
polymorphism	O
of	O
the	O
RAD51	O
gene	O
may	O
not	O
be	O
directly	O
involved	O
in	O
the	O
development	O
and/or	O
progression	O
of	O
breast	O
cancer	O
and	O
so	O
it	O
may	O
not	O
be	O
useful	O
as	O
an	O
independent	O
marker	O
in	O
this	O
disease	O
.	O

Mutation	O
analysis	O
of	O
DMBT1	O
in	O
glioblastoma	O
,	O
medulloblastoma	O
and	O
oligodendroglial	O
tumors	O
.	O

DMBT1	O
has	O
been	O
implicated	O
as	O
a	O
candidate	O
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
10q	O
for	O
brain	O
,	O
gastrointestinal	O
and	O
lung	O
cancer	O
.	O

Homozygous	O
deletion	O
and	O
lack	O
of	O
expression	O
are	O
2	O
known	O
mechanisms	O
for	O
inactivating	O
DMBT1	O
.	O

We	O
evaluated	O
whether	O
somatic	O
mutation	O
,	O
which	O
represents	O
a	O
major	O
inactivation	O
mechanism	O
for	O
most	O
tumor	O
suppressor	O
genes	O
,	O
occurs	O
in	O
the	O
DMBT1	O
gene	O
.	O

A	O
total	O
of	O
102	O
primary	O
brain	O
tumors	O
,	O
consisting	O
of	O
25	O
glioblastoma	O
multiforme	O
,	O
24	O
medulloblastoma	O
and	O
53	O
oligodendroglial	O
tumors	O
,	O
were	O
analyzed	O
by	O
conformation-sensitive	O
gel	O
electrophoresis	O
in	O
all	O
54	O
coding	O
exons	O
of	O
DMBT1	O
.	O

Twelve	O
different	O
base	O
substitutions	O
were	O
detected	O
in	O
26	O
(25%)	O
tumors	O
.	O

Eight	O
base	O
substitutions	O
resulted	O
in	O
amino	O
acid	O
changes	O
and	O
4	O
were	O
silent	O
.	O

These	O
base	O
changes	O
were	O
also	O
detected	O
in	O
tumor-matched	O
blood	O
samples	O
,	O
however	O
,	O
indicating	O
that	O
the	O
base	O
variations	O
represent	O
genetic	O
polymorphisms	O
.	O

We	O
also	O
assessed	O
homozygous	O
deletions	O
of	O
the	O
DMBT1	O
gene	O
in	O
the	O
series	O
and	O
found	O
that	O
16	O
of	O
95	O
(	O
5	O
glioblastomas	O
,	O
5	O
medulloblastomas	O
,	O
6	O
oligodendroglial	O
tumors	O
;	O
total	O
17%	O
)	O
tumors	O
harbor	O
such	O
alteration	O
.	O

High-quality	O
blood	O
DNA	O
samples	O
were	O
available	O
in	O
5	O
tumors	O
carrying	O
homozygous	O
deletion	O
and	O
,	O
using	O
long-range	O
PCR	O
,	O
3	O
of	O
these	O
blood	O
samples	O
showed	O
germline	O
hemizygous	O
deletions	O
in	O
a	O
region	O
between	O
introns	O
10	O
and	O
26	O
of	O
DMBT1	O
.	O

Our	O
results	O
showed	O
that	O
mutation	O
does	O
not	O
play	O
a	O
role	O
in	O
inactivation	O
of	O
DMBT1	O
in	O
brain	O
tumors	O
.	O

Intragenic	O
homozygous	O
deletion	O
of	O
DMBT1	O
is	O
common	O
in	O
brain	O
tumors	O
and	O
is	O
likely	O
a	O
result	O
of	O
a	O
germline	O
deletion	O
of	O
1	O
allele	O
followed	O
by	O
loss	O
of	O
the	O
second	O
allele	O
during	O
tumor	O
development	O
.	O

Relation	O
of	O
shyness	O
in	O
grade	O
school	O
children	O
to	O
the	O
genotype	O
for	O
the	O
long	O
form	O
of	O
the	O
serotonin	O
transporter	O
promoter	O
region	O
polymorphism	O
.	O

OBJECTIVE	O
:	O
Studies	O
have	O
shown	O
that	O
genetic	O
factors	O
are	O
significant	O
in	O
predisposing	O
individuals	O
to	O
shyness	O
and	O
social	O
phobia	O
.	O

Toward	O
further	O
elucidating	O
the	O
genetic	O
structure	O
of	O
shyness	O
,	O
the	O
authors	O
examined	O
four	O
functional	O
polymorphisms	O
that	O
make	O
biological	O
sense	O
for	O
contributing	O
to	O
the	O
development	O
of	O
this	O
phenotype	O
:	O
serotonin	O
transporter	O
promoter	O
region	O
44	O
base	O
pair	O
insertion/deletion	O
(5-HTTLPR)	O
,	O
dopamine	O
D(4)	O
receptor	O
exon	O
III	O
repeat	O
(DRD4)	O
,	O
catechol	O
O-methyltransferase	O
(COMT)	O
,	O
and	O
monoamine	O
oxidase	O
A	O
promoter	O
region	O
repeat	O
(MAO(A))	O
.	O

METHOD	O
:	O
The	O
authors	O
assessed	O
shyness	O
after	O
recruitment	O
of	O
a	O
nonclinical	O
sample	O
(	O
N=118	O
,	O
unscreened	O
second-grade	O
children	O
)	O
using	O
a	O
composite	O
scale	O
derived	O
from	O
questionnaires	O
administered	O
to	O
the	O
children	O
,	O
parents	O
,	O
and	O
teachers	O
.	O

DNA	O
from	O
buccal	O
smears	O
successfully	O
obtained	O
from	O
98	O
children	O
was	O
genotyped	O
by	O
polymerase	O
chain	O
reaction	O
methods	O
for	O
the	O
5-HTTLPR	O
,	O
DRD4	O
,	O
COMT	O
,	O
and	O
MAO(A)	O
polymorphisms	O
.	O

RESULTS	O
:	O
Significant	O
correlations	O
were	O
observed	O
for	O
parents'	O
,	O
teachers'	O
,	O
and	O
children's	O
ratings	O
of	O
shyness	O
,	O
and	O
Cronbach's	O
alpha	O
reliability	O
was	O
high	O
for	O
all	O
three	O
scales	O
.	O

A	O
significant	O
association	O
was	O
observed	O
between	O
the	O
long	O
5-HTTLPR	O
polymorphism	O
and	O
shyness	O
,	O
both	O
by	O
the	O
functional	O
classification	O
of	O
Lesch	O
as	O
well	O
as	O
by	O
consideration	O
of	O
all	O
three	O
genotypes	O
.	O

No	O
significant	O
association	O
was	O
observed	O
for	O
the	O
DRD4	O
,	O
COMT	O
,	O
or	O
MAO(A)	O
polymorphisms	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provisionally	O
identifies	O
a	O
common	O
genetic	O
polymorphism	O
,	O
5-HTTLPR	O
,	O
that	O
modestly	O
(	O
effect	O
size=7%	O
)	O
contributed	O
to	O
greater	O
shyness	O
scores	O
in	O
a	O
nonclinical	O
group	O
of	O
second-grade	O
students	O
.	O

These	O
first	O
findings	O
may	O
be	O
relevant	O
to	O
previous	O
reports	O
that	O
have	O
shown	O
an	O
association	O
between	O
the	O
5-HTTLPR	O
long	O
form	O
and	O
obsessive-compulsive	O
disorder	O
and	O
autism	O
.	O

Restricted	O
genetic	O
defects	O
underlie	O
human	O
complement	O
C6	O
deficiency	O
.	O

Complement	O
C6	O
homozygous	O
deficiency	O
(C6D)	O
has	O
been	O
rarely	O
observed	O
in	O
Caucasians	O
but	O
was	O
reported	O
at	O
higher	O
prevalence	O
among	O
African-Americans	O
.	O

We	O
report	O
on	O
the	O
molecular	O
basis	O
of	O
C6D	O
in	O
seven	O
unrelated	O
black	O
individuals	O
of	O
North	O
or	O
Central	O
Africa	O
descent	O
who	O
live	O
in	O
France	O
.	O

These	O
patients	O
have	O
presented	O
Neisseria	O
meningitidis	O
infection	O
(	O
four	O
cases	O
)	O
,	O
focal	O
and	O
segmental	O
glomerulosclerosis	O
with	O
hyalinosis	O
(	O
one	O
case	O
)	O
,	O
systemic	O
lupus	O
erythematosus	O
(	O
one	O
case	O
)	O
or	O
Still's	O
disease	O
(	O
one	O
case	O
)	O
.	O

All	O
patients	O
exhibited	O
undetectable	O
antigenic	O
C6	O
by	O
using	O
a	O
sensitive	O
ELISA	O
assay	O
.	O

An	O
additional	O
four	O
cases	O
of	O
complete	O
C6	O
deficiency	O
with	O
no	O
associated	O
disease	O
have	O
been	O
characterized	O
after	O
family	O
studies	O
.	O

Exons	O
6	O
,	O
7	O
and	O
12	O
have	O
been	O
described	O
recently	O
as	O
the	O
location	O
of	O
molecular	O
defects	O
on	O
the	O
C6	O
gene	O
in	O
randomly	O
chosen	O
black	O
Americans	O
.	O

Genomic	O
DNA	O
from	O
the	O
seven	O
patients	O
were	O
subjected	O
to	O
direct	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
these	O
three	O
exons	O
.	O

Nucleotide	O
sequencing	O
analysis	O
of	O
the	O
amplified	O
DNA	O
fragments	O
revealed	O
a	O
homozygous	O
single-base	O
deletion	O
1936delG	B-DNAMutation
in	O
exon	O
12	O
in	O
three	O
cases	O
and	O
four	O
compound	O
heterozygous	O
deletions	O
for	O
a	O
single	O
base	O
in	O
exon	O
7	O
1195delC	B-DNAMutation
or	O
in	O
exon	O
6	O
878delA	B-DNAMutation
associated	O
with	O
the	O
same	O
deletion	O
in	O
exon	O
12	O
1936delG	B-DNAMutation
.	O

Our	O
observations	O
further	O
establish	O
the	O
restricted	O
pattern	O
of	O
genetic	O
defects	O
associated	O
with	O
homozygous	O
C6	O
complement	O
deficiency	O
in	O
individuals	O
of	O
African	O
descent	O
.	O